PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	VanGijn, J				VanGijn, J			Slip-ups in diagnosis of subarachnoid haemorrhage	LANCET			English	Editorial Material							HEMORRHAGE				VanGijn, J (corresponding author), UNIV UTRECHT,DEPT NEUROL,NL-3504 GA UTRECHT,NETHERLANDS.		van Gijn, Jan/A-9444-2008					Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660; Linn FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625; LINN FHH, 1994, LANCET, V344, P590, DOI 10.1016/S0140-6736(94)91970-4; Mayer PL, 1996, STROKE, V27, P1558, DOI 10.1161/01.STR.27.9.1558; NeilDwyer G, 1997, J ROY COLL PHYS LOND, V31, P49; Pascual J, 1996, NEUROLOGY, V46, P1520, DOI 10.1212/WNL.46.6.1520; VANDERWEE N, 1995, J NEUROL NEUROSUR PS, V58, P357, DOI 10.1136/jnnp.58.3.357; VERMEULEN M, 1989, J NEUROL NEUROSUR PS, V52, P826, DOI 10.1136/jnnp.52.7.826	8	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 24	1997	349	9064					1492	1492		10.1016/S0140-6736(05)62095-8	http://dx.doi.org/10.1016/S0140-6736(05)62095-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167456				2022-12-28	WOS:A1997XA90100006
J	Murray, CJL; Lopez, AD				Murray, CJL; Lopez, AD			Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study	LANCET			English	Article							CONSUMPTION; TRANSITION; ALCOHOL	Background Prevention and control of disease and injury require information about the leading medical causes of illness and exposures or risk factors, The assessment of the public-health importance of these has been hampered by the lack of common methods to investigate the overall, worldwide burden. The Global Burden of Disease Study (GBD) provides a standardised approach to epidemiological assessment and uses a standard unit, the disability-adjusted life year (DALY), to aid comparisons. Methods DALYs for each age-sex group in each GBD region for 107 disorders were calculated, based on the estimates of mortality by cause, incidence, average age of onset, duration, and disability severity. Estimates of the burden and prevalence of exposure in different regions of disorders attributable to malnutrition, poor water supply, sanitation and personal and domestic hygiene, unsafe sex, tobacco use, alcohol, occupation, hypertension, physical inactivity, use of illicit drugs, and air pollution were developed. Findings Developed regions account for 11.6% of the worldwide burden from all causes of death and disability, and account for 90.2% of health expenditure worldwide. Communicable, maternal, perinatal, and nutritional disorders explain 43.9%; noncommunicable causes 40.9%; injuries 15.1%; malignant neoplasms 5.1%: neuropsychiatric conditions 10.5%; and cardiovascular conditions 9.7% of DALYs worldwide. The ten leading specific causes of global DALYs are, in descending order, lower respiratory infections, diarrhoeal diseases, perinatal disorders, unipolar major depression, ischaemic heart disease, cerebrovascular disease, tuberculosis, measles, road-traffic accidents, and congenital anomalies, 15.9% of DALYs worldwide are attributable to childhood malnutrition and 6.8% to poor water, and sanitation and personal and domestic hygiene. Interpretation The three leading contributors to the burden of disease are communicable and perinatal disorders affecting children. The substantial burdens of neuropsychiatric disorders and injuries are under-recognised. The epidemiological transition in terms of DALYs has progressed substantially in China, Latin America and the Caribbean, other Asia and islands, and the middle eastern crescent. If the burdens of disability and death are taken into account, our list differs substantially from other lists of the leading causes of death, DALYs provide common metric to aid meaningful comparison of the burden of risk factors, diseases, and injuries.	WHO,CH-1211 GENEVA,SWITZERLAND	World Health Organization	Murray, CJL (corresponding author), HARVARD UNIV,CTR POPULAT & DEV STUDIES,SCH PUBL HLTH,9 BOW ST,CAMBRIDGE,MA 02138, USA.		Lopez, Alan D/F-1487-2010; Lopez, Alan/AAA-2734-2022	Lopez, Alan D/0000-0001-5818-6512; 				ANAND S, IN PRESS J HLTH EC; [Anonymous], 1996, GLOBAL BURDEN DIS CO; BERKLEY S, 1996, HLTH DIMENSIONS SEX; BOFFETTA P, 1990, EPIDEMIOLOGY, V1, P432; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; DONOGHOE M, 1996, QUANTIFYING GLOBAL B; English D.R., 1995, QUANTIFICATION DRUG; Frenk J., 1989, Health Policy and Planning, V4, P29, DOI 10.1093/heapol/4.1.29; HONG CJ, 1996, QUANTIFYING GLOBAL B; HUTTLY S, 1996, QUANTIFYING GLOBAL B; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; LEIGH J, 1996, QUANTIFYING GLOBAL B; Lozano R., 1995, J INT DEV, V7, P555, DOI DOI 10.1002/JID.3380070314; MASON JB, 1996, QUANTIFYING GLOBAL B; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; MURRAY CJL, 1996, QUANTIFYING GLOBAL B; MURRAY CJL, 1994, GLOBAL COMP ASSESSME, P141; MURRAY CJL, IN PRESS J HLTH EC; NICHOLS SR, 1996, QUANTIFYING GLOBAL B; NOTANI PN, 1996, TOBACCO HLTH INDIAN, P63; OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375; PARKIN DM, 1994, INT J CANCER, V59, P495; PARRY C, 1986, CURATIONIS, V19, P1; PETO R, 1994, MORTALITY SMOKING; PRATT M, 1996, QUANTIFYING GLOBAL B; THUN M, UNPUB ALCOHOL MORTAL	26	2833	2979	14	505	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 17	1997	349	9063					1436	1442		10.1016/S0140-6736(96)07495-8	http://dx.doi.org/10.1016/S0140-6736(96)07495-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164317				2022-12-28	WOS:A1997WZ76500011
J	Antoch, MP; Song, EJ; Chang, AM; Vitaterna, MH; Zhao, YL; Wilsbacher, LD; Sangoram, AM; King, DP; Pinto, LH; Takahashi, JS				Antoch, MP; Song, EJ; Chang, AM; Vitaterna, MH; Zhao, YL; Wilsbacher, LD; Sangoram, AM; King, DP; Pinto, LH; Takahashi, JS			Functional identification of the mouse circadian Clock gene by transgenic BAC rescue	CELL			English	Article							MESSENGER-RNA LEVELS; DROSOPHILA-MELANOGASTER; PERIOD LOCUS; BIOLOGICAL CLOCKS; DNA; RHYTHMICITY; EXPRESSION; AUTOREGULATION; TRANSFORMATION; MUTAGENESIS	As a complementary approach to positional cloning, we used in vivo complementation with bacterial artificial chromosome (BAC) clones expressed in transgenic mice to identify the circadian Clock gene. A 140 kb BAC transgene completely rescued both the long period and the loss-of-rhythm phenotypes in Clock mutant mice. Analysis with overlapping BAC transgenes demonstrates that a large transcription unit spanning similar to 100,000 base pairs is the Clock gene and encodes a novel basic-helix-loop-helix-PAS domain protein. Overexpression of the Clock transgene can shorten period length beyond the wild-type range, which provides additional evidence that Clock is an integral component of the circadian pacemaking system. Taken together, these results provide a proof of principle that ''cloning by rescue'' is an efficient and definitive method in mice.	NORTHWESTERN UNIV, DEPT NEUROBIOL & PHYSIOL, NATL SCI FDN CTR BIOL TIMING, EVANSTON, IL 60208 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University			Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019	Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878; Antoch, mantoch/0000-0003-3001-8511; Chang, Anne-Marie/0000-0002-3943-416X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039592] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NICHD NIH HHS [P30 HD28048] Funding Source: Medline; NIGMS NIH HHS [T32 GM008152, T32 GM08152] Funding Source: Medline; NIMH NIH HHS [R37 MH39592] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKAGI J, 1988, BIOCHEM BIOPH RES CO, V157, P548, DOI 10.1016/S0006-291X(88)80284-5; ALUBAIDI MR, 1990, J BIOL CHEM, V265, P20563; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BLOCK GD, 1993, INT REV CYTOL, V146, P83, DOI 10.1016/S0074-7696(08)60381-2; Bracewell R. N., 1986, HARTLEY TRANSFORM; BRUNKOW ME, 1995, GENOMICS, V25, P421, DOI 10.1016/0888-7543(95)80042-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTE GG, 1986, J THEOR BIOL, V121, P487, DOI 10.1016/S0022-5193(86)80104-7; DIETRICH W, 1992, GENETICS, V131, P423; DOVE WF, 1987, GENETICS, V116, P5; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; FAVELLO A, 1995, GENOMIC DNA SEQUENCI, P551; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; GIBSON S, 1993, TRENDS BIOCHEM SCI, V21, P93; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HAMBLEN M, 1986, J NEUROGENET, V3, P249, DOI 10.3109/01677068609106855; HAMILTON BA, 1997, IN PRESS NEURON; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; Hogan B, 1994, MANIPULATING MOUSE E; Kim UJ, 1996, GENOMICS, V34, P213, DOI 10.1006/geno.1996.0268; Klein D.C., 1991, SUPRACHIASMATIC NUCL; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; MCCLUNG CR, 1989, NATURE, V339, P558, DOI 10.1038/339558a0; MEIJER JH, 1989, PHYSIOL REV, V69, P671, DOI 10.1152/physrev.1989.69.3.671; Mello C, 1995, METHOD CELL BIOL, P452; MOORE RY, 1995, CIBA F SYMP, V183, P88; Moore RY, 1996, PROG BRAIN RES, V111, P103, DOI 10.1016/S0079-6123(08)60403-3; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; Peterson KR, 1997, TRENDS GENET, V13, P61, DOI 10.1016/S0168-9525(97)01003-2; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; RUTILA JE, 1992, J NEUROGENET, V8, P101, DOI 10.3109/01677069209084155; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SMITH DJ, 1995, GENOMICS, V27, P425, DOI 10.1006/geno.1995.1073; SMITH RF, 1981, MOL GEN GENET, V183, P243, DOI 10.1007/BF00270625; SOKOLOVE PG, 1978, FDN P, V38, P2589; TAKAHASHI JS, 1993, ANNU REV PHYSIOL, V55, P729, DOI 10.1146/annurev.physiol.55.1.729; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; TUREK FW, 1994, RECENT PROG HORM RES, V49, P43; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Yamaguchi T, 1996, J BIOCHEM-TOKYO, V120, P494; ZEHRING WA, 1984, CELL, V39, P369, DOI 10.1016/0092-8674(84)90015-1; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; [No title captured]; [No title captured]; [No title captured]	57	508	526	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	1997	89	4					655	667		10.1016/S0092-8674(00)80246-9	http://dx.doi.org/10.1016/S0092-8674(00)80246-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160756	Green Accepted, Bronze			2022-12-28	WOS:A1997WZ32300018
J	Mothes, W; Heinrich, SU; Graf, R; Nilsson, IM; vonHeijne, G; Brunner, J; Rapoport, TA				Mothes, W; Heinrich, SU; Graf, R; Nilsson, IM; vonHeijne, G; Brunner, J; Rapoport, TA			Molecular mechanism of membrane protein integration into the endoplasmic reticulum	CELL			English	Article							SIGNAL-SEQUENCE; SECRETORY PROTEINS; ER MEMBRANE; NASCENT POLYPEPTIDES; CONDUCTING CHANNEL; ESCHERICHIA-COLI; TRANSLOCATION; INSERTION; ENVIRONMENT; GLYCOPROTEIN	As proteins are integrated into the membrane of the endoplasmic reticulum, some hydrophilic polypeptide segments are transported through the translocation channel, others remain in the cytosol, and hydrophobic transmembrane sequences are released into the lipid phase. We have addressed the molecular mechanism by which these events occur. We demonstrate that both the lumenal and the cytosolic domains of a membrane protein are synthesized while the ribosome is membrane bound, so that even cytosolic domains come in contact with the translocation channel. We also find that, before translation of the protein is terminated, transmembrane sequences can laterally exit the translocation channel and enter the lipid environment. These results have significant implications for the folding and assembly of membrane proteins.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; ETH ZURICH,BIOCHEM LAB,CH-8092 ZURICH,SWITZERLAND; UNIV STOCKHOLM,ARRHENIUS LAB,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN	Harvard University; Harvard Medical School; Swiss Federal Institutes of Technology Domain; ETH Zurich; Stockholm University			Nilsson, IngMarie/H-2887-2012; von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569				BIBI E, 1991, P NATL ACAD SCI USA, V88, P7271, DOI 10.1073/pnas.88.16.7271; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; BRUNNER J, 1980, J BIOL CHEM, V255, P3313; BRUNNER J, 1980, J BIOL CHEM, V255, P3319; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; EHRMANN M, 1991, J BIOL CHEM, V266, P16530; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HANEIN D, 1996, CELL, V87, P731; HEDGE RS, 1996, CELL, V85, P217; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; LINGAPPA VR, 1978, J BIOL CHEM, V253, P8667; LOCKER JK, 1992, J BIOL CHEM, V267, P21911; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MATLACK KES, 1995, J BIOL CHEM, V270, P6170, DOI 10.1074/jbc.270.11.6170; MCCUNE JM, 1980, J EXP MED, V152, P463, DOI 10.1084/jem.152.2.463; MCGOVERN K, 1991, EMBO J, V10, P2773, DOI 10.1002/j.1460-2075.1991.tb07826.x; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; RAPOPORT TA, 1985, FEBS LETT, V187, P1, DOI 10.1016/0014-5793(85)81202-3; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; SKACH WR, 1993, J BIOL CHEM, V268, P23552; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	44	172	175	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					523	533		10.1016/S0092-8674(00)80234-2	http://dx.doi.org/10.1016/S0092-8674(00)80234-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160744	Bronze			2022-12-28	WOS:A1997WZ32300006
J	Tskhovrebova, L; Trinick, J; Sleep, JA; Simmons, RM				Tskhovrebova, L; Trinick, J; Sleep, JA; Simmons, RM			Elasticity and unfolding of single molecules of the giant muscle protein titin	NATURE			English	Article							STRIATED-MUSCLE; FIBRONECTIN; CONNECTIN; FILAMENTS; DOMAINS	The giant muscle protein titin, also called connectin, is responsible for the elasticity of relaxed striated muscle, as well as acting as the molecular scaffold for thick-filament formation(1,2). The titin molecule consists largely of tandem domains of the immunoglobulin and fibronectin-III types, together with specialized binding regions and a putative elastic region, the PEVK domain(3). We have done mechanical experiments on single molecules of titin to determine their visco-elastic properties, using an optical-tweezers technique. On a fast (0.1s) timescale tit in is elastic and force-extension data can be fitted with standard random-coil polymer models, showing that there are two main sources of elasticity: one deriving from the entropy of straightening the molecule; the other consistent with extension of the polypeptide chain in the PEVK region. On a slower timescale and above a certain force threshold, the molecule displays stress-relaxation, which occurs in rapid steps of a few piconewtons, corresponding to yielding of internal structures by about 20 nm. This stress-relaxation probably derives from unfolding of immunoglobulin and fibronectin domains.	UNIV LONDON KINGS COLL,MRC,MUSCLE & CELL MOTIL UNIT,RANDALL INST,LONDON WC2B 5RL,ENGLAND; UNIV BRISTOL,DEPT VET CLIN SCI,MUSCLE RES GRP,BRISTOL BS18 7DY,AVON,ENGLAND	University of London; King's College London; University of Bristol								ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; FIXMAN M, 1973, J CHEM PHYS, V58, P1564, DOI 10.1063/1.1679396; FLORY PJ, 1989, STAT MECH CHAIN MOL, P316; Fong S, 1996, J MOL BIOL, V264, P624, DOI 10.1006/jmbi.1996.0665; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; Gautel M, 1996, FEBS LETT, V385, P11, DOI 10.1016/0014-5793(96)00338-9; HIGUCHI H, 1993, BIOPHYS J, V65, P1906, DOI 10.1016/S0006-3495(93)81261-X; KELLERMAYER MS, IN PRESS SCIENCE; Kellermayer MSZ, 1996, BIOCHEM BIOPH RES CO, V221, P491, DOI 10.1006/bbrc.1996.0624; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Linke WA, 1996, J MUSCLE RES CELL M, V17, P425, DOI 10.1007/BF00123359; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; LITVINOVICH SV, 1992, BIOCHIM BIOPHYS ACTA, V1119, P57, DOI 10.1016/0167-4838(92)90234-5; MARUYAMA K, 1994, BIOPHYS CHEM, V50, P73, DOI 10.1016/0301-4622(94)85021-6; Plaxco KW, 1996, P NATL ACAD SCI USA, V93, P10703, DOI 10.1073/pnas.93.20.10703; POLITOU AS, 1994, BIOCHEMISTRY-US, V33, P4730, DOI 10.1021/bi00181a604; Politou AS, 1995, BIOPHYS J, V69, P2601, DOI 10.1016/S0006-3495(95)80131-1; RIEF M, IN PRESS SCIENCE; Simmons RM, 1996, BIOPHYS J, V70, P1813, DOI 10.1016/S0006-3495(96)79746-1; SOTERIOU A, 1993, P ROY SOC B-BIOL SCI, V254, P83, DOI 10.1098/rspb.1993.0130; SOTERIOU A, 1993, J CELL SCI, V104, P119; Trinick J, 1996, CURR BIOL, V6, P258, DOI 10.1016/S0960-9822(02)00472-4; Tskhovrebova L, 1997, J MOL BIOL, V265, P100, DOI 10.1006/jmbi.1996.0717; WANG K, 1993, BIOPHYS J, V64, P1161, DOI 10.1016/S0006-3495(93)81482-6; WHITING A, 1989, J MOL BIOL, V205, P263, DOI 10.1016/0022-2836(89)90381-1	25	640	647	1	79	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					308	312		10.1038/387308a0	http://dx.doi.org/10.1038/387308a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153398				2022-12-28	WOS:A1997WZ16700059
J	Manski, TJ; Heffner, DK; Glenn, GM; Patronas, NJ; Pikus, AT; Katz, D; Lebovics, R; Sledjeski, K; Choyke, PL; Zbar, B; Linehan, WM; Oldfield, EH				Manski, TJ; Heffner, DK; Glenn, GM; Patronas, NJ; Pikus, AT; Katz, D; Lebovics, R; Sledjeski, K; Choyke, PL; Zbar, B; Linehan, WM; Oldfield, EH			Endolymphatic sac tumors - A source of morbid hearing loss in von Hippel-Lindau disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MIDDLE-EAR; SUPPRESSOR GENE; TEMPORAL BONE; PAPILLARY CYSTADENOMA; ADENOCARCINOMA; ADENOMA; IDENTIFICATION; MUTATIONS; ORIGIN	Objectives.-Isolated reports suggest a possible association of endolymphatic sac tumors (ELSTs), which are extremely rare in the general population, with von Hippel-Lindau disease (VHL). To determine if hearing loss and ELSTs are a component of VHL, we examined prevalence, clinical presentation, and natural history of hearing loss and ELSTs in VHL. Design.-Brain magnetic resonance images (MRIs) from 374 patients screened for VHL were reviewed for evidence of ELSTs. The VHL patients with MRI evidence suggestive of ELSTs or a history of hearing loss, tinnitus, or vertigo underwent additional radiologic and audiologic evaluations. To further assess prevalence of hearing loss and ELST in VHL, the next 66 patients screened in the VHL clinic (49 with proven VHL, 17 at risk for VHL) received MRI and audiologic assessment, Setting.-Referral center. Participants.-Study subjects comprised 374 persons screened for VHL, 66 consecutive patients with VHL or at risk for VHL, 4 patients with 6 ELSTs, and 13 previously reported patients with VHL and invasive tumors of the temporal bone. Intervention.-Magnetic resonance image and computed tomographic (CT) scan of the posterior fossa and audiologic assessment. Main Outcome Measures.-Any ELST visible on MRI or CT and hearing loss compatible with ELST. Results.-Magnetic resonance imaging revealed evidence of 15 ELSTs in 13 (11%) of 121 patients with VHL, but in none of the 253 patients without evidence of VHL (P<.001), Clinical findings in these 13 patients included hearing toss (13), tinnitus (12), vertigo (8), and facial paresis (1). Mean age al onset of hearing loss was 22 years (range, 12-50 years). Hearing for pure tones was abnormal in all affected ears and in 6 of the 11 additional, allegedly unaffected ears. In 8 patients (62%), hearing loss was the first manifestation of VHL. Presence or absence of hearing loss was associated with duration of symptoms (P<.002) and with tumor size (P<.01). Further, 43 (65%) of the 66 patients from the VHL clinic had pure tone threshold abnormalities, abnormalities that occurred bilaterally in 23 (54%) of the 43 affected subjects; however, evidence is lacking for a definitive association with ELST (3 [6%] of 49 patients with proven VHL had ELST evident on MRI). Conclusions.-Hearing loss and ELSTs are frequently associated with VHL syndrome and should be considered when screening individuals at risk for VHL and when monitoring patients with an established diagnosis of VHL. Many patients with VHL have hearing loss without radiographic evidence of an ELST. Whether it is caused by an ELST that is too small to be detected by MRI or is produced by some other etiology is still unknown. Audiologic evaluation and MRI should allow early detection and enhance management of hearing loss in these patients.	NINCDS, SURG NEUROL BRANCH, NIH, BETHESDA, MD 20892 USA; NATL NAVAL MED CTR, DEPT NEUROSURG, BETHESDA, MD 20889 USA; ARMED FORCES INST PATHOL, DEPT OTOLARYNG PATHOL, BETHESDA, MD USA; NCI, GENET EPIDEMIOL BRANCH, DIV CANC EPIDEMIOL & GENET, BETHESDA, MD 20892 USA; NIH, DEPT RADIOL, HENRY M JACKSON FDN, WARREN GRANT MAGNUSON CLIN CTR, BETHESDA, MD 20892 USA; NATL INST DEAFNESS & OTHER COMMUN DISORDERS, NEUROOTOL BRANCH, BETHESDA, MD USA; NINCDS, OFF CLIN DIRECTOR, BETHESDA, MD 20892 USA; NCI, PATHOL LAB, BETHESDA, MD 20892 USA; NCI, IMMUNOBIOL LAB, DIV CANC BIOL DIAG & CTR, FREDERICK CANC RES FACIL, BETHESDA, MD 20892 USA; NCI, UROL ONCOL BRANCH,CLIN ONCOL PROGRAM, DIV CANC THERAPY,NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Walter Reed National Military Medical Center; United States Department of Defense; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANSON BJ, 1970, ANN OTO RHINOL LARYN, V79, P710, DOI 10.1177/000348947007900404; ANSON BJ, 1969, ARCH OTOLARYNGOL, V89, P70; ANSON BJ, 1968, ANN OTO RHINOL LARYN, V77, P588; BENECKE JE, 1990, AM J OTOL, V11, P20; BLAMIRES TL, 1992, EYE, V6, P90, DOI 10.1038/eye.1992.18; BLAMIRES TL, 1992, J LARYNGOL OTOL, V106, P429, DOI 10.1017/S0022215100119747; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CHRISTOFERSON L, 1961, JAMA-J AM MED ASSOC, V178, P280, DOI 10.1001/jama.1961.03040420020005; CILLUFFO JM, 1981, J NEUROSURG, V55, P952, DOI 10.3171/jns.1981.55.6.0952; Donaldson J, 1992, SURG ANATOMY TEMPORA; Donaldson JA, 1991, OTOLARYNGOLOGY, P23; EBY TL, 1988, ANN OTO RHINOL LARYN, V97, P605, DOI 10.1177/000348948809700606; Freedman Steven F., 1992, Ear Nose and Throat Journal, V71, P655; GLENN GM, 1990, PROBL UROL, V4, P312; GUSSEN R, 1971, LARYNGOSCOPE, V81, P1695; HASSARD AD, 1984, J OTOLARYNGOL, V13, P213; HEFFNER DK, 1989, CANCER, V64, P2292, DOI 10.1002/1097-0142(19891201)64:11<2292::AID-CNCR2820641119>3.0.CO;2-#; Jefferson G, 1931, BRIT J SURG, V19, P55, DOI 10.1002/bjs.1800197307; JUHN SK, 1991, OTOLARYNGOLOGY, P523; KANNO H, 1994, CANCER RES, V54, P4845; KERR D, 1992, J NEUROPATH EXP NEUR, V51, P367; KRANES A, 1966, NEW ENGL J MED, V275, P950, DOI 10.1056/NEJM196610272751710; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LAURITSEN JG, 1973, ACTA CHIR SCAND, V139, P482; LAWRENCE M, 1969, ARCH OTOLARYNGOL, V89, P85; Lawrence M., 1991, OTOLARYNGOLOGY, P199; LI JC, 1993, LARYNGOSCOPE, V103, P1342; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; LO WWM, 1993, RADIOLOGY, V189, P199, DOI 10.1148/radiology.189.1.8372194; LO WWM, 1993, AM J NEURORADIOL, V14, P1322; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; MEYER JR, 1993, AM J NEURORADIOL, V14, P1319; MEYER JS, 1964, CANCER, V17, P1241, DOI 10.1002/1097-0142(196410)17:10<1241::AID-CNCR2820171004>3.0.CO;2-Y; Michaels, 1987, EAR NOSE THROAT HIST; NADOL JB, 1993, NEW ENGL J MED, V329, P1092, DOI 10.1056/NEJM199310073291507; PALLANCH JF, 1982, LARYNGOSCOPE, V92, P47; PALMER JM, 1989, OTOLARYNG HEAD NECK, V100, P64, DOI 10.1177/019459988910000110; POE DS, 1993, OTOLARYNG HEAD NECK, V108, P80, DOI 10.1177/019459989310800112; PRICE EB, 1971, ARCH PATHOL, V91, P456; PYESMITH PH, 1884, T PATHOL SOC LOND, V36, P17; RENGACHARY SS, 1985, NEUROSURGERY, P50; Schuknecht H.F., 1974, PATHOLOGY EAR; THOMAS CB, 1993, SURG PATHOL, V5, P63; VIGNAUD J, 1986, EAR DIAGNOSTIC IMAGI, P8	44	186	192	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	1997	277	18					1461	1466		10.1001/jama.277.18.1461	http://dx.doi.org/10.1001/jama.277.18.1461			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX852	9145719				2022-12-28	WOS:A1997WX85200031
J	Eke, T; Bates, AK; Carr, S				Eke, T; Bates, AK; Carr, S			Acute angle closure glaucoma associated with paroxetine	BRITISH MEDICAL JOURNAL			English	Article									LEICESTER ROYAL INFIRM,DRUG INFORMAT CTR,LEICESTER LE1 5WW,LEICS,ENGLAND	University of Leicester	Eke, T (corresponding author), TAUNTON & SOMERSET HOSP,DEPT OPHTHALMOL,TAUNTON TA1 5HT,SOMERSET,ENGLAND.							BRILEY M, 1993, CLIN NEUROPHARMACOL, V16, P387, DOI 10.1097/00002826-199310000-00002; BRION N, 1985, THERAPIE, V40, P9; KRAMER R, 1973, J PHARM PHARMACOL, V25, P575, DOI 10.1111/j.2042-7158.1973.tb09161.x; Osborne Neville N., 1994, Acta Neurobiologiae Experimentalis (Warsaw), V54, P57; *SMITK BEECH PHARM, 1996, ABPI DAT SHEET COMP, P1739	5	43	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1387	1387						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ169	9161312				2022-12-28	WOS:A1997WZ16900029
J	Skjaerven, R; Wilcox, AJ; Oyen, N; Magnus, P				Skjaerven, R; Wilcox, AJ; Oyen, N; Magnus, P			Mothers' birth weight and survival of their offspring: Population based study	BRITISH MEDICAL JOURNAL			English	Article							GESTATIONAL-AGE; PERINATAL-MORTALITY; GENERATIONS; GROWTH	Objective: To test the hypothesis that a baby's survival is related to the mother's birth weight. Design: Population based dataset for two generations. Setting: Population registry in Norway. Subjects: All birth records for women born in Norway since 1967 were linked to births during 1981-94, thereby forming 105 104 mother-offspring units. Main outcome measures: Perinatal mortality specific for weight for offspring in groups of maternal birth weight (with 500 g categories in both). Results: A mother's birth weight was strongly associated with the weight of her baby. Maternal birth weight was associated with perinatal survival of her baby only for mothers with birth weights under 2000 g. These mothers were more likely to lose a baby in the perinatal period (odds ratio 2.3, 95% confidence interval 1.4 to 3.7). Among mothers with a birth weight over 2000 g there was no overall association between mother's weight and infant survival. There was, however, a strong interaction between mother's birth weight, infant birth weight, and infant survival. Mortality among small babies was much higher for those whose mothers had been large at birth. For example, babies weighing 2500-2999 g had a threefold higher mortality if their mother's birth weight had been high (greater than or equal to 4000 g) than if the mother had been small (2500-2999 g). Conclusion: Mothers who weighed less than 2000 g at birth have a higher risk of losing their own babies. For mothers who weighed greater than or equal to 2000 g their birth weight provides a benchmark for judging the growth of their offspring. Babies who are small relative to their mother's birth weight are at increased risk of mortality.	NIEHS,EPIDEMIOL BRANCH,RES TRIANGLE PK,NC 27709; UNIV BERGEN,DEPT PUBL HLTH & PRIMARY HLTH CARE,N-5021 BERGEN,NORWAY; NATL INST PUBL HLTH,DEPT EPIDEMIOL,N-0403 OSLO,NORWAY	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Bergen	Skjaerven, R (corresponding author), UNIV BERGEN,MED INFORMAT & STAT SECT,ARMAUER HANSENS BLDG,N-5021 BERGEN,NORWAY.		Wilcox, Allen J/C-7723-2019	Wilcox, Allen J/0000-0002-3376-1311				Alberman E, 1992, Paediatr Perinat Epidemiol, V6, P134, DOI 10.1111/j.1365-3016.1992.tb00755.x; BAKKETEIG LS, 1983, ACTA OBSTET GYN SCAN, V62, P385, DOI 10.3109/00016348309154207; BAKKETEIG LS, 1986, EARLY HUM DEV, V14, P187, DOI 10.1016/0378-3782(86)90180-5; Barker DJP, 1992, FETAL INFANT ORIGINS; BILLEWICZ WZ, 1973, J OBSTET GYN BR COMM, V80, P491; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; CAWLEY RH, 1954, AM J HUM GENET, V6, P448; DIXON WJ, 1992, BMDP STATISTICAL SOF, V2; EMANUEL I, 1992, BRIT J OBSTET GYNAEC, V99, P67, DOI 10.1111/j.1471-0528.1992.tb14396.x; HACKMAN E, 1983, JAMA-J AM MED ASSOC, V250, P2016, DOI 10.1001/jama.250.15.2016; KLEBANOFF MA, 1984, JAMA-J AM MED ASSOC, V252, P2423, DOI 10.1001/jama.252.17.2423; Little R E, 1987, Paediatr Perinat Epidemiol, V1, P19, DOI 10.1111/j.1365-3016.1987.tb00084.x; MAGNUS P, 1984, CLIN GENET, V25, P15; MAGNUS P, 1993, ANN HUM BIOL, V20, P231, DOI 10.1080/03014469300002662; MAGNUS P, 1984, CLIN GENET, V26, P397; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PARKER DJP, 1994, MOTHERS BABIES DIS L; SANDERSON M, 1995, PAEDIATR PERINAT EP, V9, P391, DOI 10.1111/j.1365-3016.1995.tb00162.x; SKJAERVEN R, 1988, INT J EPIDEMIOL, V17, P830, DOI 10.1093/ije/17.4.830; Skjaerven R, 1989, Paediatr Perinat Epidemiol, V3, P432, DOI 10.1111/j.1365-3016.1989.tb00531.x; SMITH DM, 1996, 96192 U LANC DEP MAT; *STAT SCI, 1995, S PLUS GUID STAT MAT; Wang XB, 1995, NEW ENGL J MED, V333, P1744, DOI 10.1056/NEJM199512283332606; WILCOX AJ, 1986, INT J EPIDEMIOL, V15, P188, DOI 10.1093/ije/15.2.188; WILCOX AJ, 1983, EARLY HUM DEV, V8, P189, DOI 10.1016/0378-3782(83)90001-4	25	55	55	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1376	1380						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ169	9161309	Green Published			2022-12-28	WOS:A1997WZ16900023
J	Zhang, PM; Liegeois, NJ; Wong, C; Finegold, M; Hou, H; Thompson, JC; Silverman, A; Harper, JW; DePinho, RA; Elledge, SJ				Zhang, PM; Liegeois, NJ; Wong, C; Finegold, M; Hou, H; Thompson, JC; Silverman, A; Harper, JW; DePinho, RA; Elledge, SJ			Altered cell differentiation and proliferation in mice lacking p57(KIP2) indicates a role in Beckwith-Wiedemann syndrome	NATURE			English	Article							DEPENDENT KINASE INHIBITOR; DISRUPTION; PROTEIN; PALATE; TUMOR; MOUSE; GENE	Mice lacking the imprinted Cdk inhibitor p57(KIP2) have altered cell proliferation and differentiation, leading to abdominal muscle defects; cleft palate; endochondral bone ossification defects with incomplete differentiation of hypertrophic chondrocytes; renal medullary dysplasia; adrenal cortical hyperplasia and cytomegaly; and lens cell hyperproliferation and apoptosis. Many of these phenotypes are also seen in patients with Beckwith-Wiedemann syndrome, a pleiotropic hereditary disorder characterized by overgrowth and predisposition to cancer, suggesting that loss of p57(KIP2) expression may play a role in the condition.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030	Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine			Thompson, Jessica/GXW-0323-2022	DePinho, Ronald/0000-0002-5625-577X; Liegeois, Nanette/0000-0001-5002-1799; Harper, Jeffrey/0000-0002-6944-7236				BECKWITH J B, 1969, Birth Defects Original Article Series, V5, P188; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DYNLACHT BD, IN PRESS METHODS ENZ; ELLIOTT M, 1994, CLIN GENET, V46, P168; FERGUSON MWJ, 1988, DEVELOPMENT, V103, P41; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HEPINSTALL RH, 1992, PATHOLOGY KIDNEY, V1, P114; Hoovers JMN, 1995, P NATL ACAD SCI USA, V92, P12456, DOI 10.1073/pnas.92.26.12456; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; Junien C, 1992, CURR OPIN GENET DEV, V2, P431, DOI 10.1016/S0959-437X(05)80154-6; Kaufman M.H., 1992, ATLAS MOUSE DEV; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MCAVOY JW, 1996, DIFFERENTIATION, V17, P137; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOTELOAVILA C, 1980, J PEDIATR-US, V96, P47, DOI 10.1016/S0022-3476(80)80322-2; TAKATO T, 1989, ANN PLAS SURG, V22, P347, DOI 10.1097/00000637-198904000-00011; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; WIEDEMANN HR, 1983, EUR J PEDIATR, V141, P129, DOI 10.1007/BF00496807	33	618	641	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					151	158		10.1038/387151a0	http://dx.doi.org/10.1038/387151a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144284				2022-12-28	WOS:A1997WX94500046
J	Tingle, AJ; Mitchell, LA; Grace, M; Middleton, P; Mathias, R; MacWilliam, L; Chalmers, A				Tingle, AJ; Mitchell, LA; Grace, M; Middleton, P; Mathias, R; MacWilliam, L; Chalmers, A			Randomised double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women	LANCET			English	Article							RHEUMATOID-ARTHRITIS; PROLONGED ARTHRITIS; VIRUS INFECTION; JOINT REACTIONS; VACCINE; IMMUNIZATION; ASSOCIATION; VIREMIA	Background The objective of our study was to investigate the association of adverse clinical musculoskeletal and neurological events in healthy postpartum women with live attenuated (RA27/3 strain) rubella-virus vaccine, and to assess the frequency of acute and recurrent arthralgia and arthritis and associations with acute and recurrent muscle pain (myalgia) and neurological manifestations (paraesthesias). Methods We used a randomised placebo-controlled, double-blind design in a community setting. 636 women were enrolled and, after 90 women dropped out, 546 healthy women aged 18-41 years, who were rubella seronegative on routine screening were immunised parenterally with either monovalent live attenuated (RA27/3 strain) rubella vaccine (n=270) or saline placebo (n=276) in the postpartum period. Outcome measures were the occurrence of acute and persistent or recurrent joint manifestations (arthralgia or arthritis) at 1, 3, 6, 9, and 12 months after immunisation. Occurrence of muscle pain (myalgia), and neurological symptoms (paraesthesia) was also assessed at the same times. Findings 543 women completed 1-month follow-up, 456 women completed the 12-month assessment. There were no differences at the time of immunisation between rubella vaccine and placebo groups in distribution of age, ethnic origin, parity, time between delivery and immunisation, breastfeeding history, or histories of earlier rubella vaccination or joint complaints. Results indicated a significantly higher incidence (p=0.006; odds ratio=1.73 [95% CI=1.17-2.57]) of acute joint manifestations in rubella-vaccine recipients (30%) than in placebo recipients (20%). Frequency of chronic (recurrent) arthralgia or arthritis was only marginally significant (p=0.042; 1.58 [1.01-2.45]). Interpretation RA27/3 rubella vaccine given to seronegative women during the postpartum period was significantly associated with development of acute arthralgia or arthritis. Although the numbers of women assessed and length of follow-up revealed only marginally significant differences in persistent or recurrent joint manifestations between rubella vaccine and placebo recipients, it is possible that susceptible women who are given rubella vaccination may experience this outcome.	UNIV BRITISH COLUMBIA,DEPT PAEDIAT,VANCOUVER,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PATHOL,VANCOUVER,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC,CANADA; UNIV ALBERTA,DEPT ORAL HLTH SCI & SURG,EDMONTON,AB,CANADA; CTR DIS CONTROL,VANCOUVER,BC,CANADA; BRITISH COLUMBIA INST CHILD & FAMILY HLTH,CTR EVALUAT STUDIES,VANCOUVER,BC V5Z 4H4,CANADA	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of Alberta; Child & Family Research Institute								ALLEN AD, 1988, MED HYPOTHESES, V27, P217, DOI 10.1016/0306-9877(88)90146-6; BARNES EK, 1972, AM J EPIDEMIOL, V95, P59, DOI 10.1093/oxfordjournals.aje.a121371; CHANTLER JK, 1985, NEW ENGL J MED, V313, P1117, DOI 10.1056/NEJM198510313131803; COOPER LZ, 1969, AM J DIS CHILD, V118, P218, DOI 10.1001/archpedi.1969.02100040220011; CUTOLO M, 1991, CLIN EXP RHEUMATOL, V9, P641; Gutierrez MA, 1996, INT ARCH ALLERGY IMM, V109, P229, DOI 10.1159/000237242; HART H, 1977, ARTHRITIS RHEUM, V5, P378; HORSTMANN DM, 1970, LANCET, V2, P1003; HOWSON CP, 1992, CLIN INFECT DIS, V15, P307, DOI 10.1093/clinids/15.2.307; Howson CP, 1991, ADVERSE EFFECTS PERT; JANSSON R, 1987, CLIN EXP IMMUNOL, V70, P68; KLINKHOFF AV, 1988, J RHEUMATOL, V15, P492; LEE P R, 1960, Calif Med, V93, P125; LEE PR, 1962, BRIT MED J, P925; LERMAN SJ, 1971, ANN INTERN MED, V74, P67, DOI 10.7326/0003-4819-74-1-67; MARTENIS TW, 1968, ARTHRITIS RHEUM, V11, P683, DOI 10.1002/art.1780110511; OGRA PL, 1975, LANCET, V1, P1157; PELTOLA H, 1986, LANCET, V1, P939; POLK BF, 1982, AM J EPIDEMIOL, V115, P19, DOI 10.1093/oxfordjournals.aje.a113276; RAY P, 1994, 34 INT C ANT AG CHEM; SLATER PE, 1995, VACCINE, V13, P1529, DOI 10.1016/0264-410X(95)00096-J; SPRUANCE SL, 1971, AM J DIS CHILD, V122, P105, DOI 10.1001/archpedi.1971.02110020039002; SWARTZ TA, 1971, AM J EPIDEMIOL, V94, P245; THOMPSON GR, 1971, ARTHRITIS RHEUM, V14, P19, DOI 10.1002/art.1780140104; THOMPSON GR, 1973, AM J DIS CHILD, V125, P526, DOI 10.1001/archpedi.1973.04160040040008; TINGLE AJ, 1983, INFECT IMMUN, V40, P22, DOI 10.1128/IAI.40.1.22-28.1983; TINGLE AJ, 1979, ANN INTERN MED, V90, P203, DOI 10.7326/0003-4819-90-2-203; TINGLE AJ, 1985, J INFECT DIS, V152, P606, DOI 10.1093/infdis/152.3.606; TINGLE AJ, 1979, ARTHRITIS RHEUM, V22, P400, DOI 10.1002/art.1780220414; TINGLE AJ, 1986, ANN RHEUM DIS, V45, P110, DOI 10.1136/ard.45.2.110; TINGLE AJ, 1984, LANCET, V1, P1475; VALENSIN PE, 1987, VACCINE, V5, P289, DOI 10.1016/0264-410X(87)90154-X; WALLACE RB, 1972, AM J PUBLIC HEALTH N, V62, P658, DOI 10.2105/AJPH.62.5.658; WEIBEL RE, 1980, P SOC EXP BIOL MED, V165, P44, DOI 10.3181/00379727-165-40931; WEIBEL RE, 1972, J AMER MED ASSOC, V222, P805, DOI 10.1001/jama.222.7.805	35	54	54	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1277	1281		10.1016/S0140-6736(96)12031-6	http://dx.doi.org/10.1016/S0140-6736(96)12031-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142061				2022-12-28	WOS:A1997WW89900008
J	Fears, R; Ferguson, MWJ; Stewart, W; Poste, G				Fears, R; Ferguson, MWJ; Stewart, W; Poste, G			Life-sciences R&D, national prosperity, and industrial competitiveness	SCIENCE			English	Editorial Material									UNIV MANCHESTER,MANCHESTER M13 9PT,LANCS,ENGLAND; BIOIND ASSOC,LONDON SW1X 8PS,ENGLAND	University of Manchester	Fears, R (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,RES & DEV,NEW FRONTIERS SCI PK,HARLOW CM19 5AW,ESSEX,ENGLAND.							ANDERSON J, 1996, VALUING EVALUATING A; Bush, 1945, SCI THE ENDLESS FRON, DOI DOI 10.1016/j.techsoc.2019.03.007; BUXTON M, 1994, ASSESSING PAYBACK DE; BYERLY R, 1995, SCIENCE, V269, P1531, DOI 10.1126/science.269.5230.1531; *DEP TRAD IND, 1995, 1995 UK R D SCOR; DRILHON G, 1995, OECD OBS, V196, P28; EVANS G, 1995, PUBLIC UNDERST SCI, V0004; FEARS R, 1995, SCI TECHNOL INNOVATI, V8, P26; GIBBONS M., 1994, NEW PRODUCTION KNOWL; JENKINS B, 1995, MISSING LINK CITY SC; Macintyre S., 1995, PUBLIC UNDERST SCI, V4, P223, DOI DOI 10.1088/0963-6625/4/3/001; Myners Paul, 1995, DEV WINNING PARTNERS; *OFF SCI TECHN, 1995, PROGR PARTN; SMITH R, 1995, BRIT MED J, V311, P961; *TECHN FOR PAN HLT, 1995, PROGR PARTN; VARMUS H, 1995, NEW ENGL J MED, V333, P811, DOI 10.1056/NEJM199509213331224; [No title captured]	17	2	2	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					759	760		10.1126/science.276.5313.759	http://dx.doi.org/10.1126/science.276.5313.759			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9157555				2022-12-28	WOS:A1997WW90000047
J	Khan, WA; Seas, C; Dhar, U; Salam, MA; Bennish, ML				Khan, WA; Seas, C; Dhar, U; Salam, MA; Bennish, ML			Treatment of shigellosis .5. Comparison of azithromycin and ciprofloxacin - A double-blind, randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							SINGLE-DOSE AZITHROMYCIN; TRIMETHOPRIM-SULFAMETHOXAZOLE; NALIDIXIC-ACID; DYSENTERIAE TYPE-1; ENTERIC PATHOGENS; INVITRO ACTIVITY; AMPICILLIN; THERAPY; NORFLOXACIN; BANGLADESH	Background: Treatment of shigellosis is currently limited by the high prevalence of multidrug-resistant strains of Shigella. Objective: To determine the efficacy of azithromycin in the treatment of shigellosis. Design: Randomized, double-blind clinical trial. Setting: Diarrhea treatment center in Dhaka, Bangladesh. Patients: 70 men with shigellosis that had lasted 72 hours or less. Interventions: Patients stayed in the hospital for 6 days. Thirty-four patients were randomly assigned to receive 500 mg of azithromycin on study day 1, followed by 250 mg once daily for 4 days; 36 patients were assigned to receive 500 mg of ciprofloxacin every 12 hours for 5 days. Measurements: Clinical treatment failure was considered to have occurred if frank dysentery persisted for 72 hours after therapy began or if on study day 5 a patient had more than six stools, had any bloody-mucoid stools, had more than one watery stool, or had an oral body temperature exceeding 37.8 degrees C. Bacteriologic treatment failure was considered to have occurred if Shigella strains could be isolated from a stool sample after study day 2. Therapy was considered either clinically or bacteriologically successful in patients who completed therapy and did not meet criteria for failure. Results: Therapy was clinically successful in 28 (82%) patients who received azithromycin and 32 (89%) patients who received ciprofloxacin (difference, -7% [95% CI, -23% to 10%]). Therapy was bacteriologically successful in 32 (94%) patients receiving azithromycin and 36 (100%) patients receiving ciprofloxacin (difference. -6% [CI, -14% to 2%]). Peak serum concentrations of azithromycin were equal to the minimum inhibitory concentration (MIG) of the infecting Shigella strains, whereas serum concentrations of ciprofloxacin were 28 times the MIG. Stool concentrations of both drugs were more than 200 times the MIG. Conclusion: Azithromycin is effective in the treatment of moderate to severe shigellosis caused by multidrug-resistant Shigella strains.	TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; INT CTR DIARRHOEAL DIS RES, DHAKA 1000, BANGLADESH; UNIV PERUANA CAYETANO HEREDIA, INST MED TROP ALEXANDER VON HUMBOLDT, LIMA, PERU	Tufts Medical Center; International Centre for Diarrhoeal Disease Research (ICDDR); Universidad Peruana Cayetano Heredia				Seas, Carlos/0000-0001-7067-9141				BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9; BASSILY S, 1994, AM J TROP MED HYG, V51, P219, DOI 10.4269/ajtmh.1994.51.219; BELLAMY C, 1997, STATE WORLDS CHILDRE, V80; Bennish Michael L., 1995, P1499; BENNISH ML, 1990, J INFECT DIS, V162, P711, DOI 10.1093/infdis/162.3.711; BENNISH ML, 1992, ANN INTERN MED, V117, P727, DOI 10.7326/0003-4819-117-9-727; BENNISH ML, 1992, CLIN INFECT DIS, V14, P1055, DOI 10.1093/clinids/14.5.1055; BENNISH ML, 1991, REV INFECT DIS, V13, pS245; BHATTACHARYA SK, 1991, AM J TROP MED HYG, V45, P683, DOI 10.4269/ajtmh.1991.45.683; DEMOL P, 1987, J ANTIMICROB CHEMOTH, V19, P695, DOI 10.1093/jac/19.5.695; FOULDS G, 1993, J ANTIMICROB CHEMOTH, V31, P39, DOI 10.1093/jac/31.suppl_E.39; GILMAN RH, 1981, J INFECT DIS, V143, P164, DOI 10.1093/infdis/143.2.164; GLADUE RP, 1990, ANTIMICROB AGENTS CH, V34, P1056, DOI 10.1128/AAC.34.6.1056; GLADUE RP, 1989, ANTIMICROB AGENTS CH, V33, P277, DOI 10.1128/AAC.33.3.277; GLASS RI, 1983, J INFECT DIS, V148, P292, DOI 10.1093/infdis/148.2.292; GORDILLO ME, 1993, ANTIMICROB AGENTS CH, V37, P1203, DOI 10.1128/AAC.37.5.1203; GOTUZZO E, 1989, ANTIMICROB AGENTS CH, V33, P1101, DOI 10.1128/AAC.33.7.1101; GROB PR, 1992, SCAND J INFECT DIS, P7; HALTALIN KC, 1968, J PEDIATR-US, V72, P708, DOI 10.1016/S0022-3476(68)80021-6; HALTALIN KC, 1972, AM J DIS CHILD, V123, P40, DOI 10.1001/archpedi.1972.02110070090011; HOPKINS S, 1993, J ANTIMICROB CHEMOTH, V31, P111, DOI 10.1093/jac/31.suppl_E.111; JONES K, 1988, DRUG EXP CLIN RES, V14, P613; KABIR I, 1984, ANTIMICROB AGENTS CH, V25, P643, DOI 10.1128/AAC.25.5.643; KEUSCH GT, 1991, BACTERIAL INFECTIONS, P593; KUSCHNER RA, 1995, CLIN INFECT DIS, V21, P536, DOI 10.1093/clinids/21.3.536; MANDELL GL, 1994, CLIN INFECT DIS, V19, P922, DOI 10.1093/clinids/19.5.922; MARTIN DH, 1992, NEW ENGL J MED, V327, P921, DOI 10.1056/NEJM199209243271304; Murphy GS, 1996, CLIN INFECT DIS, V22, P868, DOI 10.1093/clinids/22.5.868; NELSON JD, 1975, ANTIMICROB AGENTS CH, V7, P415, DOI 10.1128/AAC.7.4.415; ORENSTEIN WA, 1981, AM J MED SCI, V282, P27, DOI 10.1097/00000441-198107000-00004; QUINTILIANI R, 1994, INFECT DIS CLIN PRAC, V3, P1, DOI 10.1097/00019048-199401000-00001; RIES AA, 1994, J INFECT DIS, V169, P1035, DOI 10.1093/infdis/169.5.1035; ROGERIE F, 1986, ANTIMICROB AGENTS CH, V29, P883, DOI 10.1128/AAC.29.5.883; SALAM MA, 1988, J PEDIATR-US, V113, P901, DOI 10.1016/S0022-3476(88)80029-5; SALAM MA, 1995, ANN INTERN MED, V123, P505, DOI 10.7326/0003-4819-123-7-199510010-00005; SALAM MA, 1991, REV INFECT DIS, V13, pS332; SCHAAD UB, 1995, PEDIATR INFECT DIS J, V14, P1, DOI 10.1097/00006454-199501000-00001; TOOLE MJ, 1995, LANCET, V345, P339, DOI 10.1016/S0140-6736(95)90338-0; TYNDALL MW, 1994, SEX TRANSM DIS, V21, P231, DOI 10.1097/00007435-199407000-00010	39	125	127	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1997	126	9					697	703		10.7326/0003-4819-126-9-199705010-00004	http://dx.doi.org/10.7326/0003-4819-126-9-199705010-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW147	9139555				2022-12-28	WOS:A1997WW14700004
J	McWhinney, IR; Epstein, RM; Freeman, TR				McWhinney, IR; Epstein, RM; Freeman, TR			Rethinking somatization	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY CARE; MODEL		UNIV ROCHESTER, DEPT FAMILY MED & PSYCHIAT, ROCHESTER, NY 14620 USA; BYRON FAMILY MED CTR, LONDON, ON N6K 1C7, CANADA	University of Rochester	McWhinney, IR (corresponding author), UNIV WESTERN ONTARIO, CTR STUDIES FAMILY MED, LONDON, ON N6A 3K7, CANADA.			Freeman, Tom/0000-0002-2284-3442				American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BARON RJ, 1985, ANN INTERN MED, V103, P606, DOI 10.7326/0003-4819-103-4-606; BRIDGES KW, 1985, J PSYCHOSOM RES, V29, P563, DOI 10.1016/0022-3999(85)90064-9; BROWN TM, 1989, PSYCHOSOMATICS, V30, P322, DOI 10.1016/S0033-3182(89)72280-5; CIOMPI L, 1991, BRIT J PSYCHIAT, V159, P97, DOI 10.1192/bjp.159.1.97; CROOKSHANK PF, 1926, LANCET           NOV, P939; Damasio A.R., 2005, DESCARTES ERROR EMOT; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; DUDEN B, 1991, DOCTORS PATIENTS 18; ENGEL GL, 1980, AM J PSYCHIAT, V137, P535; GOODNICK PJ, 1993, CHRONIC FATIGUE RELA; James William, 1950, PRINCIPLES PSYCHOL, V2; Kirmayer L. J., 1988, BIOMEDICINE EXAMINED, P57; Kirmayer Laurence J., 1991, CURRENT CONCEPTS SOM, P181; KIRMAYER LJ, 1994, CAN J PSYCHIAT, V39, P584, DOI 10.1177/070674379403901002; KIRMAYER LJ, 1991, J NERV MENT DIS, V179, P647, DOI 10.1097/00005053-199111000-00001; KIRMAYER LJ, 1991, CURRENT CONCEPTS SOM, P1; LIPKOWSKI ZJ, 1988, AM J PSYCHIAT, V145, P1358; MCDANIEL S, 1990, FAMILY ORIENTED PRIM, P248; RATHRE LJ, 1965, MIND BODY 18 CENTURY; Schur M, 1955, PSYCHOANAL STUD CHIL, V10, P119, DOI 10.1080/00797308.1955.11822553; SEABURN DB, 1995, COUNSELING FAMILIES; STEWART M, 1995, PATIENT CENTERED MED; Styron W., 1990, DARKNESS VISIBLE MEM; TYRER PJ, 1973, LANCET, P915	26	46	46	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1997	126	9					747	750		10.7326/0003-4819-126-9-199705010-00037	http://dx.doi.org/10.7326/0003-4819-126-9-199705010-00037			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WW147	9139578				2022-12-28	WOS:A1997WW14700035
J	Brown, MJ				Brown, MJ			Science, medicine, and the future - Hypertension	BRITISH MEDICAL JOURNAL			English	Review							CORONARY HEART-DISEASE; BLOOD-PRESSURE; STROKE	The abundance of drugs now available for treating hypertension, and evidence that small reductions in blood pressure reverse the associated risk of stroke have shifted clinical concerns away from hypertension. However, we do not understand the cause of hypertension in 95% of patients, fail to achieve a normal blood pressure in 50% of patients, and are unable fully to reverse the cardiac and vascular changes that predate the diagnosis and treatment of hypertension. Consequently, hypertension remains the commonest cause of strokes in Britain and of renal failure in the United States. Essential hypertension is a polygenic disease whose understanding can now be advanced through molecular genetic analyses. Several different syndromes are likely to be recognised; most will be due to interactions between genetic and environmental factors, but there are also likely to be further monogenic syndromes in families with multiple affected members. Recognition of these syndromes will permit accurate genetic prediction of prognosis and optimal treatment and perhaps lead to new and more powerful classes of antihypertensive treatment.			Brown, MJ (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,CLIN PHARMACOL UNIT,BOX 110,CAMBRIDGE CB2 2QQ,ENGLAND.							BROWN MJ, 1986, LANCET, V2, P427; Brown MJ, 1996, BRIT J CLIN PHARMACO, V42, P21, DOI 10.1046/j.1365-2125.1996.03785.x; CALVER A, 1992, J HYPERTENS, V10, P1025; Churchill D, 1997, LANCET, V349, P7, DOI 10.1016/S0140-6736(96)06297-6; COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; CUSI D, 1994, KIDNEY INT, V91, P3999; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DAVENPORT AP, 1990, CLIN SCI, V78, P261, DOI 10.1042/cs0780261; GODFREY KM, 1993, BRIT MED J, V307, P405, DOI 10.1136/bmj.307.6901.405; Hingorani AD, 1996, HYPERTENSION, V28, P907, DOI 10.1161/01.HYP.28.5.907; HINGORANI AD, IN PRESS QJ MED; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; Levy BI, 1997, J HYPERTENS, V15, P251, DOI 10.1097/00004872-199715030-00006; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Mancia G, 1997, LANCET, V349, P454, DOI 10.1016/S0140-6736(96)07099-7; *MRC WORK PART MIL, 1986, BRIT MED J, V293, P988; MULVANY MJ, 1993, J HYPERTENS, V11, pS7; Pennisi E, 1996, SCIENCE, V272, P1736, DOI 10.1126/science.272.5269.1736; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Rubattu S, 1996, NAT GENET, V13, P429, DOI 10.1038/ng0896-429; SHARMA P, 1996, CLIN SCI, V90; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; STEVENS PA, 1995, J CARDIOVASC PHARM, V26, pS9; SULIVAN JM, 1983, HYPERTENSION, V5, P844	27	23	23	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 26	1997	314	7089					1258	1261		10.1136/bmj.314.7089.1258	http://dx.doi.org/10.1136/bmj.314.7089.1258			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW718	9154032	Green Published			2022-12-28	WOS:A1997WW71800033
J	McVean, GT; Hurst, LD				McVean, GT; Hurst, LD			Evidence for a selectively favourable reduction in the mutation rate of the X chromosome	NATURE			English	Article							DRIVEN MOLECULAR EVOLUTION; DELETERIOUS MUTATIONS; SEX; NUCLEOTIDE; SUBSTITUTION; RODENTS; GENES; USAGE	The equilibrium per-genome mutation rate in sexual species is thought to result from a trade-off between the benefits of reducing the deleterious mutation rate and the costs of increasing fidelity(1,2). We propose that selection will often favour a lower mutation rate on the X chromosome than on autosomes, owing to the exposure of deleterious recessive mutations on hemizygous chromosomes. We tested this hypothesis by examining 33 X-linked genes that have been sequenced in both mouse and rat, and compared their rate of evolution against 238 autosomal genes. The X-linked genes were found to have a significantly lower rate of synonymous substitution than the autosomal genes. Neither the supposed higher mutation rate in males nor stronger purifying selection against slightly deleterious mutations on the X chromosome can account for the low value. The most parsimonious explanation is that rodents have a lower mutation rate on the X chromosome than on autosomes. It is therefore likely that previous indirect estimates of the excess male mutation rate are inaccurate. Indeed, after correction we find no evidence for a male-biased mutation rate in rodents. Furthermore, the rate of synonymous substitution in Y-linked genes is not significantly different from that in autosomal ones. The extent to which enhanced male mutation rates are problematic(3) for the mutational deterministic model(4) of the evolution of sex must, in turn, be questioned.	UNIV BATH,SCH BIOL & BIOCHEM,BATH BA2 7AY,AVON,ENGLAND	University of Bath	McVean, GT (corresponding author), UNIV CAMBRIDGE,DEPT GENET,DOWNING ST,CAMBRIDGE CB2 3EH,ENGLAND.		Hurst, Laurence/F-9215-2010	Hurst, Laurence/0000-0002-1002-1054				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bulmer M.G., 1979, PRINCIPLES STAT; CHANG BHJ, 1994, P NATL ACAD SCI USA, V91, P827, DOI 10.1073/pnas.91.2.827; CHANG BHJ, 1995, J MOL EVOL, V40, P70, DOI 10.1007/BF00166597; CHARLESWORTH B, 1987, AM NAT, V130, P113, DOI 10.1086/284701; CHARLESWORTH B, 1994, GENET RES, V63, P213, DOI 10.1017/S0016672300032365; Crow JF, 1983, GENET BIOL DROSOPHIL, P1; DRISCOLL DJ, 1990, SOMAT CELL MOLEC GEN, V16, P267, DOI 10.1007/BF01233363; EYREWALKER AC, 1991, J MOL EVOL, V33, P442, DOI 10.1007/BF02103136; *GCG, 1994, WISC PACK VERS 8 MAN; GILLESPIE JH, 1995, J MOL EVOL, V40, P64, DOI 10.1007/BF00166596; Hurst LD, 1996, TRENDS ECOL EVOL, V11, pA46; *JACKS LAB, 1996, MOUS GEN DAT 3 1 MOU; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; KETTERLING RP, 1993, AM J HUM GENET, V52, P152; KIMURA M, 1967, GENET RES, V9, P23, DOI 10.1017/S0016672300010284; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1995, GENET RES, V66, P53, DOI 10.1017/S001667230003439X; LEIGH EG, 1970, AM NAT, V104, P301, DOI 10.1086/282663; LI WH, 1985, MOL BIOL EVOL, V2, P150; LI WH, 1987, J MOL EVOL, V24, P337, DOI 10.1007/BF02134132; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; Li WH, 1996, MOL PHYLOGENET EVOL, V5, P182, DOI 10.1006/mpev.1996.0012; MIYATA T, 1987, COLD SPRING HARB SYM, V52, P863, DOI 10.1101/SQB.1987.052.01.094; OHTA T, 1993, P NATL ACAD SCI USA, V90, P10676, DOI 10.1073/pnas.90.22.10676; REDFIELD RJ, 1994, NATURE, V369, P145, DOI 10.1038/369145a0; SHARP PM, 1989, EVOLUTION ANIMAL BRE, P24; SHIMMIN LC, 1993, J MOL EVOL, V37, P160, DOI 10.1007/BF02407351; WOLFE KH, 1989, NATURE, V337, P283, DOI 10.1038/337283a0; WOLFE KH, 1993, J MOL EVOL, V37, P441, DOI 10.1007/BF00178874	30	117	117	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					388	392		10.1038/386388a0	http://dx.doi.org/10.1038/386388a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121553				2022-12-28	WOS:A1997WQ17000062
J	RodriguezEsteban, C; Schwabe, JWR; DeLaPena, J; Foys, B; Eshelman, B; Belmonte, JCI				RodriguezEsteban, C; Schwabe, JWR; DeLaPena, J; Foys, B; Eshelman, B; Belmonte, JCI			Radical fringe positions the apical ectodermal ridge at the dorsoventral boundary of the vertebrate limb	NATURE			English	Article							CHICK LIMB; DEVELOPMENTAL BIOLOGY; WING DEVELOPMENT; ADDITIONAL LIMB; SONIC-HEDGEHOG; GROWTH-FACTORS; FEEDBACK LOOP; BUD; GENE; DORSAL	Vertebrate limb outgrowth requires a structure called the apical ectodermal ridge, formation of which follows the previous establishment of the dorsoventral limb axis. Radical fringe is expressed in the dorsal ectoderm before the ridge appears, and is repressed by Engrailed-I, which is expressed in the ventral ectoderm. Misexpression of these genes indicates that a ridge is formed wherever there is a boundary between cells expressing and not expressing Radical fringe, Thus, as in Drosophila, Radical fringe positions the ridge at the dorsoventral limb boundary.	SALK INST BIOL STUDIES,GENE EXPRESS LAB,LA JOLLA,CA 92037	Salk Institute			Schwabe, John WR/A-9132-2008	Schwabe, John WR/0000-0003-2865-4383				COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; COPE LD, 1991, MOL MICROBIOL, V5, P1113, DOI 10.1111/j.1365-2958.1991.tb01884.x; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; deCelis JF, 1996, DEVELOPMENT, V122, P359; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DUBOULE D, 1994, SCIENCE, V266, P575, DOI 10.1126/science.7939709; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GARCIABELLIDO A, 1994, EUR REV, V2, P15; GILBERT SF, 1995, DEV BIOL; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Loomis CA, 1996, NATURE, V382, P360, DOI 10.1038/382360a0; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; MADEN M, 1994, NATURE, V371, P560, DOI 10.1038/371560a0; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; Marigo V, 1996, DEVELOPMENT, V122, P1225; MARTIN GR, 1995, NATURE, V374, P410, DOI 10.1038/374410a0; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; Myat A, 1996, DEV BIOL, V174, P233, DOI 10.1006/dbio.1996.0069; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; OHUCHI H, 1995, BIOCHEM BIOPH RES CO, V209, P809, DOI 10.1006/bbrc.1995.1572; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PAUTOU MP, 1973, CR ACAD SCI D NAT, V277, P1225; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; Ros MA, 1996, DEVELOPMENT, V122, P2319; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; TODT WL, 1984, J EMBRYOL EXP MORPH, V80, P21; Vogel A, 1996, DEVELOPMENT, V122, P1737; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0; Wu JY, 1996, SCIENCE, V273, P355, DOI 10.1126/science.273.5273.355; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8; ZECCA M, 1995, DEVELOPMENT, V121, P2265	51	161	164	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					360	366		10.1038/386360a0	http://dx.doi.org/10.1038/386360a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121551				2022-12-28	WOS:A1997WQ17000055
J	Kivelson, MG; Khurana, KK; Joy, S; Russell, CT; Southwood, DJ; Walker, RJ; Polanskey, C				Kivelson, MG; Khurana, KK; Joy, S; Russell, CT; Southwood, DJ; Walker, RJ; Polanskey, C			Europa's magnetic signature: Report from Galileo's pass on 19 December 1996	SCIENCE			English	Article							FIELD	On 19 December 1996 as Galileo passed close to Jupiter's moon, Europa, the magnetometer measured substantial departures from the slowly Varying background field of Jupiter's magnetosphere. Currents coupling Europa to Jupiter's magnetospheric plasma could produce perturbations of the observed size. However, the trend of the field perturbations is here modeled as the signature of a Europa-centered dipole moment whose maximum surface magnitude is similar to 240 nanotesla, giving a rough upper limit to the internal field. The dipole orientation is oblique to Europa's spin axis. This orientation may not be probable for a field generated by a core dynamo, but higher order multipoles may be important as they are at Uranus and Neptune. Although the data can be modeled as contributions of an internal field of Europa, they do not confirm its existence. The dipole orientation is also oblique to the imposed field of Jupiter and thus not directly produced as a response to that field. Close to Europa, plasma currents appear to produce perturbations with scale sizes that are smalt compared with a Europa radius.	UNIV CALIF LOS ANGELES,DEPT EARTH & SPACE SCI,LOS ANGELES,CA 90095; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT PHYS,LONDON SW7 2BZ,ENGLAND; JET PROPULS LAB,PASADENA,CA 91109	University of California System; University of California Los Angeles; Imperial College London; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Kivelson, MG (corresponding author), UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,LOS ANGELES,CA 90095, USA.		Kivelson, Margaret G/I-9019-2012; Russell, Christopher T/E-7745-2012	Kivelson, Margaret G/0000-0003-3859-8581; Russell, Christopher T/0000-0003-1639-8298; Khurana, Krishan/0000-0002-2856-1171				Anderson JD, 1996, SCIENCE, V272, P709, DOI 10.1126/science.272.5262.709; ANDERSON JD, 1997, SCIENCE, V276, P1237; CONNERNEY JEP, 1991, J GEOPHYS RES-PLANET, V96, P19023, DOI 10.1029/91JA01165; CONNERNEY JEP, 1987, J GEOPHYS RES, V92, P15329, DOI 10.1029/JA092iA13p15329; Dessler A.J., 1983, PHYS JOVIAN MAGNETOS, P498; Khurana KK, 1997, NATURE, V387, P262, DOI 10.1038/387262a0; KHURANA KK, IN PRESS J GEOPHYS R; KIVELSON MG, 1992, SPACE SCI REV, V60, P357, DOI 10.1007/BF00216862; Kivelson MG, 1996, SCIENCE, V273, P337, DOI 10.1126/science.273.5273.337; Kivelson MG, 1996, SCIENCE, V274, P396, DOI 10.1126/science.274.5286.396; Kivelson MG, 1996, NATURE, V384, P537, DOI 10.1038/384537a0; RUSSELL CB, UNPUB; Schubert G, 1996, NATURE, V384, P544, DOI 10.1038/384544a0; *UCLA I GEOPHY PLA, UCLA I GEOPH PLAN PH, V4864	14	72	73	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1239	1241		10.1126/science.276.5316.1239	http://dx.doi.org/10.1126/science.276.5316.1239			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157878				2022-12-28	WOS:A1997XA49700037
J	Deshler, JO; Highett, MI; Schnapp, BJ				Deshler, JO; Highett, MI; Schnapp, BJ			Localization of Xenopus Vg1 mRNA by vera protein and the endoplasmic reticulum	SCIENCE			English	Article							MATERNAL MESSENGER-RNA; IN-VITRO; OOCYTES; EXTRACTS; TRANSLOCATION; MICROTUBULES; EXPRESSION; ATTACHMENT; OOGENESIS; MEMBRANES	In many organisms, pattern formation in the embryo develops from the polarized distributions of messenger RNAs (mRNAs) in the egg, in Xenopus, the mRNA encoding Vg1, a growth factor involved in mesoderm induction, is localized to the vegetal cortex of oocytes. A protein named Vera was shown to be involved in Vg1 mRNA localization. Vera cofractionates with endoplasmic reticulum (ER) membranes, and endogenous Vg1 mRNA is associated with a subcompartment of the ER. Vera may promote mRNA localization in Xenopus oocytes by mediating an interaction between the Vg1 3' untranslated region and the ER subcompartment.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016114] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026846] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM16114-03] Funding Source: Medline; NINDS NIH HHS [NS-26846] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; ALLAN V, 1995, J CELL BIOL, V128, P879, DOI 10.1083/jcb.128.5.879; ALLAN V, 1994, J CELL SCI, V107, P1885; BANERJEE U, 1987, CELL, V49, P281, DOI 10.1016/0092-8674(87)90569-1; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; DALE L, 1989, EMBO J, V8, P1057, DOI 10.1002/j.1460-2075.1989.tb03473.x; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; KLOC M, 1995, DEVELOPMENT, V121, P287; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MOURY KL, 1997, P NATL ACAD SCI USA, V93, P14608; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; SCHWARTZ SP, 1992, P NATL ACAD SCI USA, V89, P11895, DOI 10.1073/pnas.89.24.11895; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; TANNER NK, 1988, BIOCHEMISTRY-US, V27, P8852, DOI 10.1021/bi00424a025; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; TREMBLEAU A, 1994, J NEUROSCI, V14, P39; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; WATERMANSTORER CM, 1995, J CELL BIOL, V130, P1161, DOI 10.1083/jcb.130.5.1161; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	30	233	235	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	1997	276	5315					1128	1131		10.1126/science.276.5315.1128	http://dx.doi.org/10.1126/science.276.5315.1128			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9148809				2022-12-28	WOS:A1997WZ22500049
J	Ostareck, DH; OstareckLederer, A; Wilm, M; Thiele, BJ; Mann, M; Hentze, MW				Ostareck, DH; OstareckLederer, A; Wilm, M; Thiele, BJ; Mann, M; Hentze, MW			mRNA silencing in erythroid differentiation: hnRNP K and hnRNP E1 regulate 15-lipoxygenase translation from the 3' end	CELL			English	Article							MESSENGER-RNA; BINDING-PROTEIN; UNTRANSLATED REGION; INITIATION; SEQUENCE; LIPOXYGENASE; COMPLEX; DOMAIN; ASSAY; GENE	Although LOX mRNA accumulates early during differentiation, a differentiation control element in its 3' untranslated region confers translational silencing until late stage erythropoiesis. We have purified two proteins from rabbit reticulocytes that specifically mediate LOX silencing and identified them as hnRNPs K and E1. Transfection of hnRNP K and hnRNP E1 into HeLa cells specifically silenced the translation of reporter mRNAs bearing a differentiation control element in their 3' untranslated region. Silenced LOX mRNA in rabbit reticulocytes specifically coimmunoprecipitated with hnRNP K. In a reconstituted cell-free translation system, addition of recombinant hnRNP K and hnRNP E1 recapitulates this regulation via a specific inhibition of 80S ribosome assembly on LOX mRNA. Both proteins can control cap-dependent and internal ribosome entry site-mediated translation by binding to differentiation control elements. Our data suggest a specific cytoplasmic function for hnRNPs as translational regulatory proteins.	EUROPEAN MOL BIOL LAB,GENE EXPRESS PROGRAMME,D-69117 HEIDELBERG,GERMANY; EUROPEAN MOL BIOL LAB,PROT & PEPTIDE GRP,D-69117 HEIDELBERG,GERMANY; HUMBOLDT UNIV BERLIN,INST BIOCHEM,D-10115 BERLIN,GERMANY	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL); Humboldt University of Berlin			Mann, Matthias/A-3454-2013; Hentze, Matthias W/V-3980-2017	Mann, Matthias/0000-0003-1292-4799; Hentze, Matthias W/0000-0002-4023-7876; Ostareck, Dirk/0000-0001-9406-7190; Ostareck-Lederer, Antje/0000-0003-0733-7071; Wilm, Matthias/0000-0002-5461-6834				AASHEIM HC, 1994, NUCLEIC ACIDS RES, V22, P959, DOI 10.1093/nar/22.6.959; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FLEMING J, 1989, GENE, V79, P181, DOI 10.1016/0378-1119(89)90103-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GRAY NK, 1993, EUR J BIOCHEM, V218, P657, DOI 10.1111/j.1432-1033.1993.tb18420.x; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAHM K, 1993, NUCLEIC ACIDS RES, V21, P3894, DOI 10.1093/nar/21.16.3894; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HOHNE M, 1988, BIOMED BIOCHIM ACTA, V47, P75; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; HUNT T, 1989, TRENDS BIOCHEM SCI, V14, P393, DOI 10.1016/0968-0004(89)90280-6; IZAURRAIDE E, 1997, IN PRESS J CELL BIOL; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; Kollmus H, 1996, RNA, V2, P316; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MATUNIS EL, 1994, P NATL ACAD SCI USA, V91, P2781, DOI 10.1073/pnas.91.7.2781; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SCHEWE T, 1986, ADV ENZYMOL RAMB, V58, P191; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THIELE BJ, 1982, EUR J BIOCHEM, V129, P133, DOI 10.1111/j.1432-1033.1982.tb07031.x; THIELE BJ, 1981, ACTA BIOL MED GER, V40, P597; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; WANG XM, 1995, MOL CELL BIOL, V15, P1769; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WICKENS M, 1993, NATURE, V363, P305, DOI 10.1038/363305a0; Wickens M., 1996, TRANSLATIONAL CONTRO, P411; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9	56	429	437	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					597	606		10.1016/S0092-8674(00)80241-X	http://dx.doi.org/10.1016/S0092-8674(00)80241-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160751	hybrid			2022-12-28	WOS:A1997WZ32300013
J	Degner, LF; Kristjanson, LJ; Bowman, D; Sloan, JA; Carriere, KC; ONeil, J; Bilodeau, B; Watson, P; Mueller, B				Degner, LF; Kristjanson, LJ; Bowman, D; Sloan, JA; Carriere, KC; ONeil, J; Bilodeau, B; Watson, P; Mueller, B			Information needs and decisional preferences in women with breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMUNICATION; RADIATION; ILLNESS; SURGERY	Objective.-To determine the degree of involvement women with breast cancer wanted in medical decision making, extent to which they believed they had achieved their preferred level of involvement, and types of information they judged to be most important. Design and Setting.-Cross-sectional survey at 2 tertiary oncology referral clinics and 2 community hospital oncology clinics in Winnipeg, Manitoba. Patients.-Consecutive sample of 1012 women with a confirmed diagnosis of breast cancer who were scheduled for a visit at 1 of 4 hospital oncology clinics. Main Outcome Measures.-The following measures were used: (1) Preferences about various levels of participation in treatment decision making; (2) the extent to which subjects believed they had achieved their preferred levels of involvement in decision making; and (3) priority needs for information and how these needs differed by selected sociodemographic, disease, and treatment variables. Results.-A total of 22% of women wanted to select their own cancer treatment, 44% wanted to select their treatment collaboratively with their physicians, and 34% wanted to delegate this responsibility to their physicians. Only 42% of women believed they had achieved their preferred level of control in decision making. The 2 most highly ranked types of information were related to knowing about chances of cure and spread of disease. Women younger than 50 years rated information about physical and sexual attractiveness as more important than did older women (P<.001); women older than 70 years rated information about self-care as more important than did younger women (P=.002); and women who had a positive family history of breast cancer rated information about family risk as more important than did other women (P=.03). Conclusions.-The substantial discrepancy between women's preferred and attained levels of involvement in treatment decision making suggests that systematic approaches to assess and respond to women's desired level of participation in treatment decision making need to be evaluated. Priorities for information identified in this study provide an empirical basis to guide communication with women seeking care for breast cancer.	UNIV MANITOBA,FAC NURSING,WINNIPEG,MB,CANADA; UNIV MANITOBA,FAC MED,DEPT INTERNAL MED,WINNIPEG,MB R3E 0W3,CANADA; UNIV MANITOBA,FAC MED,DEPT COMMUNITY HLTH SCI,WINNIPEG,MB,CANADA; UNIV MANITOBA,FAC MED,DEPT PATHOL,WINNIPEG,MB,CANADA; MANITOBA CANC TREATMENT & RES FDN,WINNIPEG,MB R3E 0V9,CANADA; UNIV ALBERTA,DEPT MATH SCI,EDMONTON,AB,CANADA	University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba; University of Alberta								Beaver K, 1996, CANCER NURS, V19, P8, DOI 10.1097/00002820-199602000-00002; Bilodeau B A, 1996, Oncol Nurs Forum, V23, P691; BLANCHARD CG, 1988, SOC SCI MED, V27, P1139, DOI 10.1016/0277-9536(88)90343-7; CASSELITH BR, 1990, ANN INTERN MED, V92, P832; CAWLEY M, 1990, CANCER NURS, V13, P90; Cooley M E, 1995, Oncol Nurs Forum, V22, P1345; Davison B J, 1995, Oncol Nurs Forum, V22, P1401; Degner L. F., 1987, LIFE DEATH DECISIONS; DEGNER LF, 1988, RES NURS HEALTH, V11, P367, DOI 10.1002/nur.4770110604; DEGNER LF, 1992, J CLIN EPIDEMIOL, V45, P941, DOI 10.1016/0895-4356(92)90110-9; DERDIARIAN AK, 1986, NURS RES, V35, P276; DODD MJ, 1987, CANCER NURS, V10, P244; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; Galloway S., 1994, CAN ONCOL NURS J, V4, P29; HACK TF, 1994, SOC SCI MED, V39, P279, DOI 10.1016/0277-9536(94)90336-0; HAILEY BJ, 1988, WOMEN HEALTH, V14, P75, DOI 10.1300/J013v14n01_06; Hopkins M B, 1986, Cancer Nurs, V9, P256; LAUER P, 1982, NURS RES, V31, P11; LUKER KA, 1995, J ADV NURS, V22, P134, DOI 10.1046/j.1365-2648.1995.22010134.x; Maranell GM, 1974, SCALING SOURCEBOOK B, P81; MESSERLI ML, 1980, AM J ORTHOPSYCHIAT, V50, P728, DOI 10.1111/j.1939-0025.1980.tb03339.x; MYEROWITZ BE, 1983, CANCER, V52, P1541; NAYFIELD SG, 1994, J NATL CANCER I, V86, P1202, DOI 10.1093/jnci/86.16.1202; Neufeld K R, 1993, Oncol Nurs Forum, V20, P631; NORTHOUSE LL, 1989, CANCER NURS, V12, P276; PIERCE PF, 1993, NURS RES, V42, P22; RAINEY LC, 1985, CANCER, V56, P1056, DOI 10.1002/1097-0142(19850901)56:5<1056::AID-CNCR2820560516>3.0.CO;2-Z; REYNOLDS PM, 1981, BRIT MED J, V282, P1449, DOI 10.1136/bmj.282.6274.1449; Ross R. T, 1974, SCALING SOURCEBOOK B, P106; SIMINOFF LA, 1989, J CLIN ONCOL, V7, P1192, DOI 10.1200/JCO.1989.7.9.1192; STREET RL, 1991, SOC SCI MED, V32, P541, DOI 10.1016/0277-9536(91)90288-N; *SUBC STAT WOM, 1992, REP STAND COMM HLTH, P33; SUTHERLAND HJ, 1989, J ROY SOC MED, V82, P260, DOI 10.1177/014107688908200506; WALLER M, 1995, CAN MED ASSOC J, V152, P165; WARD S, 1989, CANCER NURS, V12, P344; [No title captured]	36	852	862	3	68	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	1997	277	18					1485	1492		10.1001/jama.277.18.1485	http://dx.doi.org/10.1001/jama.277.18.1485			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WX852	9145723				2022-12-28	WOS:A1997WX85200038
J	Scholz, SE; Knothe, C; Thiel, A; Hempelmann, G				Scholz, SE; Knothe, C; Thiel, A; Hempelmann, G			Improved oxygen delivery by positive pressure ventilation with continuous negative external chest pressure	LANCET			English	Article											Scholz, SE (corresponding author), UNIV GIESSEN,DEPT ANAESTHESIOL & INTENS CARE MED,D-35392 GIESSEN,GERMANY.							BERSTEN AD, 1990, AM REV RESPIR DIS, V141, P1198, DOI 10.1164/ajrccm/141.5_Pt_1.1198; KRUMPE PE, 1977, AM REV RESPIR DIS, V115, P39; RANIERI VM, 1991, AM REV RESPIR DIS, V144, P544, DOI 10.1164/ajrccm/144.3_Pt_1.544	3	6	6	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1295	1296		10.1016/S0140-6736(05)62507-X	http://dx.doi.org/10.1016/S0140-6736(05)62507-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142069				2022-12-28	WOS:A1997WW89900016
J	Elliott, G				Elliott, G			Upper-extremity deep vein thrombosis	LANCET			English	Editorial Material									UNIV UTAH,SALT LAKE CITY,UT 84143	Utah System of Higher Education; University of Utah	Elliott, G (corresponding author), LATTER DAY ST HOSP,DIV PULM & CRIT CARE,SALT LAKE CITY,UT 84143, USA.							BECKER DM, 1991, ARCH INTERN MED, V151, P1934, DOI 10.1001/archinte.151.10.1934; HYERS TM, 1995, CHEST, V108, pS335, DOI 10.1378/chest.108.4_Supplement.335S; LINBLAD B, 1988, EUR J VASCULAR SURG, V2, P161; Prandoni P, 1997, ARCH INTERN MED, V157, P57, DOI 10.1001/archinte.157.1.57; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X	5	28	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1188	1189		10.1016/S0140-6736(05)62408-7	http://dx.doi.org/10.1016/S0140-6736(05)62408-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130936				2022-12-28	WOS:A1997WW71700004
J	Fazeli, A; Dickinson, SL; Hermiston, ML; Tighe, RV; Steen, RG; Small, CG; Stoeckli, ET; KeinoMasu, K; Masu, M; Rayburn, H; Simons, J; Bronson, RT; Gordon, JI; TessierLavigne, M; Weinberg, RA				Fazeli, A; Dickinson, SL; Hermiston, ML; Tighe, RV; Steen, RG; Small, CG; Stoeckli, ET; KeinoMasu, K; Masu, M; Rayburn, H; Simons, J; Bronson, RT; Gordon, JI; TessierLavigne, M; Weinberg, RA			Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene	NATURE			English	Article							MULTIPLE INTESTINAL NEOPLASIA; EPITHELIAL-CELL LINEAGES; TRANSGENIC MICE; DIFFERENTIATION PROGRAMS; COMMISSURAL AXONS; C-ELEGANS; MOUSE; EXPRESSION; CHROMOSOME-18; PROGRESSION	The DCC (Deleted in colorectal cancer) gene was first identified as a candidate for a tumour-suppressor gene on human chromosome 18q. More recently, in vitro studies In rodents have provided evidence that DCC might function as a receptor for the axonal chemoattractant netrin-1. Inactivation of the murine Dcc gene caused defects in axonal projections that are similar to those observed in netrin-1-deficient mice but did not affect growth, differentiation, morphogenesis or tumorigenesis in mouse intestine. These observations fail to support a tumour-suppressor function for Dcc, but are consistent with the hypothesis that DCC Is a component of a receptor for netrin-1.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; MIT,WHITEHEAD INST GENOME CTR,CAMBRIDGE,MA 02142; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM DEV BIOL & NEUROSCI,SAN FRANCISCO,CA 94143; NATL DEF MED COLL,DEPT PHYSIOL,TOKOROZAWA,SAITAMA 359,JAPAN; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; JOHNS HOPKINS UNIV,JAMES BUCHANAN BRADY UROL INST,BALTIMORE,MD 21207; TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; TUFTS UNIV,SCH VET MED,DEPT PATHOL,BOSTON,MA 02111	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Washington University (WUSTL); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Defense Medical College - Japan; Massachusetts Institute of Technology (MIT); Johns Hopkins University; Tufts University; Tufts University				Stoeckli, Esther/0000-0002-8485-0648				BOLAND CR, 1995, NAT MED, V1, P902, DOI 10.1038/nm0995-902; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; Ekstrand BC, 1995, ONCOGENE, V11, P2393; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fearon ER, 1995, MOL BASIS CANC, P340; GOODMAN CS, 1994, CELL, V78, P353, DOI 10.1016/0092-8674(94)90413-8; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HERMISTON ML, 1993, P NATL ACAD SCI USA, V90, P8866, DOI 10.1073/pnas.90.19.8866; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HOHNE MW, 1992, CANCER RES, V52, P2616; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; JUSTICE MJ, 1992, GENOMICS, V13, P1281, DOI 10.1016/0888-7543(92)90047-V; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEVY DB, 1994, CANCER RES, V54, P5953; LOUVARD D, 1992, ANNU REV CELL BIOL, V8, P157, DOI 10.1146/annurev.cb.08.110192.001105; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; LUONGO C, 1994, CANCER RES, V54, P5947; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NARAYANAN R, 1992, ONCOGENE, V7, P553; PLACZEK M, 1990, DEVELOPMENT, V110, P19; ROTH KA, 1990, P NATL ACAD SCI USA, V87, P6408, DOI 10.1073/pnas.87.16.6408; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5	50	636	647	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					796	804		10.1038/386796a0	http://dx.doi.org/10.1038/386796a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126737				2022-12-28	WOS:A1997WV70600045
J	Rethans, JJ; Saebu, L				Rethans, JJ; Saebu, L			Do general practitioners act consistently in real practice when they meet the same patient twice? Examination of intradoctor variation using standardised (simulated) patients	BRITISH MEDICAL JOURNAL			English	Article							STRUCTURED CLINICAL EXAMINATION; PERFORMANCE	Objective: To assess the variation within individual general practitioners facing the same problem twice in actual practice under unbiased conditions. Design: General practitioners were consulted during normal surgery hours by a standardised patient portraying a patient with angina pectoris. Six weeks later the same general practitioners were consulted again by a similar standardised patient portraying a similar case. The patients reported on the consultations. Setting: Trondheim, Norway. Subjects: Of 87 general practitioners invited by letter, 28 (32%) agreed to participate without hesitation; nine others (10%) wanted more information before consenting. From these 24 were selected and visited. Main outcome measures: Number of actions undertaken from a guideline in both rounds of consultations. Duration of consultations. Results: The mean (range, interquartile range) guideline score, total score, and duration of consultation were not significantly different between the first and second patient encounters for the group as a whole. For individual doctors the mean (SD) difference was -0.09 (3.36) for the guideline score, 0.30 (8.1) for the total score, and -0.87 (9.01) for consultation time. Conclusions: The study shows that assessment of performance in real practice for a group of general practitioners is consistent from the first round of consultations to the second round. However, significant variation occurs in performance of individual physicians.	UNIV TRONDHEIM,DEPT GEN PRACTICE,N-7034 TRONDHEIM,NORWAY		Rethans, JJ (corresponding author), UNIV LIMBURG,CTR RES QUAL ASSURANCE GEN PRACTICE,DEPT GEN PRACTICE,POB 616,NL-6200 MD MAASTRICHT,NETHERLANDS.							ANDERSON TF, 1990, CHALLENGE MED PRACTI; AOKI N, 1977, JPN CIRC J, V41, P11, DOI 10.1253/jcj.41.11; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Elstein AS, 1978, MED PROBLEM SOLVING; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; HODDER RV, 1989, MED EDUC, V23, P184, DOI 10.1111/j.1365-2923.1989.tb00884.x; MARINUS A, 1993, THESIS; MCCLURE CL, 1985, J FAM PRACTICE, V20, P457; MCPHERSON K, 1981, SOC SCI MED-MED SOC, V15, P273, DOI 10.1016/0271-7123(81)90011-0; MCPHERSON K, 1988, HLTH CARE VARIATIONS, P120; NEWBLE D, 1994, CERTIFICATION RECERT; NORMAN GR, 1985, MED EDUC, V19, P344, DOI 10.1111/j.1365-2923.1985.tb01336.x; RETHANS JJ, 1991, BRIT MED J, V303, P1377, DOI 10.1136/bmj.303.6814.1377; RETHANS JJ, 1991, BRIT J GEN PRACT, V41, P94; RETHANS JJ, 1991, BRIT J GEN PRACT, V41, P97; RETHANS JJE, 1987, BRIT MED J, V294, P809, DOI 10.1136/bmj.294.6575.809; ROBERTS J, 1990, MED EDUC, V24, P219, DOI 10.1111/j.1365-2923.1990.tb00004.x; RUTTEN FH, 1994, HUISARTS WET, V37, P398; Saebo L., 1995, Tidsskrift for den Norske Laegeforening, V115, P3117; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; WENNBERG JE, 1984, NEW ENGL J MED, V311, P295, DOI 10.1056/NEJM198408023110505	21	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 19	1997	314	7088					1170	1173		10.1136/bmj.314.7088.1170	http://dx.doi.org/10.1136/bmj.314.7088.1170			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV705	9146391	Green Published			2022-12-28	WOS:A1997WV70500025
J	Bhagwanjee, S; Muckart, DJJ; Jeena, PM; Moodley, P				Bhagwanjee, S; Muckart, DJJ; Jeena, PM; Moodley, P			Does HIV status influence the outcome of patients admitted to a surgical intensive care unit? A prospective double blind study	BRITISH MEDICAL JOURNAL			English	Article							MULTIPLE-ORGAN FAILURE; SEPSIS; PRINCIPLES; DISEASE; SYSTEM; AIDS	Objectives: (a) To assess the impact of HIV status (HIV negative, HIV positive, AIDS) on the outcome of patients admitted to intensive care units for diseases unrelated to HIV; (b) to decide whether a positive test result for HIV should be a criterion for excluding patients from intensive care for diseases unrelated to HIV. Design: A prospective double blind study of all admissions over six months. HIV status was determined in all patients by enzyme linked immunosorbent assay (ELISA), immunofluorescence assay, western blotting, and now cytometry. The ethics committee considered the clinical implications of the study important enough to waive patients' right to informed consent Staff and patients were blinded to HIV results. On discharge patients could be advised of their HIV status if they wished. Setting: A 16 bed surgical intensive care unit. Subjects: All 267 men and 135 women admitted to the unit during the study period. Interventions: None. Main outcome measures: APACHE II score (acute physiological, age, and chronic health evaluation), organ failure, septic shock, durations of intensive care unit and hospital stay, and intensive care unit and hospital mortality. Results: No patient had AIDS. 52 patients were tested positive for HIV and 350 patients were tested negative. The two groups were similar in sex distribution but differed significantly in age, incidence of organ failure (37 (71%) v 171 (49%) patients), and incidence of septic shock (20 (38%) v 54 (15%)). After adjustment for age there were no differences in intensive care unit or hospital mortality or in the durations of stay in die intensive care unit or hospital. Conclusions: Morbidity was higher in HIV positive patients but there was no difference in mortality. In this patient population a positive HIV test result should not be a criterion for excluding a patient from intensive care.			Bhagwanjee, S (corresponding author), UNIV NATAL,FAC MED,PRIVATE BAG 7,ZA-4013 CONGELLA,SOUTH AFRICA.							BAUE AE, 1992, ARCH SURG-CHICAGO, V127, P1451; BROWN J, 1993, CRIT CARE CLIN, V9, P115, DOI 10.1016/S0749-0704(18)30211-2; CHENG EY, 1993, CURR OPIN ANAESTH, V6, P309; DHAINAUT JFA, 1994, CRIT CARE MED, V22, P1720, DOI 10.1097/00003246-199422110-00005; Ellison GTH, 1996, S AFR MED J, V86, P1257; GILKS CF, 1993, LANCET, V342, P1037, DOI 10.1016/0140-6736(93)92885-W; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LIN RY, 1994, CRIT CARE MED, V22, P1595; LUCE JM, 1992, CRIT CARE MED, V20, P313, DOI 10.1097/00003246-199203000-00001; *MEMB AM COLL CHES, 1992, CRIT CARE MED, V20, P864; MUNOZ C, 1991, J CLIN INVEST, V88, P1747, DOI 10.1172/JCI115493; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; ROSEN MJ, 1993, CRIT CARE CLIN, V9, P107, DOI 10.1016/S0749-0704(18)30210-0; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; 1992, MMWR-MORBID MORTAL W, V41, P1	19	64	65	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 12	1997	314	7087					1077	1081		10.1136/bmj.314.7087.1077a	http://dx.doi.org/10.1136/bmj.314.7087.1077a			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU236	9133887	Green Published			2022-12-28	WOS:A1997WU23600021
J	Reif, B; Hennig, M; Griesinger, C				Reif, B; Hennig, M; Griesinger, C			Direct measurement of angles between bond vectors in high-resolution NMR	SCIENCE			English	Article							CHEMICAL-SHIFT TENSORS; LARGER PROTEINS; EXCHANGE SPECTROSCOPY; BACKBONE DYNAMICS; C-13; N-15; RELAXATION; MACROMOLECULES; CALMODULIN; SPECTRA	Angles between two interatomic vectors are measured for structure elucidation in solution nuclear magnetic resonance (NMR). The angles can be determined directly by using the effects of dipole-dipole cross-correlated relaxation of double-quantum and zero-quantum coherences. The measured rates can be directly related to the angular geometry without need for calibration of a Karplus-type curve, as is the case for scalar coupling measurements, and depend only on the rotational correlation time of the molecule as an empirical parameter. This makes the determination of torsional angles independent from the measurement of coupling constants. The two interatomic vectors can in principle be arbitrarily far apart. The method was demonstrated on the measurement of the peptide backbone angle psi in the protein rhodniin, which is difficult to determine in solution by NMR spectroscopy.	UNIV FRANKFURT, INST ORGAN CHEM, D-60439 FRANKFURT, GERMANY	Goethe University Frankfurt				Reif, Bernd/0000-0001-7368-7198				ABRAGAM A, 1961, PRINCIPLES NUCLEAR M; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BATEY RT, 1992, NUCLEIC ACIDS RES, V20, P4515, DOI 10.1093/nar/20.17.4515; BAX A, 1991, Journal of Biomolecular NMR, V1, P99, DOI 10.1007/BF01874573; BLOEMBERGEN N, 1948, PHYS REV, V73, P679, DOI 10.1103/PhysRev.73.679; BRUSCHWEILER R, 1989, J AM CHEM SOC, V111, P8034; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; DABBAGH G, 1994, MACROMOLECULES, V27, P6183, DOI 10.1021/ma00099a038; DUNCAN TM, 1990, COMPILATION CHEM SHI; EMSLEY L, 1989, J MAGN RESON, V82, P211, DOI 10.1016/0022-2364(89)90185-6; EMSLEY L, 1990, CHEM PHYS LETT, V165, P469, DOI 10.1016/0009-2614(90)87025-M; Feng X, 1996, CHEM PHYS LETT, V257, P314, DOI 10.1016/0009-2614(96)00558-1; FU RQ, 1995, CHEM PHYS LETT, V245, P415, DOI 10.1016/0009-2614(95)01037-A; GRIESINGER C, 1987, J AM CHEM SOC, V109, P7227, DOI 10.1021/ja00257a074; GRIESINGER C, 1987, J MAGN RESON, V73, P574, DOI 10.1016/0022-2364(87)90027-8; HARTZELL CJ, 1987, J AM CHEM SOC, V109, P5966, DOI 10.1021/ja00254a012; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; JANES N, 1983, J MAGN RESON, V54, P111, DOI 10.1016/0022-2364(83)90150-6; KARPLUS M, 1959, J CHEM PHYS, V30, P11, DOI 10.1063/1.1729860; KARPLUS M, 1963, J AM CHEM SOC, V85, P2870, DOI 10.1021/ja00901a059; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; LINDER M, 1980, J CHEM PHYS, V73, P4959, DOI 10.1063/1.439973; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; LUMSDEN MD, 1994, J AM CHEM SOC, V116, P1403, DOI 10.1021/ja00083a028; MADI Z, 1989, WTEST PROGRAM PACKAG; Maurer M. T., UNPUB; MICHNICKA MJ, 1993, BIOCHEMISTRY-US, V32, P395, DOI 10.1021/bi00053a002; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4507, DOI 10.1093/nar/20.17.4507; OH BH, 1988, SCIENCE, V240, P908, DOI 10.1126/science.3129784; OSCHKINAT H, 1988, NATURE, V332, P374, DOI 10.1038/332374a0; Phan IQH, 1996, J BIOMOL NMR, V8, P369, DOI 10.1007/BF00228140; QUANT S, 1994, THL, V36, P6649; Schmidt-Rohr K, 1996, J AM CHEM SOC, V118, P7601, DOI 10.1021/ja9605782; Schmidt-Rohr K, 1996, MACROMOLECULES, V29, P3975, DOI 10.1021/ma9517106; Smith LJ, 1996, J MOL BIOL, V255, P494, DOI 10.1006/jmbi.1996.0041; SOLOMON I, 1955, PHYS REV, V99, P559, DOI 10.1103/PhysRev.99.559; SOLOMON I, 1956, J CHEM PHYS, V25, P261, DOI 10.1063/1.1742867; Tjandra N, 1996, J AM CHEM SOC, V118, P6264, DOI 10.1021/ja960106n; TJANDRA N, 1995, EUR J BIOCHEM, V230, P1014, DOI 10.1111/j.1432-1033.1995.tb20650.x; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; TOLMAN JR, 1995, P NATL ACAD SCI USA, V92, P9279, DOI 10.1073/pnas.92.20.9279; VANDELOCHT A, 1995, EMBO J, V14, P5149, DOI 10.1002/j.1460-2075.1995.tb00199.x; WANG AC, 1995, J AM CHEM SOC, V117, P1810, DOI 10.1021/ja00111a021; Werbelow L.G., 1977, ADV MAGN RESON, V9, P189, DOI 10.1016/b978-0-12-025509-2.50008-7; WOESSNER DE, 1962, J CHEM PHYS, V36, P1, DOI 10.1063/1.1732274; WOESSNER DE, 1962, J CHEM PHYS, V37, P647, DOI 10.1063/1.1701390; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZUIDERWEG ERP, 1991, J AM CHEM SOC, V113, P370, DOI 10.1021/ja00001a060	53	265	267	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	1997	276	5316					1230	1233		10.1126/science.276.5316.1230	http://dx.doi.org/10.1126/science.276.5316.1230			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157875				2022-12-28	WOS:A1997XA49700034
J	Feinberg, M				Feinberg, M			Hidden dangers of incompletely suppressive antiretroviral therapy	LANCET			English	Editorial Material											Feinberg, M (corresponding author), NIH,OFF AIDS RES,BETHESDA,MD 20892, USA.							*BHIVA GUID COORD, 1997, LANCET, V349, P1086; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; Lange JMA, 1997, SCIENCE, V276, P548, DOI 10.1126/science.276.5312.548; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	7	33	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 17	1997	349	9063					1408	1409		10.1016/S0140-6736(97)22020-9	http://dx.doi.org/10.1016/S0140-6736(97)22020-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164310				2022-12-28	WOS:A1997WZ76500002
J	Weldon, M				Weldon, M			A useful collagenous colitis registry	LANCET			English	Editorial Material							DIARRHEA				Weldon, M (corresponding author), ST GEORGE HOSP,SCH MED,DIV GASTROENTEROL ENDOCRINOL & METAB,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.							CARPENTER HA, 1992, DIGEST DIS SCI, V37, P1903, DOI 10.1007/BF01308086; Halaby IA, 1996, DIS COLON RECTUM, V39, P573, DOI 10.1007/BF02058714; JARNEROT G, 1995, GASTROENTEROLOGY, V109, P449, DOI 10.1016/0016-5085(95)90332-1; LEWIS FW, 1991, DIGEST DIS SCI, V36, P1161, DOI 10.1007/BF01297466; LINDSTROM CG, 1976, PATHOL EUR, V11, P87; RASKMADSEN J, 1983, DIGEST DIS SCI, V28, P1141, DOI 10.1007/BF01295815; TYSK BJ, 1996, GUT, V39, P846	7	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 17	1997	349	9063					1410	1411		10.1016/S0140-6736(05)63720-8	http://dx.doi.org/10.1016/S0140-6736(05)63720-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164312				2022-12-28	WOS:A1997WZ76500005
J	Hamman, BD; Chen, JC; Johnson, EE; Johnson, AE				Hamman, BD; Chen, JC; Johnson, EE; Johnson, AE			The aqueous pore through the translocon has a diameter of 40-60 angstrom during cotranslational protein translocation at the ER membrane	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; NICOTINAMIDE ADENINE-DINUCLEOTIDE; SOLUTION CONFORMATIONAL DYNAMICS; NUCLEAR MAGNETIC-RESONANCE; SIGNAL-SEQUENCE; 3-DIMENSIONAL STRUCTURE; PYRIDINE DINUCLEOTIDES; PHOTOCROSS-LINKING; COMPLEX; TUNNEL	Eukaryotic secretory proteins are cotranslationally translocated through the endoplasmic reticulum (ER) membrane via aqueous pores that span the lipid bilayer. Fluorescent probes were incorporated into nascent secretory proteins using modified Lys-tRNAs, and the resulting nascent chains were sealed off from the cytosol in fully assembled translocation intermediates. Fluorescence quenching agents of different sizes were then introduced into the ER lumen in order to determine which were small enough to enter the pore and to quench the fluorescence of probes inside the ribosome and/or the pore. These accessibility studies showed that the aqueous pore in a functioning translocon is 40-60 Angstrom in diameter, making it the largest hole observed to date in a membrane that must maintain a permeability barrier.	TEXAS A&M UNIV, DEPT MED BIOCHEM & GENET, COLLEGE STN, TX 77843 USA; TEXAS A&M UNIV, DEPT CHEM, COLLEGE STN, TX 77843 USA; TEXAS A&M UNIV, DEPT BIOCHEM & BIOPHYS, COLLEGE STN, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station			Johnson, Arthur E/G-3457-2012		NIGMS NIH HHS [GM 26494] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; CHATTOPADHYAY SK, 1983, J AM CHEM SOC, V105, P6205, DOI 10.1021/ja00358a002; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Harlow E., 1988, ANTIBODIES LAB MANUA; HEDGE RS, 1996, CELL, V85, P217; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HIGH S, 1993, J BIOL CHEM, V268, P26745; Johnson AE, 1995, COLD SPRING HARB SYM, V60, P71, DOI 10.1101/SQB.1995.060.01.010; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Li M, 1996, P NATL ACAD SCI USA, V93, P6902, DOI 10.1073/pnas.93.14.6902; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WIERTZ EJH, 1996, CELL, V84, P669; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; WILSON IA, 1991, METHOD ENZYMOL, V203, P153; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; ZENS AP, 1975, J AM CHEM SOC, V97, P2850, DOI 10.1021/ja00843a040; ZENS AP, 1976, J AM CHEM SOC, V98, P7559, DOI 10.1021/ja00440a019; [No title captured]	37	233	238	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	1997	89	4					535	544		10.1016/S0092-8674(00)80235-4	http://dx.doi.org/10.1016/S0092-8674(00)80235-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160745	Bronze			2022-12-28	WOS:A1997WZ32300007
J	Kellermayer, MSZ; Smith, SB; Granzier, HL; Bustamante, C				Kellermayer, MSZ; Smith, SB; Granzier, HL; Bustamante, C			Folding-unfolding transitions in single titin molecules characterized with laser tweezers	SCIENCE			English	Article							SKELETAL-MUSCLE; STRIATED-MUSCLE; SARCOMERE-LENGTH; PASSIVE TENSION; CARDIAC-MUSCLE; ELASTICITY; FILAMENTS; PROTEIN; FIBRONECTIN; CONNECTIN	Titin, a giant filamentous polypeptide, is believed to play a fundamental role in maintaining sarcomeric structural integrity and developing what is known as passive force in muscle. Measurements of the force required to stretch a single molecule revealed that titin behaves as a highly nonlinear entropic spring. The molecule unfolds in a high-force transition beginning at 20 to 30 piconewtons and refolds in a low-force transition at similar to 2.5 piconewtons. A fraction of the molecule (5 to 40 percent) remains permanently unfolded, behaving as a wormlike chain with a persistence length (a measure of the chain's bending rigidity) of 20 angstroms. Force hysteresis arises from a difference between the unfolding and refolding kinetics of the molecule relative to the stretch and release rates in the experiments, respectively. Scaling the molecular data up to sarcomeric dimensions reproduced many features of the passive force versus extension curve of muscle fibers.	WASHINGTON STATE UNIV,DEPT VET COMPARAT ANAT PHARMACOL & PHYSIOL,PULLMAN,WA 99164; UNIV OREGON,HOWARD HUGHES MED INST,INST MOL BIOL,EUGENE,OR 97403	Washington State University; Howard Hughes Medical Institute; University of Oregon					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR042652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032543, R37GM032543] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-42652] Funding Source: Medline; NIGMS NIH HHS [GM-32543] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; FRITZ JD, 1993, COMP BIOCHEM PHYS B, V105, P357, DOI 10.1016/0305-0491(93)90241-V; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; GOTO Y, 1982, J MOL BIOL, V156, P911, DOI 10.1016/0022-2836(82)90147-4; GRANZIER HL, 1995, BIOPHYS J, V68, P1027, DOI 10.1016/S0006-3495(95)80278-X; GRANZIER HLM, 1993, BIOPHYS J, V65, P2141, DOI 10.1016/S0006-3495(93)81262-1; GRANZIER HLM, 1991, AM J PHYSIOL, V260, pC1060, DOI 10.1152/ajpcell.1991.260.5.C1060; HIGUCHI H, 1993, BIOPHYS J, V65, P1906, DOI 10.1016/S0006-3495(93)81261-X; HOROWITS R, 1987, J CELL BIOL, V105, P2217, DOI 10.1083/jcb.105.5.2217; HOROWITS R, 1986, NATURE, V323, P160, DOI 10.1038/323160a0; KIEFHABER T, 1992, J MOL BIOL, V224, P217, DOI 10.1016/0022-2836(92)90585-8; KRATKY O, 1949, RECL TRAV CHIM PAY B, V68, P1106; Kuhn W, 1942, KOLLOID Z, V101, P248, DOI 10.1007/BF01793684; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; MARUYAMA K, 1994, BIOPHYS CHEM, V50, P73, DOI 10.1016/0301-4622(94)85021-6; NAVE R, 1989, J CELL BIOL, V109, P2177, DOI 10.1083/jcb.109.5.2177; PAN KM, 1994, BIOCHEMISTRY-US, V33, P8255, DOI 10.1021/bi00193a012; Plaxco KW, 1996, P NATL ACAD SCI USA, V93, P10703, DOI 10.1073/pnas.93.20.10703; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; SMITH SS, UNPUB; SOTERIOU A, 1993, P ROY SOC B-BIOL SCI, V254, P83, DOI 10.1098/rspb.1993.0130; TRINICK J, 1984, J MOL BIOL, V180, P331, DOI 10.1016/S0022-2836(84)80007-8; TROMBITAS K, 1993, J MUSCLE RES CELL M, V14, P416, DOI 10.1007/BF00121293; Tskhovrebova L, 1997, J MOL BIOL, V265, P100, DOI 10.1006/jmbi.1996.0717; WANG K, 1984, P NATL ACAD SCI-BIOL, V81, P3685, DOI 10.1073/pnas.81.12.3685; Wang K, 1985, Cell Muscle Motil, V6, P315	32	977	1003	1	144	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 16	1997	276	5315					1112	1116		10.1126/science.276.5315.1112	http://dx.doi.org/10.1126/science.276.5315.1112			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9148805				2022-12-28	WOS:A1997WZ22500044
J	Zheng, WP; Flavell, RA				Zheng, WP; Flavell, RA			The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells	CELL			English	Article							MURINE IL-4 GENE; TYROSINE PHOSPHORYLATION; MESSENGER-RNAS; DIFFERENTIATION; INTERLEUKIN-4; PROMOTER; MICE; ACTIVATION; INHIBITION; DISRUPTION	CD4 T cells potentiate the inflammatory or humoral immune response through the action of Th1 and Th2 cells, respectively. The molecular basis of the differentiation of these cells from naive T cell precursors is, however, unclear. We found that GATA-3 was selectively expressed in Th2 cells. GATA-3 is expressed at a high level in naive, freshly activated T cells and Th2 lineage cells, but subsides to a minimal level in Th1 lineage cells as naive cells commit to their Th subset. Antisense GATA-3 inhibited the expression of all Th2 cytokine genes in the Th2 clone D10. GATA-3 directly activated an IL-4 promoter-luciferase reporter gene in M12 cells. In transgenic mice, elevated GATA-3 in CD4 T cells caused Th2 cytokine gene expression in developing Th1 cells. Thus, GATA-3 is necessary and sufficient for Th2 cytokine gene expression.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06520	Howard Hughes Medical Institute; Yale University								Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ABEHSIRAAMAR O, 1992, J IMMUNOL, V148, P3820; BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; CROFT M, 1995, J IMMUNOL, V154, P4269; DAVYDOV IV, 1995, J IMMUNOL, V155, P5273; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Hattori N, 1996, J EXP MED, V184, P1137, DOI 10.1084/jem.184.3.1137; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hodge MR, 1996, SCIENCE, V274, P1903, DOI 10.1126/science.274.5294.1903; HODGE MR, 1995, J IMMUNOL, V154, P6397; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; KAMOGAWA Y, 1993, CELL, V75, P985, DOI 10.1016/0092-8674(93)90542-X; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KLEIN SC, 1995, APMIS, V103, P345, DOI 10.1111/j.1699-0463.1995.tb01118.x; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Lederer JA, 1996, J EXP MED, V184, P397, DOI 10.1084/jem.184.2.397; LEE HJ, 1994, J ALLERGY CLIN IMMUN, V94, P594, DOI 10.1016/0091-6749(94)90135-X; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Nakamura T, 1997, J IMMUNOL, V158, P1085; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAO A, 1991, CRIT REV IMMUNOL, V10, P495; REINER SL, 1994, J IMMUNOL METHODS, V175, P275, DOI 10.1016/0022-1759(94)90370-0; Rincon M, 1997, MOL CELL BIOL, V17, P1522, DOI 10.1128/MCB.17.3.1522; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; Rincon Mercedes, 1997, Genes and Function, V1, P51; ROCKEN M, 1992, J IMMUNOL, V148, P1031; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCOTT LM, 1992, BLOOD, V80, P1725; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	54	1823	1919	3	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					587	596		10.1016/S0092-8674(00)80240-8	http://dx.doi.org/10.1016/S0092-8674(00)80240-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160750	hybrid			2022-12-28	WOS:A1997WZ32300012
J	Krainer, M; SilvaArrieta, S; FitzGerald, MG; Shimada, A; Ishioka, C; Kanamaru, R; MacDonald, DJ; Unsal, H; Finkelstein, DM; Bowcock, A; Isselbacher, KJ; Haber, DA				Krainer, M; SilvaArrieta, S; FitzGerald, MG; Shimada, A; Ishioka, C; Kanamaru, R; MacDonald, DJ; Unsal, H; Finkelstein, DM; Bowcock, A; Isselbacher, KJ; Haber, DA			Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OVARIAN-CANCER; SUSCEPTIBILITY GENE; FAMILIAL BREAST; MUTATIONS; LINKAGE	Background Germ-line mutations in the BRCA1 and BRCA2 genes predispose women to breast cancer. BRCA1 mutations are found in approximately 12 percent of women with breast cancer of early onset, and the specific mutation causing a deletion of adenine and guanine (185delAG), which is present in 1 percent of the Ashkenazi Jewish population, contributes to 21 percent of breast cancers among young Jewish women. The contribution of BRCA2 mutations to breast cancer of early onset is unknown. Methods Lymphocyte specimens from 73 women with breast cancer diagnosed by the age of 32 were studied for heterozygous mutations of BRCA2 by a complementary-DNA-based protein-truncation assay, followed by automated nucleotide sequencing, In addition, specimens from 39 Jewish women with breast cancer diagnosed by the age of 40 were tested for specific mutations by an allele-specific polymerase chain reaction. Results Definite BRCA2 mutations were found in 2 of the 73 women with early-onset breast cancer (2.7 percent; 95 percent confidence interval, 0.4 to 9.6 percent), suggesting that BRCA2 is associated with fewer cases than BRCA1 (P = 0.03). The specific BRCA2 mutation causing a deletion of thymine (6174delT), which is found in 1.3 percent of the Ashkenazi Jewish population, was observed in 1 of the 39 young Jewish women with breast cancer (2.6 percent; 95 percent confidence interval, 0.09 to 13.5 percent), indicating that it has a small role as a risk factor for early-onset breast cancer. Among young women with breast cancer, there are BRCA2 mutations that cause truncation of the extreme C terminus of the protein and that may be functionally silent, along with definite truncating mutations. Conclusions Germ-line mutations in BRCA2 contribute to fewer cases of breast cancer among young women than do mutations in BRCA1. Carriers of BRCA2 mutations may have a smaller increase in the risk of early-onset breast cancer. (C) 1997, Massachusetts Medical Society.	MASSACHUSETTS GEN HOSP,CTR CANC,GENET MOL LAB,CHARLESTOWN,MA 02129; CTR CANC RISK ANAL,CHARLESTOWN,MA; MASSACHUSETTS GEN HOSP,DIV BIOSTAT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA; TOHOKU UNIV,DEPT CLIN ONCOL,SENDAI,MIYAGI 980,JAPAN; UNIV TEXAS,SW MED CTR,DIV PEDIAT HEMATOL ONCOL,DALLAS,TX	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Tohoku University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Bowcock, Anne/0000-0001-8691-9090; Krainer, Michael/0000-0002-7011-4957	NCI NIH HHS [CA60650] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060650] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berman DB, 1996, AM J HUM GENET, V58, P1166; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Ishioka C, 1997, P NATL ACAD SCI USA, V94, P2449, DOI 10.1073/pnas.94.6.2449; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; Mazoyer S, 1996, NAT GENET, V14, P253, DOI 10.1038/ng1196-253; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Muto MG, 1996, CANCER RES, V56, P1250; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Offit K, 1996, LANCET, V347, P1643, DOI 10.1016/S0140-6736(96)91484-1; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; Ries L, 1994, NIH PUBLICATION, V94-2789; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; ROWELL S, 1994, AM J HUM GENET, V55, P861; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	28	170	176	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	1997	336	20					1416	1421		10.1056/NEJM199705153362003	http://dx.doi.org/10.1056/NEJM199705153362003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY577	9145678				2022-12-28	WOS:A1997WY57700003
J	Barlow, H				Barlow, H			Neuroscience - Adaptation by hyperpolarization	SCIENCE			English	Editorial Material											Barlow, H (corresponding author), UNIV CAMBRIDGE,PHYSIOL LAB,DOWNING ST,CAMBRIDGE CB2 3EG,ENGLAND.							Blakemore C, 1973, BAFFLED BRAIN, P8; Carandini M, 1997, SCIENCE, V276, P949, DOI 10.1126/science.276.5314.949; CARANDINI M, IN PRESS PHILOS T B; DEANGELIS GC, 1995, P NATL ACAD SCI USA, V92, P9682, DOI 10.1073/pnas.92.21.9682; Reynolds J., 1996, Society for Neuroscience Abstracts, V22, P1197; Scanziani M, 1997, NATURE, V385, P630, DOI 10.1038/385630a0	6	6	6	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					913	914		10.1126/science.276.5314.913	http://dx.doi.org/10.1126/science.276.5314.913			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9163036				2022-12-28	WOS:A1997WY79200035
J	Manzanares, M; Cordes, S; Kwan, CT; Sham, MH; Barsh, GS; Krumlauf, R				Manzanares, M; Cordes, S; Kwan, CT; Sham, MH; Barsh, GS; Krumlauf, R			Segmental regulation of Hoxb-3 by kreisler	NATURE			English	Article							GENE-EXPRESSION; 2 RHOMBOMERES; ETS DOMAIN; HINDBRAIN; MUTANT; MOUSE; JUN; FOS; PROTOONCOGENES; KROX-20	Hox genes control regional identity during segmentation of the vertebrate hindbrain into rhombomeres(1-3). Here we use transgenic analysis to investigate the upstream mechanisms for regulation of Hoxb-3 in rhombomere(r)5. We identified enhancers from the mouse and chick genes sufficient for r5-restricted expression. Sequence comparisons revealed two blocks of similarity (of 19 and 45 base pairs), which each contain in vitro binding sites for the kreisler protein (Kmrl1), a Maf/b-Zip protein expressed in r5 and r6 (ref. 4). Both sites are required for r5 activity, suggesting that Hoxb-3 is a direct target of kreisler. Multimers of the 19-base-pair (bp) block recreate a Krml1-like pattern in r5/r6, but the 45-bp block mediates expression only in r5. Therefore elements within the 45-bp block restrict the response to Krml1. We identified additional sequences that contain an Ets-related activation site, required for both the activation and restriction to r5. These studies demonstrate that Krml1 directly activates expression of Hoxb-3 in r5 in combination with an Ets-related activation site, and suggest that kreisler plays a primary role in regulating segmental identity through Hox genes.	NATL INST MED RES, MRC, DIV DEV NEUROBIOL, LONDON NW7 1AA, ENGLAND; STANFORD UNIV, MED CTR, BECKMAN CTR MOL & GENET MED, DEPT PEDIAT, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, BECKMAN CTR MOL & GENET MED, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, BECKMAN CTR MOL & GENET MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; UNIV HONG KONG, DEPT BIOCHEM, HONG KONG, HONG KONG	MRC National Institute for Medical Research; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; University of Hong Kong			Manzanares, Miguel/AAZ-8305-2021; Cordes, Sabine P/A-5423-2012; Krumlauf, Robb/AAH-5012-2019; Sham, Mai Har/C-4387-2009; Manzanares, Miguel/E-1702-2015; Sham, Mai Har/AAX-3781-2020	Manzanares, Miguel/0000-0003-4849-2836; Krumlauf, Robb/0000-0001-9102-7927; Manzanares, Miguel/0000-0003-4849-2836; Sham, Mai Har/0000-0003-1179-7839				CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; DEOL MS, 1964, J EMBRYOL EXP MORPH, V12, P475; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; Goddard JM, 1996, DEVELOPMENT, V122, P3217; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MARK M, 1993, DEVELOPMENT, V119, P319; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MCKAY I, IN PRESS EUR J NEURO; MCKAY IJ, 1994, DEVELOPMENT, V120, P2199; Nonchev S, 1996, P NATL ACAD SCI USA, V93, P9339, DOI 10.1073/pnas.93.18.9339; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; Shore P, 1996, MOL CELL BIOL, V16, P3338; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Studer M, 1996, NATURE, V384, P630, DOI 10.1038/384630a0; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	26	126	127	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 8	1997	387	6629					191	195		10.1038/387191a0	http://dx.doi.org/10.1038/387191a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144291				2022-12-28	WOS:A1997WX94500057
J	Nichols, BJ; Ungermann, C; Pelham, HRB; Wickner, WT; Haas, A				Nichols, BJ; Ungermann, C; Pelham, HRB; Wickner, WT; Haas, A			Homotypic vacuolar fusion mediated by t- and v-SNAREs	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; IN-VITRO; VESICULAR TRANSPORT; PROTEIN; YEAST; INHERITANCE; GENE; ENDOCYTOSIS; RECEPTOR	Membrane fusion is necessary both in the eukaryotic secretory pathway and for the inheritance of organelles during the cell cycle. In the secretory pathway, heterotypic fusion takes place between small transport vesicles and organelles. It requires N-ethylmaleimide-sensitive fusion protein (NSF/Sec18p), soluble NSF attachment proteins (SNAPs/Sec17p) and SNAP receptors (SNAREs). SNAREs are integral membrane proteins (v-SNAREs on vesicles, t-SNAREs on the target organelles) and are thought to provide specificity to the fusion process(1-5). It has been suggested that Sec17p and Sec18p bind to v-SNARE/t-SNARE complexes and mediate the membrane fusion event(1-3). Homotypic fusion of yeast vacuoles also requires Sec17p and Sec18p (ref, 6), but in vitro they are needed only to 'prime' the vacuoles, not for subsequent docking or fusion(7,8). It has been unclear whether these reactions involve SNAREs that are similar to those previously identified in heterotypic fusion systems and, hence, whether the actions of Sec18p/NSF and Sec17p/alpha SNAP in these systems can be compared, Here we identify typical v- and t-SNAREs on the yeast vacuolar membrane, Although both are normally present, vacuoles containing only the v-SNARE can fuse with those containing only the t-SNARE. Vacuoles containing neither SNARE cannot fuse with those containing both, demonstrating that docking is mediated by cognate SNAREs on the two organelle membranes. Even when t- and v-SNAREs are on separate membranes, Sec17p and Sec18p act at the priming stage. Their action is not required at the point of assembly of the SNARE complex, nor for the fusion event itself.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	MRC Laboratory Molecular Biology; Dartmouth College								AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; DASCHER C, 1994, J BIOL CHEM, V269, P29363; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steel GJ, 1996, EMBO J, V15, P745, DOI 10.1002/j.1460-2075.1996.tb00410.x; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WADA Y, 1992, J BIOL CHEM, V267, P18671; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	29	385	390	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					199	202		10.1038/387199a0	http://dx.doi.org/10.1038/387199a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144293				2022-12-28	WOS:A1997WX94500059
J	Winters, JC; Sobel, JS; Groenier, KH; Arendzen, HJ; MeyboomdeJong, B				Winters, JC; Sobel, JS; Groenier, KH; Arendzen, HJ; MeyboomdeJong, B			Comparison of physiotherapy, manipulation, and corticosteroid injection for treating shoulder complaints in general practice: Randomised, single blind study	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; TRIAL	Objective: To compare the efficacy of physiotherapy, manipulation, and corticosteroid injection for treating patients with shoulder complaints in general practice. Design: Randomised, single blind study. Setting: Seven general practices in the Netherlands. Subjects: 198 patients with shoulder complaints, of whom 172 were divided, on the basis of physical examination, into two diagnostic groups: a shoulder girdle group (n=58) and a synovial group (n=114). Interventions: Patients in the shoulder girdle group were randomised to manipulation or physiotherapy, and patients in the synovial group were randomised to corticosteroid injection, manipulation, or physiotherapy. Main outcome measures: Duration of shoulder complaints analysed by survival analysis. Results: In the shoulder girdle group duration of complaints was significantly shorter after manipulation compared with physiotherapy (P < 0.001). Also the number of patients reporting treatment failure was less with manipulation. In the synovial group duration of complaints was shortest after corticosteroid injection compared with manipulation and physiotherapy (P < 0.001). Drop out due to treatment failure was low in the injection group (17%) and high in the manipulation group (59%) and physiotherapy group (51%). Conclusions: For treating shoulder girdle disorders, manipulation seems to be the preferred treatment For the synovial disorders, corticosteroid injection seems the best treatment.	UNIV GRONINGEN,DEPT GEN PRACTICE,NL-9713 AW GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,DEPT REHABIL MED,NL-9700 RB GRONINGEN,NETHERLANDS	University of Groningen; University of Groningen								Bakker JF, 1990, HUISARTS WETENSCHAP, V33, P196; CYRIAX J, 1984, TXB ORTHOPAEDIC MED, V1, P127; JONQUIERE M, 1986, THESIS ERASMUS U, P121; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; LACEY PH, 1984, EUR J RHEUMATOL INFL, V7, P95; LAMBERTS H, 1993, INT CLASSIFICATION P; ROY S, 1976, LANCET, V1, P1322; SOBEL JS, 1995, HUISARTS WET, V38, P342; STEINBROCKER O, 1974, ARCH PHYS MED REHAB, V55, P209; VANDERHEIJDEN BJM, 1992, NEDERLANDS TIJDSCHRI, V102, P38; VECCHIO PC, 1993, BRIT J RHEUMATOL, V32, P743; Winters JC, 1996, SCAND J REHABIL MED, V28, P163; WINTERS JC, 1955, HUISARTS WETENSCHAP, V38, P339; WINTERS JC, 1995, HUISARTS WETENSCHAP, V38, P347; Winters JC, 1995, HUISARTS WETENSCHAP, V38, P164	15	153	153	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 3	1997	314	7090					1320	1325		10.1136/bmj.314.7090.1320	http://dx.doi.org/10.1136/bmj.314.7090.1320			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX975	9158469	Green Published			2022-12-28	WOS:A1997WX97500026
J	VadhanRaj, S; Murray, LJ; BuesoRamos, C; Patel, S; Reddy, SP; Hoots, WK; Johnston, T; Papadopolous, NE; Hittelman, WN; Johnston, DA; Yang, TA; Paton, VE; Cohen, RL; Hellmann, SD; Benjamin, RS; Broxmeyer, HE				VadhanRaj, S; Murray, LJ; BuesoRamos, C; Patel, S; Reddy, SP; Hoots, WK; Johnston, T; Papadopolous, NE; Hittelman, WN; Johnston, DA; Yang, TA; Paton, VE; Cohen, RL; Hellmann, SD; Benjamin, RS; Broxmeyer, HE			Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer	ANNALS OF INTERNAL MEDICINE			English	Article						thrombopoietin; megakaryocytes; thrombocytopenia; blood platelet count; sarcoma	C-MPL LIGAND; CELL LUNG-CANCER; PROGENITOR CELLS; UNITED-STATES; IN-VIVO; GRANULOCYTE; CHEMOTHERAPY; BLOOD; TRANSPLANTATION; TRANSFUSION	Background: Thrombocytopenia is frequently encountered in patients with cancer. It is associated with an increased risk for clinically important bleeding episodes, which increases the demand for platelet transfusion. Objective: To assess hematopoietic response to and clinical tolerance of recombinant human thrombopoietin, a recently cloned novel cytokine. Design: Phase I and II clinical cohort study. Setting: The University of Texas M.D. Anderson Cancer Center, Houston, Texas. Patients: 12 patients with sarcoma who had high risk for severe chemotherapy-induced thrombocytopenia. Intervention: A single intravenous dose of thrombopoietin (0.3 to 2.4 mu g/kg of body weight) 3 weeks before chemotherapy. Measurements: Peripheral blood and bone marrow evaluation before and after thrombopoietin administration. Results: A single dose of thrombopoietin was associated with an increase in platelet counts (mean increase from baseline, 61% to 213%; P = 0.002) in a dose-related manner. This increase began by day 4 in most patients and peaked on a median of day 12. This sustained response was associated with a prolonged serum thrombopoietin half life (20 to 30 hours). The platelets appeared morphologically normal and showed normal aggregation in response to various agonists. Platelet response was accompanied by a dose-related increase in bone marrow megakaryocytes (as much as 4-fold); the expansion of the bone marrow progenitors of myeloid, erythroid, multipotential, and megakaryocytic lineages; and the marked mobilization of progenitors (maximum, 5.7-fold to 10-fold) of multiple cell lineages in the peripheral blood. Treatment was well tolerated, and no serious adverse events occurred. Conclusions: Thrombopoietin, administered as a single dose. is a potent stimulus for prolonged platelet production in humans. It merits further evaluation for the prevention and treatment of thrombocytopenia.	SYSTEMIX INC, SAN FRANCISCO, CA USA; GENENTECH INC, San Francisco, CA 94080 USA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN USA	Roche Holding; Genentech; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	VadhanRaj, S (corresponding author), UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOIMMUNOTHERAPY, BOX 002, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056416, P01HL053586, R01HL054037] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL56416, R01 HL54037, P01 HL53586] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1994, J CLIN ONCOL, V12, P2471; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; BENSINGER W, 1993, BLOOD, V81, P3158; BLESMA B, 1992, BLOOD, V80, P1141; BROXMEYER HE, 1989, EXP HEMATOL, V17, P455; BRUNO E, 1988, EXP HEMATOL, V16, P371; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; CRAWFORD J, 1992, P AN M AM SOC CLIN, V11, P299; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; Emmons RVB, 1996, BLOOD, V87, P4068, DOI 10.1182/blood.V87.10.4068.bloodjournal87104068; Fanucchi M, 1997, NEW ENGL J MED, V336, P404, DOI 10.1056/NEJM199702063360603; FARESE AM, 1995, BLOOD, V86, P54, DOI 10.1182/blood.V86.1.54.bloodjournal86154; Fielder PJ, 1996, BLOOD, V87, P2154, DOI 10.1182/blood.V87.6.2154.bloodjournal8762154; HEYMAN MR, 1990, SEMIN ONCOL, V17, P198; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KELEMEN E., 1958, ACTA HAEMATOL, V20, P350; KORBLING M, 1995, BLOOD, V86, P2842; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Levin J, 1997, NEW ENGL J MED, V336, P434, DOI 10.1056/NEJM199702063360609; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; Murray L. J., 1996, Blood, V88, p351A; Murray LJ, 1996, EXP HEMATOL, V24, P236; NEIDHART JA, 1992, J CLIN ONCOL, V10, P1460, DOI 10.1200/JCO.1992.10.9.1460; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; RODAK BF, 1995, DIAGNOSTIC HEMATOL, P554; SHEA TC, 1992, J CLIN ONCOL, V10, P464, DOI 10.1200/JCO.1992.10.3.464; SMITH JW, 1993, NEW ENGL J MED, V328, P756, DOI 10.1056/NEJM199303183281103; SOCINSKI MA, 1988, LANCET, V1, P1194; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; Tepler I, 1996, BLOOD, V87, P3607; THOMAS GR, 1996, STEM CELLS        S1, V1, P246; Vadhan-Raj S., 1996, Blood, V88, p448A; VADHANRAJ S, 1995, BLOOD, V86, P2098, DOI 10.1182/blood.V86.6.2098.bloodjournal8662098; VADHANRAJ S, 1994, J CLIN ONCOL, V12, P707, DOI 10.1200/JCO.1994.12.4.707; VADHANRAJ S, 1994, J CLIN ONCOL, V12, P715, DOI 10.1200/JCO.1994.12.4.715; VADHANRAJ S, 1992, J CLIN ONCOL, V10, P1266, DOI 10.1200/JCO.1992.10.8.1266; VELDHUIS GJ, 1995, J CLIN ONCOL, V13, P2585, DOI 10.1200/JCO.1995.13.10.2585; VOSE JM, 1991, BONE MARROW TRANSPL, V7, P139; WALLACE EL, 1995, TRANSFUSION, V35, P802, DOI 10.1046/j.1537-2995.1995.351096026360.x; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0	41	173	193	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1997	126	9					673	+		10.7326/0003-4819-126-9-199705010-00001	http://dx.doi.org/10.7326/0003-4819-126-9-199705010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW147	9139552				2022-12-28	WOS:A1997WW14700001
J	Weaver, T; Talor, F; Cunningham, B; Kavanagh, S; Maden, A; Rees, S; Renton, A				Weaver, T; Talor, F; Cunningham, B; Kavanagh, S; Maden, A; Rees, S; Renton, A			Impact of a dedicated service for male mentally disordered remand prisoners in north west London: Retrospective study	BRITISH MEDICAL JOURNAL			English	Article									UNIV KENT,PERSONAL SOCIAL SERV RES UNIT,CANTERBURY CT2 7NF,KENT,ENGLAND; INST PSYCHIAT,DEPT FORENS PSYCHIAT,LONDON SE5 8AF,ENGLAND; EALING HAMMERSMITH HLTH AGCY,DEPT PUBL HLTH,SOUTHALL UB2 4SA,MIDDX,ENGLAND	University of Kent; University of London; King's College London	Weaver, T (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT EPIDEMIOL & PUBL HLTH,PRAED ST,LONDON W2 1PG,ENGLAND.			Weaver, Tim/0000-0002-3437-3556				COID JW, 1988, BRIT MED J, V296, P1779, DOI 10.1136/bmj.296.6639.1779; CRIPPS J, 1995, J FORENSIC PSYCHIATR, V6, P77, DOI 10.1080/09585189508409877; DELL S, 1991, MENTALLY DISORDERED; *DEP HLTH HOM OFF, 1992, REV HLTH SOC SERV ME; *NHS MAN EX, 1992, EL926 NHSE MAN EX	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 26	1997	314	7089					1244	1245		10.1136/bmj.314.7089.1244	http://dx.doi.org/10.1136/bmj.314.7089.1244			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW718	9154028	Green Published			2022-12-28	WOS:A1997WW71800019
J	Coppolino, MG; Woodside, MJ; Demaurex, N; Grinstein, S; StArnaud, R; Dedhar, S				Coppolino, MG; Woodside, MJ; Demaurex, N; Grinstein, S; StArnaud, R; Dedhar, S			Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion	NATURE			English	Article							GENE-EXPRESSION; MODULATION; INCREASES; RECEPTOR; BINDING; ANTIGEN	Integrins are important mediators of cell adhesion to extracellular ligands and can transduce biochemical signals both into and out of cells(1,2). The cytoplasmic domains of integrins interact with several structural and signalling proteins and consequently participate in the regulation of cell shape, motility, growth and differentiation(3). It has been shown that calreticulin associates with the cytoplasmic domains of integrin a-subunits and that this interaction can influence integrin-mediated cell adhesion to extracellular matrix(4,5). We have now developed calreticulin-deficient embryonic stem (ES) cells and isolated embryonic fibroblasts from calreticulin mutant mice. We find that in both cell types integrin-mediated adhesion is severely impaired, although integrin expression is unaltered. Expression of recombinant calreticulin in double knockout ES cells by complementary DNA transfection rescued integrin-mediated adhesion. In wild-type cells, engagement of surface integrins induced a transient elevation in cytosolic calcium concentration owing to influx of extracellular calcium. This calcium transient was absent in calreticulin-deficient cells. In contrast, the amount of calcium in endomembrane stores, which is sensitive to both inositol 1,4,5-trisphosphate and thapsigargin, was indistinguishable in the two cell types. Our results indicate that calreticulin is an essential modulator both of integrin adhesive functions and integrin-initiated signalling, but that it may not play a significant role in the storage of luminal calcium.	UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DIV CANC RES,TORONTO,ON M4N 3M5,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4N 3M5,CANADA; HOSP SICK CHILDREN,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA; SHRINERS HOSP CRIPPLED CHILDREN,GENET UNIT,MONTREAL,PQ H3G 1A6,CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University				Demaurex, Nicolas/0000-0002-9933-6772; Dedhar, Shoukat/0000-0003-4355-1657				BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Hogan B, 1994, MANIPULATING MOUSE E; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; LIU NG, 1994, J BIOL CHEM, V269, P28635; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCCAULIFFE DP, 1990, J CLIN INVEST, V86, P332, DOI 10.1172/JCI114704; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Opas M, 1996, J CELL BIOL, V135, P1913, DOI 10.1083/jcb.135.6.1913; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SJAASTAD MD, 1996, MOL BIOL CELL, V1, P1025; SONTHEIMER RD, 1995, J INVEST MED, V43, P362; STARNAUD R, 1995, J CELL BIOL, V131, P1351, DOI 10.1083/jcb.131.5.1351; VONTSCHARNER V, 1986, J BIOL CHEM, V261, P163; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0	29	332	352	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					843	847		10.1038/386843a0	http://dx.doi.org/10.1038/386843a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126744				2022-12-28	WOS:A1997WV70600057
J	Asplund, K; Berman, P; Blomstrand, C; Dennis, M; Douglas, J; Erila, T; Garraway, M; Hamrin, E; Hankey, G; Ilmavirta, M; Indredavik, B; Kalra, L; Kaste, M; Langhorne, P; Rodgers, H; Sivenius, J; Slattery, J; Stevens, R; Svensson, A; Warlow, C; Williams, B; WoodDauphinee, S				Asplund, K; Berman, P; Blomstrand, C; Dennis, M; Douglas, J; Erila, T; Garraway, M; Hamrin, E; Hankey, G; Ilmavirta, M; Indredavik, B; Kalra, L; Kaste, M; Langhorne, P; Rodgers, H; Sivenius, J; Slattery, J; Stevens, R; Svensson, A; Warlow, C; Williams, B; WoodDauphinee, S			Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SAVE LIVES; REHABILITATION; METAANALYSIS; DISABILITY; NEED	Objectives: To define the characteristics and determine the effectiveness of organised inpatient (stroke unit) care compared with conventional care in reducing death, dependency, and the requirement for long term institutional care after stroke. Design: Systematic review of all randomised trials which compared organised inpatient stroke care with the contemporary conventional care. Specialist stroke unit interventions were defined as either a ward or team exclusively managing stroke (dedicated stroke unit) or a ward or team specialising in the management of disabling illnesses, which include stroke (mixed assessment/rehabilitation unit). Conventional care was usually provided in a general medical ward. Setting: 19 trials (of which three had two treatment arms). 12 trials randomised a total of 2060 patients to a dedicated stroke unit or a general medical ward, six trials (647 patients) compared a mixed assessment/rehabilitation unit with a general medical ward, and four trials (542 patients) compared a dedicated stroke unit with a mixed assessment/rehabilitation unit. Main outcome measures: Death, institutionalisation, and dependency. Results: Organised inpatient (stroke unit) care, when compared with conventional care, was best characterised by coordinated multidisciplinary rehabilitation, programmes of education and training in stroke, and specialisation of medical and nursing staff. The stroke unit care was usually housed in a geographically discrete ward. Stroke unit care was associated with a long term (median one year follow up) reduction of death (odds ratio 0.83, 95% confidence interval 0.69 to 0.98; P < 0.05) and of the combined poor outcomes of death or dependency (0.69, 0.59 to 0.82; P < 0.0001) and death or institutionalisation (0.75, 0.65 to 0.87; P < 0.0001). Beneficial effects were independent of patients' age, sex, or stroke severity and of variations in stroke unit organisation. Length. of stay in a hospital or institution was reduced by 8% (95% confidence interval 3% to 13%) compared with conventional care but there was considerable heterogeneity of results. Conclusions: Organised stroke unit care resulted in long term reductions in death, dependency, and the need for institutional care. The observed benefits were not restricted to any particular subgroup of patients or model of stroke unit care. No systematic increase in the use of resources (in terms of length of stay) was apparent.	GLASGOW ROYAL INFIRM, ACAD SECT GERIATR, GLASGOW G4 0SF, LANARK, SCOTLAND	University of Glasgow			Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328; young, john/0000-0003-4085-9306				Aitken PD, 1993, AGE AGEING S2, V22, P4; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; BARER D, 1993, AGE AGEING S3, V22, P15; BERGMAN L, 1995, STROKE, V26, P1830, DOI 10.1161/01.STR.26.10.1830; Bracken Michael B., 1992, P13; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; DENNIS M, 1994, BMJ-BRIT MED J, V309, P1273, DOI 10.1136/bmj.309.6964.1273; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Ebrahim S, 1990, CLIN EPIDEMIOLOGY ST, P116; FAGERBERG B, 1993, LANCET, V342, P992; FELDMAN DJ, 1962, J CHRON DIS, V15, P297, DOI 10.1016/0021-9681(62)90013-9; GARRAWAY WM, 1980, BRIT MED J, V281, P827, DOI 10.1136/bmj.281.6244.827; Gladman J, 1996, BRIT MED J, V312, P1623, DOI 10.1136/bmj.312.7047.1623; GORDON EE, 1966, J CHRON DIS, V19, P3, DOI 10.1016/0021-9681(66)90148-2; HAMRIN E, 1982, SCAND J REHABIL MED, V14, P101; HANKEY G, 1995, CEREBROVASC DIS, V5, P228; IMLAVIRTA M, 1994, THESIS U TAMPERE FM, V410; INDREDAVIK B, 1991, STROKE, V22, P1026, DOI 10.1161/01.STR.22.8.1026; Juby LC, 1996, CEREBROVASC DIS, V6, P106, DOI 10.1159/000108005; KALRA L, 1993, STROKE, V24, P1462, DOI 10.1161/01.STR.24.10.1462; KALRA L, 1995, STROKE, V26, P2031, DOI 10.1161/01.STR.26.11.2031; KASTE M, 1995, STROKE, V26, P249, DOI 10.1161/01.STR.26.2.249; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; MULROW CD, 1994, BRIT MED J, V309, P597, DOI 10.1136/bmj.309.6954.597; PEACOCK PB, 1972, BIRMINGHAM STROKE EP, P231; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; SIVENIUS J, 1985, STROKE, V16, P928, DOI 10.1161/01.STR.16.6.928; SMURAWSKA LT, 1994, STROKE, V25, P1628, DOI 10.1161/01.STR.25.8.1628; STEVENS RS, 1984, AGE AGEING, V13, P65, DOI 10.1093/ageing/13.2.65; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; STRAND T, 1985, STROKE, V16, P29, DOI 10.1161/01.STR.16.1.29; *STROK UN TRIAL CO, 1995, COCHR DAT SYST REV; SVENSSON A, UNPUB; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; WADE D, 1990, MEASUREMENT NEUROLOG, P175; WADE DT, 1987, J NEUROL NEUROSUR PS, V50, P177, DOI 10.1136/jnnp.50.2.177; WOODDAUPHINEE S, 1984, STROKE, V15, P864, DOI 10.1161/01.STR.15.5.864	37	600	609	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	1997	314	7088					1151	1159						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV705	9146387				2022-12-28	WOS:A1997WV70500021
J	Tarlinton, D				Tarlinton, D			Immunology - Antigen presentation by memory B cells: The sting is in the tail	SCIENCE			English	Editorial Material							RECEPTOR				Tarlinton, D (corresponding author), WALTER & ELIZA HALL INST MED RES,PO ROYAL MELBOURNE HOSP,MELBOURNE,VIC 3050,AUSTRALIA.			Tarlinton, David/0000-0001-9928-686X				Achatz G, 1997, SCIENCE, V276, P409, DOI 10.1126/science.276.5311.409; AMIGORENA S, 1992, NATURE, V358, P337, DOI 10.1038/358337a0; BONNEROT C, 1995, IMMUNITY, V3, P335, DOI 10.1016/1074-7613(95)90118-3; Kaisho T, 1997, SCIENCE, V276, P412, DOI 10.1126/science.276.5311.412; KNIGHT AM, IN PRESS EMBO J; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; Weiser P, 1997, SCIENCE, V276, P407, DOI 10.1126/science.276.5311.407	9	26	26	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					374	375		10.1126/science.276.5311.374	http://dx.doi.org/10.1126/science.276.5311.374			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9139358				2022-12-28	WOS:A1997WU47700028
J	Tramer, MR; Moore, RA; Reynolds, DJM; McQuay, HJ				Tramer, MR; Moore, RA; Reynolds, DJM; McQuay, HJ			A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting	BRITISH MEDICAL JOURNAL			English	Article							PREVENTION; CHILDREN; ANESTHESIA; PLACEBO; SURGERY; QUALITY	Objectives: To test the evidence for a dose-response with ondansetron for treatment of postoperative nausea and vomiting and to establish whether differences in efficacy between doses are of clinical relevance. Design: Quantitative systematic review of published randomised controlled trials. Data sources: Seven trials from 1991 to January 1996 retrieved from a systematic literature search (Medline, reference lists, hand searching of anaesthetic journals, manufacturer's database); no restriction on language. Main outcome measures: Estimation of efficacy (incidence of complete control of further nausea and vomiting) by using odds ratios and the ''number needed to treat'' method for early (within 6 hours of administration) and late (within 24 hours) periods. Results: Four placebo controlled trials with 1043 patients studied intravenous ondansetron 1 mg, 4 mg, or 8 mg. All doses were more efficacious than placebo in preventing further episodes of nausea or vomiting. For combined data, the point estimates for the number needed to treat were between 3.1 (8 mg) and 3.8 (1 mg) for early efficacy and between 4, 1 (8 mg) and 4.8 (1 mg) for late efficacy, without significant differences between doses. No difference was found between ondansetron and droperidol in two trials with 129 patients or between ondansetron and metoclopramide in one trial with 80 patients. Conclusions: Further nausea and vomiting could be prevented with ondansetron compared with placebo in 25% of patients who had nausea or vomiting (number needed to treat, about 4). There was no evidence of a clinically relevant dose-response between 1 mg and 8 mg or a difference between ondansetron and either droperidol or metoclopramide in a limited dataset A false impression of ondansetron's efficacy may arise because a quarter of all relevant published reports are duplicates, and reporting of study results is uncritical.	RADCLIFFE INFIRM,DEPT CLIN PHARMACOL,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary	Tramer, MR (corresponding author), CHURCHILL OXFORD RADCLIFFE HOSP,NUFFIELD DEPT ANAESTHET,OXFORD OX3 7LJ,ENGLAND.							ADRIANI J, 1961, JAMA-J AM MED ASSOC, V175, P666, DOI 10.1001/jama.1961.03040080022005; ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844; BELLVILLE J, 1961, ANESTHESIOLOGY, V22, P773, DOI 10.1097/00000542-196109000-00011; BODNER M, 1991, ANESTH ANALG, V73, P250; CLARKE RSJ, 1984, BRIT J ANAESTH, V56, P19, DOI 10.1093/bja/56.1.19; CLAYBON L, 1994, ANAESTHESIA, V49, P24, DOI 10.1111/j.1365-2044.1994.tb03579.x; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; Du Pen S, 1992, Eur J Anaesthesiol Suppl, V6, P55; FORREST JB, 1990, ANESTHESIOLOGY, V72, P262, DOI 10.1097/00000542-199002000-00009; GARDNER MJ, 1989, BRIT MED J, P55; HANTLER C, 1992, Anesthesiology (Hagerstown), V77, pA16, DOI 10.1097/00000542-199209001-00016; HEIM C, 1994, ANAESTHESIST, V43, P504, DOI 10.1007/s001010050085; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; KARLSSON E, 1990, ACTA ANAESTH SCAND, V34, P515, DOI 10.1111/j.1399-6576.1990.tb03136.x; KERMODE J, 1995, ANAESTH INTENS CARE, V23, P196, DOI 10.1177/0310057X9502300213; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LARIJANI GE, 1991, ANESTH ANALG, V73, P246; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; MARKHAM A, 1993, DRUGS, V45, P931, DOI 10.2165/00003495-199345060-00006; PALAZZO MGA, 1984, CAN ANAESTH SOC J, V31, P407, DOI 10.1007/BF03015417; Polati E., 1995, Acta Anaesthesiologica Italica, V46, P85; QUINN AC, 1994, ANAESTHESIA, V49, P62, DOI 10.1111/j.1365-2044.1994.tb03316.x; RIDING JE, 1963, BRIT J ANAESTH, V35, P180, DOI 10.1093/bja/35.3.180; ROCHON PA, 1994, JAMA-J AM MED ASSOC, V272, P108, DOI 10.1001/jama.272.2.108; SCUDERI P, 1993, ANESTHESIOLOGY, V78, P15, DOI 10.1097/00000542-199301000-00004; TRAMER M, 1995, BRIT J ANAESTH, V75, P556, DOI 10.1093/bja/75.5.556; UMMENHOFER W, 1994, ANESTHESIOLOGY, V81, P804, DOI 10.1097/00000542-199410000-00006; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; ZAHL K, 1993, J CLIN ANESTH, V5, pS52	29	96	100	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 12	1997	314	7087					1088	1092		10.1136/bmj.314.7087.1088	http://dx.doi.org/10.1136/bmj.314.7087.1088			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU236	9133892	Green Published			2022-12-28	WOS:A1997WU23600026
J	SosaPineda, B; Chowdhury, K; Torres, M; Oliver, G; Gruss, P				SosaPineda, B; Chowdhury, K; Torres, M; Oliver, G; Gruss, P			The Pax4 gene is essential for differentiation of insulin-producing beta cells In the mammalian pancreas	NATURE			English	Article							TRANSCRIPTION FACTOR; ENDOCRINE-CELLS; HOMEOBOX GENE; EXPRESSION; NEURONS; XENOPUS	The mammalian pancreas contains two distinct cell populations: endocrine cells which secrete hormones into the bloodstream, and exocrine cells, which secrete enzymes into the digestive tract(1). The four endocrine cell types found in the adult pancreas-alpha, beta, delta and PP-synthesize glucagon, insulin, somatostatin and pancreatic polypeptide, respectively(2). All of these endocrine cells arise from common multipotent precursors, which coexpress several hormones when they start to differentiate(3). Expression of some homeobox genes in the early developing pancreas has been reported(4-7). The Pax4 gene is expressed in the early pancreas, but is later restricted to beta cells, Inactivation of Pax4 by homologous recombination results in the absence of mature insulin- and somatostatin-producing cells (beta and delta, respectively) in the pancreas of Pax4 homozygous mutant mice, but glucagon-producing cr cells are present in considerably higher numbers. We propose that the early expression of Pax4 in a subset of endocrine progenitors is essential for the differentiation of the beta and delta cell lineages. A default pathway would explain the elevated number of alpha cells in the absence of Pax4.	MAX PLANCK INST BIOPHYS CHEM, D-37077 GOTTINGEN, GERMANY	Max Planck Society			Torres, Miguel/A-7388-2013; Torres, Miguel/CAG-0003-2022	Torres, Miguel/0000-0003-0906-4767; Torres, Miguel/0000-0003-0906-4767				ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; DENT JA, 1989, DEVELOPMENT, V105, P61; Githens Sherwood, 1993, P21; GITTES GK, 1992, P NATL ACAD SCI USA, V89, P1128, DOI 10.1073/pnas.89.3.1128; GUZ Y, 1995, DEVELOPMENT, V121, P11; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1994, EMBO J, V13, P1145; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; PICTET RL, 1972, DEV BIOL, V29, P436, DOI 10.1016/0012-1606(72)90083-8; RAJU K, 1993, MECH DEVELOP, V44, P51, DOI 10.1016/0925-4773(93)90016-Q; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WRIGHT CVE, 1989, DEVELOPMENT, V105, P787	19	615	642	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 27	1997	386	6623					399	402		10.1038/386399a0	http://dx.doi.org/10.1038/386399a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121556				2022-12-28	WOS:A1997WQ17000065
J	Martinot, M; Marcellin, P; Boyer, N; Detmer, J; Pouteau, M; Castelnau, C; Degott, C; Auperin, A; Collins, M; Kolberg, J; Wilber, J; Benhamou, JP; Erlinger, S				Martinot, M; Marcellin, P; Boyer, N; Detmer, J; Pouteau, M; Castelnau, C; Degott, C; Auperin, A; Collins, M; Kolberg, J; Wilber, J; Benhamou, JP; Erlinger, S			Influence of hepatitis G virus infection on the severity of liver disease and response to interferon-alpha in patients with chronic hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Article						hepatitis C; hepatitis agents, GB; hepatitis, viral, human; hepatitis C-like viruses; interferon-alpha	ASSAY; RNA	Background: Dual infection with hepatitis G virus (HGV) and hepatitis C virus (HCV) is common. The effect of HGV infection on chronic hepatitis C is not well known. Objective: To assess the prevalence of HGV infection; the effect of HCV infection on the clinical, virologic, and histologic features of patients with chronic hepatitis C treated with interferon-alpha; and the influence of HGV infection on response to interferon-alpha therapy. Design: Retrospective study. Setting: A university hospital in France. Patients: 228 patients with chronic hepatitis C treated with interferon-alpha (3 million U or 5 million U subcutaneously 3 times a week for 3, 6, or 12 months). Measurements: Before initiation of treatment, serum HCV RNA and serum HCV RNA were detected with branched-DNA assays and HCV genotype was determined with a line probe assay. Serum HGV RNA and serum HCV RNA were detected by polymerase chain reaction at the end of treatment and 6 months after treatment. Results: Infection with HGV was detected in 21% of patients and 32% of intravenous drug users. The median serum HGV RNA level was 33 x 10(6) genome equivalents/mL. Infection with HGV was more frequently found in men with a history of intravenous drug use and was associated with HCV genotype 3a (P = 0.02) independent of the source of infection. Serum HCV RNA levels, liver histologic findings, and response to interferon-a therapy did not differ between patients with and those without HGV infection. The loss of serum HCV RNA was not correlated with the biochemical response contrarily to the loss of serum HCV RNA. Conclusions: Infection with HGV occurred frequently in this sample of patients with chronic hepatitis C, especially in patients infected with HCV genotype 3a. The level of HGV viremia was high relative to the level of HCV viremia. Infection with HGV did not influence the severity of liver disease or response to interferon-alpha therapy.	HOP BEAUJON, INSERM, U24, F-92118 CLICHY, FRANCE; HOP BEAUJON, SERV HEPATOL, F-92118 CLICHY, FRANCE; HOP BEAUJON, SERV ANAT & CYTOL PATHOL, F-92118 CLICHY, FRANCE; CHIRON CORP, EMERYVILLE, CA 94608 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Novartis								Aikawa T, 1996, NEW ENGL J MED, V334, P195, DOI 10.1056/NEJM199601183340316; ALLIE R, 1996, LANCET, V347, P1552; Alter HJ, 1996, NEW ENGL J MED, V334, P1536, DOI 10.1056/NEJM199606063342310; BELLEZZO JM, 1995, HEPATOLOGY, V22, P1036; BENHAMOU JP, 1995, HEPATOLOGY, V22, P37; COLLINS ML, 1995, ANAL BIOCHEM, V226, P120, DOI 10.1006/abio.1995.1199; deLamballerie X, 1996, NEW ENGL J MED, V334, P1549, DOI 10.1056/NEJM199606063342319; Detmer J, 1996, J CLIN MICROBIOL, V34, P901, DOI 10.1128/JCM.34.4.901-907.1996; Feucht HH, 1996, LANCET, V347, P615, DOI 10.1016/S0140-6736(96)91309-4; HORN T, 1995, TETRAHEDRON LETT, V36, P2033, DOI 10.1016/0040-4039(95)00230-A; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Kuroki T, 1996, LANCET, V347, P908, DOI 10.1016/S0140-6736(96)91395-1; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; MARCELLIN P, 1994, HEPATOLOGY, V20, pA154; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; Masuko K, 1996, NEW ENGL J MED, V334, P1485, DOI 10.1056/NEJM199606063342301; Nubling CM, 1996, LANCET, V347, P68, DOI 10.1016/S0140-6736(96)91605-0; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; Schmidt B, 1996, LANCET, V347, P909, DOI 10.1016/S0140-6736(96)91396-3; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; Tanaka E, 1996, ANN INTERN MED, V125, P740, DOI 10.7326/0003-4819-125-9-199611010-00007; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7; YOUNG KKY, 1993, J CLIN MICROBIOL, V31, P882, DOI 10.1128/JCM.31.4.882-886.1993	26	62	63	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1997	126	11					874	+		10.7326/0003-4819-126-11-199706010-00004	http://dx.doi.org/10.7326/0003-4819-126-11-199706010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA911	9163288				2022-12-28	WOS:A1997XA91100004
J	Lakhani, SR; Easton, DF; Stratton, MR; StorferIsser, A; Anderson, TJ; Farid, LM; Gusterson, BA; Jaquemier, J; Sloane, JP; Venter, D; VandeVijver, MJ; Bishop, DT; Barkardottir, RB; Bignon, YJ; Cornelisse, C; ChangClaude, J; Daly, PA; Devilee, P; Egilsson, V; Ford, D; Goldgar, D; Haites, N; Hamann, U; Klijn, JGM; Lasset, C; Lenoir, G; McManus, R; Neuhausen, S; Ormiston, W; Ponder, BAJ; Peto, J; Steel, CM; StoppaLyonnet, D; Smyth, E; Sobol, H; Spurr, NK; Scott, RJ; Scherneck, S; Streuwing, JP; Vasen, H; Weber, B				Lakhani, SR; Easton, DF; Stratton, MR; StorferIsser, A; Anderson, TJ; Farid, LM; Gusterson, BA; Jaquemier, J; Sloane, JP; Venter, D; VandeVijver, MJ; Bishop, DT; Barkardottir, RB; Bignon, YJ; Cornelisse, C; ChangClaude, J; Daly, PA; Devilee, P; Egilsson, V; Ford, D; Goldgar, D; Haites, N; Hamann, U; Klijn, JGM; Lasset, C; Lenoir, G; McManus, R; Neuhausen, S; Ormiston, W; Ponder, BAJ; Peto, J; Steel, CM; StoppaLyonnet, D; Smyth, E; Sobol, H; Spurr, NK; Scott, RJ; Scherneck, S; Streuwing, JP; Vasen, H; Weber, B			Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases	LANCET			English	Article							SUSCEPTIBILITY GENE; HISTOPROGNOSTIC GRADE; PROGNOSTIC FACTORS; HISTORY; ASSOCIATION; CARCINOMA	Background A few breast cancer cases are attributable to a hereditary predisposition to the disease. We aimed to compare the histological features of breast cancer in women carrying mutations in the susceptibility genes BRCA1 and BRCA2 with controls unselected for family history. Methods The morphological characteristics of specimens from 440 patients with familiar breast cancer, including 118 in carriers of BRCA1 mutations and 78 in carriers of BRCA2 mutations, were compared with those from 547 age-matched controls, unselected for family history, by seven pathologists. Findings Cancers in carriers of BRCA1 (p<0.0001) and BRCA2 mutations (p=0.04) were, on average, of a higher overall grade than in controls, For example, the proportions in grade 3 were 66% of 139, 41% of 58 and 36% of 368 specimens, respectively. However, when the three grade indices were considered independently, breast cancers in BRCA1-mutation carriers showed more pleomorphism (p=0.006), a higher mitotic count (p<0.0001), and less tubule formation than controls (p=0.006), whereas cancers in BRCA2-mutation carriers showed less tubule formation (p=0.003), but no difference in pleomorphism or mitotic count, The occurrence of invasive lobular carcinoma and invasive ductal carcinoma was not significantly different between carriers of BRCA1 or BRCA2 mutations and controls. Medullary or atypical medullary carcinoma was, however, found more often in BRCA1 (13%, p<0.0001) than in BRCA2-mutation carriers (3%) or controls (2%). Tubular carcinoma was less common in BRCA2-mutation carriers. The few mucoid carcinomas were all in familiar cases, Carriers of BRCA1 mutations showed less ductal carcinoma in situ around the invasive lesion than controls (41 vs 56%, p=0.001). Lobular carcinoma in situ was less common in familiar cancers (p=0.013), but differences were not significant for BRCA1-mutations or BRCA2-mutation carriers, separately. Interpretation The histology of breast cancers in predisposed women differs from that in sporadic cases, and there are differences between breast cancers in carriers of BRCA1 and BRCA2 mutations. The findings suggest that breast cancer due to BRCA1, has a different natural history to BRCA2 or apparently sporadic disease, which may have implications for screening and management.	INST CANC RES, HADDOW LABS, SECT MOL CARCINOGENESIS, SUTTON SM2 5NG, SURREY, ENGLAND; INST CANC RES, HADDOW LABS, EPIDEMIOL SECT, SUTTON SM2 5NG, SURREY, ENGLAND; INST CANC RES, HADDOW LABS, SECT CELL BIOL & EXPT PATHOL, SUTTON SM2 5NG, SURREY, ENGLAND; ST JAMES UNIV HOSP, IMPERIAL CANC RES FUND, GENET EPIDEMIOL LAB, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND; UNIV HOSP ICELAND, CELL BIOL LAB, REYKJAVIK, ICELAND; LEIDEN UNIV, DEPT GENET & PATHOL, LEIDEN, NETHERLANDS; INT AGCY RES CANC, F-69372 LYON, FRANCE; UNIV CAMBRIDGE, INST PUBL HLTH, DEPT COMMUNITY MED, CAMBRIDGE, ENGLAND; ADDENBROOKES HOSP, CRC, HUMAN CANC GENET RES GRP, CAMBRIDGE, ENGLAND; UNIV ABERDEEN, DEPT MED & THERAPEUT, ABERDEEN, SCOTLAND; KANTONSSPITAL, DEPT HUMAN GENET, CH-4031 BASEL, SWITZERLAND; ONCOL MOL LAB, CLERMONT FERRAND, FRANCE; WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; DEUTSCH KREBSFORSCHUNGSZENTRUM, DIV EPIDEMIOL, HEIDELBERG, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, DIV MOL GENOME ANAL, D-6900 HEIDELBERG, GERMANY; UNIV PENN, CTR CANC, PHILADELPHIA, PA 19104 USA; UNIV PENN, MED CTR, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; GENET EPIDEMIOL BRANCH, BETHESDA, MD USA; UNIV UTAH, DEPT MED INFORMAT, SALT LAKE CITY, UT 84112 USA; UNIV EDINBURGH, SCH MED, DEPT PATHOL, EDINBURGH, MIDLOTHIAN, SCOTLAND; ROYAL LIVERPOOL UNIV HOSP, DEPT HISTOPATHOL, LIVERPOOL, MERSEYSIDE, ENGLAND; INST J PAOLI I CALMETTES, DEPT ONCOL GENET, F-13009 MARSEILLE, FRANCE; PETER MACCALLUM CANC INST, MELBOURNE, VIC 3000, AUSTRALIA; UNIV MELBOURNE, MELBOURNE, VIC, AUSTRALIA; CTR LEON BERARD, F-69373 LYON, FRANCE; UNIV ST ANDREWS, SCH BIOL & MED SCI, ST ANDREWS, FIFE, SCOTLAND; ST JAMES HOSP, DEPT MED, DUBLIN 8, IRELAND; INST CURIE, PARIS, FRANCE; NETHERLANDS CANC INST, AMSTERDAM, NETHERLANDS; MAX DELBRUCK CTR MOL MED, BERLIN, GERMANY; DR DANIEL DEN HOED CANC CTR, NL-3008 AE ROTTERDAM, NETHERLANDS; ACAD HOSP LEIDEN, LEIDEN, NETHERLANDS	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; Saint James's University Hospital; Landspitali National University Hospital; Leiden University; Leiden University - Excl LUMC; World Health Organization; International Agency for Research on Cancer (IARC); University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Aberdeen; Kantonsspital Aarau AG (KSA); University of Basel; University of Edinburgh; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Pennsylvania; University of Pennsylvania; Utah System of Higher Education; University of Utah; University of Edinburgh; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; UNICANCER; Institut Paoli-Calmette (IPC); Peter Maccallum Cancer Center; University of Melbourne; UNICANCER; Centre Leon Berard; University of St Andrews; Trinity College Dublin; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Netherlands Cancer Institute; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Leiden University; Leiden University Medical Center (LUMC)			gusterson, barry a/D-3752-2009; McManus, Ross/AAE-9236-2020; Struewing, Jeffery P/C-3221-2008; Lakhani, Sunil R/I-1970-2018; Struewing, Jeffery P/I-7502-2013; , bignon/Y-3243-2019; Scott, Rodney J/B-2827-2013; DEVILEE, PETER/ABR-2140-2022	Lakhani, Sunil R/0000-0003-4067-2760; Struewing, Jeffery P/0000-0002-4848-3334; Scott, Rodney J/0000-0001-7724-3404; Bishop, Tim/0000-0002-8752-8785	NCI NIH HHS [CA61231] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061231] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTOMAA S, 1992, ONCOLOGY-BASEL, V49, P1; BIGNON YJ, 1995, LANCET, V346, P258, DOI 10.1016/S0140-6736(95)91310-6; CANNONALBRIGHT LA, 1994, CANCER RES, V54, P2378; CLAUS EB, 1993, CANCER, V71, P147, DOI 10.1002/1097-0142(19930101)71:1<147::AID-CNCR2820710124>3.0.CO;2-V; EASTON DF, 1995, AM J HUM GENET, V56, P265; Eisinger F, 1996, CANCER RES, V56, P471; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; ERDREICH LS, 1980, SOUTHERN MED J, V73, P28, DOI 10.1097/00007611-198001000-00012; Fleiss JL, 1981, STAT METHODS RATES P; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Huber P.J., 1967, P 5 BERKELEY S MATH, V1, P221; JACQUEMIER J, 1995, LANCET, V345, P1503, DOI 10.1016/S0140-6736(95)91060-3; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; LAGIOS MD, 1980, AM J CLIN PATHOL, V73, P25; LIVOLSI VA, 1982, CANCER, V49, P1937, DOI 10.1002/1097-0142(19820501)49:9<1937::AID-CNCR2820490931>3.0.CO;2-H; LYNCH HT, 1984, CANCER GENET CYTOGEN, V13, P43, DOI 10.1016/0165-4608(84)90087-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MARCUS JN, 1994, MONOGR NATL CANC I, V16, P23; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; ROSEN PP, 1982, CANCER, V50, P171, DOI 10.1002/1097-0142(19820701)50:1<171::AID-CNCR2820500132>3.0.CO;2-M; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; *UK NAT COORD GROU, 1995, PATH REP BREAST CANC; WOOSTER R, 1992, NAT GENET, V2, P132, DOI 10.1038/ng1092-132; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	29	452	459	0	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	1997	349	9064					1505	1510						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167459				2022-12-28	WOS:A1997XA90100009
J	Lupashin, VV; Waters, MG				Lupashin, VV; Waters, MG			t-SNARE activation through transient interaction with a Rab-like guanosine triphosphatase	SCIENCE			English	Article							BINDING YPT1 PROTEIN; INTEGRAL MEMBRANE-PROTEIN; SYNAPTIC VESICLE DOCKING; ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; GENE-PRODUCT; SECRETION MACHINERY; VESICULAR TRANSPORT; GOLGI TRANSPORT; FUSION PROTEIN	Intracellular vesicle targeting involves the interaction of vesicle proteins, termed v-SNAREs, with target membrane proteins, termed t-SNAREs. Assembly of v-SNARE-t-SNARE targeting complexes is modulated by members of the Sec1-Sly1 protein family, and by small guanosine triphosphatases termed Rabs. The interactions of these proteins during assembly of the endoplasmic reticulum-to-Golgi targeting complex in Saccharomyces cerevisiae were studied. The data suggest that the Rab protein Ypt1p transiently interacts with the t-SNARE Sed5p and results in displacement of the negative regulator Sly1p, allowing subsequent formation of the v-SNARE-t-SNARE targeting complex.	PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Princeton University			Lupashin, Vladimir/AAB-4312-2020; Lupashin, Vladimir/E-3013-2013	Lupashin, Vladimir/0000-0002-2350-1962; Lupashin, Vladimir/0000-0002-2350-1962	NIGMS NIH HHS [GM48753] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048753] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; Halachmi N, 1996, J NEUROCHEM, V66, P889; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Harlow E., 1988, ANTIBODIES LAB MANUA; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; Rose MD., 1990, METHODS YEAST GENETI; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SIKORSKI RS, 1989, GENETICS, V122, P19; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	32	181	183	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1255	1258		10.1126/science.276.5316.1255	http://dx.doi.org/10.1126/science.276.5316.1255			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157884				2022-12-28	WOS:A1997XA49700043
J	Jacobson, JM; Greenspan, JS; Spritzler, J; Ketter, N; Fahey, JL; Jackson, JB; Fox, L; Chernoff, M; Wu, AW; MacPhail, LA; Vasquez, GJ; Wohl, DA				Jacobson, JM; Greenspan, JS; Spritzler, J; Ketter, N; Fahey, JL; Jackson, JB; Fox, L; Chernoff, M; Wu, AW; MacPhail, LA; Vasquez, GJ; Wohl, DA			Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA PRODUCTION; GIANT MUCOCUTANEOUS APHTHAE; ERYTHEMA-NODOSUM LEPROSUM; HIV-INFECTION; OROGENITAL ULCERATION; SOLUBLE RECEPTORS; TYPE-1 INFECTION; RECURRENT; AIDS	Background In patients with advanced human immunodeficiency virus (HIV) infection, aphthous ulceration of the mouth and oropharynx can become extensive and debilitating. Preliminary reports suggest that thalidomide may promote the healing of oral aphthous ulcers. Methods We performed a double-blind, randomized, placebo-controlled study of thalidomide as therapy for oral aphthous ulcers in HIV-infected patients. The patients received a four-week course of either 200 mg of thalidomide or placebo orally once per day. They were evaluated weekly for the condition of the ulcers, their quality of life, and evidence of toxicity. Assays were performed for plasma tumor necrosis factor alpha (TNF-alpha), soluble TNF-alpha receptors, and HIV RNA. Results Sixteen of 29 patients in the thalidomide group (55 percent) had complete healing of their aphthous ulcers after four weeks, as compared with only 2 of 28 patients in the placebo group (7 percent; odds ratio, 15; 95 percent confidence interval after adjustment for group sequential testing, 1.8 to 499; unadjusted P < 0.001). Pain diminished and the ability to eat improved with thalidomide treatment. The adverse effects noted with thalidomide included somnolence and rash (7 patients each), and 6 of the 29 patients discontinued treatment because of toxicity. Thalidomide treatment increased HIV RNA levels (median increase, 0.42 log(10) copies per milliliter; increase with placebo, 0.05; P = 0.04). With thalidomide treatment there were unexpected increases in the plasma concentrations of TNF-alpha and soluble TNF-alpha receptors. Conclusions Thalidomide is an effective treatment for aphthous ulceration of the mouth and oropharynx in patients with HIV infection. (C) 1997, Massachusetts Medical Society.	MT SINAI SCH MED, NEW YORK, NY USA; UNIV CALIF SAN FRANCISCO, DEPT STOMATOL, SAN FRANCISCO, CA 94143 USA; HARVARD UNIV, SCH PUBL HLTH, STAT & DATA ANAL CTR, BOSTON, MA 02115 USA; NIAID, DIV AIDS, BETHESDA, MD 20892 USA; UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; UNIV PUERTO RICO, SCH MED, DEPT MED, SAN JUAN, PR 00936 USA; UNIV N CAROLINA, DEPT MED, CHAPEL HILL, NC USA	Icahn School of Medicine at Mount Sinai; University of California System; University of California San Francisco; Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California Los Angeles; Johns Hopkins University; Johns Hopkins University; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of North Carolina; University of North Carolina Chapel Hill	Jacobson, JM (corresponding author), VET AFFAIRS MED CTR, DEPT MED, 130 W KINGSBRIDGE RD, BRONX, NY 10468 USA.		Greenspan, John/AAE-9321-2020; Wu, Albert/AAJ-4780-2021	jackson, brooks/0000-0001-9458-135X				AUKRUST P, 1994, J INFECT DIS, V169, P420, DOI 10.1093/infdis/169.2.420; AUKRUST P, 1994, J INFECT DIS, V169, P1186; BACH MC, 1988, ANN INTERN MED, V109, P388; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOWERS PW, 1983, BRIT MED J, V287, P799, DOI 10.1136/bmj.287.6395.799; BRESLOW N, 1980, IARC SCI PUBL, V32, P128; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; GEORGHIOU PR, 1990, MED J AUSTRALIA, V152, P382, DOI 10.5694/j.1326-5377.1990.tb125225.x; GODFRIED MH, 1994, J INFECT DIS, V169, P739, DOI 10.1093/infdis/169.4.739; GODFRIED MH, 1993, AIDS, V7, P33, DOI 10.1097/00002030-199301000-00005; GORIN I, 1990, LANCET, V335, P1343, DOI 10.1016/0140-6736(90)91223-W; GRINSPAN D, 1985, J AM ACAD DERMATOL, V12, P85, DOI 10.1016/S0190-9622(85)70014-X; JENKINS JS, 1984, LANCET, V2, P1424; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIM K, 1987, BIOMETRIKA, V74, P149, DOI 10.2307/2336029; Klausner JD, 1996, J ACQ IMMUN DEF SYND, V11, P247, DOI 10.1097/00042560-199603010-00005; KOTLER DP, 1992, J CLIN GASTROENTEROL, V15, P284, DOI 10.1097/00004836-199212000-00004; KREIPE U, 1967, Archiv fuer Kinderheilkunde, V176, P33; KURKCUOGLU N, 1985, BRIT J DERMATOL, V112, P632; LEHMANN EL, 1975, NONPARAMETRICS STAT, P55; LENZ W, 1962, LANCET, V1, P45; MACPHAIL LA, 1991, ORAL SURG ORAL MED O, V71, P678, DOI 10.1016/0030-4220(91)90273-F; MAKONKAWKEYOON S, 1993, P NATL ACAD SCI USA, V90, P5974, DOI 10.1073/pnas.90.13.5974; MASCARO JM, 1979, ARCH DERMATOL, V115, P636, DOI 10.1001/archderm.1979.04010050060027; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; NOWACK E, 1965, HUMANGENETIK, V1, P516, DOI 10.1007/BF00338341; PATERSON DL, 1995, CLIN INFECT DIS, V20, P250, DOI 10.1093/clinids/20.2.250; PETERSON PK, 1995, J INFECT DIS, V172, P1137, DOI 10.1093/infdis/172.4.1137; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; RADEFF B, 1990, J AM ACAD DERMATOL, V23, P523, DOI 10.1016/S0190-9622(08)81115-2; REVUZ J, 1990, ARCH DERMATOL, V126, P923, DOI 10.1001/archderm.126.7.923; RYAN J, 1992, NEW ENGL J MED, V327, P208, DOI 10.1056/NEJM199207163270319; SAMPAIO EP, 1992, J EXP MED, V175, P1729, DOI 10.1084/jem.175.6.1729; SAMPAIO EP, 1991, J EXP MED, V173, P699, DOI 10.1084/jem.173.3.699; SAMPAIO EP, 1993, J INFECT DIS, V168, P408, DOI 10.1093/infdis/168.2.408; Sheskin J, 1969, Int J Lepr Other Mycobact Dis, V37, P135; TORRAS H, 1982, ARCH DERMATOL, V118, P875, DOI 10.1001/archderm.1982.01650230003002; TRAMONTANA JM, 1995, MOL MED, V1, P384, DOI 10.1007/BF03401576; VOGELSANG GB, 1992, NEW ENGL J MED, V326, P1055, DOI 10.1056/NEJM199204163261604; Woo SB, 1996, J AM DENT ASSOC, V127, P1202, DOI 10.14219/jada.archive.1996.0412; WU AW, 1991, MED CARE, V29, P786, DOI 10.1097/00005650-199108000-00011; WULFF CH, 1985, BRIT J DERMATOL, V112, P475, DOI 10.1111/j.1365-2133.1985.tb02323.x; YOULE M, 1989, BRIT MED J, V298, P432, DOI 10.1136/bmj.298.6671.432	44	298	325	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	1997	336	21					1487	1493		10.1056/NEJM199705223362103	http://dx.doi.org/10.1056/NEJM199705223362103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ767	9154767	Green Published			2022-12-28	WOS:A1997WZ76700003
J	Molmenti, EP				Molmenti, EP			Perforated duodenal ulcer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Molmenti, EP (corresponding author), THOMAS E STARZL TRANSPLANTAT INST,PITTSBURGH,PA 15213, USA.								0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 22	1997	336	21					1499	1499		10.1056/NEJM199705223362105	http://dx.doi.org/10.1056/NEJM199705223362105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ767	9154769				2022-12-28	WOS:A1997WZ76700005
J	Gullette, ECD; Blumenthal, JA; Babyak, M; Jiang, W; Waugh, RA; Frid, DJ; OConnor, CM; Morris, JJ; Krantz, DS				Gullette, ECD; Blumenthal, JA; Babyak, M; Jiang, W; Waugh, RA; Frid, DJ; OConnor, CM; Morris, JJ; Krantz, DS			Effects of mental stress on myocardial ischemia during daily life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; ST-SEGMENT DEPRESSION; AMBULATORY PATIENTS; CASE-CROSSOVER; HEART-DISEASE; INFARCTION; MORTALITY; RISK; ASSOCIATION; PROGNOSIS	Objective.-To determine the relative risk of myocardial ischemia triggered by specific emotions during daily life. Design and Setting.-Relative risk was calculated by the recently developed case-crossover method, in which the frequency of a presumed trigger during nonischemic, or control, hours is compared with the trigger's frequency during ischemic, or case, hours. Outpatients at Duke University Medical Center, Durham, NC, underwent 48 hours of ambulatory electrocardiographic (EGG) monitoring with concurrent self-report measures of activities and emotions. Occurrences of negative emotions in the hour before the onset of myocardial ischemia were compared with their usual frequency based on all hours in which ischemia did not occur. Subjects.-From a sample of 132 patients with coronary artery disease and recent evidence of exercise-induced ischemia who underwent 48 hours of ambulatory ECG. monitoring, 58 patients exhibited ambulatory ischemia and were included in the analysis. Outcome Measures.-Myocardial ischemia during 48-hour ECG monitoring was defined as horizontal or downsloping ST-segment depression of 1 mm (0.1 mV) or more for 1 minute or longer compared with resting baseline. The ECG data were cross-tabulated with subjects' concurrent diary ratings of 3 negative emotions-tension, sadness, and frustration-and 2 positive emotions-happiness and feeling in control-on a 5-point scale of intensity. Results.-The unadjusted relative risk of occurrence of myocardial ischemia in the hour following high levels of negative emotions was 3.0 (95% confidence interval [CI], 1.5-5.9; P<.01) for tension, 2.9 (95% CI, 1.0-8.0; P<.05) for sadness, and 2.6 (95% CI, 1.3-5.1; P<.01) for frustration. The corresponding risk ratios adjusted for physical activity and time of day were 2.2 (95% CI, 1.1-4.5; P<.05) for tension, 2.2 (95% CI, 0.7-6.4; P=.16) for sadness, and 2.2 (95% CI, 1.1-4.3; P<.05) for frustration. Conclusions.-Mental stress during daily life, including reported feelings of tension, frustration, and sadness, can more than double the risk of myocardial ischemia in the subsequent hour. The clinical significance of mental stress-induced ischemia during daily life needs to be further evaluated.	DUKE UNIV, SCH MED, DEPT MED, DURHAM, NC 27710 USA; OHIO STATE UNIV, DEPT MED, COLUMBUS, OH 43210 USA; UNIFORMED SERV UNIV HLTH SCI, DEPT MED & CLIN PSYCHOL, BETHESDA, MD 20814 USA	Duke University; University System of Ohio; Ohio State University; Uniformed Services University of the Health Sciences - USA	Gullette, ECD (corresponding author), DUKE UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BEHAV CARDIOL LAB, BOX 3119, DURHAM, NC 27710 USA.		Krantz, David S./L-5364-2015	Krantz, David/0000-0002-1671-1355	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049572, R01HL047337, R01HL043028] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47337, HL 49572, HL 43028] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAIREY CN, 1991, J AM COLL CARDIOL, V17, P1388, DOI 10.1016/S0735-1097(10)80152-4; BAREFOOT JC, 1983, PSYCHOSOM MED, V45, P59, DOI 10.1097/00006842-198303000-00008; BARRY J, 1988, AM J CARDIOL, V61, P989, DOI 10.1016/0002-9149(88)90112-9; BLUMENTHAL JA, 1995, CIRCULATION, V92, P2102, DOI 10.1161/01.CIR.92.8.2102; Burg MM, 1993, J AM COLL CARDIOL, V22, P440, DOI 10.1016/0735-1097(93)90048-6; Cohn K, 1976, Adv Cardiol, V17, P85; DEANFIELD JE, 1984, LANCET, V2, P1001; ELLESTAD MH, 1979, PROG CARDIOVASC DIS, V21, P431, DOI 10.1016/0033-0620(79)90025-2; FRASURESMITH N, 1995, HEALTH PSYCHOL, V14, P388, DOI 10.1037/0278-6133.14.5.388; FREEMAN LJ, 1987, AM HEART J, V114, P477, DOI 10.1016/0002-8703(87)90741-1; Gabbay FH, 1996, J AM COLL CARDIOL, V27, P585, DOI 10.1016/0735-1097(95)00510-2; GOTTDIENER JS, 1994, J AM COLL CARDIOL, V24, P1645, DOI 10.1016/0735-1097(94)90169-4; GOTTLIEB SO, 1988, JAMA-J AM MED ASSOC, V259, P1030, DOI 10.1001/jama.259.7.1030; HEDGES SM, 1990, J PSYCHOPATHOL BEHAV, V12, P203, DOI 10.1007/BF00960618; JIANG W, 1997, J AM COLL CARDIOL  S, V29, P236; KARK JD, 1995, JAMA-J AM MED ASSOC, V273, P1208, DOI 10.1001/jama.273.15.1208; Kawachi I, 1996, CIRCULATION, V94, P2090, DOI 10.1161/01.CIR.94.9.2090; KAWACHI I, 1994, CIRCULATION, V90, P2225, DOI 10.1161/01.CIR.90.5.2225; KRANTZ DS, 1994, AM HEART J, V128, P703, DOI 10.1016/0002-8703(94)90268-2; Kubzansky LD, 1997, CIRCULATION, V95, P818; Leor J, 1996, NEW ENGL J MED, V334, P413, DOI 10.1056/NEJM199602153340701; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; MITTLEMAN MA, 1995, AM J EPIDEMIOL, V142, P91, DOI 10.1093/oxfordjournals.aje.a117550; MITTLEMAN MA, 1995, CIRCULATION, V92, P1720, DOI 10.1161/01.CIR.92.7.1720; MODENA MG, 1989, CLIN CARDIOL, V12, P21, DOI 10.1002/clc.4960120104; Muller JE, 1996, JAMA-J AM MED ASSOC, V275, P1405, DOI 10.1001/jama.275.18.1405; NABEL EG, 1988, CIRCULATION, V78, P60, DOI 10.1161/01.CIR.78.1.60; PARMLEY WW, 1989, CIRCULATION, V80, P68; PATTERSON SM, 1993, PSYCHOPHYSIOLOGY, V30, P296, DOI 10.1111/j.1469-8986.1993.tb03356.x; ROZANSKI A, 1987, AM HEART J, V114, P627, DOI 10.1016/0002-8703(87)90761-7; ROZANSKI A, 1988, NEW ENGL J MED, V318, P1005, DOI 10.1056/NEJM198804213181601; SCHANG SJ, 1977, AM J CARDIOL, V39, P396, DOI 10.1016/S0002-9149(77)80095-7; TAVAZZI L, 1990, ADV CARDIOL, V37, P53	34	229	233	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	1997	277	19					1521	1526		10.1001/jama.277.19.1521	http://dx.doi.org/10.1001/jama.277.19.1521			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WY969	9153365				2022-12-28	WOS:A1997WY96900029
J	Watson, AR; Irving, WL; Ansell, ID				Watson, AR; Irving, WL; Ansell, ID			Playing in a scrapyard and acute renal failure	LANCET			English	Article							HANTAVIRUS INFECTION		CITY HOSP NOTTINGHAM,DEPT PATHOL,NOTTINGHAM NG5 1PB,ENGLAND; UNIV NOTTINGHAM HOSP,DIV MICROBIOL,NOTTINGHAM NG7 2UH,ENGLAND	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham	Watson, AR (corresponding author), CITY HOSP NOTTINGHAM,CHILDREN & YOUNG PEOPLES KIDNEY UNIT,HUCKNALL RD,NOTTINGHAM NG5 1PB,ENGLAND.			Irving, William/0000-0002-7268-3168				MCKEE KT, 1991, TXB HUMAN VIROLOGY, P615; MUSTONEN J, 1994, CLIN NEPHROL, V41, P121; PETHER JVS, 1993, EPIDEMIOL INFECT, V111, P171, DOI 10.1017/S095026880005679X; RICE P, 1993, J INFECTION, V27, P342, DOI 10.1016/0163-4453(93)92532-2; WALKER E, 1984, LANCET, V2, P982	5	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 17	1997	349	9063					1446	1446		10.1016/S0140-6736(97)01408-6	http://dx.doi.org/10.1016/S0140-6736(97)01408-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164319				2022-12-28	WOS:A1997WZ76500013
J	Wong, PC; Zheng, H; Chen, H; Becher, MW; Sirinathsinghji, DJS; Trumbauer, ME; Chen, HY; Price, DL; VanderPloeg, LHT; Sisodia, SS				Wong, PC; Zheng, H; Chen, H; Becher, MW; Sirinathsinghji, DJS; Trumbauer, ME; Chen, HY; Price, DL; VanderPloeg, LHT; Sisodia, SS			Presenilin 1 is required for Notch1 DII1 expression in the paraxial mesoderm	NATURE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; MISSENSE MUTATIONS; VERTEBRAL COLUMN; GENE; SOMITES; EMBRYO; PAX-1; CELLS	Approximately 10% of cases of Alzheimer's disease are familial and associated with autosomal dominant inheritance of mutations in genes encoding the amyloid precursor protein(1), presenilin 1 (PS1)(2) and presenilin 2 (pS2)(3,4). Mutations in PSI are Linked to about 25% of cases of early-onset familial Alzheimer's disease(5). PS1, which is endoproteolytically processed in vivo(6), is a multipass transmembrane protein and is a functional homologue of SEL-12 (ref. 7), a Caenorhabditis elegans protein that facilitates signalling mediated by the Notch/LIN-12 family of receptors(8,9). To examine 1 potential roles for PS1 in facilitating Notch-mediated signalling during mammalian embryogenesis, we generated mice with targeted disruptions of PSI alleles (PS1(-/-) mice). PS1(-/-) embryos exhibited abnormal patterning of the axial skeleton and spinal ganglia, phenotypes traced to defects in somite segmentation and differentiation. Moreover, expression of mRNA encoding Notch1 and Dill (delta-like gene 1)(10), a vertebrate Notch ligand, is markedly reduced in the presomitic mesoderm of PS1(-/-) embryos compared to controls. Hence, PS1 is required for the spatiotemporal expression of Notch1 and Dll1, which are essential for somite segmentation and maintenance of somite borders(11-13).	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,NEUROPATHOL LAB,BALTIMORE,MD 21205; MERCK RES LABS,DEPT GENET & MOL BIOL,RAHWAY,NJ 07065; MERCK SHARP & DOHME RES LABS,NEUROSCI RES CTR,HARLOW CM20 2QR,ESSEX,ENGLAND	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Merck & Company; Merck & Company	Wong, PC (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205, USA.							ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; Busfield Frances, 1995, P59, DOI 10.1016/B978-012286965-5/50006-6; CHRIST B, 1992, ANN ANAT, V174, P23, DOI 10.1016/S0940-9602(11)80337-7; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Cruts M, 1996, HUM MOL GENET, V5, P1449, DOI 10.1093/hmg/5.Supplement_1.1449; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Hogan B, 1994, MANIPULATING MOUSE E; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; KALCHEIM C, 1989, DEVELOPMENT, V106, P85; KOSEKI H, 1993, DEVELOPMENT, V119, P649; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MONTARRAS D, 1991, NEW BIOL, V3, P592; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STERN CD, 1987, DEVELOPMENT, V99, P261; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; VERBOUT AJ, 1985, ADV ANAT EMBRYOL CEL, V90, P1; ZHENG H, 1995, CELL, V81, P571	30	623	647	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					288	292		10.1038/387288a0	http://dx.doi.org/10.1038/387288a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153393				2022-12-28	WOS:A1997WZ16700054
J	Ely, EW; Rainer, RO				Ely, EW; Rainer, RO			Myelodysplasia?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Ely, EW (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,300 S HAWTHORNE RD,WINSTON SALEM,NC 27103, USA.		Ely, E. Wesley/Z-2018-2019	Ely, E. Wesley/0000-0003-3957-2172					0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 8	1997	336	19					1364	1364		10.1056/NEJM199705083361905	http://dx.doi.org/10.1056/NEJM199705083361905			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX851	9134877				2022-12-28	WOS:A1997WX85100005
J	Swannell, AJ				Swannell, AJ			Fortnightly review - Polymyalgia rheumatica and temporal arteritis: Diagnosis and management	BRITISH MEDICAL JOURNAL			English	Review							GIANT-CELL ARTERITIS; COMPLICATIONS; INFARCTION				Swannell, AJ (corresponding author), NOTTINGHAM CITY HOSP NHS TRUST,NOTTINGHAM NG5 1PB,ENGLAND.							ACHKAR AA, 1995, J RHEUMATOL, V22, P360; ALHUSSAINI AS, 1985, BRIT J RHEUMATOL, V24, P27; ALLISON MC, 1984, ANN RHEUM DIS, V43, P416, DOI 10.1136/ard.43.3.416; ANDERSON R, 1991, BAILLIERE CLIN RHEUM, P409; BEHN AR, 1983, ANN RHEUM DIS, V42, P374, DOI 10.1136/ard.42.4.374; BENGTSSON BA, 1981, ARTHRITIS RHEUM, V24, P899, DOI 10.1002/art.1780240706; BENGTSSON BA, 1991, BAILLIERE CLIN RHEUM, P380; BOESEN P, 1987, ARTHRITIS RHEUM, V30, P294, DOI 10.1002/art.1780300308; CALAMIA KT, 1980, CLIN RHEUM DIS, P391; CHAKRAVARTY K, 1994, BRIT J RHEUMATOL, V33, P152; CHUANG TY, 1982, ANN INTERN MED, V97, P190; CULLEN JF, 1972, BRIT J OPHTHALMOL, V56, P584, DOI 10.1136/bjo.56.8.584; DIXON ASJ, 1966, ANN RHEUM DIS, V25, P203, DOI 10.1136/ard.25.3.203; ELLIS ME, 1983, ANN RHEUM DIS, V42, P168, DOI 10.1136/ard.42.2.168; EVANS JM, 1994, ARTHRITIS RHEUM-US, V37, P1539, DOI 10.1002/art.1780371020; HAYREH SS, 1991, BAILLIERE CLIN RHEUM, P434; HAZLEMAN BL, 1992, PRACTICAL PROBLEMS R; HEALEY A, 1991, BAILLIERE CLIN RHEUM, P372; HERNANDEZGARCIA C, 1994, SCAND J RHEUMATOL, V23, P295, DOI 10.3109/03009749409099276; HOLLENHORST RW, 1960, NEUROLOGY, V10, P490, DOI 10.1212/WNL.10.5.490; HOSIE G, 1995, MUSCULOSKEL MED, V2, P10; JONES JG, 1991, BAILLIERE CLIN RHEUM, P414; Kyle V, 1991, BAILLIERE CLIN RHEUM, P486; KYLE V, 1991, BAILLIERE CLIN RHEUM, P476; MULDER H, 1994, BRIT J RHEUMATOL, V33, P348; NESHER G, 1994, J RHEUMATOL, V21, P1283; NESHER G, 1994, CLIN RHEUMATOL, V13, P289; PATTERSON A, 1992, ORAL SURG ORAL MED O, V74, P582, DOI 10.1016/0030-4220(92)90348-T; PAULLEY JW, 1980, ACTA MED SCAND, V208, P257; SADLER NZ, 1995, J AM DENT ASSOC, V126, P1263; SALVARINI C, 1991, ARTHRITIS RHEUM, V3, P351; SANDERCOCK PAG, 1989, BRIT MED J, V298, P75, DOI 10.1136/bmj.298.6666.75; SONNENBLICK M, 1994, BRIT J RHEUMATOL, V33, P938	33	35	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 3	1997	314	7090					1329	1332		10.1136/bmj.314.7090.1329	http://dx.doi.org/10.1136/bmj.314.7090.1329			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX975	9158471	Green Published			2022-12-28	WOS:A1997WX97500028
J	Levitt, JB; Lund, JS				Levitt, JB; Lund, JS			Contrast dependence of contextual effects in primate visual cortex	NATURE			English	Article							NEOCORTICAL PYRAMIDAL NEURONS; CLASSICAL RECEPTIVE-FIELD; CAT STRIATE CORTEX; INTRINSIC CONNECTIONS; MACAQUE MONKEY; ORIENTATION SELECTIVITY; FUNCTIONAL ARCHITECTURE; RESPONSES; MECHANISMS; CIRCUITS	The responses of neurons in the visual cortex to stimuli presented within their receptive fields can be markedly modulated by stimuli presented in surrounding regions that do not themselves evoke responses(1-7). This modulation depends on the relative orientation and direction of motion of the centre and surround stimuli, and it has been suggested that local cortical circuits linking cells with similar stimulus selectivities underlie these phenomena(8-16). However, the functional relevance and nature of these integrative processes remain unclear. Here we investigate how such integration depends on the relative activity levels of neurons at different points across the cortex by varying the relative contrast of stimuli over the receptive field and surrounding regions. We show that simply altering the balance of the excitation driving centre and surround regions can dramatically change the sign and stimulus selectivity of these contextual effects. Thus, the way that single neurons integrate information across the visual field depends not only on the precise form of stimuli at different locations, but also crucially on their relative contrasts. We suggest that these effects reflect a complex gain-control mechanism that regulates cortical neuron responsiveness, which permits dynamic modification of response properties of cortical neurons.			Levitt, JB (corresponding author), UCL, INST OPHTHALMOL, DEPT VISUAL SCI, BATH ST, LONDON EC1V 9EL, ENGLAND.							ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P407, DOI 10.1146/annurev.ne.08.030185.002203; AMIR Y, 1993, J COMP NEUROL, V334, P19, DOI 10.1002/cne.903340103; DEANGELIS GC, 1994, J NEUROPHYSIOL, V71, P347, DOI 10.1152/jn.1994.71.1.347; DEUCHARS J, 1994, J PHYSIOL-LONDON, V478, P423, DOI 10.1113/jphysiol.1994.sp020262; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GILBERT CD, 1983, J NEUROSCI, V3, P1116; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P181, DOI 10.1017/S0952523800009640; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; LAMME VAF, 1995, J NEUROSCI, V15, P1605; LI CY, 1994, VISION RES, V34, P2337, DOI 10.1016/0042-6989(94)90280-1; LUND JS, 1993, CEREB CORTEX, V3, P148, DOI 10.1093/cercor/3.2.148; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MARKRAM H, 1995, J PHYSIOL-LONDON, V485, P1; NELSON JI, 1978, BRAIN RES, V139, P359, DOI 10.1016/0006-8993(78)90937-X; ROCKLAND KS, 1983, J COMP NEUROL, V216, P303, DOI 10.1002/cne.902160307; ROCKLAND KS, 1982, J COMP NEUROL, V209, P41, DOI 10.1002/cne.902090105; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; SOMERS DC, 1995, J NEUROSCI, V15, P5448; STUART G, 1995, NEURON, V15, P1065, DOI 10.1016/0896-6273(95)90095-0; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; Toth LJ, 1996, P NATL ACAD SCI USA, V93, P9869, DOI 10.1073/pnas.93.18.9869; TSO DY, 1986, J NEUROSCI, V6, P1160; Yoshioka T, 1996, CEREB CORTEX, V6, P297, DOI 10.1093/cercor/6.2.297; Zipser K, 1996, J NEUROSCI, V16, P7376	26	414	421	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	1997	387	6628					73	76		10.1038/387073a0	http://dx.doi.org/10.1038/387073a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139823				2022-12-28	WOS:A1997WW75800049
J	CiesielskiCarlucci, C; Lee, BK; Boxer, LM; Leung, LLK				CiesielskiCarlucci, C; Lee, BK; Boxer, LM; Leung, LLK			A woman who had a stroke, then a myocardial infarction	LANCET			English	Article									STANFORD UNIV,DEPT MED,SCH MED,DIV HAEMATOL,STANFORD,CA 94305	Stanford University								Bostom AG, 1996, JAMA-J AM MED ASSOC, V276, P544, DOI 10.1001/jama.276.7.544; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; HARPEL PC, 1992, P NATL ACAD SCI USA, V89, P10193, DOI 10.1073/pnas.89.21.10193; McCully KS, 1996, NAT MED, V2, P386, DOI 10.1038/nm0496-386; PALABRICA TM, 1995, NAT MED, V1, P256, DOI 10.1038/nm0395-256	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1218	1218		10.1016/S0140-6736(97)02029-1	http://dx.doi.org/10.1016/S0140-6736(97)02029-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130944				2022-12-28	WOS:A1997WW71700012
J	Marotte, C; Razafimbahiny, HR				Marotte, C; Razafimbahiny, HR			Living with Haiti's violent past	LANCET			English	Editorial Material											Marotte, C (corresponding author), HUMAN RIGHTS FUND,17 CITE WILSON II,PORT AU PRINCE,HAITI.							HELLER A, 1993, OXFORD AMNESTY LECT; MAROTTE C, IN PRESS FORGOTTEN M	2	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1248	1248		10.1016/S0140-6736(05)62440-3	http://dx.doi.org/10.1016/S0140-6736(05)62440-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130962				2022-12-28	WOS:A1997WW71700046
J	Leonardo, ED; Hinck, L; Masu, M; KeinoMasu, K; Ackerman, SL; TessierLavigne, M				Leonardo, ED; Hinck, L; Masu, M; KeinoMasu, K; Ackerman, SL; TessierLavigne, M			Vertebrate homologues of C-elegans UNC-5 are candidate netrin receptors	NATURE			English	Article							PIONEER AXON MIGRATIONS; SPINAL-CORD; FLOOR PLATE; GUIDES CELL; MOTOR AXONS; PROTEIN; CHEMOREPELLENT; ELONGATION; GUIDANCE; GROWTH	In the developing nervous system, migrating cells and axons are guided to their targets by cues in the extracellular environment. The netrins are a family of phylogenetically conserved guidance cues that can function as diffusible attractants and repellents for different classes of cells and axons(1-10). In vertebrates, insects and nematodes, members of the DCC subfamily of the immunoglobulin superfamily have been implicated as receptors that are involved in migration towards netrin sources(6,11-13,15). The mechanisms that direct migration away from netrin sources (presumed repulsions) are less well understood. In Caenorhabditis elegans, the transmembrane protein UNC-5 (ref. 14) has been implicated in these responses, as loss of unc-5 function causes migration defects(16,17) and ectopic expression of unc-5 in some neurons can redirect their axons away from a netrin source(18). Whether UNC-5 is a netrin receptor or simply an accessory to such a receptor has not, however, been defined. We now report the identification of two vertebrate homologues of UNC-5 which, with UNC-5 and the product of the mouse rostral cerebellar malformation gene (rcm)(19), define a new subfamily of the immunoglobulin superfamily, and whose messenger RNAs show prominent expression in various classes of differentiating neurons. We provide evidence that these two UNC-5 homologues, as well as the rcm gene product, are netrin-binding proteins, supporting the hypothesis that UNC-5 and its relatives are netrin receptors.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM CELL & DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,NEUROSCI PROGRAM,SAN FRANCISCO,CA 94143; NATL DEF MED COLL,DEPT PHYSIOL,TOKOROZAWA,SAITAMA 359,JAPAN; JACKSON LAB,BAR HARBOR,ME 04609	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; National Defense Medical College - Japan; Jackson Laboratory			Leonardo, Eduardo/AAH-1525-2020	Leonardo, Eduardo/0000-0001-7426-0217; Hinck, Lindsay/0000-0002-4009-3913				Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; Cajal S. R., 1911, HISTOLOGIE SYSTEME N, V2; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; GUTHRIE S, 1995, NEURON, V14, P1117, DOI 10.1016/0896-6273(95)90260-0; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V2, P61; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LIVESEY FJ, IN PRESS MOL CELL NE; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SHIRASAKI R, 1995, NEURON, V14, P961, DOI 10.1016/0896-6273(95)90334-8; Shirasaki R, 1996, NEURON, V17, P1079, DOI 10.1016/S0896-6273(00)80241-X; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834	32	414	434	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					833	838		10.1038/386833a0	http://dx.doi.org/10.1038/386833a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126742				2022-12-28	WOS:A1997WV70600055
J	McElduff, P; Dobson, AJ				McElduff, P; Dobson, AJ			How much alcohol and how often? Population based case-control study of alcohol consumption and risk of a major coronary event	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; MYOCARDIAL-INFARCTION; HEALTH; MEN; MORTALITY	Objective: To quantify the effects of quantity and frequency of alcohol consumption on risk of acute myocardial infarction and coronary death. Design: Case-control study. Setting: Lower Hunter region of New South Wales, Australia, 1983-94. Subjects: Men and women aged 35-69 years. Main outcome measure: Acute myocardial infarction or coronary death. Results: Alcohol consumption patterns were compared between 11 511 cases of acute myocardial infarction or coronary death and 6077 controls randomly selected from the same study population. After adjusting for the effects of age, smoking, and medical history, men and women who consumed one or two drinks of alcohol on five or six days a week had a reduction in risk of a major coronary event compared with men and women who were non-drinkers (odds ratios: men 0.31 (95% confidence interval 0.22 to 0.45); women 0.33 (0.18 to 0.59)). A similar reduction in risk was found after excluding non-drinkers who were formerly moderate to heavy drinkers. An acute protective effect of alcohol consumption was also found for regular drinkers who consumed one or two drinks in the 24 hours preceding the onset of symptoms (odds ratios: men 0.74 (0.51 to 1.09); women 0.43 (0.20 to 0.95)). Conclusions: Frequency and quantity of alcohol consumption are important in assessing the risk of a major coronary event Risk is lowest among men who report one to four drinks daily on five or six days a week and among women who report one or two drinks daily on five or six days a week.	UNIV NEWCASTLE,CTR CLIN EPIDEMIOL & BIOSTAT,NEWCASTLE,NSW 2308,AUSTRALIA	University of Newcastle	McElduff, P (corresponding author), UNIV NEWCASTLE,DEPT STAT,NEWCASTLE,NSW 2308,AUSTRALIA.		Dobson, Annette J/B-5273-2008					CULLEN KJ, 1993, AM J EPIDEMIOL, V137, P242, DOI 10.1093/oxfordjournals.aje.a116665; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; JACKSON R, 1992, AM J EPIDEMIOL, V136, P819, DOI 10.1093/aje/136.7.819; KAUFMAN DW, 1985, AM J EPIDEMIOL, V121, P548, DOI 10.1093/oxfordjournals.aje.a114032; MIDANIK L, 1982, BRIT J ADDICT, V77, P357; MILLER GJ, 1990, INT J EPIDEMIOL, V19, P923, DOI 10.1093/ije/19.4.923; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROMELSJO A, 1995, INT J EPIDEMIOL, V24, P929, DOI 10.1093/ije/24.5.929; RUSSELL M, 1991, AM J PUBLIC HEALTH, V81, P452, DOI 10.2105/AJPH.81.4.452; *SAS I INC, 1993, P243 SAS I INC; SHAPER AG, 1994, INT J EPIDEMIOL, V23, P482, DOI 10.1093/ije/23.3.482; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; WOODWARD M, 1995, J EPIDEMIOL COMMUN H, V49, P354, DOI 10.1136/jech.49.4.354	15	196	198	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 19	1997	314	7088					1159	1164		10.1136/bmj.314.7088.1159	http://dx.doi.org/10.1136/bmj.314.7088.1159			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV705	9146388	Green Published			2022-12-28	WOS:A1997WV70500022
J	Leone, G; DeGregori, J; Sears, R; Jakoi, L; Nevins, JR				Leone, G; DeGregori, J; Sears, R; Jakoi, L; Nevins, JR			Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F	NATURE			English	Article							SIGNAL-TRANSDUCTION; ACTIVATION; PROTEIN; TRANSFORMATION; INHIBITION; KINASES; GROWTH	Considerable evidence points to a role for G1 cyclin-dependent kinase (CDK) in allowing the accumulation of E2F transcription factor activity and induction of the S phase of the cell cycle(1,2). Numerous experiments have also demonstrated a critical role for both Myc and Ras activities in allowing cell-cycle progression(3). Here we show that inhibition of pas activity blocks the normal growth-dependent activation of G1 CDK, prevents activation of the target genes of E2F, and results in cell-cycle arrest in G1. We also show that Ras is essential for entry into the S phase in Rb+/+ fibroblasts but not in Rb-/- fibroblasts, establishing a link between Ras and the G1 CDK/Rb/E2F pathway, However, although expression of pas alone will not induce G1 CDK activity or S phase, coexpression of Ras with Myc allows the generation of cyclin E-dependent kinase activity and the induction of S phase, coincident with the loss of the p27 cyclin-dependent kinase inhibitor (CKI). These results suggest that pas, along with the activation of additional pathways, is required for the generation of G1 CDK activity, and that activation of cyclin E-dependent kinase in particular depends on the cooperative action of Ras and Myc.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT GENET,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute				DeGregori, James/0000-0002-1287-1976				Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; EISENMAN RN, 1995, NATURE, V378, P438, DOI 10.1038/378438a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; HATEKAYAMA M, 1994, GENE DEV, V8, P1759; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOHL NE, 1987, ONCOGENE, V2, P41; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEONE G, UNPUB P NATL ACAD SC; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NEVINS JR, IN PRESS METHODS ENZ; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	27	401	418	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					422	426		10.1038/387422a0	http://dx.doi.org/10.1038/387422a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163430				2022-12-28	WOS:A1997XA49600065
J	Horton, R				Horton, R			Sponsorship, authorship, and a tale of two media	LANCET			English	Editorial Material																		*INT COMM MED J ED, 1997, ANN INTERN MED, V126, P36; Marshall E, 1997, SCIENCE, V276, P524; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1238, DOI 10.1001/jama.277.15.1238; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244	4	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 17	1997	349	9063					1411	1412		10.1016/S0140-6736(05)63721-X	http://dx.doi.org/10.1016/S0140-6736(05)63721-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164313				2022-12-28	WOS:A1997WZ76500006
J	Tagliavini, F; McArthur, RA; Canciani, B; Giaccone, G; Porro, M; Bugiani, M; Lievens, PMJ; Bugiani, O; Peri, E; DallAra, P; Rocchi, M; Poli, G; Forloni, G; Bandiera, T; Varasi, M; Suarato, A; Cassutti, P; Cervini, MA; Lansen, J; Salmona, M; Post, C				Tagliavini, F; McArthur, RA; Canciani, B; Giaccone, G; Porro, M; Bugiani, M; Lievens, PMJ; Bugiani, O; Peri, E; DallAra, P; Rocchi, M; Poli, G; Forloni, G; Bandiera, T; Varasi, M; Suarato, A; Cassutti, P; Cervini, MA; Lansen, J; Salmona, M; Post, C			Effectiveness of anthracycline against experimental prion disease in Syrian hamsters	SCIENCE			English	Article							INCUBATION PERIOD; PROTEIN-FRAGMENT; PRP ACCUMULATION; AMYLOID FIBRILS; DEXTRAN SULFATE; MOUSE SCRAPIE; CONGO RED; 4'-IODO-4'-DEOXYDOXORUBICIN; REPLICATION; INHIBITION	Prion diseases are transmissible neurodegenerative conditions characterized by the accumulation of protease-resistant forms of the prion protein (PrP), termed PrPres, in the brain. Insoluble PrPres tends to aggregate into amyloid fibrils. The anthracycline 4'-iodo-4'-deoxy-doxorubicin (IDX) binds to amyloid fibrils and induces amyloid resorption in patients with systemic amyloidosis. To test IDX in an experimental model of prion disease, Syrian hamsters were inoculated intracerebrally either with scrapie-infected brain homogenate or with infected homogenate coincubated with IDX. In IDX-treated hamsters, clinical signs of disease were delayed and survival time was prolonged. Neuropathological examination showed a parallel delay in the appearance of brain changes and in the accumulation of PrPres and PrP amyloid.	PHARMACIA & UPJOHN SPA, CNS RES, I-20014 NERVIANO, MI, ITALY; UNIV MILAN, IST MICROBIOL & IMMUNOL VET, I-20133 MILAN, ITALY; IST RIC FARMACOL MARIO NEGRI, I-20157 MILAN, ITALY; PHARMACIA & UPJOHN SPA, ONCOL RES, I-20014 NERVIANO, MI, ITALY	Pfizer; University of Milan; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Pfizer	Tagliavini, F (corresponding author), IST NAZL NEUROL CARLO BESTA, VIA CELORIA 11, I-20133 MILAN, ITALY.		Canciani, Barbara/AAJ-6943-2020; Giaccone, Giorgio/J-6212-2012; Forloni, Gianluigi/AAB-2115-2020; giaccone, giorgio/AAB-9978-2019; salmona, mario/AAA-7116-2020; salmona, mario/ABI-4066-2020; Tagliavini, Fabrizio/AAO-7891-2021; Dall'Ara, Paola/L-8658-2017	Canciani, Barbara/0000-0003-1942-1174; Forloni, Gianluigi/0000-0001-5374-3914; giaccone, giorgio/0000-0002-4803-0802; salmona, mario/0000-0002-9098-9873; Tagliavini, Fabrizio/0000-0003-1039-7315; Dall'Ara, Paola/0000-0002-8542-9476; Varasi, Mario/0000-0003-0367-8290				ADJOU KT, 1995, ANTIMICROB AGENTS CH, V39, P2810, DOI 10.1128/AAC.39.12.2810; BARBIERI B, 1987, CANCER RES, V47, P4001; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Brown P, 1990, ANTIVIR CHEM CHEMOTH, V1, P75, DOI 10.1177/095632029000100201; BROWN P, 1988, ANTIVIRAL AGENTS DEV, V2, P13; BRUCE ME, 1989, NEUROSCI LETT, V102, P1, DOI 10.1016/0304-3940(89)90298-X; CAUGHEY B, 1992, J NEUROCHEM, V59, P768, DOI 10.1111/j.1471-4159.1992.tb09437.x; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; DEARMOND SJ, 1993, P NATL ACAD SCI USA, V90, P6449, DOI 10.1073/pnas.90.14.6449; DEARMOND SJ, 1992, E H S NEURO, P483; EHLERS B, 1984, J GEN VIROL, V65, P1325, DOI 10.1099/0022-1317-65-8-1325; FARQUHAR CF, 1986, J GEN VIROL, V67, P463, DOI 10.1099/0022-1317-67-3-463; FOMELLI F, 1987, CANCER RES, V47, P5401; FORLONI G, 1994, EUR J NEUROSCI, V6, P1415, DOI 10.1111/j.1460-9568.1994.tb01003.x; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GIANNI L, 1995, BLOOD, V86, P855; INGROSSO L, 1995, J VIROL, V69, P506, DOI 10.1128/JVI.69.1.506-508.1995; KIMBERLIN RH, 1986, ANTIMICROB AGENTS CH, V30, P409, DOI 10.1128/AAC.30.3.409; KIMBERLIN RH, 1993, ARCH VIROL, V78, P9; MERLINI G, 1995, P NATL ACAD SCI USA, V92, P2959, DOI 10.1073/pnas.92.7.2959; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; POCCHIARI M, 1987, J GEN VIROL, V68, P219, DOI 10.1099/0022-1317-68-1-219; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Sambrook J., 2002, MOL CLONING LAB MANU; TAGLIAVINI F, 1994, CELL, V79, P695, DOI 10.1016/0092-8674(94)90554-1; XI YG, 1992, NATURE, V356, P598, DOI 10.1038/356598a0	30	155	170	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	1997	276	5315					1119	1122		10.1126/science.276.5315.1119	http://dx.doi.org/10.1126/science.276.5315.1119			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9148807				2022-12-28	WOS:A1997WZ22500046
J	Partin, AW; Kattan, MW; Subong, ENP; Walsh, PC; Wojno, KJ; Oesterling, JE; Scardino, PT; Pearson, JD				Partin, AW; Kattan, MW; Subong, ENP; Walsh, PC; Wojno, KJ; Oesterling, JE; Scardino, PT; Pearson, JD			Combination of prostate-specific antigen, clinical stage, and gleason score to predict pathological stage of localized prostate cancer - A multi-institutional update	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADICAL PROSTATECTOMY; GRADE; RISK; METASTASES; MEN	Objective.-To combine the clinical data from 3 academic institutions that serve as centers of excellence for the surgical treatment of clinically localized prostate cancer and develop a multi-institutional model combining serum prostate-specific antigen (PSA) level, clinical stage, and Gleason score to predict pathological stage for men with clinically localized prostate cancer. Design.-In this update, we have combined clinical and pathological data for a group of 4133 men treated by several surgeons from 3 major academic urologic centers within the United States. Multinomial log-linear regression was performed for the simultaneous prediction of organ-confined disease, isolated capsular penetration, seminal vesicle involvement, or pelvic lymph node involvement. Bootstrap estimates of the predicted probabilities were used to develop nomograms to predict pathological stage, Additional bootstrap analyses were then obtained to validate the performance of the nomograms. Patients and Settings.-A total of 4133 men who had undergone radical retropubic prostatectomy for clinically localized prostate cancer at The Johns Hopkins Hospital (n=3116), Baylor College of Medicine (n=782), and the University of Michigan School of Medicine (n=235) were enrolled into this study. None of the patients had received preoperative hormonal or radiation therapy. Outcome Measures.-Simultaneous prediction of organ-confined disease, isolated capsular penetration, seminal vesicle involvement, or pelvic lymph node involvement using updated nomograms. Results.-Prostate-specific antigen level, TNM clinical stage, and Gleason score contributed significantly to the prediction of pathological stage (P<.001). Bootstrap estimates of the median and 95% confidence interval of the predicted probabilities are presented in the nomograms. For most cells in the nomograms, there is a greater than 25% probability of qualifying for more than one of the pathological stages. In the validation analyses, 72.4% of the time the nomograms correctly predicted the probability of a pathological stage to within 10% (organ-confined disease, 67.3%; isolated capsular penetration, 59.6%; seminal vesicle involvement, 79.6%; pelvic lymph node involvement, 82.9%). Conclusions.-The data represent a multi-institutional modeling and validation of the clinical utility of combining PSA level measurement, clinical stage, and Gleason score to predict pathological stage for a group of men with localized prostate cancer. Clinicians can use these nomograms when counseling individual patients regarding the probability of their tumor being a specific pathological stage; this will enable patients and physicians to make more informed treatment decisions based on the probability of a pathological stage, as well as risk tolerance and the values they place on various potential outcomes.	JOHNS HOPKINS UNIV,SCH MED,DEPT UROL,BALTIMORE,MD 21205; UNIV MICHIGAN,SCH MED,DEPT UROL & PATHOL,ANN ARBOR,MI; UNIV MICHIGAN,SCH MED,MICHIGAN PROSTATE INST,ANN ARBOR,MI; BAYLOR COLL MED,SCOTT DEPT UROL,HOUSTON,TX 77030; MERCK RES LABS,RAHWAY,NJ	Johns Hopkins University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Baylor College of Medicine; Merck & Company	Partin, AW (corresponding author), JOHNS HOPKINS UNIV HOSP,DEPT UROL,JAMES BUCHANAN BRADY UROL INST,BALTIMORE,MD 21287, USA.		Fahimifar, Sepideh/M-5303-2019; Kattan, Michael/AAF-9735-2021	Kattan, Michael/0000-0002-3840-4161	NCI NIH HHS [CA 69568, CA 58204, CA 58236] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058204, P50CA069568, P50CA058236] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN DA, 1993, J UROLOGY, V150, P1845, DOI 10.1016/S0022-5347(17)35912-8; AGRESTI A, 1990, CATEGORICAL DATA ANA, P307; Badalament RA, 1996, J UROLOGY, V156, P1375, DOI 10.1016/S0022-5347(01)65590-3; Baker L H, 1996, Oncology (Williston Park), V10, P265; BLACKWELL KL, 1994, J UROLOGY, V151, P1565, DOI 10.1016/S0022-5347(17)35303-X; BLUESTEIN DL, 1994, J UROLOGY, V151, P1315, DOI 10.1016/S0022-5347(17)35239-4; Bostwick DG, 1996, J UROLOGY, V155, P1361, DOI 10.1016/S0022-5347(01)66267-0; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; ELFRON B, 1993, INTRO BOOKSTRAP; KATTAN MN, 1996, CANCER, V79, P528; KLEER E, 1993, UROLOGY, V41, P207, DOI 10.1016/0090-4295(93)90558-R; MORTON RA, 1991, J UROLOGY, V145, P1197, DOI 10.1016/S0022-5347(17)38574-9; NARAYAN P, 1994, UROLOGY, V44, P519, DOI 10.1016/S0090-4295(94)80050-2; NARAYAN P, 1995, UROLOGY, V46, P205, DOI 10.1016/S0090-4295(99)80195-2; OESTERLING JE, 1988, J UROLOGY, V139, P766, DOI 10.1016/S0022-5347(17)42630-9; OESTERLING JE, 1987, J UROLOGY, V138, P92, DOI 10.1016/S0022-5347(17)43003-5; PARKER SL, 1996, CANCER STAT 1996; PARTIN AW, 1993, J UROLOGY, V150, P110, DOI 10.1016/S0022-5347(17)35410-1; PARTIN AW, 1993, UROL CLIN N AM, V20, P713; Pound CR, 1997, UROL CLIN N AM, V24, P395, DOI 10.1016/S0094-0143(05)70386-4; ROACH M, 1994, INT J RADIAT ONCOL, V28, P33, DOI 10.1016/0360-3016(94)90138-4; Rogers E, 1996, BRIT J UROL, V78, P419, DOI 10.1046/j.1464-410X.1996.00117.x; SANDS ME, 1994, UROLOGY, V44, P215	23	1449	1493	1	74	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	1997	277	18					1445	1451		10.1001/jama.277.18.1445	http://dx.doi.org/10.1001/jama.277.18.1445			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX852	9145716				2022-12-28	WOS:A1997WX85200028
J	Kelley, RL; Wang, JW; Bell, L; Kuroda, MI				Kelley, RL; Wang, JW; Bell, L; Kuroda, MI			Sex lethal controls dosage compensation in Drosophila by a non-splicing mechanism	NATURE			English	Article							X-CHROMOSOME; TRANSLATIONAL REGULATION; MESSENGER-RNAS; GENE; BINDING; INITIATION; PROTEIN; MELANOGASTER; EXPRESSION; ENCODES	Dosage compensation in Drosophila requires the male-specific lethal (msl) proteins (MSL) to make gene expression from the single male X chromosome equivalent to that from both female X chromosomes(1,2). Expression of msl2 is repressed post-transcriptionally by Sex lethal (SXL), a female-specific RNA-binding protein that regulates alternative splicing in the sex-determination hierarchy, Although msl2 RNA is alternatively spliced in males and females, this does not alter its coding potential and splicing is not required for male-specific expression of MSL2 protein. Instead, our results suggest that the association of SXL protein with multiple sites in the 5' and 3' untranslated regions of the mxl2 transcript represses its translation in females. Thus, this well characterized alternative splicing factor regulates at least one target transcript by a distinct mechanism.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; UNIV SO CALIF,PROGRAM MOL BIOL,LOS ANGELES,CA 90089	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Southern California								BAKER BS, 1994, ANNU REV GENET, V28, P491, DOI 10.1146/annurev.ge.28.120194.002423; BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; CAUGHMAN SW, 1988, J BIOL CHEM, V263, P19048; CLINE TW, 1984, GENETICS, V107, P231; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PALMER MJ, 1993, GENETICS, V134, P545; PALMER MJ, 1994, GENE DEV, V8, P698, DOI 10.1101/gad.8.6.698; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; WANG JW, 1994, GENE DEV, V8, P2072, DOI 10.1101/gad.8.17.2072; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x	25	209	216	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					195	199		10.1038/387195a0	http://dx.doi.org/10.1038/387195a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144292				2022-12-28	WOS:A1997WX94500058
J	Feldhaus, KM; KoziolMcLain, J; Amsbury, HL; Norton, IM; Lowenstein, SR; Abott, JT				Feldhaus, KM; KoziolMcLain, J; Amsbury, HL; Norton, IM; Lowenstein, SR; Abott, JT			Accuracy of 3 brief screening questions for detecting partner violence in the emergency department	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOMESTIC VIOLENCE; PREVALENCE; PREGNANCY; MEDICINE; WOMEN; ABUSE; CARE	Objective.-To devise a brief screening instrument to detect partner violence and to partially validate this screen against established instruments. Design.-Prospective survey. Setting.-Two urban, hospital-based emergency departments. Participants.-Of 491 women presenting during 48 randomly selected 4-hour time blocks, 322 (76% of eligible patients) participated. Respondents had a median age of 36 years; 19% were black, 45% white, and 30% Hispanic, while 6% were of other racial or ethnic groups; 54% were insured. Interventions.-We developed a partner violence screen (PVS), consisting of 3 questions about past physical violence and perceived personal safety. We administered the PVS and 2 standardized measures of partner violence, the Index of Spouse Abuse (ISA) and the Conflict Tactics Scale (CTS). Main Outcome Measures.-Sensitivity, specificity, and predictive values of the PVS were compared with the ISA and the CTS as criterion standards. Results.-The prevalence rate of partner violence using the PVS was 29.5% (95% confidence interval [CI], 24.6%-34.8%). For the ISA and CTS, the prevalence rates were 24.3% (95% CI, 19.2%-30.1%) and 27.4% (95% CI, 21.7%-33.6%), respectively. Compared with the ISA, the sensitivity of the PVS in detecting partner abuse was 64.5%; the specificity was 80.3%. When compared with the CTS, sensitivity of the PVS was 71.4%; the specificity was 84.4%. Positive predictive values ranged from 51.3% to 63.4%, and negative predictive values ranged from 87.6% to 88.7%. Overall, 13.7% of visits were the result of acute episodes of partner violence. Conclusion.-Three brief directed questions can detect a large number of women who have a history of partner violence.			Feldhaus, KM (corresponding author), DENVER HLTH MED CTR, DEPT EMERGENCY MED, 777 BANNOCK ST, 0180, DENVER, CO 80204 USA.			Koziol-McLain, Jane/0000-0003-3453-023X				ABBOTT J, 1995, JAMA-J AM MED ASSOC, V273, P1763, DOI 10.1001/jama.273.22.1763; *AM COLL EM PHYS, 1995, ANN EMERG MED, V25, P442; [Anonymous], 1994, AM FAM PHYSICIAN, V50, P1636; ASHUR MLC, 1993, JAMA-J AM MED ASSOC, V269, P2367, DOI 10.1001/jama.269.18.2367; BACHMAN R, 1995, US DEP JUSTICE PUBLI; Bullock L, 1989, Nurse Pract, V14, P53; Chescheir N, 1996, ANN EMERG MED, V27, P766, DOI 10.1016/S0196-0644(96)70199-3; Dowd MD, 1996, AM J PUBLIC HEALTH, V86, P929, DOI 10.2105/AJPH.86.7.929; Dutton M A, 1996, J Am Med Womens Assoc (1972), V51, P92; GIN NE, 1991, J GEN INTERN MED, V6, P317, DOI 10.1007/BF02597429; GOLDBERG WG, 1984, JAMA-J AM MED ASSOC, V251, P3259, DOI 10.1001/jama.251.24.3259; Gremillion DH, 1996, ANN EMERG MED, V27, P769, DOI 10.1016/S0196-0644(96)70200-7; Grunfeld A F, 1994, J Emerg Nurs, V20, P271; Hamberger L K, 1992, Fam Med, V24, P283; HELTON AS, 1987, AM J PUBLIC HEALTH, V77, P1337, DOI 10.2105/AJPH.77.10.1337; HILLARD PJA, 1985, OBSTET GYNECOL, V66, P185; HUDSON WW, 1981, J MARRIAGE FAM, V43, P873, DOI 10.2307/351344; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; McFarlane J, 1995, J Emerg Nurs, V21, P391, DOI 10.1016/S0099-1767(05)80103-5; MCLEER SV, 1987, ANN EMERG MED, V16, P1155, DOI 10.1016/S0196-0644(87)80476-6; MCLEER SV, 1989, AM J PUBLIC HEALTH, V79, P65, DOI 10.2105/AJPH.79.1.65; Neufeld B, 1996, AM FAM PHYSICIAN, V53, P2575; NORTON LB, 1995, OBSTET GYNECOL, V85, P321, DOI 10.1016/0029-7844(94)00429-H; Olson L, 1996, ANN EMERG MED, V27, P741, DOI 10.1016/S0196-0644(96)70193-2; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P3190; Parker B., 1991, AM J MATERNAL CHILD, V16, P161, DOI DOI 10.1097/00005721-199105000-00013; *PHS, 1991, DHHS PHS PUBL, P237; STARK E, 1979, INT J HEALTH SERV, V9, P461, DOI 10.2190/KTLU-CCU7-BMNQ-V2KY; STARK E, 1981, WIFE ABUSE MED SETTI; STRAUS MA, 1992, J MARRIAGE FAM, V54, P346, DOI 10.2307/353066; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; *US DEP JUST, 1984, CRIM US 1983; Walker L., 1984, BATTERED WOMAN SYNDR; Waller AE, 1996, ANN EMERG MED, V27, P754, DOI 10.1016/S0196-0644(96)70195-6; Wilt S, 1996, J Am Med Womens Assoc (1972), V51, P77	35	358	363	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	1997	277	17					1357	1361		10.1001/jama.277.17.1357	http://dx.doi.org/10.1001/jama.277.17.1357			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WW261	9134940				2022-12-28	WOS:A1997WW26100024
J	Meydani, SN; Meydani, M; Blumberg, JB; Leka, LS; Siber, G; Loszewski, R; Thompson, C; Pedrosa, MC; Diamond, RD; Stollar, BD				Meydani, SN; Meydani, M; Blumberg, JB; Leka, LS; Siber, G; Loszewski, R; Thompson, C; Pedrosa, MC; Diamond, RD; Stollar, BD			Vitamin E supplementation and in vivo immune response in healthy elderly subjects - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CELL-MEDIATED-IMMUNITY; DELAYED-HYPERSENSITIVITY; PNEUMOCOCCAL VACCINE; NURSING-HOME; MORTALITY; ANTIBODY; MICE; CANCER; POPULATION; EXPRESSION	Objective.-To determine whether long-term supplementation with vitamin E enhances in vivo, clinically relevant measures of cell-mediated immunity in healthy elderly subjects. Design.-Randomized, double-blind, placebo-controlled intervention study. Setting and Participants.-A total of 88 free-living, healthy subjects at least 65 years of age. Intervention.-Subjects were randomly assigned to a placebo group or to groups consuming 60, 200, or 800 mg/d of vitamin E for 235 days. Main Outcome Measures.-Delayed-type hypersensitivity skin response (DTH); antibody response to hepatitis B, tetanus and diphtheria, and pneumococcal vaccines; and autoantibodies to DNA and thyroglobulin were assessed before and after supplementation. Results.-Supplementation with vitamin E for 4 months improved certain clinically relevant indexes of cell-mediated immunity in healthy elderly. Subjects consuming 200 mg/d of vitamin E had a 65% increase in DTH and a 6-fold increase in antibody titer to hepatitis B compared with placebo (17% and S-fold, respectively), 60-mg/d (41% and 3-fold, respectively), and 800-mg/d (49% and 2.5-fold, respectively) groups. The 200-mg/d group also had a significant increase in antibody titer to tetanus vaccine. Subjects in the upper tertile of serum a-tocopherol (vitamin E) concentration (>48.4 mu mol/l [2.08 mg/dL]) after supplementation had higher antibody response to hepatitis B and DTH. Vitamin E supplementation had no effect on antibody titer to diphtheria and did not affect immunoglobulin levels or levels of T and B cells. No significant effect of vitamin E supplementation on autoantibody levels was observed. Conclusions.-Our results indicate that a level of vitamin E greater than currently recommended enhances certain clinically relevant in vivo indexes of T-cell-mediated function in healthy elderly persons. No adverse effects were observed with vitamin E supplementation.	TUFTS UNIV,USDA,JEAN MAYER HUMAN NUTR RES CTR AGING,VASC BIOL LAB,BOSTON,MA 02111; TUFTS UNIV,USDA,JEAN MAYER HUMAN NUTR RES CTR AGING,ANTIOXIDANTS RES LAB,BOSTON,MA 02111; DANA FARBER CANC INST,INFECT DIS LAB,BOSTON,MA 02115; VET AFFAIRS MED CTR,DEPT GASTROENTEROL,BOSTON,MA; BOSTON UNIV HOSP,DIS PROGRAM,BOSTON,MA; TUFTS UNIV,DEPT BIOCHEM,BOSTON,MA 02111	Tufts University; United States Department of Agriculture (USDA); Tufts University; United States Department of Agriculture (USDA); Harvard University; Dana-Farber Cancer Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); Boston University; Tufts University	Meydani, SN (corresponding author), TUFTS UNIV,USDA,JEAN MAYER HUMAN NUTR RES CTR AGING,NUTR IMMUNOL LAB,711 WASHINGTON ST,BOSTON,MA 02111, USA.		Blumberg, Jeffrey/ABH-7888-2020					Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; Bartocci A., 1982, PROSTAGLANDINS CANC, P725; BEHARKA AA, 1997, MECH AGEING DEV, V94, P157; BIERI JG, 1979, AM J CLIN NUTR, V32, P2143, DOI 10.1093/ajcn/32.10.2143; BOGDEN JD, 1994, AM J CLIN NUTR, V60, P437, DOI 10.1093/ajcn/60.3.437; BURNS EA, 1993, J GERONTOL, V48, pB231, DOI 10.1093/geronj/48.6.B231; CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C; CHAVANCE M, 1989, EUR J CLIN NUTR, V43, P827; CHRISTOU NV, 1989, ANN SURG, V210, P69, DOI 10.1097/00000658-198907000-00011; COHN JR, 1983, J AM GERIATR SOC, V31, P808, DOI 10.1111/j.1532-5415.1983.tb03404.x; DIAMOND RD, 1991, J CLIN INVEST, V87, P711, DOI 10.1172/JCI115050; ELLIS RP, 1986, J AM VET MED ASSOC, V168, P231; ERSHLER WB, 1984, J CLIN IMMUNOL, V4, P445, DOI 10.1007/BF00916574; FUJIWARA M, 1979, J IMMUNOL, V123, P263; GOODWIN JS, 1981, MED CLIN N AM, V65, P829, DOI 10.1016/S0025-7125(16)31500-0; HAYEK MG, 1994, J GERONTOL, V49, pB197, DOI 10.1093/geronj/49.5.B197; HAYEK MG, IN PRESS J INFECT DI; HEINZERLING RH, 1974, INFECT IMMUN, V10, P1292, DOI 10.1128/IAI.10.6.1292-1295.1974; HOWELLS CHL, 1975, LANCET, V1, P381; JULSETH DR, 1984, EVALUATION VITAMIN E; KARGMAN SL, 1995, CANCER RES, V55, P2556; KISHIMOTO S, 1980, J IMMUNOL, V125, P2347; MAKINODANT, 1995, NUTR REV, V58, pS27; MEYDANI M, 1991, J NUTR, V121, P484, DOI 10.1093/jn/121.4.484; MEYDANI M, 1992, NUTRITION ELDERLY BO, P103; MEYDANI SN, 1990, AM J CLIN NUTR, V52, P557, DOI 10.1093/ajcn/52.3.557; MEYDANI SN, 1994, AM J CLIN NUTR, V60, P704, DOI 10.1093/ajcn/60.5.704; MEYDANI SN, 1986, MECH AGEING DEV, V34, P191, DOI 10.1016/0047-6374(86)90034-5; MEYDANI SN, 1993, J CLIN INVEST, V92, P105, DOI 10.1172/JCI116537; Mikstacki, 1985, NUTRITION IMMUNITY I, P137; REDDY PG, 1985, J DAIRY SCI, V69, P164; ROBERTST.IC, 1974, LANCET, V2, P368; RODYSILL KJ, 1989, J AM GERIATR SOC, V37, P435, DOI 10.1111/j.1532-5415.1989.tb02640.x; ROWLEY MJ, 1968, LANCET, V2, P24; RUBEN FL, 1985, J INFECT DIS, V151, P845, DOI 10.1093/infdis/151.5.845; SANO H, 1995, CANCER RES, V55, P3785; SHAHID NS, 1995, LANCET, V346, P1252, DOI 10.1016/S0140-6736(95)91861-2; SIBER GR, 1990, NEW ENGL J MED, V323, P1387, DOI 10.1056/NEJM199011153232005; TEIGE J, 1982, RES VET SCI, V32, P95, DOI 10.1016/S0034-5288(18)32445-7; Tengerdy R.P., 1978, TOCOPHEROL OXYGEN BI, P191; *USDA, 1990, GRAND DAT ONL; WANG YJ, 1994, J NUTR, V124, P2024, DOI 10.1093/jn/124.10.2024; WAYNE SJ, 1990, J GERONTOL, V45, pM45, DOI 10.1093/geronj/45.2.M45; WHITTINGHAM S, 1978, CLIN EXP IMMUNOL, V34, P170; ZOUALI M, 1986, J IMMUNOL METHODS, V90, P105, DOI 10.1016/0022-1759(86)90390-X; [No title captured]	46	415	434	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	1997	277	17					1380	1386		10.1001/jama.277.17.1380	http://dx.doi.org/10.1001/jama.277.17.1380			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW261	9134944				2022-12-28	WOS:A1997WW26100028
J	Vadher, B; Patterson, DLH; Leaning, M				Vadher, B; Patterson, DLH; Leaning, M			Evaluation of a decision support system for initiation and control of oral anticoagulation in a randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WARFARIN THERAPY; PREDICTION; MANAGEMENT; AUDIT	Objectives: To determine whether a computerised decision support system for initiation and control of oral anticoagulant treatment improves quality of anticoagulant control achieved by trainee doctors. Design: Randomised controlled trial. Setting: District general hospital in North London. Subjects: 148 inpatients requiring start of warfarin treatment. Interventions: Management by trainee doctors (to achieve therapeutic range of international normalised ratio of 2 to 3) with indirect assistance from computerised decision support system (intervention group) or without such assistance (control group). Main outcome measures: Median time to therapeutic range, stable dose, and first pseudoevent (excessive international normalised ratio after therapeutic range has been reached) and person time spent in the therapeutic range. Results: 72 patients were randomised to the intervention group and 76 to control group. Median time to reach international normalised ratio of greater than or equal to 2 was not significantly different in the two groups (3 days). Median time to achieve a stable dose was significantly lower in intervention group than in controls (7 days v 9 days, P = 0.01) without excessive overtreatment or undertreatment with anticoagulant Patients in intervention group spent greater proportion of time in therapeutic range, both as inpatients (59% v 52%) and outpatients (64% v 51%). Conclusion: The computerised decision support system was safe and effective and improved the quality of initiation and control of warfarin treatment by trainee doctors.	UCL, WHITTINGTON HOSP, CTR HLTH INFORMAT & MULTIPROFESS EDUC, LONDON N19 5NF, ENGLAND	University of London; University College London	Vadher, B (corresponding author), WHITTINGTON HOSP, DEPT CARDIOVASC, LONDON N19 5NF, ENGLAND.							ABBRECHT PH, 1982, CLIN PHARMACOL THER, V32, P129, DOI 10.1038/clpt.1982.136; Altman D.G., 1991, PRACTICAL STAT MED R; CARTER BL, 1987, CLIN PHARMACY, V6, P37; *DEP HLTH, 1985, ANT TREATM; DOBLE N, 1987, J ROY SOC MED, V80, P627, DOI 10.1177/014107688708001009; DOECKE CJ, 1991, AUST NZ J MED, V21, P319, DOI 10.1111/j.1445-5994.1991.tb04697.x; DUXBURY BM, 1982, BRIT MED J, V284, P702, DOI 10.1136/bmj.284.6317.702; FENNERTY A, 1984, BRIT MED J, V288, P1268, DOI 10.1136/bmj.288.6426.1268; Fitzmaurice DA, 1996, BRIT MED J, V312, P1431, DOI 10.1136/bmj.312.7044.1431; Glynn RJ, 1996, BMJ-BRIT MED J, V312, P364; HOLFORD NHG, 1986, CLIN PHARMACOKINET, V11, P483, DOI 10.2165/00003088-198611060-00005; LEWIS SM, 1988, QUALITY ASSURANCE HA, P151; MAJUMDAR G, 1985, CLIN LAB HAEMATOL, V7, P125, DOI 10.1111/j.1365-2257.1985.tb00016.x; POLLER L, 1993, J CLIN PATHOL, V46, P299, DOI 10.1136/jcp.46.4.299; ROSE PE, 1993, J CLIN PATHOL, V46, P1069; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; STUKEL TA, 1994, STAT MED, V13, P1781, DOI 10.1002/sim.4780131709; TAN G, 1993, J CLIN PATHOL, V46, P67, DOI 10.1136/jcp.46.1.67; VADHER B, 1996, BR J HAEMATOL S1, V93, P30; Vadher BD, 1995, CLIN LAB HAEMATOL, V17, P339; VOZEH S, 1985, CLIN PHARMACOKINET, V10, P457; WHITE RH, 1987, J GEN INTERN MED, V2, P141, DOI 10.1007/BF02596140; WHITE RH, 1991, THER DRUG MONIT, V13, P46, DOI 10.1097/00007691-199101000-00006; 1992, DRUG THER B, V30, P77	24	60	61	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 26	1997	314	7089					1252	1256		10.1136/bmj.314.7089.1252	http://dx.doi.org/10.1136/bmj.314.7089.1252			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW718	9154031	Green Published			2022-12-28	WOS:A1997WW71800023
J	Drevets, WC; Price, JL; Simpson, JR; Todd, RD; Reich, T; Vannier, M; Raichle, ME				Drevets, WC; Price, JL; Simpson, JR; Todd, RD; Reich, T; Vannier, M; Raichle, ME			Subgenual prefrontal cortex abnormalities in mood disorders	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; UNIPOLAR DEPRESSION; GLUCOSE-METABOLISM; (H2O)-O-15; VALIDATION; VALIDITY; COMMON; RATES	Pathological disturbances of mood may follow a 'bipolar' course, in which normal moods alternate with both depression and mania, or a 'unipolar' course, in which only depression occurs(1-3). Both bipolar and unipolar disorders can be heritable illnesses associated with neurochemical, neuroendocrine and autonomic abnormalities. The neurobiological basis for these abnormalities has not been established(2,3). Using positron emission tomographic (PET) images of cerebral blood flow and rate of glucose metabolism to measure brain activity, we have now localized an area of abnormally decreased activity in the pre-frontal cortex ventral to the germ of the corpus callosum in both familial bipolar depressives and familial unipolar depressives. This decrement in activity was at least partly explained by a corresponding reduction in cortical volume(4) as magnetic resonance imaging (MRI) demonstrated reductions in the mean grey matter volume in the same area of 39 and 48% in the bipolar and unipolar samples, respectively. This region has previously been implicated in the mediation of emotional and autonomic responses to socially significant or provocative stimuli, and in the modulation of the neurotransmitter systems targeted by antidepressant drugs(3,5-10).	WASHINGTON UNIV, SCH MED, MALLINCKRODT INST RADIOL, DIV RADIOL SCI, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROL & NEUROL SURG NEUROL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, MCDONNELL CTR STUDIES HIGHER BRAIN FUNCT, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Drevets, WC (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PSYCHIAT, ST LOUIS, MO 63110 USA.		anand, amit/A-7222-2009; Vannier, Michael W/AAI-6951-2021	Vannier, Michael/0000-0001-9898-384X				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; [Anonymous], 1993, NEUROBIOLOGY CINGULA; BAXTER LR, 1985, ARCH GEN PSYCHIAT, V42, P441; BAXTER LR, 1989, ARCH GEN PSYCHIAT, V46, P243; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; BUCHSBAUM MS, 1986, J AFFECT DISORDERS, V10, P137, DOI 10.1016/0165-0327(86)90036-4; Carmichael ST, 1995, J COMP NEUROL, V363, P615, DOI 10.1002/cne.903630408; COHEN RM, 1989, NEUROPSYCHOPHARMACOL, V2, P241, DOI 10.1016/0893-133X(89)90028-6; Damasio A, 1995, DESCARTES ERROR EMOT; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; DIROCCO RJ, 1989, COMPUT MED IMAG GRAP, V13, P81, DOI 10.1016/0895-6111(89)90080-3; DOLAN RJ, 1993, J NEUROL NEUROSUR PS, V56, P1290, DOI 10.1136/jnnp.56.12.1290; DREVETS WC, 1992, J NEUROSCI, V12, P3628; DREVETS WC, 1996, ADULT PSYCHIAT, P53; DREVETS WC, 1997, ADULT PSYCHIAT, P99; DREVETS WC, IN PRESS COGNIT EMOT; DREVETS WC, 1992, ABSTR SOC NEUROSCI, V18, P1596; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1989, J NUCL MED, V30, P141; Goodwin F, 1990, MANIC DEPRESSIVE ILL; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; MAZZIOTTA JC, 1981, J COMPUT ASSIST TOMO, V5, P734, DOI 10.1097/00004728-198110000-00029; Pearlson GD, 1997, BIOL PSYCHIAT, V41, P1, DOI 10.1016/S0006-3223(96)00373-3; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; RAICHLE ME, 1983, J NUCL MED, V24, P790; SESACK SR, 1989, J COMP NEUROL, V290, P213, DOI 10.1002/cne.902900205; Talairach J., 1988, COPLANAR STEREOTAXIC, P1; WINOKUR G, 1982, PHARMACOPSYCHIATRIA, V15, P142, DOI 10.1055/s-2007-1019527; YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429	30	1985	2041	3	146	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	1997	386	6627					824	827		10.1038/386824a0	http://dx.doi.org/10.1038/386824a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126739				2022-12-28	WOS:A1997WV70600052
J	Biddiss, M				Biddiss, M			Tomorrow's doctors and the study of the past	LANCET			English	Editorial Material											Biddiss, M (corresponding author), UNIV READING,DEPT HIST,READING RG6 6AA,BERKS,ENGLAND.							Burleigh Michael, 1994, EUTHANASIA GERMANY 1; *ED COMM GEN MED C, 1993, TOM DOCT REC UND MED; Evans R., 1987, DEATH HAMBURG SOC PO; Harris Ruth, 1989, MURDERS MADNESS; Jordanova L., 1993, HIST J, V36, P437, DOI [10.1017/S0018246X00019324, DOI 10.1017/S0018246X00019324]; Kiple K.F., 1993, CAMBRIDGE WORLD HIST; Porter R., 1993, COMPANION ENCY HIST, V2, P1576; PORTER R, 1985, HIST TODAY       MAY, P48; Shorter E., 1996, CAMBRIDGE ILLUSTRATE, P118; WEATHERALL D, 1997, TIMES HIGHER S 0117, P27	10	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					874	876		10.1016/S0140-6736(97)01435-9	http://dx.doi.org/10.1016/S0140-6736(97)01435-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121277				2022-12-28	WOS:A1997WP40300048
J	Lloyd, DA; Carty, H; Patterson, M; Butcher, CK; Roe, D				Lloyd, DA; Carty, H; Patterson, M; Butcher, CK; Roe, D			Predictive value of skull radiography for intracranial injury in children with blunt head injury	LANCET			English	Article							TRAUMA; HEMATOMA; ADULTS; RISKS	Background The value of routine skull radiography as a method of predicting intracranial injury is controversial. We aimed to assess the effectiveness of skull radiography by prospectively studying head-injured children admitted to a children's hospital that serves an urban population. Methods Over a 2-year period, 9269 children attended our accident and emergency department with head injury, and 6011 were referred for skull radiography. All children who were admitted to hospital or had a skull fracture (n=883) were included in the study. Computed tomography (CT) was done in children with skull fractures on radiography and in those without fractures if there were neurological indications. Findings Radiographs showed 162 fractures (2.7% of all radiographs and 18% of study group radiographs). Staff in the accident and emergency department missed 37 (23%) fractures. CT scan was done on 156 children, of whom 107 had a skull fracture. 23 children were found to have intracranial injuries on CT. The presence of neurological abnormalities had a sensitivity for identification of intracranial injury of 91% (21 of 23) and a negative predictive value of 97%. The corresponding values for skull fracture on radiography were 65% (15 of 23) and 83%. Four children died, of whom only one had a skull fracture. Interpretation In children, severe intracranial injury can occur in the absence of skull fracture. Skull radiography is not a reliable predictor of intracranial injury and is indicated only to confirm or exclude a suspected depressed fracture or penetrating injury, and when non-accidental injury is suspected, including in all infants younger than 2 years. Clinical neurological abnormalities are a reliable predictor of intracranial injury. If imaging is required, it should be with CT and not skull radiography.	ALDER HEY CHILDRENS HOSP,INST CHILD HLTH,DEPT RADIOL,LIVERPOOL L12 2AP,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,DEPT CHILD HLTH,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Liverpool; University of Liverpool	Lloyd, DA (corresponding author), ALDER HEY CHILDRENS HOSP,INST CHILD HLTH,DEPT PAEDIAT SURG,EATON RD,LIVERPOOL L12 2AP,MERSEYSIDE,ENGLAND.		Patterson Molloy, Marie (Mal)/A-2030-2014	Patterson Molloy, Marie (Mal)/0000-0002-5334-8567				BELL RS, 1971, NEW ENGL J MED, V284, P236, DOI 10.1056/NEJM197102042840504; Bell William O., 1995, P101; BONADIO WA, 1989, AM J DIS CHILD, V143, P194, DOI 10.1001/archpedi.1989.02150140084025; BOULIS ZF, 1978, BRIT J RADIOL, V51, P851, DOI 10.1259/0007-1285-51-611-851; CHAN KH, 1990, CHILD NERV SYST, V6, P27, DOI 10.1007/BF00262262; GORDANO U, 1992, CHILD NERV SYST, V8, P136; HARWOODNASH DC, 1971, RADIOLOGY, V101, P151, DOI 10.1148/101.1.151; LEONIDAS JC, 1982, PEDIATRICS, V69, P139; MACKWAYJONES K, 1993, ADV PAEDIAT LIFE SUP; MENDELOW AD, 1983, BRIT MED J, V287, P1173, DOI 10.1136/bmj.287.6400.1173; READ HS, 1995, INJURY, V20, P333; ROBERTS F, 1972, J ROENTGENOL, V114, P230; ROSENTHAL BW, 1989, J PEDIATR-US, V115, P346, DOI 10.1016/S0022-3476(89)80830-3; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363	15	112	113	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					821	824		10.1016/S0140-6736(96)09356-7	http://dx.doi.org/10.1016/S0140-6736(96)09356-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121256				2022-12-28	WOS:A1997WP40300009
J	Hale, SP; Auld, DS; Schmidt, E; Schimmel, P				Hale, SP; Auld, DS; Schmidt, E; Schimmel, P			Discrete determinants in transfer RNA for editing and aminoacylation	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; RECOGNITION; SYNTHETASE; ISOLEUCINE; RESOLUTION; SIEVE	During translation errors of aminoacylation are corrected in editing reactions which ensure that an amino acid is stably attached to its corresponding transfer RNA (tRNA). Previous studies have not shown whether the tRNA nucleotides needed for effecting translational editing are the same as or distinct from those required for aminoacylation, but several considerations have suggested that they are the same. Here, designed tRNAs that are highly active for aminoacylation but are not active in translational editing are presented. The editing reaction can be controlled by manipulation of nucleotides at the corner of the L-shaped tRNA. In contrast, these manipulations do not affect aminoacylation. These results demonstrate the segregation of nucleotide determinants for the editing and aminoacylation functions of tRNA.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015539, R01GM015539] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN AN, 1966, J BIOL CHEM, V241, P839; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P347; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; Hale SP, 1996, P NATL ACAD SCI USA, V93, P2755, DOI 10.1073/pnas.93.7.2755; HIPPS D, 1995, EMBO J, V14, P4050, DOI 10.1002/j.1460-2075.1995.tb00076.x; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; LADNER JE, 1975, P NATL ACAD SCI USA, V72, P4414, DOI 10.1073/pnas.72.11.4414; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; LOFTFIELD RB, 1963, BIOCHEM J, V89, P82, DOI 10.1042/bj0890082; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; NUREKI O, 1994, J MOL BIOL, V236, P710, DOI 10.1006/jmbi.1994.1184; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; SAKS ME, 1994, ADHESION SCI, V283, P191; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; SCHMIDT E, 1996, THESIS MIT CAMBRIDGE, P120; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; SHEPARD A, 1992, P NATL ACAD SCI USA, V89, P9964, DOI 10.1073/pnas.89.20.9964; Stoll A., 1958, FESTSCHRIFT A STOLL, P597; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712	23	77	79	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	1997	276	5316					1250	1252		10.1126/science.276.5316.1250	http://dx.doi.org/10.1126/science.276.5316.1250			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157882				2022-12-28	WOS:A1997XA49700041
J	Cooper, DA; Katlama, C; Montaner, J; Collis, PJ; Antunes, F; Atkinson, M; Clark, A; Clumeck, N; Collis, P; Gazzard, B; Gerstoft, J; Goh, L; Hill, A; Korsia, S; Lange, J; McCallum, L; McDade, H; Mallolas, J; Moroni, M; Norkrans, G; Opravil, M; Reiss, P; Rozenbaum, W; Scott, J; Smith, D; Staszewski, S; Stoffels, P				Cooper, DA; Katlama, C; Montaner, J; Collis, PJ; Antunes, F; Atkinson, M; Clark, A; Clumeck, N; Collis, P; Gazzard, B; Gerstoft, J; Goh, L; Hill, A; Korsia, S; Lange, J; McCallum, L; McDade, H; Mallolas, J; Moroni, M; Norkrans, G; Opravil, M; Reiss, P; Rozenbaum, W; Scott, J; Smith, D; Staszewski, S; Stoffels, P			Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial	LANCET			English	Article							CLINICAL-TRIALS; AIDS	Background Previous studies have shown that combination therapy with lamivudine plus zidovudine causes pronounced and sustained increases in CD4 counts and reductions in viral load in individuals infected with HIV-1. We assessed the clinical benefit of the addition of lamivudine to zidovudine-based regimens in patients infected with HIV-1 who had CD4 counts of 25-250/mu L. Methods Eligible patients receiving zidovudine monotherapy or zidovudine plus zalcitabine or didanosine combination therapy were assigned 52 weeks of treatment with the addition of placebo, lamivudine (150 mg twice a day), or lamivudine (150 mg twice a day) plus loviride (100 mg three times a day). Patients were unaware of type of treatment allocated. The primary endpoint was progression to a new protocol-defined AIDS event or death. Findings The study was terminated following the second interim analysis because of a highly significant reduction in progression to AIDS or death in the patients treated with lamivudine rather than placebo. In the final analysis of 1840 patients, progression had occurred in 95 (20%) of 471 placebo-treated patients, 86 (9%) of 907 lamivudine-treated patients, and 42 (9%) of 462 patients who received lamivudine plus loviride (p<0.0001, relative hazard 0.42 [95% CI 0.32-0.57]). A significant survival benefit was also seen (p=0.0007, relative hazard 0.40 [0.23-0.69]). Significantly fewer patients in the lamivudine group than in the placebo group required hospital admission, unscheduled visits, or prescribed medications for HIV-related events. There were no differences in the frequency or severity of clinical or laboratory toxicities between the treatment groups. Interpretation The addition of lamivudine to zidovudine-containing treatment regimens significantly slowed the progression of HIV disease and improved survival. However, it is unlikely that this combination alone would be sufficient to achieve long-term complete suppression of viral replication in all patients.			Cooper, DA (corresponding author), UNIV NEW S WALES, FAC MED, NATL CTR HIV EPIDEMIOL & CLIN RES, 376 VICTORIA ST, SYDNEY, NSW 2010, AUSTRALIA.							Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; Bartlett JA, 1996, ANN INTERN MED, V125, P161, DOI 10.7326/0003-4819-125-3-199608010-00001; CAMERON DW, 1996, INT C AIDS JUL 7 12; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Centers for Disease Control and Prevention, 1992, MMWR, V41; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; Gazzard BG, 1997, LANCET, V349, P1086, DOI 10.1016/S0140-6736(96)12073-0; GULICK RM, 1996, 11 INT C AIDS JUL 7; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; Katlama C, 1996, JAMA-J AM MED ASSOC, V276, P118, DOI 10.1001/jama.276.2.118; Kuritzkes DR, 1996, AIDS, V10, P975, DOI 10.1097/00002030-199610090-00007; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; LUNDGREN JD, 1994, BMJ-BRIT MED J, V308, P1068, DOI 10.1136/bmj.308.6936.1068; MONTANER JSG, 1996, 11 INT C AIDS VANC B; NEATON JD, 1994, STAT MED, V13, P2107, DOI 10.1002/sim.4780131919; NIJHUIS M, IN PRESS J INFECT DI; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PHILLIPS AN, 1997, 4 C RETR OPP INF JAN; ROZENBAUM W, 1997, 4 C RETR OPP INF JAN; SALGO MP, 1996, 11 INT C AIDS JUL 7; Saravolatz LD, 1996, NEW ENGL J MED, V335, P1099, DOI 10.1056/NEJM199610103351503; Schooley RT, 1996, J INFECT DIS, V173, P1354, DOI 10.1093/infdis/173.6.1354; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; Staszewski S, 1996, JAMA-J AM MED ASSOC, V276, P111, DOI 10.1001/jama.276.2.111; Staszewski S, 1997, AIDS, V11, P477, DOI 10.1097/00002030-199704000-00011; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282	29	218	221	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	1997	349	9063					1413	1421						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164314	Green Submitted			2022-12-28	WOS:A1997WZ76500008
J	Silverman, WA				Silverman, WA			Crap-trapping	LANCET			English	Article																		ASHER R, 1959, T MED SOC LONDON, V79, P66; BERKOWITZ P, 1996, NEW REPUBLIC    0701, P15; Moore TJ, 1995, DEADLY MED; NAFTULIN DH, 1973, J MED EDUC, V48, P630; Postman N., 1971, TEACHING SUBVERSIVE; SOKAL A, 1996, LINGUA FRANCA, V6, P62; Sokal A., 1996, SOCIAL TEXT, V46/47, P217, DOI [10.2307/466856, DOI 10.2307/466856]; 1974, LANCET, V2, P1493; 1975, PEDIATRICS, V55, P753	9	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	1997	349	9063					1471	1472		10.1016/S0140-6736(96)11147-8	http://dx.doi.org/10.1016/S0140-6736(96)11147-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164334				2022-12-28	WOS:A1997WZ76500046
J	Clark, SE; Williams, RW; Meyerowitz, EM				Clark, SE; Williams, RW; Meyerowitz, EM			The CLAVATA1 gene encodes a putative receptor kinase that controls shoot and floral meristem size in Arabidopsis	CELL			English	Article							DEPENDENT PROTEIN-KINASE; DISEASE-RESISTANCE GENE; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; PLANT TRANSFORMATION; PERICLINAL CHIMERAS; FLOWER DEVELOPMENT; MOLECULAR-CLONING; VEGETATIVE SHOOT; TYROSINE KINASES	The shoot apical meristem is responsible for aboveground organ initiation in higher plants, accomplishing continuous organogenesis by maintaining a pool of undifferentiated cells and directing descendant cells toward organ formation. Normally, proliferation and differentiation are balanced, so that the structure and size of the shoot meristem is maintained. However, Arabidopsis plants homozygous for mutations at the CLAVATA1 (CLV1) locus accumulate excess undifferentiated cells. We describe the molecular cloning and expression pattern of the CLV1 gene. It encodes a putative receptor kinase, suggesting a role in signal transduction. The extracellular domain is composed of 21 tandem leucine-rich repeats that resemble leucine-rich repeats found in animal hormone receptors. We provide evidence that CLV1 expression in the inflorescence is specifically associated with meristematic activity.	UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	Clark, SE (corresponding author), CALTECH, DEPT BIOL, PASADENA, CA 91125 USA.		Meyerowitz, Elliot M/A-7118-2009		NIGMS NIH HHS [GM07616] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Becraft PW, 1996, SCIENCE, V273, P1406, DOI 10.1126/science.273.5280.1406; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; CLARK SE, 1993, DEVELOPMENT, V119, P397; CLARK SE, 1995, DEVELOPMENT, V121, P2057; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; HANKS SK, 1989, MOL ENDOCRINOL, V3, P110, DOI 10.1210/mend-3-1-110; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANTKE SS, 1995, DEVELOPMENT, V121, P27; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; HORN MA, 1994, BBA-PROTEIN STRUCT M, V1208, P65, DOI 10.1016/0167-4838(94)90160-0; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; JACKSON D, 1994, DEVELOPMENT, V120, P405; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P9627, DOI 10.1093/nar/15.23.9627; KLEBER JJ, 1993, CELL, V72, P427; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; Laux T, 1996, DEVELOPMENT, V122, P87; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LEYSER HMO, 1992, DEVELOPMENT, V116, P397; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LOH YT, 1995, P NATL ACAD SCI USA, V92, P4181, DOI 10.1073/pnas.92.10.4181; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; LYNDON RF, 1990, TOPICS PLANT PHYSL, V3; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; McKELVIE A. D., 1962, RADIATION BOT, V1, P233; MEDFORD JI, 1992, PLANT CELL, V4, P631, DOI 10.1105/tpc.4.6.631; Meyerowitz EM, 1997, CELL, V88, P299, DOI 10.1016/S0092-8674(00)81868-1; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; PARAVICINI G, 1992, MOL BIOL CELL, V3, P415, DOI 10.1091/mbc.3.4.415; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Penninckx IAMA, 1996, PLANT CELL, V8, P2309, DOI 10.1105/tpc.8.12.2309; Perbal MC, 1996, DEVELOPMENT, V122, P3433; RUNNING MP, 1995, METHODS CELL BIOL PL, P215; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAKAI H, 1995, NATURE, V378, P199, DOI 10.1038/378199a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH LG, 1992, DEVELOPMENT, V116, P21; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; SZYMKOWIAK EJ, 1992, PLANT CELL, V4, P1089, DOI 10.1105/tpc.4.9.1089; Torii KU, 1996, PLANT CELL, V8, P735, DOI 10.1105/tpc.8.4.735; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; VALON C, 1993, PLANT MOL BIOL, V23, P415, DOI 10.1007/BF00029017; WALKER JC, 1993, PLANT J, V3, P451, DOI 10.1046/j.1365-313X.1993.t01-23-00999.x; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	64	1043	1126	5	118	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	1997	89	4					575	585		10.1016/S0092-8674(00)80239-1	http://dx.doi.org/10.1016/S0092-8674(00)80239-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160749	Bronze			2022-12-28	WOS:A1997WZ32300011
J	Eggleston, AK; Mitchell, AH; West, SC				Eggleston, AK; Mitchell, AH; West, SC			In vitro reconstitution of the late steps of genetic recombination in E-coli	CELL			English	Article							DNA STRAND EXCHANGE; HOLLIDAY JUNCTION RESOLVASE; COMPLEX IN-VITRO; ESCHERICHIA-COLI; RUVB PROTEINS; RECA PROTEIN; BRANCH MIGRATION; DUPLEX DNA; HOMOLOGOUS RECOMBINATION; REPAIR PROTEINS	Purified proteins have been used to reconstitute an in vitro system for the medial-to-late stages of recombination in E. coli. In this system, RecA protein formed recombination intermediates that were processed by the actions of the RuvA, RuvB, and RuvC proteins. RuvAB was found to promote branch migration, to dissociate the RecA filament, and to modulate the orientation of cleavage of Holliday junction resolution by RuvC. Monoclonal antibodies directed against RuvA, RuvB, or RuvC inhibited resolution in the reconstituted system. Specific protein-protein interactions between the branch migration motor (RuvB) and the resolvase (RuvC) were also observed. These results provide evidence for coordinated action during the late stages of recombination, possibly involving the assembly of a RuvABC branch migration/resolution complex.	IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND					West, Stephen/0000-0001-8848-9418; Eggleston, Angela/0000-0001-8682-397X; Mitchell, Alison/0000-0003-2001-1738				Adams DE, 1996, J MOL BIOL, V263, P582, DOI 10.1006/jmbi.1996.0600; ADAMS DE, 1995, J MOL BIOL, V247, P404, DOI 10.1006/jmbi.1995.0149; ADAMS DE, 1994, P NATL ACAD SCI USA, V91, P9901, DOI 10.1073/pnas.91.21.9901; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; Bennett RJ, 1996, P NATL ACAD SCI USA, V93, P12217, DOI 10.1073/pnas.93.22.12217; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; CHIU SK, 1990, J BIOL CHEM, V265, P21262; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HAHN TR, 1988, J BIOL CHEM, V263, P7431; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; IYPE LE, 1994, J BIOL CHEM, V269, P24967; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LLOYD RG, 1996, ESCHERICHIA COLI SAL, P2236; Mahdi AA, 1996, J MOL BIOL, V257, P561, DOI 10.1006/jmbi.1996.0185; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; Mitchell AH, 1996, J BIOL CHEM, V271, P19497, DOI 10.1074/jbc.271.32.19497; MOREL P, 1994, J BIOL CHEM, V269, P19830; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1993, J BIOL CHEM, V268, P17179; PARSONS CA, 1995, EMBO J, V14, P5736, DOI 10.1002/j.1460-2075.1995.tb00260.x; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; PUGH BF, 1987, J BIOL CHEM, V262, P1326; PUGH BF, 1987, J BIOL CHEM, V262, P1337; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; ROMAN LJ, 1991, P NATL ACAD SCI USA, V88, P3367, DOI 10.1073/pnas.88.8.3367; SAITO A, 1995, P NATL ACAD SCI USA, V92, P7470, DOI 10.1073/pnas.92.16.7470; SAMBROOK E, 1989, MOL CLONING LAB MANU; Shah R, 1997, EMBO J, V16, P1464, DOI 10.1093/emboj/16.6.1464; SHAH R, 1994, CELL, V79, P853, DOI 10.1016/0092-8674(94)90074-4; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHARPLES GJ, 1994, EMBO J, V13, P6133, DOI 10.1002/j.1460-2075.1994.tb06960.x; SHIBA T, 1993, MOL GEN GENET, V237, P395, DOI 10.1007/BF00279443; SHIBA T, 1994, NUCL ACIDS S SERIES, V31, P221; Shida T, 1996, J BIOL CHEM, V271, P26105, DOI 10.1074/jbc.271.42.26105; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WANG TCV, 1989, MOL GEN GENET, V216, P315, DOI 10.1007/BF00334370; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; Whitby MC, 1996, J MOL BIOL, V264, P878, DOI 10.1006/jmbi.1996.0684; Yu X, 1997, J MOL BIOL, V266, P217, DOI 10.1006/jmbi.1996.0799	57	105	106	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	1997	89	4					607	617		10.1016/S0092-8674(00)80242-1	http://dx.doi.org/10.1016/S0092-8674(00)80242-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160752	Bronze			2022-12-28	WOS:A1997WZ32300014
J	Gensheimer, KF				Gensheimer, KF			The making of a public health physician	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									MAINE DEPT HUMAN SERV, AUGUSTA, ME USA										0	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1997	126	10					823	824		10.7326/0003-4819-126-10-199705150-00015	http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00015			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ823	9148659				2022-12-28	WOS:A1997WZ82300015
J	Ommen, SR; Odell, JA; Stanton, MS				Ommen, SR; Odell, JA; Stanton, MS			Atrial arrhythmias after cardiothoracic surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORONARY-ARTERY BYPASS; OPEN-HEART-SURGERY; CARDIAC-SURGERY; RANDOMIZED TRIAL; SUPRAVENTRICULAR TACHYARRHYTHMIAS; CARDIOPULMONARY BYPASS; FIBRILLATION; DIGOXIN; RISK; FLUTTER		MAYO CLIN,DIV CARDIOVASC DIS,ROCHESTER,MN 55905; MAYO CLIN,DIV CARDIOVASC SURG,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic			odell, john/AAA-5834-2022					ABEL RM, 1983, ARCH SURG-CHICAGO, V118, P727; AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349; ANDREWS TC, 1991, CIRCULATION, V84, P236; [Anonymous], 1994, ARCH INTERN MED, V154, P2254; [Anonymous], 1994, ARCH INTERN MED, V154, P1449; Aranki SF, 1996, CIRCULATION, V94, P390, DOI 10.1161/01.CIR.94.3.390; BLACK IW, 1994, CIRCULATION, V89, P2509, DOI 10.1161/01.CIR.89.6.2509; Blackshear JL, 1996, ANN THORAC SURG, V61, P755, DOI 10.1016/0003-4975(95)00887-X; BUTLER J, 1993, EUR J CARDIO-THORAC, V7, P23, DOI 10.1016/1010-7940(93)90143-Y; CAMPBELL TJ, 1985, BRIT HEART J, V54, P86; CHIDAMBARAM M, 1992, THORAC CARDIOV SURG, V40, P70, DOI 10.1055/s-2007-1020115; COCHRANE AD, 1994, EUR J CARDIO-THORAC, V8, P194, DOI 10.1016/1010-7940(94)90114-7; Coumel P, 1994, ATRIAL FIBRILLATION, P171; COX JL, 1993, ANN THORAC SURG, V56, P405, DOI 10.1016/0003-4975(93)90871-E; COX JL, 1991, J THORAC CARDIOV SUR, V101, P406, DOI 10.1016/s0022-5223(19)36723-6; CRESWELL LL, 1993, ANN THORAC SURG, V56, P539, DOI 10.1016/0003-4975(93)90894-N; DANIEL WG, 1988, J AM COLL CARDIOL, V11, P1204, DOI 10.1016/0735-1097(88)90283-5; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; ELSADEK M, 1994, CARDIOLOGY, V85, P290, DOI 10.1159/000176699; FONTAN F, 1992, EUR J CARDIO-THORAC, V6, P127, DOI 10.1016/1010-7940(92)90118-H; FROST L, 1992, INT J CARDIOL, V36, P253, DOI 10.1016/0167-5273(92)90293-C; GAVAGHAN TP, 1985, AUST NZ J MED, V15, P27, DOI 10.1111/j.1445-5994.1985.tb02726.x; GAVAGHAN TP, 1988, BRIT HEART J, V60, P497; GENTILI C, 1992, AM HEART J, V123, P1225, DOI 10.1016/0002-8703(92)91026-W; HASHIMOTO K, 1991, J THORAC CARDIOV SUR, V101, P56; HEYWOOD JT, 1995, CAN J CARDIOL, V11, P823; HJELMS E, 1992, SCAND J THORAC CARD, V26, P193, DOI 10.3109/14017439209099077; HOHNLOSER SH, 1991, AM HEART J, V121, P89, DOI 10.1016/0002-8703(91)90960-P; IBERTI TJ, 1986, CRIT CARE MED, V14, P283, DOI 10.1097/00003246-198604000-00006; Jacquet L, 1994, J Cardiothorac Vasc Anesth, V8, P431, DOI 10.1016/1053-0770(94)90283-6; Kecskemeti V, 1985, Adv Myocardiol, V6, P37; KITZMAN DW, 1990, J GERONTOL, V45, pM33, DOI 10.1093/geronj/45.2.M33; KLEIN M, 1995, AM HEART J, V129, P895, DOI 10.1016/0002-8703(95)90109-4; KONINGS KTS, 1994, CIRCULATION, V89, P1665, DOI 10.1161/01.CIR.89.4.1665; KOWEY PR, 1992, AM J CARDIOL, V69, P963, DOI 10.1016/0002-9149(92)90802-6; KROHN BG, 1989, CHEST, V95, P729, DOI 10.1378/chest.95.4.729; KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490; LAUB GW, 1993, CRIT CARE MED, V21, P1474, DOI 10.1097/00003246-199310000-00014; LEITCH JW, 1990, J THORAC CARDIOV SUR, V100, P338; LOWE JE, 1991, ANN SURG, V213, P388, DOI 10.1097/00000658-199105000-00002; MCCARTY RJ, 1966, CIRCULATION, V34, P792, DOI 10.1161/01.CIR.34.5.792; MERRICK AF, 1995, EUR J CARDIO-THORAC, V9, P146, DOI 10.1016/S1010-7940(05)80062-4; MICHELUCCI A, 1994, ATRIAL FIBRILLATION, P81; MOE GK, 1962, ARCH INT PHARMACOD T, V140, P183; MULLEN JC, 1987, J THORAC CARDIOV SUR, V94, P558; NYSTROM U, 1993, THORAC CARDIOV SURG, V41, P34, DOI 10.1055/s-2007-1013817; Odell JA, 1996, ANN THORAC SURG, V61, P565, DOI 10.1016/0003-4975(95)00885-3; PETERSEN P, 1989, LANCET, V1, P175; REED GL, 1988, NEW ENGL J MED, V319, P1246, DOI 10.1056/NEJM198811103191903; SCHWARTZ M, 1988, CHEST, V93, P705, DOI 10.1378/chest.93.4.705; SEITELBERGER R, 1994, J THORAC CARDIOV SUR, V107, P811; SILVERMAN NA, 1982, ANN SURG, V196, P194, DOI 10.1097/00000658-198208000-00012; SMITH PK, 1983, J THORAC CARDIOV SUR, V85, P105; STEINBERG JS, 1993, CIRCULATION, V88, P2618, DOI 10.1161/01.CIR.88.6.2618; STODDARD MF, 1995, J AM COLL CARDIOL, V25, P452, DOI 10.1016/0735-1097(94)00396-8; WALDO AL, 1987, CIRCULATION, V75, P37; *WARM HEART INV, 1994, LANCET, V343, P559; Weber Uta Kloter, 1996, Journal of the American College of Cardiology, V27, p309A; 1991, CIRCULATION, V84, P527	59	317	330	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	1997	336	20					1429	1434		10.1056/NEJM199705153362006	http://dx.doi.org/10.1056/NEJM199705153362006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY577	9145681				2022-12-28	WOS:A1997WY57700006
J	Elwood, ET; Larsen, CP; Maurer, MH; Routenberg, KL; Neylan, NF; Whelchel, JD; OBrien, DP; Pearson, TC				Elwood, ET; Larsen, CP; Maurer, MH; Routenberg, KL; Neylan, NF; Whelchel, JD; OBrien, DP; Pearson, TC			Microchimerism and rejection in clinical transplantation	LANCET			English	Article							ALLOGRAFT RECIPIENTS; GRAFT ACCEPTANCE; CELL-MIGRATION; CHIMERISM; KIDNEY; LIVER; TOLERANCE; HEART; PCR	Background Haemopoietic microchimerism has been identified in recipients of solid-organ transplants and is thought by some to be critical for the development and maintenance of immunological tolerance. The aim of this study was to correlate prospectively the persistence of donor cells with clinical outcome in recipients of kidney, kidney and pancreas, and liver transplants. Methods Persistence of donor cells in recipient peripheral blood was assessed at. 3 days, and at 1, 3, 6, and 12 months after transplantation by a two-stage nested PCR technique to detect donor MHC HLA DR gene specifically, A pretransplant blood sample was collected from each patient to serve as an individual negative control, Seven liver, six kidney and pancreas, and 17 kidney patients were enrolled, 12 of the 17 kidney patients and all of the kidney and pancreas, and liver recipients were suitable for analysis. Exact matches for donors and recipients at the HLA DR loci (n=1) or inability to obain primer pair specificity among similar HLA DR types (n=4), meant that we were unable to analyse five patients. Findings Donor DNA was detected in 20 (80%) of 25,ten (40%) of 25, seven (30%) of 23, five (22%) of 23, and six (32%) of 19 recipients at 3 days, and 1, 3, 6 and 12 months post-transplant, respectively. Within individuals, the detection of donor DNA varied over time; only two patients had detectable donor DNA at all times. Analysis of the whole group of transplant patients showed a similar frequency and severity of rejection episodes in patients with and without microchimerism as defined by detectable donor DR genes. Interpretation These data suggest that a significant percentage of the recipients had persistent donor class II DNA in the peripheral circulation for at least 1 year after transplantation, We showed that a pretransplant blood sample is critical to avoid a false-positive result, and suggest that detectable chimerism may vary over time in individual patients, Therefore, analysis of microchimerism with a single, post-transplant analysis may not help in malting clinical decisions for individual patients.	EMORY UNIV,SCH MED,DEPT SURG,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT MED,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PATHOL,ATLANTA,GA 30322	Emory University; Emory University; Emory University			Larsen, Christian P./B-6906-2012	Larsen, Christian P./0000-0001-6573-2649				ALARD P, 1995, TRANSPLANTATION, V60, P1125, DOI 10.1097/00007890-199511270-00012; BEIN G, 1992, TISSUE ANTIGENS, V39, P68, DOI 10.1111/j.1399-0039.1992.tb01909.x; FONTES P, 1994, LANCET, V344, P151, DOI 10.1016/S0140-6736(94)92756-1; Hisanaga M, 1996, TRANSPLANTATION, V61, P40, DOI 10.1097/00007890-199601150-00010; ILDSTAD ST, 1984, NATURE, V307, P168, DOI 10.1038/307168a0; Ishida H, 1996, TRANSPLANTATION, V62, P126, DOI 10.1097/00007890-199607150-00024; KWOK S, 1994, PCR METH APPL, V3, pS39; LARSEN CP, 1990, J EXP MED, V171, P307, DOI 10.1084/jem.171.1.307; OLERUP P, 1992, TISSUE ANTIGENS, V38, P255; ROLLES K, 1994, LANCET, V343, P263, DOI 10.1016/S0140-6736(94)91113-4; RUDERT WA, 1994, TRANSPLANTATION, V58, P964, DOI 10.1097/00007890-199410270-00022; SCHLITT HJ, 1994, LANCET, V343, P1469, DOI 10.1016/S0140-6736(94)92584-4; SCHLITT HJ, 1993, TRANSPLANTATION, V56, P1001, DOI 10.1097/00007890-199310000-00042; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; SOLEZ K, 1993, KIDNEY INT, V44, P411, DOI 10.1038/ki.1993.259; STARZL TE, 1993, HEPATOLOGY, V17, P1127; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; Starzl TE, 1996, TRANSPLANTATION, V62, P703, DOI 10.1097/00007890-199609150-00035; SUBERBIELLE C, 1994, LANCET, V343, P1468, DOI 10.1016/S0140-6736(94)92583-6	19	121	132	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1358	1360		10.1016/S0140-6736(96)09105-2	http://dx.doi.org/10.1016/S0140-6736(96)09105-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149698				2022-12-28	WOS:A1997WY34200010
J	Ruff, CB; Trinkaus, E; Holliday, TW				Ruff, CB; Trinkaus, E; Holliday, TW			Body mass and encephalization in Pleistocene Homo	NATURE			English	Article							POSTCRANIAL ROBUSTICITY; BRAIN SIZE; EVOLUTION; ERECTUS; FEMUR	Many dramatic changes in morphology within the genus Homo have occurred over the past 2 million years or more, including large increases in absolute brain size and decreases in postcanine dental size and skeletal robusticity. Body mass, as the 'size' variable against which other morphological features are usually judged, has been important for assessing these changes(1-5). Yet past body mass estimates for Pleistocene Homo have varied greatly, sometimes by as much as 50% for the same individuals(2,3,6-12). Here we show that two independent methods of body-mass estimation yield concordant results when applied to Pleistocene Homo specimens. On the basis of an analysis of 163 individuals, body mass in Pleistocene Homo averaged significantly (about 10%) larger than a representative sample of living humans. Relative to body mass, brain mass in late archaic H. sapiens (Neanderthals) was slightly smaller than in early 'anatomically modern' humans, but the major increase in encephalization within Homo occurred earlier during the Middle Pleistocene (600-150 thousand years before present (kyr BP)), preceded by a long period of stasis extending through the Early Pleistocene (1,800 kyr BP).	UNIV NEW MEXICO,DEPT ANTHROPOL,ALBUQUERQUE,NM 87131; UNIV BORDEAUX 1,CNRS,F-33405 TALENCE,FRANCE; COLL WILLIAM & MARY,DEPT ANTHROPOL,WILLIAMSBURG,VA 23187	University of New Mexico; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; William & Mary	Ruff, CB (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,725 N WOLFE ST,BALTIMORE,MD 21205, USA.		Klein, Richard G/B-5910-2009					AIELLO LC, 1994, AM J PHYS ANTHROPOL, V95, P409, DOI 10.1002/ajpa.1330950405; BEALS KL, 1984, CURR ANTHROPOL, V25, P301, DOI 10.1086/203138; BROWN F, 1985, NATURE, V316, P788, DOI 10.1038/316788a0; Frayer DW, 1984, ORIGINS MODERN HUMAN, P211; GAULD SC, 1993, AM J PHYS ANTHR S, V16, P93; GRINE FE, 1995, AM J PHYS ANTHROPOL, V97, P151, DOI 10.1002/ajpa.1330970207; Hartwig-Scherer Sigrid, 1994, Courier Forschungsinstitut Senckenberg, V171, P267; HENNEBERG M, 1988, HUM BIOL, V60, P395; HOLLIDAY TW, 1995, THESIS U NEW MEXICO; Hooton EA, 1930, PAPERS PHILLIPS ACAD; Kappelman J, 1996, J HUM EVOL, V30, P243, DOI 10.1006/jhev.1996.0021; LEIGH SR, 1992, AM J PHYS ANTHROPOL, V87, P1, DOI 10.1002/ajpa.1330870102; Martin R.D., 1990, PRIMATE ORIGINS EVOL; MARTIN RD, 1981, NATURE, V293, P57, DOI 10.1038/293057a0; McHenry H.M., 1988, P133; MCHENRY HM, 1992, AM J PHYS ANTHROPOL, V87, P407, DOI 10.1002/ajpa.1330870404; MCHENRY HM, 1994, J HUM EVOL, V27, P77, DOI 10.1006/jhev.1994.1036; MCHENRY HM, 1976, AM J PHYS ANTHROPOL, V45, P77, DOI 10.1002/ajpa.1330450110; PILBEAM D, 1974, SCIENCE, V186, P892, DOI 10.1126/science.186.4167.892; Rightmire G.P., 1986, ANTHROPOS BRNO, V23, P139; RIGHTMIRE GP, 1981, PALEOBIOLOGY, V7, P241, DOI 10.1017/S0094837300004012; RUFF CB, 1993, AM J PHYS ANTHROPOL, V91, P21, DOI 10.1002/ajpa.1330910103; RUFF CB, 1991, AM J PHYS ANTHROPOL, V86, P397, DOI 10.1002/ajpa.1330860306; Ruff Christopher B., 1993, P234; Ruff Christopher B., 1994, Yearbook of Physical Anthropology, V37, P65; STEPHAN H, 1970, PRIMATE BRAIN, P289; TOBIAS PV, 1985, J HUM EVOL, V14, P347, DOI 10.1016/S0047-2484(85)80041-5; TRINKAUS E, 1994, AM J PHYS ANTHROPOL, V93, P1, DOI 10.1002/ajpa.1330930102; Walker Alan, 1993, P411; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0	30	546	569	2	108	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					173	176		10.1038/387173a0	http://dx.doi.org/10.1038/387173a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WX945	9144286				2022-12-28	WOS:A1997WX94500052
J	Hatem, DS				Hatem, DS			A crowded room	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	1997	277	17					1350	1350						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW261	9134929				2022-12-28	WOS:A1997WW26100009
J	Pearn, J				Pearn, J			Recent advances in paediatrics .2. Childhood and adolescence	BRITISH MEDICAL JOURNAL			English	Review							LAND MINES; CHILDREN; SURVIVAL; CANCER; NEUROBLASTOMA; MOZAMBIQUE; COST		ROYAL CHILDRENS HOSP,DEPT CHILD HLTH,BRISBANE,QLD 4029,AUSTRALIA	Royal Children's Hospital Brisbane	Pearn, J (corresponding author), ROYAL CHILDRENS HOSP,DEPT PAEDIAT,BRISBANE,QLD 4029,AUSTRALIA.			Pearn, John/0000-0002-8815-2994				AJIKI W, 1995, JPN J CANCER RES, V86, P13, DOI 10.1111/j.1349-7006.1995.tb02982.x; Anabwani GM, 1996, E AFR MED J, V73, P155; ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; ASCHERIO A, 1995, LANCET, V346, P721, DOI 10.1016/S0140-6736(95)91501-X; BLAIR V, 1994, EUR J CANCER, V30A, P1490, DOI 10.1016/0959-8049(94)00274-9; BLAIR V, 1994, EUR J CANCER, V30A, P1498, DOI 10.1016/0959-8049(94)00275-A; BROWN WD, 1995, NEUROSURGERY, V36, P691, DOI 10.1227/00006123-199504000-00008; Carlin JB, 1995, ACCIDENT ANAL PREV, V27, P839, DOI 10.1016/0001-4575(95)00032-1; CAYTEN CG, 1991, ANN SURG, V214, P510, DOI 10.1097/00000658-199110000-00015; Chiswick ML, 1996, ARCH DIS CHILD, V74, P1, DOI 10.1136/adc.74.1.1; DAlessandro U, 1996, ANN TROP MED PARASIT, V90, P373, DOI 10.1080/00034983.1996.11813066; Daum R, 1996, CHIRURG, V67, P584; FERDINAND RF, 1995, AM J PSYCHIAT, V152, P1586; GANS JE, 1995, ARCH PEDIAT ADOL MED, V149, P1226, DOI 10.1001/archpedi.1995.02170240044007; Gerhart G, 1996, FOREIGN AFF, V75, P170; Jensen JP, 1996, CHILDHOOD, V3, P415, DOI 10.1177/0907568296003003007; KALETSCH U, 1996, 1995 REPORT GERMAN C, P5; KALSHOVEN F, 1995, AM J INT LAW, V89, P849, DOI 10.2307/2203949; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LAYFIELD LJ, 1995, J SURG ONCOL, V59, P21, DOI 10.1002/jso.2930590107; Marsh K, 1996, ANN TROP MED PARASIT, V90, P395, DOI 10.1080/00034983.1996.11813068; MCGRATH R, 1994, REFUGEE PARTIC NETWO, V16, P4; McWhirter WR, 1996, INT J CANCER, V65, P34, DOI 10.1002/(SICI)1097-0215(19960103)65:1&lt;34::AID-IJC7&gt;3.0.CO;2-2; Mertens TE, 1996, B WORLD HEALTH ORGAN, V74, P121; Miller P, 1995, Australas Radiol, V39, P337, DOI 10.1111/j.1440-1673.1995.tb00308.x; MILLER RW, 1995, CANCER, V75, P395, DOI 10.1002/1097-0142(19950101)75:1+<395::AID-CNCR2820751321>3.0.CO;2-W; MOSTEN F, 1996, LANCET, V348, P701; MOTT MG, 1995, ANN ONCOL, V6, P3; MOTT MG, 1995, ANN ONCOL, V6, P8; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Pearn J, 1996, BRIT MED J, V312, P990; Pearn J, 1996, J PAEDIATR CHILD H, V32, P290, DOI 10.1111/j.1440-1754.1996.tb02555.x; PEARN JH, 1996, SCI 1 AID, pR17; PEARN JH, 1995, REFLECTIONS RWANDA, P25; Peters R, 1996, Inj Prev, V2, P253, DOI 10.1136/ip.2.4.253; PLESS IB, 1996, INJURY PREVENTION, V2, P245; PREMJI Z, 1995, TROP MED PARASITOL, V46, P147; PUI CH, 1995, JAMA-J AM MED ASSOC, V273, P633, DOI 10.1001/jama.273.8.633; Rivara FP, 1996, PEDIATRICS, V97, P791; Roberts WM, 1996, LEUKEMIA LYMPHOMA, V20, P181, DOI 10.3109/10428199609051607; Sebestik J, 1996, ARCH DIS CHILD, V75, P78, DOI 10.1136/adc.75.1.78; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; Stone DH, 1996, J EPIDEMIOL COMMUN H, V50, P127, DOI 10.1136/jech.50.2.127; TOWNER EML, 1994, BRIT MED J, V308, P449, DOI 10.1136/bmj.308.6926.449; VANE DW, 1995, J TRAUMA, V38, P867, DOI 10.1097/00005373-199506000-00006; vanHensbroek MB, 1996, AM J TROP MED HYG, V54, P237, DOI 10.4269/ajtmh.1996.54.237; Wesson D, 1995, Semin Pediatr Surg, V4, P83; White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107; 1996, MMWR-MORBID MORTAL W, V45, P760; 1995, LANCET, V346, P715	52	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 12	1997	314	7087					1099	1102		10.1136/bmj.314.7087.1099	http://dx.doi.org/10.1136/bmj.314.7087.1099			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU236	9133895	Green Published			2022-12-28	WOS:A1997WU23600031
J	Cohen, JD; Perlstein, WM; Braver, TS; Nystrom, LE; Noll, DC; Jonides, J; Smith, EE				Cohen, JD; Perlstein, WM; Braver, TS; Nystrom, LE; Noll, DC; Jonides, J; Smith, EE			Temporal dynamics of brain activation during a working memory task	NATURE			English	Article							SENSORY STIMULATION; CORTEX; SYSTEM	Working memory is responsible for the short-term storage and online manipulation of information necessary for higher cognitive functions, such as language, planning and problem-solving(1,2). Traditionally, working memory has been divided into two types of processes: executive control (governing the encoding manipulation and retrieval of information in working memory) and active maintenance (keeping information available 'online'). It has also been proposed that these two types of processes may be subserved by distinct cortical structures, with the prefrontal cortex housing the executive control processes, and more posterior regions housing the content-specific buffers (for example verbal versus visuospatial) responsible for active maintenance(3,4). However, studies in non-human primates suggest that dorsolateral regions of the prefrontal cortex may alsb be involved in active maintenance(5-8). We have used functional magnetic resonance imaging to examine brain activation in human subjects during performance of a working memory task. We used the temporal resolution of this technique to examine the dynamics of regional activation, and to show that prefrontal cortex along with parietal cortex appears to play a role in active maintenance.	UNIV PITTSBURGH,DEPT PSYCHIAT,PITTSBURGH,PA 15213; UNIV PITTSBURGH,MED CTR,DEPT RADIOL,PITTSBURGH,PA 15213; UNIV MICHIGAN,DEPT PSYCHOL,ANN ARBOR,MI 48109	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan	Cohen, JD (corresponding author), CARNEGIE MELLON UNIV,DEPT PSYCHOL,PITTSBURGH,PA 15213, USA.		Noll, Douglas C/D-8124-2014	Noll, Douglas C/0000-0002-0983-3805; Braver, Todd/0000-0002-2631-3393				Awh E, 1996, PSYCHOL SCI, V7, P25, DOI 10.1111/j.1467-9280.1996.tb00662.x; Baddeley A.D., 1986, WORKING MEMORY THOUG; BARCH DM, IN PRESS NEUROPSYCHO; BARONE P, 1989, EXP BRAIN RES, V78, P447; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; Cohen JD, 1996, PHILOS T R SOC B, V351, P1515, DOI 10.1098/rstb.1996.0138; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Fiez JA, 1996, J NEUROSCI, V16, P808; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; Gathercole S., 1994, NEUROPSYCHOLOGY, V8, P494, DOI DOI 10.1037/0894-4105.8.4.494; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; JONIDES J, IN PRESS J COGN NEUR; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; Miller EK, 1996, J NEUROSCI, V16, P5154; NOLL DC, 1995, JMRI-J MAGN RESON IM, V5, P49, DOI 10.1002/jmri.1880050112; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; PETRIDES M, 1991, P ROY SOC B-BIOL SCI, V246, P293, DOI 10.1098/rspb.1991.0157; SAVOY RL, 1995, SOC MAGN RES 3 M INT, P450; Shallice T., 1988, NEUROPSYCHOLOGY MENT, DOI DOI 10.1017/IPM.2020.45; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2012, DOI 10.1073/pnas.91.6.2012; VAZQUEZ AL, 1996, P INT SOC MAGN RES M, P1765; WATERS GS, 1992, J MEM LANG, V31, P54, DOI 10.1016/0749-596X(92)90005-I; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024	29	1414	1442	5	147	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 10	1997	386	6625					604	608		10.1038/386604a0	http://dx.doi.org/10.1038/386604a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WT273	9121583	Green Submitted			2022-12-28	WOS:A1997WT27300058
J	Dove, SL; Joung, JK; Hochschild, A				Dove, SL; Joung, JK; Hochschild, A			Activation of prokaryotic transcription through arbitrary protein-protein contacts	NATURE			English	Article							RNA-POLYMERASE-II; CAMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; LAMBDA-REPRESSOR; SYNERGISTIC ACTIVATION; GENE ACTIVATION; ALPHA-SUBUNIT; PROMOTER; RECOGNITION; INITIATION	Many transcriptional activators in prokaryotes are known to bind near a promoter and contact RNA polymerase(1-5), but it is not dear whether a protein-protein contact between an activator and RNA polymerase is enough to activate gene transcription, Here we show that contact between a DNA-bound protein and a heterologous protein domain fused to RNA polymerase can elicit transcriptional activation; moreover, the strength of this engineered protein-protein interaction determines the amount of gene activation, Our results indicate that an arbitrary interaction between a DNA-bound protein and RNA polymerase can activate transcription. We also find that when the DNA-bound 'activator' makes contact with two different components of the polymerase, the effect of these two interactions on transcription is synergistic.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School					OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD006862] Funding Source: NIH RePORTER; NIH HHS [DP1 OD006862] Funding Source: Medline	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BACKMAN K, 1978, CELL, V13, P65, DOI 10.1016/0092-8674(78)90138-1; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; BUSHMAN FD, 1989, CELL, V58, P1163, DOI 10.1016/0092-8674(89)90514-X; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; DOVE SL, 1994, MOL MICROBIOL, V14, P975, DOI 10.1111/j.1365-2958.1994.tb01332.x; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HOCHSCHILD A, 1988, NATURE, V336, P353, DOI 10.1038/336353a0; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; ISHIHAMA A, 1992, MOL MICROBIOL, V6, P3283, DOI 10.1111/j.1365-2958.1992.tb02196.x; JOUNG JK, 1993, P NATL ACAD SCI USA, V90, P3083, DOI 10.1073/pnas.90.7.3083; JOUNG JK, 1994, SCIENCE, V265, P1863, DOI 10.1126/science.8091212; JOUNG JK, 1996, THESIS HARVARD U; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KULDELL N, 1994, J BACTERIOL, V176, P2991, DOI 10.1128/JB.176.10.2991-2998.1994; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; Monsalve M, 1996, P NATL ACAD SCI USA, V93, P8913, DOI 10.1073/pnas.93.17.8913; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; PTASHNE M, 1992, GENETIC SWITCH GENE; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; SAUER R, 1979, THESIS HARVARD U; Sauer R T, 1990, Adv Protein Chem, V40, P1, DOI 10.1016/S0065-3233(08)60286-7; TANG H, 1994, GENE DEV, V8, P3058, DOI 10.1101/gad.8.24.3058; WHIPPLE FW, 1994, GENE DEV, V8, P1212, DOI 10.1101/gad.8.10.1212; XIAO H, 1995, MOL CELL BIOL, V15, P5757	30	214	234	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 10	1997	386	6625					627	630		10.1038/386627a0	http://dx.doi.org/10.1038/386627a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121589				2022-12-28	WOS:A1997WT27300064
J	Jayaram, M				Jayaram, M			Biochemistry - The cis-trans paradox of integrase	SCIENCE			English	Editorial Material							SITE-SPECIFIC RECOMBINATION; FLP RECOMBINASE; CATALYTIC PARTY; DNA CLEAVAGE; ACTIVE-SITE; PROTEIN; COMPLEMENTATION; MECHANISM; FAMILY		UNIV TEXAS,INST CELL & MOL BIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin	Jayaram, M (corresponding author), UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712, USA.							ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; CAMPBELL AM, 1962, ADV GENET, V11, P101; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; COZARRELLI NR, 1986, UCLA S MOL CELL BIOL, V47, P1; CRAIG NL, 1988, ANNU REV GENET, V22, P77; Fersht A., 1985, ENZYME STRUCTURE MEC; Grindley NDF, 1995, CELL, V83, P1063, DOI 10.1016/0092-8674(95)90132-9; HAN YPW, 1993, EMBO J, V12, P4577, DOI 10.1002/j.1460-2075.1993.tb06146.x; HICKMAN AB, UNPUB; JAYARAM M, 1995, TRENDS GENET, V11, P432, DOI 10.1016/S0168-9525(00)89140-4; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; NUNESDUBY SE, 1994, EMBO J, V13, P4421, DOI 10.1002/j.1460-2075.1994.tb06762.x; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; QIAN XH, 1995, GENE DEV, V9, P2053, DOI 10.1101/gad.9.16.2053; SAXENA P, IN PRESS BIOCH BIOPH; STAHL FW, 1979, COLD SPRING HARB SYM, V43, P1353, DOI 10.1101/SQB.1979.043.01.154; STARK WM, 1995, TRENDS GENET, V11, P121; WIGLEY DE, UNPUB; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972	22	27	28	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					49	51		10.1126/science.276.5309.49	http://dx.doi.org/10.1126/science.276.5309.49			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9122709				2022-12-28	WOS:A1997WR38600035
J	Mukherjee, R; Davies, PJA; Crombie, DL; Bischoff, ED; Cesario, RM; Jow, L; Hamann, LG; Boehm, MF; Mondon, CE; Nadzan, AM; Paterniti, JR; Heyman, RA				Mukherjee, R; Davies, PJA; Crombie, DL; Bischoff, ED; Cesario, RM; Jow, L; Hamann, LG; Boehm, MF; Mondon, CE; Nadzan, AM; Paterniti, JR; Heyman, RA			Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists	NATURE			English	Article							THYROID-HORMONE; NUCLEAR RECEPTOR; RESPONSE PATHWAY; AGENT CS-045; ACID; LIGAND; BINDING; CLONING; ANALOGS; GAMMA	Retinoic acid receptors (RAR), thyroid hormone receptors (TR), peroxisome proliferator activated receptors (PPARs) and the orphan receptor, LXR, bind preferentially to DNA as heterodimers with a common partner, retinoid X receptor (RXR), to regulate transcription(1-6). We investigated whether RXR-selective agonists replicate the activity of ligands for several of these receptors! We demonstrate here that RXR-selective ligands (referred to as rexinoids) function as RXR heterodimer-selective agonists, activating RXR: PPAR gamma and RXR:LXR dimers but not RXR:RAR or RXR:TR heterodimers. Because PPAR gamma is a target for antidiabetic agents, we investigated whether RXR ligands could alter insulin and glucose signalling. In mouse models of noninsulin-dependent diabetes mellitus (NIDDM) and obesity, RXR agonists function as insulin sensitizers and can decrease hyperglycaemia, hypertriglyceridaemia and hyperinsulinaemia, This antidiabetic activity can be further enhanced by combination treatment with PPAR gamma agonists, such as thiazolidinediones. These data suggest that the RXR:PPAR gamma heterodimer is a single-function complex serving as a molecular target for treatment of insulin resistance, Activation of the RXR:PPAR gamma dimer with rexinoids may provide a new and effective treatment for NIDDM.	LIGAND PHARMACEUT,DEPT RETINOID RES,SAN DIEGO,CA 92121; LIGAND PHARMACEUT,DEPT CARDIOVASC RES,SAN DIEGO,CA 92121; LIGAND PHARMACEUT,DEPT RETINOID CHEM,SAN DIEGO,CA 92121; LIGAND PHARMACEUT,DEPT ENDOCRINE CHEM,SAN DIEGO,CA 92121; UNIV TEXAS,HLTH SCI CTR,SCH MED,DEPT PHARMACOL & MED,HOUSTON,TX 77225; METABOLEX INC,HAYWARD,CA 94545	Ligand Pharmaceuticals; Ligand Pharmaceuticals; Ligand Pharmaceuticals; Ligand Pharmaceuticals; University of Texas System; University of Texas Health Science Center Houston								BERGER TS, 1992, J STEROID BIOCHEM, V41, P733, DOI 10.1016/0960-0760(92)90414-E; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MONDON CE, 1981, AM J PHYSIOL, V240, pE482, DOI 10.1152/ajpendo.1981.240.5.E482; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; SPORN MB, 1976, FED PROC, V35, P1332; SUTER SL, 1992, DIABETES CARE, V15, P193, DOI 10.2337/diacare.15.2.193; Trinder P., 1969, ANN CLIN BIOCHEM, V6, P24, DOI [10.1177/000456326900600108, DOI 10.1177/000456326900600108]; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	540	583	3	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					407	410		10.1038/386407a0	http://dx.doi.org/10.1038/386407a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121558				2022-12-28	WOS:A1997WQ17000067
J	Shen, J; Bronson, RT; Chen, DF; Xia, WM; Selkoe, DJ; Tonegawa, S				Shen, J; Bronson, RT; Chen, DF; Xia, WM; Selkoe, DJ; Tonegawa, S			Skeletal and CNS defects in Presenilin-1-deficient mice	CELL			English	Article							FAMILIAL ALZHEIMERS-DISEASE; MISSENSE MUTATIONS; GENE; SOMITES; NOTCH1	Presenilin-1 (PS1) is the major gene responsible for early-onset familiar Alzheimer's disease (FAD). To understand the normal function of PS1, we have generated a targeted null mutation in the murine homolog of PS1. We report that PS1(-/-) mice die shortly after natural birth or Caesarean section. The skeleton of homozygous mutants is grossly deformed. Hemorrhages occur in the CNS of PS1 null mutants with varying location, severity, and time of onset. The ventricular zone of PS1(-/-) brains is markedly thinner by embryonic day 14.5, indicating an impairment in neurogenesis. Bilateral cerebral cavitation caused by massive neuronal loss in specific subregions of the mutant brain is prominent after embryonic day 16.5. These results show that PS1 is required for proper formation of the axial skeleton, normal neurogenesis, and neuronal survival.	MIT,CTR CANC RES,CTR LEARNING & MEMORY,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139; TUFTS UNIV,SCH MED,DEPT PATHOL,SCH VET MED,BOSTON,MA 02111; HARVARD UNIV,SCH MED,BRIGHAM & WOMENS HOSP,DEPT NEUROL,CTR NEUROL DIS,BOSTON,MA 02115	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Tufts University; Harvard University; Brigham & Women's Hospital; Harvard Medical School			xia, weiming/E-5465-2016	xia, weiming/0000-0002-7463-3295	NIA NIH HHS [AG06173] Funding Source: Medline; NINDS NIH HHS [NS32925] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006173, R37AG006173] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BAUMEISTER R, 1997, IN PRESS GENES FUNCT; Berezovska O, 1997, J NEUROPATH EXP NEUR, V56, P40, DOI 10.1097/00005072-199701000-00004; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Burgess R, 1996, NATURE, V384, P570, DOI 10.1038/384570a0; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CAMPION D, 1995, HUM MOL GENET, V4, P2373, DOI 10.1093/hmg/4.12.2373; CHAPMAN J, 1995, LANCET, V346, P1040, DOI 10.1016/S0140-6736(95)91723-3; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CONLON RA, 1995, DEVELOPMENT, V121, P1533; CRUTS M, 1995, HUM MOL GENET, V4, P2363, DOI 10.1093/hmg/4.12.2363; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; *GROUP ALZH DIS CO, 1995, NAT GENET, V11, P219; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Sambrook J., 2002, MOL CLONING LAB MANU; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SLUNT HH, 1995, AMYLOID, V2, P188, DOI 10.3109/13506129509036925; SUSUKI T, 1996, BIOCHEM BIOPH RES CO, V219, P708; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977	36	816	847	2	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					629	639		10.1016/S0092-8674(00)80244-5	http://dx.doi.org/10.1016/S0092-8674(00)80244-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160754	Bronze			2022-12-28	WOS:A1997WZ32300016
J	Steinmetz, EJ				Steinmetz, EJ			Pre-mRNA processing and the CTD of RNA polymerase II: The tail that wags the dog?	CELL			English	Review							TRANSCRIPTION; POLYADENYLATION; SITE; GENE				Steinmetz, EJ (corresponding author), UNIV WISCONSIN,SCH MED,DEPT BIOMOL CHEM,1300 UNIV AVE,MADISON,WI 53706, USA.							BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; CHABOT B, 1995, NUCLEIC ACIDS RES, V23, P3206, DOI 10.1093/nar/23.16.3206; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; FU XD, 1995, RNA, V1, P663; GREENLEAF AL, 1993, TRENDS BIOCHEM SCI, V18, P117, DOI 10.1016/0968-0004(93)90016-G; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; RUSSO P, 1989, P NATL ACAD SCI USA, V86, P8348, DOI 10.1073/pnas.86.21.8348; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; Steinmetz EJ, 1996, MOL CELL BIOL, V16, P6993, DOI 10.1128/mcb.16.12.6993; TANI T, 1991, GENE DEV, V5, P1022, DOI 10.1101/gad.5.6.1022; Vincent M, 1996, NUCLEIC ACIDS RES, V24, P4649, DOI 10.1093/nar/24.23.4649; Wetterberg I, 1996, RNA, V2, P641; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975	21	153	156	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					491	494		10.1016/S0092-8674(00)80230-5	http://dx.doi.org/10.1016/S0092-8674(00)80230-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160740	Bronze			2022-12-28	WOS:A1997WZ32300002
J	Meaney, JFM; Weg, JG; Chenevert, TL; StaffordJohnson, D; Hamilton, BH; Prince, MR				Meaney, JFM; Weg, JG; Chenevert, TL; StaffordJohnson, D; Hamilton, BH; Prince, MR			Diagnosis of pulmonary embolism with magnetic resonance angiography	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASED-ARRAY COILS; ELECTRON-BEAM CT; VASCULATURE	Background Diagnosing pulmonary embolism may be difficult, because there is no reliable noninvasive imaging method. We compared a new noninvasive method, gadolinium-enhanced pulmonary magnetic resonance angiography, with standard pulmonary angiography for diagnosing pulmonary embolism. Methods A total of 30 consecutive patients with suspected pulmonary embolism underwent both standard pulmonary angiography and magnetic resonance angiography during the pulmonary arterial phase at the time of an intravenous bolus of gadolinium. All magnetic resonance images were reviewed for the presence or absence of pulmonary emboli by three independent reviewers who were unaware of the findings on standard angiograms. Results Pulmonary embolism was detected by standard pulmonary angiography in 8 of the 30 patients in whom pulmonary embolism was suspected. All 5 lobar emboli and 16 of 17 segmental emboli identified on standard angiograms were also identified on magnetic resonance images. Two of the three reviewers reported one false positive magnetic resonance angiogram each. As compared with standard pulmonary angiography, the three sets of readings had sensitivities of 100, 87, and 75 percent and specificities of 95, 100, and 95 percent, respectively. The interobserver correlation was good (k=0.57 to 0.83 for all vessels, 0.49 to 1.0 for main and lobar vessels, and 0.40 to 0.81 for segmental vessels). Conclusions In this preliminary study, gadolinium-enhanced magnetic resonance angiography of the pulmonary arteries, as compared with conventional pulmonary angiography, had high sensitivity and specificity for the diagnosis of pulmonary embolism. This new technique shows promise as a noninvasive method of diagnosing pulmonary embolism without the need for ionizing radiation or iodinated contrast material. (C) 1997, Massachusetts Medical Society.	UNIV MICHIGAN HOSP, DEPT INTERNAL MED, DIV PULM & CRIT CARE MED, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	Meaney, JFM (corresponding author), UNIV MICHIGAN HOSP, DEPT RADIOL, DIV MAGNET RESONANCE IMAGING, 1500 E MED CTR DR, ANN ARBOR, MI 48109 USA.		Prince, Martin R./S-6850-2016	Prince, Martin R./0000-0002-9883-0584; Meaney, James FM/0000-0003-1596-4972				BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; FOO TKF, 1992, RADIOLOGY, V183, P473, DOI 10.1148/radiology.183.2.1561352; FOO TKF, 1993, JMRI-J MAGN RESON IM, V3, P611, DOI 10.1002/jmri.1880030410; GEFTER WB, 1995, RADIOLOGY, V197, P561, DOI 10.1148/radiology.197.3.7480717; GOLDHABER SZ, 1982, AM J MED, V73, P822, DOI 10.1016/0002-9343(82)90764-1; GOODMAN LR, 1995, AM J ROENTGENOL, V164, P1369, DOI 10.2214/ajr.164.6.7754875; Goodman LR, 1996, RADIOLOGY, V199, P25, DOI 10.1148/radiology.199.1.8633154; GRIST TM, 1993, RADIOLOGY, V189, P523, DOI 10.1148/radiology.189.2.8210385; HATABU H, 1994, RADIOLOGY, V190, P791, DOI 10.1148/radiology.190.3.8115629; HATABU H, 1989, RADIOLOGY, V171, P391, DOI 10.1148/radiology.171.2.2704803; Hudson ER, 1996, RADIOLOGY, V198, P61, DOI 10.1148/radiology.198.1.8539407; LESSER BA, 1992, CHEST, V102, P17, DOI 10.1378/chest.102.1.17; MACFALL JR, 1992, INVEST RADIOL, V27, P318, DOI 10.1097/00004424-199204000-00014; MAKI J, IN PRESS J MAGN RESO; Oser RF, 1996, RADIOLOGY, V199, P31, DOI 10.1148/radiology.199.1.8633168; PRINCE MR, 1995, RADIOLOGY, V197, P785, DOI 10.1148/radiology.197.3.7480757; PRINCE MR, 1993, JMRI-J MAGN RESON IM, V3, P877, DOI 10.1002/jmri.1880030614; Prince MR, 1996, JMRI-J MAGN RESON IM, V6, P162, DOI 10.1002/jmri.1880060129; RemyJardin M, 1996, RADIOLOGY, V200, P699, DOI 10.1148/radiology.200.3.8756918; RUBIN GD, 1994, INVEST RADIOL, V29, P766, DOI 10.1097/00004424-199408000-00006; STEIN PD, 1992, CIRCULATION, V85, P462, DOI 10.1161/01.CIR.85.2.462; TEIGEN CL, 1995, RADIOLOGY, V194, P313, DOI 10.1148/radiology.194.2.7824704; TEIGEN CL, 1993, RADIOLOGY, V188, P839, DOI 10.1148/radiology.188.3.8351359; Toglia MR, 1996, NEW ENGL J MED, V335, P108, DOI 10.1056/NEJM199607113350207; vanBeek EJR, 1996, RADIOLOGY, V198, P721, DOI 10.1148/radiology.198.3.8628860; VERSCHAKELEN JA, 1993, RADIOLOGY, V188, P847, DOI 10.1148/radiology.188.3.8351360; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WEG J, 1988, ACP-APPL CARDIOPUL P, V2, P23; WEG JG, 1995, INTENS CARE MED, P660; Wielopolski P A, 1993, Magn Reson Imaging Clin N Am, V1, P295; WIELOPOLSKI PA, 1993, MAGN RESON MATER PHY, V1, P231; Wielopolski PA, 1996, RADIOLOGY, V201, P202; Woodard PK, 1995, J THORAC IMAG, V10, P59, DOI 10.1097/00005382-199501010-00006	34	358	371	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	1997	336	20					1422	1427		10.1056/NEJM199705153362004	http://dx.doi.org/10.1056/NEJM199705153362004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY577	9145679				2022-12-28	WOS:A1997WY57700004
J	Nicolaou, KC; Winssinger, N; Pastor, J; Ninkovic, S; Sarabia, F; He, Y; Vourloumis, D; Yang, Z; Li, T; Giannakakou, P; Hamel, E				Nicolaou, KC; Winssinger, N; Pastor, J; Ninkovic, S; Sarabia, F; He, Y; Vourloumis, D; Yang, Z; Li, T; Giannakakou, P; Hamel, E			Synthesis of epothilones A and B in solid and solution phase	NATURE			English	Article							TAXOL	Epothilones A and B, two compounds that have been recently isolated(1) from myxobacterium Sorangium cellulosum strain 90, have generated intense interest(2-16) among chemists, biologists and clinicians erring to the structural complexity, unusual mechanism of interaction with microtubules and anticancer potential of these molecules. Like taxol* (refs 17, 18), they exhibit cytotoxicity against tumour cells by inducing microtubule assembly and stabilization(3,4), even in taxol-resistant cell lines. Following the structural elucidation of these molecules by X-ray crystallography in 1996(1), several syntheses of epothilones A (refs 12-16) and B (ref. 19) have been reported, indicative of the potential importance of these molecules in the cancer field. Here we report the first solid-phase synthesis of epothilone A, the total synthesis of epothilone B, and the generation of a small epothilone library. The solid-phase synthesis applied here to epothilone A could open up new possibilities in natural-product synthesis and, together with solution-phase synthesis of other epothilones, paves the way for the generation of large combinatorial libraries of these important molecules for biological screening.	Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; NCI, MED BRANCH, DCS, NIH, BETHESDA, MD 20892 USA; NCI, LAB DRUG DISCOVERY RES & DEV,DEV THERAPEUT PROGRAM, DCTDC,FREDERICK CANC RES & DEV CTR, FREDERICK, MD 21702 USA	Scripps Research Institute; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Nicolaou, KC (corresponding author), Scripps Res Inst, DEPT CHEM, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Fernandez, Joaquin Pastor/I-4567-2015; Li, Tianhu/G-3531-2010; Sarabia, Francisco/M-1845-2014; Yang, Zhen/J-6306-2015; Yang, Zhen/GWQ-4960-2022; Winssinger, Nicolas/B-6710-2017	Fernandez, Joaquin Pastor/0000-0003-0553-8021; Sarabia, Francisco/0000-0002-5149-3576; Yang, Zhen/0000-0001-8036-934X; Winssinger, Nicolas/0000-0003-1636-7766				Balog A, 1996, ANGEW CHEM INT EDIT, V35, P2801, DOI 10.1002/anie.199628011; BERNARD M, 1983, J ORG CHEM, V48, P326, DOI 10.1021/jo00151a010; Bertinato P, 1996, J ORG CHEM, V61, P8000, DOI 10.1021/jo961674o; BOLLAG DM, 1995, CANCER RES, V55, P2325; Claus E, 1997, TETRAHEDRON LETT, V38, P1359, DOI 10.1016/S0040-4039(96)02493-8; Gabriel T, 1997, TETRAHEDRON LETT, V38, P1363, DOI 10.1016/S0040-4039(96)02494-X; GIANNAKAKOU P, IN PRESS J BIOL CHEM; GREVER MR, 1992, SEMIN ONCOL, V19, P622; GRUBBS RH, 1995, ACCOUNTS CHEM RES, V28, P446, DOI 10.1021/ar00059a002; Hofle GH, 1996, ANGEW CHEM INT EDIT, V35, P1567, DOI 10.1002/anie.199615671; Kowalski RJ, 1997, J BIOL CHEM, V272, P2534; Lin CM, 1996, CANCER CHEMOTH PHARM, V38, P136, DOI 10.1007/s002800050461; Meng DF, 1996, J ORG CHEM, V61, P7998, DOI 10.1021/jo961673w; Meng DF, 1997, J AM CHEM SOC, V119, P2733, DOI 10.1021/ja964275j; MILLER JF, 1997, 213 AM CHEM SOC NATL; Miller SJ, 1996, J AM CHEM SOC, V118, P9606, DOI 10.1021/ja961626l; MILLER SJ, 1997, J AM CHEM SOC; Mulzer J, 1996, TETRAHEDRON LETT, V37, P9179, DOI 10.1016/S0040-4039(96)02156-9; Nicolaou KC, 1996, ANGEW CHEM INT EDIT, V35, P2399, DOI 10.1002/anie.199623991; Nicolaou KC, 1997, ANGEW CHEM INT EDIT, V36, P525, DOI 10.1002/anie.199705251; NICOLAOU KC, 1994, ANGEW CHEM INT EDIT, V33, P15, DOI 10.1002/anie.199400151; ROGAN AM, 1984, SCIENCE, V224, P994, DOI 10.1126/science.6372095; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Schinzer D, 1996, CHEM-EUR J, V2, P1477, DOI 10.1002/chem.19960021121; Schinzer D, 1997, ANGEW CHEM INT EDIT, V36, P523, DOI 10.1002/anie.199705231; Schuster M, 1996, ANGEW CHEM INT EDIT, V35, P1979, DOI 10.1002/anie.199619791; Su DS, 1997, ANGEW CHEM INT EDIT, V36, P757, DOI 10.1002/anie.199707571; vanMaarseveen JH, 1996, TETRAHEDRON LETT, V37, P8249, DOI 10.1016/0040-4039(96)01881-3; Xu ZM, 1996, J AM CHEM SOC, V118, P10926, DOI 10.1021/ja9626603; YANG D, 1995, J ORG CHEM, V60, P3887, DOI 10.1021/jo00117a046; Yang Z, 1997, ANGEW CHEM INT EDIT, V36, P166, DOI 10.1002/anie.199701661	31	365	438	3	70	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					268	272		10.1038/387268a0	http://dx.doi.org/10.1038/387268a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	WZ167	9153390				2022-12-28	WOS:A1997WZ16700048
J	Ransohoff, DF; Lang, CA				Ransohoff, DF; Lang, CA			Screening for colorectal cancer with the fecal occult blood test: A background paper	ANNALS OF INTERNAL MEDICINE			English	Article							CONTRAST BARIUM-ENEMA; COST-EFFECTIVENESS; POLYPOID LESIONS; CONTROLLED TRIAL; PREDICTIVE VALUE; COLONOSCOPY; SURVEILLANCE; MORTALITY; HEMOCCULT; COLON	Purpose: Screening for colorectal cancer with fecal occult blood tests or sigmoidoscopy can reduce mortality rates. If occult blood testing is done, clinicians must decide how to interpret the results and plan further management. If the results are positive, a decision must be made about evaluating the colon. This report provides information that can be used to perform fecal occult blood tests, interpret the results of those tests, and plan patient management. Data Sources: The MEDLINE database was searched for data relevant to optimizing the technique of fecal occult blood testing. Studies were also identified from the bibliographies of published articles about test performance and the interpretation of test results, particularly sensitivity, specificity, and the probability of colorectal cancer after a positive test result. Study Selection and Data Extraction: Studies were selected and data were extracted on the basis of the authors' combined judgment. Data Synthesis: When used for screening, fecal occult blood tests have positive results about 1% to 16% of the time, depending on such factors as the age of the person being tested, whether the sample is rehydrated, and whether the test is used for initial screening or for rescreening. When the colons of persons who have positive test results are evaluated, the rate of finding any colorectal cancer is about 2% to 17% and the rate for early colorectal cancer (Dukes stage A or B) is about 2% to 14%. Conclusions: These results suggest that, in general, persons who have positive results on a fecal occult blood test should have a full colonic examination. More research is needed to understand and improve the sensitivity and specificity of the fecal occult blood test.	COLORADO PERMANENTE MED GRP, DENVER, CO 80205 USA	Permanente Medical Groups	Ransohoff, DF (corresponding author), UNIV N CAROLINA, CB 7105, CHAPEL HILL, NC 27599 USA.							AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; AHLQUIST DA, 1989, CANCER, V63, P1826; Allison JE, 1996, NEW ENGL J MED, V334, P1607; ALLISON JE, 1990, ANN INTERN MED, V112, P328, DOI 10.7326/0003-4819-112-5-328; Allison JE, 1996, NEW ENGL J MED, V334, P155, DOI 10.1056/NEJM199601183340304; *AM CANC SOC, 1980, CA-CANCER J CLIN, V30, P18; [Anonymous], COMMON SCREENING TES; Atkin WS, 1996, GASTROENTEROLOGY, V110, pA486; BARRY MJ, 1987, GASTROENTEROLOGY, V93, P301, DOI 10.1016/0016-5085(87)91019-5; BOLAND CR, 1989, GASTROINTESTINAL DIS, P1483; BOND JH, 1993, ANN INTERN MED, V119, P836, DOI 10.7326/0003-4819-119-8-199310150-00010; DORAN J, 1982, BRIT J SURG, V69, P711, DOI 10.1002/bjs.1800691209; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EDDY DM, 1987, GASTROENTEROLOGY, V92, P682, DOI 10.1016/0016-5085(87)90018-7; FARRANDS PA, 1983, CLIN ONCOL, V9, P217; FINK DJ, 1991, GUIDELINES CANC RELA, P8; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; FLEISHER M, 1991, ANN INTERN MED, V114, P875, DOI 10.7326/0003-4819-114-10-875; FLEMING JL, 1987, MAYO CLIN PROC, V62, P159, DOI 10.1016/S0025-6196(12)62437-9; GOLDBLOOM R, 1989, CAN MED ASSOC J, V141, P209; GREEGOR DH, 1971, CANCER, V28, P131, DOI 10.1002/1097-0142(197107)28:1<131::AID-CNCR2820280125>3.0.CO;2-I; Greenberg PD, 1996, AM J MED, V100, P598, DOI 10.1016/S0002-9343(96)00009-5; Hardcastle JD, 1996, AM J GASTROENTEROL, V91, P850; HARDCASTLE JD, 1989, LANCET, V1, P1160; JAFFE RM, 1975, ANN INTERN MED, V83, P824, DOI 10.7326/0003-4819-83-6-824; KEWENTER J, 1994, SCAND J GASTROENTERO, V29, P468, DOI 10.3109/00365529409096840; KEWENTER J, 1988, CANCER, V62, P645, DOI 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO;2-#; Kewenter J, 1996, DIS COLON RECTUM, V39, P676, DOI 10.1007/BF02056949; KNIGHT KK, 1989, JAMA-J AM MED ASSOC, V261, P587; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; KRONBORG O, 1989, SCAND J GASTROENTERO, V24, P599, DOI 10.3109/00365528909093096; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; Langebaek Carl, 1996, PREVENTION EARLY DET, P155; LEINICKE JL, 1977, GASTROINTEST RADIOL, V2, P125, DOI 10.1007/BF02256483; LEVIN B, 1992, CA-CANCER J CLIN, V42, P296, DOI 10.3322/canjclin.42.5.296; LIEBERMAN DA, 1991, AM J GASTROENTEROL, V86, P946; LILLARD L, 1986, PREVENTIVE MED CARE; LINDFORS KK, 1995, JAMA-J AM MED ASSOC, V274, P881, DOI 10.1001/jama.274.11.881; LUK GD, 1990, CURRENT THERAPY GAST, P387; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MARAN S, 1991, ANN INTERN MED, V115, P576, DOI 10.7326/0003-4819-115-7-576_2; MCPHEE S J, 1990, Journal of General Internal Medicine, V5, pS116, DOI 10.1007/BF02600856; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; Otchy DP, 1996, AM J GASTROENTEROL, V91, P448; OTT DJ, 1983, GASTROINTEST RADIOL, V8, P75, DOI 10.1007/BF01948093; RANSOHOFF DF, 1994, AM J GASTROENTEROL, V89, P1765; RANSOHOFF DF, 1990, JAMA-J AM MED ASSOC, V264, P76, DOI 10.1001/jama.264.1.76; RANSOHOFF DF, 1993, JAMA-J AM MED ASSOC, V269, P1278, DOI 10.1001/jama.269.10.1278; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; Ransohoff DF, 1997, ANN INTERN MED, V126, P808, DOI 10.7326/0003-4819-126-10-199705150-00014; Ransohoff DF, 1996, NEW ENGL J MED, V334, P189, DOI 10.1056/NEJM199601183340312; Ransohoff DF, 1996, NEW ENGL J MED, V334, P1608; REX DK, 1991, GASTROENTEROLOGY, V100, P64, DOI 10.1016/0016-5085(91)90583-7; Robinson M H, 1994, Eur J Surg Oncol, V20, P545; ROGGE JD, 1994, AM J GASTROENTEROL, V89, P1775; SACKETT DL, 1975, LANCET, V2, P357, DOI 10.1016/S0140-6736(75)92790-7; Saito H, 1996, PREVENTION EARLY DET, P301; SAVON JJ, 1995, AM J GASTROENTEROL, V90, P581; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIMON JB, 1987, CANCER METAST REV, V6, P397, DOI 10.1007/BF00144272; SPIRO HM, 1988, MT SINAI J MED, V55, P251; STEWART ET, 1994, INT WORKSH COL CANC, P2; STJOHN DJB, 1993, GASTROENTEROLOGY, V104, P1661, DOI 10.1016/0016-5085(93)90643-Q; STJOHN DJB, 1992, ANN INTERN MED, V117, P376, DOI 10.7326/0003-4819-117-5-376; THOENI RF, 1982, RADIOLOGY, V144, P257, DOI 10.1148/radiology.144.2.7089277; THOMAS WM, 1992, BRIT J CANCER, V65, P618, DOI 10.1038/bjc.1992.125; VANDAM J, 1995, ARCH INTERN MED, V155, P2389, DOI 10.1001/archinte.155.22.2389; VAS W, 1982, GASTROINTEST ENDOSC, V28, P19, DOI 10.1016/S0016-5107(82)72960-8; WAGNER JL, 1991, ANN INTERN MED, V115, P807, DOI 10.7326/0003-4819-115-10-807; WAGNER JL, 1995, COST EFFECTIVENESS C; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; YOUNG GP, 1990, CLIN BIOCHEM REV, P13; YOUNG GP, 1991, ADV LARGE BOWEL CANC, P135; 1996, GUIDE CLIN PREVENTIV, P89; 1990, COSTS EFFECTIVENESS	82	134	137	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1997	126	10					811	822		10.7326/0003-4819-126-10-199705150-00014	http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00014			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ823	9148658				2022-12-28	WOS:A1997WZ82300014
J	Geller, G; Botkin, JR; Green, MJ; Press, N; Biesecker, B; Wilfond, B; Grana, G; Daly, MB; Schneider, K; Kahn, MJE				Geller, G; Botkin, JR; Green, MJ; Press, N; Biesecker, B; Wilfond, B; Grana, G; Daly, MB; Schneider, K; Kahn, MJE			Genetic testing for susceptibility to adult-onset cancer - The process and content of informed consent	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							COMPUTER-ASSISTED-INSTRUCTION; LINE P53 MUTATIONS; OVARIAN-CANCER; PATIENT EDUCATION; BREAST-CANCER; HUNTINGTON DISEASE; COLON-CANCER; KNOWLEDGE; DISCRIMINATION; UNDERSTAND	Objective.-To provide guidance on informed consent to clinicians offering cancer susceptibility testing. Participants.-The Task Force on Informed Consent is part of the Cancer Genetics Studies Consortium (CGSC), whose members were recipients of National Institutes of Health grants to assess the implications of cancer susceptibility testing. The 10 task force members represent a range of relevant backgrounds, including various medical specialties, social science, genetic counseling, and consumer advocacy. Evidence.-The CGSC held 3 public meetings from 1994 to 1996. At its first meeting, the task force jointly established a list of topics. The cochairs (G.G. and J.R.B) then developed an outline and assigned each topic to an appropriate writer and reviewer, Writers summarized the literature on their topics and drafted recommendations, which were then revised by the reviewers. The cochairs compiled and edited the entire manuscript. All members were involved in writing this report. Consensus Process.-The first draft was distributed to task force members, after which a meeting was held to discuss its content and organization. Consensus was reached by voting. A subsequent draft was presented to the entire CGSC at its third meeting, and comments were incorporated. Conclusions.-The task force recommends that informed consent for cancer susceptibility testing be an ongoing process of education and counseling in which (1) providers elicit participant, family, and community values and disclose their own, (2) decision making is shared, (3) the style of information disclosure is individualized, and (4) specific content areas are discussed.	UNIV UTAH, ECCLES INST HUMAN GENET, UTAH CTR HUMAN GENOME RES, SALT LAKE CITY, UT USA; MILTON S HERSHEY MED CTR, DEPT HUMANITIES, HERSHEY, PA USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PSYCHIAT & BIOBEHAV SCI, LOS ANGELES, CA 90024 USA; NATL HUMAN GENOME RES INST, MED GENET BRANCH, BETHESDA, MD USA; UNIV ARIZONA, DEPT PEDIAT, TUCSON, AZ 85721 USA; CANC CTR SO NEW JERSEY, CAMDEN, NJ USA; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA; DANA FARBER CANC INST, BOSTON, MA 02115 USA; NATL BREAST CANC COALIT, RICHMOND, VA USA	Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Arizona; Fox Chase Cancer Center; Harvard University; Dana-Farber Cancer Institute	Geller, G (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, 550 N BROADWAY, SUITE 511, BALTIMORE, MD 21205 USA.		Green, Martin A/H-7567-2012	Green, Martin A/0000-0002-8860-396X; Biesecker, Barbara/0000-0001-9665-8963; Green, Michael/0000-0002-4828-4749				Allen K D, 1995, Pediatr Dent, V17, P180; *AM COUNC LIF INS, 1991, REP ACLI HIAA TASK F; ANDRES LB, 1994, ASSESSING GENETIC RI, P259; ANDREWS LB, 1987, MED GENETICS LEGAL F, P38; APPELBAUM P, 1987, INFORMED CONSENT LEG; Asch A, 1996, FEMINISM BIOETHICS R; BARBOUR GL, 1978, JAMA-J AM MED ASSOC, V240, P2741, DOI 10.1001/jama.240.25.2741; Bernhardt BA, 1996, ARCH FAM MED, V5, P336, DOI 10.1001/archfami.5.6.336; BERNHARDT BA, IN PRESS J GENET COU; BETANCOURT H, 1993, AM PSYCHOL, V48, P629, DOI 10.1037/0003-066X.48.6.629; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BLACKWELL M, 1986, PHI DELTA KAPPAN, V67, P750; Botkin JR, 1996, J NATL CANCER I, V88, P872, DOI 10.1093/jnci/88.13.872; BROWN RS, 1993, ADV GENETIC INFORMAT; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; CARRESE JA, 1995, JAMA-J AM MED ASSOC, V274, P826, DOI 10.1001/jama.274.10.826; CARTER MA, 1995, J NCI MONOGRAPHS, V17, P119; CLAYTON EW, 1995, JAMA-J AM MED ASSOC, V274, P1786, DOI 10.1001/jama.274.22.1786; COHEN MM, 1994, AM J HUM GENET, V55, pR1; COLLINS FS, 1994, JAMA-J AM MED ASSOC, V271, P785, DOI 10.1001/jama.1994.03510340075038; Croyle RT, 1997, HEALTH PSYCHOL, V16, P63, DOI 10.1037/0278-6133.16.1.63; Dixson B, 1992, J Genet Couns, V1, P267, DOI 10.1007/BF00961588; DOAK CC, 1996, TECHING PATIENTS LOW; Dodd M J, 1981, Cancer Nurs, V4, P311, DOI 10.1097/00002820-198108000-00007; EARLEY CL, 1995, AM J HUM GENET, V57, P727; ELIAS S, 1994, NEW ENGL J MED, V330, P1611, DOI 10.1056/NEJM199406023302213; *EQ EMPL OPP COMM, 1995, COMPL MAN, V1; FADEN RR, 1985, AM J PUBLIC HEALTH, V75, P1381, DOI 10.2105/AJPH.75.12.1381; FADEN RUTH R., 1986, HIST THEORY INFORMED, P86; Garber JE, 1996, JAMA-J AM MED ASSOC, V275, P1928; Garber JE, 1995, CANCER SURV, V25, P381; Geller G, 1997, HASTINGS CENT REP, V27, P28, DOI 10.2307/3527625; GELLER G, 1995, NAT GENET, V11, P364, DOI 10.1038/ng1295-364; Geller G, 1993, Arch Fam Med, V2, P1119, DOI 10.1001/archfami.2.11.1119; GELLER G, 1991, AIDS WOMEN NEXT GENE; GHOSH A, 1988, PSYCHIAT ANN, V18, P246, DOI 10.3928/0048-5713-19880401-10; Gillispie M. A., 1993, Journal of Medical Systems, V17, P119, DOI 10.1007/BF00996935; GOSTIN LO, 1995, JAMA-J AM MED ASSOC, V274, P844; GUSTAFSON DH, 1993, SIXTEENTH ANNUAL SYMPOSIUM ON COMPUTER APPLICATIONS IN MEDICAL CARE, P161; *HER SUSC WORK GRO, 1996, J CLIN ONCOL, V14, P1738; HOFMAN KJ, 1993, ACAD MED, V68, P625, DOI 10.1097/00001888-199308000-00013; Holtzman N A, 1996, Oncology (Williston Park), V10, P57; HOLTZMAN NA, 1983, PEDIATRICS, V72, P807; HOPPER KD, 1995, AM J ROENTGENOL, V164, P493, DOI 10.2214/ajr.164.2.7839996; HOPPER KD, 1994, RADIOLOGY, V192, P67, DOI 10.1148/radiology.192.1.8208968; HUDSON KL, 1995, SCIENCE, V270, P391, DOI 10.1126/science.270.5235.391; HUGGINS M, 1992, AM J MED GENET, V42, P508, DOI 10.1002/ajmg.1320420417; KAHN G, 1993, M D COMPUT, V10, P93; Kahn P, 1996, SCIENCE, V274, P496, DOI 10.1126/science.274.5287.496; Kasper J F, 1992, QRB Qual Rev Bull, V18, P183; KATZ J, 1984, HASTINGS CENT REP, V14, P35, DOI 10.2307/3560848; Katz J., 1984, SILENT WORLD DOCTOR; Kent G, 1996, SOC SCI MED, V43, P1517, DOI 10.1016/0277-9536(96)00173-6; KINZIE MB, 1993, PATIENT EDUC COUNS, V21, P51, DOI 10.1016/0738-3991(93)90059-6; KULIK CLC, 1991, COMPUT HUM BEHAV, V7, P75, DOI 10.1016/0747-5632(91)90030-5; Kumar N B, 1993, J Cancer Educ, V8, P203; Lapham EV, 1996, SCIENCE, V274, P621, DOI 10.1126/science.274.5287.621; LEE JM, 1993, NEW ENGL J MED, V328, P438, DOI 10.1056/NEJM199302113280613; LEIRER VO, 1988, J AM GERIATR SOC, V36, P877; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; LERMAN C, 1994, J CLIN ONCOL, V12, P843, DOI 10.1200/JCO.1994.12.4.843; LEVINE AJ, 1995, JAMA-J AM MED ASSOC, V273, P592, DOI 10.1001/jama.273.7.592; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; LIDZ CW, 1983, ANN INTERN MED, V99, P539, DOI 10.7326/0003-4819-99-4-539; LIDZ CW, 1988, ARCH INTERN MED, V148, P1385, DOI 10.1001/archinte.148.6.1385; LIPPMAN A, 1991, AM J LAW MED, V17, P15; LIU B, 1994, CANCER RES, V54, P4590; LYNCH HT, 1993, ARCH INTERN MED, V153, P1979; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTEAU TM, 1996, PRENAT DIAGN, V14, P1215; MAZUR DJ, 1988, J GEN INTERN MED, V3, P370, DOI 10.1007/BF02595796; MCEWEN JE, 1992, AM J HUM GENET, V51, P637; Meade C D, 1992, Oncol Nurs Forum, V19, P1523; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER R, 1974, NEW ENGL J MED, V290, P964, DOI 10.1056/NEJM197404252901712; MORROW G, 1978, CANCER, V42, P793, DOI 10.1002/1097-0142(197808)42:2<793::AID-CNCR2820420252>3.0.CO;2-C; MUSS HB, 1979, CANCER, V43, P1549, DOI 10.1002/1097-0142(197904)43:4<1549::AID-CNCR2820430449>3.0.CO;2-R; NATOWICZ MR, 1992, AM J HUM GENET, V51, P895; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; *NIH DOE WORK GROU, 1993, NIH PUBL; NIXON DW, 1991, CANCER PREVENTIO MAR, P1; *OFF PROT RES RISK, 1993, PROT HUM RES SUBJ I, P42; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; OSTRER H, 1993, AM J HUM GENET, V52, P565; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PHILIPSON SJ, 1995, J INVEST MED, V43, P459; PHILLIPS JA, 1995, AM J HUM GENET, V57, P1499; *PRES COMM PROT HU, 1979, BELM REP ETH PRINC G; *PRES COMM STUD ET, 1982, ETH LEG IMPL INF CON, V1, P74; PRESS N, 1995, HASTINGS CENT REP, V25, pS9, DOI 10.2307/3562123; PRICE RV, 1991, COMPUTER AIDED INSTR; Punales-Morejon D, 1993, J Genet Couns, V2, P155, DOI 10.1007/BF00962076; Rosoff AJ, 1981, INFORMED CONSENT GUI; Rothstein M A, 1993, Mol Genet Med, V3, P159; ROWLEY JD, 1993, JAMA-J AM MED ASSOC, V270, P2331, DOI 10.1001/jama.270.19.2331; SHARPE NF, 1994, AM J MED GENET, V50, P239, DOI 10.1002/ajmg.1320500306; Silva Mary Cipriano, 1988, IRB, V10, P1, DOI 10.2307/3564101; SINGER GGS, 1996, MORALITY NEW GENETIC; SLACK WV, 1972, NEW ENGL J MED, V286, P1304; SLACK WV, 1966, NEW ENGL J MED, V274, P194, DOI 10.1056/NEJM196601272740406; Slack WV, 1976, CHANGING HLTH CARE T, P108; Smith J M, 1988, Diabetes Educ, V14, P412, DOI 10.1177/014572178801400509; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Strass E, 1996, AM J HUM GENET, V59, P471; TAUB HA, 1984, CLIN RES, V32, P17; TAYLOR KM, 1987, SOC SCI MED, V24, P135, DOI 10.1016/0277-9536(87)90246-2; Tibbles L, 1992, Comput Nurs, V10, P208; *US C OFF TECHN AS, 1992, US C PUBLICATION; Wang Vivian, 1992, J Genet Couns, V1, P81, DOI 10.1007/BF00960087; WANG WO, 1994, J GENET COUNS, V3, P267; Weil J, 1993, J Genet Couns, V2, P159, DOI 10.1007/BF00962077; WESTREICH L, 1995, CONVULSIVE THER, V11, P32; WETSTONE SL, 1985, J RHEUMATOL, V12, P907; WHITE CS, 1995, AM J ROENTGENOL, V165, P1139, DOI 10.2214/ajr.165.5.7572491; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001; WILFOND BS, 1995, AM J HUM GENET, V57, P1233; Winter PR, 1996, AM J MED GENET, V66, P1; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	119	156	157	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	1997	277	18					1467	1474		10.1001/jama.277.18.1467	http://dx.doi.org/10.1001/jama.277.18.1467			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX852	9145720				2022-12-28	WOS:A1997WX85200032
J	Rosenstreich, DL; Eggleston, P; Kattan, M; Baker, D; Slavin, RG; Gergen, P; Mitchell, H; McNiffMortimer, K; Lynn, H; Ownby, D; Malveaux, F				Rosenstreich, DL; Eggleston, P; Kattan, M; Baker, D; Slavin, RG; Gergen, P; Mitchell, H; McNiffMortimer, K; Lynn, H; Ownby, D; Malveaux, F			The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual International Conference of the American-Thoracic-Society	MAY 11-22, 1996	NEW ORLEANS, LA	Amer Thorac Soc			HOUSE-DUST MITE; IMMEDIATE HYPERSENSITIVITY; INDOOR ALLERGENS; RISK-FACTORS; SENSITIZATION; PURIFICATION; PREVALENCE; CHILDHOOD; ANTIGENS; ALTITUDE	Background It has been hypothesized that asthma-related health problems are most severe among children in inner-city areas who are allergic to a specific allergen and also exposed to high levels of that allergen in bedroom dust. Methods From November 1992 through October 1993, we recruited 476 children with asthma (age, four to nine years) from eight inner-city areas in the United States. Immediate hypersensitivity to cockroach, house-dust-mite, and cat allergens was measured by skin testing. We then measured major allergens of cockroach (Bla g 1), dust mites (Der p 1 and Der f 1), and cat dander (Fel d 1) in household dust using monoclonal-antibody-based enzyme-linked immunosorbent assays. High levels of exposure were defined according to proposed thresholds for causing disease. Data on morbidity due to asthma were collected at base line and over a one-year period. Results Of the children, 36.8 percent were allergic to cockroach allergen, 34.9 percent to dust-mite allergen, and 22.7 percent to cat allergen. Among the children's bedrooms, 50.2 percent had high levels of cockroach allergen in dust, 9.7 percent had high levels of dust-mite allergen, and 12.6 percent had high levels of cat allergen. After we adjusted for sex, score on the Child Behavior Checklist, and family history of asthma, we found that children who were both allergic to cockroach allergen and exposed to high levels of this allergen had 0.37 hospitalization a year, as compared with 0.11 for the other children (P=0.001), and 2.56 unscheduled medical visits for asthma per year, as compared with 1.43 (P<0.001). They also had significantly more days of wheezing, missed school days, and nights with lost sleep, and their parents or other care givers were awakened during the night and changed their daytime plans because of the child's asthma significantly more frequently. Similar patterns were not found for the combination of allergy to dust mites or cat dander and high levels of the allergen. Conclusions The combination of cockroach allergy and exposure to high levels of this allergen may help explain the frequency of asthma-related health problems in inner-city children. (C)1997, Massachusetts Medical Society.	JOHNS HOPKINS UNIV,SCH MED,DIV PEDIAT ALLERGY & IMMUNOL,BALTIMORE,MD; MT SINAI SCH MED,DEPT PEDIAT,NEW YORK,NY; UNIV CALIF IRVINE,CTR ENVIRONM & OCCUPAT HLTH,IRVINE,CA 92717; ST LOUIS UNIV,SCH MED,DEPT MED,DIV ALLERGY IMMUNOL,ST LOUIS,MO 63104; NIAID,BETHESDA,MD 20892; NEW ENGLAND RES INST,WATERTOWN,MA 02172; HENRY FORD HOSP,DIV ALLERGY,DETROIT,MI 48202; HOWARD UNIV,WASHINGTON,DC 20059	Johns Hopkins University; Icahn School of Medicine at Mount Sinai; University of California System; University of California Irvine; Saint Louis University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); HealthCore, Inc; Henry Ford Health System; Henry Ford Hospital; Howard University	Rosenstreich, DL (corresponding author), ALBERT EINSTEIN COLL MED,DIV ALLERGY IMMUNOL,DEPT MED,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		Fahimifar, Sepideh/M-5303-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030752, U01AI030756, U01AI030751] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30752, UO1 AI-30751, AI-30756] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; BERKOWITZ RB, 1992, J ALLERGY CLIN IMMUN, V90, P979, DOI 10.1016/0091-6749(92)90471-D; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; BIRKHEAD G, 1989, J ALLERGY CLIN IMMUN, V84, P484, DOI 10.1016/0091-6749(89)90361-8; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHANYEUNG M, 1995, AM J RESP CRIT CARE, V152, P1805, DOI 10.1164/ajrccm.152.6.8520740; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CONOVER WJ, 1982, BIOMETRICS, V38, P715, DOI 10.2307/2530051; DEROGATIS LR, 1982, BSI MANUAL, V1; DOHRENWEND BS, 1978, J HEALTH SOC BEHAV, V19, P205, DOI 10.2307/2136536; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; HSU KHK, 1979, J PEDIATR-US, V95, P192; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; KANG B, 1978, ANN ALLERGY, V41, P333; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG BC, 1993, J ALLERGY CLIN IMMUN, V92, P802, DOI 10.1016/0091-6749(93)90057-M; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; MARKS GB, 1995, J ALLERGY CLIN IMMUN, V96, P441, DOI 10.1016/S0091-6749(95)70285-7; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1995, J ALLERGY CLIN IMMUN, V96, P435, DOI 10.1016/S0091-6749(95)70284-9; Redline S, 1996, PEDIATR PULM, V21, P203; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358	33	1058	1080	2	76	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 8	1997	336	19					1356	1363		10.1056/NEJM199705083361904	http://dx.doi.org/10.1056/NEJM199705083361904			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX851	9134876				2022-12-28	WOS:A1997WX85100004
J	Spruance, SL; Rea, TL; Thoming, C; Tucker, R; Saltzman, R; Boon, R				Spruance, SL; Rea, TL; Thoming, C; Tucker, R; Saltzman, R; Boon, R			Penciclovir cream for the treatment of herpes simplex labialis - A randomized, multicenter, double-blind, placebo-controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Clinical Dermatology 2000 International Congress	MAY   30, 1996	VANCOUVER, CANADA				TOPICAL ACYCLOVIR; ORAL ACYCLOVIR; FAMCICLOVIR; FAILURE	Objective.-To compare the safety and efficacy of topical 1% penciclovir cream with vehicle control cream (placebo) for the treatment of a recurrent episode of herpes simplex labialis (cold sores) in immunocompetent patients. Design.-Randomized, double-blind, placebo-controlled, patient-initiated, 2-armed, parallel clinical trial. Patients were prospectively dispensed study medication, and treatment was self-initiated by the patient within 1 hour of the first sign or symptom Of a recurrence. Setting.-A total of 31 ambulatory clinics in the United States in a variety of settings, including private practices, public health facilities, and universities. Patients.-Otherwise healthy individuals with a history of frequent episodes of herpes simplex labialis. A total of 2209 patients were enrolled and given study medication, and 1573 initiated treatment for a recurrence. Interventions.-Topical 1% penciclovir cream or vehicle control cream. Subjects applied treatment every 2 hours while awake for 4 consecutive days, Main Outcome Measures.-Lesion healing was the primary efficacy variable. Secondary end points included time to loss of lesion pain and time to cessation of viral shedding. Results.-Healing of classical lesions (vesicles, ulcers, and/or crusts) was 0.7 day faster for penciclovir-treated patients compared with those who received vehicle control cream (median, 4.8 days vs 5.5 days; hazard ratio [HR], 1.33; 95% confidence interval [CI], 1.18-1.49; P<.001). Pain (median, 3.5 days vs 4.1 days; HR, 1.22; 95% CI, 1.09-1.36; P<.001) and lesion virus shedding (median, 3 days vs 3 days; HR, 1.35; 95% CI, 1.10-1.64; P=.003) also resolved more quickly for penciclovir-treated patients compared with patients who applied the vehicle control, The efficacy of penciclovir cream was apparent when therapy was initiated early (prodrome or erythema lesion stage) and when initiated late (papule or vesicle stage). The incidence of adverse events was comparable between penciclovir and placebo groups. Conclusions.-Penciclovir cream is the first treatment to clearly demonstrate an impact on the course of recurrent herpes labialis in immunocompetent patients. Efficacy was seen in all clinical and laboratory measures of the disease (lesion healing, pain resolution, and cessation of viral shedding), Faster healing and pain resolution occurred both among patients who first applied penciclovir cream in the prodrome and erythema stages and among those who started treatment in the papule and vesicle lesion stages.	UNIV UTAH,DIV INFECT DIS,SALT LAKE CITY,UT 84132; VIP RES INC,BRYAN,TX; WESTOVER HTS CLIN,PORTLAND,OR; WENATCHEE VALLEY CLIN,WENATCHEE,WA; SMITHKLINE BEECHAM PHARMACEUT,PHILADELPHIA,PA; SMITHKLINE BEECHAM PHARMACEUT,BRENTFORD,MIDDX,ENGLAND	Utah System of Higher Education; University of Utah; GlaxoSmithKline; GlaxoSmithKline	Spruance, SL (corresponding author), UNIV UTAH,SCH MED,HLTH SCI AIDS CTR,50 N MED DR,ROOM 4B319,SALT LAKE CITY,UT 84132, USA.							BOYD MR, 1993, ANTIVIR CHEM CHEMOTH, V4, P3, DOI 10.1177/095632029300401S01; COX DR, 1972, J R STAT SOC B, V34, P187; FIDDIAN AP, 1983, BMJ-BRIT MED J, V286, P1699, DOI 10.1136/bmj.286.6379.1699; FIDDIAN AP, 1983, BRIT J DERMATOL, V109, P321, DOI 10.1111/j.1365-2133.1983.tb03548.x; FREEMAN DJ, 1986, ANTIMICROB AGENTS CH, V29, P730, DOI 10.1128/AAC.29.5.730; HODGE RAV, 1993, ANTIVIR CHEM CHEMOTH, V4, P67, DOI 10.1177/095632029300400201; Perkins SW, 1996, PLAST RECONSTR SURG, V98, P434; PRUSOFF WH, 1988, CLIN USE ANTIVIRAL D, P15; RABORN GW, 1987, J AM DENT ASSOC, V115, P38, DOI 10.14219/jada.archive.1987.0211; RABORN GW, 1989, ORAL SURG ORAL MED O, V67, P676, DOI 10.1016/0030-4220(89)90007-8; RABORN GW, 1989, CAN DENT ASSOC J, V55, P135; RABORN GW, 1996, 36 ANN M INT C ANT A; Sacks SL, 1996, JAMA-J AM MED ASSOC, V276, P44, DOI 10.1001/jama.276.1.44; SHAW M, 1985, BMJ-BRIT MED J, V291, P7, DOI 10.1136/bmj.291.6487.7; SPRUANCE SL, 1982, J INFECT DIS, V146, P85, DOI 10.1093/infdis/146.1.85; SPRUANCE SL, 1995, CLINICAL MANAGEMENT OF HERPES VIRUSES, P3; SPRUANCE SL, 1990, J INFECT DIS, V161, P185, DOI 10.1093/infdis/161.2.185; SPRUANCE SL, 1990, J INFECT DIS, V161, P191, DOI 10.1093/infdis/161.2.191; SPRUANCE SL, 1984, ANTIMICROB AGENTS CH, V25, P553, DOI 10.1128/AAC.25.5.553; SPRUANCE SL, 1993, J MED VIROL S, V1, P27; TYRING S, 1995, ANN INTERN MED, V123, P89, DOI 10.7326/0003-4819-123-2-199507150-00002; VANVLOTEN WA, 1983, J ANTIMICROB CHEMOTH, V12, P89, DOI 10.1093/jac/12.suppl_B.89	22	141	148	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	1997	277	17					1374	1379		10.1001/jama.277.17.1374	http://dx.doi.org/10.1001/jama.277.17.1374			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW261	9134943				2022-12-28	WOS:A1997WW26100027
J	Kay, SA				Kay, SA			Circadian rhythms - PAS, present, and future: Clues to the origins of circadian clocks	SCIENCE			English	Editorial Material							MUTANTS				Kay, SA (corresponding author), Scripps Res Inst, DEPT CELL BIOL, NATL SCI FDN, CTR BIOL TIMING, LA JOLLA, CA 92037 USA.		Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878				ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Ballario P, 1996, EMBO J, V15, P1650, DOI 10.1002/j.1460-2075.1996.tb00510.x; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Hall JC, 1996, NEURON, V17, P799, DOI 10.1016/S0896-6273(00)80211-1; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KAY SA, 1995, CELL, V83, P361, DOI 10.1016/0092-8674(95)90113-2; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; Lagarias DM, 1995, PLANT MOL BIOL, V29, P1127, DOI 10.1007/BF00020457; Linden H, 1997, EMBO J, V16, P98, DOI 10.1093/emboj/16.1.98; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595	13	60	63	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					753	754		10.1126/science.276.5313.753	http://dx.doi.org/10.1126/science.276.5313.753			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9157552				2022-12-28	WOS:A1997WW90000042
J	Sawicki, G; Salas, E; Murat, J; MisztaLane, H; Radomski, MW				Sawicki, G; Salas, E; Murat, J; MisztaLane, H; Radomski, MW			Release of gelatinase A during platelet activation mediates aggregation	NATURE			English	Article							EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; TISSUE INHIBITOR; METALLOPROTEINASES; COLLAGENASE; EXPRESSION; FAMILY; TIMP-2	Blood platelets limit blood loss at sites of vascular injury by forming a mechanical plug. They are also involved in thrombosis, atherosclerosis, inflammation and metastasis. Platelet activation is essential for these physiological and pathological reactions and depends upon their adhesion to the vessel wall and attachment to each other in the aggregation process. The two known pathways of aggregation are mediated by the release of endoperoxides/thromboxane A(2) and ADP(1-3) which amplify platelet aggregation. Here we report the identification of a new pathway of aggregation which is mediated by the release of a metalloproteinase enzyme, gelatinase A.	UNIV ALBERTA, DEPT PHARMACOL, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT OBSTET & GYNAECOL, EDMONTON, AB T6G 2H7, CANADA	University of Alberta; University of Alberta			Salas, Eduardo/AAL-4836-2020; Radomski, Marek W/C-5195-2014	Salas, Eduardo/0000-0002-6837-2471; 				BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; CHESNEY CM, 1974, J CLIN INVEST, V53, P1647, DOI 10.1172/JCI107715; COLMAN RW, 1990, FASEB J, V4, P1425, DOI 10.1096/fasebj.4.5.2407587; CRUWYS SC, 1990, BRIT J PHARMACOL, V100, P631, DOI 10.1111/j.1476-5381.1990.tb15858.x; FEINMAN RD, 1985, PLATELETS PHYSL PHAR, P429; Goetzl EJ, 1996, J IMMUNOL, V156, P1; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HERRON GS, 1986, J BIOL CHEM, V261, P2810; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; JOSEPH R, 1989, THROMB RES, V53, P485, DOI 10.1016/0049-3848(89)90203-X; Komoszynski M, 1996, BBA-MOL CELL RES, V1310, P233, DOI 10.1016/0167-4889(95)00135-2; LEVEN RM, 1990, EXP HEMATOL, V18, P743; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; MCEVER RP, 1991, THROMB HAEMOSTASIS, V66, P80; PETREQUIN PR, 1987, BLOOD, V69, P605; RADOMSKI M, 1983, THROMB RES, V30, P383, DOI 10.1016/0049-3848(83)90230-X; RADOMSKI MW, 1995, NITRIC OXIDE MODULAT, P43; RAY JM, 1994, EUR RESPIR J, V7, P2062; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SARGEANT P, 1994, PHARMACOL THERAPEUT, V64, P395, DOI 10.1016/0163-7258(94)90019-1; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SOUTHGATE KM, 1992, BIOCHEM J, V288, P93, DOI 10.1042/bj2880093; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11; ZEMBOWICZ A, 1995, J CLIN INVEST, V96, P1688, DOI 10.1172/JCI118211	29	286	296	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 10	1997	386	6625					616	619		10.1038/386616a0	http://dx.doi.org/10.1038/386616a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121586				2022-12-28	WOS:A1997WT27300061
J	Horton, R				Horton, R			A manifesto for reading medicine	LANCET			English	Editorial Material							PYLORIC CAMPYLOBACTER											BARNARD C N, 1967, South African Medical Journal, V41, P1271; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Chadwick J., 1983, HIPPOCRATIC WRITINGS; DOLL R, 1952, BMJ-BRIT MED J, V2, P1271, DOI 10.1136/bmj.2.4797.1271; FLEISCHMANN RD, 1995, SCIENCE, V269, P449; Fleming A, 1929, BRIT J EXP PATHOL, V10, P226; Fletcher W, 1907, LANCET, V1, P1776; Galen, 1985, 3 TREATISES NATURE S; GALEN, 1991, NATURAL FACULTIES; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; HEAD H, 1920, BRIT MED J, V1, P389; KANNEL WB, 1961, ANN INTERN MED, V55, P33, DOI 10.7326/0003-4819-55-1-33; KOCH ROBERT, 1932, AMER REV TUBERC, V25, P285; LASAGNA L, 1954, AM J MED, V16, P770, DOI 10.1016/0002-9343(54)90441-6; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; Lister J, 1867, LANCET, V89, P387; Lister J., 1867, LANCET, V1, P326, DOI 10.1016/S0140-6736(02)51192-2; Lister J, 1867, LANCET, V90, P95; Lister J, 1867, LANCET, V90, P353, DOI [10.1016/S0140-6736(02)51827-4, DOI 10.1016/S0140-6736(02)51827-4]; Lister J., 1867, LANCET, V1, P507; Lister Joseph, 1867, LANCET, Vi, P357, DOI [10.1016/S0140-6736(00)73482-9, DOI 10.1016/S0140-6736(00)73482-9]; LOTTA TA, 1832, LANCET, V1, P173; MALPIGHI M, 1929, P ROY SOC MED, V23, P1; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P439, DOI 10.5694/j.1326-5377.1985.tb113444.x; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; Pierce CS., 1885, MEMOIRS NATL ACAD SC, V3, P73; REED W, 1900, PHILA MED J, V6, P790; Rose G., 1992, STRATEGY PREVENTIVE; *SIS 1, 1986, LANCET, V2, P57; TRICHOPOULOS D, 1983, LANCET, V1, P441; Tuberculosis Trials Committee iMRCS, 1948, BMJ, V2, P769	34	23	23	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					872	874		10.1016/S0140-6736(97)02336-2	http://dx.doi.org/10.1016/S0140-6736(97)02336-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121276				2022-12-28	WOS:A1997WP40300047
J	Ackerman, MJ; Clapham, DE				Ackerman, MJ; Clapham, DE			Mechanisms of disease - Ion channels - Basic science and clinical disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LONG QT SYNDROME; CYSTIC-FIBROSIS GENE; INHERITED CARDIAC-ARRHYTHMIA; SULFONYLUREA RECEPTOR; POTASSIUM CHANNEL; CHLORIDE CHANNEL; NA+ CHANNEL; K+-CHANNEL; MOLECULAR MECHANISMS; LIDDLES SYNDROME		HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, CHILDRENS HOSP, MED CTR, DEPT CARDIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Ackerman, MJ (corresponding author), MAYO CLIN & MAYO FDN, MAYO EUGENIO LITTA CHILDRENS HOSP, DEPT PEDIAT & ADOLESCENT MED, ROCHESTER, MN 55905 USA.		Clapham, David/R-5974-2019; Clapham, David/S-1123-2019	Clapham, David/0000-0002-4459-9428				ACKERMAN MJ, IN PRESS MOL BASIS H; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; ALTON EWFW, 1995, GENE THER, V2, P88; ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHCROFT SJH, 1992, BIOCHIM BIOPHYS ACTA, V1175, P45, DOI 10.1016/0167-4889(92)90008-Y; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHALLINORROGERS JL, 1994, CLIN EXP PHARMACOL P, V21, P583, DOI 10.1111/j.1440-1681.1994.tb02559.x; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; Compton SJ, 1996, CIRCULATION, V94, P1018, DOI 10.1161/01.CIR.94.5.1018; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DEAN M, 1994, HUM GENET, V93, P364; Dumaine R, 1996, CIRC RES, V78, P916, DOI 10.1161/01.RES.78.5.916; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; GAN KH, 1995, NEW ENGL J MED, V333, P95, DOI 10.1056/NEJM199507133330204; GRIBKOFF VK, 1994, J BIOL CHEM, V269, P10983; HAEUSLER G, 1994, EUR HEART J, V15, P82, DOI 10.1093/eurheartj/15.suppl_C.82; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Howard M, 1996, NAT MED, V2, P467, DOI 10.1038/nm0496-467; HUDSON AJ, 1995, BRAIN, V118, P547, DOI 10.1093/brain/118.2.547; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; Keating MT, 1996, MEDICINE, V75, P1, DOI 10.1097/00005792-199601000-00001; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KNOWLES MR, 1995, CHEST, V107, pS71, DOI 10.1378/chest.107.2_Supplement.71S; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; Lopez JR, 1996, J THORAC CARDIOV SUR, V112, P820, DOI 10.1016/S0022-5223(96)70070-3; MALCOLM AD, 1993, CARDIOVASC DRUG THER, V7, P139, DOI 10.1007/BF00878323; Moss A J, 1992, Heart Dis Stroke, V1, P309; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; NERRER FH, 1980, CIBA COLLECTION MED, V7, P154; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; PELLEG A, 1993, CARDIOVASC RES, V27, P54, DOI 10.1093/cvr/27.1.54; Ramsey BW, 1996, NEW ENGL J MED, V335, P179, DOI 10.1056/NEJM199607183350307; RIORDAN JR, 1989, SCIENCE, V245, P1437; RIORDAN JR, 1989, SCIENCE, V245, P1066; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; ROMANO C, 1963, Clin Pediatr (Bologna), V45, P656; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHOTT JJ, 1995, AM J HUM GENET, V57, P1114; SCHWARTZ PJ, 1995, CIRCULATION, V92, P3381, DOI 10.1161/01.CIR.92.12.3381; SHEN WK, 1995, MAYO CLIN PROC, V70, P274, DOI 10.4065/70.3.274; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; SOREQ H, 1985, CRC CR REV BIOCH MOL, V18, P199, DOI 10.3109/10409238509085134; TERAIC A, 1995, AM J PHYSIOL, V269, pC525; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WARD O C, 1964, J Ir Med Assoc, V54, P103; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865	68	263	296	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 29	1997	336	22					1575	1586		10.1056/NEJM199705293362207	http://dx.doi.org/10.1056/NEJM199705293362207			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB087	9164815				2022-12-28	WOS:A1997XB08700007
J	Hall, AS; Murray, GD; Ball, SG				Hall, AS; Murray, GD; Ball, SG			Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) study	LANCET			English	Article							LEFT-VENTRICULAR DYSFUNCTION; EFFICACY AIRE; MORTALITY; SURVIVAL; MORBIDITY; TRIAL	Background In the Acute Infarction Ramipril Efficacy (AIRE) Study, the effect of angiotensin-converting-enzyme (ACE) inhibition on the survival of patients with clinical heart failure after acute myocardial infarction (AMI), was assessed. At an average follow-up time of 15 months after randomisation, all-cause mortality was reduced from 22.6% (placebo group) to 16.9% (ramipril group) representing an absolute mortality reduction of 5.7% and a relative risk reduction of 27% (95% CI 11-40%; p=0.002). Our aim in this study was to assess the long-term (3 years after the AIRE Study closed) magnitude, duration, and reliability of the survival benefits observed after treatment with ramipril (target dose 5 mg twice a day) when compared with placebo. Methods We investigated the mortality status of all 603 patients recruited from the 30 UK centres involved in the AIRE Study. Through government records we were able to confirm the death or survival of all 603 patients exactly 3 years after the close of the AIRE Study. Follow-up was for a minimum of 42 months and a mean of 59 months. The average duration of treatment with masked trial medication was 13.4 months for placebo and 12.4 months for ramipril. Findings By 0000 h March 1, 1996, death from all causes had occurred in 117 (38.9%) of 301 patients randomly assigned placebo and 83 (27.5%) of 302 patients randomly assigned ramipril, representing a relative risk reduction of 36% (95% CI 15-52%; p=0.002) and an absolute reduction in mortality of 11.4% (114 additional 5-year survivors per 1000 patients treated for an average of 12.4 months). Interpretation Our data provide robust evidence that administration of ramipril to patients with clinically defined heart failure after AMI results in a survival benefit that is not only large in magnitude, but also sustained over many years.			Hall, AS (corresponding author), UNIV LEEDS, YORKSHIRE HEART CTR, CARDIOVASC RES INST, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND.			Hall, Alistair/0000-0003-0306-7887; Murray, Gordon/0000-0001-9866-4734				AMBROSIONI E, 1995, NEW ENGL J MED, V332, P80, DOI 10.1056/NEJM199501123320203; BALL SG, 1993, LANCET, V342, P821; Bowker TJ, 1996, HEART, V75, P334, DOI 10.1136/hrt.75.4.334; CLELAND JGF, 1993, J CARDIOVASC PHARM, V22, pS22, DOI 10.1097/00005344-199306229-00006; Cleland JGF, 1997, EUR HEART J, V18, P41; COLLINS R, 1995, LANCET, V345, P669; DeVita C, 1996, J AM COLL CARDIOL, V27, P337; DEVITA C, 1994, LANCET, V343, P1115; *GISSI 3, 1992, AM J CARDIOL, V70, pC62; HALL AS, 1991, J CARDIOVASC PHARM, V18, pS105, DOI 10.1097/00005344-199100182-00022; HALL AS, 1989, LANCET, V2, P1527; HALL AS, 1995, CONTROVERS CARDIOL, V6, P5; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; LATINI R, 1995, CONTROVERS CARDIOL, V6, P9; LISHENG L, 1995, LANCET, V345, P686; MARTINEZ C, 1995, BR J CLIN PRACT, V49, pS26; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Sapsford R. J., 1996, European Heart Journal, V17, P62; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	23	138	146	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	1997	349	9064					1493	1497		10.1016/S0140-6736(97)04442-5	http://dx.doi.org/10.1016/S0140-6736(97)04442-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167457				2022-12-28	WOS:A1997XA90100007
J	Law, C; Marcaccio, M; Tam, P; Heddle, N; Kelton, JG				Law, C; Marcaccio, M; Tam, P; Heddle, N; Kelton, JG			High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THERAPEUTIC EXPERIENCE; GAMMA-GLOBULIN	Background High-dose intravenous immune globulin produces a temporary rise in the platelet count in patients with idiopathic thrombocytopenic purpura. Splenectomy may also be effective, but it is not possible to predict which patients will have a good response. We hypothesized that the response to intravenous immune globulin predicts the response to splenectomy. Methods We studied retrospectively 30 patients with idiopathic thrombocytopenic purpura who had first been treated with immune globulin and then undergone splenectomy. The responses to the two treatments were classified on the basis of the platelet count as poor (< 50,000 per cubic millimeter), good (50,000 to 150,000 per cubic millimeter), or excellent (> 150,000 per cubic millimeter). Results All nine patients who had poor responses to intravenous immune globulin also had poor responses to splenectomy at one year. Of the 21 patients with good or excellent responses to intravenous immune globulin, 19 had good or excellent responses to splenectomy. Conclusions Patients with idiopathic thrombocytopenic purpura who have good or excellent responses to intravenous immune globulin are likely to have good or excellent responses to splenectomy, whereas patients who have poor responses to intravenous immune globulin are unlikely to have good or excellent responses to splenectomy. (C) 1997, Massachusetts Medical Society.	MCMASTER UNIV, MED CTR, DEPT PATHOL, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, MED CTR, DEPT MED, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, MED CTR, DEPT SURG, HAMILTON, ON L8N 3Z5, CANADA; HAMILTON HLTH SCI CORP, HAMILTON, ON, CANADA	McMaster University; McMaster University; McMaster University; McMaster University								BENYEHUDA D, 1994, ACTA HAEMATOL-BASEL, V91, P1; BRENNAN MF, 1975, AM J SURG, V129, P490, DOI 10.1016/0002-9610(75)90197-X; BUSSEL JB, 1983, BLOOD, V62, P480; BUSSEL JB, 1984, BRIT J HAEMATOL, V56, P1, DOI 10.1111/j.1365-2141.1984.tb01266.x; BUSSEL JB, 1990, HEMATOL ONCOL CLIN N, V4, P179, DOI 10.1016/S0889-8588(18)30512-4; COON WW, 1987, SURG GYNECOL OBSTET, V164, P225; FABRIS F, 1989, ACTA HAEMATOL-BASEL, V81, P28; FEHR J, 1982, NEW ENGL J MED, V306, P1254, DOI 10.1056/NEJM198205273062102; FENAUX P, 1989, EUR J HAEMATOL, V42, P259; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; GEORGE JN, 1994, NEW ENGL J MED, V331, P1207, DOI 10.1056/NEJM199411033311807; Hashizume M, 1996, SURG LAPAROSC ENDOSC, V6, P129, DOI 10.1097/00019509-199604000-00008; JACOBS P, 1986, Q J MED, V58, P153; JULIA A, 1990, BRIT J HAEMATOL, V76, P250, DOI 10.1111/j.1365-2141.1990.tb07880.x; KELTON JG, 1985, BLOOD, V66, P490; KELTON JG, 1985, CURRENT CONCEPTS TRA, P51; KONRADSEN HB, 1991, ACTA PAEDIATR SCAND, V80, P423, DOI 10.1111/j.1651-2227.1991.tb11877.x; NAJEAN Y, 1991, BRIT J HAEMATOL, V79, P271, DOI 10.1111/j.1365-2141.1991.tb04532.x; PIZZUTO J, 1984, BLOOD, V64, P1179; SIEGEL RS, 1989, AM J HEMATOL, V30, P206, DOI 10.1002/ajh.2830300404	20	98	100	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	1997	336	21					1494	1498		10.1056/NEJM199705223362104	http://dx.doi.org/10.1056/NEJM199705223362104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ767	9154768	Bronze			2022-12-28	WOS:A1997WZ76700004
J	Wenneras, C; Wold, A				Wenneras, C; Wold, A			Nepotism and sexism in peer-review	NATURE			English	Editorial Material									UNIV GOTHENBURG, DEPT CLIN IMMUNOL, S-41346 GOTHENBURG, SWEDEN	University of Gothenburg	Wenneras, C (corresponding author), UNIV GOTHENBURG, DEPT MED MICROBIOL & IMMUNOL, GULDHEDSGATAN 10, S-41346 GOTHENBURG, SWEDEN.		Wold, Agnes/M-6310-2013	Wold, Agnes/0000-0001-9196-5040				CALZA L, 1995, NATURE, V374, P492, DOI 10.1038/374492a0; COLE S, 1981, SCIENCE, V214, P881, DOI 10.1126/science.7302566; ERNST E, 1992, ANN INTERN MED, V116, P958, DOI 10.7326/0003-4819-116-11-958_2; FORSDYKE DR, 1993, FASEB J, V7, P619, DOI 10.1096/fasebj.7.8.8500686; FRIEZE IH, 1975, WOMEN ACHIEVEMENT, P158; GLANTZ SA, 1994, JAMA-J AM MED ASSOC, V272, P114, DOI 10.1001/jama.272.2.114; GOLDBERG P, 1968, TRANS-ACT-SOC SCI MO, V5, P28; LONG JS, 1992, SOC FORCES, V71, P159, DOI 10.2307/2579971; NIEVA VF, 1980, ACAD MANAGE REV, V5, P267, DOI DOI 10.5465/AMR.1980.4288749; OLEARY VE, 1982, REV PERSONALITY SOCI, V2, P9; PEREZ-ENCISO M, 1995, NATURE, V378, P760, DOI 10.1038/378760c0; Sonnert G, 1996, AM SCI, V84, P63; SONNERT G, 1995, SOC STUD SCI, V25, P35, DOI 10.1177/030631295025001003; WIDNALL SE, 1988, SCIENCE, V241, P1740, DOI 10.1126/science.241.4874.1740	14	756	768	2	238	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	1997	387	6631					341	343		10.1038/387341a0	http://dx.doi.org/10.1038/387341a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XA496	9163412				2022-12-28	WOS:A1997XA49600031
J	Drummond, MF; Richardson, WS; OBrien, BJ; Levine, M; Heyland, D				Drummond, MF; Richardson, WS; OBrien, BJ; Levine, M; Heyland, D			Users' guides to the medical literature .13. How to use an article on economic analysts of clinical practice .A. Are the results of the study valid?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; TISSUE-PLASMINOGEN-ACTIVATOR; COST-EFFECTIVENESS; THROMBOLYTIC THERAPY; CONTROLLED TRIAL; GASTRIC-ULCER; STREPTOKINASE; MISOPROSTOL; INFECTION; CHARGES		UNIV YORK, CTR HLTH ECON, YORK YO1 5DD, N YORKSHIRE, ENGLAND; UNIV ROCHESTER, SCH MED & DENT, DEPT MED, ROCHESTER, NY 14642 USA; MCMASTER UNIV, HLTH SCI CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON L8N 3Z5, CANADA; ST JOSEPHS HOSP, CTR EVALUAT MED, HAMILTON, ON, CANADA; ROYAL ALEXANDRA HOSP, EDMONTON, AB, CANADA	University of York - UK; University of Rochester; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McGill University; McMaster University; Royal Alexandra Hospital								BACKHOUSE ME, 1992, HLTH EC S, V1, P1; Cairns J, 1992, Health Econ, V1, P76, DOI 10.1002/hec.4730010111; COHEN DJ, 1993, J AM COLL CARDIOL, V22, P1052, DOI 10.1016/0735-1097(93)90415-W; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; ELIXHAUSER A, 1993, MED CARE, V31, pJS1, DOI 10.1097/00005650-199307001-00001; EPSTEIN MA, 1987, JAMA-J AM MED ASSOC, V258, P2381; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; GOEL V, 1992, CAN J CARDIOL, V8, P31; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; GRAHAM DY, 1988, LANCET, V2, P1277; HILLMAN AL, 1989, ARCH INTERN MED, V149, P2061, DOI 10.1001/archinte.149.9.2061; KALISH SC, 1995, J GEN INTERN MED, V10, P321, DOI 10.1007/BF02599951; KAMLET MS, 1990, FRAMEWORK COST UTILI; Karlsson G, 1996, PHARMACOECONOMICS, V9, P113, DOI 10.2165/00019053-199609020-00003; LUCE BR, 1990, STANDARDS SOCIOECONO; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; MEHREZ A, 1989, MED DECIS MAKING, V9, P142, DOI 10.1177/0272989X8900900209; MUGFORD M, 1989, BMJ-BRIT MED J, V299, P1003, DOI 10.1136/bmj.299.6706.1003; OBRIEN BJ, 1994, MED CARE, V32, P150, DOI 10.1097/00005650-199402000-00006; Parsonage M, 1992, Health Econ, V1, P71, DOI 10.1002/hec.4730010110; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1292, DOI 10.1001/jama.273.16.1292; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; SCHULMAN KA, 1991, ANN INTERN MED, V114, P798, DOI 10.7326/0003-4819-114-9-798; SELIGMANN M, 1994, LANCET, V343, P871; SIFTON DW, 1993, 1993 RED BOOK PHARM; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; Torrance GW, 1987, METHODS EC EVALUATIO; UDVARHELYI IS, 1992, ANN INTERN MED, V116, P238, DOI 10.7326/0003-4819-116-3-238; WEISBROD BA, 1980, ARCH GEN PSYCHIAT, V37, P400; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630	32	235	240	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	1997	277	19					1552	1557		10.1001/jama.277.19.1552	http://dx.doi.org/10.1001/jama.277.19.1552			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WY969	9153371				2022-12-28	WOS:A1997WY96900035
J	Trofa, AF; DeFraites, RF; Smoak, BL; KanesaThasan, N; King, AD; Burrous, JM; MacArthy, PO; Rossi, C; Hoke, CH				Trofa, AF; DeFraites, RF; Smoak, BL; KanesaThasan, N; King, AD; Burrous, JM; MacArthy, PO; Rossi, C; Hoke, CH			Dengue fever in US military personnel in Haiti	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE; VIRUS	Objective.-To describe clinical manifestations and public health implications of an outbreak of dengue fever (DF) during Operation Uphold Democracy, Haiti, 1994. Design.-Consecutive sample, Setting.-Military combat support hospital, Port-au-Prince, Haiti, Patients.-A total of 101 US military personnel with acute febrile illnesses, Interventions.-A disease surveillance team collected clinical and epidemiologic data from US military clinics throughout Haiti, Febrile patients admitted to the combat support hospital were evaluated with standardized clinical and laboratory procedures, The surveillance team followed patients daily, Main Outcome Measures.-Arbovirus isolation and specific antibody determination and symptoms and physical findings, Results.-Febrile illnesses accounted for 103 (25%) of the 406 combat support hospital admissions during the first 8 weeks of deployment. Ail patients with febrile illness recovered. A total of 30 patients had DF; no patient had evidence of infection with malaria, Dengue virus serotypes 1,2, and 4 were isolated from 22 patients, and 8 patients developed IgM antibody to dengue virus, Patients with DF could not be distinguished from other febrile patients on clinical grounds alone, No arboviruses other than dengue were identified. Conclusions.-Active surveillance, with clinical and laboratory evaluation directed by an epidemiologic team, led to the timely recognition of an outbreak of febrile illness among US troops in Haiti, Viral isolation and serological studies were essential in confirming DF, During the surveillance period, DF accounted for at least 30% of the febrile illnesses among hospitalized US troops, Dengue fever is a significant threat to military personnel and civilian travelers in Haiti and has the potential for introduction to and transmission in the United States.	WALTER REED ARMY INST RES, DIV PREVENT MED, WASHINGTON, DC USA; WALTER REED ARMY INST RES, DIV COMMUNICABLE DIS & IMMUNOL, WASHINGTON, DC USA; USA, MED RES INST INFECT DIS, DEPT APPL DIAGNOST, FREDERICK, MD USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)								Bakker, 1996, J Travel Med, V3, P204, DOI 10.1111/j.1708-8305.1996.tb00747.x; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P845; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P353; EHRENKRANZ NJ, 1971, NEW ENGL J MED, V285, P1460, DOI 10.1056/NEJM197112232852606; GAMBEL JM, 1996, MIL REV, V76, P51; GUBLER DJ, 1993, INFECT AGENT DIS, V2, P383; GUBLER DJ, 1989, AM J TROP MED HYG, V40, P571, DOI 10.4269/ajtmh.1989.40.571; HENCHAL EA, 1982, AM J TROP MED HYG, V31, P830, DOI 10.4269/ajtmh.1982.31.830; HYAMS KC, 1993, MIL MED, V158, P729, DOI 10.1093/milmed/158.11.729; HYAMS KC, 1986, AM J TROP MED HYG, V35, P860, DOI 10.4269/ajtmh.1986.35.860; INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418; MONATH T, 1984, HUNTERS TROPICAL MED, P143; MORENS DM, 1994, CLIN INFECT DIS, V19, P500, DOI 10.1093/clinids/19.3.500; NEWTON JA, 1994, JAMA-J AM MED ASSOC, V272, P397, DOI 10.1001/jama.272.5.397; Rigau-Perez Jose G., 1994, Morbidity and Mortality Weekly Report, V43, P7; Schwartz E, 1996, AM J MED, V101, P516, DOI 10.1016/S0002-9343(96)00278-1; SHARP TW, 1995, AM J TROP MED HYG, V53, P89, DOI 10.4269/ajtmh.1995.53.89; TESH RB, 1979, AM J TROP MED HYG, V28, P1053, DOI 10.4269/ajtmh.1979.28.1053; *USD INC, 1990, EP INF VERS 5 WORD P; VENTURA AK, 1976, J INFECT DIS, V134, P436, DOI 10.1093/infdis/134.5.436; Wallace MR, 1996, AM J MED, V100, P49, DOI 10.1016/S0002-9343(96)90011-X; *WHO, 1994, WEEKLY EPIDEMIOL REC, V69, P177	22	55	59	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	1997	277	19					1546	1548		10.1001/jama.277.19.1546	http://dx.doi.org/10.1001/jama.277.19.1546			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY969	9153369				2022-12-28	WOS:A1997WY96900033
J	Brearley, AJ				Brearley, AJ			Disordered biopyriboles, amphibole, and talc in the allende meteorite: Products of nebular or parent body aqueous alteration?	SCIENCE			English	Article							CARBONACEOUS CHONDRITE; PHYLLOSILICATES; MINERALOGY; MATRIX; RIMS	Transmission electron microscope observations of the Allende carbonaceous chondrite provided evidence of widespread hydrous phases replacing enstatite in chondrules. Calcic amphibole and talc occur in thin (less than 0.3 micrometer) crosscutting veins and as alteration products of primary chondrule glass in contraction cracks within the enstatite, In addition, talc and disordered biopyriboles were found replacing enstatite grains along cracks and fractures. Although rare hydrous phases have been reported in calcium- and aluminum-rich inclusions in the Allende meteorite, these observations suggest that aqueous fluids played a much more significant role in the mineralogical and geochemical evolution of Allende than has previously been thought.			Brearley, AJ (corresponding author), UNIV NEW MEXICO, INST METEORIT, DEPT EARTH & PLANETARY SCI, ALBUQUERQUE, NM 87131 USA.			Brearley, Adrian/0000-0002-7364-8815				BARBER DJ, 1985, CLAY MINER, V20, P415, DOI 10.1180/claymin.1985.020.4.01; BERMAN RG, 1988, J PETROL, V29, P445, DOI 10.1093/petrology/29.2.445; BERMAN RG, 1991, CAN MINERAL, V29, P833; BREARLEY AJ, 1996, LUNAR PLANET SCI, V27, P161; BUNCH TE, 1980, GEOCHIM COSMOCHIM AC, V44, P1543, DOI 10.1016/0016-7037(80)90118-0; CHERNOSKY JV, 1982, CAN MINERAL, V20, P19; CLARKE RS, 1970, SMITHSON CONTRIB EAR, V5, P53; Grossman J. N., 1988, METEORITES EARLY SOL, P619; HASHIMOTO A, 1987, GEOCHIM COSMOCHIM AC, V51, P1685, DOI 10.1016/0016-7037(87)90348-6; Housley R. M., 1983, CHONDRULES THEIR ORI, P145; HUA X, 1988, GEOCHIM COSMOCHIM AC, V52, P1389, DOI 10.1016/0016-7037(88)90210-4; IKEDA Y, 1993, GEOCHIM COSMOCHIM AC, V57, P439, DOI 10.1016/0016-7037(93)90442-Y; KELLER LP, 1991, SCIENCE, V252, P946, DOI 10.1126/science.252.5008.946; KELLER LP, 1990, GEOCHIM COSMOCHIM AC, V54, P1155, DOI 10.1016/0016-7037(90)90446-R; KIMURA K, 1995, P NAT I POL RES S AN, V8, P123; Kimura M., 1996, METEORIT PLANET SCI, V31, pA70; KOJIMA T, 1993, METEORITICS, V28, P649, DOI 10.1111/j.1945-5100.1993.tb00636.x; Kojima T, 1996, GEOCHIM COSMOCHIM AC, V60, P2651, DOI 10.1016/0016-7037(96)00116-0; Krot AN, 1997, METEORIT PLANET SCI, V32, P31, DOI 10.1111/j.1945-5100.1997.tb01238.x; KROT AN, 1995, METEORITICS, V30, P738; MacPherson G.J., 1988, METEORITES EARLY SOL, P746; PECK JA, 1987, GEOCHIM COSMOCHIM AC, V51, P1503, DOI 10.1016/0016-7037(87)90332-2; TOMEOKA K, 1982, NATURE, V299, P326, DOI 10.1038/299326a0; TOMEOKA K, 1990, GEOCHIM COSMOCHIM AC, V54, P1787; VEBLEN DR, 1979, AM MINERAL, V64, P687; VEBLEN DR, 1980, AM MINERAL, V65, P599; WEINBRUCH S, 1990, METEORITICS, V25, P115, DOI 10.1111/j.1945-5100.1990.tb00983.x; YASUDA M, 1983, PHYS CHEM MINER, V9, P192, DOI 10.1007/BF00311954; ZOLENSKY M, 1993, GEOCHIM COSMOCHIM AC, V57, P3123, DOI 10.1016/0016-7037(93)90298-B; [No title captured]	30	75	75	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	1997	276	5315					1103	1105		10.1126/science.276.5315.1103	http://dx.doi.org/10.1126/science.276.5315.1103			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9148802				2022-12-28	WOS:A1997WZ22500041
J	Duan, XQ; Gimble, FS; Quiocho, FA				Duan, XQ; Gimble, FS; Quiocho, FA			Crystal structure of PI-Scel, a homing endonuclease with protein splicing activity	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-BINDING; RESTRICTION ENDONUCLEASES; ADENOSINE-TRIPHOSPHATASE; ANOMALOUS DIFFRACTION; SECONDARY STRUCTURE; CATALYTIC SUBUNIT; INTRON SEQUENCES; GENE; RECOGNITION	PI-Scel is a bifunctional yeast protein that propagates its mobile gene by catalyzing protein splicing and site specific DNA double-strand cleavage. Here, we report the 2.4 Angstrom crystal structure of the PI-Scel protein. The structure is composed of two separate domains (I and II) with novel folds and different functions. Domain I, which is elongated and formed largely from seven beta sheets, harbors the N and C termini residues and two His residues that are implicated in protein splicing. Domain II, which is compact and is primarily composed of two similar alpha/beta motifs related by local twofold symmetry, contains the putative nuclease active site with a cluster of two acidic residues and one basic residue commonly found in restriction endonucleases. This report presents prototypic structures of domains with single endonuclease and protein splicing active sites.	BAYLOR COLL MED,STRUCT & COMPUTAT BIOL & MOL BIOPHYS PROGRAM,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,HOUSTON,TX 77030; TEXAS A&M UNIV,CTR MACROMOL DESIGN INST BIOSCI & TECHNOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Texas A&M University System; Texas A&M University System			Wood, David W/B-2992-2012		NIGMS NIH HHS [R29 GM50815, GM08280] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008280, R29GM050815] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; BALDWIN GS, 1995, BIOCHEMISTRY-US, V34, P705, DOI 10.1021/bi00002a038; BELFORT M, 1989, TRENDS GENET, V5, P209, DOI 10.1016/0168-9525(89)90083-8; BREMER MCD, 1992, NUCLEIC ACIDS RES, V20, P5484, DOI 10.1093/nar/20.20.5484; BRUNGER AT, 1992, J APPL CRYSTALLOGR, V24, P958; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Gimble FS, 1996, J MOL BIOL, V263, P163, DOI 10.1006/jmbi.1996.0567; GIMBLE FS, 1995, J BIOL CHEM, V270, P5849, DOI 10.1074/jbc.270.11.5849; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GIMBLE FS, 1993, J BIOL CHEM, V268, P21844; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HENKE RM, 1995, EMBO J, V14, P5094, DOI 10.1002/j.1460-2075.1995.tb00191.x; HENSGENS LAM, 1983, CELL, V32, P379, DOI 10.1016/0092-8674(83)90457-9; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HODGES RA, 1992, NUCLEIC ACIDS RES, V20, P6153, DOI 10.1093/nar/20.23.6153; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; LAWSKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P282; LOIZOS N, 1994, P NATL ACAD SCI USA, V91, P11983, DOI 10.1073/pnas.91.25.11983; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; LykkeAndersen J, 1996, NUCLEIC ACIDS RES, V24, P3982, DOI 10.1093/nar/24.20.3982; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MUELLER JE, 1993, NUCLEASES, P111; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V47, P110; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SHELDRICK GM, 1991, ISOMORPHOUS REPLACEM; SKOWRON P, 1993, GENE, V125, P1, DOI 10.1016/0378-1119(93)90738-O; SOMERS WS, 1992, NATURE, V367, P754; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P697, DOI 10.1021/bi00002a037; WARING RB, 1982, P NATL ACAD SCI-BIOL, V79, P6332, DOI 10.1073/pnas.79.20.6332; WAUGH DS, 1993, P NATL ACAD SCI USA, V90, P9596, DOI 10.1073/pnas.90.20.9596; Wende W, 1996, NUCLEIC ACIDS RES, V24, P4123, DOI 10.1093/nar/24.21.4123; [No title captured]	48	234	259	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					555	564		10.1016/S0092-8674(00)80237-8	http://dx.doi.org/10.1016/S0092-8674(00)80237-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160747	Bronze			2022-12-28	WOS:A1997WZ32300009
J	Adams, DH; Hutchinson, IV				Adams, DH; Hutchinson, IV			Microchimerism and graft tolerance: Cause or effect?	LANCET			English	Editorial Material							BONE-MARROW; TRANSPLANTATION		UNIV MANCHESTER,SCH BIOL SCI,MANCHESTER M13 9PL,LANCS,ENGLAND	University of Manchester	Adams, DH (corresponding author), UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,LIVER RES LABS,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.		Adams, David H/C-9092-2009	Adams, David H/0000-0001-6776-0336				CHARLTON B, 1994, ANNU REV IMMUNOL, V12, P707, DOI 10.1146/annurev.immunol.12.1.707; Hutchinson I V, 1996, Adv Nephrol Necker Hosp, V25, P17; LU L, 1995, J EXP MED, V182, P379, DOI 10.1084/jem.182.2.379; ROLLES K, 1994, LANCET, V343, P263, DOI 10.1016/S0140-6736(94)91113-4; Schlitt HJ, 1997, TRANSPL P, V29, P82, DOI 10.1016/S0041-1345(96)00016-4; SRIWATANAWONGSA V, 1995, NAT MED, V1, P428, DOI 10.1038/nm0595-428; STARZL TE, 1993, HEPATOLOGY, V17, P1127; Strom TB, 1996, CURR OPIN IMMUNOL, V8, P688, DOI 10.1016/S0952-7915(96)80087-2; UEDA M, IN PRESS CLIN TRANSP; vanTwuyver E, 1996, TRANSPLANTATION, V61, P1392, DOI 10.1097/00007890-199605150-00019	10	26	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1336	1337		10.1016/S0140-6736(97)22019-2	http://dx.doi.org/10.1016/S0140-6736(97)22019-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149690				2022-12-28	WOS:A1997WY34200002
J	Zhang, FM; Basinski, MB; Beals, JM; Briggs, SL; Churgay, LM; Clawson, DK; DiMarchi, RD; Furman, TC; Hale, JE; Hsiung, HM; Schoner, BE; Smith, DP; Zhang, XY; Wery, JP; Schevitz, RW				Zhang, FM; Basinski, MB; Beals, JM; Briggs, SL; Churgay, LM; Clawson, DK; DiMarchi, RD; Furman, TC; Hale, JE; Hsiung, HM; Schoner, BE; Smith, DP; Zhang, XY; Wery, JP; Schevitz, RW			Crystal structure of the obese protein leptin-E100	NATURE			English	Article							RECEPTOR; GENE; MICE	Mutations in the obese gene (OB) or in the gene encoding the OB receptor(OB-R) result in obesity, infertility and diabetes in a variety of mouse phenotypes(1-7). The demonstration that OB protein (also known as leptin) can normalize body weight in ob/ob mice has generated enormous interests(8-11). Most human obesity does not appear to result from a mutant form of leptin: rather, serum leptin concentrations are increased and there is an apparent inability to transport it to the central nervous system (CNS)(12). Injection of leptin into the CNS of overfed rodents resistant to peripheral administration was found to induce biological activity(13). Consequently, for the leptin to act as a weight-lowering hormone in human obesity, it appears that appropriate concentrations must be present in the CNS. This places a premium on understanding the structure of the hormone in order to design more potent and selective agonists, Here we report the crystal structure at 2.4 Angstrom resolution of a human mutant OB protein (leptin-E100) that has comparable biological activity to wild type but which crystallizes more readily. The structure reveals a four-helix bundle similar to that of the long-chain helical cytokine family(14).			Zhang, FM (corresponding author), ELI LILLY & CO,LILLY RES LABS,ENDOCRINE RES DIV,RES TECHNOL & PROT,INDIANAPOLIS,IN 46285, USA.							Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HEEK MV, 1997, J CLIN INVEST, V99, P385; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5176; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MADEJ T, 1995, FEBS LETT, V373, P18; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK, P29; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Xu GY, 1996, J BIOMOL NMR, V8, P123; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	514	568	1	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					206	209		10.1038/387206a0	http://dx.doi.org/10.1038/387206a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144295				2022-12-28	WOS:A1997WX94500061
J	Stollberger, C; Finsterer, J; Bittner, RE				Stollberger, C; Finsterer, J; Bittner, RE			Angina for 14 years	LANCET			English	Article							PHOSPHOFRUCTOKINASE		KRANKENANSTALT RUDOLFSTIFTUNG WIEN,VIENNA,AUSTRIA; BOLTZMANN INST NEUROMUSKULARE ERKRANKUNGEN,VIENNA,AUSTRIA; UNIV VIENNA,INST ANAT,VIENNA,AUSTRIA	Rudolfstiftung Hospital; University of Vienna								AMIT R, 1992, MUSCLE NERVE, V15, P455, DOI 10.1002/mus.880150406; PERLOFF JK, 1984, HEART DISEASE, P1704; SHERMAN JB, 1994, AM J HUM GENET, V55, P305; Sivakumar K, 1996, NEUROLOGY, V46, P1337, DOI 10.1212/WNL.46.5.1337; WILMSHURST PT, 1990, BRIT HEART J, V63, P323	5	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1292	1292		10.1016/S0140-6736(97)02295-2	http://dx.doi.org/10.1016/S0140-6736(97)02295-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142065				2022-12-28	WOS:A1997WW89900012
J	Sweet, RL; Landers, DV				Sweet, RL; Landers, DV			Pelvic inflammatory disease in HIV-positive women	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS INFECTION				Sweet, RL (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,PITTSBURGH,PA 15213, USA.							Barbosa C, 1997, OBSTET GYNECOL, V89, P65, DOI 10.1016/S0029-7844(96)00387-0; HOEGSBERG B, 1990, AM J OBSTET GYNECOL, V163, P1135, DOI 10.1016/0002-9378(90)90671-S; KAMENGA MC, 1995, AM J OBSTET GYNECOL, V172, P919, DOI 10.1016/0002-9378(95)90022-5; KORN AP, 1993, OBSTET GYNECOL, V82, P765; KORN AP, 1996, PELVIC INFLAMMATORY; LEGA M, 1991, AIDS S1, V5, pS55	6	2	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1265	1266		10.1016/S0140-6736(05)62501-9	http://dx.doi.org/10.1016/S0140-6736(05)62501-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142056				2022-12-28	WOS:A1997WW89900003
J	Kurland, CG				Kurland, CG			Beating scientists into plowshares	SCIENCE			English	Editorial Material											Kurland, CG (corresponding author), BMC,DEPT BIOL MOL,BOX 590,S-75124 UPPSALA,SWEDEN.							Blumenthal D, 1996, NEW ENGL J MED, V335, P1734, DOI 10.1056/NEJM199612053352305; BRONOWSKI J, 1951, COMMON SENSE SCI; Bronowski J., 1977, SENSE FUTURE ESSAYS; Haber E, 1996, NAT BIOTECHNOL, V14, P441, DOI 10.1038/nbt0496-441; McGeary M, 1996, SCIENCE, V274, P1484, DOI 10.1126/science.274.5292.1484; McNeill W.H., 1982, PURSUIT POWER TECHNO; OSTHOLM I, 1996, NYA SKAPELSER LOSEC; Wallis JJ, 1986, LONG TERM FACTORS AM, P95	8	3	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					761	762		10.1126/science.276.5313.761	http://dx.doi.org/10.1126/science.276.5313.761			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9157556				2022-12-28	WOS:A1997WW90000048
J	Enerback, S; Jacobsson, A; Simpson, EM; Guerra, C; Yamashita, H; Harper, ME; Kozak, LP				Enerback, S; Jacobsson, A; Simpson, EM; Guerra, C; Yamashita, H; Harper, ME; Kozak, LP			Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese	NATURE			English	Article							BROWN ADIPOSE-TISSUE; INDUCED THERMOGENESIS; TARGETED DISRUPTION; ENERGY-EXPENDITURE; TRANSGENIC MICE; MESSENGER-RNAS; BLOOD-FLOW; FAT; RATS; GENE	The mitochondrial uncoupling protein (UCP) in the mitochondrial inner membrane of mammalian brown adipose tissue generates heat by uncoupling oxidative phosphorylation(1). This process protects against cold(2) and regulates energy balance(3). Manipulation of thermogenesis could be an effective strategy against obesity(4-9). Here we determine the role of UCP in the regulation of body mass by targeted inactivation of the gene encoding it. We find that UCP-deficient mice consume less oxygen after treatment with. a beta 3-adrenergic-receptor agonist and that they are sensitive to cold, indicating that their thermo-regulation is defective. However this deficiency caused neither hyperphagia nos obesity in mice fed on either a standard or a high-ibt diet, We propose that the loss of UCP may be compensated by UCP2, a newly discovered homologue of UCP; this gene is ubiquitously expressed and is induced in the brown fat of UCP-deficient mice.	JACKSON LAB, BAR HARBOR, ME 04609 USA; UNIV OTTAWA, FAC MED, DEPT BIOCHEM, OTTAWA, ON K1H 9M5, CANADA	Jackson Laboratory; University of Ottawa			Guerra, Carmen/K-5852-2014; Simpson, Elizabeth/H-1183-2012	Guerra, Carmen/0000-0002-3891-046X; Simpson, Elizabeth/0000-0002-0654-4303; Yamashita, Hitoshi/0000-0002-5785-5208; Harper, Mary-Ellen/0000-0003-3864-5886				BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BILLINGTON CJ, 1994, AM J PHYSIOL, V266, pR1765, DOI 10.1152/ajpregu.1994.266.6.R1765; CANNON B, 1977, FEBS LETT, V76, P284, DOI 10.1016/0014-5793(77)80169-5; CHAMPIGNY O, 1991, P NATL ACAD SCI USA, V88, P10774, DOI 10.1073/pnas.88.23.10774; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOSTER DO, 1979, CAN J PHYSIOL PHARM, V57, P257, DOI 10.1139/y79-039; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; HOLLOWAY BR, 1991, BRIT J PHARMACOL, V104, P97, DOI 10.1111/j.1476-5381.1991.tb12391.x; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Koza RA, 1996, ARCH BIOCHEM BIOPHYS, V336, P97, DOI 10.1006/abbi.1996.0536; KOZAK LP, 1983, P NATL ACAD SCI-BIOL, V80, P3020, DOI 10.1073/pnas.80.10.3020; KOZAK LP, 1991, GENE DEV, V5, P2256, DOI 10.1101/gad.5.12a.2256; KOZAK LP, 1988, J BIOL CHEM, V263, P12274; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lean M. E. J., 1986, BROWN ADIPOSE TISSUE, P339; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MA SWY, 1986, CAN J PHYSIOL PHARM, V64, P1252, DOI 10.1139/y86-211; Melnyk A, 1997, AM J PHYSIOL-REG I, V272, pR1088, DOI 10.1152/ajpregu.1997.272.4.R1088; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Thomas SA, 1997, NATURE, V387, P94, DOI 10.1038/387094a0; ZEVIANI M, 1988, GENE, V65, P1, DOI 10.1016/0378-1119(88)90411-8	31	1033	1062	1	45	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 1	1997	387	6628					90	94		10.1038/387090a0	http://dx.doi.org/10.1038/387090a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139827				2022-12-28	WOS:A1997WW75800053
J	Booy, R; Heath, PT; Slack, MPE; Begg, N; Moxon, ER				Booy, R; Heath, PT; Slack, MPE; Begg, N; Moxon, ER			Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster	LANCET			English	Article							HEMOPHILUS-INFLUENZAE; CAPSULAR POLYSACCHARIDE; PRP-T; DISEASE; EFFICACY; IMMUNIZATION; EPIDEMIOLOGY; MENINGITIS; CHILDREN; CARRIAGE	Background Diseases of early childhood associated with Haemophilus influenzae type b (Hib) can now be prevented by vaccination. The rapid implementation of routine infant vaccination with Hib polysaccharide-tetanus protein conjugate (PRP-T) vaccine has allowed us to assess whether an accelerated 2, 3, and 4 month schedule can protect in the longer term without a booster dose and whether carrier priming influences protective efficacy. The degree of protection afforded by a catch-up programme with Hib oligosaccharide conjugate (HbOC) for older children was also assessed. Methods Paediatricians and microbiologists in the UK were asked to report all cases of invasive H influenzae infection in children who had received at least one dose of Hib-conjugate vaccine. Serum samples from convalescent children were obtained and the isolate was verified. Efficacy was estimated by comparing observed rates of Hib disease in those who had been vaccinated with rates predicted by age adjustment of disease rates from the prevaccine era. Findings Of 164 reports of invasive infection between Oct 1, 1992, and Oct 1, 1995, 43 were considered true vaccine failures. The estimated overall efficacy for three doses of PRP-T was 98.1% (95% CI 97.3-98.7%). Efficacy in infants aged 5-11 months was 99.1%, 12-23 months 97.3%, and 24-35 months 94.7%. In infants aged 3-11 months, who received their first dose of PRP-T after tetanus toroid vaccination, disease was unlikely from 1 week after one dose of PRP-T vaccine (88.6% protection in the second to fourth weeks [66.8-97.7%]). The disease rate in vaccinated infants aged 2 months has declined year on year. In children aged 13 months to 2 years given HbOC, as a catch-up vaccine, the estimated efficacy was 94.0% (84.7-98.4%). Interpretation A high degree of efficacy has been observed with PRP-T vaccine given as a three-dose schedule in infancy and with HbOC as a single dose in older children. Efficacy of PRP-T appears to be enhanced by carrier priming. Although with increasing age there was a small decline in efficacy of PRP-T, Hib disease is now close to being eliminated in the UK, and we suggest that a booster is not necessary in the second year of life.	OXFORD RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD VACCINE GRP,OXFORD,ENGLAND; OXFORD RADCLIFFE HOSP,HAEMOPHILUS REFERENCE LAB,OXFORD,ENGLAND; OXFORD RADCLIFFE HOSP,PUBL HLTH LAB,OXFORD,ENGLAND; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND	University of Oxford; University of Oxford; University of Oxford; Public Health England	Booy, R (corresponding author), ST MARYS HOSP,DEPT PAEDIAT,PRAED ST,LONDON W2 1NY,ENGLAND.			Heath, Paul/0000-0002-7540-7433				ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; *ADV ASS, 1990, MARK POCK BOOK 1990, P10; BARBOUR ML, 1995, J INFECT DIS, V171, P93, DOI 10.1093/infdis/171.1.93; BLACK SB, 1987, PEDIATRICS, V79, P321; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; BOOY R, 1992, ARCH DIS CHILD, V67, P475, DOI 10.1136/adc.67.4.475; BOOY R, 1993, ARCH DIS CHILD, V69, P225, DOI 10.1136/adc.69.2.225; BOOY R, 1994, LANCET, V344, P362, DOI 10.1016/S0140-6736(94)91400-1; CATES KL, 1987, PEDIATR INFECT DIS J, V6, P512, DOI 10.1097/00006454-198706000-00004; CLEMENTS DA, 1993, PEDIATR INFECT DIS J, V12, P362, DOI 10.1097/00006454-199305000-00002; DEFEBRES OC, 1994, PEDIATR INFECT DIS J, V13, P635, DOI 10.1097/00006454-199407000-00010; DELAPORTE R, 1994, BRIT MED J, V308, P5; ESKOLA J, 1987, NEW ENGL J MED, V317, P717, DOI 10.1056/NEJM198709173171201; FALLA TJ, 1994, J CLIN MICROBIOL, V32, P2382, DOI 10.1128/JCM.32.10.2382-2386.1994; Gardner M. J., 1989, STAT CONFIDENCE; HOWARD AJ, 1991, BRIT MED J, V303, P441, DOI 10.1136/bmj.303.6800.441; KAHYTY H, 1991, AM J DIS CHILD, V145, P123; MOXON ER, 1981, J INFECT DIS, V143, P517, DOI 10.1093/infdis/143.4.517; NAZARETH B, 1992, COMM DIS REP REV, V2, P13; OBRIEN H, 1994, COMMUN DIS REP CDR R, V4, P17; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; TEARE EL, 1994, LANCET, V144, P828; URWIN G, 1994, BRIT MED J, V309, P1412, DOI 10.1136/bmj.309.6966.1412; WHITE JM, 1994, COMMUN DIS REP CDR R, V4, P51; WHITE JM, 1993, COMMUN DIS REP CDR R, V3, P117	27	96	103	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1197	1202		10.1016/S0140-6736(96)06392-1	http://dx.doi.org/10.1016/S0140-6736(96)06392-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130940				2022-12-28	WOS:A1997WW71700008
J	Falz, A				Falz, A			Health care under the Taliban	LANCET			English	Editorial Material											Falz, A (corresponding author), AMNESTY INT,LONDON,ENGLAND.								0	4	4	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1247	1248		10.1016/S0140-6736(05)62439-7	http://dx.doi.org/10.1016/S0140-6736(05)62439-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130961				2022-12-28	WOS:A1997WW71700045
J	Ramet, J; Benatar, A; Diltoer, M; Spapen, H; Huyghens, L				Ramet, J; Benatar, A; Diltoer, M; Spapen, H; Huyghens, L			Neonatal circumcision	LANCET			English	Letter											Ramet, J (corresponding author), FREE UNIV BRUSSELS,ACAD HOSP,INTENS CARE UNIT,B-1090 BRUSSELS,BELGIUM.		Benatar, Avram/AAO-7568-2020					AMBUEL B, 1992, J PEDIATR PSYCHOL, V17, P95, DOI 10.1093/jpepsy/17.1.95; McIntosh N, 1997, EUR J PEDIATR, V156, P173, DOI 10.1007/s004310050576; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0	3	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1257	1257		10.1016/S0140-6736(05)62457-9	http://dx.doi.org/10.1016/S0140-6736(05)62457-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130977				2022-12-28	WOS:A1997WW71700064
J	Lawrence, PA; Locke, M				Lawrence, PA; Locke, M			A man for our season	NATURE			English	Editorial Material									UNIV WESTERN ONTARIO,DEPT ZOOL,LONDON,ON N6A 5B7,CANADA	Western University (University of Western Ontario)	Lawrence, PA (corresponding author), MRC,MOL BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.			Lawrence, Peter/0000-0002-9554-8268				DARWIN C, 1903, MORE LETT C DARWIN, V1, P195; Henneberg M, 1996, NATURE, V384, P401, DOI 10.1038/384401b0; LAWRENCE PA, 1992, MAKING FLY, P211; LOCKE M, 1994, J INSECT PHYSIOL, V40, P823, DOI 10.1016/0022-1910(94)90014-0; LOCKE M, 1996, BIOGR MEM R SOC, V42, P541; MONTGOMERY S, 1995, SCI VOICE; WATSON JD, 1953, NATURE, V171, P964, DOI 10.1038/171964b0; WIGGLESW.VB, 1967, ANN APPL BIOL, V60, P1, DOI 10.1111/j.1744-7348.1967.tb05916.x; WIGGLESWORTH VB, 1957, PARASITOLOGY, V47, P1, DOI 10.1017/S0031182000021697; WIGGLESWORTH VB, 1950, ADV SCI, V26, P1; WIGGLESWORTH VB, 1961, INSECT POLYM, P104	11	9	9	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					757	758		10.1038/386757a0	http://dx.doi.org/10.1038/386757a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126726				2022-12-28	WOS:A1997WV70600024
J	Weetman, AP				Weetman, AP			Fortnightly review - Hypothyroidism: Screening and subclinical disease	BRITISH MEDICAL JOURNAL			English	Review							L-THYROXINE TREATMENT; POSTPARTUM THYROIDITIS; DOUBLE-BLIND; RISK FACTOR; FOLLOW-UP; DEPRESSION; HYPERTHYROIDISM; ASSOCIATION; DYSFUNCTION; THYROTROPIN				Weetman, AP (corresponding author), UNIV SHEFFIELD,NO GEN HOSP,CTR CLIN SCI,DEPT MED,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.							COOPER DS, 1984, ANN INTERN MED, V101, P18, DOI 10.7326/0003-4819-101-1-18; Danese MD, 1996, JAMA-J AM MED ASSOC, V276, P285, DOI 10.1001/jama.276.4.285; FABER J, 1994, EUR J ENDOCRINOL, V130, P350, DOI 10.1530/eje.0.1300350; FRANKLYN J, 1994, CLIN ENDOCRINOL, V41, P425, DOI 10.1111/j.1365-2265.1994.tb02572.x; Giani C, 1996, J CLIN ENDOCR METAB, V81, P990, DOI 10.1210/jc.81.3.990; HAGGERTY JJ, 1990, INT J PSYCHIAT MED, V20, P193, DOI 10.2190/ADLY-1UU0-1A8L-HPXY; HAGGERTY JJ, 1993, AM J PSYCHIAT, V150, P508; HALL R, 1995, BAILLIERE CLIN ENDOC, V9, P137, DOI 10.1016/S0950-351X(95)80883-3; HARRIS B, 1992, BMJ-BRIT MED J, V305, P152, DOI 10.1136/bmj.305.6846.152; HELFAND M, 1990, ANN INTERN MED, V112, P840, DOI 10.7326/0003-4819-112-11-840; HOWLAND RH, 1993, J CLIN PSYCHIAT, V54, P47; JOFFE RT, 1992, PSYCHONEUROENDOCRINO, V17, P215, DOI 10.1016/0306-4530(92)90060-K; KUNG AWC, 1995, CLIN ENDOCRINOL, V43, P445, DOI 10.1111/j.1365-2265.1995.tb02616.x; MISIUNAS A, 1995, THYROID, V5, P283, DOI 10.1089/thy.1995.5.283; MONZANI F, 1993, CLIN INVESTIGATOR, V71, P367; NYSTROM E, 1988, CLIN ENDOCRINOL, V29, P63, DOI 10.1111/j.1365-2265.1988.tb00250.x; Oomen HAPC, 1996, CLIN ENDOCRINOL, V45, P215, DOI 10.1046/j.1365-2265.1996.d01-1558.x; OTHMAN S, 1990, CLIN ENDOCRINOL, V32, P559, DOI 10.1111/j.1365-2265.1990.tb00898.x; RAE P, 1993, BRIT MED J, V307, P177, DOI 10.1136/bmj.307.6897.177; ROTI E, 1993, ENDOCR REV, V14, P401, DOI 10.1210/er.14.4.401; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; SINGER PA, 1995, JAMA-J AM MED ASSOC, V273, P808, DOI 10.1001/jama.273.10.808; STAUB JJ, 1992, AM J MED, V92, P631, DOI 10.1016/0002-9343(92)90782-7; SURKS MI, 1996, MA J MED, V100, P217; Tanis BC, 1996, CLIN ENDOCRINOL, V44, P643, DOI 10.1046/j.1365-2265.1996.739560.x; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; Vanderpump MPJ, 1996, BMJ-BRIT MED J, V313, P539; Vanderpump MPJ, 1996, THYROID, V6, P155; WEETMAN AP, 1994, J CLIN ENDOCR METAB, V79, P7, DOI 10.1210/jc.79.1.7; WHITE AJ, 1988, J PSYCHOSOM RES, V32, P99, DOI 10.1016/0022-3999(88)90093-1	30	84	93	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 19	1997	314	7088					1175	1178		10.1136/bmj.314.7088.1175	http://dx.doi.org/10.1136/bmj.314.7088.1175			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV705	9146393	Green Published			2022-12-28	WOS:A1997WV70500028
J	Dennis, M; ORourke, S; Slattery, J; Staniforth, T; Warlow, C				Dennis, M; ORourke, S; Slattery, J; Staniforth, T; Warlow, C			Evaluation of a stroke family care worker: Results of a randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							INTERVENTION; SCALE; ADJUSTMENT	Objective: To examine the effect of contact with a stroke family care worker on the physical, social, and psychological status of stroke patients and their carers. Design: Randomised controlled trial with broad entry criteria and blinded outcome assessment six months after randomisation. Setting: A well organised stroke service in an Edinburgh teaching hospital Subjects: 417 patients with an acute stroke in the previous 30 days randomly allocated to be contacted by a stroke family care worker (210) or to receive standard care (207). The patients represented 67% of all stroke patients assessed at the hospital during the study period. Main outcome measures: Patient completed Barthel index, Frenchay activities index, general health questionnaire, hospital anxiety and depression scale, social adjustment scale, mental adjustment to stroke scale, and patient satisfaction questionnaire; carer completed Frenchay activities index, general health questionnaire, hospital anxiety and depression scale, social adjustment scale, caregiving hassles scale, and carer satisfaction questionnaire. Results: The groups were balanced for all important baseline variables. There were no significant differences in physical outcomes in patients or carers, though patients in the treatment group were possibly more helpless', less well adjusted socially, and more depressed, whereas carers in the treatment group were possibly less hassled and anxious. However, both patients and carers in the group contacted by the stroke family care worker expressed significantly greater satisfaction with certain aspects of their care, in particular those related to communication and support. Conclusions: The introduction of a stroke family care worker improved patients' and their carers' satisfaction with services and may have had some effect on psychological and social outcomes but did not improve measures of patients' physical wellbeing.			Dennis, M (corresponding author), UNIV EDINBURGH,DEPT CLIN NEUROSCI,WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.			O'Rourke, Suzanne/0000-0003-4027-675X				ANDERSON CS, 1995, STROKE, V26, P843, DOI 10.1161/01.STR.26.5.843; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; CHRISTIE D, 1984, COMMUNITY HEALTH ST, V8, P26; EVANS RL, 1988, STROKE, V19, P1243, DOI 10.1161/01.STR.19.10.1243; Forster A, 1996, BRIT MED J, V312, P1642, DOI 10.1136/bmj.312.7047.1642; FRIEDLAND JF, 1992, ARCH PHYS MED REHAB, V73, P573; Goldberg DP., 1972, DETECTION PSYCHIATRI; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; HOLBROOK M, 1982, J ROY COLL PHYS LOND, V16, P100; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; HOUSE A, 1991, BRIT J PSYCHIAT, V158, P83, DOI 10.1192/bjp.158.1.83; KINNEY JM, 1989, GERONTOLOGIST, V29, P328, DOI 10.1093/geront/29.3.328; Mahoney F, 1965, MD STATE MED J, V14, P62; POUND P, 1995, BMJ-BRIT MED J, V311, P18, DOI 10.1136/bmj.311.6996.18; POUND P, 1994, CLIN REHABIL, V8, P7, DOI DOI 10.1177/026921559400800102; TOWLE D, 1989, J NEUROL NEUROSUR PS, V52, P519, DOI 10.1136/jnnp.52.4.519; WARLOW C, 1995, STROKE MODULE COCHRA; WATSON M, 1988, PSYCHOL MED, V18, P203, DOI 10.1017/S0033291700002026; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	21	173	174	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 12	1997	314	7087					1071	1076		10.1136/bmj.314.7087.1071	http://dx.doi.org/10.1136/bmj.314.7087.1071			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WU236	9133884	Green Published			2022-12-28	WOS:A1997WU23600018
J	Shanahan, F				Shanahan, F			Immunology - A gut reaction: Lymphoepithelial communication in the intestine	SCIENCE			English	Editorial Material							T-CELL DEVELOPMENT; EPITHELIAL-CELLS				Shanahan, F (corresponding author), NATL UNIV IRELAND,CORK UNIV HOSP,DEPT MED,CORK,IRELAND.			Shanahan, Fergus/0000-0003-0467-0936				BLALOCK JE, 1994, IMMUNOL TODAY, V15, P504, DOI 10.1016/0167-5699(94)90205-4; BOISMENU R, 1994, SCIENCE, V266, P1253, DOI 10.1126/science.7973709; Iwamoto M, 1996, J PATHOL, V180, P152; Klein JR, 1996, J EXP MED, V184, P1203, DOI 10.1084/jem.184.4.1203; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P6147, DOI 10.1073/pnas.92.13.6147; LEFRANCOIS L, 1995, IMMUNOL TODAY, V16, P16, DOI 10.1016/0167-5699(95)80065-4; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; PERDUE MH, 1994, AM J PHYSIOL, V267, pG151, DOI 10.1152/ajpgi.1994.267.2.G151; POUSSIER P, 1994, ANNU REV IMMUNOL, V12, P521, DOI 10.1146/annurev.immunol.12.1.521; PUDDINGTON L, 1994, IMMUNITY, V1, P733, DOI 10.1016/S1074-7613(94)80015-4; REINECKER HC, 1995, P NATL ACAD SCI USA, V92, P8353, DOI 10.1073/pnas.92.18.8353; ROCHA B, 1995, CURR OPIN IMMUNOL, V7, P235, DOI 10.1016/0952-7915(95)80008-5; SHANAHAN F, 1994, GUT PEPTIDES BIOCH P, P851; Shanahan Fergus, 1994, P643; WANG J, 1994, SCIENCE, V265, P1860, DOI 10.1126/science.8091211; Wang J, 1997, SCIENCE, V275, P1937, DOI 10.1126/science.275.5308.1937; Wang J, 1996, INT IMMUNOL, V8, P231, DOI 10.1093/intimm/8.2.231; WANG J, 1995, CELL IMMUNOL, V161, P299, DOI 10.1006/cimm.1995.1040; WATANABE M, 1995, J CLIN INVEST, V95, P2945, DOI 10.1172/JCI118002	19	25	26	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1897	1898		10.1126/science.275.5308.1897	http://dx.doi.org/10.1126/science.275.5308.1897			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9122691				2022-12-28	WOS:A1997WQ51300032
J	Reynolds, PP				Reynolds, PP			Hospitals and civil rights, 1945-1963: The case of Simkins v Moses H Cone Memorial Hospital	ANNALS OF INTERNAL MEDICINE			English	Article								In the 1960s, the legacy of discrimination against black persons still existed in all areas of medicine, This historical analysis investigates the strategies that were used by lawyers alongside physicians, dentists, and patients in elevating health care for black persons. Primary resources include oral histories, government documents, hospital records, archival and personal manuscripts, and professional and hospital periodicals. After World War II, leaders in the black community were determined to improve health care for black persons by ending discrimination in hospital policies and practices. Leaders of professional organizations developed a collaborative strategy that involved the court system, federal legislation, and research and education of the public and health professionals to integrate the hospital system rather than to expand the existing separate-but-equal system. Efforts culminated in the case of Simkins v Moses H. Cone Memorial Hospital; this case became the landmark decision by the U.S. Supreme Court and led to the elimination of segregated health care. Three months after the case, President Johnson ratified the Civil Rights Act of 1964, which included Title VI, thus extending the policy of equality to all federal programs. Laying a foundation for universal access to health care in the United States depended on a victory in the courts, in national health legislation, and in public opinion. All were achieved through strategic efforts to amass widespread support for the elimination of discrimination in medicine.	JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA; UNIV PENN, PHILADELPHIA, PA 19104 USA	Johns Hopkins University; University of Pennsylvania								Beardsley Edward H., 1987, HIST NEGLECT HLTH CA; Chafe William H, 1980, CIVILITIES CIVIL RIG; COBB W M, 1953, J Natl Med Assoc, V45, P333; COBB W M, 1953, J Natl Med Assoc, V45, P130; COBB W M, 1957, J Natl Med Assoc, V49, P1; COBB WM, 1953, J NATL MED ASSOC, V45, P284; COBB WM, 1948, CRISIS, V55, P107; CORNELY P B, 1957, J Natl Med Assoc, V49, P8; DOBB WM, 1947, CRISIS, V54, P201; EATON HA, 1954, COMMUNICATION   1105; EATON HA, 1955, COMMUNICATION   0310; EATON HA, 1959, COMMUNICATION   0904; EATON HA, 1958, COMMUNICATION   1203; Eaton HA., 1984, EVERY MAN SHOULD TRY; FLEMING AS, COMMUNICATION; GAMLE VN, 1995, MAKING PLACE OURSELV; GREENBERG J, 1959, COMMUNICATION   0130; GREENBERG J, 1959, COMMUNICATION   0514; GREENBERG J, 1960, COMMUNICATION   0324; GREENBERG J, 1959, COMMUNICATION   0505; GREENBERG J, 1960, COMMUNICATION   0304; *N CAR MED CAR COM, 1961, COMPL LIST N CAR HOS, P4; PEARSON CO, 1955, COMMUNICATION   1017; PEARSON CO, 1956, COMMUNICATION   0116; PEARSON CO, 1956, COMMUNICATION   0127; PEARSON CO, 1956, COMMUNICATION   0206; PEARSON CO, 1955, COMMUNCIATION   1011; PEARSON CO, 1959, COMMUNICATION   0813; PEARSON CO, 1958, COMMUNICATION   1210; QUIGLEY JM, COMMUNICATION; Reitzes Dietrich C., 1958, NEGROES MED; Resnik Henry S, 1970, PUBLIC POLICY BLACK; REYNODLS PP, 1991, WATTS HOSPITAL DURHA; REYNOLDS PP, 1986, WATTS HOSPITAL DURHA; RWAN CR, 1993, DREAM MAKERS DREAM B; SEHAM M, 1964, NEW ENGL J MED, V271, P940, DOI 10.1056/NEJM196410292711806; SHORTER H B, 1965, J Natl Med Assoc, V57, P59; SIMKISN GA, 1960, COMMUNICATION   0330; SIMKISN GC, 1960, COMMUNICATION   0317; SIMKISN GC, 1960, COMMUNICATION   0314; *US COMM CIV RIGHS, 1960, EQ PROF LAWS PUBL HI, P12; *US COMM CIV RIGHT, 1965, EQ OPP HOSP HLTH FAC; *US COMM CIV RIGHT, 1966, MED CAR COMM; *US COMM CIV RIGHT, 1963, CIV RIGHTS 63, P11; WILKINS R, 1963, CRISIS, P261; 1965, J NATL MED ASSOC, V57, P60; 1963, HOSPITALS, V37, P20; 1968, G WASHINGTON LAW REV, V36, P824; 1962, HOSPITALS, V36, P96; 1964, J NATL MED ASSOC, V56, P445; 1965, MOD HOSP, V105, P22; 1963, MED WORLD NEWS   NOV, P54	52	37	37	2	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1997	126	11					898	906		10.7326/0003-4819-126-11-199706010-00009	http://dx.doi.org/10.7326/0003-4819-126-11-199706010-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XA911	9163292				2022-12-28	WOS:A1997XA91100008
J	Bishop, NJ; Morley, R; Chir, B; Day, JP; Lucas, A				Bishop, NJ; Morley, R; Chir, B; Day, JP; Lucas, A			Aluminum neurotoxicity in preterm infants receiving intravenous-feeding solutions	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIALYSIS ENCEPHALOPATHY; PARENTERAL-NUTRITION; MILK FORMULAS; TOXICITY; OSTEODYSTROPHY; BONE	Background Aluminum, a contaminant of commercial intravenous-feeding solutions, is potentially neurotoxic. We investigated the effect of perinatal exposure to intravenous aluminum on the neurologic development of infants born prematurely. Methods We randomly assigned 227 premature infants with gestational ages of less than 34 weeks and birth weights of less than 1850 g who required intravenous feeding before they could begin enteral feeding to receive either standard or specially constituted, aluminum-depleted intravenous-feeding solutions. The neurologic development of the 182 surviving infants who could be tested was assessed by using the Bayley Scales of Infant Development at 18 months of age. Results The 90 infants who received the standard feeding solutions had a mean (+/- SD) Bayley Mental Development index of 95 +/- 22, as compared with 98 +/- 20 for the 92 infants who received the aluminum-depleted solutions (P=0.39). In a planned subgroup analysis of infants in whom the duration of intravenous feeding exceeded the median and who did not have neuromotor impairment, the mean values for the Bayley Mental Development Index for the 39 infants who received the standard solutions and the 41 infants who received the aluminum-depleted solutions were 92 +/- 20 and 102 +/- 17, respectively (P=0.2). The former were significantly more likely (39 percent, vs, 17 percent of the latter group; P=0.03) to have a Mental Development Index of less than 85, increasing their risk of subsequent educational problems. For all 157 infants without neuromotor impairment, increasing aluminum exposure was associated with a reduction in the Mental Development Index (P=0.03), with an adjusted loss of one point per day of intravenous feeding for infants receiving the standard solutions. Conclusions In preterm infants, prolonged intravenous feeding with solutions containing aluminum is associated with impaired neurologic development. (C) 1997, Massachusetts Medical Society.	MRC,DUNN NUTR UNIT,CAMBRIDGE CB4 1XJ,ENGLAND; UNIV CAMBRIDGE,DEPT PAEDIAT,CAMBRIDGE,ENGLAND; MRC,CHILDHOOD NUTR RES CTR,INST CHILD HLTH,LONDON,ENGLAND; UNIV MANCHESTER,DEPT CHEM,MANCHESTER M13 9PL,LANCS,ENGLAND	University of Cambridge; University of London; University College London; University of Manchester					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALFREY AC, 1976, NEW ENGL J MED, V294, P184, DOI 10.1056/NEJM197601222940402; *AM AC PED COMM NU, 1986, PEDIATRICS, V78, P1150; AMIELTISON C, 1989, ARCH DIS CHILD-FETAL, V64, P496, DOI 10.1136/adc.64.4_Spec_No.496; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; BETTINELLI A, 1987, INT J ARTIF ORGANS, V10, P131, DOI 10.1177/039139888701000214; BISHOP NJ, 1989, ARCH DIS CHILD, V64, P1316, DOI 10.1136/adc.64.9.1316; BOUGLE D, 1992, JPEN-PARENTER ENTER, V16, P157, DOI 10.1177/0148607192016002157; BOYCE BF, 1982, LANCET, V2, P1009; FAUGERE MC, 1986, J LAB CLIN MED, V107, P481; Gruskin A B, 1988, Adv Pediatr, V35, P281; KOO WWK, 1989, JPEN-PARENTER ENTER, V13, P516, DOI 10.1177/0148607189013005516; KOO WWK, 1992, PEDIATRICS, V89, P877; KOO WWK, 1986, J PEDIATR-US, V109, P877, DOI 10.1016/S0022-3476(86)80718-1; KOO WWK, 1988, J AM COLL NUTR, V7, P199, DOI 10.1080/07315724.1988.10720237; LUCAS A, 1990, LANCET, V335, P1477, DOI 10.1016/0140-6736(90)93026-L; MCGRAW M, 1986, LANCET, V1, P157; MORENO A, 1994, ACTA PAEDIATR, V83, P25, DOI 10.1111/j.1651-2227.1994.tb12947.x; NATHAN E, 1980, ACTA PAEDIATR SCAND, V69, P793, DOI 10.1111/j.1651-2227.1980.tb07155.x; OHARE JA, 1983, MEDICINE, V62, P129, DOI 10.1097/00005792-198305000-00001; PUNTIS JWL, 1986, LANCET, V2, P1332; ROBINSON MJ, 1987, LANCET, V2, P1206; SALUSKY IB, 1991, MINER ELECTROL METAB, V17, P273; SEDMAN AB, 1985, NEW ENGL J MED, V312, P1337, DOI 10.1056/NEJM198505233122101; SEDMAN AB, 1984, J PEDIATR-US, V105, P836, DOI 10.1016/S0022-3476(84)80318-2; WARD MK, 1978, LANCET, V1, P841; WILLS MR, 1989, CRIT REV CL LAB SCI, V27, P59, DOI 10.3109/10408368909106590	26	174	183	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	1997	336	22					1557	1561		10.1056/NEJM199705293362203	http://dx.doi.org/10.1056/NEJM199705293362203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB087	9164811	Bronze			2022-12-28	WOS:A1997XB08700003
J	Herwaldt, BL; Ackers, ML; Farrar, J; Richardson, S; Nelson, R; Fletcher, M; Levy, M; Katz, D; Kumar, S; Malecki, J; Lowdermilk, M; Mackey, L; Bell, J; Portesi, D; Lacey, C; Letendre, L; Hamlin, D; Knowlton, R; Barry, A; Chew, D; Finelli, L; Genese, C; Miller, J; Layton, M; Guzewich, J; Salehi, E; Weltman, A; Caceres, V; Ball, R; Barnett, B; Hendricks, K; Taylor, J; Bell, R; Schoenfeld, S; Bryan, F; Neamatullah, S; Werker, D; Manuel, D; LeBer, C; Arrieta, M; Morrison, D; Klein, R; Wahlquist, S; Alfano, E; Eberhard, M; Arrowood, M; HannakDonaldson, K; Beach, M; Kramer, M; Hightower, A; Swerdlow, D; Winickoff, J; Shapiro, R; Messonnier, M				Herwaldt, BL; Ackers, ML; Farrar, J; Richardson, S; Nelson, R; Fletcher, M; Levy, M; Katz, D; Kumar, S; Malecki, J; Lowdermilk, M; Mackey, L; Bell, J; Portesi, D; Lacey, C; Letendre, L; Hamlin, D; Knowlton, R; Barry, A; Chew, D; Finelli, L; Genese, C; Miller, J; Layton, M; Guzewich, J; Salehi, E; Weltman, A; Caceres, V; Ball, R; Barnett, B; Hendricks, K; Taylor, J; Bell, R; Schoenfeld, S; Bryan, F; Neamatullah, S; Werker, D; Manuel, D; LeBer, C; Arrieta, M; Morrison, D; Klein, R; Wahlquist, S; Alfano, E; Eberhard, M; Arrowood, M; HannakDonaldson, K; Beach, M; Kramer, M; Hightower, A; Swerdlow, D; Winickoff, J; Shapiro, R; Messonnier, M			An outbreak in 1996 of cyclosporiasis associated with imported raspberries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOREIGN RESIDENTS; UNITED-STATES; DIARRHEA; EPIDEMIOLOGY; TRAVELERS; ORGANISM; NEPAL	Background Cyclospora cayetanensis is a parasite that causes gastroenteritis. Until last year most of the documented cases of cyclosporiasis in North America were in overseas travelers. In 1996, a large outbreak of cyclosporiasis occurred in North America. We investigated this outbreak. Methods Health departments solicited information from clinicians and laboratories on cases of cyclosporiasis, which were then reported to the Centers for Disease Control and Prevention and to Health Canada. We conducted retrospective cohort studies for the cases associated with events (e.g., luncheons) and attempted to identify the sources of the implicated food. Results A total of 1465 cases of cyclosporiasis were reported by 20 states, the District of Columbia, and 2 provinces. Of these cases, 978 (66.8 percent) were laboratory confirmed and 725 (49.5 percent) were associated with 55 events that were held from May 3 through June 14. Raspberries were definitely served at 50 events and may have been served at 4 events, For 27 of the 41 events for which adequate data were available (65.8 percent), the associations between the consumption of berries (raspberries with or without other berries) and cyclosporiasis were statistically significant (P<0.05). For all 29 events for which there were good data, the raspberries definitely came from Guatemala (21 events, 72.4 percent) or may have come from Guatemala (8 events, 27.6 percent). As few as five Guatemalan farms could have accounted for the 25 events for which the raspberries could be traced to a single exporter per event. The mode of contamination of the raspberries remains unclear. Conclusions This large outbreak of cyclosporiasis in North America in 1996 was associated with the consumption of Guatemalan raspberries. The outbreak illustrates the need to consider that a local cluster of foodborne illness may be part of a widespread outbreak and to pursue investigations of the source of the implicated vehicle. (C) 1997, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, EPIDEM INTELLIGENCE SERV, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30341 USA; CONNECTICUT DEPT PUBL HLTH & ADDICT SERV, HARTFORD, CT 06106 USA; FLORIDA DEPT HLTH & REHABIL SERV, TALLAHASSEE, FL 32399 USA; PALM BEACH CTY HLTH DEPT, W PALM BEACH, FL USA; LAKE CTY HLTH DEPT, WAUKEGAN, IL USA; MARYLAND DEPT HLTH & MENTAL HYG, BALTIMORE, MD 21201 USA; MONTGOMERY CTY DEPT HLTH & HUMAN SERV, ROCKVILLE, MD USA; MASSACHUSETTS DEPT PUBL HLTH, BOSTON, MA 02111 USA; BOSTON DEPT HLTH & HOSP, BOSTON, MA USA; NEW JERSEY DEPT HLTH & SENIOR SERV, TRENTON, NJ USA; NEW YORK CITY DEPT HLTH, ALBANY, NY 12237 USA; NEW YORK STATE DEPT HLTH, ALBANY, NY 12237 USA; OHIO DEPT HLTH, COLUMBUS, OH 43266 USA; PENN DEPT HLTH, HARRISBURG, PA 17108 USA; S CAROLINA DEPT HLTH & ENVIRONM CONTROL, COLUMBIA, SC 29201 USA; TEXAS DEPT HLTH, AUSTIN, TX 78756 USA; HOUSTON DEPT HLTH & HUMAN SERV, HOUSTON, TX USA; VERMONT DEPT HLTH, BURLINGTON, VT 05402 USA; HLTH CANADA, OTTAWA, ON, CANADA; DEPT PUBL HLTH, ALBANY, NY 12237 USA; ONTARIO MINIST HLTH, TORONTO, ON, CANADA; MONTREAL CHILDRENS HOSP, MONTREAL, PQ H3H 1P3, CANADA; MED ENTOMOL RES & TRAINING UNIT, GUATEMALA CITY, GUATEMALA; CDC, NATL CTR INFECT DIS, DIV PARASIT DIS, ATLANTA, GA 30333 USA; CDC, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, ATLANTA, GA 30333 USA; CDC, NATL CTR INFECT DIS, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Florida Department of Health; Maryland Department of Health & Mental Hygiene; Massachusetts Department of Public Health; New Jersey Department of Health & Senior Services; New York City Department of Health & Mental Hygiene; State University of New York (SUNY) System; Texas Department of State Health Services; Health Canada; McGill University; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Herwaldt, BL (corresponding author), CTR DIS CONTROL & PREVENT, EPIDEMIOL BRANCH, DIV PARASIT DIS, 4770 BUFORD HWY NE, MAILSTOP F22, ATLANTA, GA 30341 USA.		Finelli, Lyn/AAK-2360-2020					ASHFORD RW, 1979, ANN TROP MED PARASIT, V73, P497, DOI 10.1080/00034983.1979.11687291; BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; Blaser MJ, 1996, NEW ENGL J MED, V334, P1324, DOI 10.1056/NEJM199605163342009; Carter R., 1996, 30 INT C ANT AG CHEM, P259; CHALKER RB, 1988, REV INFECT DIS, V10, P111; CHEW D, 1996, 36 INT C ANT AG CHEM; Colley DG, 1996, EMERG INFECT DIS, V2, P354, DOI 10.3201/eid0204.960413; *COMM COMM DIS AFF, 1991, PROC IMPL HAZ AN CRI, P1; CONNOR BA, 1995, LANCET, V346, P1634, DOI 10.1016/S0140-6736(95)91972-4; *DEP AGR, IN PRESS FRESH FRUIT; FLEMING C, 1996, 36 INT C ANT AG CHEM, P11; GARCIA LS, 1997, DIAGNOSTIC MED PARAS, P66; GarciaLopez HL, 1996, EMERG INFECT DIS, V2, P356, DOI 10.3201/eid0204.960414; HART AS, 1990, LANCET, V335, P169, DOI 10.1016/0140-6736(90)90042-4; HEDBERG CW, 1994, CLIN INFECT DIS, V18, P671, DOI 10.1093/clinids/18.5.671; HOGE CW, 1995, LANCET, V345, P691, DOI 10.1016/S0140-6736(95)90868-4; HOGE CW, 1993, LANCET, V341, P1175, DOI 10.1016/0140-6736(93)91002-4; Hoge CW, 1995, LANCET, V345, P1060; HUANG P, 1995, ANN INTERN MED, V123, P409, DOI 10.7326/0003-4819-123-6-199509150-00002; KATZ D, 1996, 124 ANN M EXP AM PUB; KOUMANS EH, 1996, 45 ANN EP INT SERV E, P60; *NAT ADV COMM MICR, 1992, INT J FOOD MICROBIOL, V16, P1; NEAMATULLAH S, 1996, 64 CONJ M INF DIS HA, pM6; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; Pieniazek NJ, 1996, EMERG INFECT DIS, V2, P357, DOI 10.3201/eid0204.960415; RABOLD JG, 1994, LANCET, V344, P1360, DOI 10.1016/S0140-6736(94)90716-1; Relman DA, 1996, J INFECT DIS, V173, P440, DOI 10.1093/infdis/173.2.440; ROBBINS JA, 1988, J AM SOC HORTIC SCI, V113, P474; ROXAS C, 1996, 96 GEN M AM SOC MICR, P19; Smith HV, 1996, VET REC, V138, P528; Soave R, 1996, CLIN INFECT DIS, V23, P429, DOI 10.1093/clinids/23.3.429; Sun T, 1996, AM J CLIN PATHOL, V105, P216; Tauxe RV, 1996, BMJ-BRIT MED J, V313, P1093, DOI 10.1136/bmj.313.7065.1093; Visvesvara GS, 1997, J CLIN MICROBIOL, V35, P730, DOI 10.1128/JCM.35.3.730-733.1997; ZERPA R, 1995, J TROP MED HYG, V98, P325; 1991, MMWR-MORBID MORTAL W, V40, P325; 1996, MMWR-MORBID MORTAL W, V45, P611; 1996, MMWR MORTAL WKLY REP, V45, P549	38	271	286	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 29	1997	336	22					1548	1556		10.1056/NEJM199705293362202	http://dx.doi.org/10.1056/NEJM199705293362202			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB087	9164810				2022-12-28	WOS:A1997XB08700002
J	Ni, JW; Tien, AL; Fournier, MJ				Ni, JW; Tien, AL; Fournier, MJ			Small nucleolar RNAs direct site-specific synthesis of pseudouridine in ribosomal RNA	CELL			English	Article							SMALL NUCLEAR RNAS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PEPTIDYLTRANSFERASE CENTER; SYNTHASE; PURIFICATION; RESIDUES; CLONING; SNRNAS; U8	Ten ACA yeast small nucleolar RNAs (snoRNAs) were shown to be required for site-specific synthesis of pseudouridine (psi) in ribosomal RNA. A common secondary folding motif for the snoRNAs and rRNA target segments predicts that site selection involves: (1) base pairing of the snoRNA with complementary rRNA elements flanking the site of modification, and (2) identification of a uridine located at a near-constant distance from the snoRNA ACA box. The model is supported by mutations showing that: (1) reducing the complementarity between the snoRNA and rRNA disrupts psi formation, and (2) altering the distance between the ACA box and target uridine causes an adjacent uridine to be modified. This discovery implies that most snoRNAs function in targeting nucleotide modification in rRNA: ribose methylation for the box C/D snoRNAs and psi formation for the ACA snoRNAs.	UNIV MASSACHUSETTS,PROGRAM MOL & CELLULAR BIOL,DEPT BIOCHEM & MOL BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst					NIGMS NIH HHS [GM 19351] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019351] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; BAKIN A, 1995, NUCLEIC ACIDS RES, V23, P3290, DOI 10.1093/nar/23.16.3290; BAKIN A, 1994, BIOCHEMISTRY-US, V33, P13475, DOI 10.1021/bi00249a036; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; BALAKIN AG, 1993, NUCLEIC ACIDS RES, V21, P5391, DOI 10.1093/nar/21.23.5391; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; CLARKE MW, 1990, J CELL BIOL, V11, P1741; Enright CA, 1996, RNA, V2, P1094; Enright CA, 1996, RNA, V2, P1318; Goldwasser E, 1966, Prog Nucleic Acid Res Mol Biol, V5, P399, DOI 10.1016/S0079-6603(08)60241-X; HUANG GM, 1992, MOL CELL BIOL, V12, P4456, DOI 10.1128/MCB.12.10.4456; KAMMEN HO, 1988, J BIOL CHEM, V263, P2255; Kiss T, 1996, MOL CELL BIOL, V16, P1391; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; LANE BG, 1992, FEBS LETT, V302, P1, DOI 10.1016/0014-5793(92)80269-M; LANE BG, 1995, BIOCHIMIE, V77, P7, DOI 10.1016/0300-9084(96)88098-9; Lygerou Z, 1996, SCIENCE, V272, P268, DOI 10.1126/science.272.5259.268; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; Maden T, 1996, NATURE, V383, P675, DOI 10.1038/383675a0; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; NURSE K, 1995, RNA, V1, P102; Ofengand J, 1995, BIOCHEM CELL BIOL, V73, P915, DOI 10.1139/o95-099; PARKER R, 1988, MOL CELL BIOL, V8, P3150, DOI 10.1128/MCB.8.8.3150; PATTON JR, 1994, BIOCHIMIE, V76, P1129, DOI 10.1016/0300-9084(94)90041-8; Peculis BA, 1996, CURR BIOL, V6, P1413, DOI 10.1016/S0960-9822(96)00745-2; PECULIS BA, 1994, GENE DEV, V8, P2241, DOI 10.1101/gad.8.18.2241; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; SAMARSKY DA, 1995, NUCLEIC ACIDS RES, V23, P2548, DOI 10.1093/nar/23.13.2548; SIKORSKI RS, 1989, GENETICS, V122, P19; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; TERNS MP, 1995, EMBO J, V14, P4860, DOI 10.1002/j.1460-2075.1995.tb00167.x; Tollervey D, 1996, SCIENCE, V273, P1056, DOI 10.1126/science.273.5278.1056; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; Tycowski KT, 1996, P NATL ACAD SCI USA, V93, P14480, DOI 10.1073/pnas.93.25.14480; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; WISE JA, 1983, CELL, V35, P743, DOI 10.1016/0092-8674(83)90107-1; WRZESINSKI J, 1995, BIOCHEMISTRY-US, V34, P8904, DOI 10.1021/bi00027a043; WRZESINSKI J, 1995, RNA, V1, P437	45	411	442	3	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					565	573		10.1016/S0092-8674(00)80238-X	http://dx.doi.org/10.1016/S0092-8674(00)80238-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160748	Bronze			2022-12-28	WOS:A1997WZ32300010
J	Kubbutat, MHG; Jones, SN; Vousden, KH				Kubbutat, MHG; Jones, SN; Vousden, KH			Regulation of p53 stability by Mdm2	NATURE			English	Article							EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2; PROTEIN; DOMAIN; TRANSACTIVATION; DEGRADATION; EXPRESSION; ACTIVATION; BINDING	The tumour-suppressor p53 is a short-lived protein that is maintained at low, often undetectable, levels in normal cells. Stabilization of the protein in response to an activating signal, such as DNA damage, results in a rapid rise in p53 levels and subsequent inhibition of cell growth(1). Tight regulation of p53 function is critical for normal cell growth and development, and one mechanism by which p53 function is controlled is through interaction with the Mdm2 protein(2-4). Mdm2 inhibits p53 cell-cycle arrest and apoptic functions(5,6) and we show here that interaction with Mdm2 can also result in a large reduction in p53 protein levels through enhanced proteasome-dependent degradation. Endogenous levels of Mdm2 are sufficient to regulate p53 stability, and overexpression of Mdm2 can reduce the amount of endogenous p53. Because mdm2 is transcriptionally activated by p53 (refs 7, 8), this degradative pathway may contribute to the maintenance of low p53 concentrations in normal cells. Furthermore, mechanisms regulating the Mdm2-induced degradation of p53 may play a role in controlling the extent and duration of the p53 response.	NCI,ABL BASIC RES PROGRAM,FCRDC,FREDERICK,MD 21701; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MARSTON NJ, 1996, THESIS U LONDON; MARSTON NJ, 1995, ONCOGENE, V10, P1707; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	30	2740	2814	3	187	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					299	303		10.1038/387299a0	http://dx.doi.org/10.1038/387299a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153396				2022-12-28	WOS:A1997WZ16700057
J	McKhann, GM; Borowicz, LM; Goldsborough, MA; Enger, C; Selnes, OA				McKhann, GM; Borowicz, LM; Goldsborough, MA; Enger, C; Selnes, OA			Depression and cognitive decline after coronary artery bypass grafting	LANCET			English	Article							SURGERY	Background Depression is commonly reported after coronary artery bypass grafting (CABG), and after cardiac surgery in general, Many earlier reports relied on non-standard assessments of depression, which may have overestimated its frequency, Cognitive decline has also been reported after CABG. We assessed the frequency of depression after CABG by a validated depression measure (Center for Epidemiological Study of Depression, CES-D), and examined the relation between depression and cognitive decline. Methods Patients were tested before CABG and 1 month and 1 year after surgery with a series of neuropsychological tests that assessed a range of cognitive areas, Depressed mood was measured by the CES-D scale, and defined as a score above 16. Findings 90 (73%) of the 124 patients were not depressed before surgery, and 34 were depressed at that time. Only 12 (13%) of patients not depressed before surgery were depressed at 1 month afterwards, whereas 18 (53%) of those who were depressed before surgery were depressed at 1 month (p<0.001). 8 (9%) patients not depressed before surgery were depressed at 1 year; 16 (47%) of patients who were depressed before CABG were depressed at 1 year (p<0.001). Statistical analysis showed only minimal correlation-or none at all-between depression and eight areas of cognitive outcome, or between changes in depressed status and cognitive scores. Interpretation Of those patients who were depressed after CABG, the large majority were depressed before surgery. There was no correlation, moreover, between depressed mood and cognitive decline after CABG, which suggests that depression alone cannot account for cognitive decline.	JOHNS HOPKINS UNIV HOSP,ZANVYL KRIEGER MIND BRAIN INST,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV HOSP,DEPT SURG,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV HOSP,DEPT ONCOL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV HOSP,DEPT NEUROL,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine								Borowicz LM, 1996, J CARDIOTHOR VASC AN, V10, P105, DOI 10.1016/S1053-0770(96)80185-6; BYRNE A, 1993, BRIT J PSYCHIAT, V163, P173, DOI 10.1192/bjp.163.2.173; Cassens G, 1990, J Neuropsychiatry Clin Neurosci, V2, P202; CHANNER KS, 1988, J ROY SOC MED, V81, P629, DOI 10.1177/014107688808101105; Devins G., 1985, TEST CRITIQUES, V2, P144; HIRSCHFELD MA, 1997, JAMA-J AM MED ASSOC, V277, P333; Junge A, 1996, SPINE, V21, P1056, DOI 10.1097/00007632-199605010-00013; LANGELUDDECKE P, 1989, J PSYCHOSOM RES, V33, P37, DOI 10.1016/0022-3999(89)90104-9; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lindal E, 1996, SCAND J REHABIL MED, V28, P27; MAGNI G, 1987, PSYCHOL REP, V61, P173, DOI 10.2466/pr0.1987.61.1.173; McKhann GM, 1997, ANN THORAC SURG, V63, P516; McKhann GM, 1997, ANN THORAC SURG, V63, P510; MITRUSHINA M, 1991, J CLIN PSYCHOL, V47, P790, DOI 10.1002/1097-4679(199111)47:6<790::AID-JCLP2270470610>3.0.CO;2-C; Newman S, 1993, CARDIAC SURG BRAIN, P34; RABINER CJ, 1975, J NERV MENT DIS, V160, P342; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RAYMOND M, 1984, HEART LUNG, V13, P531; SELNES O, 1995, NEUROLOGIST, V1, P273; WILLNER AE, 1990, IMPACT CARDIAC SURG	20	148	150	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1282	1284		10.1016/S0140-6736(96)09466-4	http://dx.doi.org/10.1016/S0140-6736(96)09466-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WW899	9142062	hybrid			2022-12-28	WOS:A1997WW89900009
J	Weir, CJ; Murray, GD; Dyker, AG; Lees, KR				Weir, CJ; Murray, GD; Dyker, AG; Lees, KR			Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC BRAIN INFARCTION; BLOOD-GLUCOSE; MORBIDITY; MORTALITY; PRESSURE; STRESS; DAMAGE	Objective: To determine whether raised plasma glucose concentration independently influences outcome after acute stroke or is a stress response reflecting increased stroke severity. Design: Long term follow up study of patients admitted to an acute stroke unit. Setting Western Infirmary, Glasgow. Subjects: 811 patients with acute stroke confirmed by computed tomography. Analysis was restricted to the 750 non-diabetic patients. Main outcome measures: Survival time and placement three months after stroke. Results: 645 patients (86%) had ischaemic stroke and 105 patients (14%) haemorrhagic stroke. Cox's proportional hazards modelling with stratification according to Oxfordshire Community Stroke Project categories identified increased age (relative hazard 1.36 per decade; 95% confidence interval 1.21 to 1.53), haemorrhagic stroke (relative hazard 1.67; 1.22 to 2.28), time to resolution of symptoms > 72 hours (relative hazard 2.15; 1.15 to 4.05), and hyperglycaemia (relative hazard 1.87; 1.43 to 2.45) as predictors of mortality. The effect of glucose concentration on survival nas greatest in the first month. Conclusions: Plasma glucose concentration above 8 mmol/l after acute stroke predicts a poor prognosis after correcting for age, stroke severity, and stroke subtype. Raised plasma glucose concentration is therefore unlikely to be solely a stress response and should arguably be treated actively. A randomised trial is warranted.	UNIV GLASGOW, ROBERTSON CTR BIOSTAT, GLASGOW G12 8QQ, LANARK, SCOTLAND	University of Glasgow	Weir, CJ (corresponding author), UNIV GLASGOW, WESTERN INFIRM, DEPT MED & THERAPEUT, ACUTE STROKE UNIT, GLASGOW G11 6NT, LANARK, SCOTLAND.			Murray, Gordon/0000-0001-9866-4734; Weir, Christopher/0000-0002-6494-4903				[Anonymous], 1995, J Clin Epidemiol, V48, P1441; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; CANDELISE L, 1985, ARCH NEUROL-CHICAGO, V42, P661, DOI 10.1001/archneur.1985.04060070051014; CARLBERG B, 1991, STROKE, V22, P527, DOI 10.1161/01.STR.22.4.527; CARLBERG B, 1991, CEREBROVASC DIS, V1, P281, DOI 10.1159/000108855; CHEW W, 1991, AM J NEURORADIOL, V12, P603; COX DR, 1972, J R STAT SOC B, V34, P187; DECHIARA S, 1993, CEREBROVASC DIS, V3, P111, DOI 10.1159/000108682; ENGELMAN L, 1990, BMDP STATISTICAL SOF, V2, P1013; HELGASON CM, 1988, STROKE, V19, P1049, DOI 10.1161/01.STR.19.8.1049; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; JORGENSEN HS, 1994, STROKE, V25, P1977, DOI 10.1161/01.STR.25.10.1977; KENDRICK S, 1993, HLTH B EDINB, V51, P1; KIERS L, 1992, J NEUROL NEUROSUR PS, V55, P263, DOI 10.1136/jnnp.55.4.263; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MELAMED E, 1976, J NEUROL SCI, V29, P267, DOI 10.1016/0022-510X(76)90176-3; MOHR JP, 1994, CEREBROVASC DIS, V4, P197, DOI 10.1159/000108482; MURROS K, 1993, J NEUROL SCI, V116, P12, DOI 10.1016/0022-510X(93)90083-B; MURROS K, 1992, J NEUROL SCI, V111, P59, DOI 10.1016/0022-510X(92)90112-X; ONEILL PA, 1991, STROKE, V22, P842, DOI 10.1161/01.STR.22.7.842; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; TONI D, 1992, J NEUROL, V239, P382; VANKOOTEN F, 1993, STROKE, V24, P1129, DOI 10.1161/01.STR.24.8.1129; WOO E, 1988, STROKE, V19, P185, DOI 10.1161/01.STR.19.2.185; WOO J, 1990, ARCH NEUROL-CHICAGO, V47, P1174, DOI 10.1001/archneur.1990.00530110028011	26	386	391	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	1997	314	7090					1303	1306		10.1136/bmj.314.7090.1303	http://dx.doi.org/10.1136/bmj.314.7090.1303			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX975	9158464	Green Published			2022-12-28	WOS:A1997WX97500020
J	Alland, L; Muhle, R; Hou, H; Potes, J; Chin, L; SchreiberAgus, N; DePinho, RA				Alland, L; Muhle, R; Hou, H; Potes, J; Chin, L; SchreiberAgus, N; DePinho, RA			Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression	NATURE			English	Article							THYROID-HORMONE RECEPTOR; MYC TRANSGENIC MICE; SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; YEAST; PROTEIN; ACTIVATION; COMPLEX; DOMAIN; GENES	Normal mammalian growth and development ave highly dependent on the regulation of the expression and activity of the Myo family of transcription factors. Mxi1-mediated inhibition of Myc activities requires interaction with mammalian Sin3A or Sin3B proteins, which have been purported to act as scaffolds for additional co-repressor factors. The identification of two such Sin3-associated factors, the nuclear receptor co-repressor (N-CoR) and histone deacetylase (HD1), provides a basis for Mxi1/Sin3-induced transcriptional repression and tumour suppression.	ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, NEW YORK, NY 10461 USA; ALBERT EINSTEIN COLL MED, DEPT PEDIAT, NEW YORK, NY 10461 USA; ALBERT EINSTEIN COLL MED, DIV DERMATOL, NEW YORK, NY 10461 USA	Yeshiva University; Yeshiva University; Yeshiva University				DePinho, Ronald/0000-0002-5625-577X				Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DeRubertis F, 1996, NATURE, V384, P589; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERSCHBACH BM, 1994, NATURE, V370, P309, DOI 10.1038/370309a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MATALLANA E, 1992, MOL GEN GENET, V231, P395, DOI 10.1007/BF00292708; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; Rao G, 1996, ONCOGENE, V12, P1165; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; STILLMAN DJ, 1994, GENETICS, V136, P781; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WADE PA, IN PRESS TRENDS BIOC; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Zamir I, 1996, MOL CELL BIOL, V16, P5458	50	730	740	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	1997	387	6628					49	55		10.1038/387049a0	http://dx.doi.org/10.1038/387049a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139821				2022-12-28	WOS:A1997WW75800042
J	Kaplan, MM; DeLellis, RA; Wolfe, HJ				Kaplan, MM; DeLellis, RA; Wolfe, HJ			Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment	ANNALS OF INTERNAL MEDICINE			English	Article						liver cirrhosis, biliary; colchicine; methotrexate; ursodiol	URSODEOXYCHOLIC ACID UDCA; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; METHOTREXATE; DISEASE	Background: Treatment of primary biliary cirrhosis with ursodiol or colchicine may stabilize the disease or slow its rate of progression, but no reports of spontaneous or treatment-related remission have been published. Objective: To determine whether primary biliary cirrhosis fully responds to low-dose oral methotrexate therapy. Design: Prospective case study with at least 6 years of observation. Setting: Academic medical center. Patients: 5 of 19 patients with biopsy-proven precirrhotic primary biliary cirrhosis who had been ill for at least 1 year. Three of the 5 had not responded to colchicine or had responded only partially. Intervention: Oral methotrexate, 15 mg/wk in divided doses. Measurements: Symptoms, biochemical tests of liver function, and percutaneous liver biopsies. The latter were done at baseline, 1 to 2 years after initiation of methotrexate therapy, and then every 2 to 3 years during methotrexate therapy. Results: All 5 patients completely responded to medical treatment. Results of biochemical tests of liver function became normal, symptoms remitted, and serial liver biopsy specimens showed progressive histologic improvement. Biopsy specimens obtained after 5 to 12 years of treatment showed few signs of primary biliary cirrhosis and, in 3 patients, were close to normal. Five of the other 14 patients have responded biochemically and have shown histologic improvement; the other 9 have not responded to methotrexate therapy, have discontinued therapy, or have been lost to follow-up. Conclusion: In some patients, primary biliary cirrhosis may remit in response to methotrexate alone or in combination with colchicine or ursodiol.	TUFTS UNIV, NEW ENGLAND MED CTR, DIV GASTROENTEROL, SCH MED, BOSTON, MA 02111 USA; TUPPER RES INST, BOSTON, MA USA	Tufts Medical Center; Tufts University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00054] Funding Source: Medline; NIDDK NIH HHS [P30 DK34928] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALASUBRAMANIAM K, 1990, GASTROENTEROLOGY, V98, P1567, DOI 10.1016/0016-5085(90)91091-J; Bergasa NV, 1996, AM J GASTROENTEROL, V91, P295; BUSCHER HP, 1993, J HEPATOL, V18, P9, DOI 10.1016/S0168-8278(05)80004-2; COMBES B, 1993, HEPATOLOGY, V18, pA175, DOI 10.1016/0270-9139(93)92227-Q; HEATHCOTE EJ, 1994, HEPATOLOGY, V19, P1149, DOI 10.1002/hep.1840190512; JAMES SP, 1983, ANN INTERN MED, V99, P500, DOI 10.7326/0003-4819-99-4-500; JORGENSEN RA, 1995, GUT, V36, P935, DOI 10.1136/gut.36.6.935; KAPLAN MM, 1986, NEW ENGL J MED, V315, P1448, DOI 10.1056/NEJM198612043152304; KAPLAN MM, 1984, HEPATOLOGY, V4, P727, DOI 10.1002/hep.1840040428; Kaplan MM, 1996, NEW ENGL J MED, V335, P1570, DOI 10.1056/NEJM199611213352107; KAPLAN MM, 1991, GASTROENTEROLOGY, V101, P1332, DOI 10.1016/0016-5085(91)90085-Y; LINDOR KD, 1994, GASTROENTEROLOGY, V106, P1284, DOI 10.1016/0016-5085(94)90021-3; LINDOR KD, 1994, HEPATOLOGY, V20, pA202; LOMBARD M, 1993, GASTROENTEROLOGY, V104, P519, DOI 10.1016/0016-5085(93)90422-9; POUPON RE, 1994, NEW ENGL J MED, V330, P1342, DOI 10.1056/NEJM199405123301903; SCHEUER PJ, 1967, P ROY SOC MED, V60, P1257, DOI 10.1177/003591576706001205; SHARMA A, 1994, GASTROENTEROLOGY, V107, P266, DOI 10.1016/0016-5085(94)90085-X; SHERLOCK S, 1994, Q J MED, V87, P701; SOLOWAY RD, 1972, GASTROENTEROLOGY, V63, P820; VIERLING JM, 1990, HEPATOLOGY TXB LIVER, P1181	20	106	106	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1997	126	9					682	+		10.7326/0003-4819-126-9-199705010-00002	http://dx.doi.org/10.7326/0003-4819-126-9-199705010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW147	9139553				2022-12-28	WOS:A1997WW14700002
J	Newland, AC; Evans, TGJR				Newland, AC; Evans, TGJR			ABC of clinical haematology - Haematological disorders at the extremes of life	BRITISH MEDICAL JOURNAL			English	Article									ROYAL LONDON SCH MED & DENT,LONDON,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT GEN PRACTICE & PRIMARY CARE,LONDON,ENGLAND	University of London; Queen Mary University London; University of London; King's College London	Newland, AC (corresponding author), ST BARTHOLOMEWS HOSP,LONDON,ENGLAND.							HANN IM, 1991, FETAL NEONATAL HAEMA; LILLEYMAN JS, 1992, PEDIAT HEMATOLOGY	2	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 26	1997	314	7089					1262	1265		10.1136/bmj.314.7089.1262	http://dx.doi.org/10.1136/bmj.314.7089.1262			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW718	9154033	Green Published			2022-12-28	WOS:A1997WW71800035
J	Sinicco, A; Fora, R; Raiteri, R; Sciandra, M; Bechis, G; Calvo, MM; Gioannini, P				Sinicco, A; Fora, R; Raiteri, R; Sciandra, M; Bechis, G; Calvo, MM; Gioannini, P			Is the clinical course of HIV-1 changing? Cohort study	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; CD4 LYMPHOCYTE COUNTS; DISEASE PROGRESSION; INFECTION; TYPE-1; AIDS; SEROCONVERSION; RESISTANCE; CORRELATE	Objective: To assess whether the clinical course of HIV infection has changed from 1985 to 1995. Design: Cohort study. Setting: Infectious diseases clinic. Subjects: 285 patients recruited from September 1985 to January 1995 with less than or equal to 12 months between the dates of their last seronegative and first seropositive test result and with first follow up visit in the six months after seroconversion and at least 12 months' follow up. Patients were grouped according to the date of seroconversion. Main outcome measures: Time to CD4 cell count of < 500, 400, and 200 x 10(6) cells/l and clinical outcome defining AIDS; variation in cell count per day between consecutive visits, and ratio between this variation and time from estimated date of seroconversion at each visit. Results: The groups were similar in age, number with acute primary HIV infection, CD4 cell count at intake, and cell count at the beginning of antiretroviral treatment; they differed in sex ratio, risk factors for HIV,probability of CD4 cell decline to < 500, 400, and 200 x 10(6) cells/l, and risk of developing AIDS. Acute infection, seroconversion after December 1989, and serum beta 2 microglobulin > 296 nmol/l were independent predictors of poor clinical course. The speed of CD4 cell decline, expressed as cell variation divided by the number of days between consecutive visits, increased with more recent seroconversion (P = 0.02). Ratio between the speed of CD4 cell decline and time from estimated date of seroconversion at each visit was also higher in the patients who seroconverted after December 1989. Conclusions: The faster disease progression and the higher speed of CD4 cell decline at early stages in the patients with recently acquired HIV infection suggest changes in the clinical course of HIV infection.			Sinicco, A (corresponding author), UNIV TURIN,AMEDEO SAVOIA HOSP,DEPT MED & SURG SCI,INFECT DIS SECT,I-10149 TURIN,ITALY.							ADLEMAN LM, 1993, J ACQ IMMUN DEF SYND, V6, P144; Ball J.C., 2012, EFFECTIVENESS METHAD; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CLOYD MW, 1990, VIROLOGY, V174, P103, DOI 10.1016/0042-6822(90)90059-Z; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Cox D. R., 1984, ANAL SURVIVAL DATA; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; FENYO EM, 1992, J VIROL, V66, P4414; Galai N, 1996, AM J EPIDEMIOL, V143, P278; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; GORHAM ED, 1993, ARCH INTERN MED, V153, P869, DOI 10.1001/archinte.153.7.869; HEAGY W, 1991, J CLIN INVEST, V87, P1916, DOI 10.1172/JCI115217; HOMBERG SD, 1995, J ACQ IMMUN DEF SYND, V9, P291; Hu DJ, 1996, JAMA-J AM MED ASSOC, V275, P210, DOI 10.1001/jama.275.3.210; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LEE TH, 1994, J ACQ IMMUN DEF SYND, V7, P381; LOVEDAY C, 1995, LANCET, V345, P820, DOI 10.1016/S0140-6736(95)92963-0; Lowinson J. H., 1992, COMPREHENSIVE TXB SU; MALONE JL, 1990, J ACQ IMMUN DEF SYND, V3, P144; OBRIEN TR, 1995, AM J EPIDEMIOL, V142, P636, DOI 10.1093/oxfordjournals.aje.a117687; REZZA G, 1994, HIV EPIDEMIOLOGY, P279; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHWARCZ SK, 1995, AM J EPIDEMIOL, V142, P314, DOI 10.1093/oxfordjournals.aje.a117637; SIEGRIST CA, 1994, LANCET, V344, P1771, DOI 10.1016/S0140-6736(94)92911-4; SINICCO A, 1993, J ACQ IMMUN DEF SYND, V6, P575; *SPSS, 1993, STAT PACK SOC SCI VE; *STATS, 1995, STAT 5 0; STCLAIR MH, 1993, J ACQ IMMUN DEF SYND, V6, P891; TAYLOR JMG, 1991, J ACQ IMMUN DEF SYND, V4, P69; WEISS PJ, 1992, J INFECT DIS, V166, P1149, DOI 10.1093/infdis/166.5.1149; [No title captured]	33	31	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 26	1997	314	7089					1232	1237		10.1136/bmj.314.7089.1232	http://dx.doi.org/10.1136/bmj.314.7089.1232			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW718	9154026	Green Published			2022-12-28	WOS:A1997WW71800017
J	Ackerman, SL; Kozak, LP; Przyborski, SA; Rund, LA; Boyer, BB; Knowles, BB				Ackerman, SL; Kozak, LP; Przyborski, SA; Rund, LA; Boyer, BB; Knowles, BB			The mouse rostral cerebellar malformation gene encodes an UNC-5-like protein	NATURE			English	Article							C-ELEGANS; MIGRATIONS; EXPRESSION; MUTATION; UNC-6; AXONS	Migration of neurons from proliferative zones to their functional sites is fundamental to the normal development of the central nervous system(1,2). Mice homozyous for the spontaneous rostral cerebellar malformation mutation (rcm(s)) or a newly identified transgenic insertion allele (rcm(tg)) exhibit cerebellar and midbrain defects, apparently as a result of abnormal neuronal migration. Laminar structure abnormalities in lateral regions of the rostral cerebellar cortex have been described in homozygous rcm(5)-mice(3). We now demonstrate that the cerebellum of both rcm(5) and rcm(tg) homozygotes is smaller and has fewer folia than in the wild-type, ectopic cerebellar cells are present in midbrain regions by three days after birth, and there are abnormalities in postnatal cerebellar neuronal migration. We have cloned the rcm complementary DNA, which encodes a transmembrane receptor of the immunoglobulin superfamily. The sequence of the rcm protein (Rcm) is highly similar to that of UNC-5, a Caenorhabditis elegans protein that is essential for dorsal guidance of pioneer axons and for the movement of cells away from the netrin ligand, which is encoded by the unc-6 gene(4-7). As Rcm is a member of a newly described family of vertebrate homologues of UNC-5 which are netrin-binding proteins, our results indicate that UNC-5-like proteins may have a conserved function in mediating netrin-guided migrations(8).			Ackerman, SL (corresponding author), JACKSON LAB,600 MAIN ST,BAR HARBOR,ME 04609, USA.			rund, laurie/0000-0003-0761-7196; Knowles, Barbara B./0000-0002-2597-5619				AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; BenArie N, 1996, HUM MOL GENET, V5, P1207, DOI 10.1093/hmg/5.9.1207; BOYER BB, 1991, MOL CELL BIOL, V11, P4147, DOI 10.1128/MCB.11.8.4147; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWAN WM, 1981, DEV NERVOUS SYSTEM; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; JOHNSON KR, 1992, GENOMICS, V12, P503, DOI 10.1016/0888-7543(92)90441-T; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANE PW, 1992, J HERED, V83, P315, DOI 10.1093/oxfordjournals.jhered.a111221; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LIVESEY FJ, IN PRESS MOL CELL NE; Sambrook J., 2002, MOL CLONING LAB MANU; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; STERNBERG N, 1994, GENET ANAL-BIOMOL E, V11, P171, DOI 10.1016/1050-3862(94)90038-8; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WADSWORTHH WG, 1996, NEURON, V16, P36; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834	24	296	308	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					838	842		10.1038/386838a0	http://dx.doi.org/10.1038/386838a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126743				2022-12-28	WOS:A1997WV70600056
J	Crabtree, RH				Crabtree, RH			Prebiotic chemistry - Where smokers rule	SCIENCE			English	Editorial Material											Crabtree, RH (corresponding author), YALE UNIV,DEPT CHEM,225 PROSPECT ST,NEW HAVEN,CT 06520, USA.							Bostrom K., 1983, HYDROTHERMAL PROCESS, VVolume 12; Corliss JB, 1981, OCEANOL ACTA, V4, P56; CRABTREE RH, 1994, ORGANOMETALLIC CHEM, P313; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; Huber C, 1997, SCIENCE, V276, P245, DOI 10.1126/science.276.5310.245; Lancaster J. R., 1988, BIOINORGANIC CHEM NI; MILLER S, 1973, ORIGINS LIFE EARTH; Ragsdale SW, 1996, CHEM REV, V96, P2515, DOI 10.1021/cr950058+; Schopf JW, 1983, EARTHS EARLIEST BIOS; WOESE CR, 1981, SCI AM, V244, P98, DOI 10.1038/scientificamerican0681-98	10	19	19	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					222	222		10.1126/science.276.5310.222	http://dx.doi.org/10.1126/science.276.5310.222			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9132945				2022-12-28	WOS:A1997WT92500034
J	Ghahramani, Z; Wolpert, DM				Ghahramani, Z; Wolpert, DM			Modular decomposition in visuomotor learning	NATURE			English	Article							MOTOR CONTROL; REPRESENTATIONS; ADAPTATION; DIRECTION; MOVEMENT	The principle of 'divide-and-conquer' the decomposition of a complex task into simpler subtasks each learned by a separate module, has been proposed as a computational strategy during learning(1-3). We explore the possibility that the human motor system uses such a modular decomposition strategy to learn the visuomotor map, the relationship between visual inputs and motor outputs, Using a virtual reality system, subjects were exposed to opposite prism-like visuomotor remappings-discrepancies between actual and visually perceived hand locations-for movements starting from two distinct locations, Despite this conflicting pairing between visual and motor space, subjects learned the two starting-point-dependent visuomotor mappings and the generalization of this learning to intermediate starting locations demonstrated an interpolation of the two learned maps. This interpolation was a weighted average of the two learned visuomotor mappings, with the weighting sigmoidally dependent on starting location, a prediction made by a computational model of modular learning known as the ''mixture of experts'''. These results provide evidence that the brain may employ a modular decomposition strategy during learning.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; INST NEUROL,SOBELL DEPT NEUROPHYSIOL,LONDON WC1N 3BG,ENGLAND	Massachusetts Institute of Technology (MIT); University of London; University College London				Wolpert, Daniel/0000-0003-2011-2790	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; [Anonymous], 1982, JACKKNIFE BOOTSTRAP; BAKER JF, 1987, EXP BRAIN RES, V69, P220; BEDFORD FL, 1989, J EXP PSYCHOL HUMAN, V15, P232, DOI 10.1037/0096-1523.15.2.232; BIZZI E, 1991, SCIENCE, V253, P287, DOI 10.1126/science.1857964; Bridle J. S., 1990, Neurocomputing, Algorithms, Architectures and Applications. Proceedings of the NATO Advanced Research Workshop, P227; CACCIATORE TW, 1994, ADV NEURAL INFORMATI, V6, P719; Clower DM, 1996, NATURE, V383, P618, DOI 10.1038/383618a0; Gandolfo F, 1996, P NATL ACAD SCI USA, V93, P3843, DOI 10.1073/pnas.93.9.3843; GEORGOPOULOS AP, 1995, TRENDS NEUROSCI, V18, P506, DOI 10.1016/0166-2236(95)92775-L; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Ghahramani Z, 1996, J NEUROSCI, V16, P7085; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; HAY JC, 1966, J EXP PSYCHOL, V72, P640, DOI 10.1037/h0023737; IMAMIZU H, 1995, J EXP PSYCHOL HUMAN, V21, P1174, DOI 10.1037/0096-1523.21.5.1174; JACOBS RA, 1991, COGNITIVE SCI, V15, P219, DOI 10.1207/s15516709cog1502_2; Jacobs RA, 1991, NEURAL COMPUT, V3, P79, DOI 10.1162/neco.1991.3.1.79; JORDAN MI, 1994, NEURAL COMPUT, V6, P181, DOI 10.1162/neco.1994.6.2.181; KALASKA JF, 1992, SCIENCE, V255, P1517, DOI 10.1126/science.1549781; Kohler I., 1951, OSTERREICHISCHE AKAD, V227, P1; KRAVITZ JH, 1972, PERCEPT PSYCHOPHYS, V11, P38, DOI 10.3758/BF03212680; KRAVITZ JH, 1972, PERCEPT PSYCHOPHYS, V12, P305, DOI 10.3758/BF03207210; Martin TA, 1996, BRAIN, V119, P1199, DOI 10.1093/brain/119.4.1199; MCGONIGLE BO, 1978, NATURE, V272, P364, DOI 10.1038/272364a0; SHELHAMER M, 1991, ANN NY ACAD SCI, V656, P889; SOECHTING JF, 1989, J NEUROPHYSIOL, V62, P582, DOI 10.1152/jn.1989.62.2.582; WELCH RB, 1993, PERCEPT PSYCHOPHYS, V54, P195, DOI 10.3758/BF03211756; WELCH RB, 1971, PERCEPT PSYCHOPHYS, V10, P90, DOI 10.3758/BF03214321; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931; WOLPERT DM, 1995, EXP BRAIN RES, V103, P460	30	172	176	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					392	395		10.1038/386392a0	http://dx.doi.org/10.1038/386392a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121554				2022-12-28	WOS:A1997WQ17000063
J	Weissenhorn, W; Dessen, A; Harrison, SC; Skehel, JJ; Wiley, DC				Weissenhorn, W; Dessen, A; Harrison, SC; Skehel, JJ; Wiley, DC			Atomic structure of the ectodomain from HIV-1 gp41	NATURE			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; MEMBRANE-FUSION; TRANSMEMBRANE GLYCOPROTEIN; ENVELOPE GLYCOPROTEIN; SOLUBLE CD4; TYPE-1; PH; CONFORMATION; PROTEINS; RELEASE	Fusion of viral and cellular membranes by the envelope glycoprotein gp120/gp41 effects entry of HIV-1 into the cell. The precursor, gp160, is cleaved post-translationally into gp120 and gp41 (refs 1, 2), which remain non-covalently associated. Binding to both CD4 and a co-receptor leads to the conformational changes in gp120/gp41 needed for membrane fusion(3). We used X-ray crystallography to determine the structure of the protease-resistant part(4,5) of a gp41 ectodomain solubilized with a trimeric GCN4 coiled coil in place of the amino-terminal fusion peptide(6). The core of the molecule is found to be an extended, triple-stranded alpha-helical coiled coil with the amino terminus at its tip. A carboxy-terminal alpha-helix packs in the reverse direction against the outside of the coiled coil, placing the amino and carboxy termini near each other at one end of the long rod. These features, and the existence of a similar reversal of chain direction in the fusion pH-induced conformation of influenza virus HA2 (ref. 7) and in the transmembrane subunit of Moloney murine leukaemia virus(8) (Fig. 1a-d), suggest a common mechanism for initiating fusion.	CHILDRENS HOSP, MOL MED LAB, BOSTON, MA 02215 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02215 USA; HARVARD UNIV, HOWARD HUGHES MED INST, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Howard Hughes Medical Institute; MRC National Institute for Medical Research				Dessen, Andrea/0000-0001-6487-4020				ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; Brunger AT, 1992, XPLOR VERSION 3 1 MA; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HART TK, 1991, P NATL ACAD SCI USA, V88, P2189, DOI 10.1073/pnas.88.6.2189; KANASEKI T, IN PRESS J CELL BIOL; KIRSH R, 1990, AIDS RES HUM RETROV, V6, P1209, DOI 10.1089/aid.1990.6.1209; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEIKIN S, 1993, ANNU REV PHYS CHEM, V44, P369, DOI 10.1146/annurev.pc.44.100193.002101; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; MYERS G, 1995, THEORETICAL BIOL BIO; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; Skehel JJ, 1995, COLD SPRING HARB SYM, V60, P573, DOI 10.1101/SQB.1995.060.01.061; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; WEISSENHORN W, IN PRESS P NATL ACAD; WHARTON SA, 1995, EMBO J, V14, P240, DOI 10.1002/j.1460-2075.1995.tb06997.x; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770	35	1423	1484	1	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	1997	387	6631					426	430		10.1038/387426a0	http://dx.doi.org/10.1038/387426a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163431				2022-12-28	WOS:A1997XA49600066
J	Abraham, E; Glauser, MP; Butler, T; Garbino, J; Gelmont, D; Laterre, PF; Kudsk, K; Bruining, HA; Otto, C; Tobin, E; Zwingelstein, C; Lesslauer, W; Leighton, A				Abraham, E; Glauser, MP; Butler, T; Garbino, J; Gelmont, D; Laterre, PF; Kudsk, K; Bruining, HA; Otto, C; Tobin, E; Zwingelstein, C; Lesslauer, W; Leighton, A			p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock - A randomized controlled multicenter trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd Annual Autumnal Sepsis Meeting	NOV 06, 1995	DEAUVILLE, FRANCE				MONOCLONAL-ANTIBODIES; LETHAL BACTEREMIA; CLINICAL-TRIAL; TNF RECEPTOR; SURVIVAL; EFFICACY; PRIMATES; CYTOKINE; THERAPY; CANCER	Objective.-To evaluate the safety and efficacy of p55 tumor necrosis factor receptor fusion protein, a recombinant chimeric protein of human p55 (type I) tumor necrosis factor receptor (CD120a) extracellular domain and IgG1 sequences (referred to as p55-IgG), in the treatment of patients with severe sepsis or septic shock. Design.-Randomized, prospective, multicenter, double-blind, placebo-controlled clinical trial. Setting.-Forty-four community and university-affiliate hospitals in the United States and Europe, Patients.-There were 498 patients enrolled in this clinical trial, Intervention.-Patients prospectively stratified within each site into refractory shock or severe sepsis groups were randomized to receive a single infusion of p55-IgG, 0.083 mg/kg, 0.042 mg/kg, or 0.008 mg/kg, or placebo. Patients received standard aggressive medical/surgical care during the 28-day postinfusion period. Outcome Measure.-Twenty-eight-day all-cause mortality, Results.-The distribution of variables describing demographics, organ system dysfunction or failure, infecting microorganisms, predicted mortality, plasma interleukin 6 levels, and plasma tumor necrosis factor alpha (INF-alpha) levels were similar among patients in the p55-IgG and placebo treatment arms. A planned interim analysis was performed after 201 patients were enrolled, Because a statistically nonsignificant trend toward increased mortality was present in patients who had received 0.008 mg/kg, this treatment arm was discontinued, and the study continued with 3 arms. Among all infused patients, there was a statistically nonsignificant trend toward reduced 28-day all-cause mortality in those who received p55-IgG compared with placebo-treated patients (5% reduction, 0.042 mg/kg vs placebo; 15% reduction, 0.083 mg/kg vs placebo; P=,30), However, in patients with severe sepsis and early septic shock (n=247), therapy with p55-IgG, 0.083 mg/kg, was associated with a 36% reduction in 28-day all-cause mortality compared with placebo (P=.07), 20 (23%) of 87 patients died among those treated with p55-IgG, 0.083 mg/kg; 30 (37%) of 82 among those treated with p55-IgG, 0.042 mg/kg; and 28 (36%) of 78 in the placebo group. A prospectively planned logistic regression analysis to assess treatment effect on 28-day all-cause mortality by means of predicted mortality and serum interleukin 6 levels as continuous covariates demonstrated a significant improvement in outcome for the patients with severe sepsis treated with p55-IgG, 0.083 mg/kg, compared with placebo (P=.01). Serious adverse events, including death and the development of new organ system dysfunction, were reported in 65% of patients infused with placebo, with no increased frequency (56%) present in the 2 p55-IgG treatment arms. There were no reports of immediate hypersensitivity reactions caused by p55-IgG. Conclusions.-In this dose-finding study, there was no decrease in mortality between placebo and p55-IgG in all infused patients. In the prospectively defined population of patients with severe sepsis who received p55-IgG, 0.083 mg/kg, there was a trend toward reduced mortality at day 28 that became significant when predicted mortality and plasma interleukin 6 levels were included in a logistic regression analysis.	CHU VAUDOIS, DIV INFECT DIS, CH-1011 LAUSANNE, SWITZERLAND; TEXAS TECH UNIV, HLTH SCI CTR, DIV INFECT DIS, LUBBOCK, TX 79430 USA; HOP CANTONAL UNIV GENEVA, DIV INFECT DIS, GENEVA, SWITZERLAND; UNIV SO CALIF, DIV INFECT DIS, LOS ANGELES, CA USA; HOP ST LUC, INTENS CARE SERV, BRUSSELS, BELGIUM; UNIV TENNESSEE, DEPT SURG, MEMPHIS, TN USA; ACAD HOSP ROTTERDAM DIJKZIGT, DEPT SURG, ROTTERDAM, NETHERLANDS; UNIV ARIZONA, HLTH SCI CTR, DEPT ANESTHESIOL, TUCSON, AZ USA; ALBANY MED CTR, DIV INFECT DIS, ALBANY, NY USA; F HOFFMANN LA ROCHE & CO LTD, CH-4002 BASEL, SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; University of Geneva; University of Southern California; University of Tennessee System; University of Tennessee Health Science Center; Erasmus University Rotterdam; Erasmus MC; University of Arizona; University of Arizona Health Sciences; Albany Medical College; Roche Holding	Abraham, E (corresponding author), UNIV COLORADO, HLTH SCI CTR, DIV PULM SCI & CRIT CARE MED, 4200 E 9TH AVE, BOX C272, DENVER, CO 80262 USA.							ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CHAPMAN PB, 1987, J CLIN ONCOL, V5, P1942, DOI 10.1200/JCO.1987.5.12.1942; Cohen J, 1996, CRIT CARE MED, V24, P1431, DOI 10.1097/00003246-199609000-00002; EVANS TJ, 1994, J EXP MED, V180, P2173, DOI 10.1084/jem.180.6.2173; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; FONG YM, 1989, J EXP MED, V170, P1627, DOI 10.1084/jem.170.5.1627; GOLDIE AS, 1995, JAMA-J AM MED ASSOC, V274, P172, DOI 10.1001/jama.274.2.172; HAVELL EA, 1989, J IMMUNOL, V143, P2894; HEBERT PC, 1993, CHEST, V104, P230, DOI 10.1378/chest.104.1.230; HIGUCHI M, 1992, BIOCHEM BIOPH RES CO, V182, P638, DOI 10.1016/0006-291X(92)91780-T; HINSHAW LB, 1992, J TRAUMA, V33, P568, DOI 10.1097/00005373-199210000-00013; HINSHAW LB, 1990, CIRC SHOCK, V30, P279; ISPAHANI P, 1987, Q J MED, V63, P427; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; LESSLAUER W, 1991, EUR J IMMUNOL, V21, P2883, DOI 10.1002/eji.1830211134; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; OPAL SM, 1990, J INFECT DIS, V161, P1148, DOI 10.1093/infdis/161.6.1148; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; PARRILLO JE, 1991, ANN INTERN MED, V115, P491, DOI 10.7326/0003-4819-115-6-491; PEDUZZI P, 1987, NEW ENGL J MED, V317, P659; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; Reinhart K, 1996, CRIT CARE MED, V24, P733, DOI 10.1097/00003246-199605000-00003; SELBY P, 1987, BRIT J CANCER, V56, P803, DOI 10.1038/bjc.1987.294; SHERMAN ML, 1988, J CLIN ONCOL, V6, P344, DOI 10.1200/JCO.1988.6.2.344; SUFFREDINI AF, 1995, J IMMUNOL, V155, P5038; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; VanZee KJ, 1996, J IMMUNOL, V156, P2221; WENZEL RP, 1992, NEW ENGL J MED, V326, P1151, DOI 10.1056/NEJM199204233261710; Young LS, 1990, PRINCIPLES PRACTICE, P611; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	36	280	291	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	1997	277	19					1531	1538		10.1001/jama.277.19.1531	http://dx.doi.org/10.1001/jama.277.19.1531			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WY969	9153367				2022-12-28	WOS:A1997WY96900031
J	Lockshin, MD				Lockshin, MD			Antiphospholipid antibody - Babies, blood clots, biology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTICARDIOLIPIN ANTIBODIES; PREDNISONE; THROMBOSIS		NIH,WARREN GRANT MAGNUSON CLIN CTR,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA								Asherson RA, 1996, LUPUS, V5, P414, DOI 10.1177/096120339600500516; BORCHMAN D, 1995, CLIN EXP IMMUNOL, V102, P373; Branch DW, 1996, LUPUS, V5, P409, DOI 10.1177/096120339600500515; Brey RL, 1996, LUPUS, V5, P473, DOI 10.1177/096120339600500529; CasciolaRosen L, 1996, P NATL ACAD SCI USA, V93, P1624, DOI 10.1073/pnas.93.4.1624; COWCHOCK FS, 1992, AM J OBSTET GYNECOL, V166, P1318, DOI 10.1016/0002-9378(92)91596-3; Douketis JD, 1996, THROMB HAEMOSTASIS, V75, P254; Finazzi G, 1996, AM J MED, V100, P530, DOI 10.1016/S0002-9343(96)00060-5; FISHMAN P, 1993, J CLIN INVEST, V91, P1834, DOI 10.1172/JCI116396; GINSBERG JS, 1995, BLOOD, V86, P3685, DOI 10.1182/blood.V86.10.3685.bloodjournal86103685; GINSBURG KS, 1992, ANN INTERN MED, V117, P997, DOI 10.7326/0003-4819-117-12-997; Harris EN, 1996, LUPUS, V5, P372, DOI 10.1177/096120339600500507; INGRAM SB, 1987, ARTHRITIS RHEUM, V30, P1167, DOI 10.1002/art.1780301013; Kandiah DA, 1996, LUPUS, V5, P381, DOI 10.1177/096120339600500509; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; Kutteh WH, 1996, AM J OBSTET GYNECOL, V174, P1584, DOI 10.1016/S0002-9378(96)70610-5; LOCKSHIN MD, 1989, AM J OBSTET GYNECOL, V160, P439, DOI 10.1016/0002-9378(89)90468-7; LYNCH A, 1994, ANN INTERN MED, V120, P470, DOI 10.7326/0003-4819-120-6-199403150-00004; MANTARULI B, 1996, LUPUS, V5, P303; Moll S., 1996, Lupus, V5, P522; Mori T, 1996, THROMB HAEMOSTASIS, V75, P49; Olee TW, 1996, P NATL ACAD SCI USA, V93, P8606, DOI 10.1073/pnas.93.16.8606; Piette J-C., 1996, ANTIPHOSPHOLIPID SYN, V1, P3; *PREGN LOSS STUD G, 1996, LUPUS, V5, P201; Roubey RAS, 1996, ARTHRITIS RHEUM-US, V39, P1444, DOI 10.1002/art.1780390903; SILVER RM, 1994, OBSTET GYNECOL, V83, P372; Silver RM, 1996, OBSTET GYNECOL, V87, P494, DOI 10.1016/0029-7844(95)00497-1; SIMANTOV R, 1995, J CLIN INVEST, V96, P2211, DOI 10.1172/JCI118276; Stephenson MD, 1996, FERTIL STERIL, V66, P24; WANG MX, 1995, J IMMUNOL, V155, P1629; WILSON WA, 1996, LUPUS, V5, P295	31	53	55	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	1997	277	19					1549	1551		10.1001/jama.277.19.1549	http://dx.doi.org/10.1001/jama.277.19.1549			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY969	9153370				2022-12-28	WOS:A1997WY96900034
J	Rexrode, KM; Hennekens, CH; Willett, WC; Colditz, GA; Stampfer, MJ; RichEdwards, JW; Speizer, FE; Manson, JE				Rexrode, KM; Hennekens, CH; Willett, WC; Colditz, GA; Stampfer, MJ; RichEdwards, JW; Speizer, FE; Manson, JE			A prospective study of body mass index, weight change, and risk of stroke in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; FAT DISTRIBUTION; FOLLOW-UP; PROSPECTIVE COHORT; CIGARETTE-SMOKING; DIABETES-MELLITUS; SERUM-CHOLESTEROL; HYPERTENSIVE MEN; RELATIVE WEIGHT	Objective.-To examine the associations of body mass index (BMI) and weight change with risk of stroke in women. Setting and Design.-Prospective cohort study among US female registered nurses participating in the Nurses' Health Study. Participants.-A total of 116 759 women aged 30 to 55 years in 1976 who were free from diagnosed coronary heart disease, stroke, and cancer. Main Outcome Measure.-Incidence of ischemic stroke, hemorrhagic stroke (subarachnoid or intraparenchymal hemorrhage), and total stroke. Results.-During 16 years of follow-up, 866 total strokes (including 403 ischemic strokes and 269 hemorrhagic strokes) were documented. In multivariate analyses adjusted for age, smoking, postmenopausal hormone use, and menopausal status, women with increased BMI (greater than or equal to 27 kg/m(2)) had significantly increased risk of ischemic stroke, with relative risks (RRs) of 1.75 (95% confidence interval [CI], 1.17-2.59) for BMI of 27 to 28.9 kg/m(2); 1.90 (95% CI, 1.28-2.82) for BMI of 29 to 31.9 kg/m(2); and 2.37 (95% CI, 1.60-3.50) for BMI of 32 kg/m(2) or more (P for trend<.001), as compared with those with a BMI of less than 21 kg/m(2). For hemorrhagic stroke there was a nonsignificant inverse relation between obesity and hemorrhagic stroke, with the highest risk among women in the leanest BMI category (P for trend=.20). For total stroke the RRs were somewhat attenuated compared with those for ischemic stroke but remained elevated for women with higher BMI (P for trend<.001). In multivariate analyses that also adjusted for BMI at age 18 years, weight gain from age 18 years until 1976 was associated with an RR for ischemic stroke of 1.69 (95% CI, 1.26-2.29) for a gain of 11 to 19.9 kg and 2.52 (95% CI, 1.80-3.52) for a gain of 20 kg or more (P for trend<.001), as compared with women who maintained stable weight (loss or gain <5 kg). Although weight change was not related to risk of hemorrhagic stroke (P for trend=.20), a direct relationship was observed between weight gain and total stroke risk (P for trend<.001). Conclusions.-These prospective data indicate that both obesity and weight gain in women are important risk factors for ischemic and total stroke but not hemorrhagic stroke. The relationship between obesity and total stroke depends on the distribution of stroke subtypes in the population.	BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Rexrode, KM (corresponding author), BRIGHAM & WOMENS HOSP,DIV PREVENT MED,900 COMMONWEALTH AVE E,BOSTON,MA 02115, USA.		Rexrode, Kathryn M/I-1177-2018; Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291; Rexrode, Kathryn/0000-0003-3387-8429	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT RD, 1994, STROKE, V25, P2370, DOI 10.1161/01.STR.25.12.2370; BLOOM E, 1986, JAMA-J AM MED ASSOC, V256, P2972, DOI 10.1001/jama.256.21.2972; CARMAN WJ, 1994, CIRCULATION, V89, P703, DOI 10.1161/01.CIR.89.2.703; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; DIPIETRO L, 1994, AM J PUBLIC HEALTH, V84, P14, DOI 10.2105/AJPH.84.1.14; FIEBACH NH, 1989, AM J EPIDEMIOL, V130, P646; FOLSOM AR, 1990, STROKE, V21, P701, DOI 10.1161/01.STR.21.5.701; GOLDBOURT U, 1987, HYPERTENSION, V10, P22, DOI 10.1161/01.HYP.10.1.22; HEYDEN S, 1971, ARCH INTERN MED, V128, P956, DOI 10.1001/archinte.128.6.956; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; KNEKT P, 1991, J CLIN EPIDEMIOL, V44, P933, DOI 10.1016/0895-4356(91)90056-F; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; LINDENSTROM E, 1993, STROKE, V24, P1468, DOI 10.1161/01.STR.24.10.1468; LINDSTED K, 1991, INT J OBESITY, V15, P397; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; PAFFENBARGER RS, 1971, AM J EPIDEMIOL, V94, P524, DOI 10.1093/oxfordjournals.aje.a121351; PHILLIPS A, 1989, LANCET, V1, P1005; RHOADS GG, 1983, LANCET, V1, P492; RIMM EB, 1995, AM J EPIDEMIOL, V141, P1117, DOI 10.1093/oxfordjournals.aje.a117385; SELMER R, 1995, J EPIDEMIOL COMMUN H, V49, P265, DOI 10.1136/jech.49.3.265; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; SHINTON R, 1991, J EPIDEMIOL COMMUN H, V45, P138, DOI 10.1136/jech.45.2.138; SPIEGELMAN D, 1992, AM J CLIN NUTR, V55, P1033, DOI 10.1093/ajcn/55.6.1033; Stamler J, 1991, Ann Epidemiol, V1, P347, DOI 10.1016/1047-2797(91)90045-E; STAMLER R, 1991, HYPERTENSION, V17, P553, DOI 10.1161/01.HYP.17.4.553; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; TERRY RB, 1992, INT J OBESITY, V16, P417; Thom T J, 1993, Ann Epidemiol, V3, P509; TROY LM, 1995, INT J OBESITY, V19, P570; Walker AE, 1981, STROKE S1, V12, P13; WALKER S, 1995, AM J EPIDEMIOL, V141, pS41; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460	44	411	418	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	1997	277	19					1539	1545		10.1001/jama.277.19.1539	http://dx.doi.org/10.1001/jama.277.19.1539			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY969	9153368				2022-12-28	WOS:A1997WY96900032
J	Verheugt, FWA				Verheugt, FWA			In search of a superaspirin for the heart	LANCET			English	Editorial Material							TRANSIENT ISCHEMIC ATTACK				Verheugt, FWA (corresponding author), UNIV NIJMEGEN HOSP, DEPT CARDIOL, NL-6500 HB NIJMEGEN, NETHERLANDS.		Verheugt, F.W.A./H-8105-2014					ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CLELAND M, 1996, LANCET, V75, P426; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Hanrath P, 1997, CIRCULATION, V96, P1445; Kereiakes DJ, 1996, CIRCULATION, V94, P906, DOI 10.1161/01.CIR.94.5.906; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Tcheng JE, 1996, AM J CARDIOL, V78, P35, DOI 10.1016/S0002-9149(96)00490-0; THEROUX P, 1997, 46 ANN SCI SESS AM C; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801	12	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	1997	349	9063					1409	1410		10.1016/S0140-6736(05)63719-1	http://dx.doi.org/10.1016/S0140-6736(05)63719-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164311	Green Submitted			2022-12-28	WOS:A1997WZ76500004
J	Gasche, C; Dejaco, C; Waldhoer, T; Tillinger, W; Reinisch, W; Fueger, GF; Gangl, A; Lochs, H				Gasche, C; Dejaco, C; Waldhoer, T; Tillinger, W; Reinisch, W; Fueger, GF; Gangl, A; Lochs, H			Intravenous iron and erythropoietin for anemia associated with Crohn disease - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; RHEUMATOID-ARTHRITIS; QUALITY; LIFE	Background: Anemia often complicates Crohn disease and affects quality of life. Objective: To evaluate the efficacy of intravenous iron alone and in combination with erythropoietin for the treatment of anemia associated with Crohn disease. Design: Double-blind, randomized, placebo-controlled trial with a subsequent open-label phase. Setting: University-based gastroenterology outpatient clinic. Patients: 40 patients with Crohn disease and a hemoglobin concentration of 10.5 g/dL or less. Intervention: All patients received intravenous iron saccharate for 16 weeks. During the blinded phase of the trial, they received either erythropoietin or placebo. During the open phase, the erythropoietin dose was increased in nonresponders who had received erythropoietin and erythropoietin therapy was initiated in nonresponders who had received placebo. Measurements: Response was defined as an increase in hemoglobin concentration of 2 g/dL or more. Results: 15 of 20 patients in the placebo group (75% [95% CI, 51% to 91%]) and 18 of 19 patients in the erythropoietin group (95% [CI, 74% to 100%]) responded to intravenous iron (P = 0.20). The erythropoietin group had a higher cumulative response rate (P = 0.036) and a more pronounced mean increase in hemoglobin concentration (4.9 g/dL in the erythropoietin group compared with 3.3 g/dL in the placebo group, a difference of 1.6 g/dL [CI, 0.6 g/dL to 2.5 g/dL]; P = 0.004). in the open phase, all 6 previous nonresponders had a response. Hematologic response was associated with improved quality of life (P = 0.03). Conclusions: Most patients who have anemia associated with Crohn disease respond to intravenous iron alone. Erythropoietin has additional effects on hemoglobin concentrations.	UNIV HOSP GRAZ, DEPT RADIOL, DIV NUCL MED, A-8036 GRAZ, AUSTRIA; UNIV VIENNA, A-1010 VIENNA, AUSTRIA	University of Vienna	Gasche, C (corresponding author), NEUES AKH, INNERE MED KLIN 4, WAHRINGER GURTEL 18-20, A-1090 VIENNA, AUSTRIA.		Gasche, Christoph W/A-5139-2013; Waldhoer, Thomas Johannes/I-1215-2019	Waldhoer, Thomas Johannes/0000-0003-2043-8299; Gasche, Christoph/0000-0002-3752-6685				BEST WR, 1976, GASTROENTEROLOGY, V70, P439; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; EVANS RW, 1990, JAMA-J AM MED ASSOC, V263, P825; GASCHE C, 1994, DIGEST DIS SCI, V39, P1930, DOI 10.1007/BF02088127; GRIMM G, 1990, KIDNEY INT, V38, P480, DOI 10.1038/ki.1990.229; HORINA JH, 1993, GASTROENTEROLOGY, V104, P1828, DOI 10.1016/0016-5085(93)90666-Z; LEITGEB C, 1994, CANCER-AM CANCER SOC, V73, P2535, DOI 10.1002/1097-0142(19940515)73:10<2535::AID-CNCR2820731014>3.0.CO;2-5; MACDONALD TT, 1990, CLIN EXP IMMUNOL, V81, P301; MACDOUGALL IC, 1989, BRIT MED J, V299, P157, DOI 10.1136/bmj.299.6692.157; MAHIDA YR, 1989, GUT, V30, P835, DOI 10.1136/gut.30.6.835; MEANS RT, 1992, BLOOD, V80, P1639; MERCURIALI F, 1994, TRANSFUSION, V34, P501, DOI 10.1046/j.1537-2995.1994.34694295065.x; Meyers S, 1995, INFLAMM BOWEL DIS, P695; NYVAD O, 1994, LANCET, V344, P1305, DOI 10.1016/S0140-6736(94)90797-8; PINCUS T, 1990, AM J MED, V89, P161, DOI 10.1016/0002-9343(90)90294-N; SCHLAGETER MH, 1990, CLIN CHEM, V36, P1731; Schreiber S, 1996, NEW ENGL J MED, V334, P619, DOI 10.1056/NEJM199603073341002; SUNDERPLASSMANN G, 1995, NEPHROL DIAL TRANSPL, V10, P2070; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124	19	137	147	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1997	126	10					782	787		10.7326/0003-4819-126-10-199705150-00006	http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ823	9148651				2022-12-28	WOS:A1997WZ82300007
J	Kavanagh, AM; Broom, DH				Kavanagh, AM; Broom, DH			Women's understanding of abnormal cervical smear test results: A qualitative interview study	BRITISH MEDICAL JOURNAL			English	Article								Objective: To describe how women interpret their experiences of diagnosis and treatment of a cervical abnormality and how healthcare services for such women can be improved, Design: Qualitative study using detailed individual interviews. Setting: Australian gynaecology clinics. Subjects: 29 Women who had a cervical cytological abnormality and who attended a gynaecologist Main outcome measures: Women's views on their diagnosis and their information needs. Results: Most women wanted to participate in decisions about their care but found it difficult to get the information they required from doctors because they were confused by what their doctors told them and felt unable to ask questions in the consultation. Medical terms such as wart virus and precancer were difficult to understand. Not being able to see their cervix also made it hard for women to understand what their abnormality meant and what treatment entailed. Most women tried to make sense of their abnormality in the context of their everyday lives. For some women their gynaecological care was not consistent with the way they understood their abnormality Conclusions: The inherent power structure of medical practice combined with time pressures often make it difficult for doctors to give the detailed information and reassurance patients need when a diagnosis is distressing or when investigation and treatment are strange and upsetting.	AUSTRALIAN NATL UNIV,NATL CTR EPIDEMIOL & POPULAT HLTH,CANBERRA,ACT 0200,AUSTRALIA	Australian National University	Kavanagh, AM (corresponding author), ANTICANC COUNCIL VICTORIA,CANC EPIDEMIOL CTR,1 RATHDOWNE ST,CARLTON,VIC 3053,AUSTRALIA.		Kavanagh, Anne/U-4826-2019; Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Kavanagh, Anne/0000-0002-1573-3464				BRITTEN N, 1995, BRIT MED J, V311, P251, DOI 10.1136/bmj.311.6999.251; CAMPION MJ, 1988, BRIT J OBSTET GYNAEC, V95, P175, DOI 10.1111/j.1471-0528.1988.tb06848.x; Kavanagh A M, 1996, J Med Screen, V3, P29; LATHER P, 1991, GETTING SMART FEMISI; LERMAN C, 1991, AM J OBSTET GYNECOL, V165, P658, DOI 10.1016/0002-9378(91)90304-A; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; MCDONALD TW, 1989, GYNECOL ONCOL, V34, P345, DOI 10.1016/0090-8258(89)90170-4; Posner T, 1988, PREVENTION CERVICAL; QUILLAM S, 1989, POSITIVE SMEAR; RICHARDS T, 1992, NUDIST 2 3; SCHMERLING A, 1993, MED J AUSTRALIA, V158, P619; Silverman D., 1987, COMMUNICATION MED PR	12	104	104	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1388	1391						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ169	9161314				2022-12-28	WOS:A1997WZ16900030
J	Brown, RH; Cruikshank, DP; Pendleton, Y; Veeder, GJ				Brown, RH; Cruikshank, DP; Pendleton, Y; Veeder, GJ			Surface composition of Kuiper belt object 1993SC	SCIENCE			English	Article							TRITON; PLUTO; ICES	The 1.42- to 2.40-micrometer spectrum of Kuiper belt object 1993SC was measured at the Keck Observatory in October 1996. It shows a strongly red continuum reflectance and several prominent infrared absorption features. The strongest absorptions in 1993SC's spectrum occur near 1.62, 1.79, 1.95, 2.20, and 2.32 micrometers in wavelength, Features near the same wavelengths in the spectra of Pluto and Neptune's satellite Triton are due to CH4 on their surfaces, suggesting the presence of a simple hydrocarbon ice such as CH4, C2H6, C2H4, or C2H2 on 1993SC. In addition, the red continuum reflectance of 1993SC suggests the presence of more complex hydrocarbons.	UNIV ARIZONA,STEWARD OBSERV,TUCSON,AZ 85721; NASA,AMES RES CTR,MOFFETT FIELD,CA 94035; CALTECH,JET PROP LAB,PASADENA,CA 91109	University of Arizona; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Brown, RH (corresponding author), UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721, USA.							BOHN RB, 1994, ICARUS, V111, P151, DOI 10.1006/icar.1994.1138; BROWN GN, 1979, ADV CRYOGEN ENG, V25, P662; *CEL, PROGR EPH MARK CEL; COCHRAN AJ, 1995, ASTRON J, V110, P342; CRUIKSHANK DP, 1993, SCIENCE, V261, P742, DOI 10.1126/science.261.5122.742; CRUIKSHANK DP, UNPUB; DUNCAN M, 1988, ASTROPHYS J, V328, pL69, DOI 10.1086/185162; EDGEWORTH KE, 1949, MON NOT R ASTRON SOC, V109, P600, DOI 10.1093/mnras/109.5.600; Herzberg G., 1945, INFRARED RAMAN SPECT, V2; Jewitt D, 1996, ASTRON J, V112, P1225, DOI 10.1086/118093; Kuiper G.P., 1951, ASTROPHYSICS TOPICAL, P357; Luu JX, 1996, ASTRON J, V111, P499, DOI 10.1086/117801; MARSDEN B, 1996, ORBITAL ELEMENTS OBT; Oort J. H., 1950, B ASTRON I NETH, V11, P91; OWEN TB, UNPUB; OWEN TC, 1993, SCIENCE, V261, P745, DOI 10.1126/science.261.5122.745; QUIRICO E, 1996, THESIS U J FOURNIER; SAGAN C, 1979, NATURE, V277, P102, DOI 10.1038/277102a0; SCHMITT B, 1995, 27 M DIV PLAN SCI AM; WILLIAMS IP, 1995, ICARUS, V116, P180, DOI 10.1006/icar.1995.1119	20	51	51	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					937	939		10.1126/science.276.5314.937	http://dx.doi.org/10.1126/science.276.5314.937			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9163038				2022-12-28	WOS:A1997WY79200044
J	Gottesfeld, JM; Neely, L; Trauger, JW; Baird, EE; Dervan, PB				Gottesfeld, JM; Neely, L; Trauger, JW; Baird, EE; Dervan, PB			Regulation of gene expression by small molecules	NATURE			English	Article							SEQUENCE-SPECIFIC RECOGNITION; POSITIVE TRANSCRIPTION FACTOR; DOUBLE-HELICAL DNA; RNA GENES; MINOR GROOVE; ZINC FINGERS; 5S-RNA GENE; FACTOR-IIIA; COMPLEXES; BINDING	Small molecules that target specific DNA sequences have the potential to control gene expression. Ligands designed for therapeutic application must bind any predetermined DNA sequence with high affinity and permeate living cells. Synthetic polyamides containing-N-methylimidazole and N-methylpyrrole amino acids have an affinity and specificity for DNA comparable to naturally occurring DNA-binding proteins(1). We report here that an eight-ring polyamide targeted to a specific region of the transcription factor TFIIIA binding site interferes with 5S RNA gene expression in Xenopus kidney cells. Our results indicate that pyrrole-imidazole polyamides are cell-permeable and can inhibit the transcription of specific genes.	CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA; CALTECH, BECKMAN INST, PASADENA, CA 91125 USA	California Institute of Technology; California Institute of Technology	Gottesfeld, JM (corresponding author), SCRIPPS RES INST, DEPT MOL BIOL, LA JOLLA, CA 92037 USA.			Gottesfeld, Joel/0000-0002-4643-5777				Baird EE, 1996, J AM CHEM SOC, V118, P6141, DOI 10.1021/ja960720z; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; CLEMENS KR, 1994, J MOL BIOL, V244, P23, DOI 10.1006/jmbi.1994.1701; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; GEIERSTANGER BH, 1994, SCIENCE, V266, P646, DOI 10.1126/science.7939719; HARTL P, 1993, J CELL BIOL, V120, P613, DOI 10.1083/jcb.120.3.613; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; HO SN, 1994, P NATL ACAD SCI USA, V91, P9203, DOI 10.1073/pnas.91.20.9203; KEILY JJ, 1996, P NATL ACAD SCI USA, V93, P6981; Liu C, 1996, P NATL ACAD SCI USA, V93, P940, DOI 10.1073/pnas.93.2.940; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MRKSICH M, 1992, P NATL ACAD SCI USA, V89, P7586, DOI 10.1073/pnas.89.16.7586; Parks ME, 1996, J AM CHEM SOC, V118, P6147, DOI 10.1021/ja960721r; PELTON JG, 1989, P NATL ACAD SCI USA, V86, P5723, DOI 10.1073/pnas.86.15.5723; PETERSON RC, 1980, CELL, V20, P131, DOI 10.1016/0092-8674(80)90241-X; ROEDER RG, 1983, J BIOL CHEM, V258, P1932; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; STUTZ F, 1989, GENE DEV, V3, P1190, DOI 10.1101/gad.3.8.1190; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; Trauger JW, 1996, NATURE, V382, P559, DOI 10.1038/382559a0; Trauger JW, 1996, J AM CHEM SOC, V118, P6160, DOI 10.1021/ja960726o; WADE WS, 1992, J AM CHEM SOC, V114, P8784; White S, 1996, BIOCHEMISTRY-US, V35, P12532, DOI 10.1021/bi960744i; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414	29	458	485	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					202	205		10.1038/387202a0	http://dx.doi.org/10.1038/387202a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144294				2022-12-28	WOS:A1997WX94500060
J	Vernick, JS; Teret, SP; Webster, DW				Vernick, JS; Teret, SP; Webster, DW			Regulating firearm advertisements that promise home protection - A public health intervention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUN OWNERSHIP; SUICIDE; VICTIMS	Firearms are a consumer product responsible for 38 500 deaths in the United States in 1994. Like other products, firearms are advertised, in the absence of rules governing the design of firearms, regulating the way guns are advertised may be a useful public health intervention. Some gun advertisements include messages suggesting that bringing a handgun into the home is generally protective for the occupants of the home. The best available scientific information contradicts this message, Given this disjunction, regulating those advertisements may be an appropriate response. Under federal law, the Federal Trade Commission (FTC) has authority to prohibit advertisements that are ''deceptive'' or ''unfair.'' Under the FTC's deception analysis, the focus is on whether consumers are misled by an advertisement. For a finding of unfairness, the FTC looks for advertisements that may cause substantial injury to consumers. Under either analysis, a strong argument can be made that firearm advertisements promising home protection are unlawful. On February 14, 1996, several organizations sent separate petitions to the FTC asking it to consider the issues raised by firearm advertisements that promise home protection. The FTC is still reviewing the information presented. There are no First Amendment or Second Amendment impediments to FTC regulation of deceptive firearm advertising under the US Constitution.			Vernick, JS (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,CTR GUN POLICY & RES,624 N BROADWAY,BALTIMORE,MD 21205, USA.							ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; *BER ADV, 1996, NY TIMES        1204, pA32; *BER US ADV, 1996, WOMEN GUNS       FEB, P27; Blendon RJ, 1996, JAMA-J AM MED ASSOC, V275, P1719, DOI 10.1001/jama.275.22.1719; BRENT DA, 1988, ARCH GEN PSYCHIAT, V45, P581, DOI 10.1001/archpsyc.1988.01800300079011; BRENT DA, 1991, JAMA-J AM MED ASSOC, V266, P2989, DOI 10.1001/jama.266.21.2989; *COLT ADV, 1992, LADIES HOME J    JUL; *COLT ADV, 1993, SHOT BUSINESS    JAN; Cook P.J., 1991, CRIME JUSTICE, V14, P1, DOI [10.1086/449183, DOI 10.1086/449183]; *FED BUR INV, 1995, UN CRIM REP US 1994; *FED TRAD COMM, 1984, FED REGISTER, V49, P30999; HEMENWAY D, 1995, JAMA-J AM MED ASSOC, V273, P46, DOI 10.1001/jama.273.1.46; HEMENWAY D, IN PRESS J CRIM LAW; *J HOPK CTR GUN PO, 1997, 1996 NAT GUN POL SUR; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KELLERMANN AL, 1995, JAMA-J AM MED ASSOC, V273, P1759, DOI 10.1001/jama.273.22.1759; Kleck G, 1995, J CRIM LAW CRIM, V86, P150, DOI 10.2307/1144004; MCDOWALL D, 1994, AM J PUBLIC HEALTH, V84, P1982, DOI 10.2105/AJPH.84.12.1982; *NAT HIGHW TRAFF S, 1995, TRAFF SAF FACTS 1994; PIERCE JP, 1994, JAMA-J AM MED ASSOC, V271, P608, DOI 10.1001/jama.271.8.608; RAND MR, 1994, NCJ147003 US DEP JUS; REISS AJ, 1993, UNDERSTANDING PREVEN, P265; *RR BOWK, 1995, ULR INT PER DIR; SINGH GK, 1996, MONTHLY VITAL STAT S, V45; *US DHHS, 1989, DHHS CDC PUBL; VERNICK JS, 1993, AM J PUBLIC HEALTH, V83, P1773, DOI 10.2105/AJPH.83.12.1773; WINTEMUTE G, 1995, ADVERTISING FIREARMS; Wintemute GJ, 1996, JAMA-J AM MED ASSOC, V275, P1749, DOI 10.1001/jama.275.22.1749; WINTEMUTE GJ, 1994, UNPUB	30	25	25	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	1997	277	17					1391	1397		10.1001/jama.277.17.1391	http://dx.doi.org/10.1001/jama.277.17.1391			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WW261	9134946				2022-12-28	WOS:A1997WW26100030
J	Treasure, T				Treasure, T			How much to tell parents	LANCET			English	Editorial Material											Treasure, T (corresponding author), ST GEORGE HOSP,DEPT CARDIOTHORAC SURG,LONDON SW17 0QT,ENGLAND.							Brahams D, 1996, LANCET, V348, P770, DOI 10.1016/S0140-6736(05)65207-5; FRYE RL, 1992, INT J CARDIOL, V36, P213, DOI 10.1016/0167-5273(92)90009-R; JONAS RA, 1994, ANN CARDIAC SURG, P153; KENNEDY I, 1989, MED LAW TEXT MAT, P395; TREASURE T, 1994, ANN CARDIAC SURG, P161	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1267	1268		10.1016/S0140-6736(05)62503-2	http://dx.doi.org/10.1016/S0140-6736(05)62503-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142058				2022-12-28	WOS:A1997WW89900005
J	Wagner, GR				Wagner, GR			Asbestosis and silicosis	LANCET			English	Article							LUNG-CANCER; GOLD MINERS; EXPOSURE; DUST; TUBERCULOSIS; OPACITIES; FIBROSIS; WORKERS	Interstitial fibrosis resulting from workplace exposure to asbestos and crystalline silica persists throughout the world despite knowledge of the causes and effective means for prevention. Asbestosis and silicosis occurrence is predictable among people overexposed to dusts in various industries and occupations such as mining, construction, manufacturing, and building maintenance. Asbestosis and silicosis are incurable and may be progressive even after dust exposure has ceased, therefore early recognition and supportive interventions are important. Although current disease is a result of past exposures, effective control of current workplace exposures is the only way to prevent continued occurrence of these potentially debilitating diseases. Physicians can contribute to this effort through accurate diagnosis and disease reporting.			Wagner, GR (corresponding author), NIOSH,DIV RESP DIS STUDIES,CTR DIS CONTROL & PREVENT,MORGANTOWN,WV 26505, USA.		Wagner, Gregory R/B-1014-2009					[Anonymous], DHHS NIOSH PUBL; BECKLAKE MR, 1979, BRIT J IND MED, V36, P23; BECKLAKE MR, 1992, MINERAL FIBERS HLTH, P104; BEGIN R, 1991, EXP LUNG RES, V17, P971, DOI 10.3109/01902149109064329; BEGIN R, 1989, EUR RESPIR J, V2, P988; Bollinger N., DHHS NIOSH PUBLICATI, V2005-100; BOURBEAU J, 1990, AM REV RESPIR DIS, V142, P837, DOI 10.1164/ajrccm/142.4.837; COWIE RL, 1990, TUBERCLE, V71, P39, DOI 10.1016/0041-3879(90)90059-H; Health Effects Institute (HEI), 1991, ASB PUBL COMM BUILD; HNIZDO E, 1988, AM REV RESPIR DIS, V138, P1207, DOI 10.1164/ajrccm/138.5.1207; *IARC, IN PRESS EV CARC RIS; International Labour Office, 1980, GUID US ILO INT CLAS; JOHNSON WM, 1993, J OCCUP ENVIRON MED, V35, P716, DOI 10.1097/00043764-199307000-00015; KALLENBERG CGM, 1995, NEPHROL DIAL TRANSPL, V10, P1117, DOI 10.1093/ndt/10.7.1117; KIPEN HM, 1987, BRIT J IND MED, V44, P96; MERLER E, 1994, 10 INT S EP OCC HLTH, P220; NAIDICH DP, 1989, RADIOLOGY, V171, P22, DOI 10.1148/radiology.171.1.2648472; *NAT I OCC SAF HLT, 1996, DHHS NIOSH PUBL, P96; National Institute for Occupational Safety and Health, 2014, NIOSH GEN JOB STRESS, DOI 10.26616/NIOSHPUB2018125; National Institute for Occupational Safety and Health, 1996, NIOSH PUBL, V96; PIGG BJ, 1994, ANN OCCUP HYG, V38, P453, DOI 10.1093/annhyg/38.4.453; ROSENSTOCK L, 1994, TXB CLIN OCCUPATIONA, P254; SCHWARTZ DA, 1990, AM REV RESPIR DIS, V141, P321, DOI 10.1164/ajrccm/141.2.321; SLUISCREMER GK, 1985, BRIT J IND MED, V42, P838; SMITH AH, 1995, EPIDEMIOLOGY, V6, P617, DOI 10.1097/00001648-199511000-00010; SNIDER DE, 1978, AM REV RESPIR DIS, V118, P455; STEENLAND K, 1995, AM J PUBLIC HEALTH, V85, P1372, DOI 10.2105/AJPH.85.10.1372; *US DEP INT, 1995, ASB MIN IND SURV ANN; VALIANTE DJ, 1989, JAMA-J AM MED ASSOC, V262, P3003, DOI 10.1001/jama.262.21.3003; VALLYATHAN V, 1988, AM REV RESPIR DIS, V138, P1213, DOI 10.1164/ajrccm/138.5.1213; WAGNER GR, 1993, OCCUP MED, V8, P127; WAGNER GR, 1996, SCREENIG SURVEILLANC; WILKINSON P, 1995, LANCET, V345, P1074, DOI 10.1016/S0140-6736(95)90817-X; Wilt JL, 1996, J OCCUP ENVIRON MED, V38, P619, DOI 10.1097/00043764-199606000-00014; 1994, FED REG         0810; 1930, LANCET, V1, P701	36	117	124	2	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1311	1315		10.1016/S0140-6736(96)07336-9	http://dx.doi.org/10.1016/S0140-6736(96)07336-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142077	Green Submitted			2022-12-28	WOS:A1997WW89900043
J	Martinelli, I; Cattaneo, M; Panzeri, D; Taioli, E; Mannucci, PM				Martinelli, I; Cattaneo, M; Panzeri, D; Taioli, E; Mannucci, PM			Risk factors for deep venous thrombosis of the upper extremities	ANNALS OF INTERNAL MEDICINE			English	Article							ACTIVATED PROTEIN-C; AXILLOSUBCLAVIAN VEIN-THROMBOSIS; RESISTANCE; HYPERHOMOCYST(E)INEMIA; THROMBOPHILIA; PATHOGENESIS; PREVALENCE	Background: Hypercoagulable states and triggering factors (surgery, trauma, immobilization, pregnancy, and use of oral contraceptives) are associated with an increased risk for deep venous thrombosis of the lower extremities. In contrast, risk factors for deep venous thrombosis of the upper extremities have not been identified. Objective: To evaluate the prevalence of hypercoagulable states and triggering factors in patients with primary deep venous thrombosis of the upper extremities. Design: Frequency-matched case-control study. Setting: Hemophilia and thrombosis center at a university hospital. Patients: 36 patients who had primary deep venous thrombosis of the upper extremities, 121 patients who had primary deep venous thrombosis of the lower extremities, end 108 healthy controls. Patients who had deep venous thrombosis of the lower extremities and study controls were frequency-matched by age, sex, geographic origin, and social status with patients who had deep venous thrombosis of the upper extremities. Measurements: Resistance to activated protein C was evaluated by a clotting method based on the activated partial thromboplastin time. If test results were abnormal or borderline, DNA analysis for substitution in coagulation factor V gene was done. Antithrombin, protein C, protein S, antiphospholipid antibodies, and total plasma homocysteine levels were also measured. Results: Prevalences of abnormalities of the natural anticoagulant system (9 %) and hyperhomocysteinemia (6 %) in patients who had deep venous thrombosis of the upper extremities were similar to prevalences of both factors in controls (6% and 7%, respectively) but lower than in patients who had deep venous thrombosis of the lower extremities (31% and 14%, respectively). Antiphospholipid antibodies were found only in patients who had venous thrombosis of the lower extremities (7%). The overall prevalence of hypercoagulable states in patients who had thrombosis of the upper extremities (15%) was similar to that in controls (12%) but was significantly lower than that in patients who had thrombosis of the lower extremities (56%). A recent history of strenuous exercise of muscles in the affected extremity was the most frequent triggering factor for patients who had deep venous thrombosis in the upper extremities (33%). Conclusions: This preliminary study indicates that the prevalence of hypercoagulable states is low in patients who have primary deep venous thrombosis of the upper extremities.	UNIV MILAN, MAGGIORE HOSP, IST RICOVERO & CURA CARATTERE SCI, EPIDEMIOL UNIT, I-20122 MILAN, ITALY	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Martinelli, I (corresponding author), UNIV MILAN, MAGGIORE HOSP, IST RICOVERO & CURA CARATTERE SCI, I-20122 MILAN, ITALY.		Cattaneo, Marco/AAT-4080-2020; Martinelli, ida/J-2287-2015	Martinelli, ida/0000-0001-9218-3622; Cattaneo, Marco/0000-0002-7343-4534				ABURAHMA AF, 1991, AM J SURG, V161, P459, DOI 10.1016/0002-9610(91)91112-V; AZIZ S, 1986, AM J SURG, V152, P57, DOI 10.1016/0002-9610(86)90141-8; BERNARDI E, 1995, DEEP VEIN THROMBOSIS, P191; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; DEMETER SL, 1982, ANGIOLOGY, V33, P743, DOI 10.1177/000331978203301107; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; DERONDE H, 1994, THROMB HAEMOSTASIS, V72, P880; DeStefano V, 1996, BLOOD, V87, P3531, DOI 10.1182/blood.V87.9.3531.bloodjournal8793531; DONAYRE CE, 1986, AM J SURG, V152, P179, DOI 10.1016/0002-9610(86)90238-2; FAIONI EM, 1993, THROMB HAEMOSTASIS, V70, P1067; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257; HORATTAS MC, 1988, SURGERY, V104, P561; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MALINOW MR, 1994, J INTERN MED, V236, P603, DOI 10.1111/j.1365-2796.1994.tb00854.x; Martinelli I, 1996, THROMB HAEMOSTASIS, V75, P393; PRESCOTT SM, 1979, CIRCULATION, V59, P350, DOI 10.1161/01.CIR.59.2.350; ROCHESTER JR, 1995, BRIT J SURG, V82, P433, DOI 10.1002/bjs.1800820402; Thomas D, 1994, HAEMOSTASIS THROMBOS, P1335	20	80	82	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1997	126	9					707	711		10.7326/0003-4819-126-9-199705010-00006	http://dx.doi.org/10.7326/0003-4819-126-9-199705010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW147	9139557				2022-12-28	WOS:A1997WW14700006
J	Schuman, P; Capps, L; Peng, G; Vazquez, J; ElSadr, W; Goldman, AI; Alston, B; Besch, CL; Vaughn, A; Thompson, MA; Cobb, MN; Kerkering, T; Sobel, JD				Schuman, P; Capps, L; Peng, G; Vazquez, J; ElSadr, W; Goldman, AI; Alston, B; Besch, CL; Vaughn, A; Thompson, MA; Cobb, MN; Kerkering, T; Sobel, JD			Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						fluconazole; human immunodeficiency virus infections; candidiasis, vulvovaginal; candidiasis, oral; Candida albicans	IMMUNODEFICIENCY-VIRUS-INFECTION; ESOPHAGEAL CANDIDIASIS; VAGINAL CANDIDIASIS; ORAL CANDIDIASIS; SAN-FRANCISCO; RESISTANT; AIDS; OROPHARYNGEAL; CANDIDOSIS; EMERGENCE	Background: Candidiasis is a frequent complication of infection with the human immunodeficiency virus (HIV); however, few data exist about the natural history, prevention, and treatment of mucosal candidiasis in women. Objective: To evaluate the safety and effectiveness of weekly fluconazole prophylaxis for mucosal candidiasis in women infected with HIV. Design: Randomized, double-blind, placebo-controlled trial. Setting: 14 sites participating in the Community Programs for Clinical Research on AIDS (CPCRA). Patients: 323 women with HIV infection and CD4(+) cell counts of 300 cells/mm(3) br less. Intervention: 200 mg of fluconazole per week or placebo. Open-label fluconazole for candidiasis prophylaxis was permitted after two oropharyngeal or vaginal episodes or one esophageal episode. Measurements: Development of mucosal candidiasis, clinical and in vitro resistance of Candida species to fluconazole, survival, and adverse events. Results: After a median follow-up of 29 months, 72 of 162 patients receiving fluconazole and 93 of 161 patients receiving placebo had at least one episode of candidiasis (relative risk [RR], 0.56 [95% CI, 0.41 to 0.77]; P < 0.001). Weekly fluconazole was effective in preventing oropharyngeal candidiasis (RR, 0.50 [CI, 0.33 to 0.74]; P < 0.001) and vaginal candidiasis (RR, 0.64 [CI, 0.40 to 1.00]; P = 0.05) but not esophageal candidiasis (RR, 0.91 [CI, 0.48 to 1.72]; P > 0.2). Relative risks were similar for women who had a history of mucosal candidiasis (RR, 0.51 [CI, 0.35 to 0.75]) and those who did not (RR, 0.69 [CI, 0.35 to 1.34]). Absolute risk reduction for patients with a history of infection was 25.6 per 100 person-years, which is more than twice the reduction of 11.2 per 100 person-years seen in patients with no history of infection. This difference reflects the higher risk of patients who previously had an infection. Candida albicans was not usually resistant to fluconazole in vaginal specimens in clinical or in vitro settings; such resistance occurred in less than 5% of patients in each group. Conclusions: Weekly fluconazole (200 mg) seems to be safe and effective in preventing oropharyngeal and vaginal candidiasis. This regimen has a useful role in the management of HIV-infected women who are at risk for recurrent mucosal candidiasis.	DETROIT MED CTR, DETROIT, MI 48201 USA; HARLEM HOSP MED CTR, NEW YORK, NY USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; NIH, BETHESDA, MD 20892 USA; TULANE UNIV MED CTR HOSP & CLIN, NEW ORLEANS, LA USA; NEWARK COMMUNITY HLTH CTR, NEWARK, NJ USA; AIDS RES CONSORTIUM ATLANTA, ATLANTA, GA USA; ADDICT RES & TREATMENT CORP, BROOKLYN, NY USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, RICHMOND, VA 23298 USA	Detroit Medical Center; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; Tulane University; Virginia Commonwealth University	Schuman, P (corresponding author), WAYNE STATE UNIV, DIV INFECT DIS, HARPER PROFESS BLDG, 4160 JOHN R RD, SUITE 2140, DETROIT, MI 48201 USA.							BAILY GG, 1994, AIDS, V8, P787, DOI 10.1097/00002030-199406000-00010; BOKEN DJ, 1993, CLIN INFECT DIS, V17, P1018, DOI 10.1093/clinids/17.6.1018; CHAN ISF, 1995, AIDS, V9, P1145, DOI 10.1097/00002030-199510000-00005; CHAVANET P, 1994, AIDS, V8, P945, DOI 10.1097/00002030-199407000-00011; COX DR, 1972, J R STAT SOC B, V34, P187; DEYTON L, 1991, INT C AIDS, V7, P294; ESPINELINGROFF A, 1995, J CLIN MICROBIOL, V33, P3154, DOI 10.1128/JCM.33.12.3154-3158.1995; FEIGAL DW, 1991, AIDS, V5, P519, DOI 10.1097/00002030-199105000-00007; FITCHENBAUM CJ, 1996, 11 INT C AIDS VANC 7; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; GOA KL, 1995, DRUGS, V50, P658, DOI 10.2165/00003495-199550040-00007; HORN CA, 1995, AIDS, V9, P533, DOI 10.1097/00002030-199509050-00023; HOUANG ET, 1990, ANTIMICROB AGENTS CH, V34, P909, DOI 10.1128/AAC.34.5.909; IMAM N, 1990, AM J MED, V89, P142, DOI 10.1016/0002-9343(90)90291-K; JOHNSON EM, 1995, J ANTIMICROB CHEMOTH, V35, P103, DOI 10.1093/jac/35.1.103; JUSTNUBLING G, 1991, EUR J CLIN MICROBIOL, V10, P917, DOI 10.1007/BF02005444; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEEN CLS, 1990, J INFECTION, V21, P55, DOI 10.1016/0163-4453(90)90646-P; Maenza JR, 1996, J INFECT DIS, V173, P219, DOI 10.1093/infdis/173.1.219; MANTEL N, 1959, J NATL CANCER I, V22, P719; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; PARENTE F, 1994, AM J GASTROENTEROL, V89, P416; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; REEF SE, 1995, CLIN INFECT DIS, V21, pS99, DOI 10.1093/clinids/21.Supplement_1.S99; RHOADS JL, 1987, JAMA-J AM MED ASSOC, V257, P3105, DOI 10.1001/jama.257.22.3105; SANGEORZAN JA, 1994, AM J MED, V97, P339, DOI 10.1016/0002-9343(94)90300-X; SHIBOSKI CH, 1994, J ACQ IMMUN DEF SYND, V7, P964; STEVENS DA, 1991, ARCH INTERN MED, V151, P2458, DOI 10.1001/archinte.151.12.2458; WOLFINGER R, 1993, J STAT COMPUT SIM, V48, P233, DOI 10.1080/00949659308811554; 1996, MMWR-MORBID MORTAL W, V45, P121; 1995, MMWR-MORBID MORTAL W, V44, P81	31	89	91	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1997	126	9					689	+		10.7326/0003-4819-126-9-199705010-00003	http://dx.doi.org/10.7326/0003-4819-126-9-199705010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW147	9139554				2022-12-28	WOS:A1997WW14700003
J	Pearson, G; Shann, F; Barry, P; Vyas, J; Thomas, D; Powell, C; Field, D				Pearson, G; Shann, F; Barry, P; Vyas, J; Thomas, D; Powell, C; Field, D			Should paediatric intensive care be centralised? Trent versus Victoria	LANCET			English	Article							MORTALITY	Background The mortality rate is lower among children admitted to specialist paediatric intensive care units (ICUs) than among those admitted to mixed adult and paediatric units in non-tertiary hospitals. In the UC(, however, few children receive intensive care in specialist paediatric units. We compared the ICU mortality rate in children from the area of the Trent Health Authority, UK, with the rate in children from Victoria, Australia, where paediatric intensive care is highly centralised. Methods We studied all children under 16 years of age from Trent and Victoria who received intensive care between April 1, 1994, and March 31, 1995. Children younger than 1 month were excluded unless they had cardiac disorders. We developed a logistic regression model that used information gathered at the time of admission to ICU to adjust for risk of mortality. Findings The rates of admission of children to intensive care were similar for Trent and Victoria (1.22 and 1.18 per 1000 children per year), but the mean duration of an ICU stay was 3.93 days for Trent children compared with 2.14 days for children from Victoria. 74 (7.3%) of the 1014 children from Trent died, compared with 60 (5.0%) of the 1194 children from Victoria. With adjustment for severity of illness at the time of admission to ICU, the odds ratio for the risk of death for Trent versus Victoria was 2.09 (95% CI 1.37-3.19, p<0.0005). There were 31.7 (14.0-50.4) excess deaths in Trent children, which is equivalent to 42.8% of the deaths in ICU, and 11.1% of all deaths in children between the ages of 1 month and 16 years in Trent. Interpretation If Trent is representative of the whole country, there are 453 (200-720) excess deaths a year in the UK that are probably due to suboptimal results from paediatric intensive care. If the ratio of paediatric ICUs to children were the same in the UK as in Victoria, there would be only 12 paediatric ICUs in the country. Our findings suggest that substantial reductions in mortality could be achieved if every UK child who needed endotracheal intubation for more than 12-24 h were admitted to one of 12 large specialist paediatric ICUs.	BIRMINGHAM CHILDRENS HOSP,PAEDIAT INTENS CARE UNIT,BIRMINGHAM,W MIDLANDS,ENGLAND; ROYAL CHILDRENS HOSP,INTENS CARE UNIT,MELBOURNE,VIC,AUSTRALIA; UNIV LEICESTER,DEPT CHILD HLTH,LEICESTER LE1 7RH,LEICS,ENGLAND; LEICESTER ROYAL INFIRM,LEICESTER,LEICS,ENGLAND; QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND; UNIV SHEFFIELD,DEPT PAEDIAT,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND	University of Birmingham; Royal Children's Hospital Melbourne; University of Leicester; University of Leicester; University of Nottingham; University of Sheffield			Shann, Frank/C-9510-2011; VYAS, Julian Ramesh/I-3603-2019					*BRIT PAED ASS, 1993, CAR CRIT ILL CHILDR; *BRIT PAED ASS, 1987, REP WORK PART PAED I; BURTON P, 1995, J EPIDEMIOL PUBLIC H, V48, P617; Carnall D, 1996, BRIT MED J, V312, P655; Collett D., 1991, MODELLING BINARY DAT; FARLEY DE, 1992, MED CARE, V30, P77, DOI 10.1097/00005650-199201000-00009; GEMKE RJBJ, 1995, CRIT CARE MED, V23, P238, DOI 10.1097/00003246-199502000-00007; Hall JR, 1996, J PEDIATR SURG, V31, P72, DOI 10.1016/S0022-3468(96)90322-X; HALL JR, 1993, AM J DIS CHILD, V147, P102, DOI 10.1001/archpedi.1993.02160250104031; HOSMER DW, 1989, APPL LOGISTIC REGRES; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LUFT HS, 1990, HOSPITAL VOLUME PHYS; POLLACK MM, 1991, CRIT CARE MED, V19, P150, DOI 10.1097/00003246-199102000-00007; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; Shann F, 1997, INTENS CARE MED, V23, P201, DOI 10.1007/s001340050317; SHANN F, 1993, LANCET, V342, P68, DOI 10.1016/0140-6736(93)91282-Q; THOMPSON DR, 1994, CRIT CARE MED, V22, P1306, DOI 10.1097/00003246-199408000-00015; ZWEIG MH, 1993, CLIN CHEM, V39, P561; [No title captured]	20	183	182	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1213	1217		10.1016/S0140-6736(96)12396-5	http://dx.doi.org/10.1016/S0140-6736(96)12396-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130943				2022-12-28	WOS:A1997WW71700011
J	Summerfield, JA; Sumiya, M; Levin, M; Turner, MW				Summerfield, JA; Sumiya, M; Levin, M; Turner, MW			Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY; DEFECT	Objective: To determine the extent to which mutations in the mannose binding protein gene predispose to childhood infection. Design: Clinical details and genotype of mannose binding protein determined in consecutive children attending a paediatric department. Setting: Inner city hospital paediatric service in London. Subjects: 617 children attending hospital between October 1993 and August 1995. Main outcome measure: Infection as the cause for attendance or admission in relation to mutations in the mannose binding protein gene. Results: The prevalence of mutations in the mannose binding protein gene in children with infection (146/345) was about twice that in children without infection (64/272) (P < 0.0001). Increased susceptibility to infection was found in both heterozygotic and homozygotic children. 13 out of 17 children homozygotic for variant alleles presented with strikingly severe infections, including 6 with septicaemia. Conclusions: The findings suggest that mutations in the mannose binding protein gene are an important risk factor for infections in children. Screening for such mutations should be included in the investigation of severe or frequent infections.	INST CHILD HLTH,IMMUNOBIOL UNIT,LONDON WC1N 1EH,ENGLAND	University of London; University College London	Summerfield, JA (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCH MED,PRAED ST,LONDON W2 1NY,ENGLAND.			Levin, Michael/0000-0003-2767-6919				GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; Lipscombe RJ, 1996, EUR J HUM GENET, V4, P13; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; RICHARDSON VF, 1983, ARCH DIS CHILD, V58, P799, DOI 10.1136/adc.58.10.799; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; Sumiya M, 1996, QJM-MON J ASSOC PHYS, V89, P723, DOI 10.1093/qjmed/89.10.723; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; SUPER M, 1989, LANCET, V2, P1236; Turner M W, 1991, Clin Exp Allergy, V21 Suppl 1, P182, DOI 10.1111/j.1365-2222.1991.tb01725.x	11	316	326	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 26	1997	314	7089					1229	1232		10.1136/bmj.314.7089.1229	http://dx.doi.org/10.1136/bmj.314.7089.1229			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW718	9154025	Green Published			2022-12-28	WOS:A1997WW71800016
J	Dolan, B; Parker, C				Dolan, B; Parker, C			Caesarean section: A treatment for mental disorder? Tameside & Glossop Acute Services Unit v CH (a patient) [1996] 1 FLR 762	BRITISH MEDICAL JOURNAL			English	Article									HENDERSON HOSP,SUTTON SM2 5LT,SURREY,ENGLAND; GRANTA HOUSE,LONDON E15 4BQ,ENGLAND		Dolan, B (corresponding author), ST GEORGE HOSP,SCH MED,SUTTON SM2 5LT,SURREY,ENGLAND.							DYER C, 1996, GUARDIAN        1218; GUNN M, 1995, J FORENSIC PSYCHIATR, V6, P411, DOI 10.1080/09585189508409906; RE S, 1997, UNPUB	3	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 19	1997	314	7088					1183	1184		10.1136/bmj.314.7088.1183	http://dx.doi.org/10.1136/bmj.314.7088.1183			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WV705	9146395	Green Published			2022-12-28	WOS:A1997WV70500030
J	Emerich, DF; Winn, SR; Hantraye, PM; Peschanski, M; Chen, EY; Chu, YP; McDermott, P; Baetge, EE; Kordower, JH				Emerich, DF; Winn, SR; Hantraye, PM; Peschanski, M; Chen, EY; Chu, YP; McDermott, P; Baetge, EE; Kordower, JH			Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease	NATURE			English	Article							PROGRESSIVE MOTOR NEURONOPATHY; FACTOR PREVENTS DEGENERATION; EXCITATORY AMINO-ACIDS; QUINOLINIC ACID; NEURONAL DEATH; NERVOUS-SYSTEM; IMPLANTATION; STRIATUM; MOUSE; NGF	Huntington's disease is a genetic disorder that results from degeneration of striatal neurons, particularly those containing GABA (gamma-aminobutyric acid)(1). There is no effective treatment for preventing or slowing this neuronal degeneration. Ciliary neurotrophic factor (CNTF) is a trophic factor for striatal neurons(2,3) and therefore a potential therapeutic agent for Huntington's disease. Here we evaluate CNTF as a neuroprotective agent in a nonhuman primate model of Huntington's disease. We gave cynomolgus monkeys intrastriatal implants of polymer-encapsulated baby hamster kidney fibroblasts that had been genetically modified to secrete human CNTF. One week later, monkeys received unilateral injections of quinolinic acid into the previously implanted striatum to reproduce the neuropathology seen in Huntington's disease(4,5). Human CNTF was found to exert a neuroprotective effect on several populations of striatal cells, including GABAergic, cholinergic and diaphorase-positive neurons which were all destined to die following: administration of quinolinic acid. Human CNTF also prevented the retrograde atrophy of layer V neurons in motor cortex and exerted a significant protective effect on the GABAergic innervation of the two important target fields of the striatal output neurons (the globus pallidus and pars reticulata of the substantia nigra). Our results show that human CNTF has a trophic influence on degenerating: striatal neurons as well as on critical non-striatal regions such as the cerebral cortex, supporting the idea that human CNTF may help to prevent the degeneration of vulnerable striatal populations and cortical-striatal basal ganglia circuits in Huntington's disease.	CYTOTHERAPEUT INC,PROVIDENCE,RI 02906; OREGON HLTH SCI UNIV,DEPT SURG,PORTLAND,OR 97201; SVC HOSP FREDER JOLIET,CNRS,URA 1285,F-91406 ORSAY,FRANCE; INSERM,U421,FAC MED,F-94010 CRETEIL,FRANCE; RUSH PRESBYTERIAN ST LUKES MED CTR,RES CTR BRAIN REPAIR,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT NEUROL SCI,CHICAGO,IL 60612	Oregon Health & Science University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Rush University; Rush University			Peschanski, Marc/N-5769-2017					ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; Anderson KD, 1996, P NATL ACAD SCI USA, V93, P7346, DOI 10.1073/pnas.93.14.7346; APFEL SC, 1993, BRAIN RES, V604, P1, DOI 10.1016/0006-8993(93)90345-N; BAETGE EE, 1986, P NATL ACAD SCI USA, V83, P5454, DOI 10.1073/pnas.83.15.5454; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; BEAL MF, 1989, SYNAPSE, V3, P38, DOI 10.1002/syn.890030106; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLATTERBUCK RE, 1993, P NATL ACAD SCI USA, V90, P2222, DOI 10.1073/pnas.90.6.2222; EMERICH DF, 1994, EXP NEUROL, V130, P141, DOI 10.1006/exnr.1994.1193; EMERICH DF, 1994, J COMP NEUROL, V349, P148, DOI 10.1002/cne.903490110; Emerich DF, 1996, J NEUROSCI, V16, P5168; EMERICH DF, 1992, NEUROMETHODS, V17, P65; FERRANTE RJ, 1987, BRAIN RES, V415, P178; FRIM DM, 1993, J NEUROSCI RES, V35, P452, DOI 10.1002/jnr.490350413; FRIM DM, 1993, NEUROREPORT, V4, P67; HAGG T, 1992, NEURON, V8, P145, DOI 10.1016/0896-6273(92)90116-U; HAGG T, 1993, P NATL ACAD SCI USA, V90, P6315, DOI 10.1073/pnas.90.13.6315; Kordower JH, 1996, NEUROSCIENCE, V72, P63, DOI 10.1016/0306-4522(95)00543-9; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; PARKER WD, 1990, NEUROLOGY, V40, P1231, DOI 10.1212/WNL.40.8.1231; REINER A, 1988, P NATL ACAD SCI USA, V85, P5733, DOI 10.1073/pnas.85.15.5733; ROBERTS RC, 1989, SYNAPSE, V3, P363, DOI 10.1002/syn.890030410; SAGOT Y, 1995, EUR J NEUROSCI, V7, P1313, DOI 10.1111/j.1460-9568.1995.tb01122.x; SCHUMACHER JM, 1991, NEUROSCIENCE, V45, P561, DOI 10.1016/0306-4522(91)90271-O; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; TULIPAN N, 1988, EXP NEUROL, V102, P325, DOI 10.1016/0014-4886(88)90227-0; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WINN SR, 1994, P NATL ACAD SCI USA, V91, P23	29	238	248	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					395	399		10.1038/386395a0	http://dx.doi.org/10.1038/386395a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121555				2022-12-28	WOS:A1997WQ17000064
J	Murray, CJL; Lopez, AD				Murray, CJL; Lopez, AD			Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study	LANCET			English	Article							AIDS; COUNTRIES	Background Plausible projections of future mortality and disability are a useful aid in decisions on priorities for health research, capital investment, and training. Rates and patterns of ill health are determined by factors such as socioeconomic development, educational attainment, technological developments, and their dispersion among populations, as well as exposure to hazards such as tobacco. As part of the Global Burden of Disease Study (GBD), we developed three scenarios of future mortality and disability for different age-sex groups, causes, and regions. Methods We used the most important disease and injury trends since 1950 in nine cause-of-death clusters, Regression equations for mortality rates for each cluster by region were developed from gross domestic product per person (in international dollars). average number of years of education, time (in years, as a surrogate for technical change), and smoking intensity,which shows the cumulative effects based on data for 47 countries in 1950-90. Optimistic, pessimistic, and baseline projections of the independent variables were made. We related mortality from detailed causes to mortality from a cause cluster to project more detailed causes. Based on projected numbers of deaths by cause, years of life lived with disability (YLDs) were projected from different relation models of YLDs to years of life lost (YLLs). Population projections were prepared from World Bank projections of fertility and the projected mortality rates. Findings Life expectancy at birth for women was projected to increase in all three scenarios; in established market economies to about 90 years by 2020. Far smaller gains in male life expectancy were projected than in females; in formerly socialist economies of Europe, male life expectancy may not increase at all. Worldwide mortality from communicable maternal, perinatal, and nutritional disorders was expected to decline in the baseline scenario from 17.2 million deaths in 1990 to 10.3 million in 2020. We projected that non-communicable disease mortality wilt increase from 28.1 million deaths in 1990 to 49.7 million in 2020. Deaths from injury may increase from 5.1 million to 8.4 million. Leading causes of disability-adjusted life years (DALYs) predicted by the baseline model were (in descending order): ischaemic heart disease, unipolar major depression, road-traffic accidents, cerehrovascular disease, chronic obstructive pulmonary disease, lower respiratory infections, tuberculosis, war injuries, diarrhoeal diseases, and HIV. Tobacco-attributable mortality is projected to increase from 3.0 million deaths in 1990 to 8.4 million deaths in 2020. Interpretation Health trends in the next 25 years will he determined mainly by the ageing of the world's population, the decline in age-specific mortality rates from communicable, maternal, perinatal, and nutritional disorders, the spread of HIV, and the increase in tobacco-related mortality and disability. Projections, by their nature, are highly uncertain, but we found some robust results with implications for health policy.	WHO,CH-1211 GENEVA,SWITZERLAND	World Health Organization	Murray, CJL (corresponding author), HARVARD UNIV,SCH PUBL HLTH,9 BOW ST,CAMBRIDGE,MA 02138, USA.		Azadbakht, Morteza/ABA-2569-2020; Lopez, Alan/AAA-2734-2022; Reis-Silva, Thiago M./E-6318-2013; Lopez, Alan D/F-1487-2010; Salami, Aysan/AAZ-6730-2020; Choobkar, Saeed/AAA-3212-2020; Mousavi, Zahra/AAA-3295-2020	Azadbakht, Morteza/0000-0001-8103-3506; Lopez, Alan D/0000-0001-5818-6512; 				ACHARYA A, 1996, ECONOMETRIC MODEL FO; ANDERSON R, 1993, NATURE, V363, P393, DOI 10.1038/363393a0; ANDERSON RM, 1988, NATURE, V333, P514, DOI 10.1038/333514a0; ANDERSON RM, 1991, NATURE, V352, P581, DOI 10.1038/352581a0; BAILEY NTJ, 1957, MATH THEORY INFECTIO; BARRO RJ, 1993, EC GROWTH CROSS SECT; Bezold C, 1994, World Health Forum, V15, P189; BROOKMEYER R, 1989, STAT MED, V8, P23, DOI 10.1002/sim.4780080105; BULUTAO R, 1993, EPIDEMIOLOGICAL TRAN; CALDWELL JC, 1979, POPULATION STUDIES, V41, P5; CHIN J, 1991, B WORLD HEALTH ORGAN, V69, P399; Chin James, 1992, World Health Statistics Quarterly, V45, P220; CLELAND JG, 1988, SOC SCI MED, V27, P1357, DOI 10.1016/0277-9536(88)90201-8; GARRETT MJ, 1993, FUTURES, V25, P254, DOI 10.1016/0016-3287(93)90136-H; HAHN RA, 1995, EPIDEMIOLOGY, V6, P350, DOI 10.1097/00001648-199507000-00004; KARON JM, 1988, J ACQ IMMUN DEF SYND, V1, P542; KUMARESAN JA, 1996, GLOBAL EPIDEMIOLOGY; LOWBEER D, 1996, HLTH DIMENSIONS SEX; MESLE F, 1996, TENDANCES RECENTES M; MURRAY CJL, 1996, GLOBAL BURDENDIS COM; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; Preston SH, 1976, MORTALITY PATTERNS N; RUWAARD D, 1994, PUBLIC HLTH STATUS F; SUMMERS R, 1991, Q J ECON, V106, P327, DOI 10.2307/2937941; Taket A, 1993, HLTH FUTURES SUPPORT	25	4676	4938	20	1018	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 24	1997	349	9064					1498	1504		10.1016/S0140-6736(96)07492-2	http://dx.doi.org/10.1016/S0140-6736(96)07492-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167458				2022-12-28	WOS:A1997XA90100008
J	Romero, MF; Hediger, MA; Boulpaep, EL; Boron, WF				Romero, MF; Hediger, MA; Boulpaep, EL; Boron, WF			Expression cloning and characterization of a renal electrogenic Na+/HCO3- cotransporter	NATURE			English	Article							SODIUM-BICARBONATE COTRANSPORT; ACID-BASE TRANSPORT; SQUID GIANT-AXONS; NA-H EXCHANGE; INTRACELLULAR PH; BASOLATERAL MEMBRANE; PROXIMAL TUBULE; RAT HEPATOCYTES; GLIAL-CELLS; CDNA	Bicarbonate transporters are the principal regulators of pH in animal cells, and play a vital role in acid-base movement in the stomach, pancreas, intestine, kidney, reproductive system and central nervous system. The functional family of HCO3- transporters includes Cl--HCO3- exchangers, three Na+/HCO3- cotransporters(1-3), a K+/HCO3- cotransporter(4,5), and a Na+-driven Cl--HCO3- exchanger(6,7). Molecular information is sparse on HCO3- transporters, apart from Cl--HCO3- exchangers ('anion exchangers'), whose complementary DNAs were cloned several years ago(8-11). Attempts to done other HCO3- transporters, based on binding of inhibitors, protein purification or homology with anion exchangers, have so far been unsuccessful. Here we monitor the intracellular PH and membrane voltage in Xenopus oocytes to follow the expression of the most electrogenic transporter known: the renal 1:3 electrogenic Na+/HCO3- cotransporter from the salamander Ambystoma tigrinum. We now report the successful cloning and characterization of a cDNA encoding a cation-coupled HCO3- transporter. The encoded protein is 1,035 amino acids long with several potential membrane-spanning domains. We show that when it is expressed in Xenopus oocytes, this protein is electrogenic, Na+ and HCO3- dependent, and blocked by the anion-transport inhibitor DIDS, and conclude that it is the renal electrogenic sodium bicarbonate cotransporter (NBC).	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,RENAL DIV,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Romero, MF (corresponding author), YALE UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06510, USA.		Boron, Walter/ABI-1564-2020	Hediger, Matthias/0000-0003-1946-027X; Boron, Walter/0000-0003-4741-7287; Romero, Michael F/0000-0002-1555-7835	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009342] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK009342-02, F32 DK009342-03, F32 DK009342-01, F32 DK009342] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; DART C, 1992, J PHYSIOL-LONDON, V451, P365, DOI 10.1113/jphysiol.1992.sp019169; DEITMER JW, 1987, J PHYSIOL-LONDON, V388, P261, DOI 10.1113/jphysiol.1987.sp016614; FITZ JG, 1989, AM J PHYSIOL, V256, pG491, DOI 10.1152/ajpgi.1989.256.3.G491; GLEESON D, 1989, J CLIN INVEST, V84, P312, DOI 10.1172/JCI114156; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; HOGAN EM, 1995, J GEN PHYSIOL, V106, P821, DOI 10.1085/jgp.106.5.821; HOGAN EM, 1995, J GEN PHYSIOL, V106, P845, DOI 10.1085/jgp.106.5.845; Ishiguro H, 1996, J PHYSIOL-LONDON, V495, P169, DOI 10.1113/jphysiol.1996.sp021582; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; NEWMAN EA, 1991, GLIA, V4, P424, DOI 10.1002/glia.440040411; Newman EA, 1996, J NEUROSCI, V16, P159; RAJENDRAN VM, 1991, J CLIN INVEST, V88, P1379, DOI 10.1172/JCI115444; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; RUSSELL JM, 1976, NATURE, V264, P73, DOI 10.1038/264073a0; Sambrook J., 2002, MOL CLONING LAB MANU; SOLEIMANI M, 1987, J CLIN INVEST, V79, P1276, DOI 10.1172/JCI112948; SOLEIMANI M, 1992, J BIOL CHEM, V267, P18349; THOMAS RC, 1977, J PHYSIOL-LONDON, V273, P317, DOI 10.1113/jphysiol.1977.sp012096; WEINTRAUB WH, 1989, AM J PHYSIOL, V257, pG317, DOI 10.1152/ajpgi.1989.257.3.G317; YOSHITOMI K, 1985, PFLUG ARCH EUR J PHY, V405, P360, DOI 10.1007/BF00595689	27	356	367	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					409	413		10.1038/387409a0	http://dx.doi.org/10.1038/387409a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163427				2022-12-28	WOS:A1997XA49600062
J	Quinn, J; Wells, G; Sutcliffe, T; Jarmuske, M; Maw, J; Stiell, I; Johns, P				Quinn, J; Wells, G; Sutcliffe, T; Jarmuske, M; Maw, J; Stiell, I; Johns, P			A randomized trial comparing octylcyanoacrylate tissue adhesive and sutures in the management of lacerations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PEDIATRIC FACIAL LACERATIONS; REPAIR; HISTOACRYL; SURGERY	Objective.-To assess the effectiveness of a new tissue adhesive for laceration closure. Design;-A prospective, randomized controlled trial. Setting.-An adult teaching hospital. Participants.-One hundred thirty patients with 136 lacerations who consented to enrollment during a 5-month period. The lacerations included all eligible nonmucosal facial lacerations, as well as selected extremity and torso lacerations (not on hands, feet, or joints). One hundred six lacerations were available for early followup, and 98 were available for 3-month evaluation. Interventions.-lacerations were randomly allocated to have skin closure with octylcyanoacrylate adhesive or monofilament suture. Main Outcome Measure.-A 3-month photograph of the wound was assigned a cosmesis score on a previously validated 100-mm visual analog cosmesis scale by a plastic surgeon who was unaware of the method of wound closure. Results.-There were no differences in the mean visual analog cosmesis scores (67 mm for octylcyanoacrylate vs 68 mm for sutures; P=.65). Similarly, there was no difference in the percentage of early (80% vs 82%; P=.80) or late (72% vs 75%; P=.74) optimal wound evaluation scores. The tissue adhesive was a faster method of wound repair (3.6 vs 12.4 minutes; P<.001) as well as being less painful (visual analog pain scores, 7.2 vs 18.0 mm; P<.001). Conclusions.-Octylcyanoacrylate tissue adhesive effectively closes selected lacerations. This relatively painless and fast method of wound repair can replace the need for suturing several million lacerations each year.	UNIV OTTAWA,DIV EMERGENCY MED,OTTAWA,ON,CANADA; UNIV OTTAWA,DIV PLAST SURG,OTTAWA,ON,CANADA; UNIV OTTAWA,DEPT CLIN EPIDEMIOL,OTTAWA,ON,CANADA; UNIV OTTAWA,DEPT OTOLARYNGOL,OTTAWA,ON,CANADA	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa	Quinn, J (corresponding author), UNIV MICHIGAN,SECT EMERGENCY MED,TC B1354,BOX 0303,1500 E MED CTR DR,ANN ARBOR,MI 48109, USA.			Quinn, James/0000-0002-3694-2118				APPLEBAUM JS, 1993, ANN EMERG MED, V22, P1190, DOI 10.1016/S0196-0644(05)80988-6; BRUNS TB, 1995, ACAD EMERG MED, V2, P427; COOVER HN, 1959, J SOC PLAST SURG ENG, V15, P5; EDLICH RF, 1971, AM J SURG, V117, P394; Eland JM, 1977, PAIN SOURCE BOOK NUR, P453; ELLIS DAF, 1990, J OTOLARYNGOL, V19, P68; GALIL A, 1984, J CAN DENT ASSOC, V50, P565; HALOPURO S, 1976, ANN CHIR GYNAECOL, V65, P308; HOLLANDER JE, 1995, ANN EMERG MED, V25, P675, DOI 10.1016/S0196-0644(95)70183-4; HOWELL JM, 1996, ACAD EMERG MED, V3, P426; Huskisson E., 1983, PAIN MEASUREMENT ASS, P33; KAMER FM, 1989, ARCH OTOLARYNGOL, V115, P193; Keng T M, 1989, Med J Malaysia, V44, P122; KUNG H, 1986, EVALUATION UNDESIRAB; Maw JL, 1997, J OTOLARYNGOL, V26, P26; McCaig L F, 1994, Adv Data, P1; MIZRAHI S, 1988, J PEDIATR SURG, V23, P312, DOI 10.1016/S0022-3468(88)80195-7; MORTON RJ, 1988, ARCH EMERG MED, V5, P110; Noordzij J. Pieter, 1994, Journal of Emergency Medicine, V12, P645; OSMOND MH, 1995, J PEDIATR-US, V126, P892, DOI 10.1016/S0022-3476(95)70203-2; Perry LC, 1995, EVALUATION ACUTE INC; QUINN JV, 1993, ANN EMERG MED, V22, P1130, DOI 10.1016/S0196-0644(05)80977-1; QUINN JV, 1995, AM J EMERG MED, V13, P229, DOI 10.1016/0735-6757(95)90100-0; QUINN JV, IN PRESS SURGERY; Singer AJ, 1996, ACAD EMERG MED, V3, P378, DOI 10.1111/j.1553-2712.1996.tb03454.x; Storrow A B, 1994, Acad Emerg Med, V1, P454; TORIUMI DM, 1991, LARYNGOSCOPE, V101, P339; *US FDA, 1995, INV DEV EX G950193; YARON M, 1995, ACAD EMERG MED, V2, P259	29	236	259	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	1997	277	19					1527	1530						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY969	9153366				2022-12-28	WOS:A1997WY96900030
J	Simoons, ML; Rutsch, W; Vahanian, A; Adgey, J; Maseri, A; Vassanelli, C; Col, J; Adelman, A; Macaya, C; Miller, H; deBoer, MJ; McCloskey, R; Weisman, H; Verstraete, M; deBono, D; Swedberg, K; Lessafre, E; Schotsmans, P; Tijssen, J; Bar, F; Deckers, JW; Piek, JJ; Klootwijk, APJ; Block, P; Cats, VM; Bruggeling, W; Jonkman, F; vanderMeer, P; Umans, V; Foley, D; Ansink, T; Keane, D; Sane, D; Koudstaal, P; vandenBrand, MJBM; Laarman, GJ; Hendrickx, G; deScheerder, I; Steg, PG; Beatt, K; vanPapendrecht, MH; Lenderink, T; Malbrain, S; Paul, J; deCraen, T; Cabacowic, S; Schaible, T; Anderson, K; Wang, A; Fitzpatrick, S; Daniels, M; Poulussen, T; deGraff, J; Dijkhuizen, M; Verhamme, K; Nelissen, I; Gibbs, M; Marron, S; Lochu, S; Guiot, C; Ferrari, P; Vizzotto, A; Alemany, A; Maltillo, E; Hoffmann, S; Stahl, L; Kafka, D; Suryapranata, H; Liem, AL; Velsink, G; vanderWieken, R; Ezechiels, JP; Zonneveld, S; vandenBrand, M; vanderZwaan, C; Kint, PP; Michels, RM; Bonmier, J; VanderKerkhof, I; Hanekamp, C; Peels, J; Drok, L; denHeijer, P; Plokker, T; Mast, EG; Marquez, K; VandenBos, AA; Chin, U; Cornel, JH; Arnold, A; Garbarz, E; Nallet, O; Farrah, B; Carrie, D; Puel, J; Jean, M; Charbonnier, B; Pacouret, G; Raynaud, R; Bertrand, B; Vanzetto, G; Grollier, G; Valette, B; Thery, C; Lablanche, JM; Duclos, F; Coste, P; Beaufils, P; Eiferman, E; Daubert, C; Leclercq, C; Juliard, JJM; Bassand, JP; Meneveau, N; Guermonprez, JL; Vrolix, M; VanLierde, J; Jacobs, S; Boland, J; Saat, G; Baumans, P; Staelens, F; DeBruyne, B; Taeymans, Y; Gheeraert, P; alSchwafi, K; vandenHeuvel, P; Rogiers, R; Castadot, M; deWit, E; Gulba, D; Dechend, R; Christow, S; Simon, R; AlMokthari, N; vonDahl, J; Janssens, U; Haude, M; Baumgart, D; Karsch, KR; Maier, R; Brunckhorst, C; Reifart, N; Krajcar, M; Rupprecht, HJ; Cobaugh, M; HernandezAntolin, R; Segovia, J; Garcia, P; Cequir, A; Esplugas, E; GomezHospital, J; Mauri, J; Angel, J; Ballester, R; delaTassa, CM; Barriales, F; Auge, J; Garcia, J; Melgares, R; Khan, M; Johnston, P; McKay, Y; Been, M; Kahn, A; Ilsley, C; Ewan, A; Reid, D; McDermott, A; Ward, D; Buller, N; Balcon, R; Zardini, P; Loschiavo, I; Casari, A; Piti, A; Costalunga, A; Repetto, S; Carella, S; Marzilli, M; Fedele, S; Chioin, R; Reimers, B; Mazzari, A; Specchia, G; Chiariello, M; Shepps, D; Sclarovski, S; Gal, B; Caspi, A; Ayzenberg, O; Sharir, T; Hod, H; Buser, P; Pfisterer, M; Ritz, R; Bertel, O; Rohner, F; Ducas, J; Shick, U; Cheung, P; Chisholm, R; Cohen, E; Gomez, RS; Ferreira, J; Muhlberger, V				Simoons, ML; Rutsch, W; Vahanian, A; Adgey, J; Maseri, A; Vassanelli, C; Col, J; Adelman, A; Macaya, C; Miller, H; deBoer, MJ; McCloskey, R; Weisman, H; Verstraete, M; deBono, D; Swedberg, K; Lessafre, E; Schotsmans, P; Tijssen, J; Bar, F; Deckers, JW; Piek, JJ; Klootwijk, APJ; Block, P; Cats, VM; Bruggeling, W; Jonkman, F; vanderMeer, P; Umans, V; Foley, D; Ansink, T; Keane, D; Sane, D; Koudstaal, P; vandenBrand, MJBM; Laarman, GJ; Hendrickx, G; deScheerder, I; Steg, PG; Beatt, K; vanPapendrecht, MH; Lenderink, T; Malbrain, S; Paul, J; deCraen, T; Cabacowic, S; Schaible, T; Anderson, K; Wang, A; Fitzpatrick, S; Daniels, M; Poulussen, T; deGraff, J; Dijkhuizen, M; Verhamme, K; Nelissen, I; Gibbs, M; Marron, S; Lochu, S; Guiot, C; Ferrari, P; Vizzotto, A; Alemany, A; Maltillo, E; Hoffmann, S; Stahl, L; Kafka, D; Suryapranata, H; Liem, AL; Velsink, G; vanderWieken, R; Ezechiels, JP; Zonneveld, S; vandenBrand, M; vanderZwaan, C; Kint, PP; Michels, RM; Bonmier, J; VanderKerkhof, I; Hanekamp, C; Peels, J; Drok, L; denHeijer, P; Plokker, T; Mast, EG; Marquez, K; VandenBos, AA; Chin, U; Cornel, JH; Arnold, A; Garbarz, E; Nallet, O; Farrah, B; Carrie, D; Puel, J; Jean, M; Charbonnier, B; Pacouret, G; Raynaud, R; Bertrand, B; Vanzetto, G; Grollier, G; Valette, B; Thery, C; Lablanche, JM; Duclos, F; Coste, P; Beaufils, P; Eiferman, E; Daubert, C; Leclercq, C; Juliard, JJM; Bassand, JP; Meneveau, N; Guermonprez, JL; Vrolix, M; VanLierde, J; Jacobs, S; Boland, J; Saat, G; Baumans, P; Staelens, F; DeBruyne, B; Taeymans, Y; Gheeraert, P; alSchwafi, K; vandenHeuvel, P; Rogiers, R; Castadot, M; deWit, E; Gulba, D; Dechend, R; Christow, S; Simon, R; AlMokthari, N; vonDahl, J; Janssens, U; Haude, M; Baumgart, D; Karsch, KR; Maier, R; Brunckhorst, C; Reifart, N; Krajcar, M; Rupprecht, HJ; Cobaugh, M; HernandezAntolin, R; Segovia, J; Garcia, P; Cequir, A; Esplugas, E; GomezHospital, J; Mauri, J; Angel, J; Ballester, R; delaTassa, CM; Barriales, F; Auge, J; Garcia, J; Melgares, R; Khan, M; Johnston, P; McKay, Y; Been, M; Kahn, A; Ilsley, C; Ewan, A; Reid, D; McDermott, A; Ward, D; Buller, N; Balcon, R; Zardini, P; Loschiavo, I; Casari, A; Piti, A; Costalunga, A; Repetto, S; Carella, S; Marzilli, M; Fedele, S; Chioin, R; Reimers, B; Mazzari, A; Specchia, G; Chiariello, M; Shepps, D; Sclarovski, S; Gal, B; Caspi, A; Ayzenberg, O; Sharir, T; Hod, H; Buser, P; Pfisterer, M; Ritz, R; Bertel, O; Rohner, F; Ducas, J; Shick, U; Cheung, P; Chisholm, R; Cohen, E; Gomez, RS; Ferreira, J; Muhlberger, V			Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study	LANCET			English	Article							MYOCARDIAL-INFARCTION; BALLOON ANGIOPLASTY; IIB/IIIA INTEGRIN; ARTERY DISEASE; FOLLOW-UP; ANTIBODY; FIBRINOGEN; OCCLUSION; DEATH	Background Platelet aggregation is a dominant feature in the pathophysiology of unstable angina. Percutaneous transluminal coronary angioplasty (PTCA) in patients with this disorder carries an increased risk of thrombotic complications. Abciximab (c7E3) blocks the platelet glycoprotein IIb/IIIa receptor, thus preventing platelet adhesion and aggregation. The CAPTURE study was a randomised placebo-controlled multicentre trial to assess whether abciximab can improve outcome in patients with refractory unstable angina who are undergoing PTCA. Methods The study recruited patients with refractory unstable angina, defined as recurrent myocardial ischaemia under medical treatment including heparin and nitrates. Predefined stopping rules were met at a planned interim analysis of data for 1050 patients, and recruitment was stopped. Data for 1265 patients (of 1400 scheduled) are presented here. After angiography, patients received a randomly assigned infusion of abciximab or placebo for 18-24 h before PTCA, continuing until 1 h afterwards. The primary endpoint was the occurrence within 30 days after PTCA of death (any cause), myocardial infarction, or urgent intervention for recurrent ischaemia. Analyses were by intention to treat. Findings By 30 days, the primary endpoint had occurred in 71 (11.3%) of 630 patients who received abciximab compared with 101 (15.9%) of 635 placebo recipients (p=0.012). The rate of myocardial infarction was lower in the abciximab than in the placebo group before PTCA (four [0.6%] vs 13 [2.1%], p=0.029) and during PTCA (16 [2.6%] vs 34 [5.5%], p=0.009). Major bleeding was infrequent, but occurred more often with abciximab than with placebo (24 [3.8%] vs 12 [1.9%], p=0.043). At 6-month follow-up, death, myocardial infarction, or repeal intervention had occurred in 193 patients in each group. Interpretation In patients with refractory unstable angina, treatment with abciximab substantially reduces the rate of thrombotic complications, in particular myocardial infarction, before, during, and after PTCA. There was no evidence that this regimen influenced the rate of myocardial infarction after the first few days, or the need for subsequent reintervention.			Simoons, ML (corresponding author), UNIV ROTTERDAM HOSP, THORAXCTR, BD 434, DR MOLEWATERPLEIN 40, NL-3015 GD ROTTERDAM, NETHERLANDS.		de Boer, M.J./H-8014-2014; Suryapranata, H./H-8095-2014; caspi, avshalom/AAJ-5874-2020; cornel, jan hein/Y-7065-2019; STEG, Philippe Gabriel/Z-1567-2019; Swedberg, Karl/B-2475-2008; Vanzetto, Gerald/M-5513-2014	caspi, avshalom/0000-0003-0082-4600; cornel, jan hein/0000-0002-1006-2112; 				AGUIRRE FV, 1995, CIRCULATION, V91, P2882, DOI 10.1161/01.CIR.91.12.2882; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CHOI ET, 1994, J VASC SURG, V19, P125, DOI 10.1016/S0741-5214(94)70127-X; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DEFEYTER PJ, 1991, CIRCULATION, V83, P927, DOI 10.1161/01.CIR.83.3.927; DeFeyter PJ, 1995, EUR HEART J, V16, P97, DOI 10.1093/eurheartj/16.suppl_L.97; FAITHFULL NS, 1992, ADV EXP MED BIOL, V317, P55; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; KING SB, 1996, EUR C CARD BIRM; Klootwijk P, 1996, EUR HEART J, V17, P689; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LANDEFELD CS, 1987, AM J MED, V82, P703, DOI 10.1016/0002-9343(87)90004-0; Mark DB, 1996, CIRCULATION, V94, P629, DOI 10.1161/01.CIR.94.4.629; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; *RISC GROUP, 1990, LANCET, V3376, P827; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Serruys PW, 1996, CIRCULATION, V93, P412, DOI 10.1161/01.CIR.93.3.412; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIMOONS ML, 1994, CIRCULATION, V89, P596, DOI 10.1161/01.CIR.89.2.596; TCHENG JA, 1995, C EUR SOC CARD AMST; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; TOPOL EJ, 1996, C EUR SOC CARD BIRM; VANMILTENBURGVANZIJL AJM, 1995, J AM COLL CARDIOL, V25, P1286, DOI 10.1016/0735-1097(95)00009-S; WARD SR, IN PRESS CIRCULATION	28	1100	1112	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	1997	349	9063					1429	1435						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164316				2022-12-28	WOS:A1997WZ76500010
J	King, DP; Zhao, YL; Sangoram, AM; Wilsbacher, LD; Tanaka, M; Antoch, MP; Steeves, TDL; Vitaterna, MH; Kornhauser, JM; Lowrey, PL; Turek, FW; Takahashi, JS				King, DP; Zhao, YL; Sangoram, AM; Wilsbacher, LD; Tanaka, M; Antoch, MP; Steeves, TDL; Vitaterna, MH; Kornhauser, JM; Lowrey, PL; Turek, FW; Takahashi, JS			Positional cloning of the mouse circadian Clock gene	CELL			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; MESSENGER-RNA LEVELS; DROSOPHILA PERIOD; AH-RECEPTOR; DNA-BINDING; TRANSCRIPTION FACTOR; PROTEIN-INTERACTION; DIOXIN RECEPTOR; TIMELESS; DOMAIN	We used positional cloning to identify the circadian Clock gene in mice. Clock is a large transcription unit with 24 exons spanning similar to 100,000 bp of DNA from which transcript classes of 7.5 and similar to 10 kb arise. Clock encodes a novel member of the bHLH-PAS family of transcription factors. In the Clock mutant allele, an A-->T nucleotide transversion in a splice donor site causes exon skipping and deletion of 51 amino acids in the CLOCK protein. Clock is a unique gene with known circadian function and with features predicting DNA binding, protein dimerization, and activation domains. CLOCK represents the second example of a PAS domain-containing clock protein (besides Drosophila PERIOD), which suggests that this motif may define an evolutionarily conserved feature of the circadian clock mechanism.	NORTHWESTERN UNIV, DEPT NEUROBIOL & PHYSIOL, NATL SCI FDN CTR BIOL TIMING, EVANSTON, IL 60208 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University			Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019	Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878; Antoch, mantoch/0000-0003-3001-8511	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039592] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKAGI J, 1988, BIOCHEM BIOPH RES CO, V157, P548, DOI 10.1016/S0006-291X(88)80284-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BRUNKOW ME, 1995, GENOMICS, V25, P421, DOI 10.1016/0888-7543(95)80042-K; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHARTIER FL, 1992, NAT GENET, V1, P132, DOI 10.1038/ng0592-132; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; DIETRICH W, 1992, GENETICS, V131, P423; DOVE WF, 1987, GENETICS, V116, P5; Dracopoli NC, 1994, CURRENT PROTOCOLS HU; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Fukada S, 1996, MOL REPROD DEV, V45, P285, DOI 10.1002/(SICI)1098-2795(199611)45:3&lt;285::AID-MRD4&gt;3.0.CO;2-O; Fukuda S., 1995, Development, Growth & Differentiation, V37, P379, DOI 10.1046/j.1440-169X.1995.t01-3-00004.x; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Gradin K, 1996, MOL CELL BIOL, V16, P5221; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HAWKINS TL, 1994, NUCLEIC ACIDS RES, V22, P4543, DOI 10.1093/nar/22.21.4543; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KRAWCZAK M, 1992, HUM GENET, V90, P41; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LOVETT M, 1994, TRENDS GENET, V10, P352, DOI 10.1016/0168-9525(94)90131-7; Lynch G. Robert, 1992, V8, P251; MEIJER JH, 1989, PHYSIOL REV, V69, P671, DOI 10.1152/physrev.1989.69.3.671; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOORE RY, 1995, CIBA F SYMP, V183, P88; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHWARTZ WJ, 1990, J NEUROSCI, V10, P3685; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SUHR ST, 1989, MOL ENDOCRINOL, V3, P1693, DOI 10.1210/mend-3-11-1693; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; TAKAHASHI JS, 1994, SCIENCE, V264, P1724, DOI 10.1126/science.8209253; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; TAKAHASHI JS, 1992, SCIENCE, V258, P238, DOI 10.1126/science.1384127; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; TUREK FW, 1996, HDB PHYSL 4, V2, P1329; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; Yamaguchi T, 1996, J BIOCHEM-TOKYO, V120, P494; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	74	1064	1120	2	74	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	1997	89	4					641	653		10.1016/S0092-8674(00)80245-7	http://dx.doi.org/10.1016/S0092-8674(00)80245-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160755	Green Accepted, Bronze			2022-12-28	WOS:A1997WZ32300017
J	Rief, M; Gautel, M; Oesterhelt, F; Fernandez, JM; Gaub, HE				Rief, M; Gautel, M; Oesterhelt, F; Fernandez, JM; Gaub, HE			Reversible unfolding of individual titin immunoglobulin domains by AFM	SCIENCE			English	Article							ATOMIC-FORCE MICROSCOPE; ELASTICITY; MUSCLE; PROTEINS; ADHESION; ENERGY; DNA	Single-molecule atomic force microscopy (AFM) was used to investigate the mechanical properties of titin, the giant sarcomeric protein of striated muscle. Individual titin molecules were repeatedly stretched, and the applied force was recorded as a function of the elongation. At large extensions, the restoring force exhibited a sawtoothlike pattern, with a periodicity that varied between 25 and 28 nanometers. Measurements of recombinant titin immunoglobulin segments of two different lengths exhibited the same pattern and allowed attribution of the discontinuities to the unfolding of individual immunoglobutin domains. The forces required to unfold individual domains ranged from 150 to 300 piconewtons and depended on the pulling speed. Upon relaxation, refolding of immunoglobulin domains was observed.	LEHRSTUHL ANGEW PHYS,D-80799 MUNICH,GERMANY; EUROPEAN MOL BIOL LAB,BIOL STRUCT DIV,D-69012 HEIDELBERG,GERMANY; MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,ROCHESTER,MN 55905	University of Munich; European Molecular Biology Laboratory (EMBL); Mayo Clinic			Gautel, Mathias/AAB-9860-2019					BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BINNIG G, 1987, REV MOD PHYS, V59, P615, DOI 10.1103/RevModPhys.59.615; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Cluzel P, 1996, SCIENCE, V271, P792, DOI 10.1126/science.271.5250.792; Dammer U, 1996, BIOPHYS J, V70, P2437, DOI 10.1016/S0006-3495(96)79814-4; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; Evans E, 1997, BIOPHYS J, V72, P1541, DOI 10.1016/S0006-3495(97)78802-7; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; Fong S, 1996, J MOL BIOL, V264, P624, DOI 10.1006/jmbi.1996.0665; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Gautel M, 1996, FEBS LETT, V385, P11, DOI 10.1016/0014-5793(96)00338-9; Grubmuller H, 1996, SCIENCE, V271, P997, DOI 10.1126/science.271.5251.997; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LEE GU, 1994, SCIENCE, V266, P771, DOI 10.1126/science.7973628; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; MARUYAMA K, 1977, J BIOCHEM, V82, P317; MULLER DJ, 1995, J MOL BIOL, V249, P239, DOI 10.1006/jmbi.1995.0292; PAN KM, 1994, BIOCHEMISTRY-US, V33, P8255, DOI 10.1021/bi00193a012; PERKINS TT, 1995, SCIENCE, V268, P83, DOI 10.1126/science.7701345; Politou AS, 1996, J MOL BIOL, V255, P604, DOI 10.1006/jmbi.1996.0050; Politou AS, 1995, BIOPHYS J, V69, P2601, DOI 10.1016/S0006-3495(95)80131-1; POLITOU AS, 1994, FEBS LETT, V352, P27, DOI 10.1016/0014-5793(94)00911-2; RADMACHER M, 1994, SCIENCE, V265, P1577, DOI 10.1126/science.8079171; Rief M, 1997, SCIENCE, V275, P1295, DOI 10.1126/science.275.5304.1295; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; SOTERIOU A, 1993, P ROY SOC B-BIOL SCI, V254, P83, DOI 10.1098/rspb.1993.0130; WANG K, 1979, P NATL ACAD SCI USA, V76, P3698, DOI 10.1073/pnas.76.8.3698	31	2466	2516	12	682	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 16	1997	276	5315					1109	1112		10.1126/science.276.5315.1109	http://dx.doi.org/10.1126/science.276.5315.1109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9148804				2022-12-28	WOS:A1997WZ22500043
J	Anderson, JD; Lau, EL; Sjogren, WL; Schubert, G; Moore, WB				Anderson, JD; Lau, EL; Sjogren, WL; Schubert, G; Moore, WB			Gravitational evidence for an undifferentiated Callisto	NATURE			English	Article							GALILEAN SATELLITES; GRAVITY-FIELD; TRACKING DATA; JUPITER	Before the arrival of the Galileo spacecraft at Jupiter, models for the interior structure of the four galilean satellites-Io, Europa, Ganymede and Callisto-ranged from uniform mixtures of rock and ice (that is, undifferentiated objects) or rocky cores surrounded by a mantle of water ice(1). Now it appears that Io has a large metallic core(2) and that Ganymede is strongly differentiated, most probably into a three-layer structure consisting of a metallic core, a silicate mantle and a deep outer layer of ice(3). Direct information on the interior structure of Callisto determined from previous spacecraft fly-bys(4-6) was essentially limited to an estimate of the mean density being intermediate between pure ice and pure rock, Here we report measurements of Callisto's gravitational field which reveal that, in contrast to Io and Ganymede, this galilean satellite is most probably a homogeneous object consisting of a solar mixture of 40% compressed ice and 60% rock (including iron and iron sulphide), Callisto's undifferentiated state is consistent with the apparent lack of an intrinsic magnetic field(7), and indicates that the outermost galilean satellite has not experienced a heating phase sufficiently high to separate its rock and metal components from the lighter ices.	UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,DEPT EARTH & SPACE SCI,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	Anderson, JD (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.							Anderson JD, 1996, NATURE, V384, P541, DOI 10.1038/384541a0; Anderson JD, 1996, SCIENCE, V272, P709, DOI 10.1126/science.272.5262.709; ANDERSON JD, 1974, EXPT GRAVITATION, P163; CAMPBELL JK, 1985, ASTRON J, V90, P364, DOI 10.1086/113741; DERMOTT SF, 1979, ICARUS, V37, P310, DOI 10.1016/0019-1035(79)90137-4; HUBBARD WB, 1978, ICARUS, V33, P336, DOI 10.1016/0019-1035(78)90153-7; JEFFREYS H, 1962, EARTH; Kaula W.M., 1966, THEORY SATELLITE GEO; Kaula W.M., 1968, INTRO PLANETARY PHYS; Khurana KK, 1997, NATURE, V387, P262, DOI 10.1038/387262a0; MALHOTRA R, 1991, ICARUS, V94, P399, DOI 10.1016/0019-1035(91)90237-N; MOYER TD, 1971, TR321527 JET PROP LA; NULL GW, 1976, ASTRON J, V81, P1153, DOI 10.1086/111999; NULL GW, 1975, SCIENCE, V12, P476; Schubert G, 1996, NATURE, V384, P544, DOI 10.1038/384544a0; SCHUBERT G, 1994, ICARUS, V111, P433, DOI 10.1006/icar.1994.1154; SCHUBERT G, 1986, SATELLITES, P629; TAPLEY BD, 1973, RECENT ADV DYNAMICAL, P396; ZHARKOV VN, 1985, ICARUS, V61, P92, DOI 10.1016/0019-1035(85)90157-5	19	49	52	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					264	266		10.1038/387264a0	http://dx.doi.org/10.1038/387264a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153389				2022-12-28	WOS:A1997WZ16700046
J	Golkar, L; Bernhard, JD				Golkar, L; Bernhard, JD			Mastocytosis	LANCET			English	Article							MAST-CELL DISEASE; SYSTEMIC MASTOCYTOSIS; C-KIT; URTICARIA-PIGMENTOSA; BONE-MARROW; GROWTH-FACTOR; CUTANEOUS MASTOCYTOSIS; IMPROVED DIAGNOSIS; DISORDERS; MANIFESTATIONS		UNIV MASSACHUSETTS, DIV DERMATOL, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester								AZANA JM, 1994, PEDIATR DERMATOL, V11, P102, DOI 10.1111/j.1525-1470.1994.tb00560.x; BARTON J, 1985, ARCH DERMATOL, V121, P1516, DOI 10.1001/archderm.121.12.1516; Bernhard JD., 1994, ITCH MECH MANAGEMENT; BRUNNING RD, 1983, AM J SURG PATHOL, V7, P425, DOI 10.1097/00000478-198307000-00005; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CHERNER JA, 1988, GASTROENTEROLOGY, V95, P657, DOI 10.1016/S0016-5085(88)80012-X; CZARNETZKI BM, 1994, J AM ACAD DERMATOL, V30, P500, DOI 10.1016/S0190-9622(08)81953-6; DEMIS DJ, 1963, ANN INTERN MED, V59, P194, DOI 10.7326/0003-4819-59-2-194; DEMIS DJ, 1961, ARCH DERMATOL, V83, P127, DOI 10.1001/archderm.1961.01580070133015; DUFFY TP, 1993, NEW ENGL J MED, V328, P1333, DOI 10.1056/NEJM199305063281809; FRELDMAN B, 1990, SURGERY, V107, P94; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GALLI SJ, 1993, J CLIN INVEST, V91, P148, DOI 10.1172/JCI116164; GALLI SJ, 1993, AM J PATHOL, V142, P965; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GARRIGA MM, 1988, J ALLERGY CLIN IMMUN, V82, P425, DOI 10.1016/0091-6749(88)90015-2; GASIORCHRZAN B, 1992, DERMATOLOGY, V184, P149, DOI 10.1159/000247526; GERRARD JW, 1979, J PEDIATR-US, V94, P843, DOI 10.1016/S0022-3476(79)80177-8; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GRANERUS G, 1983, J INVEST DERMATOL, V80, P410, DOI 10.1111/1523-1747.ep12555351; GRUCHALLA RS, 1995, AM J MED SCI, V309, P328, DOI 10.1097/00000441-199506000-00007; HORAN RF, 1991, J INVEST DERMATOL, V96, pS5, DOI 10.1111/1523-1747.ep12468899; HORAN RF, 1990, J ALLERGY CLIN IMMUN, V85, P852, DOI 10.1016/0091-6749(90)90067-E; HORNY HP, 1985, HUM PATHOL, V16, P808, DOI 10.1016/S0046-8177(85)80252-5; HORNY HP, 1989, CANCER-AM CANCER SOC, V63, P532, DOI 10.1002/1097-0142(19890201)63:3<532::AID-CNCR2820630322>3.0.CO;2-F; Kerdel F A, 1989, Adv Dermatol, V4, P159; KETTELHUT BV, 1989, AM J CLIN PATHOL, V91, P558, DOI 10.1093/ajcp/91.5.558; KETTELHUT BV, 1994, ANN ALLERGY, V73, P197; KETTELHUT BV, 1991, J INVEST DERMATOL, V96, pS15, DOI 10.1111/1523-1747.ep12468942; KEYZER JJ, 1983, NEW ENGL J MED, V309, P1603, DOI 10.1056/NEJM198312293092603; KIRSHENBAUM AS, 1991, J IMMUNOL, V146, P1410; KIRSHENBAUM AS, 1989, MAST CELL BASOPHIL D; KLUINNELEMANS HC, 1992, NEW ENGL J MED, V326, P619, DOI 10.1056/NEJM199202273260907; KOIDE G, 1995, BRIT J DERMATOL, V133, P91; Kors JW, 1996, J INTERN MED, V239, P157, DOI 10.1046/j.1365-2796.1996.440787000.x; KUTER I, 1992, NEW ENGL J MED, V326, P472; LAWRENCE JB, 1991, AM J MED, V91, P612, DOI 10.1016/0002-9343(91)90214-I; LERNO G, 1990, BRIT J ANAESTH, V65, P254, DOI 10.1093/bja/65.2.254; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; LONGLEY BJ, 1993, NEW ENGL J MED, V328, P1302, DOI 10.1056/NEJM199305063281803; LONGLEY J, 1994, ANN MED, V26, P115, DOI 10.3109/07853899409147338; LONGLEY J, 1995, J AM ACAD DERMATOL, V32, P545, DOI 10.1016/0190-9622(95)90336-4; MEGGS WJ, 1985, CLIN RES, V33, pA162; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS64, DOI 10.1111/1523-1747.ep12469665; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS2, DOI 10.1111/1523-1747.ep12468882; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS55, DOI 10.1111/1523-1747.ep12469049; MICAN JM, 1995, HEPATOLOGY, V22, P1163, DOI 10.1016/0270-9139(95)90625-8; MORROW JD, 1995, J INVEST DERMATOL, V104, P937, DOI 10.1111/1523-1747.ep12606209; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Norris A, 1996, BRIT J DERMATOL, V134, P299; PARWARESCH MR, 1985, PATHOL RES PRACT, V179, P439, DOI 10.1016/S0344-0338(85)80184-9; POVOA P, 1991, J INTERN MED, V229, P475, DOI 10.1111/j.1365-2796.1991.tb00379.x; REISBERG IR, 1987, AM J GASTROENTEROL, V82, P54; RIDELL B, 1986, ARCH DERMATOL, V122, P422; Roberts L J 2nd, 1982, Trans Assoc Am Physicians, V95, P36; ROBERTS LJ, 1988, ENDOCRIN METAB CLIN, V17, P415, DOI 10.1016/S0889-8529(18)30427-4; SAGHER F, 1967, MASTOCYTOSIS MAST CE; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SOTER NA, 1979, NEW ENGL J MED, V301, P465, DOI 10.1056/NEJM197908303010903; SOTER NA, 1991, J INVEST DERMATOL, V96, pS32, DOI 10.1111/1523-1747.ep12468973; Stein D H, 1986, Pediatr Dermatol, V3, P365, DOI 10.1111/j.1525-1470.1986.tb00543.x; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; THARP MD, 1988, J AM ACAD DERMATOL, V18, P298, DOI 10.1016/S0190-9622(88)70043-2; THARP MD, 1995, J INVEST DERMATOL, V104, P885, DOI 10.1111/1523-1747.ep12606153; THARP MD, 1996, PRINCIPLES PRACTICE; Topar G, 1996, J INVEST DERMATOL, V106, P529; TRAVIS WD, 1988, MEDICINE, V67, P345, DOI 10.1097/00005792-198811000-00001; TRAVIS WD, 1988, MODERN PATHOL, V1, P4; TRAVIS WD, 1988, CANCER, V62, P965, DOI 10.1002/1097-0142(19880901)62:5<965::AID-CNCR2820620520>3.0.CO;2-M; TRAVIS WD, 1986, MAYO CLIN PROC, V61, P957, DOI 10.1016/S0025-6196(12)62636-6; VALENT P, 1995, EUR J CLIN INVEST, V25, P715, DOI 10.1111/j.1365-2362.1995.tb01948.x; WASSERMAN SI, 1990, J ALLERGY CLIN IMMUN, V86, P590, DOI 10.1016/S0091-6749(05)80221-0; WEBB TA, 1982, CANCER, V49, P927, DOI 10.1002/1097-0142(19820301)49:5<927::AID-CNCR2820490517>3.0.CO;2-B; WEBER S, 1995, INT J DERMATOL, V34, P1, DOI 10.1111/j.1365-4362.1995.tb04366.x; WEIDNER N, 1991, J INVEST DERMATOL, V96, pS26, DOI 10.1111/1523-1747.ep12468966; WERSHIL BK, 1991, GASTROENTEROL CLIN N, V20, P613; WILKIN JK, 1993, CLIN DERMATOL, V11, P211, DOI 10.1016/0738-081X(93)90057-J; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YOUNG WF, 1995, MAYO CLIN PROC, V70, P757, DOI 10.4065/70.8.757	79	93	129	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 10	1997	349	9062					1379	1385		10.1016/S0140-6736(96)07056-0	http://dx.doi.org/10.1016/S0140-6736(96)07056-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149712				2022-12-28	WOS:A1997WY34200042
J	Carandini, M; Ferster, D				Carandini, M; Ferster, D			A tonic hyperpolarization underlying contrast adaptation in cat visual cortex	SCIENCE			English	Article							STRIATE CORTEX; RECEPTIVE-FIELDS; SINGLE CELLS; GAIN-CONTROL; NEURONS; INHIBITION; RESPONSES; EXCITATION	The firing rate responses of neurons in the primary visual cortex grow with stimulus contrast, the variation in the luminance of an image relative to the mean luminance. These responses, however, are reduced after a cell is exposed for prolonged periods to high-contrast visual stimuli, This phenomenon, known as contrast adaptation, occurs in the cortex and is not present at earlier stages of visual processing. To investigate the cellular mechanisms underlying cortical adaptation, intracellular recordings were performed in the visual cortex of cats, and the effects of prolonged visual stimulation were studied. Surprisingly, contrast adaptation barely affected the stimulus-driven modulations in the membrane potential of cortical cells. Moreover, it did not produce sizable changes in membrane resistance. The major effect of adaptation, evident both in the presence and in the absence of a visual stimulus, was a tonic hyperpolarization. Adaptation affects a class of synaptic inputs, most likely excitatory in nature, that exert a tonic influence on cortical cells.	NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208	Northwestern University			Carandini, Matteo/C-1922-2008; Carandini, Matteo/ABD-8296-2021	Carandini, Matteo/0000-0003-4880-7682; Carandini, Matteo/0000-0003-4880-7682	NATIONAL EYE INSTITUTE [R01EY004726] Funding Source: NIH RePORTER; NEI NIH HHS [EY04726] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBRECHT DG, 1982, J NEUROPHYSIOL, V48, P217, DOI 10.1152/jn.1982.48.1.217; ALBRECHT DG, 1984, J PHYSIOL-LONDON, V347, P713, DOI 10.1113/jphysiol.1984.sp015092; Barlow H., 1990, VISION CODING EFFICI; BLAKEMORE C, 1969, J PHYSIOL-LONDON, V203, P237, DOI 10.1113/jphysiol.1969.sp008862; BONDS AB, 1991, VISUAL NEUROSCI, V6, P239, DOI 10.1017/S0952523800006258; CARANDINI M, IN PRESS PHILOS T B; DEALY RS, 1974, J PHYSIOL-LONDON, V241, P261, DOI 10.1113/jphysiol.1974.sp010652; DEBRUYN EJ, 1986, BRAIN RES, V383, P339, DOI 10.1016/0006-8993(86)90036-3; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; DOUGLAS RJ, 1988, NATURE, V332, P642, DOI 10.1038/332642a0; FERSTER D, 1988, J NEUROSCI, V8, P1172; FERSTER D, 1992, J NEUROSCI, V12, P1262; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P181, DOI 10.1017/S0952523800009640; KULIKOWSKI JJ, 1981, J PHYSIOL-LONDON, V318, pP21; MAFFEI L, 1973, SCIENCE, V182, P1036, DOI 10.1126/science.182.4116.1036; MAFFEI L, 1986, J NEUROPHYSIOL, V55, P966, DOI 10.1152/jn.1986.55.5.966; MARLIN S, 1993, J NEUROPHYSIOL, V69, P2209, DOI 10.1152/jn.1993.69.6.2209; McLean J, 1996, VISUAL NEUROSCI, V13, P1069, DOI 10.1017/S0952523800007720; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P53, DOI 10.1113/jphysiol.1978.sp012488; MOVSHON JA, 1979, NATURE, V278, P850, DOI 10.1038/278850a0; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P79, DOI 10.1113/jphysiol.1978.sp012489; NELSON SB, IN PRESS NEUROBIOLOG; OHZAWA I, 1985, J NEUROPHYSIOL, V54, P651, DOI 10.1152/jn.1985.54.3.651; OHZAWA I, 1982, NATURE, V298, P266, DOI 10.1038/298266a0; SAUL AB, 1989, VISUAL NEUROSCI, V2, P593, DOI 10.1017/S0952523800003527; SAUL AB, 1995, VISUAL NEUROSCI, V12, P191, DOI 10.1017/S0952523800007872; SCHWINDT PC, 1988, J NEUROPHYSIOL, V59, P424, DOI 10.1152/jn.1988.59.2.424; Shou TD, 1996, VISUAL NEUROSCI, V13, P605, DOI 10.1017/S0952523800008518; TODOROV EV, IN PRESS NEUROBIOLOG; VAUTIN RG, 1977, J NEUROPHYSIOL, V40, P1051, DOI 10.1152/jn.1977.40.5.1051; VIDYASAGAR TR, 1990, NEUROSCIENCE, V36, P175, DOI 10.1016/0306-4522(90)90360-G	31	282	288	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					949	952		10.1126/science.276.5314.949	http://dx.doi.org/10.1126/science.276.5314.949			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9139658				2022-12-28	WOS:A1997WY79200048
J	RodriguezViciana, P; Warne, PH; Khwaja, A; Marte, BM; Pappin, D; Das, P; Waterfield, MD; Ridley, A; Downward, J				RodriguezViciana, P; Warne, PH; Khwaja, A; Marte, BM; Pappin, D; Das, P; Waterfield, MD; Ridley, A; Downward, J			Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIVATION; BINDING; RHO; PROTEINS; INDUCTION	The pathways by which mammalian Ras proteins induce cortical actin rearrangement and cause cellular transformation are investigated using partial loss of function mutants of Ras and activated and inhibitory forms of various postulated target enzymes for Ras. Efficient transformation by Ras requires activation of other direct effecters in addition to the MAP kinase kinase kinase Raf and is inhibited by inactivation of the PI 3-kinase pathway. Actin rearrangement correlates with the ability of Ras mutants to activate PI 3-kinase. Inhibition of PI 3-kinase activity blocks Ras induction of membrane ruffling, while activated PI 3-kinase is sufficient to induce membrane ruffling, acting through Rac. The ability of activated Ras to stimulate PI 3-kinase in addition to Raf is therefore important in Ras transformation of mammalian cells and essential in Ras-induced cytoskeletal reorganization.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UCL, DEPT BIOCHEM, LONDON WC1E 6BT, ENGLAND	Cancer Research UK; Ludwig Institute for Cancer Research; University of London; University College London			Khwaja, Asim/C-1509-2008	Downward, Julian/0000-0002-2331-4729; Ridley, Anne/0000-0001-8186-5708; Pappin, Darryl/0000-0002-8981-8401				BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; NOBES CD, 1995, J CELL SCI, V108, P225; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1995, METHOD ENZYMOL, V256, P313; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SKINNER RH, 1994, ANAL BIOCHEM, P259; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12608; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	36	912	924	0	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 2	1997	89	3					457	467		10.1016/S0092-8674(00)80226-3	http://dx.doi.org/10.1016/S0092-8674(00)80226-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150145	Bronze			2022-12-28	WOS:A1997WX89900016
J	Cohn, MJ; Patel, K; Krumlauf, R; Wilkinson, DG; Clarke, JDW; Tickle, C				Cohn, MJ; Patel, K; Krumlauf, R; Wilkinson, DG; Clarke, JDW; Tickle, C			Hox9 genes and vertebrate limb specification	NATURE			English	Article							ADDITIONAL LIMB; EXPRESSION; FLANK	Development of paired appendages at appropriate levels along the primary body axis is a hallmark of the body plan of jawed vertebrates. Hox genes are good candidates for encoding position in lateral plate mesoderm along the body axis(1,2) and thus for determining where limbs are formed. Local application of fibroblast growth factors (FGFs) to the anterior prospective flank of a chick embryo induces development of an ectopic wing, and FGF applied to posterior flank induces an ectopic leg(3). If particular combinations of Hox gene expression determine where wings and legs develop, then formation of additional limbs from flank should involve changes in Hox gene expression that reflect the type of limb induced. Here we show that the same population of flank cells can be induced to form either a wing or a leg, and that induction of these ectopic limbs is accompanied by specific changes in expression of three Hox genes in lateral plate mesoderm. This then reproduces, in the flank, expression patterns found at normal Limb levels. Hox gene expression is reprogrammed in lateral plate mesoderm, but is unaffected in paraxial mesoderm. Independent regulation of Hox gene expression in lateral plate mesoderm may have been a key step in the evolution of paired appendages.	UNIV LONDON UNIV COLL,SCH MED,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND; NATL INST MED RES,DIV DEV NEUROBIOL,LONDON NW7 1AA,ENGLAND	University of London; University College London; UCL Medical School; MRC National Institute for Medical Research			Krumlauf, Robb/AAH-5012-2019; Clarke, Jonathan/C-5347-2009	Krumlauf, Robb/0000-0001-9102-7927; Wilkinson, David/0000-0001-6757-7080	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGAR WE, 1907, T ROY SOC EDINBURGH, V45, P611; AKAM M, 1994, DEVELOPMENT, P209; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; GOODRICH ES, 1930, STUDIES STRUCTURE DE; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; NIETO MA, 1996, METHOD CELL BIOL, V51, P220; OHUCHI H, 1995, BIOCHEM BIOPH RES CO, V209, P809, DOI 10.1006/bbrc.1995.1572; RANCOURT DE, 1995, GENE DEV, V9, P108, DOI 10.1101/gad.9.1.108; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; THOROGOOD P, 1993, NATURE, V364, P196, DOI 10.1038/364196a0; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; Vogel A, 1996, DEVELOPMENT, V122, P1737; WARREN RW, 1994, NATURE, V372, P458, DOI 10.1038/372458a0; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	18	172	175	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 1	1997	387	6628					97	101		10.1038/387097a0	http://dx.doi.org/10.1038/387097a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139829				2022-12-28	WOS:A1997WW75800055
J	Gotzsche, PC; Johansen, HK				Gotzsche, PC; Johansen, HK			Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MARROW TRANSPLANT RECIPIENTS; INVASIVE FUNGAL-INFECTIONS; ACUTE MYELOGENOUS LEUKEMIA; AMPHOTERICIN-B AMBISOME; RANDOMIZED DOUBLE-BLIND; CLINICAL-TRIALS; STOPPING RULES; GRANULOCYTOPENIC PATIENTS; FLUCONAZOLE PROPHYLAXIS; CANDIDA-INFECTIONS	Objective: To determine whether antifungal agents given prophylactically or empirically decrease morbidity and mortality in patients with cancer complicated by neutropenia. Design: Meta-analysis of randomised trials of amphotericin B, various lipid soluble formulations of amphotericin B (for example, AmBisome), fluconazole, ketoconazole, miconazole, or itraconazole compared with placebo or no treatment. Setting: Trials conducted anywhere in the world. Subjects: Patients with cancer complicated by neutropenia. Main outcome measures: Mortality, invasive fungal infection (defined as positive blood culture, oesophageal candidiasis, or lung or deep tissue infection), and colonisation. Results: 24 trials with 2158 randomised patients were reviewed; the total number of deaths was 434. Prophylactic or empirical treatment with antifungals as a group had no effect on mortality (odds ratio 0.92; 95% confidence interval 0.74 to 1.14). Amphotericin B decreased mortality significantly (0.58; 0.37 to 0.93) but the studies were small and the difference in number of deaths was only 15. Antifungal treatment decreased the incidence of invasive fungal infection (0.47; 0.35 to 0.64) and fungal colonisation (0.45; 0.30 to 0.69). For every 73 patients treated (95% confidence interval 48 to 158) one case of fungal invasion was prevented in surviving patients. Conclusions: There seems to be no survival benefit of antifungal agents given prophylactically or empirically to patients with cancer complicated by neutropenia. These agents should be restricted to patients with proved infection and those in randomised trials. A large, definitive placebo controlled trial of amphotericin B is needed.			Gotzsche, PC (corresponding author), RIGSHOSP, NORD COCHRANE CTR, DEPT 7112, DK-2200 COPENHAGEN N, DENMARK.							ACUNA G, 1981, 22 INT C ANT AG CHEM; BENHAMOU E, 1991, BONE MARROW TRANSPL, V7, P127; BERLIN JA, 1989, J AM STAT ASSOC, V84, P381; BODEY GP, 1990, SEMIN ONCOL, V17, P24; BRINCKER H, 1978, ACTA MED SCAND, V204, P123; BRINCKER H, 1983, MYKOSEN, V26, P242; BUYSE M, 1993, STAT MED, V12, P509, DOI 10.1002/sim.4780120517; CASELLI D, 1990, MICROBIOLOGICA, V13, P347; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; ESTEY E, 1984, ARCH INTERN MED, V144, P1562, DOI 10.1001/archinte.144.8.1562; ESTEY EH, 1982, BLOOD, V60, P309; EZDINLI EZ, 1979, JAMA-J AM MED ASSOC, V242, P258, DOI 10.1001/jama.242.3.258; FRASER IS, 1993, BLOOD REV, V7, P208, DOI 10.1016/0268-960X(93)90007-Q; Fukuda Masataka, 1994, Japanese Journal of Antibiotics, V47, P1065; GOLDSTONE AH, 1994, BONE MARROW TRANSPL, V14, pS15; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; GOODMAN JL, 1992, NEW ENGL J MED, V327, P645; GOTZSCHE PC, 1997, INFECT DIS MODULE CO; GREEN SJ, 1987, STAT MED, V6, P361, DOI 10.1002/sim.4780060329; GUIOT HFL, 1994, CLIN INFECT DIS, V18, P525, DOI 10.1093/clinids/18.4.525; HANSEN RM, 1987, ARCH INTERN MED, V147, P710, DOI 10.1001/archinte.147.4.710; HUGHES MD, 1992, BIOMETRICS, V48, P41, DOI 10.2307/2532737; HUGHES WT, 1983, J INFECT DIS, V147, P1060, DOI 10.1093/infdis/147.6.1060; Huston P, 1996, LANCET, V347, P1628; INAGAKI J, 1974, CANCER-AM CANCER SOC, V33, P568, DOI 10.1002/1097-0142(197402)33:2<568::AID-CNCR2820330236>3.0.CO;2-2; LAU J, 1994, METAANALYST 0975 PRO; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; MEUNIER F, 1989, AM J MED, V86, P668; MEYERS JD, 1990, SEMIN ONCOL, V17, P10; PALMBLAD J, 1992, J INTERN MED, V231, P363, DOI 10.1111/j.1365-2796.1992.tb00945.x; PERFECT JR, 1992, J INFECT DIS, V165, P891, DOI 10.1093/infdis/165.5.891; PIZZO PA, 1982, AM J MED, V72, P101, DOI 10.1016/0002-9343(82)90594-0; POCOCK SJ, 1978, BRIT J CANCER, V38, P757, DOI 10.1038/bjc.1978.284; PRENTICE AG, 1989, MYCOSES, V32, P96, DOI 10.1111/j.1439-0507.1989.tb02298.x; RILEY D, 1992, 32 INT C ANT AG CHEM; RILEY DK, 1994, AM J MED, V97, P509, DOI 10.1016/0002-9343(94)90345-X; Rogers TRF, 1995, J ANTIMICROB CHEMOTH, V36, P899, DOI 10.1093/jac/36.6.899; SCHAISON G, 1990, BRIT J HAEMATOL, V76, P24, DOI 10.1111/j.1365-2141.1990.tb07931.x; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SIEGEL M, 1982, 23 INT C ANT AG CHEM; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; SIMES RJ, 1995, 3 ANN COCHR C OSL 4; SLAVIN M, 1992, 32 INT C ANT AG CHEM; SLAVIN MA, 1995, J INFECT DIS, V171, P1545, DOI 10.1093/infdis/171.6.1545; STEIN RS, 1986, SOUTHERN MED J, V79, P863, DOI 10.1097/00007611-198607000-00020; Suda T, 1980, Rinsho Ketsueki, V21, P195; TOLLEMAR J, 1993, TRANSPLANT P, V25, P1495; TOLLEMAR J, 1994, TRANSPLANT P, V26, P1833; TOLLEMAR J, 1993, BONE MARROW TRANSPL, V12, P577; VERFAILLIE C, 1991, BONE MARROW TRANSPL, V8, P177; VREUGDENHIL G, 1993, LEUKEMIA LYMPHOMA, V11, P353, DOI 10.3109/10428199309067926; WALSH T J, 1990, NCI (National Cancer Institute) Monographs, P43; WALSH TJ, 1994, CLIN INFECT DIS, V18, P793, DOI 10.1093/clinids/18.5.793; WALSH TJ, 1991, REV INFECT DIS, V13, P496; WINGARD JR, 1987, AM J MED, V83, P1103, DOI 10.1016/0002-9343(87)90949-1; WINSTON DJ, 1993, ANN INTERN MED, V118, P495, DOI 10.7326/0003-4819-118-7-199304010-00003; YAMAC K, 1995, POSTGRAD MED J, V71, P284, DOI 10.1136/pgmj.71.835.284; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	59	85	90	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 26	1997	314	7089					1238	1244		10.1136/bmj.314.7089.1238	http://dx.doi.org/10.1136/bmj.314.7089.1238			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW718	9154027	Green Published			2022-12-28	WOS:A1997WW71800018
J	Steinhoff, MC				Steinhoff, MC			Haemophilus influenzae type b infections are preventable	LANCET			English	Editorial Material							DEVELOPING-COUNTRIES; VACCINES				Steinhoff, MC (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT INT HLTH, 615 N WOLFE ST, BALTIMORE, MD 21205 USA.							FUNKHOUSER A, 1991, REV INFECT DIS, V13, pS542; KEUSCH GT, 1992, LANCET, V339, P802, DOI 10.1016/0140-6736(92)91917-W; Lagos R, 1996, PEDIATR INFECT DIS J, V15, P216, DOI 10.1097/00006454-199603000-00008; Robbins JB, 1996, JAMA-J AM MED ASSOC, V276, P1181, DOI 10.1001/jama.276.14.1181; *ROCK FDN, 1997, BELL C GLOB AV NEW V; STEINHOFF MC, 1993, LANCET, V342, P630, DOI 10.1016/0140-6736(93)91754-A; WARD J, 1994, VACCINES, P337; *WHO, 1996, P INT SEM HIB AS M W; WRIGHT PF, 1989, B WORLD HEALTH ORGAN, V67, P479	9	33	35	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 26	1997	349	9060					1186	1187		10.1016/S0140-6736(97)22017-9	http://dx.doi.org/10.1016/S0140-6736(97)22017-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130934	hybrid			2022-12-28	WOS:A1997WW71700002
J	Nakajima, K; Tatara, K; Nakanishi, N				Nakajima, K; Tatara, K; Nakanishi, N			Assessment of the zinc turbidity test and the use of risk factors in detecting asymptomatic hepatitis C virus carriers: Population based study	BRITISH MEDICAL JOURNAL			English	Article									OSAKA UNIV,SCH MED,DEPT PUBL HLTH,SUITA,OSAKA 565,JAPAN	Osaka University								BRUNO S, 1994, BRIT MED J, V308, P697, DOI 10.1136/bmj.308.6930.697; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; FRIED MW, 1995, SEMIN LIVER DIS, V15, P82, DOI 10.1055/s-2007-1007265; POPPER H, 1957, LIVER STRUCTURE FUNC, P323	4	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 19	1997	314	7088					1169	1169		10.1136/bmj.314.7088.1169	http://dx.doi.org/10.1136/bmj.314.7088.1169			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV705	9146390	Green Published			2022-12-28	WOS:A1997WV70500024
J	Sanyal, AJ; Freedman, AM; Luketic, VA; Purdum, PP; Shiffman, ML; Cole, PE; Tisnado, J; Simmons, S				Sanyal, AJ; Freedman, AM; Luketic, VA; Purdum, PP; Shiffman, ML; Cole, PE; Tisnado, J; Simmons, S			Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Association-for-Study-of-Liver-Diseases	MAY, 1994	NEW ORLEANS, LA	Amer Assoc Study Liver Dis		portosystemic shunt, surgical; sclerotherapy; endoscopy; esophageal and gastric varices; cirrhosis	THERAPEUTIC PORTACAVAL-SHUNT; CONTROLLED CLINICAL-TRIAL; INJECTION SCLEROTHERAPY; CONFIDENCE-INTERVALS; SURVIVAL ANALYSIS; COMPLICATIONS; CIRRHOSIS; ENCEPHALOPATHY; DISEASE; TIPS	Background: Transjugular intrahepatic portosystemic shunts (TIPS) have widened the use of portal decompression as therapy for variceal hemorrhage. However, no controlled studies have examined the efficacy of TIPS compared with that of other treatments. Objective: To compare the efficacy and safety of TIPS with those of endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. Design: Randomized, controlled trial. Setting: Tertiary-care academic medical center. Patients: 100 patients with cirrhosis were evaluated a mean of approximately 10 days after an episode of acute variceal bleeding; 20 patients were excluded because of portal venous thrombosis (n = 6), hepatoma (n = 3), florid alcoholic hepatitis (n = 6), and refusal to give consent (n = 5). Interventions: TIPS (n = 41) or sclerotherapy (n = 39). The latter was performed by freehand injections of 5% Na morrhuate at 2- to 3-week intervals. Recurrent variceal hemorrhage was managed by sclerotherapy followed by angiographic assessment of TIPS and dilatation of the stents (TIPS group) or crossover to TIPS (sclerotherapy group). Measurements: Rebleeding and survival were the primary end points. Complications and rates of rehospitalization were secondary end points. Results: During a mean follow-up of approximately 1000 days, recurrent gastrointestinal bleeding resulted from variceal hemorrhage (9 patients in the TIPS group and 8 in the sclerotherapy group), portal gastropathy (1 patient in each group), and gastric lipoma (0 and 1 patients, respectively). A higher mortality rate was seen with TIPS (P = 0.03). Death resulted from variceal bleeding (5 patients in the TIPS group and 3 in the sclerotherapy group), sepsis (3 and 2 patients, respectively), liver failure (2 patients in each group), hepatoma (1 and 0 patients, respectively), and hemoperitoneum (1 and 0 patients, respectively). Encephalopathy was the most common complication in the TIPS group (n = 12), and pain developing after sclerotherapy was the most common in the sclerotherapy group (n = 10). The two groups had similar rates of rehospitalization. Conclusions: Endoscopic sclerotherapy and TIPS are equivalent with respect to rebleeding developing over the long term. However, sclerotherapy may be superior to TIPS with respect to survival.			Sanyal, AJ (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, MCV STN 980711, 11TH & MARSHALL ST, RICHMOND, VA 23298 USA.				NCRR NIH HHS [RR-00065] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANYAL AJ, 1995, HEPTOLOGY, V22, pA255; BRAITMAN LE, 1991, ANN INTERN MED, V114, P515, DOI 10.7326/0003-4819-114-6-515; BURROUGHS AK, 1986, HEPATOLOGY, V6, P1407, DOI 10.1002/hep.1840060631; BURROUGHS AK, 1989, GUT, V30, pA1506; BURROUGHS AK, 1983, NEW ENGL J MED, V309, P1539, DOI 10.1056/NEJM198312223092502; BURROUGHS AK, 1992, GASTROENTEROL CLIN N, V21, P119; Cabrera J, 1996, GASTROENTEROLOGY, V110, P832, DOI 10.1053/gast.1996.v110.pm8608893; CELLO JP, 1995, GASTROENTEROLOGY, V108, pA1045; CONN HO, 1993, HEPATOLOGY, V17, P148, DOI 10.1016/0270-9139(93)90205-2; CONN HO, 1987, CURRENT HEPATOLOGY, P123; Copenhagen Esophageal Varices Sclerotherapy Project, 1984, N Engl J Med, V311, P1594; DAMICO G, 1986, DIGEST DIS SCI, V31, P468, DOI 10.1007/BF01320309; DEFRANCHIS R, 1992, GASTROENTEROL CLIN N, V21, P85; Freedman A, 1992, Va Med Q, V119, P253; FREEDMAN AM, 1994, SEMIN INTERVENT RAD, V11, P161, DOI 10.1055/s-2008-1074752; FREEDMAN AM, 1993, RADIOGRAPHICS, V13, P1185, DOI 10.1148/radiographics.13.6.8290720; GRACE ND, 1994, NEW ENGL J MED, V330, P208, DOI 10.1056/NEJM199401203300312; GRAHAM DY, 1981, GASTROENTEROLOGY, V80, P800; JACKSON FC, 1971, ANN SURG, V174, P672, DOI 10.1097/00000658-197110000-00012; JALAN R, 1995, HEPATOLOGY, V22, P578; KAHN D, 1989, SURGERY, V105, P160; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KORULA J, 1985, HEPATOLOGY, V5, P584, DOI 10.1002/hep.1840050410; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; LEBREC D, 1991, PORTAL HYPERTENSION, P117; LEE ET, 1980, STATISTICAL METHODS; MERLI M, 1994, HEPATOLOGY, V20, pA43; PAGLIARO L, 1989, GASTROENTEROL INT, V2, P71; RESNICK RH, 1974, GASTROENTEROLOGY, V67, P843; REYNOLDS TB, 1981, GASTROENTEROLOGY, V80, P1005; ROSCH J, 1971, AM J SURG, V121, P588, DOI 10.1016/0002-9610(71)90147-4; ROSSLE M, 1994, NEW ENGL J MED, V330, P165, DOI 10.1056/NEJM199401203300303; ROSSLE M, 1994, HEPATOLOGY, V20, pA44; RUEFF B, 1976, LANCET, V1, P655; SANYAL AJ, 1993, SEMIN LIVER DIS, V13, P328; SANYAL AJ, 1994, HEPATOLOGY, V20, P46, DOI 10.1002/hep.1840200109; Sanyal AJ, 1996, HEPATOLOGY, V23, P32, DOI 10.1002/hep.510230105; SANYAL AJ, 1992, ANN INTERN MED, V117, P443, DOI 10.7326/0003-4819-117-5-443; SCHUMAN BM, 1987, AM J GASTROENTEROL, V82, P823; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; SIRINGO S, 1991, GASTROINTEST ENDOSC, V37, P51, DOI 10.1016/S0016-5107(91)70621-4; SMITH JL, 1982, GASTROENTEROLOGY, V82, P968; TERBLANCHE J, 1983, LANCET, V2, P1328; TERBLANCHE J, 1987, METHODOLOGY REV CLIN, P185; WESTABY D, 1989, HEPATOLOGY, V9, P274, DOI 10.1002/hep.1840090219	45	170	170	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1997	126	11					849	+		10.7326/0003-4819-126-11-199706010-00001	http://dx.doi.org/10.7326/0003-4819-126-11-199706010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XA911	9163285				2022-12-28	WOS:A1997XA91100001
J	Lin, Q; Schwarz, J; Bucana, C; Olson, EN				Lin, Q; Schwarz, J; Bucana, C; Olson, EN			Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C	SCIENCE			English	Article							ENHANCER-BINDING FACTOR; LIGHT-CHAIN GENE; MUSCLE; EXPRESSION; DROSOPHILA; EMBRYOGENESIS; ACTIVATION; MUTATIONS; LINEAGES; PROTEINS	Members of the myocyte enhancer factor-2 (MEF2) family of MADS (MCM1, agamous, deficiens, serum response factor)-box transcription factors bind an A-T-rich DNA sequence associated with muscle-specific genes. The murine MEF2C gene is expressed in heart precursor cells before formation of the linear heart tube, In mice homozygous for a null mutation of MEF2C, the heart tube did not undergo looping morphogenesis, the future right ventricle did not form, and a subset of cardiac muscle genes was not expressed. The absence of the right ventricular region of the mutant heart correlated with down-regulation of the dHAND gene, which encodes a basic helix-loop-helix transcription factor required for cardiac morphogenesis. Thus, MEF2C is an essential regulator of cardiac myogenesis and right ventricular development.	UNIV TEXAS,SW MED CTR,DEPT MOL BIOL & ONCOL,DALLAS,TX 75235; UNIV TEXAS,SCH MED,DEPT INTERNAL MED,DIV CARDIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CELL BIOL,HOUSTON,TX 77030	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas System; UTMD Anderson Cancer Center					NHLBI NIH HHS [R01 HL053351] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053351] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTON PJR, 1988, J BIOL CHEM, V263, P12669; BIBEN C, COMMUNICATION; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; CHAMBERS AE, 1994, GENE DEV, V8, P1324, DOI 10.1101/gad.8.11.1324; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; DEHAAN RL, 1964, ORGANOGENESIS, P377; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Firulli AB, 1996, CIRC RES, V78, P196, DOI 10.1161/01.RES.78.2.196; FISCHMAN MC, 1994, CIRC RES, V74, P757; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LIN QY, UNPUB; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MOLKENTIN JD, UNPUB; NADALGINARD B, 1996, MECH DEVELOP, V57, P103; NAVANASATTUSAS S, MOL CELL BIOL, V12, P1469; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; OLSON EN, 1995, DEV BIOL, V172, P280; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; Rossant J, 1996, CIRC RES, V78, P349, DOI 10.1161/01.RES.78.3.349; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; SRIVASTAVA D, IN PRESS NATURE GENE; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; Yu YT, 1996, J BIOL CHEM, V271, P24675; YU YT, 1995, GENE DEV, V9, P1388; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693	43	730	769	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1404	1407		10.1126/science.276.5317.1404	http://dx.doi.org/10.1126/science.276.5317.1404			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9162005	Green Accepted			2022-12-28	WOS:A1997XB53300046
J	Bailar, JC; Gornik, HL				Bailar, JC; Gornik, HL			Cancer undefeated	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Ramazzini Days of the Collegium-Ramazzini	OCT 26, 1996	CARPI, ITALY	Collegium Ramazzini				Background Despite decades of basic and clinical research and trials of promising new therapies, cancer remains a major cause of morbidity and mortality. We assessed overall progress against cancer in the United States from 1970 through 1994 by analyzing changes in age-adjusted mortality rates. Methods We obtained from the National Center for Health Statistics data on all deaths from cancer and from cancer at specific sites, as well as on deaths due to cancer according to age, race, and sex, for the years 1970 through 1994. We computed age-specific mortality rates and adjusted them to the age distribution of the U.S. population in 1990. Results Age-adjusted mortality due to cancer in 1994 (200.9 per 100,000 population) was 6.0 percent higher than the rate in 1970 (189.6 per 100,000). After decades of steady increases, the age-adjusted mortality due to all malignant neoplasms plateaued, then decreased by 1.0 percent from 1991 to 1994. The decline in mortality due to cancer was greatest among black males and among persons under 55 years of age. Mortality among white males 55 or older has also declined recently. These trends reflect a combination of changes in death rates from specific types of cancer, with important declines due to reduced cigarette smoking and improved screening and a mixture of increases and decreases in the incidence of types of cancer not closely related to tobacco use. Conclusions The war against cancer is far from over. Observed changes in mortality due to cancer primarily reflect changing incidence or early detection. The effect of new treatments for cancer on mortality has been largely disappointing. The most promising approach to the control of cancer is a national commitment to prevention, with a concomitant rebalancing of the focus and funding of research. (C) 1997, Massachusetts Medical Society.			Bailar, JC (corresponding author), UNIV CHICAGO, DEPT HLTH STUDIES, 5841 S MARYLAND AVE, MC 2007, CHICAGO, IL 60637 USA.							BAILAR JC, 1990, ANN NY ACAD SCI, V609, P49, DOI 10.1111/j.1749-6632.1990.tb32056.x; BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; BAILAR JC, 1987, ISSUES SCI TECHNOL, V4, P16; BAILAR JC, 1992, CHRONIC DIS CAN S, V13, pS2; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; *BUR CENS, 1993, CURR POP REP P25, V1095; *BUR CENS, 1982, CURRENT POP REP P25, V917; Cole P, 1996, CANCER, V78, P2045, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2045::AID-CNCR3>3.0.CO;2-N; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; *FIN MAN BRANCH, 1993, NCI FACT BOOK; *NAT CANC I, 1986, NCI MONOGRAPHS, V2; *NAT CTR HLTH STAT, 1994, VIT STAT US 1970 1 A, V2; *NAT CTR HLTH STAT, 1993, VIT STAT US 1970 1 A, V2; RIES LAG, IN PRESS SEER CANC S; SHALALA DE, 1996, NEW CANC MORTALITY R; SONDIK EJ, 1990, J NATL CANCER I, V82, P825; 1988, ISSUES SCI TECHNOL, V4, P14; 1987, NEW ENGL J MED, V316, P752; 1986, NEW ENGL J MED, V315, P963	19	345	358	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 29	1997	336	22					1569	1574		10.1056/NEJM199705293362206	http://dx.doi.org/10.1056/NEJM199705293362206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XB087	9164814				2022-12-28	WOS:A1997XB08700006
J	Lee, MM; Donahoe, PK; Silverman, BL; Hasegawa, T; Hasegawa, Y; Gustafson, ML; Chang, YC; MacLaughlin, DT				Lee, MM; Donahoe, PK; Silverman, BL; Hasegawa, T; Hasegawa, Y; Gustafson, ML; Chang, YC; MacLaughlin, DT			Measurements of serum Mullerian inhibiting substance in the evaluation of children with nonpalpable gonads	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	1996 Annual Meeting of the Pediatric-Academic-Societies	MAY 05-10, 1996	WASHINGTON, D.C.	Pediat Acad Soc			HCG STIMULATION; HORMONE; CRYPTORCHIDISM; TESTOSTERONE; IMMUNOASSAY; BOYS; DIAGNOSIS; ANORCHISM; INTERSEX; INFANTS	Background Mullerian inhibiting substance, produced constitutively by the prepubertal testes, promotes involution of the mullerian ducts during normal male sexual differentiation. In children with virilization and nonpalpable gonads, only those with testicular tissue should have detectable serum concentrations of mullerian inhibiting substance. Methods We measured serum mullerian inhibiting substance in 65 children with virilization at birth and nonpalpable gonads (age at diagnosis, 2 days to 11 years) and serum testosterone in 54 of them either after the administration of human chorionic gonadotropin or during the physiologic rise in testosterone that occurs in normal infants. Results The mean (+/-SD) serum mullerian inhibiting substance concentration in the 17 children with no testicular tissue was 0.7+/-0.5 ng per milliliter, as compared with 37.5+/-39.6 ng per milliliter in the 48 children with testes (P < 0.001). In the latter group, the mean values in the 14 children with abnormal testes and the 34 with normal testes were 11.5+/-11.8 and 48.2+/-42.1 ng per milliliter, respectively (P < 0.001). The sensitivity and specificity of the serum mullerian inhibiting substance assay for detecting the absence of testicular tissue were 92 percent and 98 percent, respectively, as compared with 69 percent and 83 percent for the measurement of serum testosterone. Furthermore, measurement of serum mullerian inhibiting substance was more sensitive than serum testosterone measurement for the identification of children with abnormal testes (67 percent vs. 25 percent), whereas the specificity of the two tests was similar. Conclusions Measurements of serum mullerian inhibiting substance can be used to determine testicular status in prepubertal children with nonpalpable gonads, thus differentiating anorchia from undescended testes in boys with bilateral cryptorchidism and serving as a measure of testicular integrity in children with intersexual anomalies. (C) 1997, Massachusetts Medical Society.	MASSACHUSETTS GEN HOSP, MED PRACTICES EVALUAT CTR, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, PEDIAT SURG RES LAB, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; CHILDRENS MEM HOSP, DEPT PEDIAT ENDOCRINOL & DIABET, CHICAGO, IL 60614 USA; NW MED SCH, CHICAGO, IL USA; TOKYO METROPOLITAN KIYOSE CHILDRENS HOSP, DIV ENDOCRINOL & METAB, TOKYO, JAPAN	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Ann & Robert H. Lurie Children's Hospital of Chicago	Lee, MM (corresponding author), MASSACHUSETTS GEN HOSP, PEDIAT ENDOCRINE UNIT, ACC 709, BOSTON, MA 02114 USA.		Hasegawa, Tomonobu/L-3331-2013		NCI NIH HHS [CA 17393] Funding Source: Medline; NICHD NIH HHS [2F32HD07435] Funding Source: Medline; NIDDK NIH HHS [DK-02129] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD007435] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA017393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002129] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER ML, 1993, J CLIN ENDOCR METAB, V76, P245, DOI 10.1210/jc.76.1.245; BAKER ML, 1990, J CLIN ENDOCR METAB, V70, P11, DOI 10.1210/jcem-70-1-11; DAVENPORT M, 1995, BRIT J UROL, V76, P790, DOI 10.1111/j.1464-410X.1995.tb00776.x; FOREST MG, 1979, J CLIN ENDOCR METAB, V49, P132, DOI 10.1210/jcem-49-1-132; FOREST MG, 1974, J CLIN INVEST, V53, P819, DOI 10.1172/JCI107621; FOREST MG, 1980, PEDIATR RES, V14, P819, DOI 10.1203/00006450-198006000-00009; FRIEDLAND GW, 1988, AM J ROENTGENOL, V151, P1107, DOI 10.2214/ajr.151.6.1107; GUSTAFSON ML, 1992, NEW ENGL J MED, V326, P466, DOI 10.1056/NEJM199202133260707; GUSTAFSON ML, 1993, J PEDIATR SURG, V28, P439, DOI 10.1016/0022-3468(93)90245-G; HREBINKO RL, 1993, J UROLOGY, V150, P458, DOI 10.1016/S0022-5347(17)35510-6; HUDSON PL, 1990, J CLIN ENDOCR METAB, V70, P16, DOI 10.1210/jcem-70-1-16; IMBEAUD S, 1994, HUM MOL GENET, V3, P125, DOI 10.1093/hmg/3.1.125; JAROW JP, 1986, J UROLOGY, V136, P277, DOI 10.1016/S0022-5347(17)44840-3; JOSSO N, 1995, HORM RES, V43, P243, DOI 10.1159/000184300; JOSSO N, 1993, RECENT PROG HORM RES, V48, P1; JOSSO N, 1993, EARLY HUM DEV, V33, P91, DOI 10.1016/0378-3782(93)90204-8; JOSSO N, 1991, TRENDS ENDOCRIN MET, V2, P227, DOI 10.1016/1043-2760(91)90029-M; JOSSO N, 1990, J CLIN ENDOCR METAB, V70, P23, DOI 10.1210/jcem-70-1-23; Jost, 1947, ARCH ANAT MICR MORPH, V36, P271; Lee MM, 1996, J CLIN ENDOCR METAB, V81, P571, DOI 10.1210/jc.81.2.571; LEE MM, 1993, ENDOCR REV, V14, P152, DOI 10.1210/er.14.2.152; LUSTIG RH, 1987, J UROLOGY, V138, P587, DOI 10.1016/S0022-5347(17)43266-6; MIETTINEN OS, 1970, BIOMETRICS, V26, P75, DOI 10.2307/2529046; ORTH JM, 1988, ENDOCRINOLOGY, V122, P787, DOI 10.1210/endo-122-3-787; REY R, 1993, J CLIN ENDOCR METAB, V77, P1220, DOI 10.1210/jc.77.5.1220; REY R, 1994, J CLIN ENDOCR METAB, V79, P960, DOI 10.1210/jc.79.4.960; Rey RA, 1996, AM J OBSTET GYNECOL, V174, P958, DOI 10.1016/S0002-9378(96)70333-2; SCHOLLER R, 1975, J STEROID BIOCHEM, V6, P95, DOI 10.1016/0022-4731(75)90189-2; URBAN MD, 1987, CLIN PEDIATR, V26, P512, DOI 10.1177/000992288702601003; VOLLSET SE, 1993, STAT MED, V12, P809, DOI 10.1002/sim.4780120902; Vollset SE, 1995, STAT MED, V14, P875; WINTER JSD, 1976, J CLIN ENDOCR METAB, V42, P679, DOI 10.1210/jcem-42-4-679; WINTER JSD, 1972, J CLIN ENDOCR METAB, V34, P348, DOI 10.1210/jcem-34-2-348	33	113	122	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	1997	336	21					1480	1486		10.1056/NEJM199705223362102	http://dx.doi.org/10.1056/NEJM199705223362102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WZ767	9154766	Green Published			2022-12-28	WOS:A1997WZ76700002
J	Corti, MC; Guralnik, JM; Salive, ME; Harris, T; Ferrucci, L; Glynn, RJ; Havlik, RJ				Corti, MC; Guralnik, JM; Salive, ME; Harris, T; Ferrucci, L; Glynn, RJ; Havlik, RJ			Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons	ANNALS OF INTERNAL MEDICINE			English	Article							CARDIOVASCULAR HEALTH; FOLLOW-UP; MORTALITY; RISK; PEOPLE; HYPERCHOLESTEROLEMIA; HYPOCHOLESTEROLEMIA; ASSOCIATION; MODELS; ADULTS	Background: The importance of total cholesterol level as a risk factor for coronary heart disease in older adults is controversial. Objective: To determine whether findings showing that total cholesterol level is not an important risk factor for coronary heart disease in older adults are the result of inadequate adjustment for co-occurring diseases and frailty. Design: Multicenter, longitudinal study with 5-year follow-up for death. Participants: 4066 men and women from East Boston, Massachusetts; Iowa and Washington counties, Iowa; and New Haven, Connecticut. Measurements: In 1988, participants were interviewed about their health status and had blood samples taken. Mortality follow-up was through 1992. Results: In analyses that included all fatal coronary heart disease events (252 deaths) and did not adjust for risk factors for coronary heart disease and measures of frailty, persons with the lowest total cholesterol levels (less than or equal to 4.15 mmol/L [less than or equal to 160 mg/dL]) had the highest rate of death from coronary heart disease, whereas those with elevated total cholesterol levels (greater than or equal to 6.20 mmol/L [greater than or equal to 240 mg/dL]) seemed to have a lower risk for death from coronary heart disease (P for trend = 0.04). After adjustment for established risk factors for coronary heart disease and markers of poor health (including chronic conditions, low serum iron and albumin levels) and exclusion of 44 deaths from coronary heart disease that occurred within the first year, elevated total cholesterol levels predicted increased risk for death from coronary heart disease, and the risk for death from coronary heart disease decreased as cholesterol levels decreased (P for trend = 0.005). Conclusions: Elevated total cholesterol level is a risk factor for death from coronary heart disease in older adults, and the apparent adverse effects associated with low cholesterol levels are secondary to comorbidity and frailty. This suggests that excluding older persons from cholesterol screening is inappropriate, but interpretation of screening results in older persons requires clinical judgment. Results from controlled clinical trials are needed to clarify this issue.	US FDA, EPIDEMIOL BRANCH, CTR BIOL EVALUAT & RES, ROCKVILLE, MD 20852 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; NATL INST RES & CARE ELDERLY, FIESOLE, ITALY	US Food & Drug Administration (FDA); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; IRCCS INRCA	Corti, MC (corresponding author), NIA, EPIDEMIOL DEMOG & BIOMETRY PROGRAM,NIH, 7201 WISCONSIN AVE,GATEWAY BLDG, ROOM 3C-309, BETHESDA, MD 20892 USA.				NATIONAL INSTITUTE ON AGING [N01AG002105, N01AG002107, N01AG002106] Funding Source: NIH RePORTER; NIA NIH HHS [N01-AG-02106, N01-AG-02105, N01-AG-02107] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; Corti MC, 1997, AM J CARDIOL, V79, P120, DOI 10.1016/S0002-9149(96)00697-2; CORTI MC, 1995, JAMA-J AM MED ASSOC, V274, P539, DOI 10.1001/jama.274.7.539; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; ETTINGER WH, 1992, CIRCULATION, V86, P858, DOI 10.1161/01.CIR.86.3.858; ETTINGER WH, 1993, CORONARY ARTERY DIS, V4, P854, DOI 10.1097/00019501-199310000-00003; ETTINGER WH, 1995, J AM GERIATR SOC, V43, P264, DOI 10.1111/j.1532-5415.1995.tb07334.x; FAIRBANKS VF, 1994, MODERN NUTR HLTH DIS; Garber AM, 1996, ANN INTERN MED, V124, P515, DOI 10.7326/0003-4819-124-5-199603010-00013; GLYNN RJ, 1995, LANCET, V345, P825, DOI 10.1016/S0140-6736(95)92964-9; GURALNIK JM, 1989, VITAL HLTH STAT NATL, V170; GURALNIK JM, 1995, NIH PUB; HARRIS T, 1992, J CLIN EPIDEMIOL, V45, P595, DOI 10.1016/0895-4356(92)90131-6; HULLEY SB, 1994, JAMA-J AM MED ASSOC, V272, P1372, DOI 10.1001/jama.272.17.1372; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JACOBS DR, 1993, CIRCULATION, V87, P1033, DOI 10.1161/01.CIR.87.3.1033; KRONMAL RA, 1993, ARCH INTERN MED, V153, P1065, DOI 10.1001/archinte.153.9.1065; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; LaRosa JC, 1996, ANN INTERN MED, V124, P505, DOI 10.7326/0003-4819-124-5-199603010-00008; MALENKA DJ, 1988, ARCH INTERN MED, V148, P2247, DOI 10.1001/archinte.148.10.2247; MANOLIO TA, 1993, CIRCULATION, V87, P728, DOI 10.1161/01.CIR.87.3.728; Maseri A, 1996, BRIT MED J, V312, P1049; MITTELMARK MB, 1993, AM J EPIDEMIOL, V137, P311, DOI 10.1093/oxfordjournals.aje.a116678; OLIVER MF, 1991, LANCET, V337, P1529, DOI 10.1016/0140-6736(91)93208-Q; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1994, AM J EPIDEMIOL, V139, P155, DOI 10.1093/oxfordjournals.aje.a116977; ROTHSCHILD MA, 1988, HEPATOLOGY, V8, P385, DOI 10.1002/hep.1840080234; RUBINSTEIN A, 1994, CIRCULATION, V89, P1329; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SALIVE ME, 1992, J AM GERIATR SOC, V40, P489, DOI 10.1111/j.1532-5415.1992.tb02017.x; *SAS I INC, 1992, P229 SAS I INC; SEMPOS CT, 1994, NEW ENGL J MED, V330, P1119, DOI 10.1056/NEJM199404213301604; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STAESSEN J, 1980, J HYPERTENS, P755; 1977, JAMA-J AM MED ASSOC, V237, P2385	38	175	179	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1997	126	10					753	+		10.7326/0003-4819-126-10-199705150-00001	http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ823	9148647				2022-12-28	WOS:A1997WZ82300003
J	Gueyffier, F; Boutitie, F; Boissel, JP; Pocock, S; Coope, J; Cutler, J; Ekbom, T; Fagard, R; Friedman, L; Perry, M; Prineas, R; Schron, E				Gueyffier, F; Boutitie, F; Boissel, JP; Pocock, S; Coope, J; Cutler, J; Ekbom, T; Fagard, R; Friedman, L; Perry, M; Prineas, R; Schron, E			Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men - A meta-analysis of individual patient data from randomized, controlled trials	ANNALS OF INTERNAL MEDICINE			English	Article						antihypertensive agents; sex factors; cardiovascular diseases; outcome and process assessment (health care); hypertension	BLOOD-PRESSURE; HYPERTENSION; MORBIDITY; MORTALITY; DISEASE; INFARCTION; STROKE; HEALTH	Background: Trials of drug therapy for hypertension have shown that such therapy has a clear overall benefit in preventing cardiovascular disease. Although these trials have included slightly more women than men, it is still not clear whether treatment benefit is similar for both sexes. Objective: To quantify the average treatment effect in both sexes and to determine whether available data show significant differences in treatment effect between women and men. Design: Subgroup meta-analysis of individual patient data according to sex. Analysis was based on seven trials from the INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) database and was adjusted for possible confounders. Patients: 20 802 women and 19 975 men recruited between 1972 and 1990. Interventions: Primarily beta-blockers and thiazide diuretics. Results: In women, treatment effect was statistically significant for stroke (fatal strokes and all strokes) and for major cardiovascular events. In men, it was statistically significant for all categories of events (total and specific mortality, all coronary events, all strokes, and major cardiovascular events). The odds ratios for any category of event did not differ significantly between men and women. In absolute terms, the benefit in women was seen primarily for strokes; in men, treatment prevented as many coronary events as strokes. Graphical analyses suggest that these results Could be completely explained by the difference in untreated risk. Conclusions: In terms of relative risk, treatment benefit did not differ between women and men. The absolute risk reduction attributable to treatment seemed to depend on untreated risk. These findings underline the need to predict accurately the untreated cardiovascular risk of an individual person in order to rationalize and individualize antihypertensive treatment.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, MED STAT UNIT, LONDON WC1E 7HT, ENGLAND; BOLLINGTON MED CTR, MACCLESFIELD SK10 5JL, CHESHIRE, ENGLAND; NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, ROCKLEDGE CTR 2, BETHESDA, MD 20892 USA; UZ PELLENBERG, B-3212 PELLENBERG, BELGIUM; WASHINGTON UNIV, ST LOUIS, MO 63110 USA; UNIV MIAMI, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, MIAMI, FL 33136 USA; LUND UNIV, DALBY, SWEDEN	University of London; London School of Hygiene & Tropical Medicine; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); KU Leuven; University Hospital Leuven; Washington University (WUSTL); University of Miami; Lund University	Gueyffier, F (corresponding author), UNIV LYON 1, SERV PHARMACOL CLIN, 162 AVE LACASSAGNE, BP 3041, F-69394 LYON 03, FRANCE.		Gueyffier, François/B-8545-2008	Gueyffier, François/0000-0002-9921-0977				AMERY A, 1985, LANCET, V1, P1349; ANASTOS K, 1991, ANN INTERN MED, V115, P287, DOI 10.7326/0003-4819-115-4-287; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1973, BMJ-BRIT MED J, V3, P434; [Anonymous], 1974, JAMA-J AM MED ASSOC, V229, P409; [Anonymous], 1980, LANCET, V1, P1261; BOISSEL JP, 1993, J CARDIOVASC PHARM, V22, P356, DOI 10.1097/00005344-199309000-00003; CARTER AB, 1970, LANCET, V1, P485; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; EASY MA, 1996, REFERNCE MANUAL VERS; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; Gueyffier F, 1996, J HUM HYPERTENS, V10, P1; GUEYFFIER F, 1995, THERAPIE, V50, P353; Hypertension Detection Follow-up Program Cooperative Group, 1979, JAMA-J AM MED ASSOC, V242, P2562, DOI DOI 10.1001/JAMA.1979.03300230018021; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; KAPLAN NM, 1995, ARCH INTERN MED, V155, P563, DOI 10.1001/archinte.155.6.563; KITLER ME, 1992, AM J CARDIOL, V70, P1077, DOI 10.1016/0002-9149(92)90364-5; MACMAHON SW, 1986, PROG CARDIOVASC DIS, V29, P99, DOI 10.1016/0033-0620(86)90038-1; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; Menard Joel, 1995, P3035; Morgenstern H, 1982, EPIDEMIOLOGIC RES PR, P403; PERRY HM, 1989, STROKE, V20, P4, DOI 10.1161/01.STR.20.1.4; PERRY HM, 1978, ANN NY ACAD SCI, V304, P267; *SAS I, 1990, SAS US GUID; SMITH WM, 1977, CIRC RES, V40, P98; SPRACKLING ME, 1981, BRIT MED J, V283, P1151, DOI 10.1136/bmj.283.6300.1151; *WHO ISH JOINT LIA, 1995, ISH HYP NEWS, V1, P3; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	31	281	289	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1997	126	10					761	+		10.7326/0003-4819-126-10-199705150-00002	http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ823	9148648				2022-12-28	WOS:A1997WZ82300004
J	Chandra, RK				Chandra, RK			Graying of the immune system - Can nutrient supplements improve immunity in the elderly?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							VITAMIN-E SUPPLEMENTATION; INFECTION; NUTRITION; RESPONSES				Chandra, RK (corresponding author), MEM UNIV NEWFOUNDLAND,JANEWAY CHILD HLTH CTR,ST JOHNS,NF A1A 1R8,CANADA.							BAEHNER RL, 1977, BLOOD, V50, P327; BOGDEN JD, 1990, J AM COLL NUTR, V9, P214; CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C; CHANDRA RK, 1989, IMMUNOLOGY, V67, P141; Chandra RK, 1996, P NATL ACAD SCI USA, V93, P14304, DOI 10.1073/pnas.93.25.14304; CHANDRA RK, 1991, CAN MED ASSOC J, V145, P1475; CHANDRA RK, 1991, AM J CLIN NUTR, V53, P1087, DOI 10.1093/ajcn/53.5.1087; CHANDRA RK, 1992, NUTRITION IMMUNITY I; CHAVANCE M, 1985, BRIT MED J, V291, P1348, DOI 10.1136/bmj.291.6505.1348-b; COMBS GF, 1991, VITAMINS FUNDAMENTAL, P179; Gershwin, 1985, NUTR IMMUNITY; HOFFER LJ, 1996, ANN RCPSC, V29, P11; LESOURD BM, IN PRESS P NUTR IMM; MACHLIN LJ, 1991, HDB VITAMINS, P99; MEYDANI SN, 1990, AM J CLIN NUTR, V52, P557, DOI 10.1093/ajcn/52.3.557; Meydani SN, 1997, JAMA-J AM MED ASSOC, V277, P1380, DOI 10.1001/jama.277.17.1380; Meyers DG, 1996, ARCH INTERN MED, V156, P925, DOI 10.1001/archinte.156.9.925; MUNRO H, 1992, NUTR ELDERLY; PENN ND, 1991, AGE AGEING, V20, P169, DOI 10.1093/ageing/20.3.169; PRASAD JS, 1980, AM J CLIN NUTR, V33, P606, DOI 10.1093/ajcn/33.3.606; Sahyoun NR, 1996, AM J EPIDEMIOL, V144, P501, DOI 10.1093/oxfordjournals.aje.a008957; TALBOTT MC, 1987, AM J CLIN NUTR, V46, P659, DOI 10.1093/ajcn/46.4.659; [No title captured]; [No title captured]	24	55	61	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	1997	277	17					1398	1399		10.1001/jama.277.17.1398	http://dx.doi.org/10.1001/jama.277.17.1398			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW261	9134947				2022-12-28	WOS:A1997WW26100031
J	Garceau, NY; Liu, Y; Loros, JJ; Dunlap, JC				Garceau, NY; Liu, Y; Loros, JJ; Dunlap, JC			Alternative initiation of translation and time-specific phosphorylation yield multiple forms of the essential clock protein FREQUENCY	CELL			English	Article							CIRCADIAN CLOCK; NEUROSPORA-CRASSA; PERIOD; GENE; RHYTHMS; MUTANTS; LIGHT; AUTOREGULATION; LOCALIZATION; OSCILLATOR	The frequency (frq) gene encodes central components of the transcription/translation-based negative-feedback loop comprising the core of the Neurospora circadian oscillator; posttranscriptional regulation associated with FRQ is surprisingly complex. Alternative use of translation initiation sites gives rise to two forms of FRQ whose levels peak 4-6 hr following the peak of frq transcript. Each form of FRQ is progressively phosphorylated over the course of the day, thus providing a number of temporally distinct FRQ products. The kinetics of these regulatory processes suggest a view of the clock where relatively rapid events involving translational regulation in the synthesis of FRQ and negative feedback of FRQ on fro transcript levels are followed by slower posttranslational regulation, ultimately driving the turnover of FRQ and reactivation of the frq gene.	DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA	Dartmouth College			Dunlap, Jay/L-6232-2013; Loros, Jennifer/B-6293-2014	Dunlap, Jay/0000-0003-1577-0457; 	NIGMS NIH HHS [GM 34985] Funding Source: Medline; NIMH NIH HHS [MH01186, MH44651] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034985, R37GM034985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001186, R01MH044651] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARONSON BD, 1994, P NATL ACAD SCI USA, V91, P7683, DOI 10.1073/pnas.91.16.7683; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BellPedersen D, 1996, P NATL ACAD SCI USA, V93, P13096, DOI 10.1073/pnas.93.23.13096; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CHANG F, 1992, MOL BIOL CELL, V3, P445, DOI 10.1091/mbc.3.4.445; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COMOLLI J, 1994, J BIOL RHYTHM, V9, P13, DOI 10.1177/074873049400900102; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EBBOLE D, 1990, FUNGAL GENET NEWSL, V37, P15; EDELMANN SE, 1994, EXP MYCOL, V18, P70, DOI 10.1006/emyc.1994.1007; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; FELDMAN JF, 1973, GENETICS, V75, P606; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GRUBER A, 1995, BIOTECHNIQUES, V19, P28; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; Hall JC, 1996, NEURON, V17, P799, DOI 10.1016/S0896-6273(00)80211-1; HARDIN P, 1995, SEMIN NEUROSCI, V7, P15, DOI 10.1016/1044-5765(95)90013-6; HASTINGS M, 1995, NATURE, V376, P296, DOI 10.1038/376296a0; HOTZVITATERNA M, 1994, SCIENCE, V264, P719; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; Lewis MT, 1997, MOL GEN GENET, V253, P401, DOI 10.1007/s004380050338; LOROS J, 1995, SEMIN NEUROSCI, V7, P3, DOI 10.1016/1044-5765(95)90012-8; Merrow MW, 1997, P NATL ACAD SCI USA, V94, P3877, DOI 10.1073/pnas.94.8.3877; MICHEL S, 1993, SCIENCE, V259, P239, DOI 10.1126/science.8421785; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Mittag M, 1996, PHYSIOL PLANTARUM, V96, P727; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; NAKASHIMA H, 1981, PLANT CELL PHYSIOL, V22, P231; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; REPPERT SM, 1995, NEURON, V15, P983, DOI 10.1016/0896-6273(95)90086-1; Rosato E, 1997, NUCLEIC ACIDS RES, V25, P455, DOI 10.1093/nar/25.3.455; Sauman I, 1996, NEURON, V17, P901, DOI 10.1016/S0896-6273(00)80221-4; Sauman I, 1996, NEURON, V17, P889, DOI 10.1016/S0896-6273(00)80220-2; SEHGAL A, 1995, SEMIN NEUROSCI, V7, P27, DOI 10.1016/1044-5765(95)90014-4; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	49	290	296	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	1997	89	3					469	476		10.1016/S0092-8674(00)80227-5	http://dx.doi.org/10.1016/S0092-8674(00)80227-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150146	hybrid			2022-12-28	WOS:A1997WX89900017
J	Weichselbaum, RR; Kufe, D				Weichselbaum, RR; Kufe, D			Gene therapy of cancer	LANCET			English	Article							TUMOR-REGRESSION; EXPRESSION; DNA; MICE; COMPLEXES; VECTORS		HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Weichselbaum, RR (corresponding author), UNIV CHICAGO,CTR RADIAT THERAPY,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637, USA.				NCI NIH HHS [CA41068] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041068] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERKNER KL, 1992, CURR TOP MICROBIOL, V158, P39; Borysiewicz LK, 1996, LANCET, V347, P1523, DOI 10.1016/S0140-6736(96)90674-1; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; Chen L, 1996, J CLIN INVEST, V98, P2539, DOI 10.1172/JCI119072; Chen L, 1995, J CLIN INVEST, V96, P2775, DOI 10.1172/JCI118347; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; DALGLEISH AG, 1994, GENE THER, V1, P83; FINE HA, 1997, CANC MED, P1265; FREEMAN SM, 1993, CANCER RES, V53, P5274; HALLAHAN DE, 1995, NAT MED, V1, P786, DOI 10.1038/nm0895-786; HOROWITZ MS, 1991, FUNDAMENTAL VIROLOGY, P771; HUBER BE, 1993, CANCER RES, V53, P4619; KASHANISABET M, 1995, INTERNET BOOK GENE T, P91; MANTHORPE M, 1993, HUM GENE THER, V4, P419, DOI 10.1089/hum.1993.4.4-419; MILLER AD, 1992, CURR TOP MICROBIOL, V158, P1; MOOLTEN FL, 1986, CANCER RES, V46, P5276; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; PODDA S, 1992, P NATL ACAD SCI USA, V89, P9676, DOI 10.1073/pnas.89.20.9676; RETTINGER SD, 1994, P NATL ACAD SCI USA, V91, P1460, DOI 10.1073/pnas.91.4.1460; ROIZMAN B, 1991, VIROLOGY, P1795; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; SOBOL RE, 1996, CANCER GENE THER, V3, P265; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; TSANG KY, 1995, J NATL CANCER I, V87, P982, DOI 10.1093/jnci/87.13.982; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WANG B, 1995, HUM GENE THER, V6, P407, DOI 10.1089/hum.1995.6.4-407; WEI MX, 1995, HUM GENE THER, V6, P437, DOI 10.1089/hum.1995.6.4-437; WEN P, 1993, NUCLEIC ACIDS RES, V21, P1911, DOI 10.1093/nar/21.8.1911; WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079; WOLFF JA, 1995, INTERNET BOOK GENE T, P65	31	11	12	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY	1997	349			2			S10	S12		10.1016/S0140-6736(97)90013-1	http://dx.doi.org/10.1016/S0140-6736(97)90013-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ895	9164440	Bronze			2022-12-28	WOS:A1997WZ89500005
J	Hine, CE; Bachmann, MO				Hine, CE; Bachmann, MO			What does locality commissioning in Avon offer? Retrospective descriptive evaluation	BRITISH MEDICAL JOURNAL			English	Article								Objective: To describe the impact, direct costs of, and participants' attitudes to the first two years and eight months of locality commissioning in Avon. Design: Retrospective description of programme. Setting: Thirteen localities in Avon Health Authority area, covering 982 000 population and 147 general practices. Methods: Postal questionnaire survey of 147 general practitioners (one per practice); interviews with and questionnaire survey of 13 lead general practitioners and 13 so called link staff from the health authority. Main outcome measures: Locality initiatives, perceived influence, general practitioners' attitudes, management costs. Results: Twenty initiatives were identified that had changed services to patients, and another nine were planned. The commonest initiatives concerned primary mental health care (seven), nurse specialists for primary care of chronic diseases (three), referral and clinical practice guidelines (seven), and access to hospital outpatient departments (one, with two others planned). Localities were more likely to have influenced the authority, trust managers, and consultants than social services, community health councils, and voluntary organisations. Activity varied between localities, lead general practitioners estimating that 120/147 (82%) of practices had been involved in locality meetings (range 44-100% in different localities). The authority had spent 6 p per capita on running the scheme, and the total time used by general practitioners for locality commissioning was estimated at 1.5 whole time equivalents. Conclusion: Locality commissioning has selectively changed services with limited extra funding and without delegation of hospital and community health service budgets. General practitioners wanted more policy and financial support. Further development should be based on evidence of costs, benefits, and limitations of locality commissioning schemes.	UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND	University of Bristol	Hine, CE (corresponding author), AVON HLTH AUTHOR,DEPT PUBL HLTH MED,BRISTOL BS2 8EE,AVON,ENGLAND.							*AUD COMM, 1996, DOCT ORD STUD GEN PR; Balogh R, 1996, SOC POLICY ADMIN, V30, P99, DOI 10.1111/j.1467-9515.1996.tb00430.x; BALOGH R, 1995, HLTH SERVICES J 0810, P26; BLACK DG, 1994, BRIT MED J, V309, P930, DOI 10.1136/bmj.309.6959.930; Department of Health, 1996, PRIM CAR DEL FUT; GRAFFY JP, 1994, BRIT MED J, V308, P391, DOI 10.1136/bmj.308.6925.391; HAM C, 1992, 30 U BIRM HLTH SERV; MAYS N, 1996, PURCHASER PLURALITY; *NAT EV TEAM, 1997, TOT PURCH PROF NAT P; *NHS EX, 1996, ANN REP 1995 96; SMITH J, 1996, HOLDING LETTING GO E	11	8	8	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 26	1997	314	7089					1246	1250		10.1136/bmj.314.7089.1246	http://dx.doi.org/10.1136/bmj.314.7089.1246			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW718	9154029	Green Published			2022-12-28	WOS:A1997WW71800021
J	Jones, AH				Jones, AH			Literature and medicine: Narrative ethics	LANCET			English	Editorial Material							STORY				Jones, AH (corresponding author), UNIV TEXAS, MED BRANCH,INST MED HUMANITIES,ASHBEL SMITH BLDG, SUITE 2-210, 301 UNIV BLVD, GALVESTON, TX 77555 USA.							BANKS JT, 1986, LIT MED, V5, P1; BANKS JT, 1992, LIT MED, V11, P1; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; BENNER P, 1991, ADV NURS SCI, V14, P1; BRODY H, 1994, LIT MED, V13, P79; Brody H., 1987, STORIES SICKNESS; Bruner JS, 1986, ACTUAL MINDS POSSIBL, DOI DOI 10.4159/9780674029019; CHAMBERS TS, 1994, LIT MED, V13, P60, DOI 10.1353/lm.2011.0160; CHARON R, 1986, LIT MED, V5, P58; CHARON R, 1989, SOUNDINGS, V72, P137; Charon R., 1994, MATTER PRINCIPLES FE, P260; Churchill L, 1979, Soundings, V62, P24; COLES R, 1979, NEW ENGL J MED, V301, P444, DOI 10.1056/NEJM197908233010831; Coles R, 1989, CALL STORIES TEACHIN; DONNELLY WJ, 1988, JAMA-J AM MED ASSOC, V260, P823, DOI 10.1001/jama.260.6.823; DUBOSE ER, 1994, FERMENT US BIOETHICS; ECO U, 1988, SIGN 3 DUPIN HOLMES, P131; Frank A., 1991, WILL BODY REFLECTION; Frank AW., 2013, WOUNDED STORYTELLER; Geertz Clifford, 1988, WORKS LIVES ANTHR AU; HUNTER KM, 1995, ACAD MED, V70, P787, DOI 10.1097/00001888-199509000-00014; HUNTER KM, 1994, LIT MED, V13, P1; Jones AH, 1997, LANCET, V349, P275, DOI 10.1016/S0140-6736(96)12240-6; Jones AH, 1996, LANCET, V348, P1360, DOI 10.1016/S0140-6736(96)09219-7; JONES AH, 1994, LIT MED, V13, P190; Jones AH, 1996, LANCET, V348, P734, DOI 10.1016/S0140-6736(96)07315-1; Jones AH, 1996, J MED PHILOS, V21, P267; JONES AH, 1987, NEOHELICON, V14, P383, DOI 10.1007/BF02094701; JONES AH, 1990, ST COMPAR L, V22, P11; JONES AH, 1997, PHILOS MED BIOETHICS, P193; Jonsen A. R., 1988, ABUSE CASUISTRY HIST; KING NMP, 1992, LIT MED, V11, P185; Kleinman A., 1988, ILLNESS NARRATIVES; McLellan MF, 1997, LANCET, V349, P564, DOI 10.1016/S0140-6736(97)80120-1; McLellan MF, 1996, LANCET, V348, P1640, DOI 10.1016/S0140-6736(96)09333-6; McLellan MF, 1996, LANCET, V348, P109, DOI 10.1016/S0140-6736(96)03521-0; McLellan MF, 1996, LANCET, V348, P458, DOI 10.1016/S0140-6736(96)02421-X; McLellan MF, 1996, LANCET, V348, P1014, DOI 10.1016/S0140-6736(96)07316-3; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; PEIRCE CS, 1929, HOUND HORN, V2, P282; Polkinghorne D.E., 1988, NARRATIVE KNOWING HU; TOULMIN S, 1983, POLITICS INTERPRETAT, P99; Trautmann J., 1978, ROLE HUMANITIES MED, P32	43	38	38	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1243	1246		10.1016/S0140-6736(97)03395-3	http://dx.doi.org/10.1016/S0140-6736(97)03395-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130959				2022-12-28	WOS:A1997WW71700043
J	Mulholland, K; Hilton, S; Adegbola, R; Usen, S; Oparaugo, A; Omosigho, C; Weber, M; Palmer, A; Schneider, G; Jobe, K; Lahai, G; Jaffar, S; Secka, O; Lin, K; Ethevenaux, C; Greenwood, B				Mulholland, K; Hilton, S; Adegbola, R; Usen, S; Oparaugo, A; Omosigho, C; Weber, M; Palmer, A; Schneider, G; Jobe, K; Lahai, G; Jaffar, S; Secka, O; Lin, K; Ethevenaux, C; Greenwood, B			Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants	LANCET			English	Article							HEMOPHILUS-INFLUENZAE; WEST-AFRICA; CHILDREN; VACCINE; CARRIAGE; EFFICACY; DISEASE; EPIDEMIOLOGY; HIB	Background In developing countries, pneumonia and meningitis due to Haemophilus influenzae type b (Hib) are common in children under age 12 months and the mortality from meningitis is high. Protein-polysaccharide conjugate vaccines have brought Hib disease under control in industrialised countries. We did a double-blind randomised trial in The Gambia to assess the efficacy of a Hib conjugate vaccine for the prevention of meningitis, pneumonia, and other invasive diseases due to Hib. Methods Between March, 1993, and October, 1995, 42 848 infants were randomly allocated the conjugate vaccine Hib polysaccharide tetanus protein (PRP-T) mixed with diphtheria-tetanus-pertussis vaccine (DTP), or DTP alone at age 2 months, 3 months, and 4 months. Children who presented with signs of invasive Hib were investigated by blood culture and, where appropriate, by lumbar puncture, chest radiograph, or percutaneous lung aspirate. Children were followed up for between 5 and 36 months. Findings The median ages at which children received the study vaccine were 11 weeks, 18 weeks, and 24 weeks. 83% of children enrolled received all three doses of vaccine. 17 cases of culture-positive Hib pneumonia, 28 of Hib meningitis, and five of other forms of invasive Hib disease were detected amongst the study children. The efficacy of the vaccine for the prevention of all invasive disease after three doses was 95% (PRP-T vaccinees 1, controls 19 [95% CI 67-100]), for the prevention of Hib pneumonia after two or three doses, 100% (vaccinees 0, controls 10 [55-100]), and for the prevention of radiologically defined pneumonia at any time after enrolment, 21.1% (PRP-T vaccinees 198, controls 251 [4.6-34.9]). Interpretation PRP-T conjugate Hib vaccine prevented most cases of meningitis and pneumonia due to Hib in Gambian. infants. The reduction in the overall incidence of radiologically defined pneumonia in PRP-T vaccinees suggests that about 20% of episodes of pneumonia in young Gambian children are due to Hib. The introduction of Hib vaccines into developing countries should substantially reduce childhood mortality due to pneumonia and meningitis.	MRC LABS,FAJARA,GAMBIA; ROYAL VICTORIA HOSP,BANJUL,GAMBIA; SIBANOR MISS HOSP,SIBANOR,SENEGAL; MINIST HLTH,MED & HLTH DEPT,BANJUL,GAMBIA; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND; NATL VACCINE PROGRAM OFF,WASHINGTON,DC; PASTEUR MERIEUX SERUMS & VACCINS,LYON,FRANCE	MRC Laboratory Molecular Biology; University of London; London School of Hygiene & Tropical Medicine				Jaffar, Shabbar/0000-0002-9615-1588				ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; Adegbola RA, 1996, ANN TROP PAEDIATR, V16, P103, DOI 10.1080/02724936.1996.11747812; ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008; BIJLMER HA, 1990, J INFECT DIS, V161, P1210, DOI 10.1093/infdis/161.6.1210; BIJLMER HA, 1989, T ROY SOC TROP MED H, V83, P831, DOI 10.1016/0035-9203(89)90345-3; BIJLMER HA, 1994, DEV USES HAEMOPHILUS, P247; BOOY R, 1994, LANCET, V344, P362, DOI 10.1016/S0140-6736(94)91400-1; CHOO KE, 1990, ANN TROP PAEDIATR, V10, P89, DOI 10.1080/02724936.1990.11747415; FALLA TJ, 1994, J CLIN MICROBIOL, V32, P2382, DOI 10.1128/JCM.32.10.2382-2386.1994; FERRECCIO C, 1990, PEDIATR INFECT DIS J, V9, P488, DOI 10.1097/00006454-199007000-00007; FUNKHOUSER A, 1991, REV INFECT DIS, V13, pS542; GRATTEN M, 1984, J CLIN MICROBIOL, V19, P526, DOI 10.1128/JCM.19.4.526-528.1984; GREENWOOD B, 1992, J INFECT DIS, V165, pS26, DOI 10.1093/infdis/165-Supplement_1-S26; Greenwood M, 1915, Proc R Soc Med, V8, P113; HONIG PJ, 1973, J PEDIATR-US, V83, P215, DOI 10.1016/S0022-3476(73)80478-0; Lagos R, 1996, PEDIATR INFECT DIS J, V15, P216, DOI 10.1097/00006454-199603000-00008; MPAIRWE Y, 1970, J HYG-CAMB, V68, P337, DOI 10.1017/S0022172400028783; Mulholland EK, 1996, VACCINE, V14, P905, DOI 10.1016/0264-410X(95)00260-8; Murray C. J. L., 1996, GLOBAL BURDEN DIS; RILEY HD, 1965, AM J DIS CHILD, V110, P24, DOI 10.1001/archpedi.1965.02090030030004; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; WARD J, 1990, NEW ENGL J MED, V323, P1393, DOI 10.1056/NEJM199011153232006; WARD JI, 1988, J CLIN MICROBIOL, V26, P72, DOI 10.1128/JCM.26.1.72-78.1988	24	320	341	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1191	1197		10.1016/S0140-6736(96)09267-7	http://dx.doi.org/10.1016/S0140-6736(96)09267-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130939				2022-12-28	WOS:A1997WW71700007
J	Sharan, SK; Morimatsu, M; Albrecht, U; Lim, DS; Regel, E; Dinh, C; Sands, A; Eichele, G; Hasty, P; Bradley, A				Sharan, SK; Morimatsu, M; Albrecht, U; Lim, DS; Regel, E; Dinh, C; Sands, A; Eichele, G; Hasty, P; Bradley, A			Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2	NATURE			English	Article							MEIOTIC CHROMOSOME SYNAPSIS; CANCER SUSCEPTIBILITY GENE; FAMILIAL BREAST; OVARIAN-CANCER; RECA HOMOLOGS; PROTEIN; REPAIR; MOUSE; YEAST; RECOMBINATION	Inherited mutations in the human BRCA2 gene cause about half of the cases of early-onset breast cancer. The embryonic expression pattern of the mouse Brca2 gene is now defined and an interaction identified of the Brca2 protein with the DNA-repair protein Rad51. Developmental arrest in Brca2-deficient embryos, their radiation sensitivity, and the association of Brca2 with Rad51 indicate that Brca2 may be an essential cofactor in the Rad51-dependent DNA repair of double-strand breaks, thereby explaining the tumour-suppressor function of Brca2.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; LEXICON GENET INC,THE WOODLANDS,TX 77381; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL GENET,HOUSTON,TX 77030; HOKKAIDO UNIV,GRAD SCH VET MED,DEPT BIOMED SCI,SAPPORO,HOKKAIDO 060,JAPAN	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Lexicon Pharmaceuticals; University of Texas System; UTMD Anderson Cancer Center; Hokkaido University			Albrecht, Urs/A-9831-2011; Morimatsu, Masami/A-6698-2012; Lim, Dae-Sik/C-1599-2011	Albrecht, Urs/0000-0002-0663-8676; Morimatsu, Masami/0000-0003-0740-0157; Lim, Dae-Sik/0000-0003-2356-7555; Bradley, Allan/0000-0002-2349-8839; Hasty, Paul/0000-0003-3046-0131				ALBECHT U, 1997, MOL CELLULAR METHODS, P23; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EASTON DF, 1993, AM J HUM GENET, V52, P678; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; HU NP, 1994, ONCOGENE, V9, P1021; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P2; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; Miller J. H, 1972, EXPT MOL GENETICS; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; POWER MA, 1993, ANAT EMBRYOL, V187, P493; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RAJAN IV, 1996, P NATL ACAD SCI USA, V93, P13078; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; ROCKMILL B, 1995, GENE DEV, V9, P2684, DOI 10.1101/gad.9.21.2684; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; Wick W, 1996, ONCOGENE, V12, P973; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	46	870	896	1	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					804	810		10.1038/386804a0	http://dx.doi.org/10.1038/386804a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126738	Green Submitted			2022-12-28	WOS:A1997WV70600046
J	Duncombe, A				Duncombe, A			ABC of clinical haematology - Bone marrow and stem cell transplantation	BRITISH MEDICAL JOURNAL			English	Article									UNIV SOUTHAMPTON,ROYAL S HANTS HOSP,DEPT PRIMARY CARE,SOUTHAMPTON,HANTS,ENGLAND	University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital	Duncombe, A (corresponding author), SOUTHAMPTON UNIV HOSP,NHS TRUST,SOUTHAMPTON,HANTS,ENGLAND.								0	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 19	1997	314	7088					1179	1182		10.1136/bmj.314.7088.1179	http://dx.doi.org/10.1136/bmj.314.7088.1179			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV705	9146394	Green Published			2022-12-28	WOS:A1997WV70500029
J	Roberts, H				Roberts, H			Socioeconomic determinants of health - Children, inequalities, and health	BRITISH MEDICAL JOURNAL			English	Article							NATIONAL BIRTH COHORT; ILLNESS	This article describes a growing body of evidence showing the adverse effects of the widening income gap on the health and welfare of children and young people. The effects of this go well beyond morbidity and mortality and can also be seen in the areas of crime, violence, and educational attainment There is a need for evidence based policy in this area, but meanwhile there is scope for intervention in pregnancy and the early years, and good evidence that this is effective. A number of well evaluated interventions not necessarily directly related to health, such as early learning programmes and social support for parents, promise to have beneficial health effects.			Roberts, H (corresponding author), BARNARDOS,POLICY & DEV UNIT,ILFORD IG6 1QG,ENGLAND.			Roberts, Helen/0000-0002-6319-061X				ARBLASTER L, IN PRESS REV EFFECTI; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER WE, 1994, 14 DEP SOC WORK EARL; *BIBLE, 1911, DANIEL, V1, P10; Bryce C., 1995, CHILDREN RISK SAFETY; *DEP SOC SEC, 1996, HOUS AV INC 1979 199; DOUGLAS JWB, 1986, HOME SCH; Graham H., 1993, HARDSHIP HLTH WOMENS; Holterman S., 1995, ALL OUR FUTURES IMPA; Home Office, 1993, CRIM STAT ENGL WAL 1; JOHNSON Z, 1993, BRIT MED J, V306, P1449, DOI 10.1136/bmj.306.6890.1449; KEHNER BH, 1979, J HUM RESOUR, V14, P434; KEMPSON E, 1996, LIFE LOW INCOME; KUH DJL, 1993, SOC SCI MED, V37, P905, DOI 10.1016/0277-9536(93)90145-T; LUNDBERG O, 1993, SOC SCI MED, V36, P1047, DOI 10.1016/0277-9536(93)90122-K; MACDONALD G, 1995, WHAT WORKS EARLY YEA; MANN SL, 1992, J EPIDEMIOL COMMUN H, V46, P286, DOI 10.1136/jech.46.3.286; *NAT CHILDR HOM, 1992, NCH FACTF CHILDR BRI, P64; OAKLEY A, 1996, MAN WIFE R K TITMUSS, P190; *OFF POP CENS SURV, 1993, OPCS MORT STAT; Oppenheim C., 1993, POVERTY FACTS; PHILLIMORE P, 1994, HLTH INEQUALITY NO R; PILLING D, 1990, ESCAPE DISADVANTAGE; Power C, 1997, BRIT MED BULL, V53, P210; Power C., 1991, HLTH CLASS EARLY YEA; Roberts I, 1996, BRIT MED J, V313, P784; SCHWEINHART L, 1993, SUMMARY SIGNIFICANT; Smith GD, 1996, BRIT MED J, V313, P1584, DOI 10.1136/bmj.313.7072.1584; SMITH R, 1996, BRIT MED J, V314, P81; SWEETING H, 1995, 49 MRC MED SOC UN; Titmuss Richard, 1943, BIRTH POVERTY WEALTH; Wadsworth M. E. J., 1991, IMPRINT TIME CHILDHO; WADSWORTH MEJ, 1981, FAM PRACT, V7, P104; Wadsworth MEJ, 1986, EARLY CHILDHOOD RES, V1, P237; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC; WILKINSON RG, 1994, UNFAIR SHARES EFFECT; WOODROFFE C, 1993, CHILDREN TEENAGERS H; 1944, LONDON NEWS      JAN; 1943, LONDON NEWS      DEC; 1994, GUARDIAN        0728, P12; 1943, DAILY HERALD    0920; 1944, EVENING CITIZEN 0105	42	43	43	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 12	1997	314	7087					1122	1125		10.1136/bmj.314.7087.1122	http://dx.doi.org/10.1136/bmj.314.7087.1122			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU236	9133901	Green Published			2022-12-28	WOS:A1997WU23600038
J	Courtney, SM; Ungerleider, BG; Keil, K; Haxby, JV				Courtney, SM; Ungerleider, BG; Keil, K; Haxby, JV			Transient and sustained activity in a distributed neural system for human working memory	NATURE			English	Article							SHORT-TERM-MEMORY; PREFRONTAL CORTEX; TEMPORAL CORTEX; FRONTAL-CORTEX; NEURONS; TASK; DISSOCIATION; ACTIVATION	Working memory involves the short-term maintenance of an active representation of information so that it is available for further processing. Visual working memory tasks, in which subjects retain the memory of a stimulus over brief delays, require both the perceptual encoding of the stimulus and the subsequent maintenance of its representation after the stimulus is removed from view. Such tasks activate multiple areas in visual and prefrontal cortices(1-9). To delineate the roles these areas play in perception and working memory maintenance, we used functional magnetic resonance imaging (fMRI) to obtain dynamic measures of neural activity related to different components of a face working memory task-non-selective transient responses to visual stimuli, selective transient responses to faces, and sustained responses over memory delays. Three occipitotemporal areas in the ventral object vision pathway had mostly transient responses to stimuli, indicating their predominant role in perceptual processing, whereas three prefrontal areas demonstrated sustained activity over memory delays, indicating their predominant role in working memory. This distinction, however, was not absolute. Additionally, the visual areas demonstrated different degrees of selectivity, and the prefrontal areas demonstrated different strengths of sustained activity, revealing a continuum of functional specialization, from occipital through multiple prefrontal areas, regarding each area's relative contribution to perceptual and mnemonic processing.	NATL INST HLTH,SECT NEUROCIRCUITRY,LAB BRAIN & COGNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	Courtney, SM (corresponding author), NATL INST HLTH,SECT FUNCT BRAIN IMAGING,10 CTR DR,MSC 1366,BETHESDA,MD 20892, USA.							Buckner RL, 1996, PSYCHON B REV, V3, P149, DOI 10.3758/BF03212413; Chao LL, 1996, COGNITIVE BRAIN RES, V4, P27, DOI 10.1016/0926-6410(95)00043-7; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Courtney S. M., 1996, Society for Neuroscience Abstracts, V22, P968; Courtney SM, 1996, CEREB CORTEX, V6, P39, DOI 10.1093/cercor/6.1.39; DEMB JB, 1995, J NEUROSCI, V15, P5870; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Desimone R., 1989, HDB NEUROPSYCHOLOGY, P267; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Fiez JA, 1996, J NEUROSCI, V16, P808; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Fuster JM, 1995, MEMORY CEREBRAL CORT; Gevins A, 1996, ELECTROEN CLIN NEURO, V98, P327, DOI 10.1016/0013-4694(96)00288-X; Haxby JV, 1996, P NATL ACAD SCI USA, V93, P922, DOI 10.1073/pnas.93.2.922; Haxby JV, 1995, HUM BRAIN MAPP, V3, P68, DOI 10.1002/hbm.460030204; MCCARTHY G, 1993, P NATL ACAD SCI USA, V90, P4952, DOI 10.1073/pnas.90.11.4952; MCCARTHY G, 1994, P NATL ACAD SCI USA, V91, P8690, DOI 10.1073/pnas.91.18.8690; MILLER EK, 1993, J NEUROSCI, V13, P1460; Miller EK, 1996, J NEUROSCI, V16, P5154; MIYASHITA Y, 1988, NATURE, V331, P68, DOI 10.1038/331068a0; Owen AM, 1996, CEREB CORTEX, V6, P31, DOI 10.1093/cercor/6.1.31; Paus T, 1996, NEUROPSYCHOLOGIA, V34, P475, DOI 10.1016/0028-3932(95)00134-4; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; Talairach J., 1988, COPLANAR STEREOTAXIS; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	30	731	756	3	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 10	1997	386	6625					608	611		10.1038/386608a0	http://dx.doi.org/10.1038/386608a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121584				2022-12-28	WOS:A1997WT27300059
J	Condos, R; Rom, WN; Schluger, NW				Condos, R; Rom, WN; Schluger, NW			Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol	LANCET			English	Article							MACROPHAGES; INFECTION; MICE	Background Multidrug-resistant tuberculosis (MDR-TB) is associated with substantial morbidity, despite drug therapy. Interferon-gamma, a cytokine produced mainly by CD4 T lymphocytes, can activate alveolar macrophages, important effector cells in host immunity against Mycobacterium tuberculosis. We investigated safety and tolerability of aerosolised interferon-gamma in patients with MDR-TB, and assessed its efficacy in terms of sputum-smear grades. Methods We did an open-label trial of aerosol interferon-gamma given to five patients with smears and cultures positive for pulmonary MDR-TB, despite documented adherence to therapy. The patients received aerosol interferon-gamma 500 mu g three times a week for 1 month. Safety and tolerability were assessed, and, as well as routine clinical assessments, sputum samples for smear and culture were collected al entry and weekly. Computed tomography scans of the chest were done at baseline and after therapy ended, Findings Interferon-gamma was well tolerated by ail patients, In ail five, bodyweight stabilised or increased. Sputum acid-fast-bacillus smears became negative in all patients, and the time to positive culture increased (from 17 to 24 days, not significant), which suggested that the mycobacterial burden had decreased. The size of cavitary lesions was reduced in all patients, 2 months after treatment had ended. Interpretation Preliminary data suggest that aerosol interferon-gamma is a weil-tolerated treatment that may be useful as adjunctive therapy in patients with MDR-IB who are otherwise not responding well to therapy.	NYU, MED CTR, BELLEVUE CHEST SERV, NEW YORK, NY 10016 USA; NYU, MED CTR, DIV PULM & CRIT CARE MED, NEW YORK, NY 10016 USA	New York University; New York University			Schluger, Neil/ABA-1793-2021	Rom, William/0000-0002-8793-7028	NCRR NIH HHS [M01 RR00096] Funding Source: Medline; NHLBI NIH HHS [K07 HL03030, R01 HL55791] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055791, K07HL003030] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAN J, 1995, INFECT IMMUN, V63, P736, DOI 10.1128/IAI.63.2.736-740.1995; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; GALLIN JI, 1995, ANN INTERN MED, V123, P216, DOI 10.7326/0003-4819-123-3-199508010-00009; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; HOLLAND SM, 1994, NEW ENGL J MED, V330, P1348, DOI 10.1056/NEJM199405123301904; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HUEBNER RE, 1995, ANNU REV MED, V46, P47; *INT CHRON GRAN DI, 1991, NEW ENGL J MED, V321, P509; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; MURRAY HW, 1994, AM J MED, V97, P459, DOI 10.1016/0002-9343(94)90326-3; NATHAN CF, 1984, J EXP MED, V160, P600, DOI 10.1084/jem.160.2.600; Park MM, 1996, AM J RESP CRIT CARE, V153, P317, DOI 10.1164/ajrccm.153.1.8542137; Pfyffer GE, 1996, J CLIN MICROBIOL, V34, P834, DOI 10.1128/JCM.34.4.834-841.1996; SAMPAIO EP, 1992, J EXP MED, V175, P1729, DOI 10.1084/jem.175.6.1729; VILCEK J, 1994, INT ARCH ALLERGY IMM, V104, P311; YEW WW, 1995, EUR RESPIR J, V8, P1184, DOI 10.1183/09031936.95.08071184	16	249	271	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	1997	349	9064					1513	1515		10.1016/S0140-6736(96)12273-X	http://dx.doi.org/10.1016/S0140-6736(96)12273-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167461	hybrid			2022-12-28	WOS:A1997XA90100011
J	Lindquist, S				Lindquist, S			Mad cows meet psi-chotic yeast: The expansion of the prion hypothesis	CELL			English	Review							SACCHAROMYCES-CEREVISIAE; PROTEIN HSP104; URE3				Lindquist, S (corresponding author), UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MOL GENET & CELL BIOL, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA.							AIGLE M, 1975, MOL GEN GENET, V136, P327, DOI 10.1007/BF00341717; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Derkatch IL, 1996, GENETICS, V144, P1375; Kenward N, 1996, CELL STRESS CHAPERON, V1, P18, DOI 10.1379/1466-1268(1996)001<0018:HSPMCA>2.3.CO;2; KUSHNIROV V V, 1990, Molekulyarnaya Biologiya (Moscow), V24, P1024; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; Liu HP, 1996, GENETICS, V144, P967; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; Tuite MF, 1996, TRENDS GENET, V12, P467, DOI 10.1016/0168-9525(96)10045-7; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1996, ANNU REV GENET, V30, P109, DOI 10.1146/annurev.genet.30.1.109; Willard HF, 1996, CELL, V86, P5, DOI 10.1016/S0092-8674(00)80071-9	20	140	145	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	1997	89	4					495	498		10.1016/S0092-8674(00)80231-7	http://dx.doi.org/10.1016/S0092-8674(00)80231-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160741	Bronze			2022-12-28	WOS:A1997WZ32300003
J	Fielding, AK; Ager, S; Russell, SJ				Fielding, AK; Ager, S; Russell, SJ			ABC of clinical haematology - The future of haematology, molecular biology, and gene therapy	BRITISH MEDICAL JOURNAL			English	Article											Fielding, AK (corresponding author), UNIV CAMBRIDGE,DEPT HAEMATOL,MRC CTR,CAMBRIDGE,ENGLAND.		Fielding, adele/B-2848-2009						0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1396	1399						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ169	9161316				2022-12-28	WOS:A1997WZ16900033
J	Jenkins, R				Jenkins, R			Reducing the burden of mental illness	LANCET			English	Editorial Material											Jenkins, R (corresponding author), INST PSYCHIAT,WHO,UK MENTAL HLTH OFF,LONDON SE5 8AF,ENGLAND.		Jenkins, Rachel/H-2953-2019; Jenkins, Rachel/E-4287-2010	Jenkins, Rachel/0000-0002-2958-0331; Jenkins, Rachel/0000-0002-2958-0331				[Anonymous], 1995, WORLD MENTAL HLTH PR; *WHO, 1996, TECHN CONS DEC 1 2 1	2	22	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1340	1340		10.1016/S0140-6736(05)63200-X	http://dx.doi.org/10.1016/S0140-6736(05)63200-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WY342	9149694				2022-12-28	WOS:A1997WY34200006
J	Keatinge, WR; Donaldson, GC; Bucher, K; Jendritsky, G; Cordioli, E; Martinelli, M; Dardanoni, L; Katsouyanni, K; Kunst, AE; Mackenbach, JP; McDonald, C; Nayha, S; Vuori, I				Keatinge, WR; Donaldson, GC; Bucher, K; Jendritsky, G; Cordioli, E; Martinelli, M; Dardanoni, L; Katsouyanni, K; Kunst, AE; Mackenbach, JP; McDonald, C; Nayha, S; Vuori, I			Cold exposure and winter mortality from ischaemic heart disease, cerebrovascular disease, respiratory disease, and all causes in warm and cold regions of Europe	LANCET			English	Article							ELDERLY PEOPLE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; PLASMA-FIBRINOGEN; BODY-TEMPERATURE; BLOOD-PRESSURE; VITAMIN-C; CORONARY; DEATH; NETHERLANDS	Background Differences in baseline mortality, age structure, and influenza epidemics confound comparisons of cold-related increases in mortality between regions with different climates. The Eurowinter study aimed to assess whether increases in mortality per 1 degrees C fall in temperature differ in various European regions and to relate any differences to usual winter climate and measures to protect against cold. Methods Percentage increases in deaths per day per 1 degrees C fall in temperature below 18 degrees C (indices of cold-related mortality) were estimated by generalised linear modelling. We assessed protective factors by surveys and adjusted by regression to 7 degrees C outdoor temperature. Cause-specific data gathered from 1988 to 1992 were analysed by multiple regression for men and women aged 50-59 and 65-74 in north Finland, south Finland, Baden-Wurttemburg, the Netherlands, London, and north Italy (24 groups). We used a similar method to analyse 1992 data in Athens and Palermo. Findings The percentage increases in all-cause mortality per 1 degrees C fall in temperature below 18 degrees C were greater in warmer regions than in colder regions (eg, Athens 2.15% [95% CI 1.20-3.10] vs south Finland 0.27% [0.15-0.40]). At an outdoor temperature of 7 degrees C, the mean living-room temperature was 19.2 degrees C in Athens and 21.7 degrees C in south Finland; 13% and 72% of people in these regions, respectively, wore hats when outdoors at 7 degrees C. Multiple regression analyses (with allowance for sex and age, in the six regions with full data) showed that high indices of cold-related mortality were associated with high mean winter temperatures, low living-room temperatures, limited bedroom heating, low proportions of people wearing hats, gloves, and anoraks, and inactivity and shivering when outdoors at 7 degrees C (p<0.01 for all-cause mortality and respiratory mortality; p>0.05 for mortality from ischaemic heart disease and cerebrovascular disease). Interpretation Mortality increased to a greater extent with given fall of temperature in regions with warm winters, in populations with cooler homes, and among people who wore fewer clothes and were less active outdoors.	DEUTSCH WETTERDRENST,FREIBERG,GERMANY; UNIV BOLOGNA,I-40126 BOLOGNA,ITALY; UNIV PALERMO,I-90133 PALERMO,ITALY; UNIV ATHENS,SCH MED,GR-10679 ATHENS,GREECE; ERASMUS UNIV ROTTERDAM,ROTTERDAM,NETHERLANDS; MCDONALD RES,LONDON,ENGLAND; REG INST OCCUPAT HLTH,OULU,FINLAND; IKK INST HLTH PROMOT RES,TAMPERE,FINLAND	University of Bologna; University of Palermo; Athens Medical School; National & Kapodistrian University of Athens; Erasmus University Rotterdam	Keatinge, WR (corresponding author), UNIV LONDON QUEEN MARY & WESTFIELD COLL,DEPT PHYSIOL,MILE END RD,LONDON E1 4NS,ENGLAND.		Katsouyanni, Klea/D-4856-2014; Donaldson, Gavin/M-7992-2017	Katsouyanni, Klea/0000-0002-0132-9575; Kunst, Anton/0000-0002-3313-5273				BAINTON D, 1978, INT J EPIDEMIOL, V7, P231, DOI 10.1093/ije/7.3.231; BIEMOND BJ, 1995, CLIN SCI, V88, P587, DOI 10.1042/cs0880587; BULL G M, 1978, Age and Ageing, V7, P210, DOI 10.1093/ageing/7.4.210; CLEVELAND WS, 1993, VISUALISING DATA, P94; COLLINS KJ, 1985, CLIN SCI, V69, P465, DOI 10.1042/cs0690465; DONALDSON GC, IN PRESS J EPIDEMIOL; FARB A, 1995, CIRCULATION, V92, P1701, DOI 10.1161/01.CIR.92.7.1701; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; GRAY PG, 1950, J ROY STAT SOC A STA, V113, P150, DOI 10.2307/2981039; HANDLEY BA, 1995, J APPL BACTERIOL, V79, P368, DOI 10.1111/j.1365-2672.1995.tb03150.x; HAYWARD MG, 1981, J PHYSIOL-LONDON, V320, P229, DOI 10.1113/jphysiol.1981.sp013946; Imai Y, 1996, CLIN SCI, V90, P55, DOI 10.1042/cs0900055; KATSOUYANNI K, 1996, J EPIDEMIOL S1, V50, P512; KEATINGE WR, 1984, BMJ-BRIT MED J, V289, P1405, DOI 10.1136/bmj.289.6456.1405; KEATINGE WR, 1986, BRIT MED J, V293, P732, DOI 10.1136/bmj.293.6549.732-a; KHAW KT, 1995, BRIT MED J, V310, P1559, DOI 10.1136/bmj.310.6994.1559; KUNST AE, 1993, AM J EPIDEMIOL, V137, P331, DOI 10.1093/oxfordjournals.aje.a116680; LOVETT AA, 1986, SOC SCI MED, V23, P935, DOI 10.1016/0277-9536(86)90251-0; MACKENBACH JP, 1993, J EPIDEMIOL COMMUN H, V47, P121, DOI 10.1136/jech.47.2.121; MCKEE CM, 1989, EUR J EPIDEMIOL, V5, P178, DOI 10.1007/BF00156826; MILLQVIST E, 1987, EUR J RESPIR DIS, V71, P444; MUDGE GH, 1976, NEW ENGL J MED, V295, P1333, DOI 10.1056/NEJM197612092952401; NEILD PJ, 1994, CLIN SCI, V86, P43, DOI 10.1042/cs0860043; OPHIR D, 1987, AM J OTOLARYNG, V3, P149; SPODICK DH, 1984, AM J CARDIOL, V53, P481, DOI 10.1016/0002-9149(84)90016-X; TYRRELL D, 1989, BRIT MED J, V298, P1280, DOI 10.1136/bmj.298.6683.1280; WOODHOUSE PR, 1993, J HYPERTENS, V11, P1267; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	28	700	729	0	75	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1341	1346						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149695				2022-12-28	WOS:A1997WY34200007
J	Young, NS; Maciejewski, J				Young, NS; Maciejewski, J			Mechanisms of disease - The pathophysiology of acquired aplastic anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HEMATOPOIETIC PROGENITOR CELLS; COLONY-STIMULATING FACTOR; ANTI-THYMOCYTE GLOBULIN; NECROSIS-FACTOR-ALPHA; MARROW STROMAL CELLS; HUMAN BONE-MARROW; INTERFERON-GAMMA; ANTILYMPHOCYTE GLOBULIN; FAS ANTIGEN; T-CELLS				Young, NS (corresponding author), NHLBI,HEMATOL BRANCH,NIH,BLDG 10,RM 7C103,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ANDERSON KC, 1990, NEW ENGL J MED, V323, P315; ANDERSON KC, 1990, NEW ENGL J MED, V323, P1360; BACIGALUPO A, 1995, BLOOD, V85, P1348, DOI 10.1182/blood.V85.5.1348.bloodjournal8551348; Bacigalupo A, 1996, EUR J HAEMATOL, V57, P16; BESSLER M, 1994, LANCET, V343, P951, DOI 10.1016/S0140-6736(94)90068-X; Brodsky RA, 1996, BLOOD, V87, P491, DOI 10.1182/blood.V87.2.491.bloodjournal872491; Brown KE, 1997, NEW ENGL J MED, V336, P1059, DOI 10.1056/NEJM199704103361504; CHAMPLIN R, 1983, NEW ENGL J MED, V308, P113, DOI 10.1056/NEJM198301203080301; CHAMPLIN RE, 1984, BRIT J HAEMATOL, V56, P455, DOI 10.1111/j.1365-2141.1984.tb03975.x; CORZO D, 1995, BLOOD, V86, P3835, DOI 10.1182/blood.V86.10.3835.bloodjournal86103835; DAS REG, 1992, BRIT J HAEMATOL, V82, P601, DOI 10.1111/j.1365-2141.1992.tb06474.x; DEPLANQUE MM, 1989, BRIT J HAEMATOL, V73, P121; DEVETTEN MP, CYTOKINES TREATMENT; Dunn DE, 1996, P NATL ACAD SCI USA, V93, P7938, DOI 10.1073/pnas.93.15.7938; Emmons RVB, 1996, BLOOD, V87, P4068, DOI 10.1182/blood.V87.10.4068.bloodjournal87104068; GIBSON FM, 1995, BRIT J HAEMATOL, V91, P551, DOI 10.1111/j.1365-2141.1995.tb05346.x; HERTENSTEIN B, 1995, BLOOD, V86, P1487, DOI 10.1182/blood.V86.4.1487.bloodjournal8641487; ISSARAGRISIL S, 1991, BLOOD, V77, P2166; ISSARAGRISIL S, 1995, BRIT J HAEMATOL, V91, P80, DOI 10.1111/j.1365-2141.1995.tb05248.x; Issaragrisil S., 1995, Blood, V86, p478A; ISSARAGRISIL S, IN PRESS AM J EPIDEM; KAGAN WA, 1976, P NATL ACAD SCI USA, V73, P2890, DOI 10.1073/pnas.73.8.2890; KAUFMAN DW, 1991, MONOGRAPHS EPIDEMIOL, V18; Kawagoe K, 1996, BLOOD, V87, P3600, DOI 10.1182/blood.V87.9.3600.bloodjournal8793600; Kinoshita T, 1996, ANNU REV MED, V47, P1; KOJIMA S, 1992, BLOOD, V79, P2256; LAVER J, 1988, BRIT J HAEMATOL, V69, P545, DOI 10.1111/j.1365-2141.1988.tb02413.x; LEONARD EM, 1989, BRIT J HAEMATOL, V72, P278, DOI 10.1111/j.1365-2141.1989.tb07695.x; LYMAN SD, 1995, BLOOD, V86, P4091, DOI 10.1182/blood.V86.11.4091.bloodjournal86114091; MACIEJEWSKI J, 1995, BLOOD, V85, P3183, DOI 10.1182/blood.V85.11.3183.bloodjournal85113183; MACIEJEWSKI JP, 1995, J CLIN INVEST, V96, P1085, DOI 10.1172/JCI118094; Maciejewski JP, 1996, BLOOD, V88, P1983, DOI 10.1182/blood.V88.6.1983.bloodjournal8861983; MACIEJEWSKI JP, 1995, BRIT J HAEMATOL, V91, P245, DOI 10.1111/j.1365-2141.1995.tb05277.x; MACIEJEWSKI JP, 1994, BRIT J HAEMATOL, V87, P227, DOI 10.1111/j.1365-2141.1994.tb04903.x; MACIEJEWSKI JP, 1994, EXP HEMATOL, V22, P1102; Marmont A M, 1984, Prog Clin Biol Res, V148, P271; MARSH JCW, 1991, BRIT J HAEMATOL, V78, P258, DOI 10.1111/j.1365-2141.1991.tb04426.x; MATHE G, 1970, BMJ-BRIT MED J, V2, P131, DOI 10.1136/bmj.2.5702.131; MIGLIACCIO AR, 1992, J CELL PHYSIOL, V152, P199, DOI 10.1002/jcp.1041520125; MOEBIUS U, 1991, J CLIN INVEST, V87, P1567, DOI 10.1172/JCI115170; Molldrem J., 1996, Blood, V88, p454A; NAGAFUJI K, 1995, BLOOD, V86, P883, DOI 10.1182/blood.V86.3.883.bloodjournal863883; NAKAO S, 1994, BLOOD, V84, P4257, DOI 10.1182/blood.V84.12.4257.bloodjournal84124257; NAKAO S, 1992, BLOOD, V79, P2532; NAKAO S, 1995, EXP HEMATOL, V23, P433; NIMER SD, 1994, BLOOD, V84, P923; NISTICO A, 1994, ANN INTERN MED, V120, P463, DOI 10.7326/0003-4819-120-6-199403150-00003; Novitzky N, 1995, EXP HEMATOL, V23, P1472; PATHAK DN, 1995, CARCINOGENESIS, V16, P1803, DOI 10.1093/carcin/16.8.1803; Philpott NJ, 1995, EXP HEMATOL, V23, P1642; PLATANIAS L, 1987, BRIT J HAEMATOL, V66, P437, DOI 10.1111/j.1365-2141.1987.tb01324.x; ROSENFELD SJ, 1995, BLOOD, V85, P3058, DOI 10.1182/blood.V85.11.3058.bloodjournal85113058; SATO T, 1995, BLOOD, V86, P3373, DOI 10.1182/blood.V86.9.3373.bloodjournal8693373; SCHATTENBERG DG, 1994, MOL PHARMACOL, V46, P346; Schrezenmeier H, 1996, BLOOD, V88, P4474, DOI 10.1182/blood.V88.12.4474.bloodjournal88124474; SCOPES J, 1994, BRIT J HAEMATOL, V86, P427, DOI 10.1111/j.1365-2141.1994.tb04761.x; Selleri C, 1996, BLOOD, V87, P4149, DOI 10.1182/blood.V87.10.4149.bloodjournal87104149; SELLERI C, 1995, J CELL PHYSIOL, V165, P538, DOI 10.1002/jcp.1041650312; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; SPECK B, 1977, LANCET, V2, P1145; STARK R, 1993, BRIT J HAEMATOL, V83, P560, DOI 10.1111/j.1365-2141.1993.tb04691.x; Tamai H, 1996, ANN INTERN MED, V124, P490, DOI 10.7326/0003-4819-124-5-199603010-00005; TANI K, 1993, TOHOKU J EXP MED, V169, P325, DOI 10.1620/tjem.169.325; TONG J, 1991, EXP HEMATOL, V19, P312; TZAKIS AG, 1988, NEW ENGL J MED, V319, P393, DOI 10.1056/NEJM198808183190702; WATANABE KH, 1994, OCCUP ENVIRON MED, V51, P414, DOI 10.1136/oem.51.6.414; WATARI K, 1989, BLOOD, V73, P117; WHITE JR, 1995, BRIT J HAEMATOL, V91, P921, DOI 10.1111/j.1365-2141.1995.tb05411.x; WODNARFILIPOWICZ A, 1993, BLOOD, V81, P3259; Young N. S., 1994, APLASTIC ANEMIA ACQU; YOUNG NS, 1995, BLOOD, V85, P3367, DOI 10.1182/blood.V85.12.3367.bloodjournal85123367; YOUNG NS, 1992, BLOOD, V79, P1385, DOI 10.1182/blood.V79.6.1385.bloodjournal7961385; ZOUMBOS NC, 1985, P NATL ACAD SCI USA, V82, P188, DOI 10.1073/pnas.82.1.188	73	361	381	2	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 8	1997	336	19					1365	1372		10.1056/NEJM199705083361906	http://dx.doi.org/10.1056/NEJM199705083361906			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX851	9134878				2022-12-28	WOS:A1997WX85100006
J	Nightingale, SL				Nightingale, SL			Treatment IND for drug used in advanced reproductive technology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,MAIL CODE HFI-40,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	1997	277	17					1343	1343		10.1001/jama.277.17.1343	http://dx.doi.org/10.1001/jama.277.17.1343			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW261	9134926				2022-12-28	WOS:A1997WW26100005
J	Cork, LC; Clarkson, TB; Jacoby, RO; Gaertner, DJ; Leary, SL; Linn, JM; Pakes, SP; Ringler, DH; Strandberg, JD; Swindle, MM				Cork, LC; Clarkson, TB; Jacoby, RO; Gaertner, DJ; Leary, SL; Linn, JM; Pakes, SP; Ringler, DH; Strandberg, JD; Swindle, MM			The costs of animal research: Origins and options	SCIENCE			English	Editorial Material									WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC 27103; YALE UNIV,COMPARAT MED SECT,NEW HAVEN,CT 06511; YALE UNIV,ANIM RESORCES CTR,NEW HAVEN,CT 06511; YESHIVA UNIV,ALBERT EINSTEIN COLL MED,INST ANIM STUDIES,DEPT MICROBIOL & IMMUNOL,NEW YORK,NY 10033; WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63130; UNIV PENN,LAB ANIM RESOURCES,PHILADELPHIA,PA 19104; UNIV TEXAS,SW MED CTR,DIV COMPARAT MED,DALLAS,TX 75235; UNIV MICHIGAN,SCH MED,UNIT LAB ANIM MED,ANN ARBOR,MI 48109; JOHNS HOPKINS UNIV,SCH MED,DIV COMPARAT MED,BALTIMORE,MD 21205; MED UNIV S CAROLINA,LAB ANIM RESOURCES,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT COMPARAT MED,CHARLESTON,SC 29425	Wake Forest University; Wake Forest Baptist Medical Center; Yale University; Yale University; Yeshiva University; Washington University (WUSTL); University of Pennsylvania; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Michigan System; University of Michigan; Johns Hopkins University; Medical University of South Carolina; Medical University of South Carolina	Cork, LC (corresponding author), STANFORD UNIV,SCH MED,DEPT COMPARAT MED,STANFORD,CA 94305, USA.							1997, FED REGISTER, V60, P7107	1	18	18	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					758	759		10.1126/science.276.5313.758	http://dx.doi.org/10.1126/science.276.5313.758			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9157554				2022-12-28	WOS:A1997WW90000046
J	Kennedy, BK; Gotta, M; Sinclair, DA; Mills, K; McNabb, DS; Murthy, M; Pak, SM; Laroche, T; Gasser, SM; Guarente, L				Kennedy, BK; Gotta, M; Sinclair, DA; Mills, K; McNabb, DS; Murthy, M; Pak, SM; Laroche, T; Gasser, SM; Guarente, L			Redistribution of silencing proteins from telomeres to the nucleolus is associated with extension of life span in S-cerevisiae	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; TOPOISOMERASE-II; YEAST TELOMERES; GENE; DNA; RAP1; TRANSCRIPTION; INTERACTS; RNA	A prior genetic study indicated that activity of Sir silencing proteins at a hypothetical AGE locus is essential for long life span. In this model, the SIR4-42 mutation would direct the Sir protein complex to the AGE locus, giving rise to a long life span. We show by indirect immunofluorescence that Sir3p and Sir4p are redirected to the nucleolus in the SIR4-42 mutant. Furthermore, this relocalization is dependent on both UTH4 a novel yeast gene that extends life span, and its homologue YGL023. Strikingly, the Sir complex is relocalized from telomeres to the nucleolus in old wild-type cells. We propose that the rDNA is the AGE locus and that nucleolar function is compromised in old yeast cells in a way that may be mitigated by targeting of Sir proteins to the nucleolus.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND	Massachusetts Institute of Technology (MIT); Swiss Institute Experimental Cancer Research				Gasser, Susan/0000-0003-3610-9123; Sinclair, David/0000-0002-9936-436X; Gotta, Monica/0000-0002-4336-7860; Kennedy, Brian/0000-0002-5754-1874	NATIONAL INSTITUTE ON AGING [R01AG011119, R37AG011119] Funding Source: NIH RePORTER; NIA NIH HHS [AG11119] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOWMAN PD, 1976, EXP CELL RES, V101, P434, DOI 10.1016/0014-4827(76)90399-2; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; CHACONAS G, 1973, J NEUROCHEM, V21, P1466; CHEN WN, 1991, YEAST, V7, P309, DOI 10.1002/yea.320070314; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; COGLIEVINA M, 1995, YEAST, V11, P767, DOI 10.1002/yea.320110808; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FINCH CE, 1990, LONGEVITY SENSCENCE; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gompertz B., 1825, PHILOS T R SOC LOND, V115, P513, DOI [10.1098/rstl.1825.0026, DOI 10.1098/RSTL.1825.0026]; GOTTA M, 1997, IN PRESS EMBO J; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HARTWELL LH, 1977, J CELL BIOL, V75, P4222; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; JOHNSON R, 1972, NATURE, V240, P512; KENNEDY BK, 1994, J CELL BIOL, V127, P1985, DOI 10.1083/jcb.127.6.1985; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KIKUCHI Y, 1994, MOL GEN GENET, V245, P107, DOI 10.1007/BF00279756; KLAR AJS, 1981, NATURE, V289, P239, DOI 10.1038/289239a0; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; MACDONALD PM, 1992, DEVELOPMENT, V114, P221; MAHONEY DJ, 1989, MOL CELL BIOL, V9, P4621, DOI 10.1128/MCB.9.11.4621; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MULLER I, 1985, A VAN LEEUW J MICROB, V51, P1, DOI 10.1007/BF00444223; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PETERSON CRD, 1984, ARCH GERONTOL GERIAT, V3, P115, DOI 10.1016/0167-4943(84)90004-9; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; POHLEY HJ, 1987, MECH AGEING DEV, V38, P231, DOI 10.1016/0047-6374(87)90092-3; RATH PC, 1989, FEBS LETT, V244, P193, DOI 10.1016/0014-5793(89)81191-3; RINE J, 1987, GENETICS, V116, P9; Sherman F, 1979, METHODS YEAST GENETI; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SIKORSKI RS, 1989, GENETICS, V122, P19; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; STREHLER BL, 1986, EXP GERONTOL, V21, P283, DOI 10.1016/0531-5565(86)90038-0; SWISSHELM K, 1990, MUTAT RES, V237, P131, DOI 10.1016/0921-8734(90)90019-N; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; WAREHAM KA, 1987, NATURE, V327, P725, DOI 10.1038/327725a0; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WILSON V L, 1983, Science (Washington D C), V220, P1055, DOI 10.1126/science.6844925; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	58	310	331	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					381	391		10.1016/S0092-8674(00)80219-6	http://dx.doi.org/10.1016/S0092-8674(00)80219-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150138	Bronze			2022-12-28	WOS:A1997WX89900009
J	Nakamura, N; Lowe, M; Levine, TP; Rabouille, C; Warren, G				Nakamura, N; Lowe, M; Levine, TP; Rabouille, C; Warren, G			The vesicle docking protein p115 binds GM130, a cis-Golgi matrix protein, in a mitotically regulated manner	CELL			English	Article							ENDOPLASMIC-RETICULUM; TRANSPORT; STACK	The docking of transport vesicles with their target membrane is thought to be mediated by p115. We show here that GM130, a cis-Golgi matrix protein, interacts specifically with p115 and so could provide a membrane docking site. Deletion analysis showed that the N-terminus binds to p115, whereas the C-terminus binds to Golgi membranes. Mitotic phosphorylation of GM130 or a peptide derived from the N-terminus prevented binding to p115. The peptide also inhibited the NSF- but not the p97-dependent reassembly of Golgi cisternae from mitotic fragments, unless it was mitotically phosphorylated. Together, these data provide a molecular explanation for the COPI-mediated fragmentation of the Golgi apparatus at the onset of mitosis.	IMPERIAL CANC RES FUND, CELL BIOL LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Nakamura, Nobuhiro/F-7811-2011	Nakamura, Nobuhiro/0000-0002-8836-6714; Levine, Timothy/0000-0002-7231-0775	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; Bednarek SY, 1996, TRENDS CELL BIOL, V6, P468, DOI 10.1016/0962-8924(96)84943-9; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Levine TP, 1996, J BIOL CHEM, V271, P17304, DOI 10.1074/jbc.271.29.17304; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; STUART RA, 1993, J BIOL CHEM, V268, P4050; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WARREN G, 1995, TRENDS CELL BIOL, V5, P413, DOI 10.1016/S0962-8924(00)89094-7; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; Yamakawa H, 1996, J STRUCT BIOL, V116, P356, DOI 10.1006/jsbi.1996.0053; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	24	334	342	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	1997	89	3					445	455		10.1016/S0092-8674(00)80225-1	http://dx.doi.org/10.1016/S0092-8674(00)80225-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150144	Bronze			2022-12-28	WOS:A1997WX89900015
J	Lalioti, MD; Scott, HS; Buresi, C; Rossier, C; Bottani, A; Morris, MA; Malafosse, A; Antonarakis, SE				Lalioti, MD; Scott, HS; Buresi, C; Rossier, C; Bottani, A; Morris, MA; Malafosse, A; Antonarakis, SE			Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy	NATURE			English	Article							FRAGILE-X-SYNDROME; MYOTONIC-DYSTROPHY; MESSENGER-RNA; PROTEIN; EXPRESSION; FMR-1	Progressive myaclonus epilepsy of the Unverricht-Lundborg type (EPM1; MIM 254800) is an autosomal recessive disorder with onset between 6 and 13 years followed by variable progression to mental deterioration and cerebellar ataxia(1). It is a rare disorder but more common in Finland (1 in 20,000) and the western Mediterranean(1,2). Two point mutations in the cysteine proteinase inhibitor gene cystatin B (CSTB), proved that this gene is responsible for EPM1 (ref. 3). An extensive search in the CSTB gene revealed mutations accounting only for 14% of the 58 unrelated EPM1 alleles studied(4). Here we report that the majority of EPM1 alleles contain expansions of a dodecamer (12-mer) repeat located about 70 nucleotides upstream of the transcription start site nearest to the 5' end of the CSTB gene. Normal alleles contain 2 or 3 copies of this repeat whereas mutant alleles contain more than 60 such repeats and have reduced levels of CSTB messenger RNA in brood but not in cell lines. 'Premutation' CSTB alleles with 12-17 repeats show marked instability when transmitted to off-spring.	HOSP BELLE IDEE,DEPT GENET & MICROBIOL,LAB HUMAN MOL GENET,CH-1211 GENEVA,SWITZERLAND; UNIV GENEVA,SCH MED,CH-1211 GENEVA 4,SWITZERLAND; CANTONAL HOSP GENEVA,CH-1211 GENEVA,SWITZERLAND; HOSP BELLE IDEE,DIV NEUROPSYCHIAT,CH-1211 GENEVA,SWITZERLAND	University of Geneva; University of Geneva; University of Geneva; University of Geneva			Antonarakis, Stylianos E/N-8866-2014; Scott, Hamish/B-2122-2009	Antonarakis, Stylianos E/0000-0001-8907-5823; Scott, Hamish/0000-0002-5813-631X				Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; GENTON P, 1990, ACTA NEUROL SCAND, V81, P8; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; LABAUGE P, IN PRESS ANN NEUROL; Lafreniere RG, 1997, NAT GENET, V15, P298, DOI 10.1038/ng0397-298; Lalioti MD, 1997, AM J HUM GENET, V60, P342; LEHESJOKI AE, 1993, HUM MOL GENET, V2, P1229, DOI 10.1093/hmg/2.8.1229; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; NORIO R, 1979, CLIN GENET, V15, P82; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; Pennacchio LA, 1996, GENOME RES, V6, P1103, DOI 10.1101/gr.6.11.1103; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TALBOT CC, 1995, HUM MOL GENET, V4, P1193, DOI 10.1093/hmg/4.7.1193; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YOUSSOUFIAN H, 1993, MOL CELL BIOL, V13, P98, DOI 10.1128/MCB.13.1.98; Yu S, 1997, CELL, V88, P367, DOI 10.1016/S0092-8674(00)81875-9	30	261	269	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					847	851		10.1038/386847a0	http://dx.doi.org/10.1038/386847a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126745				2022-12-28	WOS:A1997WV70600058
J	Volkow, ND; Wang, GJ; Fowler, JS; Logan, J; Gatley, SJ; Hitzemann, R; Chen, AD; Dewey, SL; Pappas, N				Volkow, ND; Wang, GJ; Fowler, JS; Logan, J; Gatley, SJ; Hitzemann, R; Chen, AD; Dewey, SL; Pappas, N			Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects	NATURE			English	Article							HUMAN BRAIN; C-11 RACLOPRIDE; THALAMIC NUCLEUS; FRONTAL-LOBE; BINDING; PET; DRUGS; ADDICTION; RECEPTORS; ABUSERS	Cocaine blocks the reuptake of dopamine, a neurotransmitter involved in the control of movement, cognition, motivation and reward. This leads to an increase in extracellular dopamine; the reinforcing effect of cocaine is associated with elevated dopamine levels in the nucleus accumbens(1,2). But addiction to cocaine involves other effects, such as craving, loss of control and compulsive drug intake; the role of the dopamine system in these effects is less well-understood. We therefore used positron emission tomography (PET) to compare the responses of cocaine addicts and normal controls to intravenous methylphenidate, a drug that, like cocaine, causes an increase in synaptic dopamine(3). Addicts showed reduced dopamine release in the striatum, the brain region where the nucleus accumbens is located, and also had a reduced 'high' relative to controls. In contrast, addicts showed an increased response to methylphenidate in the thalamus (a region that conveys sensory input to the cortex). This thalamic response was associated with cocaine craving and was not seen in control subjects. Thus, our findings challenge the notion that addiction involves an enhanced striatal dopamine response to cocaine and/or an enhanced induction of euphoria. Moreover, they suggest a participation of thalamic dopamine pathways in cocaine addiction, a possibility that merits further investigation.	BROOKHAVEN NATL LAB, DEPT CHEM, UPTON, NY 11973 USA; SUNY STONY BROOK, DEPT PSYCHIAT, STONY BROOK, NY 11794 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Volkow, ND (corresponding author), BROOKHAVEN NATL LAB, DEPT MED, UPTON, NY 11973 USA.		anand, amit/A-7222-2009					BERGMAN J, 1989, J PHARMACOL EXP THER, V251, P150; BROWN EE, 1992, J NEUROSCI, V12, P4112; DACKIS CA, 1985, NEUROSCI BIOBEHAV R, V9, P469, DOI 10.1016/0149-7634(85)90022-3; DEWEY SL, 1993, SYNAPSE, V13, P350, DOI 10.1002/syn.890130407; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107; Gifford AN, 1996, SYNAPSE, V22, P232, DOI 10.1002/(SICI)1098-2396(199603)22:3<232::AID-SYN5>3.0.CO;2-D; GROENEWEGEN HJ, 1988, NEUROSCIENCE, V24, P379, DOI 10.1016/0306-4522(88)90339-9; INSEL TR, 1992, ARCH GEN PSYCHIAT, V49, P739; KOLB B, 1977, PHYSIOL BEHAV, V18, P237, DOI 10.1016/0031-9384(77)90128-7; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LOGAN J, 1990, J CEREBR BLOOD F MET, V10, P740, DOI 10.1038/jcbfm.1990.127; LOGAN J, 1994, J CEREBR BLOOD F MET, V14, P995, DOI 10.1038/jcbfm.1994.132; MADRAS BK, 1994, SYNAPSE, V18, P261, DOI 10.1002/syn.890180311; MCALONAN GM, 1993, NEUROSCIENCE, V52, P605, DOI 10.1016/0306-4522(93)90410-H; Modell J G, 1990, J Neuropsychiatry Clin Neurosci, V2, P123; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SEEMAN P, 1989, SYNAPSE, V3, P96, DOI 10.1002/syn.890030113; SHYU BC, 1992, BRAIN RES, V572, P216, DOI 10.1016/0006-8993(92)90472-L; VOLKOW ND, 1993, J NUCL MED, V34, P609; VOLKOW ND, 1994, SYNAPSE, V16, P255, DOI 10.1002/syn.890160402; Volkow ND, 1996, J NUCL MED, V37, P1242; VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210; VOLKOW ND, 1995, ARCH GEN PSYCHIAT, V52, P456; Wang GJ, 1997, EUR ADDICT RES, V3, P49, DOI 10.1159/000259147; WANG GJ, 1993, SYNAPSE, V15, P246, DOI 10.1002/syn.890150311; WANG GJ, 1995, LIFE SCI, V57, P187; YOUSEF KA, 1995, SYNAPSE, V19, P14, DOI 10.1002/syn.890190103	30	647	656	1	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					830	833		10.1038/386830a0	http://dx.doi.org/10.1038/386830a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126741				2022-12-28	WOS:A1997WV70600054
J	Bergerat, A; deMassy, B; Gadelle, D; Varoutas, PC; Nicolas, A; Forterre, P				Bergerat, A; deMassy, B; Gadelle, D; Varoutas, PC; Nicolas, A; Forterre, P			An atypical topoisomerase II from archaea with implications for meiotic recombination	NATURE			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; INITIATION SITE; DNA GYRASE; MEIOSIS; YEAST; PROTEIN; SEQUENCE; MUTANTS	Type II topoisomerases help regulate DNA topology during transcription, replication and recombination by catalysing DNA strand transfer through transient double-stranded breaks(1). All type II topoisomerases described so far are members of a single protein family(2). We have cloned and sequenced the genes encoding the A and B subunits of topoisomerase II from the archaeon Sulfolobus shibatae. This enzyme is the first of a new family. It has no similarity with other type II topoisomerases, except for three motifs in the B subunit probably involved in ATP binding and hydrolysis. We also found these motifs in proteins of the Hsp90(3) and MutL(4) families. The A subunit has similarities with four proteins of unknown function. One of them, the Saccharomyces cerevisiae Spo11(5) protein, is required for the initiation of meiotic recombination. Mutagenesis, performed on SPO11, of the single tyrosine conserved between the five homologues shows that this amino acid is essential for Spo11 activity. By analogy with the mechanism of action of known type II topoisomerases, we suggest that Spell catalyses the formation of double-strand breaks that initiate meiotic recombination in S. cervisiae.	UNIV PARIS 11,CNRS,URA 1354,INST GENET & MICROBIOL,F-91405 ORSAY,FRANCE; INST CURIE,SECT RECH,CNRS,UMR 144,F-75248 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite				Varoutas, Paul-Christophe/0000-0001-9127-4418				ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Aronshtam A, 1996, NUCLEIC ACIDS RES, V24, P2498, DOI 10.1093/nar/24.13.2498; ATCHESON CL, 1987, P NATL ACAD SCI USA, V84, P8035, DOI 10.1073/pnas.84.22.8035; ATCHESON CL, 1993, CURR OPIN GENET DEV, V3, P736, DOI 10.1016/S0959-437X(05)80092-9; BERGERAT A, 1994, J BIOL CHEM, V269, P27663; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Caron Paul R., 1994, V29B, P271; DEMASSY B, 1995, EMBO J, V14, P4589, DOI 10.1002/j.1460-2075.1995.tb00138.x; DEMASSY B, 1994, P NATL ACAD SCI USA, V91, P11929, DOI 10.1073/pnas.91.25.11929; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GUPTA RS, 1995, MOL BIOL EVOL, V12, P1063; HOMES ML, 1991, J BACTERIOL, V173, P3807; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KEENEY S, 1995, P NATL ACAD SCI USA, V92, P11274, DOI 10.1073/pnas.92.24.11274; LIN YK, 1994, GENETICS, V136, P769; LIU JH, 1995, EMBO J, V14, P4599, DOI 10.1002/j.1460-2075.1995.tb00139.x; LOIDL J, 1994, J CELL BIOL, V125, P1191, DOI 10.1083/jcb.125.6.1191; LOUVION EL, 1996, P NATL ACAD SCI USA, V93, P13937; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SZENTGYORGYI C, 1995, MOL CELL BIOL, V15, P6754; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088	28	688	721	0	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					414	417		10.1038/386414a0	http://dx.doi.org/10.1038/386414a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121560				2022-12-28	WOS:A1997WQ17000069
J	Appella, DH; Christianson, LA; Klein, DA; Powell, DR; Huang, XL; Barchi, JJ; Gellman, SH				Appella, DH; Christianson, LA; Klein, DA; Powell, DR; Huang, XL; Barchi, JJ; Gellman, SH			Residue-based control of helix shape in beta-peptide oligomers	NATURE			English	Article							SECONDARY STRUCTURE; PROGRAM; POLY(ALPHA-ISOBUTYL-L-ASPARTATE); DERIVATIVES; POLYAMIDE; ACID	Proteins and RNA are unique among known polymers in their ability to adopt compact and well-defined folding patterns. These two biopolymers can perform complex chemical operations such as catalysis and highly selective recognition, and these functions are linked to folding in that the creation of an active site requires proper juxtaposition of reactive groups. So the development of new types of polymeric backbones with well-defined and predictable folding propensities ('foldamers') might lead to molecules with useful functions(1,2). The first step in foldamer development is to identify synthetic oligomers with specific secondary structural preferences(3-13). Whereas alpha-amino acids can adopt the well-known alpha-helical motif of proteins, it was shown recently(11-13) that beta-peptides(3) constructed from carefully chosen beta-amino acids can adopt a different, stable helical conformation defined by interwoven 14-membered-ring hydrogen bonds (a 14-helix; Fig. 1a). Here we report that beta-amino acids can also be used to design beta-peptides with a very different secondary structure, a 12-helix (Fig. 1a). This demonstrates that by altering the nature of beta-peptide residues, one can exert rational control over the secondary structure.	NCI,MED CHEM LAB,DIV BASIC SCI,BETHESDA,MD 20892; UNIV WISCONSIN,DEPT CHEM,MADISON,WI 53706	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wisconsin System; University of Wisconsin Madison			Barchi, Joseph J/N-3784-2014	Barchi, Joseph/0000-0001-9906-0799				Appella DH, 1996, J AM CHEM SOC, V118, P13071, DOI 10.1021/ja963290l; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Ball P., 1994, DESIGNING MOL WORLD; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BELLA J, 1992, MACROMOLECULES, V25, P5225, DOI 10.1021/ma00046a018; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Creighton T. E., 1993, PROTEINS STRUCTURES; DADO GP, 1994, J AM CHEM SOC, V116, P1054, DOI 10.1021/ja00082a029; ESCHENMOSER A, 1994, ORIGINS LIFE EVOL B, V24, P389, DOI 10.1007/BF01582017; FERNANDEZSANTIN JM, 1984, NATURE, V311, P53, DOI 10.1038/311053a0; FERNANDEZSANTIN JM, 1987, MACROMOLECULES, V20, P62, DOI 10.1021/ma00167a013; GENNARI C, 1994, ANGEW CHEM INT EDIT, V33, P2067, DOI 10.1002/anie.199420671; HAGIHARA M, 1992, J AM CHEM SOC, V114, P6568, DOI 10.1021/ja00042a052; Hamuro Y, 1996, J AM CHEM SOC, V118, P7529, DOI 10.1021/ja9539857; HERRADON B, 1989, HELV CHIM ACTA, V72, P690, DOI 10.1002/hlca.19890720410; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; LOKEY RS, 1995, NATURE, V375, P303; LOPEZCARRASQUERO F, 1995, BIOPOLYMERS, V36, P263, DOI 10.1002/bip.360360302; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nowick JS, 1996, J AM CHEM SOC, V118, P1066, DOI 10.1021/ja9536072; Schenck HL, 1996, J AM CHEM SOC, V118, P12487, DOI 10.1021/ja962026p; Seebach D, 1996, HELV CHIM ACTA, V79, P913, DOI 10.1002/hlca.19960790402; Seebach D, 1996, HELV CHIM ACTA, V79, P2043, DOI 10.1002/hlca.19960790802; SMITH AB, 1994, J AM CHEM SOC, V116, P9947, DOI 10.1021/ja00101a017; TILLEY JW, 1992, J MED CHEM, V35, P3774, DOI 10.1021/jm00099a005; XIONG HY, 1995, P NATL ACAD SCI USA, V92, P6349, DOI 10.1073/pnas.92.14.6349; YUKI H, 1978, J POLYM SCI POL CHEM, V16, P2237, DOI 10.1002/pol.1978.170160913	30	564	566	2	125	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					381	384		10.1038/387381a0	http://dx.doi.org/10.1038/387381a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163422				2022-12-28	WOS:A1997XA49600054
J	Iavarone, A; Massague, J				Iavarone, A; Massague, J			Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15	NATURE			English	Article							DEPENDENT KINASES; GENE; PHOSPHORYLATION; PHOSPHATASES; P27(KIP1); GROWTH; ROLES; LINE	The activity of the cyclin-dependent kinases (CDKs) that control cell growth and division can be negatively regulated by tyrosine phosphorylation or by the binding of various CDK inhibitors(1). Whereas regulation by tyrosine phosphorylation is well documented in CDKs that function during mitosis, little is known about its role in the regulation of CDKs that act in the G1 phase of the cell cycle(2). In contrast, much evidence has accumulated on the regulation of G1 CDKs by CDK inhibitors(1). The cytokine TGF-beta inhibits growth by causing cell-cycle arrest as a result of increasing the concentration of the Cdk4/6 Inhibitor p15(INK4B/MTS2) (refs 3, 4). Here we report that TGF-beta can also cause the inhibition of Cdk4 and Cdk6 by increasing their level of tyrosine phosphorylation. Tyrosine phosphorylation and inactivation of Cdk4/6 in a human mammary epithelial cell line are shown to result from the ability of TGF-beta to repress expression of the CDK tyrosine phosphatase Cdc25A. Repression of Cdc25A and induction of p15 are independent effects mediating the inhibition of Cdk4/6 by TFG-beta.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center				Massague, Joan/0000-0001-9324-8408				BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GIARETTI W, 1994, METHOD CELL BIOL, V41, P389; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SOULE HD, 1990, CANCER RES, V50, P6075; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103	30	310	315	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					417	422						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163429				2022-12-28	WOS:A1997XA49600064
J	Haupt, Y; Maya, R; Kazaz, A; Oren, M				Haupt, Y; Maya, R; Kazaz, A; Oren, M			Mdm2 promotes the rapid degradation of p53	NATURE			English	Article							EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; MUTANT P53; CELL-LINES; PROTEIN; ONCOPROTEIN; EXPRESSION; ACTIVATION; PATHWAY; CANCER	The p53 tumour-suppressor protein exerts antiproliferative effects, including growth arrest and apoptosis, in response to various types of stress'. The activity of p53 is abrogated by mutations that occur frequently in tumours, as well as by several viral and cellular proteins(1,2). The Mdm2 oncoprotein is a potent inhibitor of p53 (ref. 3). Mdm2 binds the transcriptional activation domain of p53 and blocks its ability to regulate target genes(3,4) and to exert antiproliferative effects(4-7). On the other hand, p53 activates the expression of the mdm2 gene(1) in an autoregulatory feedback loop(3). The interval between p53 activation and consequent Mdm2 accumulation defines a time window during which p53 exerts its effects(8). We now report that Mdm2 also promotes the rapid degradation of p53 under conditions in which p53 is otherwise stabilized. This effect of Mdm2 requires binding of p53; moreover, a small domain of p53, encompassing the Mdm2-binding site, confers Mdm2-dependent detstabilization upon heterologous proteins. Raised amounts of Mdm2 strongly repress mutant p53 accumulation in tumour-derived cells. During recovery from DNA damage, maximal Mdm2 induction coincides with rapid p53 loss. We propose that the Mdm2-promoted degradation of p53 provides a new mechanism to ensure effective termination of the p53 signal.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,LAUTENBERG CTR GEN & TUMOR IMMUNOL,IL-91120 JERUSALEM,ISRAEL	Weizmann Institute of Science; Hebrew University of Jerusalem								BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARTEK J, 1990, ONCOGENE, V5, P893; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1995, MOL MED, V1, P141; FISCELLA M, 1993, ONCOGENE, V8, P1519; Gottlieb E, 1996, CELL GROWTH DIFFER, V7, P301; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1991, CANCER RES, V51, P6304; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Momand J, 1996, ONCOGENE, V12, P2279; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; OTTO A, 1993, ONCOGENE, V8, P2591; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39	29	3576	3704	7	325	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					296	299		10.1038/387296a0	http://dx.doi.org/10.1038/387296a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153395				2022-12-28	WOS:A1997WZ16700056
J	Strutt, DI; Weber, U; Mlodzik, M				Strutt, DI; Weber, U; Mlodzik, M			The role of RhoA in tissue polarity and Frizzled signalling	NATURE			English	Article							DROSOPHILA-MELANOGASTER; GENETIC MOSAICS; LOCUS ENCODES; CELL FATES; PROTEIN; PHENOTYPES; PATHWAYS; GTPASES; RAC1; EYE	The tissue polarity genes of Drosophila are required for correct establishment of planar polarity in epidermal structures(1,2), which in the eye is shown in the mirror-image symmetric arrangement of ommatidia relative to the dorsoventral midline. Mutations in the genes frizzled (fz), dishevelled (dsh) and prickle-spiny-legs (pk-sple) result in the loss of this mirror-image symmetry(3-5). fz encodes a serpentine receptor-like transmembrane protein required for reception and transmission of a polarity signal(5,6), Little else is known of the signalling pathway(s) involved other than that Dsh acts downstream of Fz(7). We have identified mutations in the Drosophila homologue of RhoA p21 GTPase, and by analysis of their phenotype show that RhoA is required for the generation of tissue polarity, Genetic interactions indicate a role for RhoA in signalling mediated by Fz and Dsh, and furthermore suggest that JNK/SAPK-like kinases are involved, These data are consistent with a Fz/RhoA signalling cascade analogous to the yeast pheromone signalling pathway(8) and that proposed for activation of the serum response factor (SRF) in vertebrate cells(9).	EUROPEAN MOL BIOL LAB,DEV BIOL PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Strutt, David/E-6196-2010	Strutt, David/0000-0001-8185-4515				ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; GUBB D, 1993, DEVELOPMENT, P269; HARDEN N, 1995, DEVELOPMENT, V121, P903; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; KRASNOW RE, 1994, DEVELOPMENT, V120, P1883; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; THEISEN H, 1994, DEVELOPMENT, V120, P347; TOROK T, 1993, GENETICS, V135, P71; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; XU T, 1993, DEVELOPMENT, V117, P1223; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; ZHENG L, 1995, DEVELOPMENT, V121, P3045	29	474	477	1	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					292	295		10.1038/387292a0	http://dx.doi.org/10.1038/387292a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153394				2022-12-28	WOS:A1997WZ16700055
J	Okano, Y; Yoshioka, T; Shimouchi, A; Satoh, T; Kunieda, T				Okano, Y; Yoshioka, T; Shimouchi, A; Satoh, T; Kunieda, T			Orally active prostacyclin analogue in primary pulmonary hypertension	LANCET			English	Article							THROMBOSIS; SURVIVAL		NATL CARDIOVASC CTR,RES INST,SUITA,OSAKA 565,JAPAN	National Cerebral & Cardiovascular Center - Japan	Okano, Y (corresponding author), NATL CARDIOVASC CTR,DEPT INTERNAL MED,DIV CARDIOL & PULM VASC MED,SUITA,OSAKA 565,JAPAN.							Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; SIM AK, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1816	5	87	90	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1365	1365		10.1016/S0140-6736(97)24019-5	http://dx.doi.org/10.1016/S0140-6736(97)24019-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149701				2022-12-28	WOS:A1997WY34200013
J	Vasan, RS; Larson, MG; Benjamin, EJ; Evans, JC; Levy, D				Vasan, RS; Larson, MG; Benjamin, EJ; Evans, JC; Levy, D			Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							M-MODE ECHOCARDIOGRAPHY; PROGNOSTIC IMPLICATIONS; FRAMINGHAM; MEN; DYSFUNCTION; SURVIVAL; DISEASE; VOLUME; PREDICTORS; INHIBITION	Background Left ventricular dilatation is a well-recognized precursor of ventricular dysfunction and congestive heart failure after myocardial infarction. The effect of left ventricular dilatation on the risk of heart failure in people initially free of myocardial infarction is not known. Methods We examined the relation of the left ventricular end-diastolic and end-systolic internal dimensions, as measured by M-mode echocardiography, to the risk of congestive heart failure in 4744 subjects (2661 women and 2083 men) who had not sustained a myocardial infarction and who were free of congestive heart failure. We used sex-stratified proportional-hazards regression to assess the association between base-line left ventricular internal dimensions and the subsequent risk of congestive heart failure, after adjusting for age, blood pressure, hypertension treatment, body-mass index, diabetes, valve disease, and interim myocardial infarction. Results Over an 11-year follow-up period, congestive heart failure developed in 74 subjects (38 men and 36 women). The risk-factor-adjusted hazard ratio for congestive heart failure was 1.47 (95 percent confidence interval, 1.25 to 1.73) for an increment of 1 SD in the left ventricular end-diastolic dimension, indexed for height. We obtained similar results using the left ventricular end-systolic dimension (hazard ratio, 1.43; 95 percent confidence interval, 1.24 to 1.65). Conclusions An increase in left ventricular internal dimension is a risk factor for congestive heart failure in men and women who have not had a myocardial infarction. Knowledge of the left ventricular dimension improves predictions of the risk of congestive heart failure made on the basis of traditional risk factors, perhaps by aiding in the identification of subjects with subclinical left ventricular dysfunction. (C)1997, Massachusetts Medical Society.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA 01701 USA; BETH ISRAEL HOSP, DIV CARDIOL, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BOSTON UNIV, SCH MED, CARDIOL SECT, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT PREVENT MED & EPIDEMIOL, BOSTON, MA 02118 USA; NHLBI, BETHESDA, MD 20892 USA	Framingham Heart Study; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Boston University; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021; Ramachandran, Vasan/Y-2527-2019; Benjamin, Emelia/E-7103-2011	Levy, Daniel/0000-0003-1843-8724; Ramachandran, Vasan/0000-0001-7357-5970; Larson, Martin/0000-0002-9631-1254; Benjamin, Emelia/0000-0003-4076-2336	NHLBI NIH HHS [N0I-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-ROI-NS17950-11] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERNING J, 1990, AM J CARDIOL, V65, P567, DOI 10.1016/0002-9149(90)91032-2; CAIDAHL K, 1988, BRIT HEART J, V59, P329; COHN JN, 1995, CIRCULATION, V91, P2504, DOI 10.1161/01.CIR.91.10.2504; Cox D. R., 1984, ANAL SURVIVAL DATA; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; ERIKSSON SV, 1995, BRIT HEART J, V74, P124; FRISHMAN WH, 1992, AM HEART J, V124, P1026, DOI 10.1016/0002-8703(92)90987-7; GALDERISI M, 1992, AM J CARDIOL, V70, P971, DOI 10.1016/0002-9149(92)90345-Y; GAUDRON P, 1992, AM HEART J, V123, P377, DOI 10.1016/0002-8703(92)90649-G; GAUDRON P, 1993, CIRCULATION, V87, P755, DOI 10.1161/01.CIR.87.3.755; GREENBERG B, 1995, CIRCULATION, V91, P2573, DOI 10.1161/01.CIR.91.10.2573; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P89, DOI 10.1161/01.CIR.59.1.89; JACOB R, 1988, BASIC RES CARDIOL, V83, P461, DOI 10.1007/BF01906676; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1987, NIH PUBLICATION; KEREN A, 1986, CARDIOLOGY, V73, P139, DOI 10.1159/000173997; KLEBER FX, 1991, AM J CARDIOL, V68, pD121; LAUER MS, 1995, J AM COLL CARDIOL, V26, P1039, DOI 10.1016/0735-1097(95)00275-0; LAUER MS, 1992, AM J CARDIOL, V70, P1180, DOI 10.1016/0002-9149(92)90052-Z; LEE TH, 1993, AM J CARDIOL, V72, P672, DOI 10.1016/0002-9149(93)90883-E; LINZBACH AJ, 1960, AM J CARDIOL, V5, P370, DOI 10.1016/0002-9149(60)90084-9; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; ROSS J, 1976, PROG CARDIOVASC DIS, V18, P255, DOI 10.1016/0033-0620(76)90021-9; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SANDVIK L, 1993, EUR HEART J, V14, P592, DOI 10.1093/eurheartj/14.5.592; *SAS I INC, 1989, SAS STAT US GUID VER, V2, P1351; *SAS I INC, 1996, SAS STAT SOFTW CHANG, P381; SAVAGE DD, 1987, HYPERTENSION, V9, P40; SUTTON MS, 1994, CIRCULATION, V89, P68, DOI 10.1161/01.CIR.89.1.68; UNVERFERTH DV, 1984, AM J CARDIOL, V54, P147, DOI 10.1016/0002-9149(84)90320-5; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WONG M, 1993, CIRCULATION, V87, P65; 1993, ARCH INTERN MED, V153, P154	35	272	283	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 8	1997	336	19					1350	1355		10.1056/NEJM199705083361903	http://dx.doi.org/10.1056/NEJM199705083361903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX851	9134875	Bronze			2022-12-28	WOS:A1997WX85100003
J	Nightingale, SL				Nightingale, SL			Action to prevent accidental iron poisonings in children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,MAIL CODE HFI-40,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	1997	277	17					1343	1343		10.1001/jama.277.17.1343	http://dx.doi.org/10.1001/jama.277.17.1343			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW261	9134926				2022-12-28	WOS:A1997WW26100006
J	Yue, DT				Yue, DT			Medicine - Quenching the spark in the heart	SCIENCE			English	Editorial Material							CARDIAC SARCOPLASMIC-RETICULUM; INDUCED RELEASE; CALCIUM; MUSCLE; CELLS; CA2+				Yue, DT (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOMED ENGN,PROGRAM MOL & CELLULAR SYST PHYSIOL,BALTIMORE,MD 21205, USA.							ADUCHIAKAHANE S, 1996, J GEN PHYSIOL, V108, P435; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; CARL SL, 1995, J CELL BIOL, V129, P672; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LOPEZLOPEZ JR, 1994, J PHYSIOL-LONDON, V480, P21, DOI 10.1113/jphysiol.1994.sp020337; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; SUN XH, 1995, J CELL BIOL, V129, P659, DOI 10.1083/jcb.129.3.659; WIER WG, 1994, J PHYSIOL-LONDON, V474, P463, DOI 10.1113/jphysiol.1994.sp020037	13	14	14	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					755	756		10.1126/science.276.5313.755	http://dx.doi.org/10.1126/science.276.5313.755			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9157553				2022-12-28	WOS:A1997WW90000044
J	Gemke, RJBJ				Gemke, RJBJ			Centralisation of paediatric intensive care to improve outcome	LANCET			English	Editorial Material							IMPACT				Gemke, RJBJ (corresponding author), UNIV UTRECHT,CHILDRENS HOSP WILHELMINA,NL-3501 CA UTRECHT,NETHERLANDS.							*BRIT PAED ASS, 1993, CAR CRIT ILL CHILDR; BRITTO J, 1995, BRIT MED J, V311, P836, DOI 10.1136/bmj.311.7009.836; GEMKE RJBJ, 1995, CRIT CARE MED, V23, P238, DOI 10.1097/00003246-199502000-00007; POLLACK MM, 1991, CRIT CARE MED, V19, P150, DOI 10.1097/00003246-199102000-00007; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; Ryan DW, 1996, BRIT MED J, V312, P654; THOMPSON DR, 1994, CRIT CARE MED, V22, P1306, DOI 10.1097/00003246-199408000-00015	7	11	12	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1187	1188		10.1016/S0140-6736(05)62407-5	http://dx.doi.org/10.1016/S0140-6736(05)62407-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130935				2022-12-28	WOS:A1997WW71700003
J	Lethem, R; Orrell, M				Lethem, R; Orrell, M			Antioxidants and dementia	LANCET			English	Editorial Material							ALZHEIMERS-DISEASE; OXIDATION; STROKE		UCL, SCH MED, DEPT PSYCHIAT & BEHAV SCI, LONDON W1N 8AA, ENGLAND; WHITTINGTON HOSP, DEPT PSYCHIAT, LONDON N19 5NF, ENGLAND	University of London; University College London; UCL Medical School; University of London; University College London				Orrell, Martin/0000-0002-1169-3530				DESMOND DW, 1993, ARCH NEUROL-CHICAGO, V50, P162, DOI 10.1001/archneur.1993.00540020040015; Frey WH, 1996, BRAIN RES, V714, P87, DOI 10.1016/0006-8993(95)01497-7; Gale CR, 1996, BRIT MED J, V312, P608; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; JACKSON CVE, 1988, J MENT DEFIC RES, V32, P479; RICHARDSON JS, 1993, ANN NY ACAD SCI, V695, P73, DOI 10.1111/j.1749-6632.1993.tb23031.x; RUBINSZTEIN DC, 1995, PSYCHOL MED, V25, P223, DOI 10.1017/S0033291700036138; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; SPARKS DL, 1994, EXP NEUROL, V126, P88, DOI 10.1006/exnr.1994.1044; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9	12	48	50	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1189	1190		10.1016/S0140-6736(05)62409-9	http://dx.doi.org/10.1016/S0140-6736(05)62409-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130937				2022-12-28	WOS:A1997WW71700005
J	Pollock, AM; Dunnigan, M; Gaffney, D; Macfarlane, A; Majeed, FA				Pollock, AM; Dunnigan, M; Gaffney, D; Macfarlane, A; Majeed, FA			What happens when the private sector plans hospital services for the NHS: Three case studies under the private finance initiative	BRITISH MEDICAL JOURNAL			English	Article											Pollock, AM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.			pollock, allyson/0000-0002-7388-3110				CLARKE A, 1992, BRIT MED J, V305, P1307, DOI 10.1136/bmj.305.6865.1307; *DEP ENV PRIV FIN, 1997, INTRO PRIV FIN IN; *DEP HLTH, STAT B, V9520; *DEP HLTH, STAT B, V1093; *DEP HLTH, 1996, STAT B, V23; *DEP HLTH SOC SEC, STAT B, V585; *HC, 1996, 90 HC; *HM TREAS, 1995, PRIV OPP PUBL BEN; *HM TREAS, 1997, INTRO PROV FIN INT; *INF STAT DIV, 1996, SCOTT HLTH STAT 1996; *INF STAT DIV, 1996, NHS SCOTL HOSP BED U; *NHS EX, 1995, 9515 NHSE HSG; *NHS EX, 1997, COD PRACT OP NHS; *NHS EX, 1995, PFI CAP INV MAN BUS; *NHS EX, 1996, BED AV ENGL FIN YEAR; POLLOCK AM, 1995, LANCET, V346, P683, DOI 10.1016/S0140-6736(95)92286-5; *RAD STAT HLTH GRO, 1992, BRIT MED J, V304, P705; STEWART A, 1996, SEIZE INITIATIVE; *UN, 1996, UN NEG GUID PFI NHS	19	42	43	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 26	1997	314	7089					1266	1271		10.1136/bmj.314.7089.1266	http://dx.doi.org/10.1136/bmj.314.7089.1266			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW718	9154034	Green Published			2022-12-28	WOS:A1997WW71800036
J	Senn, S				Senn, S			Are placebo run ins justified?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHYSICIANS HEALTH; CLINICAL-TRIALS; EFFICIENCY; COST				Senn, S (corresponding author), UCL, DEPT STAT SCI, MORTIMER ST, LONDON WC1E 6BT, ENGLAND.		Senn, Stephen J/A-8101-2008; Senn, Stephen/B-2903-2013	Senn, Stephen/0000-0002-7558-8473				[Anonymous], 1988, NEW ENGL J MED, V318, P262; ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844; BRITTAIN E, 1990, CONTROL CLIN TRIALS, V11, P327, DOI 10.1016/0197-2456(90)90174-Z; BURING JE, 1990, STAT MED, V9, P29, DOI 10.1002/sim.4780090109; Fisher RA, 1990, STAT METHODS EXPT DE; Freedman Benjamin, 1990, IRB, V12, P1, DOI 10.2307/3564541; Hulley S., 2007, DESIGNING CLIN RES E; LANG JM, 1990, STAT MED, V9, P87, DOI 10.1002/sim.4780090115; LANG JM, 1991, STAT MED, V10, P1585, DOI 10.1002/sim.4780101010; MITCHELL J, 1995, BRIT MED J, V310, P43, DOI 10.1136/bmj.310.6971.43; Pocock SJ., 2013, CLIN TRIALS PRACTICA; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SCHECHTMAN KB, 1993, STAT MED, V12, P111, DOI 10.1002/sim.4780120204; SENN S, 1994, STAT MED, V13, P217, DOI 10.1002/sim.4780130305; Senn S, 1995, STAT MED, V14, P2661, DOI 10.1002/sim.4780142406; SENN SJ, 1991, STAT MED, V10, P1361, DOI 10.1002/sim.4780100905; Spilker B., 1991, GUIDE CLIN TRIALS; Temple R, 1982, DRUG INF J, V10-17, DOI DOI 10.1177/009286158201600102	18	32	32	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	1997	314	7088					1191	1193		10.1136/bmj.314.7088.1191	http://dx.doi.org/10.1136/bmj.314.7088.1191			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV705	9146400	Green Published			2022-12-28	WOS:A1997WV70500035
J	Coast, J				Coast, J			The rationing debate: Rationing within the NHS should be explicit - The case against	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; NEEDS ASSESSMENT				Coast, J (corresponding author), UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND.			Coast, Joanna/0000-0002-3537-5166				AARON HJ, 1984, PAINFUL PRESCRIPTION; BAKER R, 1992, BROOKINGS D, P208; *BRIDG GROUP, 1992, COR DEB STAG ON WE D; CALLAHAN D, 1991, HLTH AFF         SUM, P78; COHEN D, 1994, BRIT MED J, V309, P781, DOI 10.1136/bmj.309.6957.781; DEAN M, 1991, LANCET, V337, P480, DOI 10.1016/0140-6736(91)93408-2; DONALDSON C, 1994, BRIT MED J, V309, P784, DOI 10.1136/bmj.309.6957.784; DONALDSON C, 1993, HEALTH POLICY, V25, P95, DOI 10.1016/0168-8510(93)90105-X; EVANS RG, 1980, FAITH HOPE CHARITY H; Frankel, 1996, PRIORITY SETTING HLT; FUCHS VR, 1984, NEW ENGL J MED, V311, P1572, DOI 10.1056/NEJM198412133112411; GRIMES DS, 1987, LANCET, V1, P615; HUNTER D, 1993, RATIONING DILEMMAS H; KLEIN R, 1993, BRIT MED J, V307, P309, DOI 10.1136/bmj.307.6899.309; KLEIN R, 1984, BRIT MED J, V289, P143, DOI 10.1136/bmj.289.6438.143; MECHANIC D, 1995, BRIT MED J, V310, P1655, DOI 10.1136/bmj.310.6995.1655; MOONEY G, 1993, SOC SCI MED, V37, P873, DOI 10.1016/0277-9536(93)90140-Y; New B, 1996, BRIT MED J, V312, P1593, DOI 10.1136/bmj.312.7046.1593; NEW B, 1996, RATIONING NHS PRINCI; PARSONS V, 1991, BRIT MED J, V303, P1553, DOI 10.1136/bmj.303.6816.1553-a; Price D, 1996, BRIT MED J, V312, P167; REDMAYNE S, 1993, SHARING RESOURCES PU; SMITH R, 1991, BRIT MED J, V303, P1561, DOI 10.1136/bmj.303.6817.1561; SMITH R, 1993, RATIONING ACTION; TOYNBEE P, 1995, INDEPENDENT     1027, P23	25	26	26	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 12	1997	314	7087					1118	1122		10.1136/bmj.314.7087.1118	http://dx.doi.org/10.1136/bmj.314.7087.1118			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU236	9162270	Green Published			2022-12-28	WOS:A1997WU23600037
J	Ptashne, M; Gann, A				Ptashne, M; Gann, A			Transcriptional activation by recruitment	NATURE			English	Review							RNA-POLYMERASE-II; BINDING-PROTEIN NTRC; ALPHA-SUBUNIT; LAMBDA-REPRESSOR; GENE-REGULATION; SYNERGISTIC ACTIVATION; BACTERIOPHAGE-LAMBDA; UPSTREAM ACTIVATOR; RECEPTOR PROTEIN; POSITIVE CONTROL	The recruitment model for gene activation stipulates that an activator works by bringing the transcriptional machinery to the DNA. Recent experiments in bacteria and yeast indicate that many genes can be activated by this mechanism. These findings have implications for our understanding of the nature of activating regions and their targets, and for the role of histones in gene regulation.	UNIV LANCASTER, DIV BIOL SCI, LANCASTER LA1 4YQ, ENGLAND	Lancaster University	Ptashne, M (corresponding author), HARVARD UNIV, DEPT MOL & CELLULAR BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.							ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BENJTLEY D, 1995, CURR OPIN GENE DEV, V5, P210; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; Blau J, 1996, MOL CELL BIOL, V16, P2044; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BUCK M, 1989, NUCLEIC ACIDS RES, V17, P2597, DOI 10.1093/nar/17.7.2597; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; BUSBY S, 1994, J MOL BIOL, V241, P341, DOI 10.1006/jmbi.1994.1511; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; BUSBY S, IN PRESS MOL MICROBI; BUSHMAN FD, 1989, CELL, V58, P1163, DOI 10.1016/0092-8674(89)90514-X; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAREY MF, 1995, CURR BIOL, V5, P1003, DOI 10.1016/S0960-9822(95)00201-6; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; CHOY HE, 1995, EMBO J, V14, P4523, DOI 10.1002/j.1460-2075.1995.tb00131.x; COUTO G, IN PRESS P NATL ACAD; DeRubertis F, 1996, NATURE, V384, P589; Dove SL, 1997, NATURE, V386, P627, DOI 10.1038/386627a0; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; GAUDREAU L, IN PRESS CELL; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P2236, DOI 10.1073/pnas.79.7.2236; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; JOUNG JK, 1994, SCIENCE, V265, P1863, DOI 10.1126/science.8091212; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KULDELL N, 1994, J BACTERIOL, V176, P2991, DOI 10.1128/JB.176.10.2991-2998.1994; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; LI M, IN PRESS P NATL ACAD; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAGASANIK B, 1993, J CELL BIOCHEM, V51, P34, DOI 10.1002/jcb.240510108; MALAN TP, 1982, J MOL BIOL, V157, P493; MARSOLIER MC, 1995, GENE DEV, V9, P410, DOI 10.1101/gad.9.4.410; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MEYER BJ, 1980, J MOL BIOL, V139, P195, DOI 10.1016/0022-2836(80)90304-6; Miller A, 1997, SCIENCE, V275, P1655, DOI 10.1126/science.275.5306.1655; Monsalve M, 1996, EMBO J, V15, P383, DOI 10.1002/j.1460-2075.1996.tb00368.x; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; NORTH A, IN PRESS J MOL BIOL; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PTASHNE M, 1992, GENETIC SWITCH GENE; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RASMUSSEN EB, 1995, J MOL BIOL, V252, P522, DOI 10.1006/jmbi.1995.0517; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SCOTT S, 1995, MOL MICROBIOL, V18, P521, DOI 10.1111/j.1365-2958.1995.mmi_18030521.x; Smith TL, 1996, P NATL ACAD SCI USA, V93, P8868, DOI 10.1073/pnas.93.17.8868; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Tanaka M, 1996, P NATL ACAD SCI USA, V93, P4311, DOI 10.1073/pnas.93.9.4311; TANG H, 1994, GENE DEV, V8, P3058, DOI 10.1101/gad.8.24.3058; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WRANA JL, 1989, NUCLEIC ACIDS RES, V17, P10119, DOI 10.1093/nar/17.23.10119; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XIAO H, 1995, MOL CELL BIOL, V15, P5757; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081	101	933	954	1	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 10	1997	386	6625					569	577		10.1038/386569a0	http://dx.doi.org/10.1038/386569a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121580				2022-12-28	WOS:A1997WT27300049
J	Belisle, JT; Vissa, VD; Sievert, T; Takayama, K; Brennan, PJ; Besra, GS				Belisle, JT; Vissa, VD; Sievert, T; Takayama, K; Brennan, PJ; Besra, GS			Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis	SCIENCE			English	Article							CYCLOPROPANATED MYCOLIC ACIDS; PROTEINS; IDENTIFICATION; BIOSYNTHESIS; ETHAMBUTOL; SEQUENCE; COMPLEX; TARGET	The dominant exported proteins and protective antigens of Mycobacterium tuberculosis are a triad of related gene products called the antigen 85 (Ag85) complex. Each has also been implicated in disease pathogenesis through its fibronectin-binding capacities, A carboxylesterase domain was found within the amino acid sequences of Ag85A, B, and C, and each protein acted as a mycolyltransferase involved in the final stages of mycobacterial cell wall assembly, as shown by direct enzyme assay and site-directed mutagenesis. Furthermore, the use of an antagonist (6-azido-6-deoxy-alpha,alpha'-trehalose) of this activity demonstrates that these proteins are essential and potential targets for new antimycobacterial drugs.	UNIV WISCONSIN, WILLIAM S MIDDLETON MEM VET HOSP, MYCOBACTERIOL RES LAB, MADISON, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	Belisle, JT (corresponding author), COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA.		Belisle, John T/B-8944-2017	Belisle, John T/0000-0002-2539-2798; Besra, Gurdyal/0000-0002-5605-0395	NIAID NIH HHS [AI-38087, AI-35220, AI-18357] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035220, R22AI018357, U19AI038087, R01AI018357, R37AI018357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215, DOI 10.1146/annurev.bi.65.070196.001243; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P63; CHUNG GAC, 1995, ANTIMICROB AGENTS CH, V39, P2235, DOI 10.1128/AAC.39.10.2235; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; DOBOS KM, 1995, INFECT IMMUN, V63, P2846, DOI 10.1128/IAI.63.8.2846-2853.1995; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P441; GEORGE KM, 1995, J BIOL CHEM, V270, P27292, DOI 10.1074/jbc.270.45.27292; HANESSIAN S, 1972, J ANTIBIOT, V25, P683, DOI 10.7164/antibiotics.25.683; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530; JOLIFF G, 1992, MOL MICROBIOL, V6, P2349, DOI 10.1111/j.1365-2958.1992.tb01410.x; KAZLAUSKAS RJ, 1994, TRENDS BIOTECHNOL, V12, P464, DOI 10.1016/0167-7799(94)90022-1; KHANOLKARYOUNG S, 1992, INFECT IMMUN, V60, P3925, DOI 10.1128/IAI.60.9.3925-3927.1992; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RE, 1995, J AM CHEM SOC, V117, P11829, DOI 10.1021/ja00153a002; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; Mikusova K, 1996, J BIOL CHEM, V271, P7820, DOI 10.1074/jbc.271.13.7820; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAGAI S, 1991, INFECT IMMUN, V59, P372, DOI 10.1128/IAI.59.1.372-382.1991; PEAKE P, 1993, INFECT IMMUN, V61, P4834; PHILIPP WJ, 1996, P NATL ACAD SCI USA, V93, P3137; PRICE NC, 1996, PROTEIN LABFAX, P270; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; SATHYAMOORTHY N, 1987, J BIOL CHEM, V262, P13417; Slayden RA, 1996, ANTIMICROB AGENTS CH, V40, P2813, DOI 10.1128/AAC.40.12.2813; WIKER HG, 1990, INFECT IMMUN, V58, P272, DOI 10.1128/IAI.58.1.272-274.1990; WIKER HG, 1992, MICROBIOL REV, V56, P66; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; YOUNG LJS, 1988, HUM GENET, V79, P137, DOI 10.1007/BF00280552; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630	32	566	618	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	1997	276	5317					1420	1422		10.1126/science.276.5317.1420	http://dx.doi.org/10.1126/science.276.5317.1420			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9162010				2022-12-28	WOS:A1997XB53300051
J	Chen, CS; Mrksich, M; Huang, S; Whitesides, GM; Ingber, DE				Chen, CS; Mrksich, M; Huang, S; Whitesides, GM; Ingber, DE			Geometric control of cell life and death	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; FIBROBLAST GROWTH-FACTOR; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; INTEGRIN ALPHA(V)BETA(3); GENE-EXPRESSION; FOCAL ADHESIONS; BLOOD-VESSELS; ANGIOGENESIS; SHAPE	Human and bovine capillary endothelial cells were switched from growth to apoptosis by using micropatterned substrates that contained extracellular matrix-coated adhesive islands of decreasing size to progressively restrict cell extension. Cell spreading also was varied while maintaining the total cell-matrix contact area constant by changing the spacing between multiple focal adhesion-sized islands. Cell shape was found to govern whether individual cells grow or die, regardless of the type of matrix protein or antibody to integrin used to mediate adhesion. Local geometric control of cell growth and viability may therefore represent a fundamental mechanism for developmental regulation within the tissue microenvironment.	HARVARD UNIV,SCH MED,CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHILDRENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University			Mrksich, Milan/G-2469-2011; Ingber, Donald E/AAC-5894-2019; Chen, Christopher S./ABD-8499-2021; Ladoux, Benoit/A-9879-2013	Chen, Christopher S./0000-0003-2445-8449; Mrksich, Milan/0000-0002-4964-796X	NATIONAL CANCER INSTITUTE [R01CA055833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [S15HL047699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030367, R37GM030367] Funding Source: NIH RePORTER; NCI NIH HHS [CA55833] Funding Source: Medline; NHLBI NIH HHS [HL47699] Funding Source: Medline; NIGMS NIH HHS [GM30367] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark ER, 1939, AM J ANAT, V64, P251, DOI 10.1002/aja.1000640203; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; Dike LE, 1996, J CELL SCI, V109, P2855; DRAKE CJ, 1995, J CELL SCI, V108, P2655; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FOLKMAN J, 1975, BIOCHIM BIOPHYS ACTA, V417, P217; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Ingber D. E., 1982, TUMOR INVASION METAS, P335; INGBER DE, 1993, CELL, V75, P1249, DOI 10.1016/0092-8674(93)90612-T; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; INGBER DE, 1993, J CELL SCI, V104, P613; INGBER DE, 1986, ENDOCRINOLOGY, V119, P1768, DOI 10.1210/endo-119-4-1768; INGBER DE, 1981, P NATL ACAD SCI-BIOL, V78, P3901, DOI 10.1073/pnas.78.6.3901; INGBER DE, 1997, ANN REV PHYS, V59, P75; INGBER DE, 1985, AM J PATHOL, V12, P248; Ingber DE., 1985, GENE EXPRESSION NORM, P13; INGBER DE, 1989, CELL, V58, P308; KUMAR A, 1994, LANGMUIR, V10, P1498, DOI 10.1021/la00017a030; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MRKSICH M, 1995, TRENDS BIOTECHNOL, V13, P228, DOI 10.1016/S0167-7799(00)88950-7; OWENS LV, 1995, CANCER RES, V55, P2752; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Stamenovic D, 1996, J THEOR BIOL, V181, P125, DOI 10.1006/jtbi.1996.0120; STOKER M, 1968, INT J CANCER, V3, P683, DOI 10.1002/ijc.2910030517; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TUCKER R W, 1981, Journal of Supramolecular Structure and Cellular Biochemistry, V15, P29, DOI 10.1002/jsscb.1981.380150104; WANG N, 1994, BIOPHYS J, V66, P2181, DOI 10.1016/S0006-3495(94)81014-8; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wang N, 1995, BIOCHEM CELL BIOL, V73, P327, DOI 10.1139/o95-041; WICHA MS, 1980, DEV BIOL, V80, P253, DOI 10.1016/0012-1606(80)90402-9; WITTELSBERGER SC, 1981, CELL, V24, P859, DOI 10.1016/0092-8674(81)90111-2; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	59	3866	4037	18	801	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1425	1428		10.1126/science.276.5317.1425	http://dx.doi.org/10.1126/science.276.5317.1425			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9162012				2022-12-28	WOS:A1997XB53300053
J	Henderson, IC; Patek, AJ				Henderson, IC; Patek, AJ			Are breast cancers in young women qualitatively distinct?	LANCET			English	Editorial Material							C-ERBB-2 EXPRESSION; THERAPY				Henderson, IC (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143, USA.							Albain K S, 1994, J Natl Cancer Inst Monogr, P35; ALLRED DC, 1992, J CLIN ONCOL, V10, P599, DOI 10.1200/JCO.1992.10.4.599; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z; *EARL BREAST CANC, 1992, LANCET, V339, P1; *EARL BREAST CANC, 1992, LANCET, V339, P71; Eisinger F, 1996, CANCER RES, V56, P471; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; SILVESTRINI R, 1985, CANCER, V56, P1982, DOI 10.1002/1097-0142(19851015)56:8<1982::AID-CNCR2820560816>3.0.CO;2-I; WALKER R, 1996, LANCET, V74, P1796	13	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 24	1997	349	9064					1488	1489		10.1016/S0140-6736(97)22021-0	http://dx.doi.org/10.1016/S0140-6736(97)22021-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167452				2022-12-28	WOS:A1997XA90100002
J	Conrad, MN; Dominguez, AM; Dresser, ME				Conrad, MN; Dominguez, AM; Dresser, ME			Ndj1p, a meiotic telomere protein required for normal chromosome synapsis and segregation in yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; RECOMBINATION; GENE; MINICHROMOSOMES; LOCALIZATION; MEIOSIS	The Saccharomyces cerevisiae gene NDJ1 (nondisjunction) encodes a protein that accumulates at telomeres during meiotic prophase. Deletion of NDJ1 (ndj1 Delta) caused nondisjunction, impaired distributive segregation of linear chromosomes, and disordered the distribution of telomeric Rap1p, but it did not affect distributive segregation of circular plasmids. Induction of meiotic recombination and the extent of crossing-over were largely normal in ndj1 Delta cells, but formation of axial elements and synapsis were delayed. Thus, Ndj1p may stabilize homologous DNA interactions at telomeres, and possibly at other sites, and it is required for a telomere activity in distributive segregation.	OKLAHOMA MED RES FDN,PROGRAM MOL & CELL BIOL,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation					NIGMS NIH HHS [GM45250] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045250] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; CONRAD M, UNPUB; DAWSON DS, 1986, SCIENCE, V234, P713, DOI 10.1126/science.3535068; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; FLATTERS M, 1993, GENETICS, V134, P423; GOLDWAY M, 1993, GENETICS, V133, P149; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; Hawley R.S., 1988, GENETIC RECOMBINATIO, P497; KABACK DB, 1989, CURR GENET, V15, P385, DOI 10.1007/BF00376792; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; LOLDL J, 1994, P NATL ACAD SCI USA, V91, P331; MAGUIRE MP, 1978, EXP CELL RES, V112, P297, DOI 10.1016/0014-4827(78)90213-6; MANN C, 1986, P NATL ACAD SCI USA, V83, P6017, DOI 10.1073/pnas.83.16.6017; Moses M. J., 1968, Annual Review of Genetics, V2, P363, DOI 10.1146/annurev.ge.02.120168.002051; NILSSONTILLGREN T, 1986, CARLSBERG RES COMMUN, V51, P309, DOI 10.1007/BF02907164; PERKINS DD, 1949, GENETICS, V34, P607; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; SEARS DD, 1994, GENETICS, V138, P1055; SEARS DD, 1992, P NATL ACAD SCI USA, V89, P5296, DOI 10.1073/pnas.89.12.5296; VANDENBOL M, 1995, YEAST, V11, P1069, DOI 10.1002/yea.320111108; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3	23	160	164	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1252	1255		10.1126/science.276.5316.1252	http://dx.doi.org/10.1126/science.276.5316.1252			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157883				2022-12-28	WOS:A1997XA49700042
J	Strandberg, TE; Tilvis, RS; Vuoristo, M; Lindroos, M; Kosunen, TU				Strandberg, TE; Tilvis, RS; Vuoristo, M; Lindroos, M; Kosunen, TU			Prospective study of Helicobacter pylori seropositivity and cardiovascular diseases in a general elderly population	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; RISK-FACTORS		UNIV HELSINKI,DEPT MED,DIV GERIATR,FIN-00290 HELSINKI,FINLAND; UNIV HELSINKI,DEPT BACTERIOL & IMMUNOL,FIN-00290 HELSINKI,FINLAND; VAASA CENT HOSP,DEPT CARDIOL,VAASA,FINLAND	University of Helsinki; University of Helsinki; Vaasa Central Hospital								KOSUNEN TU, 1989, SCAND J GASTROENTERO, V24, P110, DOI 10.3109/00365528909092247; LINDROOS M, 1993, J AM COLL CARDIOL, V21, P1220, DOI 10.1016/0735-1097(93)90249-Z; MURRAY LJ, 1995, BRIT HEART J, V74, P497; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711	4	50	54	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 3	1997	314	7090					1317	1318		10.1136/bmj.314.7090.1317	http://dx.doi.org/10.1136/bmj.314.7090.1317			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX975	9158467	Green Published			2022-12-28	WOS:A1997WX97500023
J	Daniele, A; Albanese, A; Gainotti, G; Gregori, B; Bartolomeo, P				Daniele, A; Albanese, A; Gainotti, G; Gregori, B; Bartolomeo, P			Zolpidem in Parkinson's disease	LANCET			English	Article									INSERM, U324, PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	Daniele, A (corresponding author), UNIV CATTOLICA SACRO CUORE, INST NEUROL, I-00168 ROME, ITALY.		Daniele, Antonio/I-4516-2012; Daniele, Antonio/AAD-1935-2022; Daniele, Antonio/AFQ-9918-2022; Albanese, Alberto/K-7396-2016; Bartolomeo, Paolo/B-3046-2009; G, G/GWR-3235-2022; G, Gainotti/AAD-6504-2022	Albanese, Alberto/0000-0002-5864-0006; Bartolomeo, Paolo/0000-0002-2640-6426; 				GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; GRAFTON ST, 1995, ANN NEUROL, V37, P776, DOI 10.1002/ana.410370611; JANKOVIC J, 1988, PARKINSONS DISEASE M, P95; Langer SZ, 1988, IMIDAZOPYRIDINES SLE, P55; Schwarz J., 1993, Neurology, V43, pS17	5	68	70	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1222	1223		10.1016/S0140-6736(05)62416-6	http://dx.doi.org/10.1016/S0140-6736(05)62416-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130951				2022-12-28	WOS:A1997WW71700019
J	White, RF; Proctor, SP				White, RF; Proctor, SP			Solvents and neurotoxicity	LANCET			English	Article							OCCUPATIONAL EXPOSURE; ORGANIC-SOLVENTS; TOXIC ENCEPHALOPATHY; NORMAL-HEXANE	We describe the clinical evaluation of the nervous-system effects of solvent exposure. We review the current evidence in the epidemiological literature on neurotoxicological effects of solvents, and outline methods and issues to be taken into account in assessment of the patient whose symptoms may be related to solvent toxicity. Primary prevention of these disorders is essential, because treatment options are limited.	BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; BOSTON UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA USA; BOSTON DVA MED CTR, PSYCHOL SERV, BOSTON, MA 02130 USA	Boston University; Boston University	White, RF (corresponding author), BOSTON DVA MED CTR, BOSTON ENVIRONM HAZARDS CTR, 150 S HUNTINGTON AVE 116B-4, BOSTON, MA 02130 USA.			White, Roberta/0000-0002-2001-6646				ALTMANN L, 1990, INT ARCH OCC ENV HEA, V62, P493, DOI 10.1007/BF00381179; *AM C GOV IND HYG, 1994, 1994 1995 THRESH LIM; ANGER WK, 1984, NEUROBEH TOXICOL TER, V6, P147; BAKER EL, 1994, J OCCUP ENVIRON MED, V36, P1079, DOI 10.1097/00043764-199410000-00010; BAKER EL, 1985, INT J MENT HEALTH, V14, P135, DOI 10.1080/00207411.1985.11449006; BAKER EL, 1985, CHRONIC EFFECTS ORGA; CALLENDER TJ, 1993, ENVIRON RES, V60, P295, DOI 10.1006/enrs.1993.1039; CHANG YC, 1987, J NEUROL NEUROSUR PS, V50, P269, DOI 10.1136/jnnp.50.3.269; CULLEN MR, 1987, WORKERS MULTIPLE CHE, P655; ECHEVERRIA D, 1995, JOEM, V37, P1; FELDMAN RG, 1985, AM J IND MED, V8, P119, DOI 10.1002/ajim.4700080206; Feldman RG, 1984, NEUROLOGY PHYSICIANS, P191; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; GRASSO P, 1984, FOOD CHEM TOXICOL, V22, P819, DOI 10.1016/0278-6915(84)90121-2; HANNINEN H, 1976, Scandinavian Journal of Work Environment and Health, V2, P240; HANNINEN H, 1971, BRIT J IND MED, V28, P374; HANNINEN H, 1988, NEUROTOXICOL TERATOL, V10, P485, DOI 10.1016/0892-0362(88)90013-X; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; JUNTUNEN J, 1982, ACTA NEUROL SCAND, V66, P89; KATZ GV, 1985, NEUTOXICITY IND COMM, V1, P149; Lauwerys RR, 1996, CASARETT DOULLS TOXI, P987; *NIOSH USDHHS, 1994, NIOSH POCK GUID CHEM; *NIOSH USDHHS, 1987, CURR INT B, P48; PASTORE C, 1994, MUSCLE NERVE, V17, P981, DOI 10.1002/mus.880170904; PETERS HA, 1988, ARCH NEUROL-CHICAGO, V45, P537, DOI 10.1001/archneur.1988.00520290069016; ROSENBERG NL, 1988, NEUROTOXICOL TERATOL, V10, P489, DOI 10.1016/0892-0362(88)90014-1; SEPPALAINEN AM, 1981, ELECTROEN CLIN NEURO, V51, P148, DOI 10.1016/0013-4694(81)90003-1; SEPPALAINEN AM, 1978, SCAND J WORK ENV HEA, V4, P304, DOI 10.5271/sjweh.2695; Snyder R., 1996, CASARETT DOULLS TOXI, V5, P737; URBAN P, 1990, BRIT J IND MED, V47, P819; *US C, 1970, OTABA436 US C; *US INT TRAD COMM, 1985, USITC PUBL, V1745, P9; WHITE RF, 1992, J OCCUP ENVIRON MED, V34, P140, DOI 10.1097/00043764-199202000-00013; WHITE RF, 1995, AM J IND MED, V28, P221, DOI 10.1002/ajim.4700280207; WHITE RF, 1994, OCCUP ENVIRON MED, V51, P102, DOI 10.1136/oem.51.2.102; WHITE RF, 1993, ENVIRON RES, V61, P117, DOI 10.1006/enrs.1993.1055; WHITE RF, 1987, CLIN NEUROPSYCHOL, V1, P153; WHITE RF, 1992, CLIN SYNDROMES ADULT, P1; YOKOYAMA K, 1990, MUSCLE NERVE, V13, P314, DOI 10.1002/mus.880130406	39	111	116	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 26	1997	349	9060					1239	1243		10.1016/S0140-6736(96)07218-2	http://dx.doi.org/10.1016/S0140-6736(96)07218-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130958	hybrid			2022-12-28	WOS:A1997WW71700042
J	Volkow, ND; Wang, GJ; Fischman, MW; Foltin, RW; Fowler, JS; Abumrad, NN; Vitkun, S; Logan, J; Gatley, SJ; Pappas, N; Hitzemann, R; Shea, CE				Volkow, ND; Wang, GJ; Fischman, MW; Foltin, RW; Fowler, JS; Abumrad, NN; Vitkun, S; Logan, J; Gatley, SJ; Pappas, N; Hitzemann, R; Shea, CE			Relationship between subjective effects of cocaine and dopamine transporter occupancy	NATURE			English	Article							NUCLEUS-ACCUMBENS; MOLECULAR MECHANISMS; BINDING-SITES; PET; INHIBITORS; INVIVO; HUMANS; DRUGS; BRAIN	Cocaine is believed to work by blocking the dopamine transporter (DAT) and thereby increasing the availability of free dopamine within the brain(1-4). Although this concept is central to current cocaine research and to treatment development, a direct relationship between DAT blockade and the subjective effects of cocaine has not been demonstrated in humans. We have used positron emission tomography to determine what level of DAT occupancy is required to produce a subjective 'high' in human volunteers who regularly abuse cocaine. We report here that intravenous cocaine at doses commonly abused by humans (0.3-0.6 mg kg(-1)) blocked between 60 and 77% of DAT sites in these subjects. The magnitude of the self-reported high was correlated with the degree of DAT occupancy, and at least 47% of the transporters had to be blocked for subjects to perceive cocaine's effects. Furthermore, the time course for the high paralleled that of cocaine concentration within the striatum, a brain region implicated in the control of motivation and reward. This is the first demonstration in humans that the doses used by cocaine abusers lead to significant blockade of DAT, and that this blockade is associated with the subjective effects of cocaine. Although these findings provide justification to target the DAT for medication development they suggest that for drugs to be effective in blocking cocaine's effects they would have to be given at doses that achieve almost complete DAT occupancy.	BROOKHAVEN NATL LAB,DEPT CHEM,UPTON,NY 11973; SUNY STONY BROOK,DEPT PSYCHIAT,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT ANESTHESIOL,STONY BROOK,NY 11794; COLUMBIA UNIV,DEPT PSYCHIAT,NEW YORK,NY 10032; N SHORE UNIV HOSP,DEPT SURG,MANHASSET,NY 11030	United States Department of Energy (DOE); Brookhaven National Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Columbia University; Northwell Health; North Shore University Hospital	Volkow, ND (corresponding author), BROOKHAVEN NATL LAB,DEPT MED,UPTON,NY 11973, USA.							BALSTER RL, 1973, J EXP ANAL BEHAV, V20, P119, DOI 10.1901/jeab.1973.20-119; Fischman M W, 1989, NIDA Res Monogr, V92, P211; FISCHMAN MW, 1991, BRIT J ADDICT, V86, P1563; FOWLER JS, 1989, SYNAPSE, V4, P371, DOI 10.1002/syn.890040412; Gatley SJ, 1996, EUR J PHARMACOL, V296, P145, DOI 10.1016/0014-2999(95)00698-2; GATLEY SJ, 1997, BIOCHEM PHARMACOL, V51, P43; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; IZENWASSER S, 1990, BRAIN RES, V520, P303, DOI 10.1016/0006-8993(90)91719-W; JAVAID JI, 1978, SCIENCE, V202, P227, DOI 10.1126/science.694530; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LOGAN J, 1990, J CEREBR BLOOD F MET, V10, P740, DOI 10.1038/jcbfm.1990.127; LOGAN J, 1994, J CEREBR BLOOD F MET, V14, P995, DOI 10.1038/jcbfm.1994.132; MADRAS BK, 1989, J PHARMACOL EXP THER, V251, P131; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; PETTIT HO, 1991, BRAIN RES, V539, P94, DOI 10.1016/0006-8993(91)90690-W; PETTIT HO, 1984, PSYCHOPHARMACOLOGY, V84, P167, DOI 10.1007/BF00427441; POGUN S, 1991, EUR J PHARMACOL, V198, P203; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROTHMAN RB, 1990, LIFE SCI, V46, P17; STATHIS M, 1995, PSYCHOPHARMACOLOGY, V119, P376, DOI 10.1007/BF02245852; VERBEY K, 1988, PSYCHIAT ANN, V18, P513; VOLKOW ND, 1995, J NUCL MED, V36, P1289; Volkow ND, 1996, PSYCHOPHARMACOLOGY, V123, P26, DOI 10.1007/BF02246277	24	491	504	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					827	830		10.1038/386827a0	http://dx.doi.org/10.1038/386827a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126740				2022-12-28	WOS:A1997WV70600053
J	Cello, JP; Ring, EJ; Olcott, EW; Koch, J; Gordon, R; Sandhu, J; Morgan, DR; Ostroff, JW; Rockey, DC; Bacchetti, P; LaBerge, J; Lake, JR; Somberg, K; Doherty, C; Davila, M; McQuaid, K; Wall, SD				Cello, JP; Ring, EJ; Olcott, EW; Koch, J; Gordon, R; Sandhu, J; Morgan, DR; Ostroff, JW; Rockey, DC; Bacchetti, P; LaBerge, J; Lake, JR; Somberg, K; Doherty, C; Davila, M; McQuaid, K; Wall, SD			Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Digestive Disease Week	MAY 13-19, 1995	SAN DIEGO, CA	Amer Gastroenterol Assoc		portosystemic shunt, transjugular; sclerotherapy; esophageal and gastric varices; liver cirrhosis; hemorrhage	BLEEDING ESOPHAGEAL-VARICES; PORTACAVAL-SHUNT; SEVERE CIRRHOSIS; LIGATION; TIPS	Background: Hemorrhage from esophageal varices remains a substantial management problem. Endoscopic sclerotherapy was preferred for more than a decade, but fluoroscopically placed intrahepatic portosystemic stents have recently been used with increasing frequency. Objective: To compare sclerotherapy with transjugular intrahepatic portosystemic shunt (TIPS) in patients with bleeding from esophageal varices. Design: Randomized, controlled clinical trial. Setting: Three teaching hospitals. Patients: 49 adults hospitalized with acute variceal hemorrhage from November 1991 to December 1995: 25 assigned to sclerotherapy and 24 assigned to TIPS. Intervention: Patients assigned to repeated sclerotherapy had the procedure weekly. In those assigned to TIPS, an expandable mesh stent was fluoroscopically placed between an intrahepatic portal vein and an adjacent hepatic vein. Measurements: Pretreatment measures included demographic and laboratory data. Postrandomization data included index hospitalization survival, duration of followup, successful obliteration of varices, rebleeding from va rices, number of variceal rebleeding events, total days of hospitalization for variceal bleeding, blood transfusion requirements after randomization, prevalence of encephalopathy, and total health care costs. Results: Mean follow-up (+/-SE) was 567 +/- 104 days in the sclerotherapy group and 575 +/- 109 days in the TIPS group. Varices were obliterated more reliably by TIPS than by sclerotherapy (P < 0.001). Patients having TIPS were significantly less likely to rebleed from esophageal varices than patients receiving sclerotherapy (3 of 24 compared with 12 of 25; P = 0.012). No other follow-up measures differed significantly between groups. A trend toward improved survival, which was not statistically significant, was noted in the TIPS group (hazard ratio, 0.53 [95 % CI, 0.18 to 1.5]). Conclusions: In obliterating varices and reducing rebleeding events from esophageal varices, TIPS was more effective than sclerotherapy. However, TIPS did not decrease morbidity after randomization or improve health care costs. It seemed to produce better survival, but the increase in survival was not statistically significant.	VET AFFAIRS MED CTR, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, DEPT RADIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, GASTROENTEROL CONSULT SERV, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco	Cello, JP (corresponding author), UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP,MED CTR,DIV GASTROENTEROL, 1001 POTRERO AVE, NH 3D, SAN FRANCISCO, CA 94110 USA.			Lake, John/0000-0002-4332-0528	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK26743] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRESLOW N, 1974, BIOMETRICS, V30, P89, DOI 10.2307/2529620; Cabrera J, 1996, GASTROENTEROLOGY, V110, P832, DOI 10.1053/gast.1996.v110.pm8608893; CELLO JP, 1987, NEW ENGL J MED, V316, P11, DOI 10.1056/NEJM198701013160103; CELLO JP, 1984, NEW ENGL J MED, V311, P1589, DOI 10.1056/NEJM198412203112501; GIMSON AES, 1993, LANCET, V342, P391, DOI 10.1016/0140-6736(93)92812-8; Groupe d'Etude de Anastomoses Intra-Hepatiques, 1995, HEPATOLOGY, V22, p297A; Harrell FE, 1986, P 11 ANN SAS US GROU; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; LAINE L, 1993, ANN INTERN MED, V119, P1, DOI 10.7326/0003-4819-119-1-199307010-00001; LO GH, 1995, HEPATOLOGY, V22, P466, DOI 10.1016/0270-9139(95)90567-7; Merli M, 1996, GASTROENTEROLOGY, V110, pA1265; PUGH RNH, 1992, GUT, V33, P1583, DOI 10.1136/gut.33.11.1583; ROSSLE M, 1994, NEW ENGL J MED, V330, P165, DOI 10.1056/NEJM199401203300303; ROSSLE M, 1994, HEPATOLOGY, V20, pA107; SANYAL AJ, 1994, GASTROENTEROLOGY, V106, pA975; Sauer P, 1996, GASTROENTEROLOGY, V110, pA1313; SOMBERG KA, 1995, AM J GASTROENTEROL, V90, P549; STIEGMANN GV, 1992, NEW ENGL J MED, V326, P1527, DOI 10.1056/NEJM199206043262304	18	167	167	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1997	126	11					858	+		10.7326/0003-4819-126-11-199706010-00002	http://dx.doi.org/10.7326/0003-4819-126-11-199706010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XA911	9163286				2022-12-28	WOS:A1997XA91100002
J	Wilms, JL				Wilms, JL			Alienation and imagination: The literature of exclusion	ANNALS OF INTERNAL MEDICINE			English	Article											Wilms, JL (corresponding author), INST MED & HUMANITIES, POB 4587, MISSOULA, MT 59806 USA.							Brody H., 1987, STORIES SICKNESS; CASSELL EJ, 1991, NATURE SUFFERING GOA, P43; HOLUB M, 1990, VANISHING LUNG SYNDR, P9; KAFKA F, 1948, PENAL COLONY OTHER S; Langer L., 1991, HOLOCAUST TESTIMONIE, P61; LANGER LL, 1991, HOLOCAUST TESTIMONIE, pR15; LANGER LL, 1991, HOLOCAUST TESTIMONIE, P53; LEVI P, 1986, DROWNED SAVED, P12; LIFTON RJ, 1973, HOME WAR VIETNAM VET, P39; MIDDLEBROOK C, 1996, SEEING CRAB MEMOIR D, P169; PLATH S, 1972, BELL JAR; Styron W., 1990, DARKNESS VISIBLE MEM; STYRON W, 1990, DARKNESS VISIBLE MEM, P56	13	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1997	126	11					923	926		10.7326/0003-4819-126-11-199706010-00036	http://dx.doi.org/10.7326/0003-4819-126-11-199706010-00036			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	XA911	9163311				2022-12-28	WOS:A1997XA91100035
J	Mullan, F				Mullan, F			The National Health Service Corps and inner-city hospitals	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							GRADUATE MEDICAL-EDUCATION; PHYSICIAN WORKFORCE				Mullan, F (corresponding author), HLTH AFFAIRS,BETHESDA,MD 20814, USA.							*ASS AM MED COLL, 1996, AAMC DAT BOOK STAT I; *COUNC GRAD MED ED, 1995, COGME 1995 PHYS WORK; *COUNC GRAD MED ED, 1994, REC IMPR ACC HLTH CA; GAMLIEL S, 1995, HEALTH AFFAIR, V14, P131, DOI 10.1377/hlthaff.14.2.131; GINZBERG E, 1971, URBAN HLTH SERVICES, P96; GRONVALL JA, 1989, ACAD MED, V64, P61, DOI 10.1097/00001888-198902000-00002; *I MED, 1996, NAT PHYS WORKF OPT B; MAGNUSON PB, 1960, RING NIGHT BELL AUTO, P298; Miller RS, 1996, JAMA-J AM MED ASSOC, V275, P708, DOI 10.1001/jama.275.9.708; MULLAN F, 1993, HEALTH AFFAIR, V12, P138, DOI 10.1377/hlthaff.12.suppl_1.138; MULLAN F, 1995, JAMA-J AM MED ASSOC, V273, P1521, DOI 10.1001/jama.273.19.1521; *PEW HLTH PROF COM, 1995, REF GRAD MED ED REP; SHINE KI, 1995, JAMA-J AM MED ASSOC, V273, P1057, DOI 10.1001/jama.273.13.1057; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WHITCOMB ME, 1995, JAMA-J AM MED ASSOC, V274, P696, DOI 10.1001/jama.274.9.696; Whitcomb ME, 1996, JAMA-J AM MED ASSOC, V276, P700; 1997, NY TIMES        0218, pA1; 1997, NY TIMES        0301, pA7	18	21	21	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	1997	336	22					1601	1604		10.1056/NEJM199705293362212	http://dx.doi.org/10.1056/NEJM199705293362212			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB087	9164820				2022-12-28	WOS:A1997XB08700012
J	Deeks, SG; Abrams, DI				Deeks, SG; Abrams, DI			Genotypic-resistance assays and antiretroviral therapy	LANCET			English	Editorial Material							IN-VIVO				Deeks, SG (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,AIDS PROGRAM,SAN FRANCISCO,CA 94114, USA.							COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Jacobsen H, 1996, J INFECT DIS, V173, P1379, DOI 10.1093/infdis/173.6.1379; JAPOUR AJ, 1995, J INFECT DIS, V171, P1172, DOI 10.1093/infdis/171.5.1172; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804	6	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 24	1997	349	9064					1489	1490		10.1016/S0140-6736(05)62092-2	http://dx.doi.org/10.1016/S0140-6736(05)62092-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167453				2022-12-28	WOS:A1997XA90100003
J	Muers, MF				Muers, MF			Streptokinase for empyema	LANCET			English	Editorial Material							INTRAPLEURAL STREPTOKINASE				Muers, MF (corresponding author), KILLINGBECK HOSP,DEPT MED,LEEDS LS14 6UQ,W YORKSHIRE,ENGLAND.							BERGH NP, 1977, SCAND J THORAC CARD, V11, P265; Davies RJO, 1997, THORAX, V52, P416, DOI 10.1136/thx.52.5.416; Ferguson AD, 1996, QJM-MON J ASSOC PHYS, V89, P285; LAHORRA JM, 1993, AJR, V160, P71; TAYLOR RFH, 1994, THORAX, V49, P856, DOI 10.1136/thx.49.9.856; TILLETT WS, 1949, J CLIN INVEST, V28, P173, DOI 10.1172/JCI102046	6	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 24	1997	349	9064					1491	1492		10.1016/S0140-6736(05)62094-6	http://dx.doi.org/10.1016/S0140-6736(05)62094-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167455				2022-12-28	WOS:A1997XA90100005
J	Charnov, EL				Charnov, EL			Trade-off-invariant rules for evolutionarily stable life histories	NATURE			English	Article							OFFSPRING SIZE	Optimization models have been widely and successfully used in evolutionary ecology to predict the attributes of organisms(1-8). Most such models maximize darwinian fitness in the face of tradeoffs and constraints; the numerical results usually depend on the exact form of the trade-offs or constraints. But not always(9): for example, earlier work(9) predicted that the optimal range in offspring size ought to show a -1 scaling with small litter size, independent of most details of the underlying offspring-survival/offspring-size trade-off relation. Here I report that in nongrowing (stationary), age-structured populations, three major life-history attributes (age at first breeding, size of an offspring in large litters, and reproductive effort) are likely to evolve to equilibrium values that satisfy a universal numerical rule; the underlying trade-off will have a slope of -1 at the optimum, independent of most other aspects of the trade-off. Each of these three attributes can be viewed as an allocation problem between just two alternatives; the trade-off is then between having more of one alternative and less of the other. The slope of the trade-off is simply the slope of the curve of allowed combinations of the two alternatives. The theory predicts that natural selection will push to an equilibrium where the slope is always -1. The economic structure is the same as that which underlies evolution of the sex ratio where the two alternatives are sons and daughters(2,10).			Charnov, EL (corresponding author), UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA.							Bulmer M., 1994, THEORETICAL EVOLUTIO; Charlesworth B., 1994, EVOLUTION AGE STRUCT, DOI [10.1017/CBO9780511525711, DOI 10.1017/CBO9780511525711]; CHARNOV E L, 1982; CHARNOV EL, 1991, P NATL ACAD SCI USA, V88, P1134, DOI 10.1073/pnas.88.4.1134; CHARNOV EL, 1995, NATURE, V376, P418, DOI 10.1038/376418a0; Charnov Eric L., 1993, Evolutionary Anthropology, V1, P191, DOI 10.1002/evan.1360010604; Charnov Eric L., 1993, P1; GODFRAY HC, 1994, J PARASITOIDS; LLOYD DG, 1987, AM NAT, V129, P800, DOI 10.1086/284676; MacArthur RH, 1965, THEORETICAL MATH BIO, P388, DOI DOI 10.1038/NATURE04624; Mock D. W., 1997, EVOLUTION SIBLING RI; PARKER GA, 1990, NATURE, V348, P27, DOI 10.1038/348027a0; Seger Jon, 1996, P93; Stearns S.C., 1992, pi; STEARNS SC, 1989, FUNCT ECOL, V3, P259, DOI 10.2307/2389364; WILLIAMS GC, 1966, AM NAT, V100, P687, DOI 10.1086/282461	16	80	82	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	1997	387	6631					393	394		10.1038/387393a0	http://dx.doi.org/10.1038/387393a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163423				2022-12-28	WOS:A1997XA49600058
J	Hakansson, K; Doherty, AJ; Shuman, S; Wigley, DB				Hakansson, K; Doherty, AJ; Shuman, S; Wigley, DB			X-ray crystallography reveals a large conformational change during guanyl transfer by mRNA capping enzymes	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; MUTATIONAL ANALYSIS; COVALENT CATALYSIS; NUCLEOTIDYL TRANSFER; DNA-LIGASE; RNA; GUANYLYLTRANSFERASE; MECHANISM; COMPLEX; MOTIF	We have solved the crystal structure of an mRNA capping enzyme at 2.5 Angstrom resolution. The enzyme comprises two domains with a deep, but narrow, cleft between them. The two molecules in the crystallographic asymmetric unit adopt very different conformations; both contain a bound GTP, but one protein molecule is in an open conformation while the other is in a closed conformation. Only in the closed conformation is the enzyme able to bind manganese ions and undergo catalysis within the crystals to yield the covalent guanylated enzyme intermediate. These structures provide direct evidence for a mechanism that involves a significant conformational change in the enzyme during catalysis.	UNIV OXFORD,MOL BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	University of Oxford; Memorial Sloan Kettering Cancer Center				Doherty, Aidan/0000-0002-6370-1109	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHOLA T, 1995, P NATL ACAD SCI USA, V92, P507, DOI 10.1073/pnas.92.2.507; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CONG PJ, 1995, MOL CELL BIOL, V15, P6222; CONG PJ, 1993, J BIOL CHEM, V268, P7256; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2281, DOI 10.1093/nar/24.12.2281; DOHERTY AJ, 1997, IN PRESS ACTA CRYS D; FRESCO LD, 1994, P NATL ACAD SCI USA, V91, P6624, DOI 10.1073/pnas.91.14.6624; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; Ho CK, 1996, J VIROL, V70, P6658, DOI 10.1128/JVI.70.10.6658-6664.1996; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEATHERBARROW RJ, 1985, P NATL ACAD SCI USA, V82, P7840, DOI 10.1073/pnas.82.23.7840; LI Y, 1995, VIROLOGY, V212, P134, DOI 10.1006/viro.1995.1462; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; Sheldrick G. M., 1991, CRYSTALLOGRAPHIC COM, V5, P145; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; Shuman S, 1996, STRUCTURE, V4, P653, DOI 10.1016/S0969-2126(96)00070-6; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1995, VIROLOGY, V211, P73, DOI 10.1006/viro.1995.1380; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; YamadaOkabe T, 1996, MICROBIOL-UK, V142, P2515, DOI 10.1099/00221287-142-9-2515	28	216	218	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					545	553		10.1016/S0092-8674(00)80236-6	http://dx.doi.org/10.1016/S0092-8674(00)80236-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160746	Bronze			2022-12-28	WOS:A1997WZ32300008
J	Lauer, SA; Rathod, PK; Ghori, N; Haldar, K				Lauer, SA; Rathod, PK; Ghori, N; Haldar, K			A membrane network for nutrient import in red cells infected with the malaria parasite	SCIENCE			English	Article							PLASMODIUM-FALCIPARUM; ERYTHROCYTES; TRANSPORT; MATURATION; SECRETION; PATHWAYS; CHANNEL; STAGE	The human malaria parasite Plasmodium falciparum exports an interconnected network of tubovesicular membranes (the TVM) that extends from the parasite's vacuolar membrane to the periphery of the red cell. Here it is shown that extracellular solutes such as Lucifer yellow enter the TVM and are delivered to the parasite. Blocking the assembly of the network blocked the delivery of exogenous Lucifer yellow, nucleosides, and amino acids to the parasite without inhibiting secretion of plasmodial; proteins. These data suggest that the NM is a transport network that allows nutrients efficient access to the parasite and could be used to deliver antimalarial drugs directly into the parasite.	STANFORD UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; CATHOLIC UNIV AMER, INST BIOMOL STUDIES, DEPT BIOL, WASHINGTON, DC 20064 USA	Stanford University; Catholic University of America			Haldar, Kasturi/C-6685-2014		NIAID NIH HHS [AI26670, AI26912, AI39071] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026912, R01AI039071, R01AI026912, R01AI026670, R22AI026670] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHASIS JA, 1989, BLOOD, V74, P1112, DOI 10.1182/blood.V74.3.1112.1112; CRARY JL, 1992, MOL BIOCHEM PARASIT, V53, P185, DOI 10.1016/0166-6851(92)90020-K; Deitsch KW, 1996, MOL BIOCHEM PARASIT, V76, P1, DOI 10.1016/0166-6851(95)02575-8; DESAI SA, 1993, NATURE, V362, P643, DOI 10.1038/362643a0; ELFORD BC, 1995, BIOCHEM J, V308, P361, DOI 10.1042/bj3080361; ELFORD BC, 1993, PARASITOL TODAY, V9, P80, DOI 10.1016/0169-4758(93)90205-T; ELMENDORF HG, 1994, J CELL BIOL, V124, P449, DOI 10.1083/jcb.124.4.449; ELMENDORF HG, 1992, MOL BIOCHEM PARASIT, V52, P215, DOI 10.1016/0166-6851(92)90054-N; GERO AM, 1988, MOL BIOCHEM PARASIT, V27, P159, DOI 10.1016/0166-6851(88)90035-7; GERO AM, 1994, PARASITOL TODAY, V10, P395, DOI 10.1016/0169-4758(94)90231-3; GRONOWICZ G, 1984, J CELL SCI, V171, P163; HALDAR K, 1992, MOL BIOCHEM PARASIT, V50, P161, DOI 10.1016/0166-6851(92)90253-G; HALDAR K, 1994, PARASITOL TODAY, V10, P393, DOI 10.1016/0169-4758(94)90230-5; HALDAR K, 1989, J CELL BIOL, V108, P2183, DOI 10.1083/jcb.108.6.2183; KIRK K, 1994, J BIOL CHEM, V269, P3339; LAUER SA, 1995, P NATL ACAD SCI USA, V92, P9181, DOI 10.1073/pnas.92.20.9181; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; POUVELLE B, 1994, MOL BIOCHEM PARASIT, V66, P83, DOI 10.1016/0166-6851(94)90038-8; RATHOD PK, 1989, ANTIMICROB AGENTS CH, V33, P1090, DOI 10.1128/AAC.33.7.1090; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; TARASCHI TF, 1994, PARASITOL TODAY, V10, P399, DOI 10.1016/0169-4758(94)90232-1	21	172	177	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	1997	276	5315					1122	1125		10.1126/science.276.5315.1122	http://dx.doi.org/10.1126/science.276.5315.1122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9148808				2022-12-28	WOS:A1997WZ22500047
J	Ringach, DL; Hawken, MJ; Shapley, R				Ringach, DL; Hawken, MJ; Shapley, R			Dynamics of orientation tuning in macaque primary visual cortex	NATURE			English	Article							CAT STRIATE CORTEX; LATERAL INHIBITION; SIMPLE CELLS; SELECTIVITY; ORGANIZATION; DIRECTION; MONKEY; SPECIFICITY; SENSITIVITY; POTENTIALS	Orientation tuning of neurons is one of the chief emergent characteristics of the primary visual cortex, V1 (refs 1, 2). Neurons of the lateral geniculate nucleus, which comprise the thalamic input to V1, are not orientation-tuned, but the majority of VI neurons are quite selective. How orientation tuning arises within V1 is still controversial(1,3-17). To study this problem, we measured how the orientation tuning of neurons evolves with time(18-20) using a new method: reverse correlation in the orientation domain. Orientation tuning develops after a delay of 30-45 milliseconds and persists-for 40-85 ms. Neurons in layers 4C alpha or 4C beta, which receive direct input from the thalamus, show a single orientation preference which remains unchanged throughout the response period. In contrast, the preferred orientations of output layer neurons (in layers 2, 3, 4B, 5 or 6) usually change with time, and in many cases the orientation tuning may have more than one peak This difference in dynamics is accompanied by a change in the sharpness of orientation tuning; cells in the input layers are more broadly tuned than cells in the output layers. Many of these observed properties of output layer neurons cannot be explained by simple feedforward models(1,3-6), whereas they arise naturally in feedback networks(7-17). Our results indicate that V1 is more than a bank of static oriented filters; the dynamics of output layer cells appear to be shaped by intracortical feedback.			Ringach, DL (corresponding author), NYU,CTR NEURAL SCI,4 WASHINGTON PL,NEW YORK,NY 10003, USA.			Shapley, Robert/0000-0003-0099-9849				ANDREWS DP, 1965, NATURE, V205, P1218, DOI 10.1038/2051218a0; BENEVENTO LA, 1972, NATURE-NEW BIOL, V238, P124, DOI 10.1038/newbio238124a0; BENYISHAI R, 1995, P NATL ACAD SCI USA, V92, P3844, DOI 10.1073/pnas.92.9.3844; BLAKEMOR.C, 1970, NATURE, V228, P37, DOI 10.1038/228037a0; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; BLASDEL GG, 1984, J NEUROSCI, V4, P880; BONDS AB, 1989, VISUAL NEUROSCI, V2, P41, DOI 10.1017/S0952523800004314; CELEBRINI S, 1993, VISUAL NEUROSCI, V10, P811, DOI 10.1017/S0952523800006052; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; DEBOER E, 1968, IEEE T BIO-MED ENG, VBM15, P169, DOI 10.1109/TBME.1968.4502561; DEVALOIS RL, 1982, VISION RES, V22, P531, DOI 10.1016/0042-6989(82)90112-2; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; FERSTER D, 1986, J NEUROSCI, V6, P1284; Ferster D, 1996, NATURE, V380, P249, DOI 10.1038/380249a0; HAWKEN MJ, 1988, J NEUROSCI, V8, P3541; HENRY GH, 1974, J NEUROPHYSIOL, V37, P1394, DOI 10.1152/jn.1974.37.6.1394; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; LEVENTHAL AG, 1995, J NEUROSCI, V15, P1808, DOI 10.1523/JNEUROSCI.15-03-01808.1995; LUND JS, 1988, ANNU REV NEUROSCI, V11, P253, DOI 10.1146/annurev.ne.11.030188.001345; MORRONE MC, 1982, PROC R SOC SER B-BIO, V216, P335, DOI 10.1098/rspb.1982.0078; NELSON SB, 1991, J NEUROSCI, V11, P344; PEI X, 1994, J NEUROSCI, V14, P7130; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; SHEVELEV IA, 1993, NEUROSCIENCE, V56, P865, DOI 10.1016/0306-4522(93)90133-Z; SHEVELEV IA, 1994, NEUROSCIENCE, V61, P965, DOI 10.1016/0306-4522(94)90416-2; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; SILLITO AM, 1980, BRAIN RES, V194, P517, DOI 10.1016/0006-8993(80)91234-2; SOMERS DC, 1995, J NEUROSCI, V15, P5448; WORGOTTER F, 1991, J NEUROSCI, V11, P1959	30	420	421	1	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					281	284		10.1038/387281a0	http://dx.doi.org/10.1038/387281a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153392				2022-12-28	WOS:A1997WZ16700052
J	Carter, HB; Epstein, JI; Chan, DW; Fozard, JL; Pearson, JD				Carter, HB; Epstein, JI; Chan, DW; Fozard, JL; Pearson, JD			Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUMOR VOLUME; MEN; PROGRESSION	Objective.-To evaluate prostate-specific antigen (PSA) testing intervals that maintain the detection of curable cancer and reduce unnecessary testing. Design and Patients.-Historical prospective study of serial PSA measurements at 2- and 4-year intervals from frozen serum samples of 40 men who eventually developed prostate cancer and 272 men without prostate cancer who were participants in a prospective aging study (Gerontology Research Center of the National Institute on Aging, the Baltimore Longitudinal Study of Aging) and the case series of 389 consecutive men treated surgically for nonpalpable prostate cancer. Main Outcome Measures.-Probability of a PSA conversion to 4.1 to 5.0 ng/mL and to greater than 5.0 ng/mL at 2 and 4 years and probability of detecting curable prostate cancer by age and PSA level. Results.-When the pretreatment PSA level was less than or equal to 4.0 ng/mL, nonpalpable prostate cancers were highly likely (34/36, 94%) to be curable (organ-confined or capsular penetration with Gleason score <7 and negative margins), and the majority (25/36, 69%) were small cancers (confined tumor less than or equal to 0.5 cm(3) with no Gleason pattern 4 or 5). When the pretreatment PSA level was greater than 4.0 ng/mL and less than or equal to 5.0 ng/mL, cancers were highly likely to be curable (32/36, 89%), and a minority were small cancers (12/36, 33%), When the pretreatment PSA level was greater than 5.0 ng/mL, 96 (30%) of 317 cancers were noncurable. The PSA conversion (for cancer cases) to a level at which cure is less likely (>5.0 ng/mL) is rare (0%) after 2 or 4 years when the initial PSA is less than 2.0 ng/mL. PSA conversion to a range at which cancers are likely to be curable and less likely to be small (4.1-5.0 ng/mL) is rare after 2 years (0%-4%) when the baseline PSA level is less than 2.0 ng/mL but common when the baseline PSA level is between 2.1 and 3.0 ng/mL (27%) or 3.1 and 4.0 ng/mL (36%). Conclusions.-These data suggest that for men with no cancer suspected on digital rectal examination, a PSA level of 4.0 to 5.0 ng/mL is an acceptable range for maintaining the detection of curable prostate cancer and a 2-year PSA testing interval is not likely to miss a curable prostate cancer when the initial PSA level is less than 2.0 ng/mL. Recognizing that 70% of a screened population between the ages of 50 years and 70 years have PSA levels less than 2.0 ng/mL, elimination of annual PSA testing for these men would result in large health care cost savings.	JOHNS HOPKINS UNIV, JOHNS HOPKINS HOSP,JAMES BUCHANAN BRADY UROL INST, SCH MED,DEPT PATHOL, BALTIMORE, MD 21287 USA; NIA, GERONTOL RES CTR, BALTIMORE, MD 21224 USA; MERCK RES LABS, DEPT EPIDEMIOL, BLUE BELL, PA USA	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Merck & Company	Carter, HB (corresponding author), JOHNS HOPKINS UNIV, JOHNS HOPKINS HOSP, JAMES BUCHANAN BRADY UROL INST, SCH MED, DEPT UROL, BALTIMORE, MD 21287 USA.		Fozard, James Leonard/B-3660-2009					CARTER HB, 1995, UROLOGY, V45, P591, DOI 10.1016/S0090-4295(99)80049-1; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; EPSTEIN JI, 1993, CANCER-AM CANCER SOC, V71, P3582, DOI 10.1002/1097-0142(19930601)71:11<3582::AID-CNCR2820711120>3.0.CO;2-Y; EPSTEIN JI, 1993, J UROLOGY, V150, P135, DOI 10.1016/S0022-5347(17)35415-0; Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Humphrey PA, 1996, J UROLOGY, V155, P816, DOI 10.1016/S0022-5347(01)66316-X; JACOBSEN SJ, 1995, UROLOGY, V45, P447, DOI 10.1016/S0090-4295(99)80014-4; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860; PARTIN AW, 1989, J UROLOGY, V141, P341, DOI 10.1016/S0022-5347(17)40761-0; Prestigiacomo AF, 1996, J UROLOGY, V155, P1977, DOI 10.1016/S0022-5347(01)66067-1; Shock N, 1984, NIH PUBLICATION; Smith DS, 1996, JAMA-J AM MED ASSOC, V276, P1309, DOI 10.1001/jama.276.16.1309; STAMEY TA, 1993, CANCER, V71, P933, DOI 10.1002/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L; Stone CJ, 1985, P STAT COMP SECT AM, P45; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P119	20	125	128	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	1997	277	18					1456	1460		10.1001/jama.277.18.1456	http://dx.doi.org/10.1001/jama.277.18.1456			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX852	9145718				2022-12-28	WOS:A1997WX85200030
J	Craft, I				Craft, I			An ethical dilemma - Should egg donors be paid? An ''inconvenience allowance'' would solve the egg shortage	BRITISH MEDICAL JOURNAL			English	Article											Craft, I (corresponding author), LONDON GYNAECOL & FERTIL CTR,COZENS HOUSE,112A HARLEY ST,LONDON W1N 1AF,ENGLAND.			johnson, martin/0000-0002-5906-5883				Craft I, 1994, Med Leg J, V62 ( Pt 2), P81; CRAFT I, 1994, INDEPENDENT      AUG; *HUM FERT EMBR AUT, 1996, CH966 HFEA; *HUM FERT EMBR AUT, 1995, CH954 HFEA; KRAFT I, 1995, INDEPENDENT     1102	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1400	1401						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ169	9161317				2022-12-28	WOS:A1997WZ16900034
J	Sperber, AD; Weitzman, S				Sperber, AD; Weitzman, S			Mind over matter about keeping warm	LANCET			English	Editorial Material									SOROKA MED CTR,DEPT GASTROENTEROL,IL-84101 BEER SHEVA,ISRAEL; SOROKA MED CTR,DEPT EPIDEMIOL & HLTH SERV EVALUAT,IL-84101 BEER SHEVA,ISRAEL; BEN GURION UNIV NEGEV,FAC HLTH SCI,IL-84101 BEER SHEVA,ISRAEL	Ben Gurion University; Soroka Medical Center; Ben Gurion University; Soroka Medical Center; Ben Gurion University	Sperber, AD (corresponding author), SOROKA MED CTR,UNIT HLTH PROMOT & DIS PREVENT,IL-84101 BEER SHEVA,ISRAEL.		Sperber, Ami/S-7873-2019; Sperber, Ami/G-1693-2018	Sperber, Ami/0000-0002-7634-3689				Hennekens C.H., 1987, EPIDEMIOLOGY MED; KAHNEMANN D, 1982, JUDGMENT CERTAINTY; SLOME C, 1986, BASIC EPIDEMIOLOGICA; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0; ZARLING EJ, 1983, JAMA-J AM MED ASSOC, V250, P1177	7	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1337	1338		10.1016/S0140-6736(05)63197-2	http://dx.doi.org/10.1016/S0140-6736(05)63197-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149691				2022-12-28	WOS:A1997WY34200003
J	Parente, F; Maconi, G; Imbesi, V; Sangaletti, O; Poggio, M; Rossi, E; Duca, P; Porro, GB				Parente, F; Maconi, G; Imbesi, V; Sangaletti, O; Poggio, M; Rossi, E; Duca, P; Porro, GB			Helicobacter pylori infection and coagulation in healthy people	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK-FACTORS; CORONARY HEART-DISEASE		UNIV MILAN,L SACCO HOSP,DEPT GASTROENTEROL,I-20157 MILAN,ITALY; UNIV MILAN,L SACCO HOSP,DEPT HAEMATOL,I-20157 MILAN,ITALY; UNIV MILAN,DEPT MED STAT & BIOMETRY,I-20157 MILAN,ITALY	University of Milan; Luigi Sacco Hospital; University of Milan; Luigi Sacco Hospital; University of Milan			Maconi, Giovanni/V-7836-2017; Duca, Piergiorgio/S-7525-2017	Maconi, Giovanni/0000-0003-0810-4026; Duca, Piergiorgio/0000-0003-4499-8805				MANNUCCI PM, 1992, THROMB HAEMOSTASIS, V67, P200; MENDALL MA, 1994, BRIT HEART J, V71, P437; MURRAY LJ, 1995, BRIT HEART J, V74, P497; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836	5	35	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 3	1997	314	7090					1318	1319		10.1136/bmj.314.7090.1318	http://dx.doi.org/10.1136/bmj.314.7090.1318			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX975	9158468	Green Published, Green Submitted			2022-12-28	WOS:A1997WX97500024
J	Swales, JD				Swales, JD			Science in a health service	LANCET			English	Article											Swales, JD (corresponding author), DEPT HLTH,RICHMOND HOUSE,LONDON SW1A 2NS,ENGLAND.							COMROE JH, 1983, EXPLORING HEART DISC, P318; Gibbons M., 1994, NEW PRODUCITON KNOWL; HAQ IU, 1996, CLIN SCI, V91, P399; HUXLEY TH, 1991, SCI CULTURE OTHER ES, P325; IRVINE D, 1994, OXFORD MED COMPANION, P251; Johannesson M, 1997, NEW ENGL J MED, V336, P332, DOI 10.1056/NEJM199701303360503; Klein R, 1996, QJM-MON J ASSOC PHYS, V89, P85, DOI 10.1093/oxfordjournals.qjmed.a030142; Maynard A, 1997, LANCET, V349, P126, DOI 10.1016/S0140-6736(96)05153-7; MCNEIL BJ, 1978, NEW ENGL J MED, V299, P1397, DOI 10.1056/NEJM197812212992506; SMITH R, 1987, BRIT MED J, V295, P1335, DOI 10.1136/bmj.295.6609.1335; SWALES JD, 1995, GROWTH MED SCI LESSO; Ubel PA, 1996, NEW ENGL J MED, V334, P1174, DOI 10.1056/NEJM199605023341807; WENNBERG J, 1990, NEW ENGL J MED, V333, P1202; WHITEHEAD AN, 1934, NATURE CONSCIOUSNESS, P16; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; 1981, LANCET, V1, P494	16	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1319	1321		10.1016/S0140-6736(97)02260-5	http://dx.doi.org/10.1016/S0140-6736(97)02260-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142079				2022-12-28	WOS:A1997WW89900045
J	Wilkins, MR; Redondo, J; Brown, LA				Wilkins, MR; Redondo, J; Brown, LA			The natriuretic-peptide family	LANCET			English	Article							ANGIOTENSIN-CONVERTING ENZYME; CONGESTIVE-HEART-FAILURE; NEUTRAL ENDOPEPTIDASE; BLOOD-PRESSURE; TRANSGENIC MICE; C-RECEPTOR; HYPERTENSION; INHIBITION; BRAIN; RATS				Wilkins, MR (corresponding author), ROYAL POSTGRAD MED SCH, DEPT CLIN PHARMACOL, DU CANE RD, LONDON W12 0NN, ENGLAND.							ANANDSRIVASTAVA MB, 1993, PHARMACOL REV, V45, P455; ANDERSON JV, 1986, CLIN SCI, V70, P507, DOI 10.1042/cs0700507; Arakawa N, 1996, J AM COLL CARDIOL, V27, P1656, DOI 10.1016/0735-1097(96)00067-8; Darbar D, 1996, AM J CARDIOL, V78, P284, DOI 10.1016/S0002-9149(96)00278-0; Davidson NC, 1996, AM J CARDIOL, V77, P828, DOI 10.1016/S0002-9149(97)89176-X; ESPINER EA, 1995, ENDOCRIN METAB CLIN, V24, P481, DOI 10.1016/S0889-8529(18)30028-8; FAVRAT B, 1995, J HYPERTENS, V13, P797; FRENCH JF, 1995, J CARDIOVASC PHARM, V26, P107, DOI 10.1097/00005344-199507000-00017; FURUYA M, 1991, BIOCHEM BIOPH RES CO, V177, P927, DOI 10.1016/0006-291X(91)90627-J; Gonzalez W, 1996, J PHARMACOL EXP THER, V278, P573; HARRIS PJ, 1987, NATURE, V326, P697, DOI 10.1038/326697a0; Hunt PJ, 1996, J CLIN ENDOCR METAB, V81, P3871, DOI 10.1210/jc.81.11.3871; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; JANSSEN WMT, 1989, HYPERTENSION, V13, P640, DOI 10.1161/01.HYP.13.6.640; John SWM, 1996, AM J PHYSIOL-REG I, V271, pR109, DOI 10.1152/ajpregu.1996.271.1.R109; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; KENNY AJ, 1993, BIOCHEM J, V291, P83, DOI 10.1042/bj2910083; Kishimoto I, 1996, P NATL ACAD SCI USA, V93, P6215, DOI 10.1073/pnas.93.12.6215; KLINGER JR, 1993, J APPL PHYSIOL, V75, P198, DOI 10.1152/jappl.1993.75.1.198; KOEPKE JP, 1989, J PHARMACOL EXP THER, V249, P172; KOLLER KJ, 1992, CIRCULATION, V86, P1081, DOI 10.1161/01.CIR.86.4.1081; Kugiyama K, 1996, ARTERIOSCL THROM VAS, V16, P1080, DOI 10.1161/01.ATV.16.8.1080; LEVIN ER, 1993, AM J PHYSIOL, V264, pE483, DOI 10.1152/ajpendo.1993.264.4.E483; LIN KF, 1995, HYPERTENSION, V26, P847, DOI 10.1161/01.HYP.26.6.847; LOPEZ MJ, 1995, NATURE, V378, P65, DOI 10.1038/378065a0; LU B, 1995, J EXP MED, V181, P2271, DOI 10.1084/jem.181.6.2271; Maack T, 1996, KIDNEY INT, V49, P1732, DOI 10.1038/ki.1996.257; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.physiol.54.1.11; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; Marie C, 1995, J PHARMACOL EXP THER, V275, P1324; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; MUNZEL T, 1992, CIRCULATION, V86, P1089, DOI 10.1161/01.CIR.86.4.1089; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; RAPP JP, 1995, HYPERTENSION, V25, P1121, DOI 10.1161/01.HYP.25.6.1121; RINS BA, 1996, CURR OPIN NEPHROL HY, V5, P170; ROQUES BP, 1993, PHARMACOL REV, V45, P87; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; SAPER CB, 1995, J COMP NEUROL, V356, P166, DOI 10.1002/cne.903560203; SCHULZKNAPPE P, 1988, KLIN WOCHENSCHR, V66, P752, DOI 10.1007/BF01726570; Seymour AA, 1996, J PHARMACOL EXP THER, V276, P708; SEYMOUR AA, 1995, CLIN EXP PHARMACOL P, V22, P63, DOI 10.1111/j.1440-1681.1995.tb01920.x; STEINHELPER ME, 1990, HYPERTENSION, V16, P301, DOI 10.1161/01.HYP.16.3.301; STINGO AJ, 1992, AM J PHYSIOL, V263, pH1318, DOI 10.1152/ajpheart.1992.263.4.H1318; STRUTHERS AD, 1994, BMJ-BRIT MED J, V308, P1615, DOI 10.1136/bmj.308.6944.1615; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; TRIPPODO NC, 1995, J PHARMACOL EXP THER, V275, P745; VESELY DL, 1994, CIRCULATION, V90, P1129, DOI 10.1161/01.CIR.90.3.1129; VESELY DL, 1992, ATRIAL NATRIURETIC H; WADA A, 1994, CIRCULATION, V89, P2232, DOI 10.1161/01.CIR.89.5.2232; WILKINS MR, 1993, KIDNEY INT, V43, P273, DOI 10.1038/ki.1993.44; WILKINS MR, 1990, J CLIN INVEST, V85, P1274, DOI 10.1172/JCI114564; Yamamoto K, 1996, HYPERTENSION, V28, P988, DOI 10.1161/01.HYP.28.6.988; YOSHIMURA M, 1991, CIRCULATION, V84, P1581, DOI 10.1161/01.CIR.84.4.1581; ZHANG PL, 1994, J AM SOC NEPHROL, V5, P1099	55	173	199	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 3	1997	349	9061					1307	1310		10.1016/S0140-6736(96)07424-7	http://dx.doi.org/10.1016/S0140-6736(96)07424-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142076				2022-12-28	WOS:A1997WW89900042
J	Brown, MS; Goldstein, JL				Brown, MS; Goldstein, JL			The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor	CELL			English	Review							COENZYME-A REDUCTASE; LEUCINE ZIPPER PROTEIN; BINDING; ELEMENT; DOMAIN; GENE; ACTIVATION; DEGRADATION; EXPRESSION; PROMOTER				Brown, MS (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUCHER NLR, 1960, BIOCHIM BIOPHYS ACTA, V40, P491, DOI 10.1016/0006-3002(60)91390-1; CHANG TY, 1997, IN PRESS CURR OPIN L; CHIN J, 1981, J BIOL CHEM, V256, P6304; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; EVANS MJ, 1993, MOL CELL BIOL, V13, P5175, DOI 10.1128/MCB.13.9.5175; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOLDSTEIN JL, 1974, P NATL ACAD SCI USA, V71, P4288, DOI 10.1073/pnas.71.11.4288; GOULD RG, 1953, J BIOL CHEM, V201, P519; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P481, DOI 10.1007/BF02255839; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; KEYS A, 1975, ATHEROSCLEROSIS, V22, P149, DOI 10.1016/0021-9150(75)90001-5; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; Lamb BT, 1997, NAT MED, V3, P28, DOI 10.1038/nm0197-28; LISCUM L, 1985, J BIOL CHEM, V260, P522; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Miserez AR, 1997, GENOMICS, V40, P31, DOI 10.1006/geno.1996.4525; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Murre  C., 1992, TRANSCRIPTIONAL REGU, P861; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Nohturfft A, 1996, P NATL ACAD SCI USA, V93, P13709, DOI 10.1073/pnas.93.24.13709; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Osborne TF, 1995, CRIT REV EUKAR GENE, V5, P317, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.50; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SATO R, 1994, J BIOL CHEM, V269, P17267; Schoenheimer R, 1933, J BIOL CHEM, V103, P439; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; SIPERSTEIN MD, 1966, J BIOL CHEM, V241, P602; SMALL DM, 1974, SCIENCE, V185, P222, DOI 10.1126/science.185.4147.222; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SPADY DK, 1993, ANNU REV NUTR, V13, P355, DOI [10.1146/annurev.nutr.13.1.355, 10.1146/annurev.nu.13.070193.002035]; Theopold U, 1996, P NATL ACAD SCI USA, V93, P1195, DOI 10.1073/pnas.93.3.1195; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	62	2838	2993	6	209	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					331	340		10.1016/S0092-8674(00)80213-5	http://dx.doi.org/10.1016/S0092-8674(00)80213-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150132	Bronze			2022-12-28	WOS:A1997WX89900003
J	Brzana, RJ; Koch, KL				Brzana, RJ; Koch, KL			Gastroesophageal reflux disease presenting with intractable nausea	ANNALS OF INTERNAL MEDICINE			English	Article							ESOPHAGITIS; DIAGNOSIS; SYMPTOMS; ACID	Background: Typical symptoms of gastroesophageal reflux disease are heartburn and regurgitation. A subset of patients present with atypical symptoms, such as chest pain, cough, wheezing, and hoarseness. Objective: To review the clinical presentation and treatment of patients who presented with nausea as the primary symptom of gastroesophageal reflux disease. Design: Case series. Setting: Outpatient department of a university hospital. Patients: 10 outpatients who had chronic, intractable nausea and had not responded to empirical therapies. Measurements: Patients were evaluated by esophagogastroduodenoscopy, 24-hour esophageal pH studies, gastric-emptying tests, electrogastrography, or a Bernstein test. Results: Abnormal acid reflux was found to be the cause of intractable nausea in all 10 patients. In 5 of the 10 patients, esophagitis was documented by esophagogastroduodenoscopy. Six patients had abnormal results on the 24-hour esophageal pH study. In these 6 patients, 32 of 33 episodes of nausea were accompanied by an episode of acid reflux. One patient had positive results on the Bernstein test. Nausea resolved after treatment with omeprazole in 7 patients, after treatment with cisapride or ranitidine in 2 patients, and after Nissen fundoplication in 1 patient. Conclusions: Intractable nausea is an atypical symptom that can occur in a subset of patients with gastroesophageal reflux disease. A 24-hour esophageal pH study should be considered in patients who have unexplained nausea but normal findings on esophagogastroduodenoscopy, a gastric-emptying test, and electrogastrography. Nausea related to gastroesophageal reflux disease resolves or is markedly reduced with proton-pump inhibitors or promotility drugs.	PENN STATE UNIV, MILTON S HERSHEY MED CTR, DIV GASTROENTEROL, HERSHEY, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health								CLOUD ML, 1991, AM J GASTROENTEROL, V86, P1735; COLLEN MJ, 1987, GASTROENTEROLOGY, V92, P1350; DAVIES HA, 1985, J CLIN GASTROENTEROL, V7, P477, DOI 10.1097/00004836-198512000-00007; DEMEESTER TR, 1980, J THORAC CARDIOV SUR, V79, P656; FITZGERALD JM, 1989, CAN MED ASSOC J, V140, P520; HORROCKS JC, 1978, GUT, V19, P19, DOI 10.1136/gut.19.1.19; JOHNSSON F, 1987, GUT, V28, P1145, DOI 10.1136/gut.28.9.1145; JOHNSSON F, 1987, SCAND J GASTROENTERO, V22, P714, DOI 10.3109/00365528709011148; KLAUSER AG, 1989, AM J GASTROENTEROL, V84, P362; KLAUSER AG, 1990, LANCET, V335, P205, DOI 10.1016/0140-6736(90)90287-F; KOCH KL, 1989, AM J GASTROENTEROL, V84, P1069; Koch KL, 1993, ILLUSTRATED GUIDE GA, P290; ROBERTSON DAF, 1987, GUT, V28, P946, DOI 10.1136/gut.28.8.946; ROKKAS T, 1988, AM J GASTROENTEROL, V83, P629; SCHOFIELD PM, 1989, DIGESTION, V42, P70, DOI 10.1159/000199828; SCHROEDER PL, 1995, ANN INTERN MED, V122, P809, DOI 10.7326/0003-4819-122-11-199506010-00001; SHAY SS, 1992, AM J GASTROENTEROL, V87, P1094; YOU CH, 1980, GASTROENTEROLOGY, V79, P311	18	37	37	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1997	126	9					704	707		10.7326/0003-4819-126-9-199705010-00005	http://dx.doi.org/10.7326/0003-4819-126-9-199705010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW147	9139556				2022-12-28	WOS:A1997WW14700005
J	Smedley, J; Egger, P; Cooper, C; Coggon, D				Smedley, J; Egger, P; Cooper, C; Coggon, D			Prospective cohort study of predictors of incident low back pain in nurses	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-POPULATION; OCCUPATION; WORKERS; RISK; EPIDEMIOLOGY; INJURIES; HEIGHT	Objective: To assess the impact of handling patients and indicators of individual susceptibility on risk of low back pain in nurses. Design: Prospective cohort study with follow up by repeated self administered questionnaires every three months over two years. Setting: NHS university hospitals trust. Subjects: 961 female nurses who had been free from low back pain for at least one month at the time of completing a baseline questionnaire. Main outcome measures: Incidence of new low back pain during follow up and of pain leading to absence from work. Results: Of 838 women who provided data suitable for analysis, 322 (38%) developed low back pain during follow up (mean 18.6 months), including 93 (11%) whose pain led to absence from work. The strongest predictor of new low back pain was earlier history of the symptom, and risk was particularly high if previous pain had lasted for over a month in total and had occurred within the 12 months before entry to the study (incidence during follow up 66%). Frequent low mood at baseline was strongly associated with subsequent absence from work for back pain (odds ratio 3.4; 95% confidence interval 1.4 to 8.2). After adjustment for earlier history of back pain and other potential confounders, risk was higher in nurses who reported frequent manual transfer of patients between bed and chair, manual repositioning of patients on the bed, and lifting patients in or out of the bath with a hoist. Conclusions: Of the indicators of individual susceptibility that were examined, only history of back trouble was sufficiently predictive to justify selective exclusion of some applicants for nursing posts. The main route to prevention of back disorders among nurses is likely to lie in improved ergonomics.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND	University of Southampton								ALLISON PD, 1988, SOCIOL METHODS RES, V15, P355; ASTRAND NE, 1987, BRIT J IND MED, V44, P327; BATY D, 1987, INT J NURS STUD, V24, P239; BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND S, V170, P1; BIERINGSORENSEN F, 1984, SPINE, V9, P106, DOI 10.1097/00007632-198403000-00002; BIERINGSORENSEN F, 1983, SCAND J REHABIL MED, V15, P71; BIGOS SJ, 1991, SPINE, V16, P1, DOI 10.1097/00007632-199101000-00001; BURDORF A, 1991, ERGONOMICS, V34, P909, DOI 10.1080/00140139108964834; Clinical Standards Advisory Group, 1994, EP REV EP COST BACK; CROFT P, 1994, BR J RHEUMATOL S1, V33, P105; DILLANE JB, 1966, BRIT MED J, V2, P82, DOI 10.1136/bmj.2.5505.82; EGGER PJ, 1992, THESIS U SOUTHAMPTON; FRYMOYER JW, 1980, SPINE, V5, P419, DOI 10.1097/00007632-198009000-00005; GYNTELBERG F, 1974, DAN MED B, V21, P109; HARBER P, 1985, J OCCUP ENVIRON MED, V27, P518; HIRSCH C, 1969, CLIN ORTHOPAEDICS, V63, P171; Horal J, 1969, Acta Orthop Scand Suppl, V118, P1; HULT L, 1954, Acta Orthop Scand Suppl, V17, P1; KUH DJL, 1993, BRIT J RHEUMATOL, V32, P911; LLOYD DCEF, 1983, J SOC OCCUP MED, V33, P66; MAGORA A, 1973, SCAND J REHABIL MED, V5, P191; MAGORA A, 1973, SCAND J REHABIL MED, V5, P186; NAGI SZ, 1973, J CHRON DIS, V26, P769, DOI 10.1016/0021-9681(73)90012-X; PUNNETT L, 1991, SCAND J WORK ENV HEA, V17, P337, DOI 10.5271/sjweh.1700; SMEDLEY J, 1995, OCCUP ENVIRON MED, V52, P160, DOI 10.1136/oem.52.3.160; SUADICANI P, 1994, OCCUP MED-OXFORD, V44, P217, DOI 10.1093/occmed/44.4.217; SVENSSON HO, 1989, SPINE, V14, P517, DOI 10.1097/00007632-198905000-00008; UNDEUTSCH K, 1982, SCAND J WORK ENV H S, V1, P92; VENNING PJ, 1987, J OCCUP ENVIRON MED, V29, P820; VIDEMAN T, 1984, SPINE, V9, P400, DOI 10.1097/00007632-198405000-00013; WALSH K, 1992, J EPIDEMIOL COMMUN H, V46, P227, DOI 10.1136/jech.46.3.227; WALSH K, 1991, SCAND J WORK ENV HEA, V17, P420, DOI 10.5271/sjweh.1680; YASSI A, 1995, OCCUP MED-OXFORD, V45, P215, DOI 10.1093/occmed/45.4.215; ZWERLING C, 1993, SPINE, V18, P1242, DOI 10.1097/00007632-199307000-00020	34	189	192	0	21	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 26	1997	314	7089					1225	1228		10.1136/bmj.314.7089.1225	http://dx.doi.org/10.1136/bmj.314.7089.1225			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW718	9154024	Green Published			2022-12-28	WOS:A1997WW71800015
J	Calman, KC				Calman, KC			Equity, poverty and health for all	BRITISH MEDICAL JOURNAL			English	Article											Calman, KC (corresponding author), DEPT HLTH,LONDON SW1A 2NS,ENGLAND.		Calman, Kenneth C/C-9855-2010					CALMAN KC, 1984, J MED ETHICS, V10, P124, DOI 10.1136/jme.10.3.124; *DEP HLTH, 1995, VAR HLTH WHAT CAN DE; DOWNIE RS, 1994, HLTH RESPECT; Galbraith John K., 1996, GOOD SOC HUMANE AGEN; Hart HLA, 2012, CONCEPT LAW, P208; Rawls J., 1972, SOCIAL JUSTICE LIBER; Rowntree B.S., 1902, POVERTY STUDY TOWN L, V2nd ed.; Townsend P, 1992, INEQUALITIES HLTH BL	8	11	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 19	1997	314	7088					1187	1191		10.1136/bmj.314.7088.1187a	http://dx.doi.org/10.1136/bmj.314.7088.1187a			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WV705	9146399	Green Published			2022-12-28	WOS:A1997WV70500034
J	Davies, A; Huxley, P				Davies, A; Huxley, P			Survey of general practitioners' opinions on treatment of opiate users	BRITISH MEDICAL JOURNAL			English	Article											Davies, A (corresponding author), UNIV MANCHESTER,SCH PSYCHIAT & BEHAV SCI,MANCHESTER M13 9PL,LANCS,ENGLAND.		Huxley, Peter/AAE-7007-2019					BELL G, 1990, HLTH TRENDS, V2, P56; DONMALL MC, 1993, DRUGLINK, V8, P8; GLANZ A, 1986, BRIT MED J, V293, P486, DOI 10.1136/bmj.293.6545.486; Kirkwood B., 1988, BR K ESSENTIALS MED; *MED WORK GROUP DR, 1994, GUID GOOD CLIN PRACT	5	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 19	1997	314	7088					1173	1174		10.1136/bmj.314.7088.1173	http://dx.doi.org/10.1136/bmj.314.7088.1173			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV705	9146392	Green Published			2022-12-28	WOS:A1997WV70500026
J	Hillis, DM				Hillis, DM			Evolution - Biology recapitulates phylogeny	SCIENCE			English	Editorial Material							OUTBREAK; TAXONOMY				Hillis, DM (corresponding author), UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712, USA.		Hillis, David M/B-4278-2008; Hillis, David/L-5421-2019					Becerra JX, 1997, SCIENCE, V276, P253, DOI 10.1126/science.276.5310.253; BROOKS DR, 1991, PHYLOGNY ECOLOGY BEH; CHASE MW, 1993, ANN MO BOT GARD, V80, P528, DOI 10.2307/2399846; CHEVERUD JM, 1985, EVOLUTION, V39, P1335, DOI 10.1111/j.1558-5646.1985.tb05699.x; Cornish-Bowden A., 1990, CONTROL METABOLIC PR; COX DR, 1961, 4TH P BERK S MATH ST, V1, P105; Darwin C., ORIGIN SPECIES; DEQUEIROZ K, 1990, SYST ZOOL, V39, P307, DOI 10.2307/2992353; DEQUEIROZ K, 1992, ANNU REV ECOL SYST, V23, P449, DOI 10.1146/annurev.ecolsys.23.1.449; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; GARLAND T, 1992, SYST BIOL, V41, P18, DOI 10.2307/2992503; Gibbs A, 1995, MOL BASIS VIRUS EVOL, DOI New York, NY, USA; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Hillis DM, 1996, NATURE, V383, P130, DOI 10.1038/383130a0; Hillis DM., 1996, MOL SYSTEMATICS, V2nd; HJELLE B, 1994, J VIROL, V68, P592, DOI 10.1128/JVI.68.2.592-596.1994; Huelsenbeck John P., 1996, P19; Huelsenbeck JP, 1997, SCIENCE, V276, P227, DOI 10.1126/science.276.5310.227; HUEY RB, 1987, EVOLUTION, V41, P1098, DOI 10.1111/j.1558-5646.1987.tb05879.x; LI WH, 1991, FUNDAMENTALS MOL EVO; Martins E. P., 1996, PHYLOGENIES COMP MET; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; Pierce VA, 1997, SCIENCE, V276, P256, DOI 10.1126/science.276.5310.256; RYAN MJ, 1995, SCIENCE, V269, P390, DOI 10.1126/science.269.5222.390; Smith JS, 1996, CLIN MICROBIOL REV, V9, P166, DOI 10.1128/CMR.9.2.166; Van Valen L., 1973, EVOL THEORY REV, V1, P1, DOI DOI 10.1038/344864A0; Vogel G, 1997, SCIENCE, V275, P1559, DOI 10.1126/science.275.5306.1559	28	17	18	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					218	219		10.1126/science.276.5310.218	http://dx.doi.org/10.1126/science.276.5310.218			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9132943				2022-12-28	WOS:A1997WT92500031
J	Forte, P; Copland, M; Smith, LM; Milne, E; Sutherland, J; Benjamin, N				Forte, P; Copland, M; Smith, LM; Milne, E; Sutherland, J; Benjamin, N			Basal nitric oxide synthesis in essential hypertension	LANCET			English	Article							MONOMETHYL-L-ARGININE; NITRATE; THERAPY; AIR	Background There is indirect evidence that nitric oxide (NO) synthesis in vascular endothelium of patients with hypertension is altered. The aim of this study was to estimate more directly NO production in patients with untreated essential hypertension by measurement of synthesis of inorganic nitrate, which is the end product of NO oxidation in humans. Two separate studies were undertaken in patients with hypertension and appropriate healthy controls.(1) Methods In the first study, ten patients and 13 controls were given a diet containing 82 mu moles nitrate per day for 2 days, with urinary and plasma nitrate measurement and 24 h ambulatory blood pressure monitoring on the 2nd day. In the second study, 11 patients and 11 controls were studied in the postabsorptive state; a bolus of 200 mg L-[N-15](2) arginine was administered intravenously over 10 min. 24 h ambulatory blood pressure monitoring was done and complete urine collections were made for the next 36 h. Findings In the first study, 24 h urinary nitrate excretion was lower in the hypertensive patients than in the control group (mean 450 [SEM 37] vs 760 mu moles [77] per 24 h; p<0001). There was an inverse correlation between average mean daytime ambulatory blood pressure and nitrate excretion (p=0.007; r(2)=-0.73). In the second study, mean 36 h urinary N-15 nitrate excretion was significantly lower in the hypertensive than in the control group (1313 [50] vs 2133 [142] pmoles; p<0.001). There was an inverse correlation also between average mean daytime ambulatory blood pressure and 24 h urinary N-15 nitrate excretion expressed per mmole of creatinine (p=0.002, r(2)=-0.59). In addition, total urinary N-15 nitrate excretion in the hypertensive group was significantly higher in women than in men (285 [16] vs 198 [14] mu g N-15 nitrate per kg; p=0.026). Interpretation These data suggest that whole-body NO production in patients with essential hypertension is diminished under basal conditions. The origin of the NO we measured is not known, and we cannot tell whether the impaired synthesis is primary or secondary to a rise in blood pressure.	ST BARTHOLOMEWS & ROYAL SCH MED & DENT,DEPT CLIN PHARMACOL,LONDON EC1M 6BQ,ENGLAND; UNIV ABERDEEN,DEPT MED & THERAPEUT,ABERDEEN,SCOTLAND; ROWETT RES INST,ABERDEEN,SCOTLAND	University of London; Queen Mary University London; University of Aberdeen; University of Aberdeen								ARCHER S, 1993, FASEB J, V7, P349, DOI 10.1096/fasebj.7.2.8440411; BROOKS PD, 1989, SOIL SCI SOC AM J, V53, P1707, DOI 10.2136/sssaj1989.03615995005300060016x; CALVER A, 1992, J HYPERTENS, V10, P1025; CHOWIENCZYK PJ, 1993, BRIT J PHARMACOL, V110, P736, DOI 10.1111/j.1476-5381.1993.tb13873.x; CHOWIENCZYK PJ, 1994, J HYPERTENS, V12, P1322; COCKCROFT JR, 1994, NEW ENGL J MED, V330, P1036, DOI 10.1056/NEJM199404143301502; Crcager MA, 1992, J VASC RES, V29, P97; DUFF F, 1953, J PHYSIOL-LONDON, V120, P160, DOI 10.1113/jphysiol.1953.sp004883; GIBALDI M, 1982, PHARMACOKINETICS DRU, V1; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HAUCK R. D., 1958, SOIL SCI, V86, P287, DOI 10.1097/00010694-195811000-00011; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HIRATA Y, 1985, BIOCHEM BIOPH RES CO, V128, P538, DOI 10.1016/0006-291X(85)90080-4; HISHIKAWA K, 1994, HYPERTENSION, V24, P386; Jilma B, 1996, LIFE SCI, V58, P469, DOI 10.1016/0024-3205(95)02311-9; Jungersten L, 1996, CLIN PHYSIOL, V16, P369, DOI 10.1111/j.1475-097X.1996.tb00726.x; LYONS D, 1994, J HYPERTENS, V12, P1047; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; *NAT AC SCI COMM N, 1981, HLTH EFFECTS NITRATE; PANZA JA, 1993, J AM COLL CARDIOL, V21, P1145, DOI 10.1016/0735-1097(93)90238-V; SCHILLING J, 1994, EUR RESPIR J, V7, P467, DOI 10.1183/09031936.94.07030467; Taddei S, 1996, CIRCULATION, V94, P1298, DOI 10.1161/01.CIR.94.6.1298; TAKAHASHI H, 1992, J CARDIOVASC PHARM, V20, pS214, DOI 10.1097/00005344-199204002-00061; TESCH JW, 1976, J CHROMATOGR, V126, P743, DOI 10.1016/S0021-9673(01)84117-0; VALLANCE P, 1992, J CARDIOVASC PHARM, V20, pS60, DOI 10.1097/00005344-199204002-00018; VALLANCE P, 1995, LANCET, V346, P153, DOI 10.1016/S0140-6736(95)91211-8; VALLANCE P, 1989, LANCET, V2, P997; WENNMALM A, 1993, CIRC RES, V73, P1121, DOI 10.1161/01.RES.73.6.1121; WESTFELT UN, 1995, BRIT J PHARMACOL, V114, P1621, DOI 10.1111/j.1476-5381.1995.tb14948.x; Winquist R J, 1984, J Hypertens, V2, P541, DOI 10.1097/00004872-198410000-00015	30	316	332	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					837	842		10.1016/S0140-6736(96)07631-3	http://dx.doi.org/10.1016/S0140-6736(96)07631-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121259				2022-12-28	WOS:A1997WP40300012
J	Arnett, D; Bazan, G				Arnett, D; Bazan, G			Nucleosynthesis in stars: Recent developments	SCIENCE			English	Article							GAMMA-RAY LINE; NEUTRINO-DRIVEN WINDS; METAL-POOR STARS; SUPERNOVA 1987A; COMPTEL OBSERVATIONS; PROTONEUTRON STARS; HALO STARS; EMISSION; SN-1987A; CONVECTION	The development of new observational, experimental, and computational technologies is changing our understanding of the origins of the elements by thermonuclear burning in stars. Gamma-ray lines from newly made radioactive nuclei have been identified using instruments onboard low-Earth orbiting satellites. Grains in meteorites have isotopic anomalies which suggest that the grains were put together in a stellar explosion such as a supernova. Computer simulations allow such anomalies to be used to probe how these events happen. The simulations are being independently tested by experiments with high-energy density lasers, These developments are beginning to provide a quantitative diagnostic of galactic evolution, and of the epoch of formation of the first stars and galaxies.	LAWRENCE LIVERMORE NATL LAB, LIVERMORE, CA 94551 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Arnett, D (corresponding author), UNIV ARIZONA, STEWARD OBSERV, TUCSON, AZ 85721 USA.		Bazan, Guillermo/AAJ-5313-2020					Amari S, 1996, ASTROPHYS J, V470, pL101, DOI 10.1086/310306; AMARI S, 1995, ASTROPHYS J, V447, pL147, DOI 10.1086/309573; ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; ARNETT D, 1994, ASTROPHYS J, V427, P932, DOI 10.1086/174199; ARNETT D, 1989, ASTROPHYS J, V341, pL63, DOI 10.1086/185458; Arnett D., 1996, SUPERNOVAE NUCLEOSYN; ARNETT WD, 1974, ASTROPHYS J, V194, P373, DOI 10.1086/153254; ARNETT WD, 1977, ASTROPHYS J SUPPL S, V35, P145, DOI 10.1086/190472; ARNETT WD, 1988, ASTROPHYS J, V331, P377, DOI 10.1086/166564; ARNETT WD, 1989, ANNU REV ASTRON ASTR, V27, P629, DOI 10.1146/annurev.aa.27.090189.003213; ARNETT WD, 1987, ESO WORKSH SN1987A, P373; BAZAN G, 1994, ASTROPHYS J, V433, pL41, DOI 10.1086/187543; BAZAN G, IN PRESS ASTROPHYS J; BLACK DC, 1969, EARTH PLANET SC LETT, V6, P395, DOI 10.1016/0012-821X(69)90190-3; BURBIDGE EM, 1957, REV MOD PHYS, V29, P547, DOI 10.1103/RevModPhys.29.547; CAMERON AGW, 1957, CRL41 AT EN CAN LTD; Cavallo RM, 1996, ASTROPHYS J, V464, pL79, DOI 10.1086/310089; Chevalier RA, 1997, SCIENCE, V276, P1374, DOI 10.1126/science.276.5317.1374; ChristensenDalsgaard J, 1996, SCIENCE, V272, P1286, DOI 10.1126/science.272.5266.1286; Clayton D. D., 1968, PRINCIPLES STELLAR E; CLAYTON DD, 1969, ASTROPHYS J, V155, P75, DOI 10.1086/149849; COOK WR, 1988, ASTROPHYS J, V334, pL87, DOI 10.1086/185318; Cowan JJ, 1996, ASTROPHYS J, V460, pL115, DOI 10.1086/309982; DIEHL R, 1995, ASTRON ASTROPHYS, V298, P445; Diehl R, 1995, ASTRON ASTROPHYS, V298, P25; EASTMAN RG, 1991, SUPERNOVAE //, P425; ELEID MF, 1994, ASTRON ASTROPHYS, V285, P915; Gehrels N, 1988, AIP C P, V170, P87; Glanz J, 1997, SCIENCE, V276, P351, DOI 10.1126/science.276.5311.351; GRATTON RG, 1994, ASTRON ASTROPHYS, V287, P927; GUELIN M, 1995, ASTRON ASTROPHYS, V297, P183; HANUSCHIK RW, 1987, ASTRON ASTROPHYS, V192, pL29; HARKNESS R, 1991, SUPERNOVAE //, P454; Hoflich P, 1996, ASTROPHYS J, V472, pL81, DOI 10.1086/310363; HOFLICH P, 1991, SUPERNOVAE //, P415; IYUDIN AF, 1994, ASTRON ASTROPHYS, V284, pL1; JANKA HT, 1995, ASTROPHYS J, V448, pL109, DOI 10.1086/309604; Janka HT, 1996, ASTRON ASTROPHYS, V306, P167; Kaler J. B., 1989, STARS THEIR SPECTRA; Kane J, 1997, ASTROPHYS J, V478, pL75, DOI 10.1086/310556; Kippenhahn R., 1990, STELLAR STRUCTURE EV; KOEHLER S, 1996, ASTRON ASTROPHYS, V312, P33; KUNTH D, 1995, ASTRON ASTROPHYS, V297, P634; Langer GE, 1995, PUBL ASTRON SOC PAC, V107, P1177, DOI 10.1086/133676; Lauroesch JT, 1996, PUBL ASTRON SOC PAC, V108, P641, DOI 10.1086/133780; Lu LM, 1996, ASTROPHYS J SUPPL S, V107, P475, DOI 10.1086/192373; LUCY LB, 1991, SUPERNOVAE //, P82; LUCY LB, 1987, ESO WORKSH SN 1987A, P417; MAGAIN P, 1995, ASTRON ASTROPHYS, V297, P686; MAHONEY WA, 1988, ASTROPHYS J, V334, pL81, DOI 10.1086/185317; Martin CL, 1996, ASTROPHYS J, V465, P680, DOI 10.1086/177453; MATZ SM, 1988, NATURE, V331, P416, DOI 10.1038/331416a0; Mazzali PA, 1997, MON NOT R ASTRON SOC, V284, P151, DOI 10.1093/mnras/284.1.151; MAZZALI PA, 1995, ASTRON ASTROPHYS, V297, P509; MCCRAY R, 1993, ANNU REV ASTRON ASTR, V31, P175, DOI 10.1146/annurev.aa.31.090193.001135; MCWILLIAM A, 1995, ASTRON J, V109, P2757, DOI 10.1086/117486; MORRISON H, 1996, FORMATION GALACTIC H; Mowlavi N, 1996, ASTRON ASTROPHYS, V311, P803; NISSEN PE, 1994, ASTRON ASTROPHYS, V285, P440; NITTLER LR, 1995, ASTROPHYS J, V453, pL25, DOI 10.1086/309743; NITTLER LR, 1996, ASTROPHYS J, V462, pL131; Nomoto K, 1997, SCIENCE, V276, P1378, DOI 10.1126/science.276.5317.1378; NOMOTO K, 1988, PHYS REP, V163, P13, DOI 10.1016/0370-1573(88)90032-4; Oberlack U., 1996, A AS, V120, P311; PETTINI M, 1995, ASTRON ASTROPHYS, V297, P63; PINTO P, IN PRESS ASTROPHYS J; PINTO PA, 1988, ASTROPHYS J, V329, P820, DOI 10.1086/166426; REMINGTON BA, 1995, PHYS PLASMAS, V2, P241, DOI 10.1063/1.871096; REYNOLDS JH, 1964, J GEOPHYS RES, V69, P3263, DOI 10.1029/JZ069i015p03263; SANDIE WG, 1988, ASTROPHYS J, V342, pL91; SCHONFELDER V, 1996, ASTRON ASTROPHYS S, V120, P13; SCHWARZ D, 1991, SUPERNOVAE, P434; SHIGEYAMA T, 1990, ASTROPHYS J, V360, P242, DOI 10.1086/169114; SHRADER CR, 1995, PUBL ASTRON SOC PAC, V107, P606, DOI 10.1086/133600; STATHAKIS RA, 1991, SUPERNOVAE //, P95; TEEGARDEN BJ, 1989, NATURE, V339, P122, DOI 10.1038/339122a0; THIELEMANN FK, 1986, ASTRON ASTROPHYS, V158, P17; UNSOLD AOJ, 1969, SCIENCE, V163, P1015, DOI 10.1126/science.163.3871.1015; WALLERST.G, 1968, SCIENCE, V162, P625, DOI 10.1126/science.162.3854.625; WASSERBURG GJ, 1995, ASTROPHYS J, V447, pL37, DOI 10.1086/309555; WHEELER JC, 1991, ASTR SOC P, V20, P483; WITTI J, 1994, ASTRON ASTROPHYS, V286, P841; WOOSLEY SE, 1995, ASTROPHYS J SUPPL S, V101, P181, DOI 10.1086/192237; WOOSLEY SE, 1986, ANNU REV ASTRON ASTR, V24, P205, DOI 10.1146/annurev.aa.24.090186.001225	86	14	14	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1359	1362		10.1126/science.276.5317.1359	http://dx.doi.org/10.1126/science.276.5317.1359			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9161994				2022-12-28	WOS:A1997XB53300035
J	Couch, FJ; DeShano, ML; Blackwood, MA; Calzone, K; Stopfer, J; Campeau, L; Ganguly, A; Rebbeck, T; Weber, BL; Jablon, L; Cobleigh, MA; Hoskins, K; Garber, JE				Couch, FJ; DeShano, ML; Blackwood, MA; Calzone, K; Stopfer, J; Campeau, L; Ganguly, A; Rebbeck, T; Weber, BL; Jablon, L; Cobleigh, MA; Hoskins, K; Garber, JE			BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OVARIAN-CANCER; SUSCEPTIBILITY GENE; FAMILY HISTORY; CARRIERS; KINDREDS	Background To define the incidence of BRCA1 mutations among patients seen in clinics that evaluate the risk of breast cancer, we analyzed DNA samples from women seen in this setting and constructed probability tables to provide estimates of the likelihood of finding a BRCA1 mutation in individual families. Methods Clinical information, family histories, and blood for DNA analysis were obtained from 263 women with breast cancer. Conformation-sensitive gel electrophoresis and DNA sequencing were used to identify BRCA1 mutations. Results BRCA1 mutations were identified in 16 percent of women with a family history of breast cancer. Only 7 percent of women from families with a history of breast cancer but not ovarian cancer had BRCA1 mutations. The rates were higher among women from families with a history of both breast and ovarian cancer. Among family members, an average age of less than 55 years at the diagnosis of breast cancer, the presence of ovarian cancer, the presence of breast and ovarian cancer in the same woman, and Ashkenazi Jewish ancestry were all associated with an increased risk of detecting a BRCA1 mutation. No association was found between the presence of bilateral breast cancer or the number of breast cancers in a family and the detection of a BRCA1 mutation, or between the position of the mutation in the BRCA1 gene and the presence of ovarian an cancer in a family. Conclusions Among women with breast cancer and a family history of the disease, the percentage with BRCA1 coding-region mutations is less than the 45 percent predicted by genetic-linkage analysis. These results suggest that even in a referral clinic specializing in screening women from high-risk families, the majority of tests for BRCA1 mutations will be negative and therefore uninformative. (C) 1997, Massachusetts Medical Society.	UNIV PENN,DEPT MED,STELLAR CHANCE LABS 1009,PHILADELPHIA,PA 19104; UNIV PENN,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOSTAT & EPIDEMIOL,PHILADELPHIA,PA 19104; ALBERT EINSTEIN MED CTR,PHILADELPHIA,PA 19141; RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612; ROCKFORD MEM HOSP,ROCKFORD,IL; DANA FARBER CANC INST,BOSTON,MA 02115	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Yeshiva University; Rush University; Harvard University; Dana-Farber Cancer Institute			Rebbeck, Timothy/GLU-8348-2022	Rebbeck, Timothy/0000-0002-4799-1900; Calzone, Kathleen/0000-0002-2354-6810				Bapat B, 1996, AM J HUM GENET, V59, P736; Berry DA, 1997, J NATL CANCER I, V89, P227, DOI 10.1093/jnci/89.3.227; BROWNSTEIN MH, 1978, CANCER, V41, P2393, DOI 10.1002/1097-0142(197806)41:6<2393::AID-CNCR2820410644>3.0.CO;2-K; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P1548; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; EASTON DF, 1995, AM J HUM GENET, V56, P265; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; LI FP, 1988, CANCER RES, V48, P5358; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MUIR EG, 1967, BRIT J SURG, V54, P191, DOI 10.1002/bjs.1800540309; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; SLATTERY ML, 1993, JAMA-J AM MED ASSOC, V270, P1563, DOI 10.1001/jama.270.13.1563; STATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535; STREUWING JP, 1995, NAT GENET, V11, P198; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	28	535	547	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	1997	336	20					1409	1415		10.1056/NEJM199705153362002	http://dx.doi.org/10.1056/NEJM199705153362002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY577	9145677				2022-12-28	WOS:A1997WY57700002
J	Benbow, SJ; Gill, G				Benbow, SJ; Gill, G			Paroxetine and hepatotoxicity	BRITISH MEDICAL JOURNAL			English	Article											Benbow, SJ (corresponding author), UNIV LIVERPOOL,ROYAL LIVERPOOL UNIV HOSP,DEPT GERIATR MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							CASTIELLA A, 1994, AM J GASTROENTEROL, V89, P458; DUNBAR GC, 1993, ACTA PSYCHIAT SCAND, V87, P302, DOI 10.1111/j.1600-0447.1993.tb03376.x; MARS F, 1991, GASTROENTEROL CLIN B, V15, P271	3	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1387	1387						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ169	9161313				2022-12-28	WOS:A1997WZ16900028
J	Lee, JK; Houk, KN				Lee, JK; Houk, KN			A proficient enzyme revisited: The predicted mechanism for orotidine monophosphate decarboxylase	SCIENCE			English	Article							OROTIDYLATE DECARBOXYLASE; ACID; CATALYSIS; OROTATE; 5'-MONOPHOSPHATE; 5'-PHOSPHATE	A mechanism is proposed to explain the activity of orotidine 5'-monophosphate decarboxylase (ODCase). This enzyme is the one of the most proficient known, with a catalytic proficiency (k(cat)/K-m)/k(non) = 10(23) M-1. Quantum mechanical calculations predict a mechanism involving a stabilized carbene intermediate, which represents a previously unrecognized mode of enzymatic activity for ODCase. The proposed mechanism involves proton transfer from a weak acid (pK(a) = 7, where K-a is the acid constant) concerted with decarboxylation, in a nonpolar enzyme environment. Such a mechanism makes possible different approaches to the design of ODCase inhibitors. Furthermore, the prediction that general acid catalysis may only be effective in low dielectric media is of general significance for understanding the activity of many enzymes.			Lee, JK (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,405 HILGARD AVE,LOS ANGELES,CA 90095, USA.							ACHESON SA, 1990, BIOCHEMISTRY-US, V29, P3198, DOI 10.1021/bi00465a007; ARDUENGO AJ, 1994, J AM CHEM SOC, V116, P6812, DOI 10.1021/ja00094a040; BEAK P, 1976, J AM CHEM SOC, V98, P3601, DOI 10.1021/ja00428a035; BELL JB, 1991, PROTEINS, V9, P143, DOI 10.1002/prot.340090208; BENDER ML, 1971, MECH HOMOGENEOUS CAT, P165; BRUICE TC, 1966, BIOORGANIC MECH, V2, P188; CARTER CM, COMMUNICATION; Castellano J.A., 1992, HDB DISPLAY TECHNOLO; GILSON MK, 1986, BIOPOLYMERS, V25, P2097, DOI 10.1002/bip.360251106; Hehre W. J., 1986, AB INITIO MOL ORBITA; JENCKS WP, 1972, J AM CHEM SOC, V94, P4731, DOI 10.1021/ja00768a052; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; KING G, 1991, J CHEM PHYS, V95, P4366, DOI 10.1063/1.461760; KLUGER R, 1987, CHEM REV, V87, P863, DOI 10.1021/cr00081a001; Kohn W, 1996, J PHYS CHEM-US, V100, P12974, DOI 10.1021/jp960669l; Lavorato D, 1996, J AM CHEM SOC, V118, P11898, DOI 10.1021/ja961954l; LEVINE HL, 1980, BIOCHEMISTRY-US, V19, P4993, DOI 10.1021/bi00563a010; LIAS SG, 1988, J PHYS CHEM REF D S1, V17; MCCLARD RW, 1980, BIOCHEMISTRY-US, V19, P4699, DOI 10.1021/bi00561a024; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; Schlegel HB., 2009, GAUSSIAN 09 REVISION; SHOSTAK K, 1992, BIOCHEMISTRY-US, V31, P12155, DOI 10.1021/bi00163a026; SILVERMAN RB, 1982, J AM CHEM SOC, V104, P6434, DOI 10.1021/ja00387a047; Simonson T, 1996, J AM CHEM SOC, V118, P8452, DOI 10.1021/ja960884f; SMILEY JA, 1991, BIOCHEMISTRY-US, V30, P6216, DOI 10.1021/bi00239a020; SMILEY JA, 1994, P NATL ACAD SCI USA, V91, P8319, DOI 10.1073/pnas.91.18.8319; SMILEY JA, 1992, BIOCHEMISTRY-US, V31, P12162, DOI 10.1021/bi00163a027; SMILEY JA, 1995, J AM CHEM SOC, V117, P3877, DOI 10.1021/ja00118a028; WAGNER R, 1970, HELV CHIM ACTA, V53, P299, DOI 10.1002/hlca.19700530210; WARSHEL A, 1991, ANNU REV BIOPHYS BIO, V20, P267, DOI 10.1146/annurev.biophys.20.1.267	30	162	162	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					942	945		10.1126/science.276.5314.942	http://dx.doi.org/10.1126/science.276.5314.942			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9139656				2022-12-28	WOS:A1997WY79200046
J	Luboldt, W; Bauerfeind, P; Steiner, P; Fried, M; Krestin, GP; Debatin, JF				Luboldt, W; Bauerfeind, P; Steiner, P; Fried, M; Krestin, GP; Debatin, JF			Preliminary assessment of three-dimensional magnetic resonance imaging for various colonic disorders	LANCET			English	Article							GD-DTPA	Background Improvements in magnetic resonance imaging (MRI) technology have enabled the acquisition of three-dimensional MRI datasets in a single breath hold. We adopted this technique to make a three-dimensional intraluminal and extraluminal assessment of the colon in three patients with various colonic disorders. Methods One patient was studied after having a double-contrast barium enema. Two patients had MRI scans after colonoscopy, which showed three colonic tumours in one and multiple polyps in the ascending colon of the other. The process of rectal filling with 1.5-2.0 L water mixed with 15-20 mt 0.5 mol/L gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) was monitored with MR fluoroscopic sequence. Three-dimensional datasets of the contrast-filled colon were taken with patients in prone (before and after intravenous administration of 0.1 mmol/kg bodyweight Gd-DTPA) and supine positions. 64 sections with a voxel-resolution of 2.0X2.0x1.25 mm(3)-were taken during a 28 s breath hold. Three-dimensional maximum intensity projection, multiplanar reconstruction, and virtual colonoscopic images of the colon were created from these. Findings Analysis of the coronal source images in conjunction with multiplanar reconstructions revealed all relevant abnormalities, including diverticula, carcinomas, and polyps. Three dimensional maximum-intensity projections gave a morphological overview of the whole colon. Targeted projections, made up of a limited number of coronal source images, showed diverticula and smaller polyps more clearly. After patients were given intravenous contrast all colonic mass lesions were enhanced. Datasets obtained in prone patients gave the best intraluminal views of the colon. Virtual magnetic resonance colonoscopy showed colonic haustra as well as the ileocaecal valve, but did not show clearly the diverticula. All intraluminal mass lesions, on the other hand, were easy to see. Interpretation The potential of three-dimensional colonic MRI to provide accurate, minimally invasive, cost-effective polyp screening, as well as comprehensive colonic tumour staging, warrants further investigation.	UNIV ZURICH HOSP, INST DIAGNOST RADIOL, CH-8091 ZURICH, SWITZERLAND; UNIV ZURICH HOSP, INST GASTROENTEROL, CH-8091 ZURICH, SWITZERLAND	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital			Bauerfeind, Peter/AAV-2069-2020					COHAN RH, 1991, INVEST RADIOL, V26, P224, DOI 10.1097/00004424-199103000-00005; Davis CP, 1996, RADIOLOGY, V199, P37, DOI 10.1148/radiology.199.1.8633169; Hara AK, 1996, RADIOLOGY, V200, P49, DOI 10.1148/radiology.200.1.8657944; Hara AK, 1996, GASTROENTEROLOGY, V110, P284, DOI 10.1053/gast.1996.v110.pm8536869; LEUNG DA, 1996, RADIOLOGY, V201, P569; PRINCE MR, 1995, RADIOLOGY, V197, P785, DOI 10.1148/radiology.197.3.7480757; Rubin GD, 1996, RADIOLOGY, V199, P321, DOI 10.1148/radiology.199.2.8668772; SCHUHMANNGIAMPIERI G, 1991, INVEST RADIOL, V26, P975, DOI 10.1097/00004424-199111000-00009; WEISS KL, 1990, MAGN RESON IMAGING, V8, P817, DOI 10.1016/0730-725X(90)90019-X	9	100	101	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1288	1291		10.1016/S0140-6736(96)11332-5	http://dx.doi.org/10.1016/S0140-6736(96)11332-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142064				2022-12-28	WOS:A1997WW89900011
J	Nagy, L; Kao, HY; Chakravarti, D; Lin, RJ; Hassig, CA; Ayer, DE; Schreiber, SL; Evans, RM				Nagy, L; Kao, HY; Chakravarti, D; Lin, RJ; Hassig, CA; Ayer, DE; Schreiber, SL; Evans, RM			Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase	CELL			English	Article							THYROID-HORMONE RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS; RETINOIC ACID; ERBB ONCOGENES; CO-REPRESSOR; V-ERBA; EXPRESSION; DIFFERENTIATION; ACTIVATION; INTERACTS	The transcriptional corepressors SMRT and N-CoR function as silencing mediators for retinoid and thyroid hormone receptors. Here we show that SMRT and N-CoR directly interact with mSin3A, a corepressor for the Mad-Max heterodimer and a homolog of the yeast global-transcriptional repressor Sin3p. In addition, we demonstrate that the recently characterized histone deacetylase 1 (HDAC1) interacts with Sin3A and SMRT to form a multisubunit repressor complex. Consistent with this model, we find that HDAC inhibitors synergize with retinoic acid to stimulate hormone-responsive genes and differentiation of myeloid leukemia (HL-60) cells. This work establishes a convergence of repression pathways for bHLH-Zip proteins and nuclear receptors and suggests this type of regulation may be more widely conserved than previously suspected.	UNIV CALIF SAN DIEGO,SCH MED,GRAD PROGRAM MOL PATHOL,LA JOLLA,CA 92093; HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138; UNIV UTAH,HUNTSMAN CANC INST,DEPT ONCOL SCI,SALT LAKE CITY,UT 84112	University of California System; University of California San Diego; Harvard University; Howard Hughes Medical Institute; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Nagy, L (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037, USA.		Nagy, Laszlo/A-3814-2008; Evans, Ronald/AAF-4001-2019	Nagy, Laszlo/0000-0001-6653-2155; Evans, Ronald/0000-0002-9986-5965; Lin, Richard/0000-0002-0834-7880; Ayer, Donald/0000-0002-5595-3269; Chakravarti, Debabrata/0000-0001-8446-8599	NICHD NIH HHS [HD27183] Funding Source: Medline; NIGMS NIH HHS [GM26444] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026444, R37GM026444] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; BRACKMAN D, 1995, LEUKEMIA RES, V19, P57, DOI 10.1016/0145-2126(94)00061-E; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COLLINS SJ, 1987, BLOOD, V70, P1233; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HICKS RM, 1983, P NUTR SOC, V43, P83; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; Li C, 1997, P NATL ACAD SCI USA, V94, P2278, DOI 10.1073/pnas.94.6.2278; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STILLMAN DJ, 1994, GENETICS, V136, P781; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Wolffe AP, 1996, CURR BIOL, V6, P234, DOI 10.1016/S0960-9822(02)00465-7; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang Men-Ming, 1996, Proceedings of the National Academy of Sciences of the United States of America, V93, P12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	39	1079	1109	2	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					373	380		10.1016/S0092-8674(00)80218-4	http://dx.doi.org/10.1016/S0092-8674(00)80218-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150137	Bronze			2022-12-28	WOS:A1997WX89900008
J	Nusse, R				Nusse, R			A versatile transcriptional effector of wingless signaling	CELL			English	Review							DROSOPHILA				Nusse, R (corresponding author), STANFORD UNIV,BECKMAN CTR,HOWARD HUGHES MED INST,DEPT DEV BIOL,MED CTR,STANFORD,CA 94305, USA.							Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Clevers HC, 1996, IMMUNOL TODAY, V17, P336, DOI 10.1016/0167-5699(96)10019-0; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X	22	132	133	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					321	323		10.1016/S0092-8674(00)80210-X	http://dx.doi.org/10.1016/S0092-8674(00)80210-X			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150130	Bronze			2022-12-28	WOS:A1997WX89900001
J	Featherstone, C				Featherstone, C			Escherichia coli O157: Superbug or mere sensation?	LANCET			English	News Item																			0	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					930	930		10.1016/S0140-6736(05)62711-0	http://dx.doi.org/10.1016/S0140-6736(05)62711-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9132514				2022-12-28	WOS:A1997WR25400031
J	Hetzer, M; Wurzer, G; Schweyen, RJ; Mueller, MW				Hetzer, M; Wurzer, G; Schweyen, RJ; Mueller, MW			Trans-activation of group II intron splicing by nuclear U5 snRNA	NATURE			English	Article							RNA; SPLICEOSOME; INVITRO; SITES; LARIAT	Similarities between RNA splicing during autocatalytic excision of group II introns and pre-mRNA processing led to the hypothesis that group II introns might be the evolutionary predecessors of spliceosomal small nuclear RNAs(1-4). The ID3 subdomain stem-loop structure of group II introns, the proposed analogue of the spliceosomal U5 snRNA(5), is thought to be essential for 5' splice site recognition and anchoring of the free 5' exon(6). Using the group II intron bI1 we have analysed the role of ID3 in splicing. In the absence of ID3 the 5' splice site was recognized accurately and efficiently, but exon anchoring was greatly reduced. This step was restored in the presence of RNA fragments consisting of either the terminal stem-loop structure of ID3 or spliceosomal U5 snRNA. This suggests that the predominant role of both RNAs is to anchor the 5' exon during exon ligation. Furthermore, as U5 complements for the loss of ID3, a similar network of structural RNAs may form the catalytic core of both group II introns and spliceosomes.	UNIV VIENNA,INST MICROBIOL & GENET,A-1030 VIENNA,AUSTRIA	University of Vienna			Wurzer, Georg/AAE-3159-2022	Wurzer, Georg/0000-0002-2532-0073				BACHL J, 1990, J MOL BIOL, V212, P113, DOI 10.1016/0022-2836(90)90308-9; FRANK DN, 1994, MOL CELL BIOL, V14, P2180, DOI 10.1128/MCB.14.3.2180; HARRISKERR CL, 1993, P NATL ACAD SCI USA, V90, P10658, DOI 10.1073/pnas.90.22.10658; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MICHELS WJ, 1995, BIOCHEMISTRY-US, V34, P2965, DOI 10.1021/bi00009a028; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; MUELLER M W, 1991, Journal of Molecular Biology, V222, P145; MUELLER MW, 1993, SCIENCE, V261, P1035, DOI 10.1126/science.8351516; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; OKeefe RT, 1996, CELL, V86, P679, DOI 10.1016/S0092-8674(00)80140-3; PADGETT RA, 1994, SCIENCE, V266, P1685, DOI 10.1126/science.7527587; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; SCHMELZER C, 1986, CELL, V46, P557, DOI 10.1016/0092-8674(86)90881-0; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; SUCHY M, 1991, J MOL BIOL, V222, P179, DOI 10.1016/0022-2836(91)90204-J; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WISE JA, 1993, SCIENCE, V262, P1978, DOI 10.1126/science.8266091	24	62	67	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					417	420		10.1038/386417a0	http://dx.doi.org/10.1038/386417a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121561				2022-12-28	WOS:A1997WQ17000070
J	Tu, JV; Pashos, CL; Naylor, CD; Chen, EL; Normand, SL; Newhouse, JP; McNeil, BJ				Tu, JV; Pashos, CL; Naylor, CD; Chen, EL; Normand, SL; Newhouse, JP; McNeil, BJ			Use of cardiac procedures and outcomes in elderly patients with myocardial infarction in the United States and Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE; MORTALITY; MANAGEMENT; POPULATION; EXPERIENCE; TRIAL	Background Acute myocardial infarction is a leading cause of morbidity and mortality in the United States and Canada. We performed a population-based study to compare the use of cardiac procedures and outcomes after acute myocardial infarction in elderly patients in the two countries. Methods We compared the use of invasive cardiac procedures and the mortality rates among 224,258 elderly Medicare beneficiaries in the United States and 9444 elderly patients in Ontario, Canada, each of whom had a new acute myocardial infarction in 1991. Results The U.S. patients were significantly more likely than the Canadian patients to undergo coronary angiography (34.9 percent vs. 6.7 percent, P < 0.001), percutaneous transluminal coronary angioplasty (11.7 percent vs. 1.5 percent, P < 0.001), and coronary-artery bypass surgery (10.6 percent vs. 1.4 percent, P < 0.001) during the first 30 days after the index infarction. These differences in the use of cardiac procedures narrowed but persisted through 180 days of follow-up. The 30-day mortality rates were slightly but significantly lower for the U.S. patients than for the Canadian patients (21.4 percent vs. 22.3 percent, P = 0.03). However, the one-year mortality rates were virtually identical (34.3 percent in the United States vs. 34.4 percent in Ontario, P = 0.94). Conclusions Short-term mortality after an acute myocardial infarction was slightly lower in the United States than in Ontario, but these differences did not persist through one year of follow-up. The strikingly higher rates of use of cardiac procedures in the United States, as compared with Canada, do not appear to result in better long-term survival rates for elderly U.S. patients with acute myocardial infarction. (C) 1997, Massachusetts Medical Society.	UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DEPT MED,TORONTO,ON,CANADA; ABT ASSOCIATES INC,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; ABT Associates; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University; Harvard Medical School	Tu, JV (corresponding author), INST CLIN EVALUAT SCI,G-106,2075 BAYVIEW AVE,N YORK,ON M4N 3M5,CANADA.		Newhouse, Joseph/AGJ-5632-2022	Normand, Sharon-Lise/0000-0001-7027-4769; Tu, Jack/0000-0003-0111-722X	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008071] Funding Source: NIH RePORTER; AHRQ HHS [HS08071] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BARER ML, 1992, J HEALTH POLIT POLIC, V17, P763, DOI 10.1215/03616878-17-4-763; Commission on Professional and Hospital Activities, 1992, INT CLASS DIS; *GEN ACC OFF, 1994, GAOPEMD945 PUBL, P1; GORDON M, 1992, J AM GERIATR SOC, V40, P421, DOI 10.1111/j.1532-5415.1992.tb02148.x; Hennekens C.H., 1987, EPIDEMIOLOGY MED; Hennekens CH, 1996, NEW ENGL J MED, V335, P1660, DOI 10.1056/NEJM199611283352207; Jha P, 1996, J AM COLL CARDIOL, V27, P1335, DOI 10.1016/0735-1097(96)00018-6; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; *MIN IND SCI TECHN, 1993, CAN CLASS DIAGN THER; NAYLOR CD, 1994, J AM COLL CARDIOL, V24, P1431, DOI 10.1016/0735-1097(94)90136-8; NORMAND SLT, 1995, J CLIN EPIDEMIOL, V48, P229, DOI 10.1016/0895-4356(94)00126-B; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; PETERSON ED, 1994, ANN INTERN MED, V121, P919, DOI 10.7326/0003-4819-121-12-199412150-00003; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; ROOS LL, 1992, HEALTH AFFAIR, V11, P56, DOI 10.1377/hlthaff.11.2.56; Rosner B., 2011, FUNDAMENTALS BIOSTAT, V7th; Rouleau JL, 1996, J AM COLL CARDIOL, V27, P1119, DOI 10.1016/0735-1097(95)00599-4; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; *SAS I, 1996, SAS REL 6 11; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; VANDEWERF F, 1995, JAMA-J AM MED ASSOC, V273, P1586, DOI 10.1001/jama.273.20.1586; 1994, CIRCULATION, V89, P1545	25	247	253	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 22	1997	336	21					1500	1505		10.1056/NEJM199705223362106	http://dx.doi.org/10.1056/NEJM199705223362106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ767	9154770				2022-12-28	WOS:A1997WZ76700006
J	Lau, R				Lau, R			Drug interactions with zileuton	LANCET			English	Letter											Lau, R (corresponding author), UNIV WASHINGTON,MED CTR,SEATTLE,WA 98195, USA.							Awni W M, 1995, Clin Pharmacokinet, V29 Suppl 2, P67; Granneman G R, 1995, Clin Pharmacokinet, V29 Suppl 2, P77; McGill KA, 1996, LANCET, V348, P519, DOI 10.1016/S0140-6736(95)12297-4	3	6	6	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 17	1997	349	9063					1479	1479		10.1016/S0140-6736(05)63765-8	http://dx.doi.org/10.1016/S0140-6736(05)63765-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164345				2022-12-28	WOS:A1997WZ76500061
J	Venables, KM; ChanYeung, M				Venables, KM; ChanYeung, M			Occupational asthma	LANCET			English	Article							AIRWAYS DYSFUNCTION SYNDROME; PERSISTENT ASTHMA; LUNG-FUNCTION; FATAL ASTHMA; EXPOSURE; MECHANISMS; ALLERGY; WORKERS; CEDAR; ACID	Occupational asthma is a common disorder that may be caused by several hundred agents and has a variety of pathogenetic mechanisms. Level of exposure is an important risk factor, and reduction of exposure is the only certain method of prevention. Atopy and smoking are further risk factors for IgE-mediated asthma but have not been found to increase risk in forms of the disorder that have other mechanisms. The key to diagnosis is a low threshold of suspicion; several investigative procedures can be used to confirm the diagnosis. Many patients suffer from continued asthma despite cessation of exposure; early diagnosis and early removal from exposure are the most important factors for improving the long-term outcome.	UNIV BRITISH COLUMBIA, DEPT MED, OCCUPAT & ENVIRONM LUNG DIS UNIT, VANCOUVER, BC, CANADA	University of British Columbia	Venables, KM (corresponding author), NATL HEART & LUNG INST, IMPERIAL COLL SCH MED, DEPT OCCUPAT & ENVIRONM MED, DOVEHOUSE ST, LONDON SW3 6LR, ENGLAND.							Balboni A, 1996, EUR RESPIR J, V9, P207, DOI 10.1183/09031936.96.09020207; BERNSTEIN DI, 1993, ASTHMA WORKPLACE, P1; BHERER L, 1994, OCCUP ENVIRON MED, V51, P225, DOI 10.1136/oem.51.4.225; BIAGINI RE, 1986, AM REV RESPIR DIS, V134, P719; BLANC P, 1987, CHEST, V92, P613, DOI 10.1378/chest.92.4.613; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; BURGE PS, 1982, EUR J RESPIR DIS, V63, P47; Cartier Andre, 1993, P215; Chan-Yeung Moira, 1993, P299; CHANYEUNG M, 1994, AM J RESP CRIT CARE, V149, P1676, DOI 10.1164/ajrccm.149.6.8004329; CHANYEUNG M, 1993, AM REV RESPIR DIS, V147, P1056; CHANYEUNG M, 1994, EUR RESPIR J, V7, P346, DOI 10.1183/09031936.94.07020346; CHANYEUNG M, 1994, CHEST, V98, pS124; CONTRERAS GR, 1994, OCCUP ENVIRON MED, V51, P710, DOI 10.1136/oem.51.10.710; COTE J, 1990, AM REV RESPIR DIS, V141, P373, DOI 10.1164/ajrccm/141.2.373; DEZOTTI R, 1988, INT ARCH OCC ENV HEA, V61, P7, DOI 10.1007/BF00381601; EHRLICH RI, 1994, AM J IND MED, V26, P799, DOI 10.1002/ajim.4700260608; FABBRI LM, 1988, AM REV RESPIR DIS, V137, P1494, DOI 10.1164/ajrccm/137.6.1494; FREW A, 1993, J ALLERGY CLIN IMMUN, V92, P466, DOI 10.1016/0091-6749(93)90126-Z; GAUTRIN D, 1994, J ALLERGY CLIN IMMUN, V93, P12, DOI 10.1016/0091-6749(94)90228-3; HUNTER D, 1945, BRIT J IND MED, V2, P92; JUNIPER CP, 1977, J SOC OCCUP MED, V27, P3; KERN DG, 1991, AM REV RESPIR DIS, V144, P1058, DOI 10.1164/ajrccm/144.5.1058; KOBAYASHI S, 1974, ALLERGOLOGIE, P124; LOW B, 1988, TISSUE ANTIGENS, V31, P224, DOI 10.1111/j.1399-0039.1988.tb02085.x; MALO JL, 1988, AM REV RESPIR DIS, V138, P807, DOI 10.1164/ajrccm/138.4.807; MAPP CE, 1994, EUR RESPIR J, V7, P544, DOI 10.1183/09031936.94.07030544; MEREDITH SK, 1991, BRIT J IND MED, V48, P292; MUSK AW, 1989, BRIT J IND MED, V46, P636; Sallie B, 1996, ANN OCCUP HYG, V40, P211, DOI 10.1016/0003-4878(95)00067-4; Taylor AJN, 1996, THORAX, V51, P541, DOI 10.1136/thx.51.5.541; VENABLES KM, 1987, J ALLERGY CLIN IMMUN, V80, P212, DOI 10.1016/0091-6749(87)90131-X; VENABLES KM, 1988, BRIT J IND MED, V45, P660; VENABLES KM, 1989, BMJ-BRIT MED J, V299, P939, DOI 10.1136/bmj.299.6705.939; YOUNG RP, 1995, AM J RESP CRIT CARE, V151, P219, DOI 10.1164/ajrccm.151.1.7812558; ZETTERSTROM O, 1985, J ALLERGY CLIN IMMUN, V75, P594, DOI 10.1016/0091-6749(85)90035-1	36	108	113	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	1997	349	9063					1465	1469		10.1016/S0140-6736(96)07219-4	http://dx.doi.org/10.1016/S0140-6736(96)07219-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164332				2022-12-28	WOS:A1997WZ76500044
J	Fred, HL; Basaria, S				Fred, HL; Basaria, S			Liver abscess with septic pulmonary emboli	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Fred, HL (corresponding author), UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX 77030, USA.			Basaria, Shehzad/0000-0002-8533-2383; Basaria, Shehzad/0000-0003-1749-8549					0	2	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	1997	336	20					1428	1428		10.1056/NEJM199705153362005	http://dx.doi.org/10.1056/NEJM199705153362005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY577	9145680				2022-12-28	WOS:A1997WY57700005
J	Frisse, ME; Florance, V				Frisse, ME; Florance, V			A library for internists .9. Recommendations from the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Bibliography											Frisse, ME (corresponding author), AMER COLL PHYSICIANS, INDEPENDENCE MALL W, 6TH ST & RACE, PHILADELPHIA, PA 19106 USA.		Frisse, Mark E/B-3824-2016	Frisse, Mark E/0000-0003-0382-6222; Florance, Valerie/0000-0001-9135-3562					0	5	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1997	126	10					836	846		10.7326/0003-4819-126-10-199705150-00043	http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00043			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ823	9148677				2022-12-28	WOS:A1997WZ82300041
J	Rozenman, Y; Gilon, D; Fuchs, S				Rozenman, Y; Gilon, D; Fuchs, S			Where did good old clinical diagnosis go?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFECTIVE ENDOCARDITIS; ECHOCARDIOGRAPHY				Rozenman, Y (corresponding author), HADASSAH UNIV HOSP,DEPT CARDIOL,POB 12000,EIN KEREM,IL-91120 JERUSALEM,ISRAEL.							ARBER N, 1991, AM J MED, V90, P758; HERMANS PE, 1982, MAYO CLIN PROC, V57, P15; KASSIRER JP, 1989, AM J MED, V86, P433, DOI 10.1016/0002-9343(89)90342-2; KASSIRER JP, 1989, ANN INTERN MED, V110, P893, DOI 10.7326/0003-4819-110-11-893; KASSIRER JP, 1985, HOSP PRACT, V20, P56; KASSIRER JP, 1985, HOSP PRACT, V20, P61; Lindner JR, 1996, CIRCULATION, V93, P730, DOI 10.1161/01.CIR.93.4.730; MUGGE A, 1989, J AM COLL CARDIOL, V14, P631; Rosser WW, 1996, J FAM PRACTICE, V42, P139; SEWARD JB, 1988, MAYO CLIN PROC, V63, P649, DOI 10.1016/S0025-6196(12)65529-3	10	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	1997	336	20					1435	1438		10.1056/NEJM199705153362007	http://dx.doi.org/10.1056/NEJM199705153362007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY577	9145682				2022-12-28	WOS:A1997WY57700007
J	Pan, D; Hsu, K; Ray, SC				Pan, D; Hsu, K; Ray, SC			Ecchymoses and eschars at sites of injection	LANCET			English	Article							RENAL-FAILURE; CALCIPHYLAXIS; NECROSIS		JOHNS HOPKINS UNIV HOSP,DEPT MED,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine			Ray, Stuart C./B-7527-2008	Ray, Stuart C./0000-0002-1051-7260				GIPSTEIN RM, 1976, ARCH INTERN MED, V136, P1273, DOI 10.1001/archinte.136.11.1273; MEHTA RL, 1990, AM J MED, V88, P252, DOI 10.1016/0002-9343(90)90150-C; ROE SM, 1994, AM SURGEON, V60, P81; Ruggian JC, 1996, AM J KIDNEY DIS, V28, P409, DOI 10.1016/S0272-6386(96)90499-0; Selye H., 1962, CALCIPHYLAXIS, P48	5	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1364	1364		10.1016/S0140-6736(97)03156-5	http://dx.doi.org/10.1016/S0140-6736(97)03156-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149700				2022-12-28	WOS:A1997WY34200012
J	Perelson, AS; Essunger, P; Cao, YZ; Vesanen, M; Hurley, A; Saksela, K; Markowitz, M; Ho, DD				Perelson, AS; Essunger, P; Cao, YZ; Vesanen, M; Hurley, A; Saksela, K; Markowitz, M; Ho, DD			Decay characteristics of HIV-1-infected compartments during combination therapy	NATURE			English	Article							DENDRITIC CELLS; VIRUS; INFECTION; LYMPHOCYTES; HIV-1; QUANTITATION; MACROPHAGES; AIDS	Analysis of changes in viral load after initiation of treatment with potent antiretroviral agents has provided substantial insight into the dynamics of human immunodeficiency virus type 1 (HIV-1)(1-3). The concentration of HIV-1 in plasma drops by similar to 99% in the first two weeks of treatment owing to the rapid elimination of free virus with a half-life (t(1/2)) of less than or equal to 6 hours and loss of productively infected cells with a t(1/2) of 1.6 days(3). Here we show that with combination therapy this initial decrease is followed by a slower second-phase decay of plasma viraemia. Detailed mathematical analysis shows that the loss of long-lived infected cells (t(1/2) of 1-4 weeks) is a major contributor to the second phase, whereas the activation of latently infected lymphocytes (t(1/2) of 0.5-2 weeks) is only a minor source. Based on these decay characteristics, we estimate that 2.3-3.1 years of a completely inhibitory treatment would be required to eliminate HIV-1 from these compartments. To eradicate HIV-1 completely, even longer treatment may be needed because of the possible existence of undetected viral compartments or sanctuary sites.	ROCKEFELLER UNIV, AARON DIAMOND AIDS RES CTR, NEW YORK, NY 10016 USA; LOS ALAMOS NATL LAB, DIV THEORET, LOS ALAMOS, NM 87545 USA; TAMPERE UNIV, INST MED TECHNOL, FIN-33101 TAMPERE, FINLAND	Rockefeller University; United States Department of Energy (DOE); Los Alamos National Laboratory; Tampere University			Perelson, Alan S/Z-1959-2019	Perelson, Alan S/0000-0002-2455-0002				CAO YZ, 1992, AIDS, V6, P65, DOI 10.1097/00002030-199201000-00008; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; DESTGROTH SF, 1982, J IMMUNOL METHODS, V49, pR11, DOI 10.1016/0022-1759(82)90269-1; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; Herz AVM, 1996, P NATL ACAD SCI USA, V93, P7247, DOI 10.1073/pnas.93.14.7247; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; MITCHIE CA, 1992, NATURE, V360, P264; Moreno P, 1996, AIDS, V10, P682, DOI 10.1097/00002030-199606000-00019; Nowak MA, 1997, J THEOR BIOL, V184, P205, DOI 10.1006/jtbi.1996.0307; Patick AK, 1996, ANTIMICROB AGENTS CH, V40, P292, DOI 10.1128/AAC.40.2.292; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; SHAW GM, 1995, 10 C CENT GARD, P9; TREPEL F, 1974, KLIN WOCHENSCHR, V52, P511, DOI 10.1007/BF01468720; VANFURTH R, 1992, INFLAMMATION BASIC P, P325; Vesanen M, 1996, J VIROL, V70, P9035, DOI 10.1128/JVI.70.12.9035-9040.1996; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	25	1482	1531	3	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 8	1997	387	6629					188	191		10.1038/387188a0	http://dx.doi.org/10.1038/387188a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144290				2022-12-28	WOS:A1997WX94500056
J	Todorov, LD; MihaylovaTodorova, S; Westfall, TD; Sneddon, P; Kennedy, C; Bjur, RA; Westfall, DP				Todorov, LD; MihaylovaTodorova, S; Westfall, TD; Sneddon, P; Kennedy, C; Bjur, RA; Westfall, DP			Neuronal release of soluble nucleotidases and their role in neurotransmitter inactivation	NATURE			English	Article							PIG VAS-DEFERENS; EXTRACELLULAR ATP; TOXOPLASMA-GONDII; URINARY-BLADDER; ECTONUCLEOTIDASES; 5'-NUCLEOTIDASE; ANALOGS	Efficient control of synaptic transmission requires a rapid mechanism for terminating the actions of neurotransmitters. For amino acids and monoamines, this is achieved by their uptake into the cell by specific high-affinity transporters(1); acetylcholine is first broken down in the extracellular space and then choline is taken up by the cell(2). Because ATP is hydrolysed to adenosine by membrane-bound enzymes (ectonucleotidases) that are present in most tissues(3,4), it has been assumed that these enzymes terminate the neurotransmitter actions of ATP in the brain(5) and in the periphery(6,7). We show here, however that stimulation of sympathetic nerves innervating the guinea-pig vas deferens releases not only neuronal ATP, but also soluble nucleotidases that. break down this ATP to adenosine, indicating that inactivation of ATP is increased by nerve activity. This release of specific nucleotidases together with ATP represents a new mechanism for terminating the actions of a neurotransmitter.	UNIV NEVADA,SCH MED,DEPT PHARMACOL,RENO,NV 89557; UNIV STRATHCLYDE,ROYAL COLL,DEPT PHYSIOL & PHARMACOL,GLASGOW G1 1XW,LANARK,SCOTLAND	Nevada System of Higher Education (NSHE); University of Nevada Reno; University of Strathclyde					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ASAI T, 1995, J BIOL CHEM, V270, P11391, DOI 10.1074/jbc.270.19.11391; BAILEY SJ, 1994, BRIT J PHARMACOL, V112, P219, DOI 10.1111/j.1476-5381.1994.tb13055.x; BERMUDES D, 1994, J BIOL CHEM, V269, P29252; BOWMAN WC, 1980, TXB PHARM; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CRACK BE, 1995, BRIT J PHARMACOL, V114, P475, DOI 10.1111/j.1476-5381.1995.tb13251.x; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HOURANI SMO, 1989, GEN PHARMACOL, V20, P413, DOI 10.1016/0306-3623(89)90188-2; KENNEDY C, 1995, TRENDS PHARMACOL SCI, V16, P168, DOI 10.1016/S0165-6147(00)89010-0; KHAKH BS, 1995, BRIT J PHARMACOL, V115, pP2; LEVITT B, 1984, ANAL BIOCHEM, V137, P93, DOI 10.1016/0003-2697(84)90352-X; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; MISUMI Y, 1990, EUR J BIOCHEM, V191, P563, DOI 10.1111/j.1432-1033.1990.tb19158.x; MISUMI Y, 1990, J BIOL CHEM, V265, P2178; PEARSON JD, 1985, BIOCHEM J, V230, P503, DOI 10.1042/bj2300503; PLESNER L, 1995, INT REV CYTOL, V158, P141; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; Sneddon P, 1996, SEMIN NEUROSCI, V8, P201, DOI 10.1006/smns.1996.0026; Stout JG, 1995, BIOCHEM MOL BIOL INT, V36, P927; Todorov LD, 1996, J PHYSIOL-LONDON, V496, P731, DOI 10.1113/jphysiol.1996.sp021723; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; WELFORD LA, 1987, EUR J PHARMACOL, V141, P123, DOI 10.1016/0014-2999(87)90418-3; WELFORD LA, 1986, EUR J PHARMACOL, V129, P217, DOI 10.1016/0014-2999(86)90431-0; Westfall TD, 1996, BRIT J PHARMACOL, V117, P867, DOI 10.1111/j.1476-5381.1996.tb15273.x; ZIGANSHIN AU, 1994, DRUG DEVELOP RES, V32, P134, DOI 10.1002/ddr.430320303	27	206	209	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 1	1997	387	6628					76	79		10.1038/387076a0	http://dx.doi.org/10.1038/387076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139824				2022-12-28	WOS:A1997WW75800050
J	Walker, SA; Kennedy, MT; Zasadzinski, JA				Walker, SA; Kennedy, MT; Zasadzinski, JA			Encapsulation of bilayer vesicles by self-assembly	NATURE			English	Article							MEMBRANE-FUSION; LIPID VESICLES; LIPOSOMES; PHARMACOKINETICS	Vesicles of lipid bilayers have been investigated as drug-delivery vehicles for almost 20 years(1-8). The vesicles' interior space is separated from the surrounding solution because small molecules have only limited permeability through the bilayer. Single-walled (unilamellar) vesicles are made by a variety of non-equilibrium techniques, including mechanical disruption of lamellar phases by sonication or extrusion through filters, or chemical disruption by detergent dialysis or solvent removal(5). These techniques do not, however, allow the encapsulation of a specific volume, nor can they be used to encapsulate other vesicles. Here we show that molecular-recognition processes mediated by lipophilic receptors and substrates (here the biotin-streptavidin complex)(9) can be used to produce a multicompartmental aggregate of tethered vesicles encapsulated within a large bilayer vesicle. We call these encapsulated aggregates vesosomes. Encapsulation is achieved by unrolling bilayers from cochleate clyinders(5,10-12) which are tethered to the aggregate by biotin-streptavidin coupling. These compartmentalized vesosomes could provide vehicles for multicomponent or multifunctional drug delivery(2-4,6); in particular the encapsulating membrane could significantly modify permeation properties, or could be used to enhance the biocompatibility of the system.	UNIV CALIF SANTA BARBARA,DEPT CHEM ENGN,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,MAT RES LAB,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara								ALLEN TM, 1995, ADV DRUG DELIVER REV, V16, P267, DOI 10.1016/0169-409X(95)00029-7; ALLEN TM, 1987, FEBS LETT, V223, P42, DOI 10.1016/0014-5793(87)80506-9; [Anonymous], 1988, LIPOSOMES DRUG CARRI; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; CHIRUVOLU S, 1994, SCIENCE, V264, P1753, DOI 10.1126/science.8209255; CHIRUVOLU S, 1994, STRUCTURE FLOW SURFA, pCH5; COOSSEN JR, 1995, BIOPHYS J, V68, P1009; Fendler J., 1983, MEMBRANE MIMETIC CHE; KENNEDY MT, 1998, THESIS U CALIFORNIA; LASIC DD, 1993, LIPOSOMES PHYSICS AP; New R.R., 1990, LIPOSOMES PRACTICAL; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P483, DOI 10.1016/0005-2736(75)90299-0; PAPAHADJOPOULOS D, 1977, BIOCHIM BIOPHYS ACTA, V465, P579, DOI 10.1016/0005-2736(77)90275-9; PAPAHADJOPOULOS D, 1976, BIOCHIM BIOPHYS ACTA, V448, P265, DOI 10.1016/0005-2736(76)90241-8; Spector MS, 1996, LANGMUIR, V12, P4704, DOI 10.1021/la960218s; SZOKA F, 1980, ANNU REV BIOPHYS BIO, V9, P467, DOI 10.1146/annurev.bb.09.060180.002343; Tardi PG, 1996, J DRUG TARGET, V4, P129, DOI 10.3109/10611869609015970; Uster PS, 1996, FEBS LETT, V386, P243, DOI 10.1016/0014-5793(96)00452-8; WALKER SA, 1996, THESIS U CALIFORNIA; Wong JY, 1997, SCIENCE, V275, P820, DOI 10.1126/science.275.5301.820; Zalipsky S, 1996, J CONTROL RELEASE, V39, P153, DOI 10.1016/0168-3659(95)00149-2	22	176	180	0	79	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 1	1997	387	6628					61	64		10.1038/387061a0	http://dx.doi.org/10.1038/387061a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139822				2022-12-28	WOS:A1997WW75800045
J	Ellington, AD; Robertson, MP; Bull, J				Ellington, AD; Robertson, MP; Bull, J			In vitro evolution - Ribozymes in wonderland	SCIENCE			English	Editorial Material							SEQUENCES		UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712; UNIV TEXAS,INST CELL & MOL BIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Ellington, AD (corresponding author), INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405, USA.							BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BREAKER RR, 1994, P NATL ACAD SCI USA, V91, P6093, DOI 10.1073/pnas.91.13.6093; Bull JJ, 1995, J MOL EVOL, V41, P1160, DOI 10.1007/BF00173197; EKLAND EH, 1995, SCIENCE, V269, P364, DOI 10.1126/science.7618102; GUATELLI JC, 1990, P NATL ACAD SCI USA, V87, P1874, DOI 10.1073/pnas.87.5.1874; Wlotzka B, 1997, CHEM BIOL, V4, P25, DOI 10.1016/S1074-5521(97)90234-9; Wright MC, 1997, SCIENCE, V276, P614, DOI 10.1126/science.276.5312.614	7	7	9	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					546	547		10.1126/science.276.5312.546	http://dx.doi.org/10.1126/science.276.5312.546			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9148415				2022-12-28	WOS:A1997WV72100032
J	Lange, JMA				Lange, JMA			Current problems and the future of antiretroviral drug trials	SCIENCE			English	Editorial Material							SOLUBLE CD4; IN-VIVO; THERAPY; NEVIRAPINE; ZIDOVUDINE; INFECTION; RESISTANT; PROTEASE; VIRIONS				Lange, JMA (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,NATL AIDS THERAPY EVALUAT CTR,MEIBERGDREEF 9,NL-1105 AZ AMSTERDAM,NETHERLANDS.							BOUCHER CAB, 1994, VIRAL VARIATION THER; BRYANT M, 1995, ANTIMICROB AGENTS CH, V39, P2229, DOI 10.1128/AAC.39.10.2229; CAMERON B, 1996, 3 C RETR OPP INF WAS; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DEJONG MD, 1994, J INFECT DIS, V169, P1346, DOI 10.1093/infdis/169.6.1346; EMINI EA, 1996, 3 C RETR OPP INF WAS; FOUDRAINE N, 1997, 4 C RETR OPP INF WAS; GEORGES DL, 1995, 2 NAT C HUM RETR REL; Gisslen M, 1997, J INFECT DIS, V175, P434, DOI 10.1093/infdis/175.2.434; GULICK RM, 1996, 11 INT C AIDS VANC 7; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; LANE HC, 1995, 4 INT WORKSH HIV DRU; Lange J M, 1996, Antivir Ther, V1, P126; Lange J M, 1996, Antivir Ther, V1, P69; MANION DJ, 1997, 4 C RETR OPP INF WAS; MARKOWITZ M, 1996, 11 INT C AIDS VANC 7; MASSARI F, 1996, 3 C RETR OPP INF WAS; MATHEZ D, 1996, 11 INT C AIDS VANC 7; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MEYERS MW, 1996, 11 INT C AIDS VANC 7; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PERELSON AS, 1996, 11 INT C AIDS VANC 7; REY D, 1996, ANTIVIR THER, V1, P24; Richman D D, 1996, Antivir Ther, V1, P208; Richman DD, 1996, SCIENCE, V272, P1886, DOI 10.1126/science.272.5270.1886; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Ryan Frank, 1992, FORGOTTEN PLAGUE BAT; SAIMOT AG, 1996, 11 INT C AIDS VANC 7; Schooley Robert T., 1996, AIDS (London), V10, pS1; SCHUURMAN R, 1995, J INFECT DIS, V171, P1431; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; YARCHOAN R, 1994, J INFECT DIS, V169, P9, DOI 10.1093/infdis/169.1.9	38	30	30	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					548	550		10.1126/science.276.5312.548	http://dx.doi.org/10.1126/science.276.5312.548			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9148417	Green Submitted			2022-12-28	WOS:A1997WV72100034
J	Tibbs, GR; Goulding, EH; Siegelbaum, SA				Tibbs, GR; Goulding, EH; Siegelbaum, SA			Allosteric activation and tuning of ligand efficacy in cyclic-nucleotide-gated channels	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR CHANNEL; MOLECULAR MECHANISM; POTASSIUM CHANNELS; INACTIVATION; BINDING; PROTEIN; DOMAIN; SUBUNIT	Despite recent advances in the identification of ligand-binding(1,2) and voltage-sensing(3) regions of ion channels, the domains that couple such regions to channel opening have not been identified, Moreover, it is uncertain whether ligand binding or depolarization are obligatory steps that must precede channel opening (according to linear reaction schemes(4,5)) or whether they act to stabilize the channel in an open state that can exist independently of ligand binding or depolarization (according to cyclic allosteric models(6-8)), By comparing ligand-independent and ligand-dependent channel openings, we now show that retinal and olfactory cyclic-nucleotide-gated channels(2) are activated by a cyclic allosteric mechanism, We further show that an amino-terminal domain, distinct from the pore and ligand-binding motifs, participates in the allosteric gating transition, accounting for differences in the free energy of gating of the two channels, The allosteric transition provides an important mechanism for tuning the physiological response of ligand-binding proteins, such as cyclic-nucleotidegated channels, to different biological signals.	COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT PHARMACOL,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	Tibbs, GR (corresponding author), COLUMBIA UNIV,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,722 W 168 ST,NEW YORK,NY 10032, USA.							Auerbach A, 1996, J PHYSIOL-LONDON, V494, P155, DOI 10.1113/jphysiol.1996.sp021482; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BUBIS J, 1988, J BIOL CHEM, V263, P9668; DELCASTILLO J, 1957, PROC R SOC SER B-BIO, V146, P369; GORDON SE, 1992, NEURON, V9, P739, DOI 10.1016/0896-6273(92)90036-D; GORDON SE, 1995, NEURON, V14, P857, DOI 10.1016/0896-6273(95)90229-5; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; JACKSON MB, 1984, P NATL ACAD SCI-BIOL, V81, P3901, DOI 10.1073/pnas.81.12.3901; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KRAMER RH, 1994, NEURON, V12, P655, DOI 10.1016/0896-6273(94)90220-8; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P977, DOI 10.1085/jgp.102.6.977; PERUTZ M, 1990, MECH COOPERATIVITY A, P10; PICONES A, 1995, J PHYSIOL-LONDON, V485, P699, DOI 10.1113/jphysiol.1995.sp020763; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SHEN NV, 1993, NEURON, V11, P67; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; VARNUM MD, 1995, NEURON, V15, P619, DOI 10.1016/0896-6273(95)90150-7; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	30	92	94	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 10	1997	386	6625					612	615		10.1038/386612a0	http://dx.doi.org/10.1038/386612a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121585				2022-12-28	WOS:A1997WT27300060
J	Maltepe, E; Schmidt, JV; Baunoch, D; Bradfield, CA; Simon, MC				Maltepe, E; Schmidt, JV; Baunoch, D; Bradfield, CA; Simon, MC			Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT	NATURE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; AH-RECEPTOR; TRANSCRIPTIONAL REGULATION; FACTOR EXPRESSION; FACTOR-I; GENES; ELEMENTS; ISCHEMIA; CLONING; CELLS	The arylhydrocarbon-receptor nuclear translocator (ARNT) is a member of the basic-helix-loop-helix-PAS family of heterodimeric transcription factors which includes the arylhydrocarbon receptor (AHR), hypoxia-inducible factor-1 alpha (HIF-1 alpha) and the Drosophila single-minded protein (Sim)(1-4), ARNT forms heterodimeric complexes with the arylhydrocarbon receptor, HIF-1 alpha, Sim and the PAS protein Per(2,4-6). In response to environmental pollutants, AHR-ARNT heterodimers regulate genes involved in the metabolism of xenobiotics(7-9), whereas ARNT-HIF-1 alpha heterodimers probably regulate those involved in the response to oxygen deprivation(10-13). By generating a targeted disruption of the Arnt locus in the mouse, we show here that Arnt(-/-) embryonic stem cells fail to activate genes that normally respond to low oxygen tension, Arnt(-/-) ES cells also failed to respond to a decrease in glucose concentration, indicating that ARNT is crucial in the response to hypoxia and to hypoglycaemia. Arnt(-/-) embryos were not viable past embryonic day 10.5 and showed defective angiogenesis of the yolk sac and branchial arches, stunted development and embryo wasting, The defect in blood vessel formation in Arnt(-/-) yolk sacs is similar to the angiogenic abnormalities reported for mice deficient in vascular endothelial growth factor(14,15) or tissue factor(16). On the basis of these findings, we propose a model in which increasing tissue mass during organogenesis leads to the formation of hyoxic/nutrient-deprived cells, the subsequent activation of ARNT, and a concomitant increase in the expression of genes (including that encoding vascular endothelial growth factor) that promote vascularization of the developing yolk sac and solid tissues.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,MOL GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; NORTHWESTERN UNIV,SCH MED,DEPT MOL PHARMACOL & BIOL CHEM,CHICAGO,IL 60611; UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago; Northwestern University; University of Wisconsin System; University of Wisconsin Madison	Maltepe, E (corresponding author), UNIV CHICAGO,DEPT PATHOL,5841 S MARYLAND AVE,MC 1028,CHICAGO,IL 60637, USA.		Simon, Celeste/AAG-3941-2021					Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; COMPEAU CG, 1994, AM J RESP CELL MOL, V11, P446, DOI 10.1165/ajrcmb.11.4.7917312; Ema M, 1996, BIOCHEM BIOPH RES CO, V218, P588, DOI 10.1006/bbrc.1996.0104; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hirose K, 1996, MOL CELL BIOL, V16, P1706; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Isaac DD, 1996, GENE DEV, V10, P103, DOI 10.1101/gad.10.1.103; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; STEIN I, 1995, MOL CELL BIOL, V15, P5363; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	30	604	616	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					403	407		10.1038/386403a0	http://dx.doi.org/10.1038/386403a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121557				2022-12-28	WOS:A1997WQ17000066
J	Horwich, AL; Weissman, JS				Horwich, AL; Weissman, JS			Deadly conformations - Protein misfolding in prion disease	CELL			English	Review							CREUTZFELDT-JAKOB DISEASE; TRANSMISSIBLE MINK ENCEPHALOPATHY; NEURO-BLASTOMA CELLS; SCRAPIE PRION; TRANSGENIC MICE; CULTURED-CELLS; MOUSE SCRAPIE; CELLULAR PRP; AGENT-STRAIN; BRAIN		YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT MOL & CELLULAR PHARMACOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; Yale University; University of California System; University of California San Francisco	Horwich, AL (corresponding author), YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA.			Weissman, Jonathan/0000-0003-2445-670X				Aguzzi A, 1996, NATURE, V383, P666, DOI 10.1038/383666a0; AIZAWA SI, 1990, J MOL BIOL, V211, P673, DOI 10.1016/0022-2836(90)90064-S; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; ALPER T, 1966, BIOCHEM BIOPH RES CO, V22, P278, DOI 10.1016/0006-291X(66)90478-5; Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; ASAKURA S, 1964, J MOL BIOL, V10, P42, DOI 10.1016/S0022-2836(64)80026-7; ASAKURA S, 1966, J MOL BIOL, V16, P302, DOI 10.1016/S0022-2836(66)80174-2; ASAKURA S, 1968, J MOL BIOL, V35, P237, DOI 10.1016/S0022-2836(68)80051-8; BAKER D, 1994, BIOCHEMISTRY-US, V33, P7505, DOI 10.1021/bi00190a002; BAKER D, 1994, STRUCTURE, V2, P907, DOI 10.1016/S0969-2126(94)00091-3; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Brandner S, 1996, P NATL ACAD SCI USA, V93, P13148, DOI 10.1073/pnas.93.23.13148; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUCE ME, 1976, NEUROPATH APPL NEURO, V2, P471, DOI 10.1111/j.1365-2990.1976.tb00521.x; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CARP RI, 1991, J GEN VIROL, V72, P293, DOI 10.1099/0022-1317-72-2-293; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHESEBRO B, 1985, NATURE, V315, P331, DOI 10.1038/315331a0; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; DEARMOND SJ, 1993, P NATL ACAD SCI USA, V90, P6449, DOI 10.1073/pnas.90.14.6449; DEARMOND SJ, 1995, AM J PATHOL, V146, P785; DEARMOND SJ, 1996, MOL GENETIC BASIS NE, P145; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; EKLUND CM, 1967, J INFECT DIS, V117, P15, DOI 10.1093/infdis/117.1.15; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; FRASER H, 1973, J COMP PATHOL, V83, P29, DOI 10.1016/0021-9975(73)90024-8; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GAJDUSEK DC, 1988, J NEUROIMMUNOL, V20, P95; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; GAJDUSEK DC, 1977, SCIENCE, V197, P943, DOI 10.1126/science.142303; GAJDUSEK DC, 1959, AM J MED, V26, P442, DOI 10.1016/0002-9343(59)90251-7; Gerstmann J., 1936, Z NEUROL, V154, P736, DOI [10.1007/BF02865827, DOI 10.1007/BF02865827]; GIBBS CJ, 1968, SCIENCE, V161, P388, DOI 10.1126/science.161.3839.388; GORDON WS, 1946, VET REC, V58, P518; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HADLOW WJ, 1959, LANCET, V2, P289; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; Heller J, 1996, PROTEIN SCI, V5, P1655, DOI 10.1002/pro.5560050819; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KELLINGS K, 1992, J GEN VIROL, V73, P1025, DOI 10.1099/0022-1317-73-4-1025; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; KIMBERLIN RH, 1979, J COMP PATHOL, V89, P551, DOI 10.1016/0021-9975(79)90046-X; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; Lasmezas CI, 1996, J VIROL, V70, P1292; LATARJET R, 1970, NATURE, V227, P1341, DOI 10.1038/2271341a0; Lledo PM, 1996, P NATL ACAD SCI USA, V93, P2403, DOI 10.1073/pnas.93.6.2403; MANETTO V, 1992, NEUROLOGY, V42, P312, DOI 10.1212/WNL.42.2.312; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; MERZ PA, 1981, ACTA NEUROPATHOL, V54, P63, DOI 10.1007/BF00691333; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; MURAMOTO T, 1992, AM J PATHOL, V140, P1411; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1980, BIOCHEMISTRY-US, V19, P4883, DOI 10.1021/bi00562a028; PRUSINER SB, 1996, MOL GENETIC BASIS NE, P165; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SIFERS RN, 1995, NAT STRUCT BIOL, V2, P355, DOI 10.1038/nsb0595-355; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TAN SY, 1995, AM J KIDNEY DIS, V26, P267, DOI 10.1016/0272-6386(95)90647-9; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Weissmann C, 1996, COLD SPRING HARB SYM, V61, P511; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WHITTINGTON MA, 1995, NAT GENET, V9, P197, DOI 10.1038/ng0295-197; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	114	241	259	1	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	1997	89	4					499	510		10.1016/S0092-8674(00)80232-9	http://dx.doi.org/10.1016/S0092-8674(00)80232-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160742	hybrid			2022-12-28	WOS:A1997WZ32300004
J	Casasnovas, JM; Springer, TA; Liu, JH; Harrison, SC; Wang, JH				Casasnovas, JM; Springer, TA; Liu, JH; Harrison, SC; Wang, JH			Crystals structure of ICAM-2 reveals a distinctive integrin recognition surface	NATURE			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; CELL-ADHESION; PLASMODIUM-FALCIPARUM; BINDING-SITE; IMMUNOGLOBULIN SUPERFAMILY; HUMAN RHINOVIRUS; LFA-1; RECEPTOR; FRAGMENT; DOMAIN-1	Recognition by integrin proteins on the cell surface regulates the adhesive interactions between cells and their surroundings(1,2). The structure of the 'I' domain that is found in some but not all integrins, has been determined(3,4). However, the only integrin ligands for which structures are known, namely fibronectin and VCAM-1 (refs 5-7), are recognized by integrins that lack I domains. The intercellular adhesion molecules ICAM-1, 2 and 3 are, like VCAM-1, members of the immunoglobulin superfamily (IgSF), but they are recognized by an I domain-containing integrin, lymphocyte-function-associated antigen 1 (LFA-1, or CD11a/CD18). Here we present the crystal structure of the extracellular region of ICAM-2. The glutamic acid residue at position 37 is critical for LFA-1 binding and is proposed to coordinate the Mg2+ ion in the I domain; this Glu 37 is surrounded by a relatively flat recognition surface and lies in a beta-strand, whereas the critical aspartic acid residue in VCAM-1 and fibronectin lie in protruding loops. This finding suggests that there are differences in the architecture of recognition sites between integrins that contain or lack I domains. A bend between domains 1 and 2 of ICAM-2 and a tripod-like arrangement of N-linked glycans in the membrane-proximal region of domain 2 may be important for presenting the recognition surface to LFA-1. A model of ICAM-1 based on the ICAM-2 structure provides a framework for understanding its recognition by pathogens.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,DEPT CELLULAR & MOL BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard University; Howard Hughes Medical Institute			Casasnovas, Jose M/L-6299-2014	Casasnovas, Jose M/0000-0002-2873-6410				BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CASASNOVAS JM, 1995, J BIOL CHEM, V270, P13216, DOI 10.1074/jbc.270.22.13216; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; Klickstein LB, 1996, J BIOL CHEM, V271, P23920, DOI 10.1074/jbc.271.39.23920; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MCCLELLAND A, 1991, P NATL ACAD SCI USA, V88, P7993, DOI 10.1073/pnas.88.18.7993; MUSAFIA B, 1995, J MOL BIOL, V254, P761, DOI 10.1006/jmbi.1995.0653; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OCKENHOUSE CF, 1992, CELL, V68, P63, DOI 10.1016/0092-8674(92)90206-R; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; REGISTER RB, 1991, J VIROL, V65, P6589, DOI 10.1128/JVI.65.12.6589-6596.1991; SADHU C, 1994, CELL ADHES COMMUN, V2, P429, DOI 10.3109/15419069409004453; SALI A, 1991, THESIS U LONDON; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714; Wang JH, 1996, ACTA CRYSTALLOGR D, V52, P369, DOI 10.1107/S0907444995012352; WILLIAMS AF, 1987, IMMUNOL TODAY, V8, P298, DOI 10.1016/0167-5699(87)90016-8	31	92	93	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					312	315		10.1038/387312a0	http://dx.doi.org/10.1038/387312a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153399				2022-12-28	WOS:A1997WZ16700060
J	Iskos, D; Lurie, KG; Sakaguchi, S; Benditt, DG				Iskos, D; Lurie, KG; Sakaguchi, S; Benditt, DG			Termination of implantable pacemaker therapy: Experience in five patients	ANNALS OF INTERNAL MEDICINE			English	Article							LYME CARDITIS; HEART-BLOCK	Background: Established guidelines direct the initial implantation of permanent pacemakers, Elective replacement of these devices is common. However, no guidelines exist for the removal of permanent pacemakers and the termination of long-term cardiac pacing. Objective: To describe the feasibility and safety of terminating cardiac pacing in carefully selected patients. Design: Case series, Setting: University hospital, Patients: Five adults with permanent pacemakers who were referred for pacemaker replacement or a complication related to cardiac pacing. All patients showed alleviation or reversal of the electric disturbance that originally led to the implantation of the device. The patients had received a pacemaker for a class I or II indication (that is, symptomatic bradycardia or asymptomatic, persistent third-degree atrioventricular block at the level of the atrioventricular node). Intervention: After an appropriate natural rhythm was documented, pacemakers were removed from all patients. Measurements: Time without recurrence of symptomatic bradycardia. Results: No patient had recurrent symptomatic bradycardia after 18 to 48 months of clinical follow-up. Conclusions: The presence of a permanent pacemaker does not necessarily imply a permanent need for cardiac pacing. Discontinuation of cardiac pacing may be considered in certain patients. Establishing consensus criteria about the potential indications, methods, and timing of the termination of cardiac pacing seems appropriate.	UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities								BLUHM GL, 1985, SCAND J THORAC CARD, V19, P231, DOI 10.3109/14017438509102724; BRENNAN JA, 1979, J TRAUMA, V19, P784, DOI 10.1097/00005373-197910000-00013; BRIGNOLE M, 1992, EUR J CPE, V2, P109; BUCKINGHAM TA, 1991, PACE, V14, P1437, DOI 10.1111/j.1540-8159.1991.tb04060.x; CLARKE M, 1991, BRIT HEART J, V66, P185; DREIFUS LS, 1991, CIRCULATION, V84, P455, DOI 10.1161/01.CIR.84.1.455; FLEG JL, 1983, ARCH INTERN MED, V143, P1821, DOI 10.1001/archinte.143.9.1821; GODMAN MJ, 1974, CIRCULATION, V49, P214, DOI 10.1161/01.CIR.49.2.214; Heimberger T S, 1989, Infect Dis Clin North Am, V3, P221; JOSEPHSON ME, 1993, CLIN CARDIAC ELECTRO, P616; Kusumoto FM, 1996, NEW ENGL J MED, V334, P89, DOI 10.1056/NEJM199601113340206; KUTALEK SP, 1995, CLIN CARDIAC PACING, P523; LEWIS AB, 1985, J THORAC CARDIOV SUR, V89, P758; MCALISTER HF, 1989, ANN INTERN MED, V110, P339, DOI 10.7326/0003-4819-110-5-339; MIYAMOTO Y, 1990, CIRCULATION, V82, P313; NAGI KS, 1995, CAN J CARDIOL, V11, P335; NIELSEN H, 1986, ACTA CARDIOL, V41, P451; OTSUJI Y, 1994, EUR HEART J, V15, P407, DOI 10.1093/oxfordjournals.eurheartj.a060514; Stegman SS, 1996, PACE, V19, P899, DOI 10.1111/j.1540-8159.1996.tb03385.x	19	15	15	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1997	126	10					787	790		10.7326/0003-4819-126-10-199705150-00007	http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ823	9148652				2022-12-28	WOS:A1997WZ82300008
J	Prechtl, HFR; Einspieler, C; Cioni, G; Bos, AF; Ferrari, F; Sontheimer, D				Prechtl, HFR; Einspieler, C; Cioni, G; Bos, AF; Ferrari, F; Sontheimer, D			An early marker for neurological deficits after perinatal brain lesions	LANCET			English	Article							GENERAL MOVEMENTS; QUALITATIVE CHANGES; PRETERM INFANTS; MOTOR BEHAVIOR; TERM INFANTS; MOTILITY; FETUS	Background In normal awake infants, fidgety movements are seen from the age of 6 weeks to 20 weeks. The aim of the study was to test the predictive value of absent or abnormal spontaneous movements in young infants for the later development of neurological deficits. Methods In a collaborative study involving five hospitals we collected data on the normal and abnormal quality of fidgety movements of 130 infants and compared it with assessments of neurological development done longitudinally until the age of 2 years. On the basis of ultrasound scans infants were classified as at low-risk or at high-risk of neurological deficits. Infants were videoed for Ih every week from birth to discharge and then for 15 min every 3 to 4 weeks; quality of general movements was assessed, Repeated neurological assessments were also done until 24 months of corrected age. Findings 67 (96%) of 70 infants with normal fidgety movements had a normal neurological outcome. Abnormal quality or total absence of fidgety movements was followed by neurological abnormalities in 57 (95%) of the 60 infants (49 had cerebral palsy and eight had developmental retardation or minor neurological signs). Specificity and sensitivity of fidgety movement assessment were higher (96% and 95%, respectively) than of ultrasound imaging of the infants' brain (83% and 80%, respectively). Interpretation Our technique of assessing spontaneous motor activity can identify and distinguish between those infants who require early intervention for neurological abnormalities and those who do not. Our technique is simple, non-intrusive, reliable, quick, and can be done on very young infants.	UNIV PISA, INST DEV NEUROL PSYCHIAT & EDUC PSYCHOL, PISA, ITALY; STELLA MARIS FDN, PISA, ITALY; UNIV GRONINGEN, UNIV HOSP GRONINGEN, BEATRIX CHILDRENS HOSP, DIV NEONATOL, DEPT PAEDIAT, GRONINGEN, NETHERLANDS; UNIV HOSP, DIV NEONATOL, DEPT PAEDIAT, MODENA, ITALY; UNIV HOSP, DIV NEONATOL, DEPT PAEDIAT, HEIDELBERG, GERMANY	University of Pisa; IRCCS Fondazione Stella Maris; University of Groningen; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia Hospital; Ruprecht Karls University Heidelberg	Prechtl, HFR (corresponding author), KARL FRANZENS UNIV GRAZ, DEPT PHYSIOL, HARRACHGASSE 21-5, A-8010 GRAZ, AUSTRIA.		Cioni, Giovanni/A-4178-2015; Ferrari, Fabrizio/F-5980-2012	Cioni, Giovanni/0000-0002-6526-5566; Ferrari, Fabrizio/0000-0001-6504-4715				ALBERS S, 1994, BIOL NEONATE, V66, P182; Amiel-Tison C., 1983, NEUROLOGIC EVALUATIO; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; BEKEDAM DJ, 1985, EARLY HUM DEV, V12, P155, DOI 10.1016/0378-3782(85)90178-1; CIONI G, 1990, EARLY HUM DEV, V23, P159, DOI 10.1016/0378-3782(90)90012-8; CIONI G, 1989, EARLY HUM DEV, V18, P247, DOI 10.1016/0378-3782(89)90020-0; CIONI G, 1997, IN PRESS J PEDIAT; DEVRIES JIP, 1982, EARLY HUM DEV, V7, P301, DOI 10.1016/0378-3782(82)90033-0; DEVRIES LS, 1992, BEHAV BRAIN RES, V49, P1, DOI 10.1016/S0166-4328(05)80189-5; EINSPIELER C, 1994, EARLY HUM DEV, V36, P31, DOI 10.1016/0378-3782(94)90031-0; FERRARI F, 1990, EARLY HUM DEV, V23, P193, DOI 10.1016/0378-3782(90)90013-9; GEERDINK JJ, 1993, EUR J PEDIATR, V152, P362, DOI 10.1007/BF01956755; GRIFFITHS R, 1954, ABILITIES BABIES; HADDERSALGRA M, 1992, EARLY HUM DEV, V28, P201, DOI 10.1016/0378-3782(92)90167-F; HOPKINS B, CONTINUITY NEURAL FU; LEVINE MI, 1982, ARCH DIS CHILD, V57, P410; PRECHTL HFR, 1990, EARLY HUM DEV, V23, P151, DOI 10.1016/0378-3782(90)90011-7; PRECHTL HFR, 1986, EARLY HUM DEV, V14, P233, DOI 10.1016/0378-3782(86)90184-2; PRECHTL HFR, 1979, DEV MED CHILD NEUROL, V21, P3; PRECHTL HFR, 1993, EARLY HUM DEV, V35, P91, DOI 10.1016/0378-3782(93)90096-D; PRECHTL HFR, 1989, FETAL NEUROLOGY, P1; TOUWEN BCL, 1976, CDM, V58	22	419	436	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 10	1997	349	9062					1361	1363		10.1016/S0140-6736(96)10182-3	http://dx.doi.org/10.1016/S0140-6736(96)10182-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149699				2022-12-28	WOS:A1997WY34200011
J	Shaper, AG; Wannamethee, SG; Walker, M				Shaper, AG; Wannamethee, SG; Walker, M			Body weight: Implications for the prevention of coronary heart disease, stroke, and diabetes mellitus in a cohort study of middle aged men	BRITISH MEDICAL JOURNAL			English	Article							BRITISH MEN; RISK-FACTORS; BLOOD-LIPIDS; MORTALITY; SMOKING; WOMEN; DEATH	Objective: To determine the body mass index associated with the lowest morbidity and mortality. Design: Prospective study of a male cohort. Setting: One general practice in each of 24 British towns. Subjects:7735 men aged 40-59 years at screening. Main outcome measures: All cause death rate, heart attacks, and stroke (fatal and non-fatal) and development of diabetes, or any of these outcomes (combined end point) over an average follow up of 14.8 years. Results: There were 1271 deaths from all causes, 974 heart attacks, 290 strokes, and 245 new cases of diabetes mellitus. All cause mortality was increased only in men with a body mass index (kg/m(2)) <20 and in men with an index greater than or equal to 30. However, risk of cardiovascular death, heart attack, and diabetes increased progressively from an index of <20 even after age, smoking, social dass, alcohol consumption, and physical activity were adjusted for. For the combined end point the lowest risks were seen for an index of 20.0-23.9. In never smokers and former smokers, deaths from any cause rose progressively from an index of 20.0-21.9 and for the combined end point, from 20.0-23.9. Age adjusted levels of a wide range of cardiovascular risk factors rose or felt progressively from an index <20. Conclusion: A healthy body mass index in these middle aged British men seems to be about 22.			Shaper, AG (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE & POPULAT SCI,LONDON NW3 2PF,ENGLAND.		Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351; Wannamethee, Sasiwarang/0000-0001-9484-9977				*AM HLTH FDN, 1996, AM J CLIN NUTR S, V63, P409; *AM I NUTR, 1994, J NUTR, V124, P2240; Bennett N, 1995, HLTH SURVEY ENGLAND; BYERS T, 1995, NEW ENGL J MED, V333, P723, DOI 10.1056/NEJM199509143331109; COX DR, 1972, J R STAT SOC B, V34, P187; *DEP HLTH, 1995, OB REV INCR PROBL OB; *DEP HTLH, 1992, HLTH NAT STRAT HLTH; GARRISON RJ, 1993, INT J OBESITY, V17, P417; Garrow J. S., 1988, OBESITY RELATED DIS; Jousilahti P, 1996, CIRCULATION, V93, P1372, DOI 10.1161/01.CIR.93.7.1372; KUSHNER RF, 1993, NUTR REV, V51, P127, DOI 10.1111/j.1753-4887.1993.tb03089.x; LARSSON B, 1992, AM J EPIDEMIOL, V135, P266, DOI 10.1093/oxfordjournals.aje.a116280; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Metropolitan Life Foundation New weight standards for men and women, 1959, STAT B, V40, P1; PAMUK ER, 1993, ANN INTERN MED, V119, P744, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00023; PERRY IJ, 1995, BRIT MED J, V310, P560, DOI 10.1136/bmj.310.6979.560; PERRY IJ, IN PRESS AM J EPIDEM; SHAPER AG, 1993, BRIT HEART J, V70, P49; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; THELLE DS, 1983, BRIT HEART J, V49, P205, DOI 10.1136/hrt.49.3.205; TOKUNAGA K, 1991, INT J OBESITY, V15, P1; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WALKER M, 1995, INT J EPIDEMIOL, V24, P694, DOI 10.1093/ije/24.4.694; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; WANNAMETHEE G, 1992, J EPIDEMIOL COMMUN H, V46, P197, DOI 10.1136/jech.46.3.197; WANNAMETHEE G, 1994, J EPIDEMIOL COMMUN H, V48, P112, DOI 10.1136/jech.48.2.112; WILLIAMSON DF, 1995, AM J EPIDEMIOL, V141, P1128, DOI 10.1093/oxfordjournals.aje.a117386	29	164	174	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 3	1997	314	7090					1311	1317		10.1136/bmj.314.7090.1311	http://dx.doi.org/10.1136/bmj.314.7090.1311			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX975	9158466	Green Published			2022-12-28	WOS:A1997WX97500022
J	Abovich, N; Rosbash, M				Abovich, N; Rosbash, M			Cross-intron bridging interactions in the yeast commitment complex are conserved in mammals	CELL			English	Article							PRE-MESSENGER-RNA; 5' SPLICE SITE; SMALL NUCLEAR RIBONUCLEOPROTEIN; U2 SNRNP ADDITION; U1 SNRNA; PREMESSENGER RNA; BIOCHEMICAL-CHARACTERIZATION; POLYPYRIMIDINE TRACT; AUXILIARY FACTOR; WW DOMAIN	The commitment complex is the first defined step in the yeast (S. cerevisiae) splicing pathway. It contains U1 snRNP as well as Mud2p, which resembles human U2AF65. In a genetic screen, we identified the yeast gene MSL-5, which is a novel commitment complex component. Genetic and biochemical criteria indicate a direct interaction between MsI5p and both Mud2p and the U1 snRNP protein Prp40p. This defines a bridge between the two ends of the intron. MsI5p (renamed BBP for branchpoint bridging protein) has a mammalian ortholog, the splicing factor SF1. Our results show that SF1 interacts strongly with human U2AF65, and that SF1 is a bona fide E complex component. This implies that aspects of these novel cross-intron protein-protein interactions are conserved between yeast and mammals.	BRANDEIS UNIV, HOWARD HUGHES MED INST, DEPT BIOL, WALTHAM, MA 02254 USA	Brandeis University; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023549] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-23549] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1994, GENE DEV, V8, P843, DOI 10.1101/gad.8.7.843; Arning S, 1996, RNA, V2, P794; Ast G, 1996, SCIENCE, V272, P881, DOI 10.1126/science.272.5263.881; BEDFORD MT, 1997, IN PRESS EMBO J; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; FABRIZIO P, 1994, SCIENCE, V264, P261, DOI 10.1126/science.8146658; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; FRANK D, 1992, GENE DEV, V6, P2112, DOI 10.1101/gad.6.11.2112; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; JACKSON SP, 1988, MOL CELL BIOL, V8, P1067, DOI 10.1128/MCB.8.3.1067; JAMISON SF, 1992, P NATL ACAD SCI USA, V89, P5482, DOI 10.1073/pnas.89.12.5482; Kao HY, 1996, MOL CELL BIOL, V16, P960; KRAMER A, 1992, MOL CELL BIOL, V12, P4545; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; LEGRAIN P, 1988, MOL CELL BIOL, V8, P3755, DOI 10.1128/MCB.8.9.3755; LIAO XC, 1992, THESIS BRANDEIS U WA; LIAO XLC, 1992, NUCLEIC ACIDS RES, V20, P4237, DOI 10.1093/nar/20.16.4237; LIAO XLC, 1993, GENE DEV, V7, P419, DOI 10.1101/gad.7.3.419; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; NANDABALAN K, 1993, CELL, V73, P407, DOI 10.1016/0092-8674(93)90239-M; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; Rutila JE, 1996, NEURON, V17, P921, DOI 10.1016/S0896-6273(00)80223-8; RYMOND BC, 1985, NATURE, V317, P735, DOI 10.1038/317735a0; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SIEBEL CW, 1995, GENE DEV, V9, P269, DOI 10.1101/gad.9.3.269; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH V, 1991, EMBO J, V10, P2627, DOI 10.1002/j.1460-2075.1991.tb07805.x; TODA T, 1994, HUM MOL GENET, V3, P465, DOI 10.1093/hmg/3.3.465; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHANG Y, 1995, EMBO J, V14, P5358, DOI 10.1002/j.1460-2075.1995.tb00220.x; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	55	277	284	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	1997	89	3					403	412		10.1016/S0092-8674(00)80221-4	http://dx.doi.org/10.1016/S0092-8674(00)80221-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150140	Bronze			2022-12-28	WOS:A1997WX89900011
J	Laherty, CD; Yang, WM; Sun, JM; Davie, JR; Seto, E; Eisenman, RN				Laherty, CD; Yang, WM; Sun, JM; Davie, JR; Seto, E; Eisenman, RN			Histone deacetylases associated with the mSin3 corepressor mediate Mad transcriptional repression	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; RAS COTRANSFORMATION; DNA-BINDING; MYC-MAX; EXPRESSION; PROTEIN; SIN3; MXI1; DIFFERENTIATION; TRANSFORMATION	Transcriptional repression by Mad-Max heterodimers requires interaction of Mad with the corepressors mSin3A/B. Sin3p, the S. cerevisiae homolog of mSin3, functions in the same pathway as Rpd3p, a protein related to two recently identified mammalian histone deacetylases, HDAC1 and HDAC2 Here, we demonstrate that mSin3A and HDAC1/2 are associated in vivo. HDAC2 binding requires a conserved region of mSin3A capable of mediating transcriptional repression. In addition, Mad1 forms a complex with mSin3 and HDAC2 that contains histone deacetylase activity. Trichostatin A, an inhibitor of histone deacetylases, abolishes Mad repression. We propose that Mad-Max functions by recruiting the mSin3-HDAC corepressor complex that deacetylates nucleosomal histones, producing alterations in chromatin structure that block transcription.	UNIV S FLORIDA,H LEE MOFFITT CANC CTR & RES INST,DEPT MED MICROBIOL & IMMUNOL,TAMPA,FL 33612; UNIV MANITOBA,DEPT BIOCHEM & MOL BIOL,WINNIPEG,MB R3E 0W3,CANADA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Manitoba	Laherty, CD (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Yang, Wen-Ming/0000-0002-5871-5979; Davie, James/0000-0002-0420-6888				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BRASIER AR, 1995, CURRENT PROTOCOLS MO, V3; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; DAVIE JR, 1994, J CELL BIOCHEM, V55, P98, DOI 10.1002/jcb.240550112; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; HEINZEL T, 1997, IN PRESS NATURE, V387; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Rao G, 1996, ONCOGENE, V12, P1165; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Roth SY, 1996, NAT GENET, V14, P3, DOI 10.1038/ng0996-3; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; STILLMAN DJ, 1994, GENETICS, V136, P781; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VanLint C, 1996, GENE EXPRESSION, V5, P245; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	48	837	876	0	33	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					349	356		10.1016/S0092-8674(00)80215-9	http://dx.doi.org/10.1016/S0092-8674(00)80215-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150134	Bronze			2022-12-28	WOS:A1997WX89900005
J	Liu, Y; Garceau, NY; Loros, JJ; Dunlap, JC				Liu, Y; Garceau, NY; Loros, JJ; Dunlap, JC			Thermally regulated translational control of FRQ mediates aspects of temperature responses in the Neurospora circadian clock	CELL			English	Article							MESSENGER-RNA; DROSOPHILA; PROTEIN; FREQUENCY; MUTANTS; PERIOD; PHASE; CYANOBACTERIA; COMPENSATION; TIMELESS	Two forms of FRQ, a central component of the Neurospora circadian clock, arise through alternative inframe initiation of translation. Either form alone suffices for a functional clock at some temperatures, but both are always necessary for robust rhythmicity. Temperature regulates the ratio of FRQ forms by favoring different initiation codons at different temperatures; when either initiation codon is eliminated, the temperature range permissive for rhythmicity is demonstrably reduced. This temperature-influenced choice of translation - initiation site represents a novel adaptive mechanism that extends the physiological temperature range over which clocks function. Additionally, a temperature-dependent threshold level of FRQ is required to establish the feedback loop comprising the oscillator. These data may explain how temperature limits permissive for rhythmicity are established, thus providing a molecular understanding for a basic characteristic of circadian clocks.	DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College			Dunlap, Jay/L-6232-2013; Loros, Jennifer/B-6293-2014	Dunlap, Jay/0000-0003-1577-0457; 	NIGMS NIH HHS [GM34985] Funding Source: Medline; NIMH NIH HHS [MH44651, MH01186] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034985, R01GM034985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044651, K05MH001186] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARONSON BD, 1994, P NATL ACAD SCI USA, V91, P7683, DOI 10.1073/pnas.91.16.7683; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BellPedersen D, 1996, P NATL ACAD SCI USA, V93, P13096, DOI 10.1073/pnas.93.23.13096; BellPedersen D, 1996, MOL CELL BIOL, V16, P513; Bunning E, 1973, PHYSL CLOCK; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DUNCAN RF, 1996, TRANSLATIONAL CONTRO, P271; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; FELDMAN J F, 1973, Genetics, V75, P605; FRANCIS CD, 1979, PLANT PHYSIOL, V64, P1000, DOI 10.1104/pp.64.6.1000; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; GOOCH VD, 1994, J BIOL RHYTHM, V9, P83, DOI 10.1177/074873049400900108; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HASTINGS JW, 1957, P NATL ACAD SCI USA, V43, P804, DOI 10.1073/pnas.43.9.804; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; KALMUS HANS, 1934, ZEITSCHR WISS BIOL ABT C ZEITSCHR VERGLEICH PHYSIOL, V20, P405; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LAKINTHOMAS PI, 1991, J BIOL RHYTHM, V6, P281, DOI 10.1177/074873049100600401; LIU Y, 1995, GENE DEV, V9, P1469, DOI 10.1101/gad.9.12.1469; LOROS JJ, 1989, SCIENCE, V243, P385, DOI 10.1126/science.2563175; Luo ZL, 1996, J BACTERIOL, V178, P2172, DOI 10.1128/jb.178.8.2172-2177.1996; MARTINOCATT S, 1992, P NATL ACAD SCI USA, V89, P3731, DOI 10.1073/pnas.89.9.3731; Merrow MW, 1997, P NATL ACAD SCI USA, V94, P3877, DOI 10.1073/pnas.94.8.3877; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Nakashima H, 1996, SEMIN CELL DEV BIOL, V7, P765, DOI 10.1006/scdb.1996.0094; NJUS D, 1977, J COMP PHYSIOL, V117, P335, DOI 10.1007/BF00691559; NJUS D, 1974, NATURE, V248, P116, DOI 10.1038/248116a0; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; SARGENT ML, 1972, PLANT PHYSIOL, V50, P171, DOI 10.1104/pp.50.1.171; SEHGAL A, 1995, SEMIN NEUROSCI, V7, P27, DOI 10.1016/1044-5765(95)90014-4; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SWEENEY BM, 1960, COLD SPRING HARB SYM, V25, P87, DOI 10.1101/SQB.1960.025.01.009; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Worden, 1974, NEUROSCIENCES 3RD ST, P437; ZIMMERMAN WF, 1968, J INSECT PHYSIOL, V14, P669, DOI 10.1016/0022-1910(68)90226-6	43	191	198	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					477	486		10.1016/S0092-8674(00)80228-7	http://dx.doi.org/10.1016/S0092-8674(00)80228-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150147	hybrid			2022-12-28	WOS:A1997WX89900018
J	Campos, EC				Campos, EC			Future directions in the treatment of amblyopia	LANCET			English	Editorial Material											Campos, EC (corresponding author), UNIV BOLOGNA,EYE SERV 1,I-40138 BOLOGNA,ITALY.							CAMPOS E, 1995, SURV OPHTHALMOL, V40, P23, DOI 10.1016/S0039-6257(95)80044-1; CAMPOS EC, 1995, GRAEF ARCH CLIN EXP, V233, P307, DOI 10.1007/BF00177654; Campos EC, 1991, G IT ORTOTTE TEC STR, V8, P185; FoleyNolan A, 1997, BRIT J OPHTHALMOL, V81, P54, DOI 10.1136/bjo.81.1.54; GOTTLOB I, 1992, INVEST OPHTH VIS SCI, V33, P2722; JAMPOLSKY AJ, 1978, S STRAB T NEW ORL AC, P358; REPKA MX, 1993, OPHTHALMOLOGY, V100, P769; VONNOORDEN GK, 1979, AM J OPHTHALMOL, V55, P511	8	11	11	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1190	1190		10.1016/S0140-6736(05)62410-5	http://dx.doi.org/10.1016/S0140-6736(05)62410-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130938				2022-12-28	WOS:A1997WW71700006
J	Bartley, M; Blane, D; Montgomery, S				Bartley, M; Blane, D; Montgomery, S			Socioeconomic determinants of health - Health and the life course: Why safety nets matter .4.	BRITISH MEDICAL JOURNAL			English	Article							NATIONAL BIRTH COHORT; FACTORY CLOSURE; UNEMPLOYMENT	This article argues that a life course approach is necessary to understand social variations in health. This is needed in order to take into account the complex ways in which biological risk interacts with economic, social, and psychological factors in the development of chronic disease. Such an approach reveals biological and social ''critical periods'' during which social policies that will defend individuals against an accumulation of risk are particularly important In many ways, the authors of modern welfare states were implicitly addressing these issues, and the contribution of these policies to present day high standards of health in developed countries should not be ignored.	CHARING CROSS & WESTMINSTER MED SCH, ACAD DEPT PSYCHIAT, LONDON W6 8RP, ENGLAND; UNIV LONDON, ROYAL FREE HOSP, SCH MED, DEPT MED, LONDON NW3 2QG, ENGLAND	Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Bartley, M (corresponding author), UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, MORTIMER ST, LONDON WC1E 6BT, ENGLAND.							ADAMS M, 1988, EMPLOYMENT GAZETTE, V96, P75; ASHTON DN, 1987, ED UNEMPLOYMENT LABO, P160; ATKINSON AB, 1993, AGE WORK SOCIAL SECU, P132; Barker D. J. P., 1994, MOTHERS BABIES DIS L; Barker DJP, 1992, FETAL INFANT ORIGINS; BARTLEY M, 1994, BMJ-BRIT MED J, V309, P1475, DOI 10.1136/bmj.309.6967.1475; Bartley M, 1996, BRIT MED J, V313, P445; Bartley M, 1996, SOCIOL HEALTH ILL, V18, P455, DOI 10.1111/1467-9566.ep10939068; BARTLEY M, 1996, BENEFITS, V17, P2; BEALE N, 1985, J ROY COLL GEN PRACT, V35, P510; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; BLANE D, 1996, HLTH SOCIAL ORG; Brown G., 1978, SOCIAL ORIGINS DEPRE; Butler NR, 1986, BIRTH 5 STUDY HLTH B; CASELLI G, 1991, SOCIOECONOMIC DIFFER, V7, P242; CHARLTON D, 1997, ADULT HLTH HIST ASPE; Cobb S, 1977, TERMINATION CONSEQUE; CONNOLLY S, 1992, OCCUPATIONAL SUCCCES; *DEP EMPL, 1988, EMPLOYMENT GAZETTE, V96, P28; Dorling D, 1995, Geogr Rev (Oxf), V8, P18; DOROZYNSKI A, 1994, BRIT MED J, V308, P1257, DOI 10.1136/bmj.308.6939.1257a; Esping-Anderson G., 1990, 3 WORLDS WELFARE CAP; ESSEN J, 1982, CONTINUITIES CHILDHO; GODDARD G, 1988, EMPLOYMENT GAZETTE, V96, P15; HALPERN DS, 1992, BRIT MED J, V304, P1229, DOI 10.1136/bmj.304.6836.1229; Johnson P., 1996, 2 NATIONS INHERITANC; Kaplan GA, 1996, BRIT MED J, V312, P999; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; KING S, 1988, EMPLOYMENT GAZETTE, V96, P238; KUH DJ, IN PRESS LIFE COURSE; KUH DJL, 1993, SOC SCI MED, V37, P905, DOI 10.1016/0277-9536(93)90145-T; MANN SL, 1992, J EPIDEMIOL COMMUN H, V46, P286, DOI 10.1136/jech.46.3.286; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; MATTIASSON I, 1990, BRIT MED J, V301, P461, DOI 10.1136/bmj.301.6750.461; MONTGOMERY S, 1996, ASS FAMILY CONFLICT; Montgomery SM, 1996, J EPIDEMIOL COMMUN H, V50, P415, DOI 10.1136/jech.50.4.415; POWER C, 1992, HLTH CLASS EARLY YEA; Power C., 1996, HLTH SOCIAL ORG, P188; Pringle Mia Kellmer, 1966, 11000 7 YEAR OLDS 1; ROBINSON JC, 1986, J HEALTH POLIT POLIC, V11, P1, DOI 10.1215/03616878-11-1-1; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P486, DOI 10.2105/AJPH.86.4.486; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; SMITH GD, IN PRESS BMJ; Titmuss, 1958, ESSAYS WELFARE STATE; VANDERLUCHT F, 1995, SOC SCI MED, V40, P1305, DOI 10.1016/0277-9536(94)00185-V; *VAR SUBGR CHIEF M, 1995, VAR HLTH WHAT CAN DE; VIINAMAKI H, 1993, EUR J PSYCHIAT, V7, P95; Wadsworth M. E. J., 1991, IMPRINT TIME CHILDHO; Wunsch G, 1996, EUR J POPUL, V12, P167, DOI 10.1007/BF01797082; Wynn M., 1979, PREVENTION HANDICAP	50	144	149	2	21	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 19	1997	314	7088					1194	1196		10.1136/bmj.314.7088.1194	http://dx.doi.org/10.1136/bmj.314.7088.1194			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WV705	9146402	Green Published			2022-12-28	WOS:A1997WV70500037
J	Mead, GM				Mead, GM			ABC of clinical haematology - Malignant lymphomas and chronic lymphocytic leukaemia	BRITISH MEDICAL JOURNAL			English	Article											Mead, GM (corresponding author), ROYAL S HANTS HOSP,WESSEX MED ONCOL UNIT,SOUTHAMPTON SO9 4PE,HANTS,ENGLAND.							AISENBERG AC, 1995, J CLIN ONCOL, V13, P2656, DOI 10.1200/JCO.1995.13.10.2656; DEVITA VT, 1993, NEW ENGL J MED, V328, P560; OBRIEN S, 1995, BLOOD, V85, P307	3	10	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 12	1997	314	7087					1103	1106		10.1136/bmj.314.7087.1103	http://dx.doi.org/10.1136/bmj.314.7087.1103			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU236	9133896	Green Published			2022-12-28	WOS:A1997WU23600032
J	Cai, RH; Pouget, A; SchlagRey, M; Schlag, J				Cai, RH; Pouget, A; SchlagRey, M; Schlag, J			Perceived geometrical relationships affected by eye-movement signals	NATURE			English	Article							VERNIER ACUITY; VISUAL HYPERACUITY; NEURONS; CORTEX; TASKS; REPRESENTATION; POSITION; SACCADES; VISION; CELLS	To determine the location of visual objects relative to the observer, the visual system must take account not only of the location of the stimulus on the retina, but also of the direction of gaze(1). In contrast, the perceived spatial relationship between visual stimuli is normally assumed to depend on retinal information alone, and not to require information about eye position. We now show, however, that the perceived alignment of three dots-tested by a veinier alignment task(2,3)-is systematically altered in the period immediately preceding a saccade. Thus, information about eye position can modify not only the perceived relationship of the entire retinal image to the observer, but also the relations between elements within the image. The processing of relative position and of egocentric (observer-centred) position may therefore be less distinct than previously believed(4-6).	GEORGETOWN UNIV,INST COGNIT & COMPUTAT SCI,WASHINGTON,DC 20007	Georgetown University	Cai, RH (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90095, USA.			Pouget, Alexandre/0000-0003-3054-6365				ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; DEVALOIS RL, 1991, VISION RES, V31, P1619, DOI 10.1016/0042-6989(91)90138-U; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; FAHLE M, 1981, PROC R SOC SER B-BIO, V213, P451, DOI 10.1098/rspb.1981.0075; GALLETTI C, 1989, J NEUROSCI, V9, P1112; GROLL SL, 1987, J OPT SOC AM A, V4, P1535, DOI 10.1364/JOSAA.4.001535; Grusser O J, 1982, Hum Neurobiol, V1, P73; HONDA H, 1991, VISION RES, V31, P1915, DOI 10.1016/0042-6989(91)90186-9; Honda H., 1990, ATTENTION PERFORM, V13, P567; LEVI DM, 1994, VISION RES, V34, P2215, DOI 10.1016/0042-6989(94)90104-X; Levi DM, 1996, VISION RES, V36, P2111, DOI 10.1016/0042-6989(95)00264-2; LINDBLOM B, 1989, J OPT SOC AM A, V6, P585, DOI 10.1364/JOSAA.6.000585; MACKAY DM, 1973, HDB SENSORY PHYSIOLO, V7, P307; MATIN L, 1972, HDB SENSORY PHYSIOL, V7, P307; PARKER A, 1985, J OPT SOC AM A, V2, P1101, DOI 10.1364/JOSAA.2.001101; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; Pouget A, 1997, J COGNITIVE NEUROSCI, V9, P222, DOI 10.1162/jocn.1997.9.2.222; POUGET A, 1993, J COGNITIVE NEUROSCI, V5, P150, DOI 10.1162/jocn.1993.5.2.150; Ross J, 1997, NATURE, V386, P598, DOI 10.1038/386598a0; SCHLAG J, 1995, VISION RES, V35, P2347, DOI 10.1016/0042-6989(95)00021-Q; SHAPLEY R, 1986, SCIENCE, V231, P999, DOI 10.1126/science.3945816; SWINDALE NV, 1986, NATURE, V319, P591, DOI 10.1038/319591a0; TROTTER Y, 1992, SCIENCE, V257, P1279, DOI 10.1126/science.1519066; VOLKMANN FC, 1969, J OPT SOC AM, V58, P562; WEHRHAHN C, 1993, VISUAL NEUROSCI, V10, P13, DOI 10.1017/S0952523800003187; WESTHEIMER G, 1977, VISION RES, V17, P941, DOI 10.1016/0042-6989(77)90069-4; WESTHEIMER G, 1975, INVEST OPHTH VISUAL, V14, P570; WEYAND TG, 1993, J NEUROPHYSIOL, V69, P2258, DOI 10.1152/jn.1993.69.6.2258; WHITAKER D, 1992, VISION RES, V32, P1481, DOI 10.1016/0042-6989(92)90204-V	29	95	95	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 10	1997	386	6625					601	604		10.1038/386601a0	http://dx.doi.org/10.1038/386601a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121582				2022-12-28	WOS:A1997WT27300057
J	Ross, J; Morrone, MC; Burr, DC				Ross, J; Morrone, MC; Burr, DC			Compression of visual space before saccades	NATURE			English	Article							EYE-MOVEMENTS; DISPLACEMENT; REPRESENTATION; LOCALIZATION; IMAGE	Saccadic eye movements, in which the eye moves rapidly between two resting positions, shift the position of our retinal images, If our perception of the world is to remain stable, the visual directions associated with retinal sites, and others they report to, must be updated to compensate for changes in the point of gaze, It has long been suspected that this compensation is achieved by a uniform shift of coordinates driven by an extraretinal position signal(1-3), although some consider this to be unnecessary(4-6). Considerable effort has been devoted to a search for such a signal and to measuring its time course and accuracy, Here, by using multiple as well as single targets under normal viewing conditions, we show that changes in apparent visual direction anticipate saccades and are not of the same size, or even in the same direction, for all parts of the visual field, We also show that there is a compression of visual space sufficient to reduce the spacing and even the apparent number of pattern elements,The results are in part consistent with electrophysiological findings of anticipatory shifts in the receptive fields of neurons in parietal cortex(7) and superior colliculi(8).	CNR,IST NEUROFISIOL,I-56127 PISA,ITALY; UNIV ROMA LA SAPIENZA,DEPT PSYCHOL,I-00185 ROME,ITALY; UNIV WESTERN AUSTRALIA,DEPT PSYCHOL,VIS LAB,NEDLANDS,WA 6907,AUSTRALIA	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of Western Australia			Morrone, Maria Concetta/C-6756-2014	Morrone, Maria Concetta/0000-0002-1025-0316; Burr, David/0000-0003-1541-8832				BENHAMED S, 1996, SOC NEUR ABSTR, P1619; BISCHOF N, 1968, PSYCHOL FORSCH, V32, P185, DOI 10.1007/BF00418660; BOWEN RW, 1981, VISION RES, V21, P1457, DOI 10.1016/0042-6989(81)90216-9; BRIDGEMAN B, 1991, VISION RES, V31, P1903, DOI 10.1016/0042-6989(91)90185-8; BRIDGEMAN B, 1994, BEHAV BRAIN SCI, V17, P247, DOI 10.1017/S0140525X00034361; BURR DC, 1994, NATURE, V371, P511, DOI 10.1038/371511a0; DANIEL PM, 1961, J PHYSIOL-LONDON, V159, P203, DOI 10.1113/jphysiol.1961.sp006803; DASSONVILLE P, 1992, VISUAL NEUROSCI, V9, P261, DOI 10.1017/S0952523800010671; Deubel H, 1996, VISION RES, V36, P985, DOI 10.1016/0042-6989(95)00203-0; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; HONDA H, 1995, VISION RES, V35, P3021, DOI 10.1016/0042-6989(95)00108-C; HONDA H, 1993, VISION RES, V33, P709, DOI 10.1016/0042-6989(93)90190-8; MACKAY DM, 1970, NATURE, V225, P90, DOI 10.1038/225872a0; MATIN L, 1965, SCIENCE, V148, P1485, DOI 10.1126/science.148.3676.1485; MATIN L, 1972, HDB SENSORY PHYSIOLO, V7, P331; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; OREGAN JK, 1984, PERCEPT PSYCHOPHYS, V36, P1, DOI 10.3758/BF03206348; Sperling G., 1990, EYE MOVEMENTS THEIR, P307; SPERRY RW, 1950, J COMP PHYSIOL PSYCH, V43, P482, DOI 10.1037/h0055479; VONHELMHOLTZ H, 1866, HDB PHYSIOL OPTIK; VONHOLST E, 1954, NATURWISSENSCHAFTEN, V37, P464; WALKER MF, 1995, J NEUROPHYSIOL, V73, P1988, DOI 10.1152/jn.1995.73.5.1988	22	345	346	1	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 10	1997	386	6625					598	601		10.1038/386598a0	http://dx.doi.org/10.1038/386598a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121581				2022-12-28	WOS:A1997WT27300056
J	Mathiowitz, E; Jacob, JS; Jong, YS; Carino, GP; Chickering, DE; Chaturvedi, P; Santos, CA; Vijayaraghavan, K; Montgomery, S; Bassett, M; Morrell, C				Mathiowitz, E; Jacob, JS; Jong, YS; Carino, GP; Chickering, DE; Chaturvedi, P; Santos, CA; Vijayaraghavan, K; Montgomery, S; Bassett, M; Morrell, C			Biologically erodable microsphere as potential oral drug delivery system	NATURE			English	Article							DIRECT GENE-TRANSFER; PEYERS PATCHES; BIOADHESIVE MICROSPHERES; BIOERODIBLE POLYMERS; MUSCLE INVIVO; LATEX; POLYANHYDRIDES; MICROSCOPY; EPITHELIUM; PARTICLES	Biologically adhesive delivery systems offer important advantages(1-5) over conventional drug delivery systems(6). Here we show that engineered polymer microspheres made of biologically erodable polymers, which display strong adhesive interactions with gastrointestinal mucus and cellular linings, can traverse both the mucosal absorptive epithelium and the follicle-associated epithelium covering the lymphoid tissue of Peyer's patches. The polymers maintain contact with intestinal epithelium for extended periods of time and actually penetrate it, through and between cells. Thus, once loaded with compounds of pharmacological interest, the microspheres could be developed as delivery systems to transfer biologically active molecules to the circulation, We show that these microspheres increase the absorption of three model substances of widely different molecular size: dicumarol, insulin and plasmid DNA.			Mathiowitz, E (corresponding author), BROWN UNIV,DEPT MOL PHARMACOL PHYSIOL & BIOTECHNOL,DIV BIOL & MED,PROVIDENCE,RI 02912, USA.							AKERS MJ, 1973, J PHARM SCI, V62, P391, DOI 10.1002/jps.2600620308; [Anonymous], 1990, BIODEGRADABLE POLYM; BOCKMAN DE, 1973, AM J ANAT, V136, P455, DOI 10.1002/aja.1001360406; Carino G., 1995, P 22 INT S CONTR REL, P314; Chickering D, 1996, BIOTECHNOL BIOENG, V52, P96, DOI 10.1002/(SICI)1097-0290(19961005)52:1<96::AID-BIT9>3.0.CO;2-U; CHICKERING DE, 1995, REACT POLYM, V25, P189, DOI 10.1016/0923-1137(94)00098-P; CHICKERING DE, 1995, J CONTROL RELEASE, V34, P251, DOI 10.1016/0168-3659(95)00011-V; DAVIS SS, 1988, BIOMATERIALS, V9, P111, DOI 10.1016/0142-9612(88)90081-6; DOMB AJ, 1991, J POLYM SCI POL CHEM, V29, P571, DOI 10.1002/pola.1991.080290413; ERMAK TH, 1995, CELL TISSUE RES, V279, P433, DOI 10.1007/s004410050300; FLORENCE AT, 1994, DRUG SAFETY, V10, P233, DOI 10.2165/00002018-199410030-00005; FLORENCE AT, 1995, J CONTROL RELEASE, V36, P39, DOI 10.1016/0168-3659(95)00059-H; FRISBIE CD, 1994, SCIENCE, V265, P2071, DOI 10.1126/science.265.5181.2071; Goodman L., 1975, PHARM BASIS THERAPEU; HILLERY AM, 1994, J DRUG TARGET, V2, P151, DOI 10.3109/10611869409015904; JACOB J, 1995, P 22 INT S CONTR REL, P312; JANI P, 1990, J PHARM PHARMACOL, V42, P821, DOI 10.1111/j.2042-7158.1990.tb07033.x; JANI P, 1989, J PHARM PHARMACOL, V41, P809, DOI 10.1111/j.2042-7158.1989.tb06377.x; LAU C, 1995, HUM GENE THER, V6, P1145, DOI 10.1089/hum.1995.6.9-1145; LEE SW, 1993, CIRC RES, V73, P797, DOI 10.1161/01.RES.73.5.797; LEFEVRE ME, 1978, P SOC EXP BIOL MED, V159, P298; LEFEVRE ME, 1985, P SOC EXP BIOL MED, V179, P522; Lenaerts V., 1990, BIOADHESIVE DRUG DEL, P93; MATHIOWITZ E, 1993, MACROMOLECULES, V26, P6756, DOI 10.1021/ma00077a010; Peppas N.A., 1987, HYDROGELS MED PHARM; PONCHEL G, 1991, HIGH PERFORMANCE BIO, P231; SANDERS E, 1961, EXP CELL RES, V22, P137, DOI 10.1016/0014-4827(61)90092-1; TUTWILER GF, 1978, DIABETES, V27, P856, DOI 10.2337/diabetes.27.8.856; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WOLFF JA, 1991, BIOTECHNIQUES, V11, P474	30	703	798	3	200	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					410	414		10.1038/386410a0	http://dx.doi.org/10.1038/386410a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121559				2022-12-28	WOS:A1997WQ17000068
J	Pini, P				Pini, P			A history for the future	LANCET			English	Editorial Material																		PRICE R, 1995, J ROY SOC MED, V88, pP280	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					820	820		10.1016/S0140-6736(05)61749-7	http://dx.doi.org/10.1016/S0140-6736(05)61749-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121255				2022-12-28	WOS:A1997WP40300008
J	vanderVliet, JA; Boll, APM				vanderVliet, JA; Boll, APM			Abdominal aortic aneurysm	LANCET			English	Article							TERM RELATIVE SURVIVAL; RISK-FACTORS; OPERATIVE MORTALITY; SCREENING-PROGRAM; IRISH POPULATION; III PROCOLLAGEN; EXPANSION RATE; CARDIAC RISK; PREVALENCE; ULTRASOUND				vanderVliet, JA (corresponding author), UNIV NIJMEGEN ST RADBOUD HOSP,DEPT SURG,DIV VASC & TRANSPLANT SURG,POB 9101,NL-6500 HB NIJMEGEN,NETHERLANDS.							ADAMS DCR, 1993, EUR J VASCULAR SURG, V7, P709, DOI 10.1016/S0950-821X(05)80721-2; ADAMSON J, 1992, BRIT J SURG, V79, P897, DOI 10.1002/bjs.1800790914; AKKERSDIJK GJM, 1994, BRIT J SURG, V81, P706, DOI 10.1002/bjs.1800810526; AUNE S, 1995, EUR J VASC ENDOVASC, V10, P338, DOI 10.1016/S1078-5884(05)80053-X; AUNE S, 1995, EUR J VASC ENDOVASC, V9, P293, DOI 10.1016/S1078-5884(05)80133-9; BARON JF, 1994, NEW ENGL J MED, V330, P663, DOI 10.1056/NEJM199403103301002; BAXENDALE B, 1995, BRIT J ANAESTH, V74, P138; BEATTIE DK, 1996, TRIALS TRIBULATIONS, P153; BEEDE SD, 1990, ARCH INTERN MED, V150, P549, DOI 10.1001/archinte.150.3.549; BENGTSSON H, 1992, BRIT J SURG, V79, P1142, DOI 10.1002/bjs.1800791108; BENGTSSON H, 1989, WORLD J SURG, V13, P266, DOI 10.1007/BF01659032; BENGTSSON H, 1992, EUR J SURG, V158, P19; BENGTSSON H, 1993, BRIT J SURG, V80, P718, DOI 10.1002/bjs.1800800613; Bergqvist David, 1994, P49; Blum U, 1997, NEW ENGL J MED, V336, P13, DOI 10.1056/NEJM199701023360103; CARTY GA, 1993, J VASC SURG, V17, P696, DOI 10.1016/0741-5214(93)90113-Z; COLLIN J, 1993, BRIT J SURG, V80, P518; CRONENWETT JL, 1990, J VASC SURG, V11, P260; FITZGERALD P, 1995, BRIT J SURG, V82, P483, DOI 10.1002/bjs.1800820418; GARGIULO M, 1993, EUR J VASCULAR SURG, V7, P546, DOI 10.1016/S0950-821X(05)80368-8; HOLDSWORTH JD, 1994, BRIT J SURG, V81, P710, DOI 10.1002/bjs.1800810527; JOHANSEN K, 1991, J VASC SURG, V13, P240, DOI 10.1016/0741-5214(91)90216-H; JOHNSTON KW, 1991, J VASC SURG, V13, P452, DOI 10.1067/mva.1991.26737; JOHNSTON KW, 1994, J VASC SURG, V20, P163, DOI 10.1016/0741-5214(94)90002-7; KATZ DA, 1994, J VASC SURG, V19, P580; Law M R, 1994, J Med Screen, V1, P110; LEDERLE FA, 1988, ARCH INTERN MED, V148, P1753, DOI 10.1001/archinte.148.8.1753; LEDERLE FA, 1994, AM J MED, V94, P163; LIMET R, 1991, J VASC SURG, V14, P540, DOI 10.1016/0741-5214(91)90249-T; LORENZ M, 1994, BRIT J SURG, V81, P839, DOI 10.1002/bjs.1800810615; LOUWRENS HD, 1993, INT ANGIOL, V12, P21; Louwrens Hendrik, 1994, P11; LUCAROTTI M, 1993, EUR J VASCULAR SURG, V7, P397, DOI 10.1016/S0950-821X(05)80256-7; MACSWEENEY STR, 1994, BRIT J SURG, V81, P935, DOI 10.1002/bjs.1800810704; MCMILLAN WD, 1995, J VASC SURG, V22, P295, DOI 10.1016/S0741-5214(95)70144-3; MOORE WS, 1994, ANN SURG, V220, P331, DOI 10.1097/00000658-199409000-00009; MORRIS GE, 1994, EUR J VASCULAR SURG, V8, P156, DOI 10.1016/S0950-821X(05)80451-7; MULUK SC, 1994, J VASC SURG, V20, P880, DOI 10.1016/0741-5214(94)90224-0; Nasim A, 1996, BRIT J SURG, V83, P810, DOI 10.1002/bjs.1800830626; OHARA PJ, 1995, J VASC SURG, V21, P830, DOI 10.1016/S0741-5214(05)80015-1; Ong G, 1996, J CLIN PATHOL, V49, P102, DOI 10.1136/jcp.49.2.102; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; PETERSEN MJ, 1995, J VASC SURG, V21, P891, DOI 10.1016/S0741-5214(95)70216-4; PLEUMEEKERS HJCM, 1994, EUR J VASCULAR SURG, V8, P119, DOI 10.1016/S0950-821X(05)80446-3; Pleumeekers HJCM, 1995, AM J EPIDEMIOL, V142, P1291, DOI 10.1093/oxfordjournals.aje.a117596; POLDERMANS D, 1993, CIRCULATION, V87, P1506, DOI 10.1161/01.CIR.87.5.1506; POWELL JT, 1993, BRIT J SURG, V80, P1246, DOI 10.1002/bjs.1800801008; POWELL JT, 1992, ATHEROSCLEROSIS, V97, P201, DOI 10.1016/0021-9150(92)90132-Z; POWELL JT, 1996, TRIALS TRIBULATIONS, P163; RAMSBOTTOM D, 1994, EUR J VASCULAR SURG, V8, P716, DOI 10.1016/S0950-821X(05)80652-8; REED D, 1992, CIRCULATION, V85, P205, DOI 10.1161/01.CIR.85.1.205; RUSSELL AJ, 1990, BRIT MED J, V301, P446, DOI 10.1136/bmj.301.6749.446; SALAMAN RA, 1994, BRIT J SURG, V81, P661, DOI 10.1002/bjs.1800810509; SATTA J, 1995, J VASC SURG, V22, P155, DOI 10.1016/S0741-5214(95)70110-9; SCOTT RAP, 1994, BRIT J SURG, V81, P1440, DOI 10.1002/bjs.1800811010; SHAPIRA OM, 1990, J CARDIOVASC SURG, V31, P170; SIMONI G, 1995, EUR J VASC ENDOVASC, V10, P207, DOI 10.1016/S1078-5884(05)80113-3; SLOOTMANS FCW, 1994, EUR J VASCULAR SURG, V8, P342, DOI 10.1016/S0950-821X(05)80153-7; SMITH FCT, 1993, BRIT J SURG, V80, P1406, DOI 10.1002/bjs.1800801117; StLeger AS, 1996, EUR J VASC ENDOVASC, V11, P183, DOI 10.1016/S1078-5884(96)80049-9; TENNANT WG, 1993, J VASC SURG, V17, P730; Thomas P R, 1994, J Med Screen, V1, P3; TILSON MD, 1993, J VASC SURG, V18, P266, DOI 10.1016/0741-5214(93)90607-N; TROMP G, 1993, J CLIN INVEST, V91, P2539, DOI 10.1172/JCI116490; TROMPMEESTERS RC, 1994, BRIT J SURG, V81, P512; TWOMEY A, 1986, INT ANGIOL, V5, P269; Van Ramshorst B, 1990, CAUSE MANAGEMENT ANE, P433; vanderVliet JA, 1996, SURGERY, V119, P129, DOI 10.1016/S0039-6060(96)80158-9; VERLOES A, 1995, J VASC SURG, V21, P646, DOI 10.1016/S0741-5214(95)70196-6; WEBSTER MW, 1991, J VASC SURG, V13, P9; Wolf Y G, 1994, Cardiovasc Surg, V2, P16	71	89	91	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					863	866						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121274				2022-12-28	WOS:A1997WP40300045
J	Schindelin, N; Kisker, C; Sehlessman, JL; Howard, JB; Rees, DC				Schindelin, N; Kisker, C; Sehlessman, JL; Howard, JB; Rees, DC			Structure of ADP center dot AIF(4)(-)-stabilized nitrogenase complex and its implications for signal transduction	NATURE			English	Article							MOLYBDENUM-IRON PROTEIN; AZOTOBACTER-VINELANDII; CRYSTAL-STRUCTURE; GTP HYDROLYSIS; CRYSTALLOGRAPHIC STRUCTURE; CONFORMATIONAL-CHANGES; FE-PROTEIN; MECHANISM; MGATP; PROGRAM	The coupling of ATP hydrolysis to electron transfer by the enzyme nitrogenase during biological nitrogen fixation is an important example of a nucleotide-dependent transduction mechanism. The crystal structure has been determined for the complex between the Fe-protein and MoFe-protein components of nitrogenase stabilized by ADP AlF4-, previously used as a nucleoside triphosphate analogue in nucleotide-switch proteins. The structure reveals that the dimeric re-protein has undergone substantial conformational changes. The beta-phosphate and AlF4- groups are stabilized through intersubunit contacts that are critical for catalysis and the redox centre is repositioned to facilitate electron transfer. Interactions in the nitrogenase complex have broad implications for signal and energy transduction mechanisms In multiprotein complexes.	UNIV MINNESOTA, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA; CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA	University of Minnesota System; University of Minnesota Twin Cities; California Institute of Technology			Schindelin, Hermann/Q-2697-2019; Kisker, Caroline/T-1724-2019	Kisker, Caroline/0000-0002-0216-6026				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOLIN JT, 1993, ACS SYM SER, V535, P186; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; CHEN L, 1994, J BIOL CHEM, V269, P3290; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Duyvis MG, 1996, FEBS LETT, V380, P233, DOI 10.1016/0014-5793(96)00019-1; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HOWARD JB, 1993, ACS SYM SER, V535, P271; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANZILOTTA WN, 1995, BIOCHEMISTRY-US, V34, P10713, DOI 10.1021/bi00034a003; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUDDEN PW, 1989, CURR TOP CELL REGUL, V30, P23; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MORTENSON LE, 1993, ADV ENZYMOL RAMB, V67, P299; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; PETERS JW, 1995, ANNU REV MICROBIOL, V49, P335, DOI 10.1146/annurev.mi.49.100195.002003; Renner KA, 1996, BIOCHEMISTRY-US, V35, P5353, DOI 10.1021/bi960441o; RYLE MJ, 1995, J BIOL CHEM, V270, P13112, DOI 10.1074/jbc.270.22.13112; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P4766, DOI 10.1021/bi960026w; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SEEFELDT LC, 1993, PROTEIN SCI, V2, P93; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Stiefel E. I., 1993, MOLYBDENUM ENZYMES C; WILLING A, 1990, J BIOL CHEM, V265, P6596; WOLLE D, 1992, J BIOL CHEM, V267, P3667; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643	44	409	416	2	39	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 22	1997	387	6631					370	376		10.1038/387370a0	http://dx.doi.org/10.1038/387370a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163420				2022-12-28	WOS:A1997XA49600051
J	Massad, SL				Massad, SL			The delivery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	1997	277	18					1420	1420						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX852	9145698				2022-12-28	WOS:A1997WX85200001
J	Gostin, L				Gostin, L			HIV-prevention strategies	LANCET			English	Letter											Gostin, L (corresponding author), GEORGETOWN UNIV,CTR LAW,WASHINGTON,DC 20001, USA.							Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P392; Gostin LO, 1997, JAMA-J AM MED ASSOC, V277, P53, DOI 10.1001/jama.277.1.53; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; Lurie P, 1997, LANCET, V349, P604, DOI 10.1016/S0140-6736(96)05439-6	4	0	0	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1394	1395		10.1016/S0140-6736(05)63233-3	http://dx.doi.org/10.1016/S0140-6736(05)63233-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WY342	9149721				2022-12-28	WOS:A1997WY34200050
J	vanHaeften, TW; deVries, J; Sixma, JJ				vanHaeften, TW; deVries, J; Sixma, JJ			Concordance of phenprocoumon dosage in married couples	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WARFARIN		UNIV UTRECHT HOSP, DEPT HAEMATOL, NL-3508 GA UTRECHT, NETHERLANDS	Utrecht University; Utrecht University Medical Center	vanHaeften, TW (corresponding author), UNIV UTRECHT HOSP, DEPT INTERNAL MED G02228, THROMBOSIS SERV, POB 85500, NL-3508 GA UTRECHT, NETHERLANDS.							BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CERMEER C, 1991, THROMB HAEMOSTASIS, V66, P153; COLVIN BT, 1990, J CLIN PATHOL, V43, P177; PEDERSEN FM, 1991, J INTERN MED, V229, P517, DOI 10.1111/j.1365-2796.1991.tb00388.x; ROUTLEDGE PA, 1979, BRIT J CLIN PHARMACO, V8, P243, DOI 10.1111/j.1365-2125.1979.tb01009.x	5	6	6	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 10	1997	314	7091					1386	1386						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ169	9161311				2022-12-28	WOS:A1997WZ16900027
J	Cavert, W; Notermans, DW; Staskus, K; Wietgrefe, SW; Zupancic, M; Gebhard, K; Henry, K; Zhang, ZQ; Mills, R; McDade, H; Goudsmit, J; Danner, SA; Haase, AT				Cavert, W; Notermans, DW; Staskus, K; Wietgrefe, SW; Zupancic, M; Gebhard, K; Henry, K; Zhang, ZQ; Mills, R; McDade, H; Goudsmit, J; Danner, SA; Haase, AT			Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection	SCIENCE			English	Article							LYMPHOCYTES	In lymphoid tissue, where human immunodeficiency virus-type 1 (HIV-1) is produced and stored, three-drug treatment with viral protease and reverse transcriptase inhibitors markedly reduced viral burden. This was shown by in situ hybridization and computerized quantitative analysis of serial tonsil biopsies from previously untreated adults. The frequency of productive mononuclear cells (MNCs) initially diminished with a half-life of about 1 day. Surprisingly, the amount of HIV-1 RNA in virus trapped on follicular dendritic cells (FDCs) decreased almost as quickly. After 24 weeks, MNCs with very few copies of HIV-1 RNA per cell were still detectable, as was proviral DNA; however, the amount of FDC-associated virus decreased by greater than or equal to 3.4 log units. Thus, 6 months of potent therapy controlled active replication and cleared >99.9 percent of virus from the secondary lymphoid tissue reservoir.	UNIV MINNESOTA,SCH MED,DEPT MICROBIOL,MINNEAPOLIS,MN 55455; UNIV AMSTERDAM,ACAD MED CTR,DIV INFECT DIS TROP MED & AIDS,NL-1100 DE AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,NATL AIDS THERAPY CTR,NL-1100 DE AMSTERDAM,NETHERLANDS; ST PAUL RAMSEY MED CTR,HIV PROGRAM,ST PAUL,MN 55101; UNIV MINNESOTA,SCH MED,DEPT MED,MINNEAPOLIS,MN 55455; ABBOTT LABS,ABBOTT PK,IL 60064; GLAXO WELLCOME RES & DEV LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND	University of Minnesota System; University of Minnesota Twin Cities; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Saint Paul Ramsey Medical Center; University of Minnesota System; University of Minnesota Twin Cities; Abbott Laboratories; GlaxoSmithKline					NIAID NIH HHS [AI 28246, AI 25017] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI028246, R01AI025017] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRAHIC M, 1989, CURR TOP MICROBIOL, V143, P9; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COHEN OJ, 1995, P NATL ACAD SCI USA, V92, P6017, DOI 10.1073/pnas.92.13.6017; Cohen OJ, 1996, J INFECT DIS, V173, P849, DOI 10.1093/infdis/173.4.849; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Faust RA, 1996, OTOLARYNG HEAD NECK, V114, P593, DOI 10.1016/S0194-5998(96)70252-8; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; Haase AT, 1987, IN SITU HYBRIDIZATIO, P197; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Lafeuillade A, 1996, J INFECT DIS, V174, P404, DOI 10.1093/infdis/174.2.404; MANDEL TE, 1980, IMMUNOL REV, V53, P29, DOI 10.1111/j.1600-065X.1980.tb01039.x; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; NOTERMANS DW, UNPUB; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Zhang Z., UNPUB	19	485	496	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					960	964		10.1126/science.276.5314.960	http://dx.doi.org/10.1126/science.276.5314.960			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9139661	Green Submitted			2022-12-28	WOS:A1997WY79200051
J	McCauley, J; Kern, DE; Kolodner, K; Dill, L; Schroeder, AF; DeChant, HK; Ryden, J; Derogatis, LR; Bass, EB				McCauley, J; Kern, DE; Kolodner, K; Dill, L; Schroeder, AF; DeChant, HK; Ryden, J; Derogatis, LR; Bass, EB			Clinical characteristics of women with a history of childhood abuse - Unhealed wounds	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC PELVIC PAIN; SEXUAL ABUSE; PHYSICAL ABUSE; GASTROINTESTINAL DISORDERS; PSYCHIATRIC DIAGNOSES; PREVALENCE; POPULATION; SYMPTOMS; SAMPLE; HEALTH	Objectives.-To determine the prevalence of childhood physical or sexual abuse in women seen in primary care practices; to identify physical and psychologic problems associated with that abuse; and to compare the effects of childhood physical vs sexual abuse and childhood vs adult abuse. Design.-Cross-sectional, self-administered, anonymous survey. Setting.-Four community-based, primary care internal medicine practices. Patients.-A total of 1931 women of varied age and marital, educational, and economic status examined from February through July 1993. Main Outcome Measures.-Prevalence of physical and sexual abuse, physical symptoms, psychological symptoms (Symptom Checklist-22), alcohol abuse (CAGE questions), and street drug use. Results.-Of the 1931 respondents, 424 (22.0%) reported childhood or adolescent physical or sexual abuse. Compared with women who reported never having experienced abuse (n=1257), women who reported abuse as children but not adults (n=204) had more physical symptoms (mean+/-SE, 6.2+/-0.2 vs 4.0+/-0.9; P<.001) and had higher scores for depression, anxiety, somatization, and interpersonal sensitivity (low self-esteem) (P<.001); were more likely to be abusing drugs (prevalence ratio [PR], 4.7; 95% confidence interval [CI], 2.9-7.6) or to have a history of alcohol abuse (PR, 2.2; 95% CI, 1.5-3.2); were more likely to have attempted suicide (PR, 3.7; 95% CI, 2.6-5.1); and were more likely to have had a psychiatric admission (PR, 3.2; 95% CI, 2.2-4.7). Women abused only as children did not differ from women who reported current, but not childhood, abuse in number of physical symptoms, emotional distress, substance abuse, or suicide attempts. Patients who reported both childhood and adult abuse had higher levels of psychological problems and physical symptoms than those who reported childhood or adult abuse alone. Conclusions.-Childhood physical or sexual abuse is associated with adult health problems including physical symptoms, psychological problems, and substance abuse; for many variables, this association is as strong as for patients experiencing current abuse.	JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD; MONTGOMERY CTY HLTH DEPT,MONTGOMERY,AL; MED COLL PENN & HAHNEMANN UNIV,DEPT CLIN PSYCHOL,PHILADELPHIA,PA	Johns Hopkins University; Drexel University				Bass, Eric/0000-0001-9106-527X				BAGLEY C, 1986, SOCIAL WORK PRAC SEX; BALA M, 1994, CAN FAM PHYSICIAN, V40, P925; BARSKY AJ, 1994, AM J PSYCHIAT, V151, P397; BENDIXEN M, 1994, CHILD ABUSE NEGLECT, V18, P837, DOI 10.1016/0145-2134(94)90063-9; BERESFORD TP, 1990, LANCET, V336, P482, DOI 10.1016/0140-6736(90)92022-A; Betts T, 1992, Seizure, V1, P27, DOI 10.1016/1059-1311(92)90051-2; BRIERE J, 1988, CHILD ABUSE NEGLECT, V12, P51, DOI 10.1016/0145-2134(88)90007-5; BROWN GR, 1991, AM J PSYCHIAT, V148, P55; BRYER JB, 1987, AM J PSYCHIAT, V144, P1426; BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; BURNAM MA, 1988, J CONSULT CLIN PSYCH, V56, P843, DOI 10.1037/0022-006X.56.6.843; CARLIN AS, 1994, CHILD ABUSE NEGLECT, V18, P393, DOI 10.1016/0145-2134(94)90024-8; Checkoway H., 1989, RES METHODS OCCUPATI; CHU JA, 1990, AM J PSYCHIAT, V147, P887; Derogatis L. R., 1994, ADM SCORING PROCEDUR; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; DROSSMAN DA, 1995, ANN INTERN MED, V123, P782, DOI 10.7326/0003-4819-123-10-199511150-00007; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828, DOI 10.7326/0003-4819-113-11-828; FELITTI VJ, 1991, SOUTHERN MED J, V84, P328, DOI 10.1097/00007611-199103000-00008; Femina D, 1990, CHILD ABUSE NEGLECT, V14, P227, DOI DOI 10.1016/0145-2134(90)90033-P; FINKELHOR D, 1987, PSYCHIAT ANN, V17, P233, DOI 10.3928/0048-5713-19870401-06; FOX KM, 1994, CHILD ABUSE NEGL, V8, P849; Gidycz C A, 1989, Violence Vict, V4, P139; HARROPGRIFFITHS J, 1988, OBSTET GYNECOL, V71, P589; LECHNER ME, 1993, J FAM PRACTICE, V36, P633; LONGSTRETH GF, 1993, DIGEST DIS SCI, V38, P1581, DOI 10.1007/BF01303163; MCCAULEY J, 1995, ANN INTERN MED, V123, P737, DOI 10.7326/0003-4819-123-10-199511150-00001; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; MOELLER TP, 1993, CHILD ABUSE NEGLECT, V17, P623, DOI 10.1016/0145-2134(93)90084-I; MULLEN PE, 1988, LANCET, V1, P841; OGATA SN, 1990, AM J PSYCHIAT, V147, P1008; PRIBOR EF, 1992, AM J PSYCHIAT, V149, P52; PRIBOR EF, 1993, AM J PSYCHIAT, V150, P1507; RAPKIN AJ, 1990, OBSTET GYNECOL, V76, P90; REITER RC, 1991, AM J OBSTET GYNECOL, V165, P104, DOI 10.1016/0002-9378(91)90235-J; ROWAN AB, 1994, CHILD ABUSE NEGLECT, V18, P51, DOI 10.1016/0145-2134(94)90095-7; Russell D E, 1983, Child Abuse Negl, V7, P133, DOI 10.1016/0145-2134(83)90065-0; SCARINCI IC, 1994, AM J MED, V97, P108, DOI 10.1016/0002-9343(94)90020-5; SEDNEY MA, 1984, J AM ACAD CHILD PSY, V23, P215, DOI 10.1097/00004583-198403000-00015; SIEGEL JM, 1987, AM J EPIDEMIOL, V126, P1141, DOI 10.1093/oxfordjournals.aje.a114752; SLOCUMB JC, 1989, GEN HOSP PSYCHIAT, V11, P48, DOI 10.1016/0163-8343(89)90025-X; SPRINGS FE, 1992, MAYO CLIN PROC, V67, P527, DOI 10.1016/S0025-6196(12)60458-3; STRAUS MA, 1994, ADOLESCENCE, V29, P543; SWETT C, 1991, AM J DRUG ALCOHOL AB, V17, P49, DOI 10.3109/00952999108992809; TALLEY NJ, 1994, GASTROENTEROLOGY, V107, P1040, DOI 10.1016/0016-5085(94)90228-3; WALKER E, 1988, AM J PSYCHIAT, V145, P75; WALKER E, 1992, PSYCHOSOM MED, V4, P658; Walker E A, 1993, J Am Board Fam Pract, V6, P465; WALLING MK, 1994, OBSTET GYNECOL, V84, P200; WISSOW LS, 1995, NEW ENGL J MED, V332, P1425, DOI 10.1056/NEJM199505253322107; WYATT GE, 1986, CHILD ABUSE NEGLECT, V10, P231, DOI 10.1016/0145-2134(86)90084-0	51	696	705	0	68	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	1997	277	17					1362	1368		10.1001/jama.277.17.1362	http://dx.doi.org/10.1001/jama.277.17.1362			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WW261	9134941				2022-12-28	WOS:A1997WW26100025
J	Wallace, R; Wallace, D				Wallace, R; Wallace, D			Socioeconomic determinants of health - Community marginalisation and the diffusion of disease and disorder in the United States	BRITISH MEDICAL JOURNAL			English	Article							DYNAMICS; AIDS	This article describes the cascading diffusion of ''inner city problems'' of disease and disorder in the United States-from the huge marginalised inner city communities of the largest municipalities, first along national travel routes to smaller cities, and then from central cities into surrounding more affluent suburbs-following the pattern of the daily journey to work public policies and economic practices which increase marginalisation act to damage the ''weak ties'' of the community social networks which bind central city neighbourhoods into functioning units. Spreading disease and disorder can be interpreted as indices of the resulting social disintegration, which is driven by policy. This ''failure of containment'' in the United States should serve as a warning for cities in Europe against reducing the municipal and other services that they provide to ''unpopular'' subpopulations.	NEW YORK STATE PSYCHIAT INST & HOSP,NEW YORK,NY 10032; PUBL INTEREST SCI CONSULTING SERV INC,NEW YORK,NY 10027	New York State Psychiatry Institute								ABLER R, 1971, SPAIAL ORG GEOGRAPHE; *COL U CTR CHILDR, 1996, ONE 4 AM YOUNGEST PO; GRANOVETTER MS, 1973, AM J SOCIOL, V78, P1360, DOI 10.1086/225469; HOLLING CS, 1992, ECOL MONOGR, V62, P447, DOI 10.2307/2937313; MCCORD C, 1990, NEW ENGL J MED, V322, P173, DOI 10.1056/NEJM199001183220306; *NAT RES COUNC, 1993, SOCIAL IMPACT AIDS U; WALLACE D, 1990, AM J PUBLIC HEALTH, V85, P875; WALLACE R, 1995, ENVIRON PLANN A, V27, P1085, DOI 10.1068/a271085; Wallace R, 1997, SOC SCI MED, V44, P935, DOI 10.1016/S0277-9536(96)00197-9; WALLACE R, 1990, SOC SCI MED, V31, P801, DOI 10.1016/0277-9536(90)90175-R; Wallace R, 1997, ENVIRON PLANN A, V29, P525, DOI 10.1068/a290525; WALLACER, 1996, SOC SCI MED, V43, P339	12	80	83	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 3	1997	314	7090					1341	1345		10.1136/bmj.314.7090.1341	http://dx.doi.org/10.1136/bmj.314.7090.1341			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WX975	9158474	Green Published			2022-12-28	WOS:A1997WX97500031
J	Dalakas, MC				Dalakas, MC			Intravenous immune globulin therapy for neurologic diseases	ANNALS OF INTERNAL MEDICINE			English	Article							GUILLAIN-BARRE-SYNDROME; MULTIFOCAL MOTOR NEUROPATHY; IMMUNOGLOBULIN THERAPY; GAMMA-GLOBULIN; MYASTHENIA-GRAVIS; PLASMA-EXCHANGE; KAWASAKI SYNDROME; DRUG-THERAPY; DOUBLE-BLIND; B-CELL	High-dose intravenous immune globulin (IVIg) has emerged as an important therapy for various neurologic diseases. Different interpretations of clinical trial results; the expected benefit of IVIg compared with that of alternate therapies; and issues about IVIg's safety, cost, and mechanisms of action have raised concern and uncertainty among practitioners. To clarify these areas, this paper examines the clinical, serologic, and immunologic data on more than 110 patients with various autoimmune neurologic diseases who received IVIg during the past 6 years at the National Institute of Neurological Disorders and Stroke. It also reviews work by other investigators on the efficacy, risks, benefits, and mechanisms of the action of IVIg in these diseases. In controlled clinical trials, IVIg has been effective in treating the Guillain-Barre syndrome, multifocal motor neuropathy, chronic inflammatory demyelinating polyneuropathy, and dermatomyositis. In other controlled or open-label trials and case reports, IVIg produced improvement in several patients with the Lambert-Eaton myasthenic syndrome and myasthenia gravis but had a variable, mild, or unsubstantiated benefit in some patients with inclusion-body myositis, paraproteinemic IgM demyelinating polyneuropathy, certain intractable childhood epilepsies, polymyositis, multiple sclerosis, optic neuritis, and the stiff-man syndrome. The primary adverse reaction was headache; aseptic meningitis, skin reactions, thromboembolic events, and renal tubular necrosis occurred rarely. The most relevant immunomodulatory actions of IVIg, operating alone or in combination, are inhibition of complement deposition, neutralization of cytokines, modulation of Fc-receptor-mediated phagocytosis, and downregulation of autoantibody production. Therapy with IVIg is effective for certain autoimmune neurologic diseases, but its spectrum of efficacy has not been fully established. Additional controlled clinical trials are needed.			Dalakas, MC (corresponding author), NIH, NINDS,BLDG 10,ROOM 4N248,10 CTR DR, MSC 1382, BETHESDA, MD 20892 USA.							ABE Y, 1994, IMMUNOL REV, V139, P5, DOI 10.1111/j.1600-065X.1994.tb00854.x; ACHIRON A, 1992, ARCH NEUROL-CHICAGO, V49, P1233, DOI 10.1001/archneur.1992.00530360031013; AHSAN N, 1994, ARCH INTERN MED, V154, P1985, DOI 10.1001/archinte.154.17.1985; ALEZMARTINEZ JE, 1993, IMMUNOL TODAY, V12, P201; AZULAY JP, 1994, NEUROLOGY, V44, P429, DOI 10.1212/WNL.44.3_Part_1.429; Bain PG, 1996, NEUROLOGY, V47, P678, DOI 10.1212/WNL.47.3.678; BASTA M, 1994, J CLIN INVEST, V94, P1729, DOI 10.1172/JCI117520; BASTA M, 1989, J CLIN INVEST, V84, P1974, DOI 10.1172/JCI114387; BERKMAN SA, 1990, ANN INTERN MED, V112, P278, DOI 10.7326/0003-4819-112-4-278; BIRD SJ, 1992, NEUROLOGY, V42, P1422, DOI 10.1212/WNL.42.7.1422; BJORKANDER J, 1987, J CLIN IMMUNOL, V7, P8, DOI 10.1007/BF00915419; BLASCZYK R, 1993, LANCET, V341, P789, DOI 10.1016/0140-6736(93)90563-V; BLICK KE, 1985, PRINCIPLES CLIN CHEM, P401; BOOM BW, 1988, ARCH DERMATOL, V124, P1550, DOI 10.1001/archderm.124.10.1550; BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207; BURKS AW, 1986, NEW ENGL J MED, V314, P560, DOI 10.1056/NEJM198602273140907; CAPPA M, 1994, J NEUROL NEUROSUR PS, V57, P69, DOI 10.1136/jnnp.57.Suppl.69; CASTRO LHM, 1993, NEUROLOGY, V43, P1034, DOI 10.1212/WNL.43.5.1034; CHANLAM D, 1987, LANCET, V1, P1436; CHAUDHRY V, 1993, ANN NEUROL, V33, P237, DOI 10.1002/ana.410330303; CONSTANTINESCU CS, 1993, NEW ENGL J MED, V329, P583, DOI 10.1056/NEJM199308193290820; COOK D, 1996, NEUROLOGY, V40, P792; COSI V, 1991, ACTA NEUROL SCAND, V84, P81, DOI 10.1111/j.1600-0404.1991.tb04912.x; DALAKAS MC, 1994, NEUROLOGY, V44, P223, DOI 10.1212/WNL.44.2.223; DALAKAS MC, 1994, ARCH NEUROL-CHICAGO, V51, P861, DOI 10.1001/archneur.1994.00540210031010; DALAKAS MC, 1995, ANN INTERN MED, V122, P316, DOI 10.7326/0003-4819-122-4-199502150-00021; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; Dalakas MC, 1997, NEUROLOGY, V48, P712, DOI 10.1212/WNL.48.3.712; DALAKAS MC, 1995, ANN NEUROL, V38, P302; DALAKAS MC, 1981, ANN NEUROL, V9, P134, DOI 10.1002/ana.410090719; DIETRICH G, 1990, J CLIN INVEST, V85, P620, DOI 10.1172/JCI114483; *DUTCH GUILL BARR, 1994, ANN NEUROL, V35, P741; DWYER JM, 1992, NEW ENGL J MED, V326, P107; DYCK PJ, 1994, ANN NEUROL, V36, P838, DOI 10.1002/ana.410360607; Eibl M M, 1989, Immunodefic Rev, V1 Suppl, P1; ELLIE E, 1992, NEW ENGL J MED, V327, P1032; ENGELHARD D, 1986, J PEDIATR-US, V108, P77, DOI 10.1016/S0022-3476(86)80772-7; Fazekas F, 1997, LANCET, V349, P589, DOI 10.1016/S0140-6736(96)09377-4; GAJDOS P, 1994, CLIN EXP IMMUNOL, V97, P49; HAGUE RA, 1990, BLUT, V61, P66, DOI 10.1007/BF02076702; Hahn AF, 1996, BRAIN, V119, P1067, DOI 10.1093/brain/119.4.1067; HART YM, 1994, NEUROLOGY, V44, P1030, DOI 10.1212/WNL.44.6.1030; HARTUNG HP, 1995, MUSCLE NERVE, V18, P137, DOI 10.1002/mus.880180202; Heafield MTE, 1996, LANCET, V347, P28, DOI 10.1016/S0140-6736(96)91559-7; Helveston WR, 1996, NEUROLOGY, V46, P584, DOI 10.1212/WNL.46.2.584; Hughes RAC, 1997, LANCET, V349, P225; IMBACH P, 1981, LANCET, V1, P1228; Imbach P., 1991, IMMUNOTHERAPY INTRAV; IRANI DN, 1993, NEUROLOGY, V43, P872, DOI 10.1212/WNL.43.5.872; JANN S, 1992, J NEUROL NEUROSUR PS, V55, P60, DOI 10.1136/jnnp.55.1.60; JAYNE DRW, 1991, LANCET, V337, P1137, DOI 10.1016/0140-6736(91)92797-6; KARLSON HW, 1994, ARTHRITIS RHEUM-US, V37, P915, DOI 10.1002/art.1780370621; Kaveri S, 1996, J CLIN INVEST, V97, P865, DOI 10.1172/JCI118488; KAZATCHKINE MD, 1994, IMMUNOL REV, V139, P79, DOI 10.1111/j.1600-065X.1994.tb00858.x; KAZATCHKINE MD, 1996, INTRAVENOUS IMMUNOGL; KIPPS TJ, 1989, ADV IMMUNOL, V47, P117, DOI 10.1016/S0065-2776(08)60663-X; KLEYWEG RP, 1991, J NEUROL NEUROSUR PS, V54, P957, DOI 10.1136/jnnp.54.11.957; KOFFMAN B, 1995, NEUROLOGY, V45, pA235; KURLANDER RJ, 1980, J CLIN INVEST, V66, P773, DOI 10.1172/JCI109915; KURLANDER RJ, 1986, J CLIN INVEST, V77, P2010, DOI 10.1172/JCI112530; KURODA Y, 1991, J NEUROL, V238, P309, DOI 10.1007/BF00315327; LEGER JM, 1994, J NEUROL NEUROSUR PS, V57, P46, DOI 10.1136/jnnp.57.Suppl.46; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; Malik U, 1996, ANN NEUROL, V39, P136, DOI 10.1002/ana.410390121; MARCHALONIS JJ, 1992, P NATL ACAD SCI USA, V89, P3325, DOI 10.1073/pnas.89.8.3325; MCKHANN, 1985, NEUROLOGY, V35, P1096; MIKOL J, 1994, MYOLOGY, P1384; MOLL JWB, 1993, J NEUROL NEUROSUR PS, V56, P112, DOI 10.1136/jnnp.56.1.112; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; NOBILEORAZIO E, 1993, NEUROLOGY, V43, P537, DOI 10.1212/WNL.43.3_Part_1.537; RIGAL D, 1994, CLIN IMMUNOL IMMUNOP, V71, P309, DOI 10.1006/clin.1994.1091; ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706; ROUX KH, 1990, J IMMUNOL, V144, P1387; SCHIFF RI, 1994, NEW ENGL J MED, V331, P1649, DOI 10.1056/NEJM199412153312409; SEKUL EA, 1994, ANN INTERN MED, V121, P259, DOI 10.7326/0003-4819-121-4-199408150-00004; SILBERT PL, 1992, NEUROLOGY, V42, P257, DOI 10.1212/WNL.42.1.257; SOUEIDAN SA, 1993, NEUROLOGY, V43, P876, DOI 10.1212/WNL.43.5.876; STEG RE, 1994, NEUROLOGY, V44, P1180, DOI 10.1212/WNL.44.6.1180; SVENSON M, 1993, J CLIN INVEST, V92, P2533, DOI 10.1172/JCI116862; TAKANO H, 1994, MUSCLE NERVE, V17, P1073, DOI 10.1002/mus.880170919; TAKEI S, 1993, J CLIN INVEST, V91, P602, DOI 10.1172/JCI116240; TANKERSLEY DL, 1988, MOL IMMUNOL, V25, P41, DOI 10.1016/0161-5890(88)90088-0; Uchuya M, 1996, J NEUROL NEUROSUR PS, V60, P388, DOI 10.1136/jnnp.60.4.388; UHER F, 1986, J IMMUNOL, V137, P3124; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; VANENGELEN BGM, 1994, J NEUROL NEUROSUR PS, V57, P72, DOI 10.1136/jnnp.57.Suppl.72; VANENGELEN BGM, 1992, ANN NEUROL, V32, P834, DOI 10.1002/ana.410320624; VARELA F, 1991, P NATL ACAD SCI USA, V88, P5917, DOI 10.1073/pnas.88.13.5917; VASSILEV T, 1993, CLIN EXP IMMUNOL, V92, P369; Voltz R, 1996, NEUROLOGY, V46, P250, DOI 10.1212/WNL.46.1.250; WIJDICKS EFM, 1994, MUSCLE NERVE, V17, P1494; WOODRUFF RK, 1986, LANCET, V2, P217; Younger DS, 1996, MUSCLE NERVE, V19, P722; 1994, MMWR-MORBID MORTAL W, V43, P505; 1987, AM J MED, V83, P1; 1994, J NEUROL NEUROSURG S, V57, P1	97	190	203	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1997	126	9					721	730		10.7326/0003-4819-126-9-199705010-00008	http://dx.doi.org/10.7326/0003-4819-126-9-199705010-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW147	9139559				2022-12-28	WOS:A1997WW14700008
J	Welsh, J				Welsh, J			Electroshock torture and the spread of stun technology	LANCET			English	Editorial Material											Welsh, J (corresponding author), AMNESTY INT,LONDON WC1X 8DJ,ENGLAND.							*AMN INT, 1996, 514596 AMR AI; *AMN INT, 1997, 400497 ACT AI	2	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1247	1247		10.1016/S0140-6736(97)30017-8	http://dx.doi.org/10.1016/S0140-6736(97)30017-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130960				2022-12-28	WOS:A1997WW71700044
J	Merlo, IM; Poloni, TE; Alfonsi, E; Messina, AL; Ceroni, M				Merlo, IM; Poloni, TE; Alfonsi, E; Messina, AL; Ceroni, M			Sciatic pain in a young sportsman	LANCET			English	Article							PIRIFORMIS MUSCLE SYNDROME		UNIV PAVIA,IRCCS,FDN INST NEUROL C MONDINO,I-27100 PAVIA,ITALY; HOSP SONDALO,DEPT NEUROSURG,SONDRIO,ITALY	IRCCS Fondazione Casimiro Mondino; University of Pavia			ceroni, mauro/G-7080-2011; Poloni, Tino Emanuele/AAH-6768-2020	ceroni, mauro/0000-0002-8947-5007; 				BEATTY RA, 1994, NEUROSURGERY, V34, P512, DOI 10.1227/00006123-199403000-00018; DURRANI Z, 1991, J PAIN SYMPTOM MANAG, V6, P374, DOI 10.1016/0885-3924(91)90029-4; PAPADOPOULOS SM, 1990, ARCH NEUROL-CHICAGO, V47, P1144, DOI 10.1001/archneur.1990.00530100114027; SAYSON SC, 1994, PAIN, V59, P149, DOI 10.1016/0304-3959(94)90060-4; YEOMAN W, 1928, LANCET, V2, P1119	5	13	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					846	846						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121261				2022-12-28	WOS:A1997WP40300014
J	Gelb, MH				Gelb, MH			Protein biochemistry - Protein prenylation, et cetera: Signal transduction in two dimensions	SCIENCE			English	Editorial Material							GAMMA SUBUNITS CONTAIN; METHYL-ESTER; BINDING; GERANYLGERANYLTRANSFERASE; TRANSFERASE; MEMBRANES; FARNESYL; P21RAS; ENZYME; YEAST		UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Gelb, MH (corresponding author), UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195, USA.			gelb, michael/0000-0001-7000-5219				BHATTACHARYA S, 1995, P NATL ACAD SCI USA, V92, P2984, DOI 10.1073/pnas.92.7.2984; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Dudler T, 1996, J BIOL CHEM, V271, P11541, DOI 10.1074/jbc.271.19.11541; DUDLER T, UNPUB; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GELB MH, UNPUB; GHOMASHCHI F, 1995, BIOCHEMISTRY-US, V34, P11910, DOI 10.1021/bi00037a032; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; Koblan KS, 1996, BIOCHEM SOC T, V24, P688, DOI 10.1042/bst0240688; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LIU LW, IN PRESS J BIOL CHEM; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; Yokoyama K, 1997, J BIOL CHEM, V272, P3944, DOI 10.1074/jbc.272.7.3944; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	26	134	137	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1750	1751		10.1126/science.275.5307.1750	http://dx.doi.org/10.1126/science.275.5307.1750			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9122679				2022-12-28	WOS:A1997WP05600026
J	Peifer, M				Peifer, M			Cancer - beta-catenin as oncogene: The smoking gun	SCIENCE			English	Editorial Material											Peifer, M (corresponding author), UNIV N CAROLINA,DEPT BIOL,CB 3280,CHAPEL HILL,NC 27599, USA.		Peifer, Mark/A-1152-2010	Peifer, Mark/0000-0003-1412-3987				Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Peifer M, 1996, SCIENCE, V272, P974, DOI 10.1126/science.272.5264.974; POLLACK A, IN PRESS; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	16	290	325	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1752	1753		10.1126/science.275.5307.1752	http://dx.doi.org/10.1126/science.275.5307.1752			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9122680				2022-12-28	WOS:A1997WP05600028
J	Badgett, RG; OKeefe, M; Henderson, MC				Badgett, RG; OKeefe, M; Henderson, MC			Using systematic reviews in clinical education	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICAL LITERATURE; ALCOHOLIC HEPATITIS; INFORMATION NEEDS; METAANALYSIS; PHYSICIANS; KNOWLEDGE; SCIENCE; TRIALS; CARE	Traditional educational methods change clinical practice only with considerable effort and difficulty. In particular, the teaching of critical appraisal in the setting of journal clubs does not increase the amount of medical research read by trainees. Experiential learning theory, corroborated by the success of problem-based learning, encourages us to link learning to the numerous medical questions that physicians generate while providing patient care. Systematic reviews can link these questions with the results of research that would otherwise be difficult to locate, read, and appraise. Systematic reviews are a uniquely powerful mechanism for teaching, and they offer teachers a new opportunity to model rational and effective use of information. Systematic reviews should be made available at clinical sites for use during ''teachable moments.'' Resistance to the use of systematic reviews can be reduced by using existing journal clubs to teach about the strengths and limitations of these reviews. The point that systematic reviews are meant to assist, not replace, clinical decision making deserves emphasis in such teaching.	AUDIE L MURPHY MEM VET ADM MED CTR, SAN ANTONIO, TX 78284 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Badgett, RG (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT MED, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.			Badgett, Robert/0000-0003-2888-3303				Alguire PC, 1996, ANN INTERN MED, V124, P321, DOI 10.7326/0003-4819-124-3-199602010-00007; ANDERSON C, 1992, NATURE, V357, P5; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; AUDET N, 1993, CAN MED ASSOC J, V148, P945; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; BAILAR JC, 1995, J CLIN EPIDEMIOL, V48, P149, DOI 10.1016/0895-4356(94)00149-K; *CAN COMM GROUP, 1994, CAN TASK FORC PER HL, P870; COLLINS R, 1995, LANCET, V345, P1374; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; CRONIN L, 1995, CRIT CARE MED, V23, P1430, DOI 10.1097/00003246-199508000-00019; CURLEY SP, 1990, MED DECIS MAKING, V10, P231, DOI 10.1177/0272989X9001000401; DALEN JE, 1995, P CHEST, V108, pS225; DAVIDOFF F, 1996, WHO HAS SEEN BLOOD S, P44; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; FREY FJ, 1992, SCHWEIZ MED WSCHR, V122, P137; HAYNES RB, 1990, ANN INTERN MED, V112, P78, DOI 10.7326/0003-4819-112-1-78; HAYNES RB, 1990, ANN INTERN MED, V113, P69, DOI 10.7326/0003-4819-113-1-69; Hunt DL, 1997, ANN INTERN MED, V126, P532, DOI 10.7326/0003-4819-126-7-199704010-00006; IMPERIALE TF, 1990, ANN INTERN MED, V113, P299, DOI 10.7326/0003-4819-113-4-299; KING PD, 1996, ACP J CLUB, V124, P13; Kolb D.A, 2014, EXPERIENTIAL LEARNIN, V2nd ed., DOI DOI 10.1016/B978-0-7506-7223-8.50017-4; LANDRY FJ, 1994, J GEN INTERN MED, V9, P436, DOI 10.1007/BF02599058; LEFERING R, 1995, CRIT CARE MED, V23, P1294, DOI 10.1097/00003246-199507000-00021; LINZER M, 1988, JAMA-J AM MED ASSOC, V260, P2537, DOI 10.1001/jama.260.17.2537; MACARTHUR C, 1995, J CLIN EPIDEMIOL, V48, P739, DOI 10.1016/0895-4356(94)00190-2; MESSER J, 1983, NEW ENGL J MED, V309, P21, DOI 10.1056/NEJM198307073090105; MOBERGWOLFF EA, 1995, AM J PHYS MED REHAB, V74, P224, DOI 10.1097/00002060-199505000-00008; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; MULROW CD, 1996, COCHRANE COLLABORATI; NEIHOUSE PF, 1989, DICP ANN PHARMAC, V23, P594, DOI 10.1177/1060028089023007-813; OSHEROFF JA, 1991, ANN INTERN MED, V114, P576, DOI 10.7326/0003-4819-114-7-576; OXMAN AD, 1993, ANN NY ACAD SCI, V703, P125, DOI 10.1111/j.1749-6632.1993.tb26342.x; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; PATERSONBROWN S, 1995, BRIT J OBSTET GYNAEC, V102, P297, DOI 10.1111/j.1471-0528.1995.tb09135.x; RAMOND MJ, 1992, NEW ENGL J MED, V326, P507, DOI 10.1056/NEJM199202203260802; ROSENBERG W, 1995, BMJ-BRIT MED J, V310, P1122, DOI 10.1136/bmj.310.6987.1122; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; Schultz HJ, 1996, ANN INTERN MED, V124, P340, DOI 10.7326/0003-4819-124-3-199602010-00011; SIDOROV J, 1995, ARCH INTERN MED, V155, P1193, DOI 10.1001/archinte.155.11.1193; Steiner CA, 1996, J GEN INTERN MED, V11, P294, DOI 10.1007/BF02598272; *US PREV SERV TASK, 1996, GUID CLIN REV SERV R, P159; VERNON DTA, 1994, ACAD MED, V69, P472, DOI 10.1097/00001888-199406000-00012; WILLIAMSON JW, 1989, ANN INTERN MED, V110, P151, DOI 10.7326/0003-4819-110-2-151; 1996, ACP J CLUB, V124, P13	46	21	23	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1997	126	11					886	891		10.7326/0003-4819-126-11-199706010-00006	http://dx.doi.org/10.7326/0003-4819-126-11-199706010-00006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA911	9163290				2022-12-28	WOS:A1997XA91100006
J	Pfeffer, LM; Mullersman, JE; Pfeffer, SR; Murti, A; Shi, W; Yang, CH				Pfeffer, LM; Mullersman, JE; Pfeffer, SR; Murti, A; Shi, W; Yang, CH			STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor	SCIENCE			English	Article							PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; ALPHA/BETA RECEPTOR; EXPRESSION; ACTIVATION; CLONING; SUBUNIT; CELLS; COMPLEX	STAT (signal transducers and activators of transcription) proteins undergo cytokine-dependent phosphorylation on serine and tyrosine, STAT3, a transcription factor for acute phase response genes, was found to act as an adapter molecule in signal transduction from the type I interferon receptor. STAT3 bound to a conserved sequence in the cytoplasmic tail of the IFNAR1 chain of the receptor and underwent interferon-dependent tyrosine phosphorylation. The p85 regulatory subunit of phosphatidylinositol S-kinase, which activates a series of serine kinases, bound to phosphorylated STAT3 and subsequently underwent tyrosine phosphorylation, Thus, STAT3 acts as an adapter to couple another signaling pathway to the interferon receptor.			Pfeffer, LM (corresponding author), UNIV TENNESSEE, HLTH SCI CTR, DEPT PATHOL, MEMPHIS, TN 38163 USA.			Pfeffer, Lawrence/0000-0003-2809-1234				BRANCA AA, 1982, J BIOL CHEM, V257, P13291; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P9598; CONSTANTINESCU SN, 1995, P NATL ACAD SCI USA, V92, P10487, DOI 10.1073/pnas.92.23.10487; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; LARNER AC, 1986, J BIOL CHEM, V261, P453; MULLERSMAN JE, 1995, TRENDS BIOCHEM SCI, V20, P55, DOI 10.1016/S0968-0004(00)88956-2; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TOKER A, 1994, J BIOL CHEM, V269, P32358; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yan H, 1996, MOL CELL BIOL, V16, P2074; Yang C. C., UNPUB; Yang CH, 1996, J BIOL CHEM, V271, P8057, DOI 10.1074/jbc.271.14.8057; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	30	224	228	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	1997	276	5317					1418	1420		10.1126/science.276.5317.1418	http://dx.doi.org/10.1126/science.276.5317.1418			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9162009				2022-12-28	WOS:A1997XB53300050
J	Karsten, J; Szijjarto, L; Lebbink, J				Karsten, J; Szijjarto, L; Lebbink, J			A boy with heart failure, a thick tongue, and double vision	LANCET			English	Article									SIONSBERG HOSP,DEPT NEUROL,DOKKUM,NETHERLANDS		Karsten, J (corresponding author), SIONSBERG HOSP,DEPT PAEDIAT,POB 39,DOKKUM,NETHERLANDS.							ADAMS RD, 1982, PRINCIPLES NEUROLOGY; ARONEY N, 1979, MED J AUSTRALIA, V2, P653, DOI 10.5694/j.1326-5377.1979.tb127262.x; ARYANPUR I, 1974, AM J DIS CHILD, V127, P738, DOI 10.1001/archpedi.1974.02110240124020; LEES AJ, 1986, LANCET, V2, P812; LEVINE SN, 1985, AM J MED, V78, P1033, DOI 10.1016/0002-9343(85)90228-1	5	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 24	1997	349	9064					1516	1516		10.1016/S0140-6736(97)02241-1	http://dx.doi.org/10.1016/S0140-6736(97)02241-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167462				2022-12-28	WOS:A1997XA90100012
J	Jiang, XQ; Payne, MA; Cao, ZH; Foster, SB; Feix, JB; Newton, SMC; Klebba, PE				Jiang, XQ; Payne, MA; Cao, ZH; Foster, SB; Feix, JB; Newton, SMC; Klebba, PE			Ligand-specific opening of a gated-porin channel in the outer membrane of living bacteria	SCIENCE			English	Article							FERRIC ENTEROBACTIN RECEPTOR; MICROBIAL IRON TRANSPORT; ESCHERICHIA-COLI K-12; CELL-ENVELOPE; SPIN-LABEL; BACTERIORHODOPSIN MUTANTS; PROTEIN; SIDEROPHORE; TONB; TRANSLOCATION	Ligand-gated membrane channels selectively facilitate the entry of iron into prokaryotic cells. The essential role of iron in metabolism makes its acquisition a determinant of bacterial pathogenesis and a target for therapeutic strategies. In Gram-negative bacteria, TonB-dependent outer membrane proteins form energized, gated pores that bind iron chelates (siderophores) and internalize them. The time-resolved operation of the Escherichia coli ferric enterobactin receptor FepA was observed in vivo with electron spin resonance spectroscopy by monitoring the mobility of covalently bound nitroxide spin labels. A ligand-binding surface loop of FepA, which normally closes its transmembrane channel, exhibited energy-dependent structural changes during iron and toxin (colicin) transport. These changes were not merely associated with ligand binding, but occurred during ligand uptake through the outer membrane bilayer. The results demonstrate by a physical method that gated-porin channels open and close during membrane transport in vivo.	UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019; MED COLL WISCONSIN,ESR CTR,BIOPHYS RES INST,MILWAUKEE,WI 53226; UNIV FED SAO PAULO,DEPT MICROBIOL,SAO PAULO,BRAZIL	University of Oklahoma System; University of Oklahoma - Norman; Medical College of Wisconsin; Universidade Federal de Sao Paulo (UNIFESP)					NIGMS NIH HHS [GM53836, GM51339] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053836, R01GM051339] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; Aprison MH, 1996, J NEUROSCI RES, V43, P127; BATY D, 1990, BIOCHIMIE, V72, P123, DOI 10.1016/0300-9084(90)90137-6; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; BENEDETTI H, 1991, J MOL BIOL, V217, P429, DOI 10.1016/0022-2836(91)90747-T; BENEDETTI H, 1989, J GEN MICROBIOL, V135, P3413; BERLINER LJ, 1983, ANN NY ACAD SCI, V414, P153, DOI 10.1111/j.1749-6632.1983.tb31681.x; BERLINER LJ, 1989, SPIN LABELING THEORY, V8; BRAUN V, 1980, J BACTERIOL, V142, P162, DOI 10.1128/JB.142.1.162-168.1980; BRAUN V, 1991, BIOL MET, V4, P14, DOI 10.1007/BF01135552; BROCHU A, 1992, ANTIMICROB AGENTS CH, V36, P2166, DOI 10.1128/AAC.36.10.2166; Burnashev N, 1996, CURR OPIN NEUROBIOL, V6, P311, DOI 10.1016/S0959-4388(96)80113-9; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DIMASI DR, 1973, J BACTERIOL, V115, P56; EICHLER DC, 1985, BIOCHEMISTRY-US, V24, P1181, DOI 10.1021/bi00326a019; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.micro.48.1.743; GUTERMAN SK, 1973, J BACTERIOL, V114, P1217, DOI 10.1128/JB.114.3.1217-1224.1973; HANNAVY K, 1990, J MOL BIOL, V216, P897, DOI 10.1016/S0022-2836(99)80009-6; HUBBELL WL, 1994, CURR OPIN STRUC BIOL, V4, P566, DOI 10.1016/S0959-440X(94)90219-4; Jentsch TJ, 1996, CURR OPIN NEUROBIOL, V6, P303, DOI 10.1016/S0959-4388(96)80112-7; JIANG XPC, UNPUB; Johnston GAR, 1996, TRENDS PHARMACOL SCI, V17, P319, DOI 10.1016/S0165-6147(96)10038-9; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KILLMANN H, 1993, EMBO J, V12, P3007, DOI 10.1002/j.1460-2075.1993.tb05969.x; KLEBBA PE, 1993, J BIOENERG BIOMEMBR, V25, P603; KLUG CS, 1995, BIOCHEMISTRY-US, V34, P14230, DOI 10.1021/bi00043a030; LAZDUNSKI CJ, 1995, MOL MICROBIOL, V16, P1059, DOI 10.1111/j.1365-2958.1995.tb02331.x; LIU J, 1993, P NATL ACAD SCI USA, V90, P10653, DOI 10.1073/pnas.90.22.10653; LIU J, 1994, BIOCHEMISTRY-US, V33, P13274, DOI 10.1021/bi00249a014; MASON RP, 1977, BIOCHEMISTRY-US, V16, P1196, DOI 10.1021/bi00625a026; MILLER MJ, 1991, BIOL MET, V4, P62, DOI 10.1007/BF01135559; Molday RS, 1996, CURR OPIN NEUROBIOL, V6, P445, DOI 10.1016/S0959-4388(96)80048-1; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; NEILANDS JB, 1982, ANNU REV MICROBIOL, V36, P285, DOI 10.1146/annurev.mi.36.100182.001441; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Newton S. L., UNPUB; Newton SMC, 1997, P NATL ACAD SCI USA, V94, P4560, DOI 10.1073/pnas.94.9.4560; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; PUGSLEY AP, 1976, J BACTERIOL, V126, P1052, DOI 10.1128/JB.126.3.1052-1062.1976; Rathouz MM, 1996, MOL NEUROBIOL, V12, P117, DOI 10.1007/BF02740649; ROOF SK, 1991, J BACTERIOL, V173, P5554, DOI 10.1128/jb.173.17.5554-5557.1991; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; RUTZ JM, 1991, J BACTERIOL, V173, P5694; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; WAYNE R, 1975, J BACTERIOL, V121, P497, DOI 10.1128/JB.121.2.497-503.1975; WAYNE R, 1976, J BACTERIOL, V126, P7, DOI 10.1128/JB.126.1.7-12.1976; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WILLIAMS PH, 1979, INFECT IMMUN, V26, P925, DOI 10.1128/IAI.26.3.925-932.1979; WISNER M, 1997, NATURE, V385, P481; WOLF MK, 1986, J GEN MICROBIOL, V132, P2949	59	88	93	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1261	1264		10.1126/science.276.5316.1261	http://dx.doi.org/10.1126/science.276.5316.1261			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157886				2022-12-28	WOS:A1997XA49700045
J	Marr, MT; Roberts, JW				Marr, MT; Roberts, JW			Promoter recognition as measured by binding of polymerase to nontemplate strand oligonucleotide	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; TRANSCRIPTION INITIATION; DNA; CHROMATOGRAPHY; SPECIFICITY; SUBUNIT	In transcription initiation, the DNA strands must be separated to expose the template to RNA polymerase. As the closed initiation complex is converted to an open one, specific protein-DNA interactions involving bases of the nontemplate strand form and stabilize the promoter complex in the region of unwinding. Specific interaction between RNA polymerase and the promoter in Escherichia coli was detected and quantified as the binding affinity of nontemplate oligonucleotide sequences. The RNA polymerase subunit sigma factor 70 contacted the bases of the nontemplate DNA strand through its conserved region 2; a mutation that affected promoter function altered the binding affinity of the oligonucleotide to the enzyme.			Marr, MT (corresponding author), CORNELL UNIV, BIOCHEM MOL & CELL BIOL SECT, BIOTECHNOL BLDG, ITHACA, NY 14853 USA.							BUCKLE M, 1991, NUCLEIC ACIDS RES, V19, P833, DOI 10.1093/nar/19.4.833; Burgess R.R., 1987, RNA POLYM REGULATION, P3; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X; Roberts CW, 1996, CELL, V86, P495; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; Severinova E, 1996, J MOL BIOL, V263, P637, DOI 10.1006/jmbi.1996.0604; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; STEFANO JE, 1982, P NATL ACAD SCI-BIOL, V79, P1069, DOI 10.1073/pnas.79.4.1069; VONHIPPE PH, 1972, ANNU REV BIOCHEM, V41, P231, DOI 10.1146/annurev.bi.41.070172.001311; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	23	150	152	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	1997	276	5316					1258	1260		10.1126/science.276.5316.1258	http://dx.doi.org/10.1126/science.276.5316.1258			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157885				2022-12-28	WOS:A1997XA49700044
J	Zhang, L; Zhou, W; Velculescu, VE; Kern, SE; Hruban, RH; Hamilton, SR; Vogelstein, B; Kinzler, KW				Zhang, L; Zhou, W; Velculescu, VE; Kern, SE; Hruban, RH; Hamilton, SR; Vogelstein, B; Kinzler, KW			Gene expression profiles in normal and cancer cells	SCIENCE			English	Article							3 ABUNDANCE CLASSES; MESSENGER-RNA; RIBOSOMAL-PROTEIN; COLON-CARCINOMA; HUMAN GUANYLIN; GROWTH; DIFFERENTIATION; PATTERNS; TUMORS	As a step toward understanding the complex differences between normal and cancer cells in humans, gene expression patterns were examined in gastrointestinal tumors. More than 300,000 transcripts derived from at least 45,000 different genes were analyzed. Although extensive similarity was noted between the expression profiles, more than 500 transcripts that were expressed at significantly different levels in normal and neoplastic cells were identified. These data provide insight into the extent of expression differences underlying malignancy and reveal genes that may prove useful as diagnostic or prognostic markers.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,HOWARD HUGHES MED INST,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,PROGRAM HUMAN GENET & MOL BIOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21231	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University			Velculescu, Victor/ABF-4846-2020; Zhang, Lin/A-7389-2009	Velculescu, Victor/0000-0003-1195-438X; Zhang, Lin/0000-0003-0018-3903	NATIONAL CANCER INSTITUTE [P50CA062924, R01CA057345, R37CA057345] Funding Source: NIH RePORTER; NCI NIH HHS [CA57345, CA62924] Funding Source: Medline; NIGMS NIH HHS [GM07309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1995, NATURE, V377, P3; BARNARD GF, 1992, CANCER RES, V52, P3067; BARNARD GF, 1993, CANCER RES, V53, P4048; BISHOP JO, 1974, NATURE, V250, P199, DOI 10.1038/250199a0; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHIAO PJ, 1992, MOL CARCINOGEN, V5, P219, DOI 10.1002/mc.2940050309; DENIS MG, 1993, INT J CANCER, V55, P275, DOI 10.1002/ijc.2910550218; DeRisi J, 1996, NAT GENET, V14, P457; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089, DOI 10.1073/pnas.89.19.9089; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIGERIO JM, 1995, HUM MOL GENET, V4, P37, DOI 10.1093/hmg/4.1.37; Gress TM, 1996, ONCOGENE, V13, P1819; HASTIE ND, 1976, CELL, V9, P761, DOI 10.1016/0092-8674(76)90139-2; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; KONDOH N, 1992, CANCER RES, V52, P791; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAMBERT S, 1990, INT J CANCER, V46, P405, DOI 10.1002/ijc.2910460313; LEWIN B, 1980, GENE EXPRESSION, V2; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MEDINA D, 1993, CANCER RES, V53, P668; MILLER AD, 1984, CELL, V36, P51; MOLL R, 1993, DIFFERENTIATION, V53, P75, DOI 10.1111/j.1432-0436.1993.tb00648.x; Okubo K, 1994, DNA Res, V1, P37, DOI 10.1093/dnares/1.1.37; Owens AH, 1982, TUMOR CELL HETEROGEN; RUBIN DC, 1989, P NATL ACAD SCI USA, V86, P1278, DOI 10.1073/pnas.86.4.1278; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; SOWDEN J, 1993, DIFFERENTIATION, V53, P67, DOI 10.1111/j.1432-0436.1993.tb00647.x; TANAKA M, 1995, CANCER RES, V55, P3228; TRICOLI JV, 1986, CANCER RES, V46, P6169; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; WIEGAND RC, 1992, FEBS LETT, V311, P150, DOI 10.1016/0014-5793(92)81387-2	34	1186	1330	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1268	1272		10.1126/science.276.5316.1268	http://dx.doi.org/10.1126/science.276.5316.1268			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157888				2022-12-28	WOS:A1997XA49700047
J	Hayes, DL; Wang, PJ; Reynolds, DW; Estes, NAM; Griffith, JL; Steffens, RA; Carlo, GL; Findlay, GK; Johnson, CM				Hayes, DL; Wang, PJ; Reynolds, DW; Estes, NAM; Griffith, JL; Steffens, RA; Carlo, GL; Findlay, GK; Johnson, CM			Interference with cardiac pacemakers by cellular telephones	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background A growing body of evidence suggests that electromagnetic interference may occur between cardiac pacemakers and wireless hand-held (cellular) telephones, posing a potential public health problem. Electromagnetic interference may occur when the pacemaker is exposed to an electromagnetic field generated by the cellular telephone. Methods In this multicenter, prospective, cross-over study, we tested 980 patients with cardiac pacemakers with five types of telephones (one analogue and four digital) to assess the potential for interference. Telephones were tested in a test mode and were programmed to transmit at the maximal power, simulating the worst-case scenario; in addition, one telephone was tested during actual transmission to simulate actual use. Patients were electrocardiographically monitored while the telephones were tested at the ipsilateral ear and in a series of maneuvers directly over the pacemaker. Interference was classified according to the type and clinical significance of the effect. Results The incidence of any type of interference was 20 percent in the 5533 tests, and the incidence of symptoms was 7.2 percent. The incidence of clinically significant interference was 6.6 percent. There was no clinically significant interference when the telephone was placed in the normal position over the ear. Interference that was definitely clinically significant occurred in only 1.7 percent of tests, and only when the telephone was held over the pacemaker. Interference was more frequent with dual-chamber pacemakers (25.3 percent) than with single-chamber pacemakers (6.8 percent, P < 0.001) and more frequent with pacemakers without feed-through filters (28.9 to 55.8 percent) than with those with such filters (0.4 to 0.8 percent, P = 0.01). Conclusions Cellular telephones can interfere with the function of implanted cardiac pacemakers. However, when telephones are placed over the ear, the normal position, this interference does not pose a health risk. (C) 1997, Massachusetts Medical Society.	TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111; UNIV OKLAHOMA,HLTH SCI CTR,OKLAHOMA CITY,OK; HLTH & ENVIRONM SCI GRP LTD,WASHINGTON,DC	Tufts Medical Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Hayes, DL (corresponding author), MAYO CLIN & MAYO FDN,DEPT CARDIOL,200 1ST ST SW,E 16,ROCHESTER,MN 55905, USA.							BARBARO V, 1995, PACE, V18, P1218, DOI 10.1111/j.1540-8159.1995.tb06961.x; BARBARO V, 1994, BIOEL SOC 16 ANN M C; BARBARO V, 1995, BIOEL 17 ANN M WASH, P24; CARRILLO R, 1995, PACING CLIN ELECTROP, V18, P1777; CARRILLO R, 1995, PACE PACING CLIN ELE, V18, P863; CARRILLO R, 1995, P 1995 IEEE INT S EL; EICHER B, 1994, BEMS COP DENM JUN, P67; HAYES DL, 1995, PACE, V18, P842; HAYES DL, 1995, PACE PACING CLIN ELE, V18, P863; IRNICH W, 1996, BIOEL 18 ANN M, P121; JOYNER KH, 1994, BEMS BIOEL SOC JUN, P67; NAEGELI B, 1995, PACING CLIN ELECTROP, V187, P842; RUGGERA PS, 1996, ANN EL COMP FOR WASH; YESIL M, 1995, PACE, V18, P1963, DOI 10.1111/j.1540-8159.1995.tb03846.x	14	175	180	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 22	1997	336	21					1473	1479		10.1056/NEJM199705223362101	http://dx.doi.org/10.1056/NEJM199705223362101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ767	9154765				2022-12-28	WOS:A1997WZ76700001
J	Tcheng, JE; Lincoff, AM; Sigmon, KN; Lee, KL; Kitt, MM; Califf, RM; Topol, EJ; Juran, N; Worley, S; Tuzi, J; Hollywood, L; Kleiman, NS; Ali, MN; Rose, D; Kereiakes, DJ; Higby, N; George, J; Heilbrunn, S; Roncevich, T; Burnheimer, B; Ivanhoe, R; Meade, L; Rund, M; Tannenaum, M; Stangle, D; Yakubov, S; Rusk, K; Ferguson, JJ; Willerson, JT; Thomas, C; Harlan, M; Browne, K; Telatnik, M; Blankenship, J; Demko, L; Timmis, G; Safian, M; Resar, J; Dudek, A; Spriggs, D; Wahl, S; Gilchrist, IC; Dabbs, A; Shadoff, N; Goebel, S; Miller, M; Burdick, M; Owens, B; McIvor, M; Reddinger, J; Hartman, C; Lunow, S; Conn, E; McWilliams, C; Aycock, R; Wilcox, T; Corbelli, J; Cooke, B; Teirstein, P; Haas, G; Talley, JD; Rawert, M; Ghalili, K; Mahaffey, T; Toggart, E; Fowler, P; Davidson, C; Bergelson, B; Schaechter, A; Navetta, F; Byars, S; Durbin, B; Muhlestein, JB; Jerman, J; Nygaard, T; White, J; Sanz, M; Mayer, D; White, R; Reatta, K; Aguirre, FV; Stonner, T; Gottlieb, R; LaVoie, J; McDonough, T; Weszt, S; Micale, P; Berry, S; Taylor, M; Clark, D; Brewer, D; Black, S; Roubin, G; Sutor, C; Heinsimer, J; Allar, N; Crawford, R; Pierson, M; Siegel, R; Vermillion, J; Bengtson, J; Prochnow, L; Griffin, J; Theodosiou, J; Parr, K; Thomas, L; Toole, J; Wise, C; Lerrick, K; Spinagotti, B; French, W; Nagelhout, D; Miller, K; Seaworth, J; Jenson, J; Collins, G; Mark, R; Sheikh, K; Rosner, E; Tenaglia, A; Friedman, I; Weiner, B; Borbone, M; Kuehl, W; Allen, S; Krauthamer, D; Chait, V; Belkin, R; Steinberg, R; Carey, D; Rogers, K; Cates, C; Davis, D; Arnold, A; Sommers, T; Herzog, W; Calamunci, N; Cowfer, J; Cohen, M; Lee, D; Slosky, D; Kaczinski, J; Simonton, C; Porter, B; Hinohara, T; Johnson, M; DelCore, M; Stangal, L; Gacioch, G; Chiodo, V; Sullebarger, JT; Ford, L; Kleavel, P; Fedak, C; Popma, J; Prunka, N; Davis, C; Faxon, D; Guerci, A; Loscalzo, J; Weaver, WD; Batts, K; Hughes, D; Joseph, D; Karnash, S; Lilley, P; Liu, M; Melton, J; Messick, M; Owens, E; Passmore, D; Pullium, M; Shavender, J; Smith, D; Smith, M; Snapp, J; Stosik, V; Sumner, D; Thel, MC; Thompson, G; Workman, J; By, S; Carter, J; Gordon, C; Gothard, P; Granger, CB; Harrington, RA; Kruse, KR; Mahaffey, KW; McClanahan, M; Miller, M; Ohman, EM; Pitzer, L; Tardiff, B; Winchell, M; Crowe, T; Debowey, D; Gates, K; Starr, S; Wagner, GS; DavidsonRay, L; Mark, DB; duMee, C; Kitt, M; Lorenz, T; OBrien, M; Scarborough, R; Swift, R				Tcheng, JE; Lincoff, AM; Sigmon, KN; Lee, KL; Kitt, MM; Califf, RM; Topol, EJ; Juran, N; Worley, S; Tuzi, J; Hollywood, L; Kleiman, NS; Ali, MN; Rose, D; Kereiakes, DJ; Higby, N; George, J; Heilbrunn, S; Roncevich, T; Burnheimer, B; Ivanhoe, R; Meade, L; Rund, M; Tannenaum, M; Stangle, D; Yakubov, S; Rusk, K; Ferguson, JJ; Willerson, JT; Thomas, C; Harlan, M; Browne, K; Telatnik, M; Blankenship, J; Demko, L; Timmis, G; Safian, M; Resar, J; Dudek, A; Spriggs, D; Wahl, S; Gilchrist, IC; Dabbs, A; Shadoff, N; Goebel, S; Miller, M; Burdick, M; Owens, B; McIvor, M; Reddinger, J; Hartman, C; Lunow, S; Conn, E; McWilliams, C; Aycock, R; Wilcox, T; Corbelli, J; Cooke, B; Teirstein, P; Haas, G; Talley, JD; Rawert, M; Ghalili, K; Mahaffey, T; Toggart, E; Fowler, P; Davidson, C; Bergelson, B; Schaechter, A; Navetta, F; Byars, S; Durbin, B; Muhlestein, JB; Jerman, J; Nygaard, T; White, J; Sanz, M; Mayer, D; White, R; Reatta, K; Aguirre, FV; Stonner, T; Gottlieb, R; LaVoie, J; McDonough, T; Weszt, S; Micale, P; Berry, S; Taylor, M; Clark, D; Brewer, D; Black, S; Roubin, G; Sutor, C; Heinsimer, J; Allar, N; Crawford, R; Pierson, M; Siegel, R; Vermillion, J; Bengtson, J; Prochnow, L; Griffin, J; Theodosiou, J; Parr, K; Thomas, L; Toole, J; Wise, C; Lerrick, K; Spinagotti, B; French, W; Nagelhout, D; Miller, K; Seaworth, J; Jenson, J; Collins, G; Mark, R; Sheikh, K; Rosner, E; Tenaglia, A; Friedman, I; Weiner, B; Borbone, M; Kuehl, W; Allen, S; Krauthamer, D; Chait, V; Belkin, R; Steinberg, R; Carey, D; Rogers, K; Cates, C; Davis, D; Arnold, A; Sommers, T; Herzog, W; Calamunci, N; Cowfer, J; Cohen, M; Lee, D; Slosky, D; Kaczinski, J; Simonton, C; Porter, B; Hinohara, T; Johnson, M; DelCore, M; Stangal, L; Gacioch, G; Chiodo, V; Sullebarger, JT; Ford, L; Kleavel, P; Fedak, C; Popma, J; Prunka, N; Davis, C; Faxon, D; Guerci, A; Loscalzo, J; Weaver, WD; Batts, K; Hughes, D; Joseph, D; Karnash, S; Lilley, P; Liu, M; Melton, J; Messick, M; Owens, E; Passmore, D; Pullium, M; Shavender, J; Smith, D; Smith, M; Snapp, J; Stosik, V; Sumner, D; Thel, MC; Thompson, G; Workman, J; By, S; Carter, J; Gordon, C; Gothard, P; Granger, CB; Harrington, RA; Kruse, KR; Mahaffey, KW; McClanahan, M; Miller, M; Ohman, EM; Pitzer, L; Tardiff, B; Winchell, M; Crowe, T; Debowey, D; Gates, K; Starr, S; Wagner, GS; DavidsonRay, L; Mark, DB; duMee, C; Kitt, M; Lorenz, T; OBrien, M; Scarborough, R; Swift, R			Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II	LANCET			English	Article							GLYCOPROTEIN IIB/IIIA; MYOCARDIAL-INFARCTION; GPIIB-IIIA; ANGIOPLASTY; INTEGRIN; OCCLUSION; PLATELETS; RECEPTORS; ANTIBODY; FAMILY	Background Platelet-mediated thrombosis has been implicated in the development of ischaemic complications of percutaneous coronary intervention. We investigated whether inhibition of the platelet glycoprotein IIb/IIIa integrin with eptifibatide (Integrilin) could prevent such complications. Methods We undertook a double-blind, placebo-controlled trial at 82 centres in the USA, enrolling 4010 patients undergoing elective, urgent, or emergency coronary intervention. Patients were assigned one of three treatments: placebo (n=1328), a bolus of 135 mu g/kg eptifibatide followed by an infusion of 0.5 mu g kg(-1) min(-1) for 20-24 h (n=1349), or 135 mu g/kg eptifibatide bolus with a 0.75 mu g kg(-1) min(-1) infusion (n=1333). The coronary procedure was started within 10-60 min of the start of study treatment. The primary endpoint. was the 30-day composite occurrence of death, myocardial infarction, unplanned surgical or repeat percutaneous revascularisation, or coronary stent implantation for abrupt closure (by intention to treat). The primary safety endpoint was major bleeding. Findings By 30 days, the composite endpoint had occurred in 151 (11.4%) patients in the placebo group compared with 124 (9.2%) in the 135/0.5 eptifibatide group (p=0.063) and 132 (9.9%) in the eptifibatide 135/0.75 group (p=0.22). By treatment-received analysis, the 135/0.5 regimen produced a significant reduction in the composite endpoint (11.6 vs 9.1%, p=0.035), but the 135/0.75 regimen produced a less substantial reduction (11.6 vs 10.0%, p=0.18). Eptifibatide treatment did not increase rates of major bleeding or transfusion. Interpretation In the 135/0.5 group, treatment with eptifibatide during coronary intervention reduced rates of early abrupt closure and ischaemic events at 30 days. Non-significant, differences were seen with the 135/0.75 regimen. The doses studied thus appear to be at the low end of the efficacy-response curve. Further investigation to refine eptifibatide dosing during coronary intervention is warranted.	CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA; ST JOSEPH LANCASTER GEN HOSP, LANCASTER, PA USA; METHODIST HOSP, BEN TAUB GEN HOSP, HOUSTON VET ADM HOSP, HOUSTON, TX 77030 USA; CHRIST HOSP, CINCINNATI, OH 45219 USA; ST FRANCIS SHADYSIDE, PITTSBURGH, PA USA; FLORIDA HOSP, APOPKA, FL USA; DUKE UNIV, MED CTR, DURHAM, NC USA; IOWA HEART CTR, DES MOINES, IA USA; RIVERSIDE METHODIST HOSP, COLUMBUS, OH 43214 USA; TEXAS HEART INST, HOUSTON, TX 77025 USA; WATSON CLIN, LAKEL, FL USA; GEISINGER MED CTR, DANVILLE, PA 17822 USA; WILLIAM BEAUMONT HOSP, ROYAL OAK, MI 48072 USA; JOHNS HOPKINS UNIV, BALTIMORE, MD USA; MORTON PLANT HOSP, LARGO, FL USA; MILTON S HERSHEY MED CTR, HERSHEY, PA USA; PRESBYTERIAN HOSP, ALBUQUERQUE, NM USA; MED UNIV S CAROLINA, CHARLESTON VET ADM HOSP, CHARLESTON, SC 29425 USA; HEART INST ST PETERSBURG, ST PETERSBURG, FL USA; SENTARA NORFOLK GEN HOSP, NORFOLK, VA USA; MEM HOSP, CHATTANOOGA, TN USA; SACRED HEART, PENSACOLA, FL USA; MILLARD FILLMORE HOSP, BUFFALO, NY 14209 USA; SCRIPPS CLIN, LA JOLLA, CA 92037 USA; UNIV ARKANSAS, JOHN J MCCLELLAN MEM HOSP, LITTLE ROCK, AR 72204 USA; BRYAN MEM HOSP, LINCOLN, NE USA; SW FLORIDA REG MED CTR, FT MYERS, FL USA; NORTHWESTERN MEM HOSP, VET ADM LAKESIDE MED CTR, CHICAGO, IL USA; MOTHER FRANCES HOSP, TYLER, TX USA; UNIV LOUISVILLE, NORTON HOSP, LOUISVILLE, KY 40292 USA; LATTER DAY ST HOSP, SALT LAKE CITY, UT 84143 USA; VIRGINIA BAPTIST HOSP, LYNCHBURG GEN HOSP, LYNCHBURG, VA USA; ST PATRICKS HOSP, MISSOULA, MT USA; OKLAHOMA HEART CTR, OKLAHOMA CITY, OK USA; ST LOUIS UNIV HOSP, ST LOUIS, MO 63110 USA; UNIV PENN, GRAD HOSP, PHILADELPHIA, PA 19104 USA; NORTHWESTERN UNIV, EVANSTON HOSP, EVANSTON, IL 60201 USA; RIVERSIDE REG MED CTR, NEWPORT NEWS, VA USA; DEBORAH HEART & LUNG CTR, BROWNS MILLS, NJ 08015 USA; ST FRANCIS, TULSA, OK USA; UNIV ALABAMA, BIRMINGHAM, AL USA; ST JOSEPH MERCY HOSP, PONTIAC, MI USA; ST FRANCIS, PEORIA, IL USA; ADV CARDIAC SPECIALISTS, PHOENIX, AZ USA; MICHIGAN HEART VASC INST, ANN ARBOR, MI USA; VIRGINIA BEACH GEN HOSP, VIRGINIA BEACH, VA USA; METHODIST HOSP INDIANAPOLIS, INDIANAPOLIS, IN USA; ST JOSEPHS HOSP, TAMPA, FL USA; ALBERT EINSTEIN MED CTR, WEILER HOSP, BRONX, NY USA; UNIV CALIF LOS ANGELES, LOS ANGELES CTY HARBOR MED CTR, TORRANCE, CA USA; N CENT HEART INST, SIOUX FALLS, SD USA; NE BAPTIST HOSP, SAN ANTONIO, TX USA; WRIGHT PATTERSON MED CTR, WRIGHT PATTERSON AFB, OH USA; WUESTHOFF MEM, ROCKLEDGE, FL USA; TULANE UNIV, MED CTR, NEW ORLEANS, LA USA; UNIV MASSACHUSETTS, MED CTR, WORCESTER, MA USA; MEM MISSION, ASHEVILLE, NC USA; S MIAMI HOSP, MIAMI, FL USA; NEW YORK MED COLL, VALHALLA, NY 10595 USA; KEESLER MED CTR, KEESLER AFB, MS USA; ST JOSEPH HOSP, ATLANTA, GA USA; ST LUKES HOSP, MILWAUKEE, WI 53215 USA; UNIV MARYLAND, BALTIMORE VET ADM HOSP, BALTIMORE, MD 21201 USA; ST FRANCIS, BEECH GROVE, IN USA; ST MARYS HOSP, MILWAUKEE, WI USA; CAROLINAS MED CTR, CHARLOTTE, NC 28203 USA; SEQUOIA HOSP, REDWOOD CITY, CA USA; ST JOSEPH, OMAHA, NE USA; ROCHESTER GEN HOSP, ROCHESTER, NY 14621 USA; TAMPA GEN HOSP, TAMPA, FL 33606 USA; LEHIGH VALLEY HOSP CTR, ALLENTOWN, PA 18102 USA; WASHINGTON HOSP CTR, WASHINGTON, DC 20010 USA; DUKE UNIV, MED CTR, ELECTROCARDIOG CORE LAB, DURHAM, NC 27706 USA	Cleveland Clinic Foundation; The Methodist Hospital System; The Methodist Hospital - Houston; Christ Hospital - Ohio; Adventist Health Services; AdventHealth; (AdventHealth) Central Florida Division; Central Florida Hospital - South; AdventHealth Apopka; Duke University; Texas Heart Institute; Geisinger Medical Center; Beaumont Health; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Medical University of South Carolina; Sentara Healthcare; State University of New York (SUNY) System; Scripps Research Institute; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Northwestern Memorial Hospital; University of Louisville; Saint Louis University; University of Pennsylvania; Pennsylvania Medicine; NorthShore University Health System; Northwestern University; University of Alabama System; University of Alabama Birmingham; Saint Joseph Mercy Health System (SJMHS); Indiana University System; Yeshiva University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Tulane University; University of Massachusetts System; University of Massachusetts Worcester; New York Medical College; University System of Maryland; University of Maryland Baltimore; Carolinas Medical Center; Rochester General Hospital; Tampa General Hospital; Lehigh Valley Hospital; MedStar Washington Hospital Center; Duke University	Tcheng, JE (corresponding author), DUKE UNIV, MED CTR, BOX 3275, DURHAM, NC 27710 USA.		Loscalzo, Joseph/ABD-8980-2021; Gilchrist, Ian/HCI-4187-2022; haas, gretchen/GQP-4644-2022; Granger, Christopher B/D-3458-2014; Blankenship, James/AAX-4084-2020	Granger, Christopher B/0000-0002-0045-3291; Blankenship, James/0000-0003-4966-533X				AGUIRRE FV, 1995, CIRCULATION, V91, P2882, DOI 10.1161/01.CIR.91.12.2882; AUDET AM, 1992, ANN INTERN MED, V116, P403, DOI 10.7326/0003-4819-116-5-403; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; COX D, 1994, MED RES REV, V14, P195, DOI 10.1002/med.2610140203; DEFEYTER PJ, 1994, AM HEART J, V127, P643, DOI 10.1016/0002-8703(94)90675-0; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; ELLIS SG, 1991, J AM COLL CARDIOL, V17, pB89; HARKER LA, 1987, AM J CARDIOL, V60, pB20; HARRINGTON RA, 1995, AM J CARDIOL, V76, P1222, DOI 10.1016/S0002-9149(99)80345-2; HARRINGTON RA, 1995, J AM COLL CARDIOL, V25, P1693, DOI 10.1016/0735-1097(95)00091-H; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JANG YS, 1994, J AM COLL CARDIOL, V24, P1591, DOI 10.1016/0735-1097(94)90162-7; KISS RG, 1994, ARTERIOSCLER THROMB, V14, P375, DOI 10.1161/01.ATV.14.3.375; LANDEFELD CS, 1987, AM J MED, V82, P703, DOI 10.1016/0002-9343(87)90004-0; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; LINCOFE AM, 1992, J AM COLL CARDIOL, V19, P926, DOI 10.1016/0735-1097(92)90272-O; MUSTARD JF, 1979, BLOOD, V54, P987; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PHILLIPS DR, 1988, BLOOD, V71, P831; PHILLIPS DR, 1977, J CLIN INVEST, V60, P535, DOI 10.1172/JCI108805; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; STEELE PM, 1985, CIRC RES, V57, P105, DOI 10.1161/01.RES.57.1.105; TCHENG JE, 1995, CIRCULATION, V91, P2151, DOI 10.1161/01.CIR.91.8.2151; Tcheng JE, 1996, AM J CARDIOL, V78, P35, DOI 10.1016/S0002-9149(96)00490-0; TENAGLIA AN, 1994, J AM COLL CARDIOL, V24, P1004, DOI 10.1016/0735-1097(94)90862-1; TENAGLIA AN, 1993, AM J CARDIOL, V72, P21, DOI 10.1016/0002-9149(93)90212-U; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; WILENTZ JR, 1987, CIRCULATION, V75, P636, DOI 10.1161/01.CIR.75.3.636	32	737	742	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 17	1997	349	9063					1422	1428						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164315				2022-12-28	WOS:A1997WZ76500009
J	Marin, M; Karis, A; Visser, P; Grosveld, F; Philipsen, S				Marin, M; Karis, A; Visser, P; Grosveld, F; Philipsen, S			Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation	CELL			English	Article							BOX-BINDING-PROTEINS; A-I-GENE; SYNERGISTIC ACTIVATION; TRANSGENIC MICE; CONTROL REGION; DNA-BINDING; GLOBIN GENE; CPG ISLAND; APRT GENE; EXPRESSION	Transcription factor Sp1 has been implicated in the expression of many genes. Moreover, it has been suggested that Sp1 is linked to the maintenance of methylation-free CpG islands, the cell cycle, and the formation of active chromatin structures. We have inactivated the mouse Sp1 gene. Sp1(-/-) embryos are retarded in development, show a broad range of abnormalities, and die around day 11 of gestation. In Sp1(-/-) embryos, the expression of many putative target genes, including cell cycle-regulated genes, is not affected, CpG islands remain methylation free, and active chromatin is formed at the globin loci. However, the expression of the methyl-CpG-binding protein MeCP2 is greatly reduced in Sp1(-/-) embryos. MeCP2 is thought to be required for the maintenance of differentiated cells. We suggest that Sp1 is an important regulator of this process.	ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL,NL-3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam				Philipsen, Sjaak/0000-0002-3690-1201				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Chestier A, 1992, DNA Seq, V2, P325, DOI 10.3109/10425179209030966; COOPER DN, 1983, NUCLEIC ACIDS RES, V11, P647, DOI 10.1093/nar/11.3.647; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; GURTNER GC, 1995, GENE DEV, V9, P1, DOI 10.1101/gad.9.1.1; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HORNSTRA IK, 1992, MOL CELL BIOL, V12, P5345, DOI 10.1128/MCB.12.12.5345; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONGSTRA J, 1984, NATURE, V307, P708, DOI 10.1038/307708a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KARISEDER J, 1996, MOL CELL BIOL, V16, P1659; KILBY NJ, 1993, TRENDS GENET, V9, P413, DOI 10.1016/0168-9525(93)90104-P; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOIVISTO UM, 1994, P NATL ACAD SCI USA, V91, P10526, DOI 10.1073/pnas.91.22.10526; LAMONFAVA S, 1992, J LIPID RES, V33, P831; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; PERKINS AC, 1995, NATURE, V375, P318; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SHAO ZH, 1995, ONCOGENE, V10, P221; SHE BR, 1995, GENE, V159, P175, DOI 10.1016/0378-1119(95)00024-Z; SHEMER R, 1991, P NATL ACAD SCI USA, V88, P11300, DOI 10.1073/pnas.88.24.11300; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; YU CY, 1991, J BIOL CHEM, V266, P8907; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	54	450	459	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					619	628		10.1016/S0092-8674(00)80243-3	http://dx.doi.org/10.1016/S0092-8674(00)80243-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160753	Bronze, Green Published			2022-12-28	WOS:A1997WZ32300015
J	Platt, S; Tannahill, A; Watson, J; Fraser, E				Platt, S; Tannahill, A; Watson, J; Fraser, E			Effectiveness of antismoking telephone helpline: Follow up survey	BRITISH MEDICAL JOURNAL			English	Article							SMOKING CESSATION; MASS-MEDIA; INTERVENTION	Objective: To evaluate the effectiveness of an antismoking campaign conducted by the Health Education Board for Scotland. Design: Descriptive survey of adult callers to a telephone helpline (Smokeline) for stopping smoking; panel study of a random sample of adult callers; assessment of changes in prevalence of smoking in Scotland before and after introduction of the helpline Setting: Telephone helpline. Subjects: Callers to Smokeline over the initial one year period. Detailed information was collected on a 10% sample (n = 8541). A cohort of adult smokers who called Smokeline (total n = 848) was followed up by telephone interview three weeks, six months, and one year after the initial call. Main outcome measures: Numbers of adult smokers calling helpline; changes in smoking behaviour, especially stopping smoking among cohort members; and changes in prevalence of smoking in the general population. Results: An estimated 82 782 regular adult smokers made genuine contact with Smokeline over the year, representing about 5.9% of all adult smokers in Scotland. At one year 143 of the cohort of 848 callers (23.6%; 95% confidence interval 20.2% to 27.0%) reported that they had stopped smoking, and 534 (88.0%; 85.4% to 90.6%) reported having made some change, About 19 500 (16 700 to 22 350) adult smokers, equivalent to 1.4% (1.2% to 1.6%) of the mean adult smoking population, stopped smoking with direct help from Smokeline. During the second year of the campaign (1994) smoking prevalence among 25-65 year olds in Scotland was 6% (2.0% to 10.0%) lower than it had been before the start of the Campaign. Conclusion: The Health Education Board for Scotland's antismoking campaign reached a high number of adult smokers, was associated with a highly acceptable quit rate among adults given direct help through Smokeline, and contributed considerably to an accelerated decline in smoking prevalence in Scotland.	HLTH EDUC BOARD SCOTLAND,EDINBURGH EH10 4SG,MIDLOTHIAN,SCOTLAND		Platt, S (corresponding author), UNIV EDINBURGH,SCH MED,RES UNIT HLTH & BEHAV CHANGE,DEPT PUBL HLTH SCI,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							BETTINGHAUS EP, 1988, PREV MED, V17, P503, DOI 10.1016/0091-7435(88)90049-7; BOSTOCK Y, 1991, SMOKING EPIDEMIC COU; Donnan PT, 1994, J SMOKING RELATED S1, V5, P271; EISER JR, 1978, BRIT J ADDICT, V73, P215; ENGLEMAN S, 1987, HLTH PROMOTION, V2, P63; ERICKSON AC, 1990, PUBLIC HEALTH REP, V105, P239; FLAY BR, 1987, AM J PUBLIC HEALTH, V77, P153, DOI 10.2105/AJPH.77.2.153; GLASGOW RE, 1993, ADDICT BEHAV, V18, P511, DOI 10.1016/0306-4603(93)90068-K; GRUDER CL, 1990, ADDICT BEHAV, V15, P505, DOI 10.1016/0306-4603(90)90051-X; *HLTH ED BOARD SCO, 1995, NONSMOKING SCOTLAND; *NAT HLTH SERV SCO, 1995, SCOTT HLTH STAT 1995; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; PETITTI DB, 1981, AM J PUBLIC HEALTH, V71, P308, DOI 10.2105/AJPH.71.3.308; REID DJ, 1992, TOB CONTROL, V1, P185; *SCOTT OFF, 1991, HLTH ED SCOTLAND NAT; Scottish Office, 1992, SCOTL HLTH CHALL US; WARNER KE, 1989, AM J PUBLIC HEALTH, V79, P144, DOI 10.2105/AJPH.79.2.144	17	53	55	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1371	1375						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WZ169	9161308				2022-12-28	WOS:A1997WZ16900021
J	Vallance, P; Collier, J; Bhagat, K				Vallance, P; Collier, J; Bhagat, K			Infection, inflammation, and infarction: Does acute endothelial dysfunction provide a link?	LANCET			English	Editorial Material							TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE; FACTOR-ALPHA; VASCULAR ENDOTHELIUM; RELAXING FACTOR; DISEASE; CELLS; ATHEROSCLEROSIS; MECHANISMS; RELAXATION		UNIV LONDON UNIV COLL,DEPT MED,LONDON WC1E 6JJ,ENGLAND; UNIV LONDON ST GEORGES HOSP,SCH MED,CLIN PHARMACOL UNIT,LONDON SW17 0RE,ENGLAND	University of London; University College London; St Georges University London	Vallance, P (corresponding author), UNIV LONDON UNIV COLL,CTR CLIN PHARMACOL TOXICOL & THERAPEUT,CRUCIFORM PROJECT,TORRINGTON PL,LONDON WC1E 6JJ,ENGLAND.							BAIGRIE RJ, 1993, AM J SURG, V166, P248, DOI 10.1016/S0002-9610(05)80967-5; Bhagat K, 1996, CARDIOVASC RES, V32, P822; BRODY JI, 1992, AM J CLIN PATHOL, V97, P8, DOI 10.1093/ajcp/97.1.8; CALVER A, 1992, J CLIN INVEST, V90, P2548, DOI 10.1172/JCI116149; CHOWIENCZYK PJ, 1992, LANCET, V340, P1430, DOI 10.1016/0140-6736(92)92621-L; FRIEDMAN HM, 1989, REV INFECT DIS, V11, pS700; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Gates P, 1987, Clin Exp Neurol, V24, P21; HABIB A, 1993, J BIOL CHEM, V268, P23448; Hornig B, 1996, CIRCULATION, V93, P210, DOI 10.1161/01.CIR.93.2.210; Kanda T, 1996, AM J CARDIOL, V77, P304, DOI 10.1016/S0002-9149(97)89400-3; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; MAMODE N, 1995, BMJ-BRIT MED J, V310, P1215, DOI 10.1136/bmj.310.6989.1215; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; MYERS PR, 1994, SHOCK, V1, P73; PALEOLOG EM, 1994, BLOOD, V84, P2578; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SIEGFRIED MR, 1992, EUR J PHARMACOL, V212, P171, DOI 10.1016/0014-2999(92)90326-Y; Smith CJ, 1996, CIRC RES, V78, P58, DOI 10.1161/01.RES.78.1.58; TILLETT HE, 1983, INT J EPIDEMIOL, V12, P344, DOI 10.1093/ije/12.3.344; VALLANCE P, 1995, OXFORD TXB MED, P2295; VALTONEN V, 1993, EUR HEART J, V14, P20; VANE JR, 1990, NEW ENGL J MED, V323, P27; Visseren F. L. J., 1996, European Journal of Clinical Investigation, V26, pA8; WANG P, 1994, AM J PHYSIOL, V266, pH2535, DOI 10.1152/ajpheart.1994.266.6.H2535; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391	30	259	276	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1391	1392		10.1016/S0140-6736(96)09424-X	http://dx.doi.org/10.1016/S0140-6736(96)09424-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149715				2022-12-28	WOS:A1997WY34200045
J	Heriche, JK; Lebrin, F; Rabilloud, T; Leroy, D; Chambaz, EM; Goldberg, Y				Heriche, JK; Lebrin, F; Rabilloud, T; Leroy, D; Chambaz, EM; Goldberg, Y			Regulation of protein phosphatase 2A by direct interaction with casein kinase 2 alpha	SCIENCE			English	Article							II ALPHA-SUBUNIT; MAP KINASE; BETA-SUBUNIT; PHOSPHORYLATION; ANTIGEN; ENZYME; GROWTH; CELLS; SITE	Timely deactivation of kinase cascades is crucial to the normal control of cell signaling and is partly accomplished by protein phosphatase 2A (PP2A). The catalytic (alpha) subunit of the serine-threonine kinase casein kinase 2 (CK2) bound to PP2A in vitro and in mitogen-starved cells; binding required the integrity of a sequence motif common to CK2 alpha and SV40 small t antigen. Overexpression of CK2 alpha resulted in deactivation of mitogen-activated protein kinase kinase (MEK) and suppression of cell growth. Moreover, CK2 alpha inhibited the transforming activity of oncogenic Ras, but not that of constitutively activated MEK. Thus, CK2 alpha may regulate the deactivation of the mitogen-activated protein kinase pathway.	COMMISS ENERGIE ATOM,DEPT BIOL MOL & STRUCT,LAB BIOCHIM REGULAT CELLULAIRES ENDOCRINES,F-38054 GRENOBLE 9,FRANCE; INSERM,U244,F-38054 GRENOBLE 9,FRANCE; COMMISS ENERGIE ATOM,DEPT BIOL MOL & STRUCT,LAB BIOENERGET CELLULAIRE & PATHOL,F-38054 GRENOBLE 9,FRANCE	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA				lebrin, franck/0000-0002-1650-6757; Goldberg, Yves/0000-0001-7446-8595; Heriche, Jean-Karim/0000-0001-6867-9425				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; COLLEY S, 1994, CELL, V77, P841; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; HERICHE JK, UNPUB; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Krehan A, 1996, BIOCHEMISTRY-US, V35, P4966, DOI 10.1021/bi951989i; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; RABILLOUD T, 1994, ELECTROPHORESIS, V15, P1552, DOI 10.1002/elps.11501501223; ROUSSOU I, 1994, MOL CELL BIOL, V14, P576, DOI 10.1128/MCB.14.1.576; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992	25	248	252	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					952	955		10.1126/science.276.5314.952	http://dx.doi.org/10.1126/science.276.5314.952			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9139659				2022-12-28	WOS:A1997WY79200049
J	Deshpande, PP; Danishefsky, SJ				Deshpande, PP; Danishefsky, SJ			Total synthesis of the potential anticancer vaccine KH-1 adenocarcinoma antigen	NATURE			English	Article							SIALYL-LEWIS-X; LEY; OLIGOSACCHARIDES; GLYCOSYLATION; CANCER; III3FUCV3FUCVI2FUCNLC6; FUCOLIPIDS; ANTIBODY; GLYCALS	Human tumours are often marked by the expression of unusual carbohydrate structural motifs(1-3). These carbohydrate domains are manifested as cell-surface bound glycolipids or glycoproteins(4). This raises the possibility of using cell-free equivalents of these domain compounds, obtained by total synthesis with a view towards triggering some level of immune response. In fact, the serum of mice immunized with fully synthetic compounds(5-7) that mimic cell-surface tumour antigens has already been shown to recognize pertinent human cancer cell lines(8). Further advances in this field depend critically on the availability of these tumour-associated carbohydrate antigens which cannot be readily isolated from natural sources in sufficient quantities. Here we present the successful total synthesis of an adenocarcinoma antigen, KH-1, and of a bioconjugatable analogue which can bind to a carrier protein. These results illustrate the capabilities of oligosaccharide synthesis for reconstructing the challenging structural motifs characteristic of carbohydrate antigens, and thereby open up near possibilities for the development of anticancer vaccines.	SLOAN KETTERING INST CANC RES,BIOORGAN CHEM LAB,NEW YORK,NY 10021; COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027	Memorial Sloan Kettering Cancer Center; Columbia University								BILODEAU MT, 1995, J AM CHEM SOC, V117, P7840, DOI 10.1021/ja00134a043; BLACKBURNE ID, 1976, AUST J CHEM, V29, P381, DOI 10.1071/CH9760381; DANISHEFSKY SJ, 1992, J AM CHEM SOC, V114, P8329, DOI 10.1021/ja00047a077; DANISHEFSKY SJ, 1995, J AM CHEM SOC, V117, P5701, DOI 10.1021/ja00126a011; DANISHEFSKY SJ, 1995, J AM CHEM SOC, V117, P1940, DOI 10.1021/ja00112a007; Danishefsky SJ, 1996, ANGEW CHEM INT EDIT, V35, P1380, DOI 10.1002/anie.199613801; FEIZI T, 1985, CANCER SURV, V4, P245; FUGEDI P, 1987, GLYCOCONJUGATE J, V4, P97, DOI 10.1007/BF01049447; GERVAY J, 1993, J ORG CHEM, V58, P5465, DOI 10.1021/jo00072a031; GRIFFITH DA, 1990, J AM CHEM SOC, V112, P5811, DOI 10.1021/ja00171a021; HAKOMORI S, 1985, CANCER RES, V45, P2405; HAKOMORI SI, 1991, CANCER CELL-MON REV, V3, P461; HELLAND AC, 1992, J CARBOHYD CHEM, V11, P77, DOI 10.1080/07328309208016143; Hummel G, 1997, TETRAHEDRON LETT, V38, P1173, DOI 10.1016/S0040-4039(97)00006-3; JEFFREY PD, 1995, NAT STRUCT BIOL, V2, P466, DOI 10.1038/nsb0695-466; KAIZU T, 1986, J BIOL CHEM, V261, P1254; KAMEYAMA A, 1991, J CARBOHYD CHEM, V10, P549, DOI 10.1080/07328309108543931; KIM IJ, 1995, J ORG CHEM, V60, P7716, DOI 10.1021/jo00129a004; KIM YS, 1986, CANCER RES, V46, P5985; KONDO T, 1996, CHEM LETT, V5, P337; Lloyd K. O., 1991, CANCER BIOL, V2, P421; LONN H, 1987, J CARBOHYD CHEM, V6, P301, DOI 10.1080/07328308708058879; NUDELMAN E, 1986, J BIOL CHEM, V261, P1247; Park TK, 1996, J AM CHEM SOC, V118, P11488, DOI 10.1021/ja962048b; Ragupathi G, 1997, ANGEW CHEM INT EDIT, V36, P125, DOI 10.1002/anie.199701251; WILDMULLER R, 1994, TETRAHEDR LETT, V35, P7927	26	68	80	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					164	166		10.1038/387164a0	http://dx.doi.org/10.1038/387164a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144285				2022-12-28	WOS:A1997WX94500049
J	Crowcroft, NS; Strachan, DP				Crowcroft, NS; Strachan, DP			The social origins of infantile colic: Questionnaire study covering 76747 infants	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEATH; RISK	Objective: To describe risk factors for infantile colic. Design: Questionnaire administered by health visitors. Settings: Sheffield. Subjects: Mothers of 76 747 infants born between 1 August 1975 and 31 May 1988, interviewed when the infant was 1 month old. Main outcome measures: Reporting of infantile colic and its duration; weight of infant, feeding, state of the home, socioeconomic characteristics of the parents, parents' age, and mother's parity. Results: The odds of reporting infantile colic were increased with breast feeding (odds ratio of breast v bottle feeding 1.35 (95% confidence interval 1.28 to 1.43)), increasing parental age, lower parity, increasing parental age at leaving full time education, and more affluent homes and districts of residence. In a logistic regression analysis, mother's age and parity and socioeconomic factors remained the most important risk factors for the reporting of infantile colic (each P < 0.005), and the effect of breast feeding was attenuated (odds ratio of breast v bottle feeding 1.09 (1.02 to 1.15)). Conclusion: At a population level, dietary factors contribute little to mothers' reporting of infantile colic, and dietary change should not be the primary intervention.	UNIV LONDON ST GEORGES HOSP, SCH MED, DEPT PUBL HLTH SCI, LONDON SW17 0RE, ENGLAND	St Georges University London								Altman D.G., 1991, PRACTICAL STAT MED R; BARR RG, 1990, INF MENTAL HLTH J, V11, P340, DOI 10.1002/1097-0355(199024)11:4<340::AID-IMHJ2280110405>3.0.CO;2-9; CARPENTER RG, 1983, LANCET, V1, P723; CARPENTER RG, 1977, ARCH DIS CHILD, V52, P606, DOI 10.1136/adc.52.8.606; FRANCIS B, 1993, GLIM SYSTEM RELEAS 4; HIDE DW, 1982, ARCH DIS CHILD, V57, P559, DOI 10.1136/adc.57.7.559; JAMESROBERTS IS, 1991, ARCH DIS CHILD, V66, P653, DOI 10.1136/adc.66.5.653; Keefe MR, 1996, NURS RES, V45, P4, DOI 10.1097/00006199-199601000-00002; LESTER BM, 1990, INF MENTAL HLTH J, V11, P321, DOI 10.1002/1097-0355(199024)11:4<321::AID-IMHJ2280110403>3.0.CO;2-E; LEWIS M, 1972, MERRILL-PALMER Q BEH, V18, P95; MILLER AR, 1991, PEDIATR CLIN N AM, V38, P1407; PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712; RAUTAVA P, 1993, BRIT MED J, V307, P600, DOI 10.1136/bmj.307.6904.600; *SAS, 1990, LANG PROC; SHAW C, 1977, CHILD CARE HLTH DEV, V3, P1, DOI 10.1111/j.1365-2214.1977.tb00021.x; SLOMAN J, 1990, CHILD PSYCHIAT HUM D, V21, P25, DOI 10.1007/BF00709925; STACEY TE, 1995, NATL R D PROGR RES M; STAHLBERG MR, 1984, EUR J PEDIATR, V143, P108; WESSEL MA, 1954, PEDIATRICS, V14, P421	19	43	46	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	1997	314	7090					1325	1328		10.1136/bmj.314.7090.1325	http://dx.doi.org/10.1136/bmj.314.7090.1325			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WX975	9158470	Green Published			2022-12-28	WOS:A1997WX97500027
J	Zahrani, AA; Levine, MA				Zahrani, AA; Levine, MA			Primary hyperparathyroidism	LANCET			English	Article							ENDOCRINE NEOPLASIA TYPE-1; ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; SPORADIC PARATHYROID ADENOMAS; HYPOCALCIURIC HYPERCALCEMIA; PREOPERATIVE LOCALIZATION; GENETIC ABNORMALITIES; POSTMENOPAUSAL WOMEN; BONE-DISEASE; SURGERY; MANAGEMENT		JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV ENDOCRINOL & METAB,BALTIMORE,MD 21205	Johns Hopkins University				Levine, Michael/0000-0003-0036-7809	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NCRR NIH HHS [5M01-RR00722] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ARNOLD A, 1989, J CLIN ENDOCR METAB, V69, P496, DOI 10.1210/jcem-69-3-496; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; ARNOLD A, 1995, J CLIN INVEST, V95, P2047, DOI 10.1172/JCI117890; ARNOLD A, 1993, J CLIN ENDOCR METAB, V77, P1108, DOI 10.1210/jc.77.5.1108; BAUMANN DS, 1993, SURGERY, V113, P130; BEARD CM, 1989, ARCH INTERN MED, V149, P1887, DOI 10.1001/archinte.149.8.1887; BILEZIKIAN JP, 1992, NEW ENGL J MED, V326, P1196; BONJER HJ, 1992, CRIT REV CL LAB SCI, V29, P1, DOI 10.3109/10408369209105244; BROADUS AE, 1983, J CLIN ENDOCR METAB, V56, P953, DOI 10.1210/jcem-56-5-953; BROWDER W, 1983, AM J SURG, V146, P360, DOI 10.1016/0002-9610(83)90416-6; BURLIS WJ, 1995, PRINCIPLES PRACTICE; CARLING T, 1995, SURGERY, V118, P924, DOI 10.1016/S0039-6060(05)80095-9; CARLING T, 1995, NAT MED, V1, P1309, DOI 10.1038/nm1295-1309; CHAN AK, 1995, ANN SURG, V222, P402, DOI 10.1097/00000658-199509000-00017; Clark O H, 1995, Adv Endocrinol Metab, V6, P1; CLARK OH, 1994, SURGERY, V116, P947; COAKLEY AJ, 1995, NUCL MED COMMUN, V16, P522, DOI 10.1097/00006231-199507000-00002; *CONS DEV C PAN, 1991, ANN INTERN MED, V114, P593; CRYNS VL, 1994, NEW ENGL J MED, V330, P757, DOI 10.1056/NEJM199403173301105; CRYNS VL, 1994, J CLIN ENDOCR METAB, V78, P1320, DOI 10.1210/jc.78.6.1320; DAVIES M, 1992, CLIN ENDOCRINOL, V36, P325, DOI 10.1111/j.1365-2265.1992.tb01454.x; DEFTOS LJ, 1993, ANNU REV MED, V44, P19; DOGLIN C, 1996, HEAD NECK SURG, V2, P92; Dotzenrath C, 1996, J CLIN ENDOCR METAB, V81, P3194, DOI 10.1210/jc.81.9.3194; ELDEIRY S, 1995, J CLIN ENDOCR METAB, V80, P3105, DOI 10.1210/jc.80.11.3105; FALCHETTI A, 1993, J CLIN ENDOCR METAB, V76, P139, DOI 10.1210/jc.76.1.139; FITZPATRICK LA, 1987, AM J MED, V82, P275, DOI 10.1016/0002-9343(87)90068-4; FRIEDMAN E, 1990, J CLIN ENDOCR METAB, V71, P293, DOI 10.1210/jcem-71-2-293; GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P780, DOI 10.1210/jc.79.3.780; GARNERO P, 1993, J CLIN ENDOCRINOL ME, V77; GARTON M, 1995, CLIN ENDOCRINOL, V42, P493, DOI 10.1111/j.1365-2265.1995.tb02668.x; HAKIM JP, 1994, J CLIN ENDOCR METAB, V78, P103, DOI 10.1210/jc.78.1.103; HEATH H, 1989, ENDOCRIN METAB CLIN, V18, P723, DOI 10.1016/S0889-8529(18)30362-1; HEATH H, 1980, NEW ENGL J MED, V302, P189, DOI 10.1056/NEJM198001243020402; HELLMAN P, 1992, WORLD J SURG, V16, P718, DOI 10.1007/BF02067367; HINDIE E, 1995, J CLIN ENDOCR METAB, V80, P302, DOI 10.1210/jc.80.1.302; HOROWITZ MJ, 1994, CURR OPIN RHEUMATOL, V6, P321; HOSOKAWA Y, 1995, J CLIN ENDOCR METAB, V80, P3107, DOI 10.1210/jc.80.11.3107; Hsi ED, 1996, J CLIN ENDOCR METAB, V81, P1736, DOI 10.1210/jc.81.5.1736; KAO PC, 1992, MAYO CLIN PROC, V67, P637, DOI 10.1016/S0025-6196(12)60717-4; KATAGIRI M, 1995, SURG TODAY, V25, P598, DOI 10.1007/BF00311432; Kifor O, 1996, J CLIN ENDOCR METAB, V81, P1598, DOI 10.1210/jc.81.4.1598; KLEEREKOPER M, 1994, AM J MED, V96, P99, DOI 10.1016/0002-9343(94)90127-9; LARSSON C, 1992, HUM GENET, V89, P187; MALLETTE LE, 1989, J CLIN ENDOCR METAB, V68, P654, DOI 10.1210/jcem-68-3-654; MALLETTE LE, 1974, MEDICINE, V53, P127, DOI 10.1097/00005792-197403000-00002; MARCUS R, 1984, ANN INTERN MED, V100, P633, DOI 10.7326/0003-4819-100-5-633; MARCUS R, 1995, J CLIN ENDOCR METAB, V70, P1489; MCBILES M, 1995, SEMIN NUCL MED, V25, P221, DOI 10.1016/S0001-2998(95)80012-3; MITCHELL BK, 1995, J CLIN ENDOCR METAB, V80, P7, DOI 10.1210/jc.80.1.7; MOLLERUP CL, 1994, EUR J SURG, V160, P485; MUNDY GR, 1980, LANCET, V1, P1317, DOI 10.1016/S0140-6736(80)91783-3; NEMETH EF, 1995, NEWS PHYSIOL SCI, V10, P1; PARFITT AM, 1993, J CLIN ENDOCR METAB, V77, P1318, DOI 10.1210/jc.77.5.1318; PARISIEN M, 1992, J BONE MINER RES, V7, P913; PARISIEN M, 1990, J CLIN ENDOCR METAB, V70, P930, DOI 10.1210/jcem-70-4-930; PARISIEN M, 1990, ENDOCRIN METAB CLIN, V19, P19, DOI 10.1016/S0889-8529(18)30337-2; PATTEN BM, 1974, ANN INTERN MED, V80, P182, DOI 10.7326/0003-4819-80-2-182; POLLAK MR, 1994, J CLIN INVEST, V93, P1108, DOI 10.1172/JCI117062; POLO V, 1995, AM J EMERG MED, V13, P680, DOI 10.1016/0735-6757(95)90067-5; POTTS JT, 1990, J CLIN ENDOCR METAB, V70, P1489, DOI 10.1210/jcem-70-6-1489; POTTS JT, 1991, J BONE MINER RES S2, V6, pS1; RAO DS, 1988, J CLIN ENDOCR METAB, V67, P1294, DOI 10.1210/jcem-67-6-1294; REASNER CA, 1993, J CLIN ENDOCR METAB, V77, P1067, DOI 10.1210/jc.77.4.1067; ROSENBERG CL, 1991, ONCOGENE, V6, P449; SEIBEL MJ, 1992, J CLIN ENDOCR METAB, V74, P481, DOI 10.1210/jc.74.3.481; SELBY PL, 1986, NEW ENGL J MED, V314, P1481, DOI 10.1056/NEJM198606053142304; SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P723, DOI 10.1210/jc.80.3.723; Silverberg SJ, 1996, J CLIN ENDOCR METAB, V81, P4007, DOI 10.1210/jc.81.11.4007; SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P729, DOI 10.1210/jc.80.3.729; SILVERBERG SJ, 1990, AM J MED, V89, P327, DOI 10.1016/0002-9343(90)90346-F; SOLOMON BL, 1994, AM J MED, V96, P101, DOI 10.1016/0002-9343(94)90128-7; Tahara H, 1996, CANCER RES, V56, P599; THOMPSON DB, 1995, J CLIN ENDOCR METAB, V80, P3377, DOI 10.1210/jc.80.11.3377; THOMPSON NW, 1982, SURGERY, V92, P814; UDEN P, 1993, WORLD J SURG, V16, P791; ZMORA O, 1995, SURGERY, V118, P932, DOI 10.1016/S0039-6060(05)80096-0	77	79	84	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1233	1238		10.1016/S0140-6736(96)06176-4	http://dx.doi.org/10.1016/S0140-6736(96)06176-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130957				2022-12-28	WOS:A1997WW71700041
J	Ostergaard, S; Russell, MB; Bendtsen, L; Olesen, J				Ostergaard, S; Russell, MB; Bendtsen, L; Olesen, J			Comparison of first degree relatives and spouses of people with chronic tension headache	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POPULATION		UNIV COPENHAGEN, GLOSTRUP HOSP, DEPT NEUROL, DK-2600 GLOSTRUP, DENMARK	University of Copenhagen				Bendtsen, Lars/0000-0002-4810-4998; Olesen, Jes/0000-0002-6712-2702				RASMUSSEN BK, 1992, J EPIDEMIOL COMMUN H, V46, P443, DOI 10.1136/jech.46.4.443; RASMUSSEN BK, 1992, ARCH NEUROL-CHICAGO, V49, P914, DOI 10.1001/archneur.1992.00530330036012; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; WEISS KM, 1982, J CHRON DIS, V35, P539, DOI 10.1016/0021-9681(82)90073-X	4	42	46	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 12	1997	314	7087					1092	1093		10.1136/bmj.314.7087.1092	http://dx.doi.org/10.1136/bmj.314.7087.1092			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU236	9133893	Green Published			2022-12-28	WOS:A1997WU23600027
J	Moore, JP				Moore, JP			Medicine - Coreceptors: Implications for HIV pathogenesis and therapy	SCIENCE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; SOLUBLE CD4; TYPE-1; PROGRESSION; PHENOTYPE; NEUTRALIZATION; DISEASE; BINDING				Moore, JP (corresponding author), ROCKEFELLER UNIV,AARON DIAMOND AIDS RES CTR,1230 YORK AVE,NEW YORK,NY 10016, USA.							ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Jansson M, 1996, P NATL ACAD SCI USA, V93, P15382, DOI 10.1073/pnas.93.26.15382; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Marcon L, 1997, J VIROL, V71, P2522, DOI 10.1128/JVI.71.3.2522-2527.1997; Mascola JR, 1996, AIDS RES HUM RETROV, V12, P1319, DOI 10.1089/aid.1996.12.1319; MONTEFIORI DC, UNPUB; Moore JP, 1996, J VIROL, V70, P427, DOI 10.1128/JVI.70.1.427-444.1996; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; Nyambi PN, 1997, AIDS RES HUM RETROV, V13, P7, DOI 10.1089/aid.1997.13.7; NYAMBI PN, 1996, J VIROL, V70, P445; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; TRKOLA A, UNPUB; Weber J, 1996, J VIROL, V70, P7827, DOI 10.1128/JVI.70.11.7827-7832.1996; WU L, IN PRESS J EXP MED; WU X, 1996, NATURE, V384, P179; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0; Zhou JY, 1997, J VIROL, V71, P2512, DOI 10.1128/JVI.71.3.2512-2517.1997	34	207	226	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					51	52		10.1126/science.276.5309.51	http://dx.doi.org/10.1126/science.276.5309.51			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9122710				2022-12-28	WOS:A1997WR38600036
J	Poynard, T; Bedossa, P; Opolon, P				Poynard, T; Bedossa, P; Opolon, P			Natural history of liver fibrosis progression in patients with chronic hepatitis C	LANCET			English	Article							NON-B-HEPATITIS; NON-A; POSTTRANSFUSION HEPATITIS; ALPHA-INTERFERON; FOLLOW-UP; TRANSFUSION; TRIAL	Background Our aim was to assess the natural history of liver fibrosis progression in hepatitis C and the factors associated with this progression. Methods We recruited 2235 patients from the Observatoire de l'Hepatite C (OBSVIRC) population, the Cohorte Hepatite C Pitie-Salpetriere (DOSVIRC) population, and the original METAVIR population. All the patients had a biopsy sample compatible with chronic hepatitis C as assessed by the METAVIR scoring system (grades the stage of fibrosis on a five-point scale, FO=no fibrosis, F4=cirrhosis, and histological activity on a four-point scale, AO=no activity, A3=severe activity). No patient had received interferon treatment before the liver biopsy sample was obtained, We assessed the effect of nine factors on fibrosis progression: age at biopsy; estimated duration of infection; sex; age at infection; alcohol consumption; hepatitis C virus C (HCV) genotype; HCV viraemia; cause of infection; and histological activity grade. We defined fibrosis progression per year as the ratio between fibrosis stage in METAVIR units and the duration of infection (1 unit=one stage, 4 units=cirrhosis). Findings The median rate of fibrosis progression per year was 0.133 fibrosis unit (95% CI 0.125-0.143), which was similar to the estimates from previous studies (0.146 to 0.154). Three independent factors were associated with an increased rate of fibrosis progression: age at infection older than 40 years, daily alcohol consumption of 50 g or more, and male sex. There was no association between fibrosis progression and HCV genotype. The median estimated duration of infection for progression to cirrhosis was 30 years (28-32), ranging from 13 years in men infected after the age of 40 to 42 years in women who did not drink alcohol and were infected before the age of 40. Without treatment, 377 (33%) patients had an expected median time to cirrhosis of less than 20 years, and 356 (31%) will never progress to cirrhosis or will not progress for at least 50 years. Interpretation The host factors of ageing, alcohol consumption, and male sex have a stronger association with fibrosis progression than virological factors in HCV infection.	HOP BICETRE,SERV ANAT PATHOL,LE KREMLIN BICETR,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP	Poynard, T (corresponding author), GRP HOSP PITIE SALPETRIERE,SERV HEPATO GASTROENTEROL,URA CNRS 1484,F-75651 PARIS 13,FRANCE.		Poynard, Thierry/C-1355-2010; Yang, Chen/G-1379-2010	Poynard, Thierry/0000-0002-3726-7230; Poynard, Thierry/0000-0002-2050-640X; Bedossa, Pierre/0000-0002-8487-7322				ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; CAMPS J, 1993, J HEPATOL, V17, P390, DOI 10.1016/S0168-8278(05)80223-5; CROWE J, 1995, GASTROENTEROLOGY, V108, pA1054, DOI 10.1016/0016-5085(95)28518-0; Delladetsima JK, 1996, J HEPATOL, V24, P27, DOI 10.1016/S0168-8278(96)80182-6; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; Dusheiko GM, 1995, HEPATOLOGY, V22, P1863, DOI 10.1016/0270-9139(95)90216-3; GENESCA J, 1991, SEMIN LIVER DIS, V11, P147, DOI 10.1055/s-2008-1040432; GOMEZRUBIO M, 1990, J HEPATOL, V11, pS63, DOI 10.1016/0168-8278(90)90166-O; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; Kobayashi M, 1996, HEPATOLOGY, V23, P695, DOI 10.1002/hep.510230406; Koff RS, 1995, HEPATOLOGY, V22, P1880; LUDWIG J, 1993, GASTROENTEROLOGY, V105, P274, DOI 10.1016/0016-5085(93)90037-D; *METAVIR COOP GROU, 1994, HEPATOLOGY, V20, P15; *OBS NAT HEP C GRO, 1995, GASTROENTEROL CLIN B, V19, P81; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; Poynard T, 1996, HEPATOLOGY, V24, P778; SAEZROYUELA F, 1991, HEPATOLOGY, V13, P327, DOI 10.1002/hep.1840130220; TAKAHASHI M, 1993, AM J GASTROENTEROL, V88, P240; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607	23	2413	2507	3	96	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					825	832		10.1016/S0140-6736(96)07642-8	http://dx.doi.org/10.1016/S0140-6736(96)07642-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121257				2022-12-28	WOS:A1997WP40300010
J	Merkel, PA; Polisson, RP; Chang, YC; Skates, SJ; Niles, JL				Merkel, PA; Polisson, RP; Chang, YC; Skates, SJ; Niles, JL			Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease	ANNALS OF INTERNAL MEDICINE			English	Article						antibodies, antineutrophil cytoplasmic; connective tissue diseases; Wegener's granulomatosis; vasculitis; enzyme-linked immunosorbent assay; fluorescent antibody technique	SYSTEMIC LUPUS-ERYTHEMATOSUS; RHEUMATOID-ARTHRITIS; ANCA; GRANULOMATOSIS; VASCULITIDES; DIAGNOSIS; INFECTION; ANTIGEN; ANTINUCLEAR	Background: Two types of antineutrophil cytoplasmic antibodies (ANCA), antiproteinase 3 antibodies (anti-PR3) and antimyeloperoxidase antibodies (anti-MPO), are useful in the diagnosis of such types of vasculitis as Wegener granulomatosis and microscopic polyangiitis. Connective tissue diseases frequently appear in the differential diagnosis of this spectrum of vasculitis. Objective: To determine the prevalence of ANCA in patients with connective tissue disease. Design: Blinded, controlled study of a 5-year inception cohort. Setting: Tertiary-care university teaching hospitals. Patients: 70 patients with rheumatoid arthritis, 70 patients with systemic lupus erythematosus, 45 patients with scleroderma, 36 patients with inflammatory myositis, 44 patients with the Sjogren syndrome, 33 patients with the antiphospholipid syndrome, and 165 patients with early undifferentiated connective tissue disease (EUCTD). Serum was taken from 200 blood donors and 52 patients who had known vasculitis and positive results on tests for anti-PR3 or anti-MPO; these patients served as controls. Measurements: The presence of anti-PR3 and anti-MPO was determined by combining the results of indirect immunofluorescence tests for cytoplasmic (C-ANCA) and perinuclear (P-ANCA) patterns with the results of enzyme-linked immunosorbent assays (ELISAs) directed to measure antigen. Results: Cytoplasmic ANCA was not detected in any study or control patient. Perinuclear ANCA was commonly detected among patients with lupus (31%) but was uncommon among patients in other groups (0% to 5%). In all cases, P-ANCA was associated with the presence of antinuclear antibodies. Atypical ANCA immunofluorescence patterns were fairly common in all groups (11% to 39%). Antiproteinase 3 was detected by ELISA in 9 study patients (1 patient with rheumatoid arthritis, 1 with lupus, 1 with polymyositis, and 6 with EUCTD). Antimyeloperoxidase was detected by ELISA in 2 study patients (1 with rheumatoid arthritis and 1 with lupus). None of the patients with positive ELISA results had evidence of renal vasculitis during follow-up. When an ANCA scoring system that combines immunofluorescence and ELISA was used, the test specificity for vasculitis was 99.5% among patients with connective tissue disease. Conclusions: Patients with connective tissue disease are known to develop multiple autoantibodies; positivity for anti-PR3 and anti-MPO ANCA in such patients is rare. Cytoplasmic ANCA immunofluorescence is highly specific for anti-PR3. However, P-ANCA immunofluorescence, which may have positive results because of the presence of antinuclear antibodies, is not a specific marker of anti-MPO. A rigorous ANCA testing system that combines the results of immunofluorescence with those of ELISA is highly specific for Wegener granulomatosis and related vasculitides even in patients with connective tissue disease.	HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Harvard Medical School	Merkel, PA (corresponding author), MASSACHUSETTS GEN HOSP, ARTHRIT UNIT, BULFINCH 165, 55 FRUIT ST, BOSTON, MA 02114 USA.							ALARCON GS, 1991, J RHEUMATOL, V18, P1332; Alarcon GS, 1996, ARTHRITIS RHEUM, V39, P403, DOI 10.1002/art.1780390308; [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BULPITT KJ, 1993, ANN INTERN MED, V118, P602, DOI 10.7326/0003-4819-118-8-199304150-00005; CAMBRIDGE G, 1994, ANN RHEUM DIS, V53, P24, DOI 10.1136/ard.53.1.24; CLEGG DO, 1991, J RHEUMATOL, V18, P1340; COHEN A S, 1971, Bulletin on the Rheumatic Diseases, V21, P643; COLLETT D, 1991, MODELING BINARY DATA; DURAND JM, 1994, CLIN EXP RHEUMATOL, V12, P579; EFTHIMIOU J, 1991, LANCET, V337, P1037, DOI 10.1016/0140-6736(91)92694-W; FIENBERG R, 1993, HUM PATHOL, V24, P160, DOI 10.1016/0046-8177(93)90295-R; GROSS WL, 1995, RHEUM DIS CLIN N AM, V21, P987; HARRIS EN, 1995, CLIN REV ALLERG IMMU, V13, P39, DOI 10.1007/BF02772247; HAUSCHILD S, 1993, ADV EXP MED BIOL, V336, P245; Hellmark T, 1997, J AM SOC NEPHROL, V8, P376; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; JUBY A, 1992, BRIT J RHEUMATOL, V31, P185; KLAASSEN RJL, 1992, CLIN EXP IMMUNOL, V87, P24, DOI 10.1111/j.1365-2249.1992.tb06408.x; KODERISCH J, 1990, LANCET, V335, P1227, DOI 10.1016/0140-6736(90)92755-7; LESAVRE P, 1991, AM J KIDNEY DIS, V18, P159, DOI 10.1016/S0272-6386(12)80873-0; MULDER AHL, 1993, ARTHRITIS RHEUM-US, V36, P1054, DOI 10.1002/art.1780360805; NILES JL, 1989, BLOOD, V74, P1888; Niles JL, 1996, ARCH INTERN MED, V156, P440, DOI 10.1001/archinte.156.4.440; NILES JL, 1991, J AM SOC NEPHROL, V2, P27; Niles JL, 1996, ANNU REV MED, V47, P303; PAUZNER R, 1994, J RHEUMATOL, V21, P1670; PUDIFIN DJ, 1994, CLIN EXP IMMUNOL, V97, P48, DOI 10.1111/j.1365-2249.1994.tb06578.x; RAO JK, 1995, ANN INTERN MED, V123, P925, DOI 10.7326/0003-4819-123-12-199512150-00005; ROPES M W, 1958, Bull Rheum Dis, V9, P175; SAMMARITANO LR, 1992, CLIN LAB MED, V12, P41; SAVIGE JA, 1991, CLIN EXP IMMUNOL, V86, P92; SCHMITT WH, 1991, LANCET, V337, P1416, DOI 10.1016/0140-6736(91)93102-F; SCHNABEL A, 1995, ARTHRITIS RHEUM-US, V38, P633, DOI 10.1002/art.1780380509	34	185	196	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1997	126	11					866	+		10.7326/0003-4819-126-11-199706010-00003	http://dx.doi.org/10.7326/0003-4819-126-11-199706010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA911	9163287				2022-12-28	WOS:A1997XA91100003
J	Tang, HL; Gaietta, GM; Fischer, WH; Ellisman, MH; WongStaal, F				Tang, HL; Gaietta, GM; Fischer, WH; Ellisman, MH; WongStaal, F			A cellular cofactor for the constitutive transport element of type D retrovirus	SCIENCE			English	Article							HELA-CELLS; RNA; INHIBITION; CYTOPLASM; NUCLEUS	A human nuclear protein that specifically interacts with the constitutive transport element (CTE) of simian retrovirus was identified as adenosine 5'-triphosphate-dependent RNA helicase A. This protein could bind to functional CTE but not to inactive CTE mutants. The interaction of helicase A with CTE was distinct from previously described helicase activity of this protein. Helicase A shuttled from the nucleus to the cytoplasm in the presence of a transcription inhibitor or in cells transiently overexpressing CTE-containing RNA. In vivo colocalization of helicase A and CTE was observed in experiments that combined in situ hybridization and immunostaining, These results suggest that helicase A plays a role in the nuclear export of CTE-containing RNA.	UNIV CALIF SAN DIEGO,DEPT MED & BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SAN DIEGO MICROSCOPY IMAGING RESOURCE,LA JOLLA,CA 92093; SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92097	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute			Tang, Hengli/F-2085-2014		NCRR NIH HHS [RR 04050] Funding Source: Medline; NINDS NIH HHS [NS 14718] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014718] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Ernst RK, 1997, MOL CELL BIOL, V17, P135, DOI 10.1128/MCB.17.1.135; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; LEE CG, 1993, J BIOL CHEM, V268, P16822; LEE CG, 1992, J BIOL CHEM, V267, P4398; Liang S, 1996, MOL CELL BIOL, V16, P5139; LUZNIK L, 1993, AIDS RES HUM RETROV, V11, P795; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; Ohno M, 1996, GENE DEV, V10, P997, DOI 10.1101/gad.10.8.997; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; Tabernero C, 1996, J VIROL, V70, P5998, DOI 10.1128/JVI.70.9.5998-6011.1996; Tang HL, 1997, VIROLOGY, V228, P333, DOI 10.1006/viro.1996.8407; Xu Yuan, 1996, Journal of Biomedical Science, V3, P82, DOI 10.1007/BF02255535; Yeakley JM, 1996, P NATL ACAD SCI USA, V93, P7582, DOI 10.1073/pnas.93.15.7582; ZOLOTUKHIN AS, 1994, J VIROL, V68, P7944, DOI 10.1128/JVI.68.12.7944-7952.1994; [No title captured]	18	125	127	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1412	1415		10.1126/science.276.5317.1412	http://dx.doi.org/10.1126/science.276.5317.1412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9162007				2022-12-28	WOS:A1997XB53300048
J	Scott, ERD; Yamaguchi, A; Krot, AN				Scott, ERD; Yamaguchi, A; Krot, AN			Petrological evidence for shock melting of carbonates in the Martian meteorite ALH84001	NATURE			English	Article							ORDINARY CHONDRITES; RECOVERY EXPERIMENTS; METAMORPHISM; IMPACT	The meteorite ALH84001-a shacked igneous rock of probable martian origin-contains chemically and isotopically heterogeneous carbonate globules(1-8), associated with which are organic and inorganic structures that have been interpreted? as possible fossil remains of ancient martian biota, A critical assumption underlying this suggestion is that the carbonates formed from low-temperature fluids penetrating the cracks and voids of the host rock(3). Here we report petrological studies of ALH84001 which investigate the effects of shock on the various mineralogical components of the rock We find that carbonate, plagiodase and silica were melted and partly redistributed by the same shock event responsible for the intense local crushing(1,2) of pyroxene in the meteorite, Texture and compositional data show that, during the period of shock decompression, monomineralic melts were injected into pyroxene fractures that were subsequently cooled and resealed within seconds, Our results therefore suggest that the carbonates in ALH84001 could not have formed at low temperatures, but instead crystallized from shock-melted material; this conclusion weakens significantly the arguments that these carbonates could host the fossilized remnants of biogenic activity.			Scott, ERD (corresponding author), UNIV HAWAII MANOA,SCH OCEAN & EARTH SCI & TECHNOL,HAWAII INST GEOPHYS & PLANETOL,HONOLULU,HI 96822, USA.			Scott, Edward/0000-0002-5137-3830				BISCHOFF A, 1983, EARTH PLANET SC LETT, V66, P1, DOI 10.1016/0012-821X(83)90121-8; Chen M, 1996, SCIENCE, V271, P1570, DOI 10.1126/science.271.5255.1570; DENCE MR, 1974, CONTRIB MINERAL PETR, V46, P81, DOI 10.1007/BF00377497; Dobson DP, 1996, EARTH PLANET SC LETT, V143, P207, DOI 10.1016/0012-821X(96)00139-2; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; IONOV DA, 1993, EARTH PLANET SC LETT, V119, P283, DOI 10.1016/0012-821X(93)90139-Z; IRVING AJ, 1975, GEOCHIM COSMOCHIM AC, V39, P35, DOI 10.1016/0016-7037(75)90183-0; Joreau P, 1997, METEORIT PLANET SCI, V32, P309, DOI 10.1111/j.1945-5100.1997.tb01268.x; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; Jull AJT, 1997, J GEOPHYS RES-PLANET, V102, P1663, DOI 10.1029/96JE03111; Kirschvink JL, 1997, SCIENCE, V275, P1629, DOI 10.1126/science.275.5306.1629; LANGE MA, 1986, EARTH PLANET SC LETT, V77, P409, DOI 10.1016/0012-821X(86)90150-0; Lee WJ, 1996, J PETROL, V37, P1125, DOI 10.1093/petrology/37.5.1125; MARTINEZ I, 1995, J GEOPHYS RES-SOL EA, V100, P15465, DOI 10.1029/95JB01151; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; RUBIN AE, 1992, GEOCHIM COSMOCHIM AC, V56, P1705, DOI 10.1016/0016-7037(92)90236-C; SCHAAL RB, 1977, P LUNAR PLANET SCI C, V8, P1697; SCHMITT RT, 1994, METEORITICS, V29, P529; SEMENENKO VP, 1994, GEOCHIM COSMOCHIM AC, V58, P1525, DOI 10.1016/0016-7037(94)90554-1; STOFFLER D, 1984, J NON-CRYST SOLIDS, V67, P465, DOI 10.1016/0022-3093(84)90171-6; STOFFLER D, 1986, GEOCHIM COSMOCHIM AC, V50, P889, DOI 10.1016/0016-7037(86)90371-6; STOFFLER D, 1991, GEOCHIM COSMOCHIM AC, V55, P3845, DOI 10.1016/0016-7037(91)90078-J; Stoffler D., 1988, METEORITES EARLY SOL, P165; THOMAS KL, 1996, LUNAR PLANET SCI, V27, P1327; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; Valley JW, 1997, SCIENCE, V275, P1633, DOI 10.1126/science.275.5306.1633; WRIGHT IP, 1989, NATURE, V340, P220, DOI 10.1038/340220a0; WYLLIE PJ, 1989, CARBONATITES GENESIS, P500	30	87	91	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					377	379		10.1038/387377a0	http://dx.doi.org/10.1038/387377a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163421				2022-12-28	WOS:A1997XA49600052
J	StOnge, L; SosaPineda, B; Chowdhury, K; Mansouri, A; Gruss, P				StOnge, L; SosaPineda, B; Chowdhury, K; Mansouri, A; Gruss, P			Pax6 Is required for differentiation of glucagon-producing alpha-cells in mouse pancreas	NATURE			English	Article							ENDOCRINE PANCREAS; ADHESION MOLECULE; GENE; EXPRESSION; AGGREGATION; POLYPEPTIDE; INSULIN; ISLETS; MICE	The functional unit of the endocrine pancreas is the islet of Langerhans. Islets are nested within the exocrine tissue of the pancreas and are composed of alpha-, beta-, delta- and gamma-cells(1). P-Cells produce insulin and form the core of the islet, whereas alpha-, delta- and gamma-cells are arranged at the periphery of the islet and secrete glucagon, somatostatin and a pancreatic polypeptide, respectively. Little is known about the molecular and genetic factors regulating the lineage of the different endocrine cells. Pancreas development is known to be abolished in Pdx1-mutant mice(2) and Pax4 mutants lack insulin-producing beta-cells(3). Here we show that the paired-box gene Pax6 is expressed during the early stages of pancreatic development and in mature endocrine cells. The pancreas of Pax6 homozygous mutant mice lack glucagon-producing cells, suggesting that Pax6 is essential for the differentiation of alpha-cells. As mice lacking Pax4 and Pax6 fail to develop any mature endocrine cells, we conclude that both Pax genes are required for endocrine fate in the pancreas.	MAX PLANCK INST BIOPHYS CHEM,D-37077 GOTTINGEN,GERMANY	Max Planck Society								CHALEPAKIS G, 1994, DNA CELL BIOL, V13, P891, DOI 10.1089/dna.1994.13.891; Dahl U, 1996, DEVELOPMENT, V122, P2895; DELTOUR L, 1991, DEVELOPMENT, V112, P1115; GITTES GK, 1992, P NATL ACAD SCI USA, V89, P1128, DOI 10.1073/pnas.89.3.1128; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; MOLLER CJ, 1992, MOL ENDOCRINOL, V6, P1332, DOI 10.1210/me.6.8.1332; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NAGY A, 1993, GENE TARGETING PRACT, P145; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; ROUILLER DG, 1991, DEV BIOL, V148, P233, DOI 10.1016/0012-1606(91)90332-W; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Stoykova A, 1996, DEVELOPMENT, V122, P3453; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Wurst W., 1993, Gene targeting: a practical approach., P33	20	634	650	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					406	409		10.1038/387406a0	http://dx.doi.org/10.1038/387406a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163426				2022-12-28	WOS:A1997XA49600061
J	Keene, N				Keene, N			He lifted his eyes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	1997	277	19					1502	1502						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY969	9153350				2022-12-28	WOS:A1997WY96900001
J	Catalona, WJ; Smith, DS; Ornstein, DK				Catalona, WJ; Smith, DS; Ornstein, DK			Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination - Enhancement of specificity with free PSA measurements	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIGEN; ALPHA-1-ANTICHYMOTRYPSIN; COMPLEX; DIAGNOSIS; EXTENT	Objective.-To determine the detection rate of prostate cancer in a screening population of men with prostate-specific antigen (PSA) concentrations of 2.6 to 4.0 ng/mL and a benign prostate examination, to assess the clinicopathological features of the cancers detected, and to assess the usefulness of measuring the ratio of free to total PSA to reduce the number of prostatic biopsies. Design.-A community-based study of serial screening for prostate cancer with serum PSA measurements and prostate examinations. Setting.-University medical center. Subjects.-A total of 914 consecutive screening volunteers aged 50 years or older with serum PSA levels of 2.6 to 4.0 ng/mL who had a benign prostate examination and no prior screening tests suspicious for prostate cancer, 332 (36%) of whom underwent biopsy of the prostate. Main Outcome Measures.-Cancer detection rate, clinical and pathological features of cancers detected, and specificity for cancer detection using measurements of percentage of free PSA. Results.-Cancer was detected in 22% (73/332) of men who underwent biopsy. All cancers detected were clinically localized, and 81% (42/52) that were surgically staged were pathologically organ confined. Ten percent of the cancers were clinically low-volume and low-grade tumors, and 17% of those surgically staged were low-volume and low-grade or moderately low-grade tumors (possibly harm less). Using a percentage of free PSA cutoff of 27% or less as a criterion for performing prostatic biopsy would have detected 90% of cancers, avoided 18% of benign biopsies, and yielded a positive predictive value of 24% in men who underwent biopsy. Conclusions.-There is an appreciable rate of detectable prostate cancer in men with serum PSA levels of 2.6 to 4.0 ng/mL. The great majority of cancers detected have the features of medically important tumors. Free serum PSA measurements may reduce the number of additional biopsies required by the lower PSA cutoff.			Catalona, WJ (corresponding author), WASHINGTON UNIV,SCH MED,DEPT SURG,DIV UROL SURG,4960 CHILDRENS PL,ST LOUIS,MO 63110, USA.							BANGMA CH, 1995, UROLOGY, V46, P773, DOI 10.1016/S0090-4295(99)80342-2; BENSON MC, 1992, J UROLOGY, V147, P815, DOI 10.1016/S0022-5347(17)37393-7; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CATALONA WJ, 1995, JAMA-J AM MED ASSOC, V274, P1214; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; CHRISTENSSON A, 1993, J UROLOGY, V150, P100, DOI 10.1016/S0022-5347(17)35408-3; COLBERG JW, 1993, J UROLOGY, V149, P507, DOI 10.1016/S0022-5347(17)36130-X; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Hosmer D, 1989, APPL LOGISTIC REGRES, P89; JACOBSEN SJ, 1995, JAMA-J AM MED ASSOC, V274, P1445, DOI 10.1001/jama.274.18.1445; LILJA H, 1991, CLIN CHEM, V37, P1618; LUDERER AA, 1995, UROLOGY, V46, P187, DOI 10.1016/S0090-4295(99)80192-7; Morgan TO, 1996, NEW ENGL J MED, V335, P304, DOI 10.1056/NEJM199608013350502; Smith DS, 1996, JAMA-J AM MED ASSOC, V276, P1309, DOI 10.1001/jama.276.16.1309; SMITH DS, 1994, J UROLOGY, V152, P1732, DOI 10.1016/S0022-5347(17)32372-8; Smith DS, 1996, J UROLOGY, V156, P1366, DOI 10.1016/S0022-5347(01)65588-5; STENMAN UH, 1991, CANCER RES, V51, P222; STENMAN UH, 1994, LANCET, V344, P1594, DOI 10.1016/S0140-6736(94)90405-7; TERRIS MK, 1991, J UROLOGY, V145, P984, DOI 10.1016/S0022-5347(17)38508-7; Wingo PA, 1996, CA-CANCER J CLIN, V46, P113, DOI 10.3322/canjclin.46.2.113	22	509	528	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	1997	277	18					1452	1455		10.1001/jama.277.18.1452	http://dx.doi.org/10.1001/jama.277.18.1452			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX852	9145717				2022-12-28	WOS:A1997WX85200029
J	Eddleston, ALWF				Eddleston, ALWF			Hepatitis B and health-care workers	LANCET			English	Editorial Material											Eddleston, ALWF (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,INST LIVER STUDIES,LONDON SE5 9PJ,ENGLAND.							CARMAN WF, 1989, LANCET, V2, P588; Harpaz R, 1996, NEW ENGL J MED, V334, P549, DOI 10.1056/NEJM199602293340901; *INC INV TEAMS OTH, 1997, NEW ENGL J MED, V336, P178; NAUMOV NV, 1994, GUT, V35, P1013; *UK HLTH DEP, 1993, PROT HLTH CAR WORK P; WELCH J, 1989, LANCET, V1, P205	6	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1339	1340		10.1016/S0140-6736(05)63199-6	http://dx.doi.org/10.1016/S0140-6736(05)63199-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149693				2022-12-28	WOS:A1997WY34200005
J	Murray, CJL; Lopez, AD				Murray, CJL; Lopez, AD			Regional patterns of disability-free life expectancy and disability adjusted life expectancy: Global Burden of Disease Study	LANCET			English	Article							ELDERLY POPULATION; UNITED-STATES; MORBIDITY; MORTALITY; HEALTH; COMPRESSION; PREVALENCE; ILLNESS; DEATH	Background Information on non-fatal health outcomes of disease and injury has been largely neglected in health planning because of the conceptual and definitional complexity of measuring morbidity and disability in populations. One of our major objectives was to quantify disability for inclusion in health policy debates. We analysed these health outcomes in terms of disability-free life expectancy (DFLE) and disability-adjusted life expectancy (DALE). Methods Published and unpublished data were systematically reviewed to estimate the incidence, prevalence, and duration of 483 disabling sequelae of 107 diseases and injuries. To ensure internal consistency of these estimates, a software programme (DISMOD) was applied many times until consistent parameters were identified. The severity of disability, on a scale of 0 (perfect health) to 1 (death), was measured in a deliberate manner by the person-trade-off method. Spearman's and Pearson's correlation coefficients were used to measure disability weights among groups. Prevalence of seven classes of disability was back-calculated from the distribution of each disabling sequela across disabilities. Prevalence for each class of disability for different age-sex groups was used to calculate seven forms of DFLE and DALE based on Sullivan's method. Findings Prevalence of most disability classes is highest in sub-Saharan Africa and lowest in established market economies. Low-severity disabilities (class I and class II) are the most common. The expectation at birth of class I disability ranges from 6.5 years in established market economies to 14.7 years in sub;Saharan Africa, and for class II disabilities, from 8.5-18.4 years. DFLE varies significantly among regions: DFLE for class I disabilities at birth ranges from 9.9 years in sub-Saharan Africa to 47.7 years in established market economies for females and DFLE for class V disabilities ranges from 43.4 years for men in sub-Saharan Africa to 74.8 years for women in established market economies, The proportion of expected life span at birth lived with disability adjusted for severity varies from about 8% in established market economies to 15% in sub-Saharan Africa, with little difference between men and women. In high-income regions, nearly 90% of expected disability is due to non-communicable diseases and most of the remainder to injuries. In poorer regions, almost half of expected disabiity is due to communicable diseases and injuries. Interpretation The higher proportion of lifespan spent disabled in high-mortality populations is consistent with the compression of morbidity hypothesis. The threshold definition of disability used substantially affects the results of DFLE. DALE, which incorporates severity weights for disabilities, is a useful summary measure of the burden of disability and mortality.	HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; WHO,CH-1211 GENEVA,SWITZERLAND	Harvard University; Harvard T.H. Chan School of Public Health; World Health Organization			Lopez, Alan/AAA-2734-2022; Lopez, Alan D/F-1487-2010	Lopez, Alan D/0000-0001-5818-6512				ALTER G, 1989, POP STUD-J DEMOG, V43, P25, DOI 10.1080/0032472031000143836; [Anonymous], 1996, GLOBAL BURDEN DIS CO; BARENDREGT JJ, 1995, REVES 8 OCT 5 7; CHIRIKOS TN, 1986, MILBANK Q, V64, P271, DOI 10.2307/3349973; CRIMMINS EM, 1989, POPUL DEV REV, V15, P235, DOI 10.2307/1973704; CRIMMINS EM, 1993, CALCULATION HLTH EXP; CRIMMINS EM, 1990, J INSURANCE MED, V22, P89; FELDMAN JJ, 1983, MILBANK FUND Q, V61, P430, DOI 10.2307/3349866; FRIES JF, 1988, PERSPECT BIOL MED, V31, P407; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; GRUENBERG EM, 1977, MILBANK FUND Q, V55, P3, DOI 10.2307/3349592; HORNBERGER JC, 1992, J CLIN EPIDEMIOL, V45, P505, DOI 10.1016/0895-4356(92)90099-9; Johansson S R, 1991, Health Transit Rev, V1, P39; MANTON KG, 1993, J GERONTOL, V48, pS153, DOI 10.1093/geronj/48.4.S153; MANTON KG, 1982, MILBANK FUND Q, V60, P183, DOI 10.2307/3349767; Mathers C, 1994, ADV HLTH EXPECTANCIE; MATHERS CD, 1993, CALCULATION HLTH EXP; MECHANIC D, 1986, PSYCHOL MED, V16, P1, DOI 10.1017/S0033291700002476; MEHREZ A, 1987, SOCIO ECON PLAN SCI, V21, P371, DOI 10.1016/0038-0121(87)90011-5; MURRAY CJL, 1992, POPUL DEV REV, V18, P481, DOI 10.2307/1973655; Murray CJL., 1996, GLOBAL HLTH STAT COM, V1996; NORD E, 1992, SOC SCI MED, V34, P559, DOI 10.1016/0277-9536(92)90211-8; Olshansky S.J., 1991, J AGING HEALTH, V3, P194, DOI DOI 10.1177/089826439100300205; RAHMAN O, 1994, GERONTOLOGIST, V34, P463, DOI 10.1093/geront/34.4.463; RICHARDSON J, 1994, SOC SCI MED, V39, P7, DOI 10.1016/0277-9536(94)90162-7; ROBINE JM, 1987, REV EPIDEMIOL SANTE, V35, P206; ROMIEU I, 1994, ADV HLTH EXPECTANCIE; SHEPARD DS, 1980, J CHRON DIS, V33, P413, DOI 10.1016/0021-9681(80)90039-9; SULLIVAN DF, 1971, HSMHA HEALTH REP, V86, P347, DOI 10.2307/4594169; [No title captured]	30	275	294	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1347	1352		10.1016/S0140-6736(96)07494-6	http://dx.doi.org/10.1016/S0140-6736(96)07494-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WY342	9149696				2022-12-28	WOS:A1997WY34200008
J	Saracci, R				Saracci, R			The World Health Organisation needs to reconsider its definition of health	BRITISH MEDICAL JOURNAL			English	Article											Saracci, R (corresponding author), CNR,PISA,ITALY.							[Anonymous], 1992, BAS DOC; CALLAHAN D, 1995, WHAT KIND LIFE LIMIT, P34; DAHRENDORF R, 1994, LIBERTA CAMBIA, P30; DOLL R, 1992, AM J PUBLIC HEALTH, V82, P933, DOI 10.2105/AJPH.82.7.933; FINBERG J, 1973, SOCIAL PHILOS, P59; FREUD S, 1975, S FREUD HOUSE CATALO, P49; *WHO, 1996, EB9716 WHO	7	98	102	2	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1409	1410						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ169	9161320				2022-12-28	WOS:A1997WZ16900040
J	Chun, TW; Carruth, L; Finzi, D; Shen, XF; DiGiuseppe, JA; Taylor, H; Hermankova, M; Chadwick, K; Margolick, J; Quinn, TC; Kuo, YH; Brookmeyer, R; Zeiger, MA; BarditchCrovo, P; Siliciano, RF				Chun, TW; Carruth, L; Finzi, D; Shen, XF; DiGiuseppe, JA; Taylor, H; Hermankova, M; Chadwick, K; Margolick, J; Quinn, TC; Kuo, YH; Brookmeyer, R; Zeiger, MA; BarditchCrovo, P; Siliciano, RF			Quantification of latent tissue reservoirs and total body viral load in HIV-1 Infection	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PERIPHERAL-BLOOD; INSITU HYBRIDIZATION; IN-VIVO; T-CELL; LYMPHOCYTES; INDIVIDUALS; PLASMA; CD4; DNA	The capacity of HIV-1 to establish latent infection of CD4(+) T cells may allow viral persistence despite immune responses and antiretroviral therapy. Measurements of infectious virus(1,2) and viral RNA(3,4) in plasma and of infectious virus(1), viral DNA(5-10) and viral messenger RNA species(11-14) in infected cells all suggest that HIV-1 replication continues throughout the course of infection. Uncertainty remains over what fraction of CD4(+) T cells are infected and whether there are latent reservoirs for the virus. We show here that during the asymptomatic phase of infection there is an extremely low total body load of latently infected resting CD4(+) T cells with replication-competent integrated provirus (< 10(7) cells). The most prevalent form of HIV-1 DNA in resting and activated CD4(+) T cells is a full-length, linear, unintegrated form that is not replication competent. The infection progresses even though at any given time in the lymphoid tissues integrated HIV-1 DNA is present in only a minute fraction of the susceptible populations, including resting and activated CD4(+) T cells and macrophages.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT SURG,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,SCH HYG & PUBL HLTH,DEPT MOL MICROBIOL & IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21205; NIAID,NIH,BETHESDA,MD 20892	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			DiGiuseppe, Joseph/AAD-1935-2019; Abrams, William R/A-5782-2008; Quinn, Thomas/A-2494-2010; Chun, Tae-Wook/W-9187-2019; Chun, Tae-Wook/AAC-3101-2020	Chun, Tae-Wook/0000-0001-5153-7340; 				ADAMS M, 1994, P NATL ACAD SCI USA, V91, P3862, DOI 10.1073/pnas.91.9.3862; BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DICKOVER RE, 1992, J ACQ IMMUN DEF SYND, V5, P31; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; MELLORS IW, 1986, SCIENCE, V272, P1167; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATEL SS, 1988, J IMMUNOL, V141, P3726; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PAUZA CD, 1990, VIROLOGY, V179, P886; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	30	1614	1664	2	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					183	188		10.1038/387183a0	http://dx.doi.org/10.1038/387183a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144289				2022-12-28	WOS:A1997WX94500055
J	Nightingale, SL				Nightingale, SL			Safety alert re risk of misdiagnosis of group B streptococcal infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,MAIL CODE HFI-40,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	1997	277	17					1343	1343		10.1001/jama.277.17.1343	http://dx.doi.org/10.1001/jama.277.17.1343			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW261	9134926				2022-12-28	WOS:A1997WW26100004
J	Harris, AL				Harris, AL			Antiangiogenesis for cancer therapy	LANCET			English	Article							ANGIOGENESIS; METASTASES; SUPPRESSION; INDICATOR; CARCINOMA				Harris, AL (corresponding author), JOHN RADCLIFFE HOSP,INST MOL MED,IMPERIAL CANC RES FUND,MOL ONCOL GRP,OXFORD OX3 9DU,ENGLAND.		Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409				Brooks PC, 1996, CANCER METAST REV, V15, P187, DOI 10.1007/BF00437471; Brown PD, 1995, ANN ONCOL, V6, P967, DOI 10.1093/oxfordjournals.annonc.a059091; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Claffey KP, 1996, CANCER METAST REV, V15, P165, DOI 10.1007/BF00437469; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Millauer B, 1996, CANCER RES, V56, P1615; Min HY, 1996, CANCER RES, V56, P2428; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; TEICHER BA, 1995, CRIT REV ONCOL HEMAT, V20, P9, DOI 10.1016/1040-8428(94)00142-G; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WILSON WR, 1995, CLIN EXP PHARMACOL P, V22, P881, DOI 10.1111/j.1440-1681.1995.tb01956.x	19	44	46	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY	1997	349			2			S13	S15		10.1016/S0140-6736(97)90014-3	http://dx.doi.org/10.1016/S0140-6736(97)90014-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ895	9164441	Bronze			2022-12-28	WOS:A1997WZ89500006
J	Kearns, BG; McGee, TP; Mayinger, P; Gedvilaite, A; Phillips, SE; Kagiwada, S; Bankaitis, VA				Kearns, BG; McGee, TP; Mayinger, P; Gedvilaite, A; Phillips, SE; Kagiwada, S; Bankaitis, VA			Essential role for diacylglycerol in protein transport from the yeast Golgi complex	NATURE			English	Article							PHOSPHOLIPID TRANSFER ACTIVITY; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL TRANSFER; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; GENE; BIOSYNTHESIS; SPHINGOLIPIDS; SEC14; TRANSLOCATION	Yeast phosphatidylinositol transfer protein (Sec14p) is required for the production of secretory vesicles from the Golgi. This requirement can be relieved by inactivation of the cytosine 5'-diphosphate (CDP)-choline pathway for phosphatidylcholine biosynthesis, indicating that Sec14p is an essential component of a regulatory pathway linking phospholipid metabolism with vesicle trafficking (the Sec14p pathway(1-6)). Sac1p (refs 7 and 8) is an integral membrane protein related to inositol-5-phosphatases such as synaptojanin(9), a protein found in rat brain, Here we show that defects in Sac1p also relieve the requirement for Sec14p by altering phospholipid metabolism so as to expand the pool of diacylglycerol (DAG) in the Golgi. Moreover, although short-chain DAG improves secretory function in strains with a temperature-sensitive Sec14p, expression of diacylglycerol kinase from Escherichia call further impairs it. The essential function of Sec14p may therefore be to maintain a sufficient pool of DAG in the Golgi to support the production of secretory vesicles.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; ZENTRUM MOL BIOL,D-69120 HEIDELBERG,GERMANY	University of Alabama System; University of Alabama Birmingham; Ruprecht Karls University Heidelberg				McGee, Todd/0000-0002-3901-1001; PHILLIPS, SCOTT/0000-0002-5451-0984	NIGMS NIH HHS [R01 GM044530] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALB JG, 1995, P NATL ACAD SCI USA, V92, P8826, DOI 10.1073/pnas.92.19.8826; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BUTTKE TM, 1982, J BACTERIOL, V152, P747; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; Fang M, 1996, EMBO J, V15, P6447, DOI 10.1002/j.1460-2075.1996.tb01036.x; GANONG BR, 1984, BIOCHEMISTRY-US, V23, P4977, DOI 10.1021/bi00316a023; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kagiwada S, 1996, GENETICS, V143, P685; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LESTER RL, 1993, ADV LIPID RES, V26, P253; LIGHTNER VA, 1983, J BIOL CHEM, V258, P856; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LOPES JM, NUCLEIC ACIDS RES, V14, P3987; Lopez M., 1994, J CELL BIOL, V124, P113; MAYINGER P, 1995, J CELL BIOL, V131, P1377, DOI 10.1083/jcb.131.6.1377; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P202; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79	30	224	227	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 1	1997	387	6628					101	105		10.1038/387101a0	http://dx.doi.org/10.1038/387101a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139830	Green Accepted			2022-12-28	WOS:A1997WW75800056
J	McQuay, HJ; Moore				McQuay, HJ; Moore			Using numerical results from systematic reviews in clinical practice	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED TRIALS; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; METAANALYSIS; DRUGS; EFFICACY; SUMATRIPTAN; PREVENTION; MANAGEMENT; ANALGESIA		UNIV OXFORD, JOHN RADCLIFFE HOSP, NUFFIELD DEPT ANAESTHET, OXFORD OX3 7LJ, ENGLAND	University of Oxford	McQuay, HJ (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, PAIN RES UNIT, S PARKS RD, OXFORD OX3 7LJ, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; BOBBIO M, 1994, LANCET, V343, P1209, DOI 10.1016/S0140-6736(94)92407-4; Chatellier G, 1996, BRIT MED J, V312, P426; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; CROWLEY PA, 1995, AM J OBSTET GYNECOL, V173, P322, DOI 10.1016/0002-9378(95)90222-8; CUMMINGS P, 1994, ANN EMERG MED, V23, P535, DOI 10.1016/S0196-0644(94)70073-7; FAHEY T, 1995, BRIT MED J, V311, P1056, DOI 10.1136/bmj.311.7012.1056; GOTZSCHE PC, 1990, J CLIN EPIDEMIOL, V43, P1313; HANEKE E, 1995, J AM ACAD DERMATOL, V32, P72, DOI 10.1016/0190-9622(95)90187-6; HAZELL P, 1995, BRIT MED J, V310, P897, DOI 10.1136/bmj.310.6984.897; LAINE L, 1995, ANN INTERN MED, V123, P280, DOI 10.7326/0003-4819-123-4-199508150-00007; LANCASTER T, 1995, BRIT J GEN PRACT, V45, P39; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEHERT P, 1994, J CARDIOVASC PHARM, V23, pS48, DOI 10.1097/00005344-199406030-00010; MCQUAY H, 1995, BRIT MED J, V311, P1047, DOI 10.1136/bmj.311.7012.1047; McQuay HJ, 1996, PAIN, V68, P217, DOI 10.1016/S0304-3959(96)03140-5; MOORE A, 1997, IN PRESS PAIN; MOORE RA, 1995, HELICOBACTER PYLORI; MORTON SC, 1994, OBSTET GYNECOL, V83, P1045, DOI 10.1097/00006250-199406000-00029; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; ONGHENA P, 1992, PAIN, V49, P205, DOI 10.1016/0304-3959(92)90144-Z; ROSENFELD RM, 1994, J PEDIATR-US, V124, P355, DOI 10.1016/S0022-3476(94)70356-6; SACKETT D, 1996, EVIDENCE BASED MED; Sackett DL, 1996, EVIDENCE BASED MED, V1, P164, DOI DOI 10.1136/EBM.1996.1.164; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; SINCLAIR JC, 1994, J CLIN EPIDEMIOL, V47, P881, DOI 10.1016/0895-4356(94)90191-0; SOLL JC, 1992, EFFECTIVE CARE NEWBO, P333; TFELTHANSEN P, 1995, LANCET, V346, P923, DOI 10.1016/S0140-6736(95)91554-0; TFELTHANSEN P, 1993, CEPHALALGIA, V13, P238, DOI 10.1046/j.1468-2982.1993.1304238.x; TRAMER M, 1995, BRIT J ANAESTH, V75, P556, DOI 10.1093/bja/75.5.556; VANDERSTICHELE RH, 1995, BMJ-BRIT MED J, V311, P604, DOI 10.1136/bmj.311.7005.604; WELLS PS, 1994, ARCH INTERN MED, V154, P67, DOI 10.1001/archinte.154.1.67; ZHANG WY, 1994, EUR J CLIN PHARMACOL, V46, P517	34	344	352	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1997	126	9					712	720		10.7326/0003-4819-126-9-199705010-00007	http://dx.doi.org/10.7326/0003-4819-126-9-199705010-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW147	9139558				2022-12-28	WOS:A1997WW14700007
J	Borges, M; Linnoila, RI; vandeVelde, HJK; Chen, H; Nelkin, BD; Mabry, M; Baylin, SB; Ball, DW				Borges, M; Linnoila, RI; vandeVelde, HJK; Chen, H; Nelkin, BD; Mabry, M; Baylin, SB; Ball, DW			An achaete-scute homologue essential for neuroendocrine differentiation in the lung	NATURE			English	Article							SMALL-CELL CARCINOMA; CANCER; GROWTH; LINES; ESTABLISHMENT; IDENTIFICATION; EXPRESSION; ENDOCRINE; TUMORS	In Drosophila and in vertebrates, the achaete-scute family of basic helix-loop-helix transcription factors plays a critical developmental role in neuronal commitment and differentiation(1-6). Relatively little is known, however about the transcriptional control of neural features in cells outside a neuronal context. A minority of normal bronchial epithelial cells and many Lung cancers, especially small-cell lung cancer, exhibit a neuroendocrine phenotype that may reflect a common precursor cell population(7-11). We show here that human achaete-scute homologue-1 (hASW1) is selectively expressed in normal fetal pulmonary neuroendocrine cells, as well as in the diverse range of lung cancers with neuroendocfine features. Strikingly, newborn mice bearing a disruption of the ASR1 gene have no detectable pulmonary neuroendocrine cells. Depletion of this transcription factor from lung cancer cells by antisense oligonucleotides results in a significant decrease in the expression of neuroendrocrine markers. Thus, a homologue of Drosophila neural fate determination genes seems to be necessary for progression of lung epithelial cells through a neuroendocrine differentiation pathway that is a feature of small-cell lung cancer, the most. lethal form of human lung cancer.	JOHNS HOPKINS MED INST, CTR ONCOL, BALTIMORE, MD 21231 USA; JOHNS HOPKINS MED INST, DEPT MED, BALTIMORE, MD 21231 USA; JOHNS HOPKINS MED INST, DEPT SURG, BALTIMORE, MD 21231 USA; NCI, MED BRANCH, DIV CLIN SCI, NIH, ROCKVILLE, MD 20850 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BALL DW, 1993, P NATL ACAD SCI USA, V90, P5648, DOI 10.1073/pnas.90.12.5648; BAYLIN SB, 1981, SMALL CELL LUNG CANC, P123; BERGH J, 1981, ANTICANCER RES, V1, P317; BROERS JLV, 1993, AM J RESP CELL MOL, V9, P33, DOI 10.1165/ajrcmb/9.1.33; BROWER M, 1986, CANCER RES, V46, P798; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CARNEY DN, 1985, CANCER RES, V45, P2913; CHEN HC, IN PRESS P NATL ACAD; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; GAZDAR AF, 1980, CANCER RES, V40, P3502; GAZDAR AF, 1985, CANCER RES, V45, P2924; GAZDAR AF, 1988, CANCER RES, V48, P4078; Gazdar AF, 1981, SMALL CELL LUNG CANC, P145; GomezSkarmeta JL, 1996, CELL, V85, P95, DOI 10.1016/S0092-8674(00)81085-5; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; JAN YN, 1994, ANNU REV GENET, V28, P373, DOI 10.1146/annurev.ge.28.120194.002105; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176; LINNOILA RI, 1988, AM J CLIN PATHOL, V90, P641, DOI 10.1093/ajcp/90.6.641; LINNOILA RI, 1994, CHEST, V106, pS367, DOI 10.1378/chest.106.6.367S; Linnoila RI, 1996, J CELL BIOCHEM, P92; LINNOILA RI, 1994, CL ALLER IM, V4, P197; LINNOILA RI, 1995, LUNG CANCER, P73; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MABRY M, 1991, CANCER CELL-MON REV, V3, P53; NELKIN BD, 1990, BIOCHEM BIOPH RES CO, V170, P140, DOI 10.1016/0006-291X(90)91251-M; PETTENGILL OS, 1980, CANCER-AM CANCER SOC, V45, P906, DOI 10.1002/1097-0142(19800301)45:5<906::AID-CNCR2820450513>3.0.CO;2-H; Sommer L, 1995, NEURON, V15, P1245, DOI 10.1016/0896-6273(95)90005-5	30	303	317	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	1997	386	6627					852	855		10.1038/386852a0	http://dx.doi.org/10.1038/386852a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126746				2022-12-28	WOS:A1997WV70600059
J	Jeltsch, M; Kaipainen, A; Joukov, V; Meng, XJ; Lakso, M; Rauvala, H; Swartz, M; Fukumura, D; Jain, RK; Alitalo, K				Jeltsch, M; Kaipainen, A; Joukov, V; Meng, XJ; Lakso, M; Rauvala, H; Swartz, M; Fukumura, D; Jain, RK; Alitalo, K			Hyperplasia of lymphatic vessels in VEGF-C transgenic mice	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; GROWTH-FACTOR; ENDOTHELIAL-CELLS; EXPRESSION; GENE; FLT4; ANGIOGENESIS; FLK-1; TIE	No growth factors specific for the lymphatic vascular system have yet been described. Vascular endothelial growth factor (VEGF) regulates vascular permeability and angiogenesis, but does not promote lymphangiogenesis. Overexpression of VEGF-C, a ligand of the VEGF receptors VEGFR-3 and VEGFR-2, in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement. Thus, VEGF-C induces selective hyperplasia of the lymphatic vasculature, which is involved in the draining of interstitial fluid and in immune function, inflammation, and tumor metastasis. VEGF-C may play a role in disorders involving the lymphatic system and may be of potential use in therapeutic lymphangiogenesis.	UNIV HELSINKI, HAARTMAN INST, MOL CANC BIOL LAB, SF-00014 HELSINKI, FINLAND; UNIV HELSINKI, INST BIOTECHNOL, HELSINKI 00014, FINLAND; MASSACHUSETTS GEN HOSP, DEPT RADIAT ONCOL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	University of Helsinki; University of Helsinki; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Jeltsch, Michael/I-5340-2012; Joukov, Vladimir/K-3525-2019; Swartz, Melody A./F-9563-2011; Alitalo, Kari K/J-5013-2014; Jain, Rakesh K/I-1384-2017	Jeltsch, Michael/0000-0003-2890-7790; Alitalo, Kari K/0000-0002-7331-0902; Jain, Rakesh K/0000-0001-7571-3548; Rauvala, Heikki/0000-0001-7809-9811				DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; FERRARA N, IN PRESS ENDOCR REV; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1996, NEW ENGL J MED, V334, P921; FOSSUM TW, 1992, J VET INTERN MED, V6, P283, DOI 10.1111/j.1939-1676.1992.tb00353.x; FUKUMURA D, 1995, CANCER RES, V55, P4824; GALLAND F, 1993, ONCOGENE, V8, P1233; Grimmond S, 1996, GENOME RES, V6, P124, DOI 10.1101/gr.6.2.124; Joukov V, 1996, EMBO J, V15, P290; JOUKOV V, UNPUB; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; KORHONEN J, 1994, ONCOGENE, V9, P395; Kukk E, 1996, DEVELOPMENT, V122, P3829; LEAK L V, 1970, Microvascular Research, V2, P361, DOI 10.1016/0026-2862(70)90031-2; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEU AJ, 1994, AM J PHYSIOL-HEART C, V267, pH1507, DOI 10.1152/ajpheart.1994.267.4.H1507; LEU HJ, 1995, VASCULAR PATHOLOGY, P509; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MILLAUER B, 1993, CELL, V72, P83; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PAJUSOLA K, 1992, CANCER RES, V52, P5738; REHN M, 1994, P NATL ACAD SCI USA, V91, P4234, DOI 10.1073/pnas.91.10.4234; SCHMELZ M, 1994, DIFFERENTIATION, V57, P97, DOI 10.1046/j.1432-0436.1994.5720097.x; Swartz MA, 1996, AM J PHYSIOL-HEART C, V270, pH324, DOI 10.1152/ajpheart.1996.270.1.H324; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	30	1013	1118	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1423	1425		10.1126/science.276.5317.1423	http://dx.doi.org/10.1126/science.276.5317.1423			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9162011				2022-12-28	WOS:A1997XB53300052
J	Anderson, JD; Lau, EL; Sjogren, WL; Schubert, G; Moore, WB				Anderson, JD; Lau, EL; Sjogren, WL; Schubert, G; Moore, WB			Europa's differentiated internal structure: Inferences from two Galileo encounters	SCIENCE			English	Article							GRAVITY-FIELD; TRACKING DATA; SATELLITES; JUPITER	Doppler data generated with the Galileo spacecraft's radio carrier wave during two Europa encounters on 19 December 1996 (E4) and 20 February 1997 (E6) were used to measure Europa's external gravitational field. The measurements indicate that Europa has a predominantly water ice-liquid outer shell about 100 to 200 kilometers thick and a deep interior with a density in excess of about 4000 kilograms per cubic meter. The deep interior could be a mixture of metal and rock or it could consist of a metal core with a radius about 40 percent of Europa's radius surrounded by a rock mantle with a density of 3000 to 3500 kilograms per cubic meter. The metallic core is favored if Europa has a magnetic field.	UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,DEPT EARTH & SPACE SCI,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	Anderson, JD (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.							Anderson JD, 1996, NATURE, V384, P541, DOI 10.1038/384541a0; Anderson JD, 1996, SCIENCE, V272, P709, DOI 10.1126/science.272.5262.709; ANDERSON JD, 1974, EXPT GRAVITATION, P163; ANDERSON JD, IN PRESS NATURE; CAMPBELL JK, 1985, ASTRON J, V90, P364, DOI 10.1086/113741; DERMOTT SF, 1979, ICARUS, V37, P310, DOI 10.1016/0019-1035(79)90137-4; HUBBARD WB, 1978, ICARUS, V33, P336, DOI 10.1016/0019-1035(78)90153-7; JEFFREYS H, 1962, EARTH; Kaula W.M., 1966, THEORY SATELLITE GEO; Kaula W.M., 1968, INTRO PLANETARY PHYS; Kivelson MG, 1997, SCIENCE, V276, P1239, DOI 10.1126/science.276.5316.1239; MOYER TD, 1973, TR321527 JET PROP LA, P396; NULL GW, 1976, ASTRON J, V81, P1153, DOI 10.1086/111999; NULL GW, 1975, SCIENCE, V188, P476, DOI 10.1126/science.188.4187.476; SCHUBERT G, 1986, SATELLITES, P629; TAPLEY BD, 1973, RECENT ADV DYNAMICAL, P396; ZHARKOV VN, 1985, ICARUS, V61, P92, DOI 10.1016/0019-1035(85)90157-5	17	111	117	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1236	1239		10.1126/science.276.5316.1236	http://dx.doi.org/10.1126/science.276.5316.1236			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157877				2022-12-28	WOS:A1997XA49700036
J	Freiberg, C; Fellay, R; Bairoch, A; Broughton, WJ; Rosenthal, A; Perret, X				Freiberg, C; Fellay, R; Bairoch, A; Broughton, WJ; Rosenthal, A; Perret, X			Molecular basis of symbiosis between Rhizobium and legumes	NATURE			English	Article							SP NGR234; NITROGEN-FIXATION; VIGNA-UNGUICULATA; PLASMID TRANSFER; STRAIN NGR234; GENES; PSOPHOCARPUS; GENOME	Access to mineral nitrogen often limits plant growth, and so symbiotic relationships have evolved between plants and a variety of nitrogen-fixing organisms, These associations are responsible for reducing 120 million tonnes of atmospheric nitrogen to ammonia each year, In agriculture, independence from nitrogenous fertilizers expands crop production and minimizes pollution of water tables, lakes and rivers. Here we present the complete nucleotide sequence and gene complement of the plasmid from Rhizobium sp. NGR234 that endows the bacterium with the ability to associate symbiotically with leguminous plants, In conjunction with transcriptional analyses, these data demonstrate the presence of new symbiotic loci and signalling mechanisms. The sequence and organization of genes involved in replication and conjugal transfer are similar to those of Agrobacterium, suggesting a recent lateral transfer of genetic information.	INST MOL BIOTECHNOL,ABT GENOMANAL,D-07745 JENA,GERMANY; UNIV GENEVA,CTR MED UNIV,CH-1292 CHAMBESY 4,GENEVE,SWITZERLAND	University of Geneva			Bairoch, Amos/X-7411-2019	Bairoch, Amos/0000-0003-2826-6444				BADENOCHJONES J, 1989, GENE, V77, P141, DOI 10.1016/0378-1119(89)90368-5; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BORODOVSKY M, 1994, NUCLEIC ACIDS RES, V22, P4756, DOI 10.1093/nar/22.22.4756; BROUGHTON WJ, 1987, FEMS MICROBIOL LETT, V40, P251; BROUGHTON WJ, 1986, J CELL BIOL, V102, P1173, DOI 10.1083/jcb.102.4.1173; BROUGHTON WJ, 1984, P NATL ACAD SCI-BIOL, V81, P3093, DOI 10.1073/pnas.81.10.3093; BROUGHTON WJ, 1972, ANAL BIOCHEM, V46, P164, DOI 10.1016/0003-2697(72)90408-3; Denarie J, 1996, ANNU REV BIOCHEM, V65, P503, DOI 10.1146/annurev.bi.65.070196.002443; FELLAY R, 1995, MOL MICROBIOL, V16, P657, DOI 10.1111/j.1365-2958.1995.tb02428.x; FELLAY R, 1995, PATHOGENESIS HOST PA, V1, P199; FISCHER HM, 1994, MICROBIOL REV, V58, P352, DOI 10.1128/MMBR.58.3.352-386.1994; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Freiberg C, 1996, GENOME RES, V6, P590, DOI 10.1101/gr.6.7.590; GALAS DJ, 1989, MOBILE DNA, P109; HANIN M, IN PRESS MOL MICROBI; JABBOURI S, 1995, J BIOL CHEM, V270, P22968, DOI 10.1074/jbc.270.39.22968; Jabbouri S, 1996, BIOLOGY OF PLANT-MICROBE INTERACTIONS, P319; KRISHNAN HB, 1995, MICROBIOL-SGM, V141, P2245, DOI 10.1099/13500872-141-9-2245; LEIGH JA, 1994, TRENDS GENET, V10, P63, DOI 10.1016/0168-9525(94)90151-1; LEWIN A, 1987, PLANT MOL BIOL, V8, P447, DOI 10.1007/BF00017990; MartinezRomero E, 1996, CRIT REV PLANT SCI, V15, P113, DOI 10.1080/713608131; MORRISON NA, 1984, J BACTERIOL, V160, P483, DOI 10.1128/JB.160.1.483-487.1984; PERRET X, 1991, P NATL ACAD SCI USA, V88, P1923, DOI 10.1073/pnas.88.5.1923; PIPER KR, 1993, NATURE, V362, P448, DOI 10.1038/362448a0; PRICE NPJ, 1992, MOL MICROBIOL, V6, P3575, DOI 10.1111/j.1365-2958.1992.tb01793.x; Spaink HP, 1996, CRIT REV PLANT SCI, V15, P559; SULLIVAN JT, 1995, P NATL ACAD SCI USA, V92, P8985, DOI 10.1073/pnas.92.19.8985; Tepfer D., 1989, Plant-microbe interactions., P294; VANSLOOTEN JC, 1990, J BACTERIOL, V172, P5563, DOI 10.1128/jb.172.10.5563-5574.1990; VANSLOOTEN JC, 1992, MOL PLANT MICROBE IN, V5, P179, DOI 10.1094/MPMI-5-179; ZHANG LH, 1993, NATURE, V362, P446, DOI 10.1038/362446a0	32	560	970	6	268	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					394	401		10.1038/387394a0	http://dx.doi.org/10.1038/387394a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163424				2022-12-28	WOS:A1997XA49600059
J	Jacoby, I; Gary, NE; Meyer, GS; McCardle, P; Aurand, J; Chamberlin, J; Potter, AL				Jacoby, I; Gary, NE; Meyer, GS; McCardle, P; Aurand, J; Chamberlin, J; Potter, AL			Retraining physicians for primary care - A study of physician perspectives and program development	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WORKFORCE	Objective.-To determine the number and kinds of programs that medical schools and managed care organizations offer or plan to offer to retrain physician specialists to practice primary care medicine and to discover physicians' attitudes toward such retraining. Design.-A survey was mailed in 1994 to all 126 medical schools and the 19 largest US managed care organizations to collect detailed information about existing and potential retraining programs, Physicians' attitudes toward retraining were elicited from participants in 3 geographically diverse focus groups, Selected specialists were polled through the national survey of the American Medical Association's Socioeconomic Monitoring System to ascertain the demand for retraining. Results.-The majority of institutions contacted perceived a need for retraining, but few programs had been established, Programs being ''considered'' varied widely in duration, class size, target audience accreditation, and projected training settings. Although unenthusiastic about retraining, physicians preferred programs that would expand their patient base, maintain the practice population, be inexpensive and close to home, and provide hands-on training in the eventual practice environment. Physicians also preferred a goal-oriented, part-time retraining program in a large group practice or managed care setting that would allow them to practice their specialty while retraining. Few planned or existing programs incorporate many of these features, The most likely candidates for retraining are subspecialty physicians who currently provide some primary care and are employed by a medical plan. Conclusions.-Despite efforts by those who perceive that a need for more generalist physicians is stimulating interest in retraining specialists and subspecialists to provide primary medical care, physician interest and program availability remain low, and programs under development are not being designed to attract those who may seek retraining, This situation is probably fortuitous, because changed perceptions about the adequacy of the generalist physician workforce since the beginning of this study have diminished the call for retraining.	UNIFORMED SERV UNIV HLTH SCI,F EDWARD HEBERT SCH MED,DEPT MED,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA	Jacoby, I (corresponding author), UNIFORMED SERV UNIV HLTH SCI,F EDWARD HEBERT SCH MED,DEPT PREVENT MED & BIOMETR,BETHESDA,MD 20814, USA.							*ASS AM MED COLL, 1997, ASS AM MED COLL REP, V6, P1; *CDCP, 1994, EP INF COMP SOFTW VE; COOPER RA, 1995, JAMA-J AM MED ASSOC, V274, P1534, DOI 10.1001/jama.274.19.1534; *COUNC GRAD MED ED, 1994, 4 COUNC GRAD MED ED; *COUNC GRAD MED ED, 1995, 6 COUNC GRAD MED ED; DIAL TH, 1995, HEALTH AFFAIR, V14, P168, DOI 10.1377/hlthaff.14.2.168; *I MED, 1996, MAT PHYS WORKF OPT B; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; LUNDERG GD, 1993, JAMA-J AM MED ASSOC, V270, P380, DOI 10.1001/jama.270.3.380; Simon CJ, 1996, HEALTH AFFAIR, V15, P124, DOI 10.1377/hlthaff.15.3.124; *STATA CORP, 1995, STATA COMP SOFTW VER; Stewart D.W., 2014, FOCUS GROUPS THEORY; WALL EM, 1994, ACAD MED, V69, P261, DOI 10.1097/00001888-199404000-00002; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222	14	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	1997	277	19					1569	1573						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY969	9153374				2022-12-28	WOS:A1997WY96900039
J	Tucker, MA; Halpern, A; Holly, EA; Hartge, P; Elder, DE; Sagebiel, RW; Guerry, D; Clark, WH				Tucker, MA; Halpern, A; Holly, EA; Hartge, P; Elder, DE; Sagebiel, RW; Guerry, D; Clark, WH			Clinically recognized dysplastic nevi - A central risk factor for cutaneous melanoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILIAL MALIGNANT-MELANOMA; ATYPICAL-MOLE SYNDROME; TUMOR PROGRESSION; GENETIC-HETEROGENEITY; MELANOCYTIC NEVI; NONFAMILIAL MELANOMA; PRECURSOR LESIONS; POPULATION; ASSOCIATION; PHENOTYPE	Objective.-To investigate the relationship of number and type of nevi to the development of melanoma. Design.-Case-control study. Setting.-Outpatient clinics in referral hospitals. Patients.-Cases were 716 consecutive patients with newly diagnosed melanoma identified at 2 melanoma centers between January 1, 1991, and December 31, 1992. Stratified random sampling of patients from outpatient clinics was used to identify 1014 participating controls of the same age, sex, race, and geographic distribution as the melanoma cases. All study subjects underwent an interview, a complete skin examination, photography of the most atypical nevi, and, if the patient was willing, a biopsy of the most atypical nevus. Main Outcome Measures.-Number and type of nevi on the entire body were systematically reported. All diagnoses of clinically dysplastic nevi were confirmed by expert examiners. Results.-Risk for melanoma was strongly related to number of small nevi, large nondysplastic nevi, and clinically dysplastic nevi. In the absence of dysplastic nevi, increased numbers of small nevi were associated with an approximately 2-fold risk, and increased numbers of both small and large nondysplastic nevi were associated with a 4-fold risk. One clinically dysplastic nevus was associated with a 2-fold risk (95% confidence interval, 1.4-3.6), while 10 or more conferred a 12-fold increased risk (95% confidence interval, 4.4-31). Congenital nevi were not associated with increased risk of melanoma. Conclusions.-Although nondysplastic nevi confer a small risk, clinically dysplastic nevi confer substantial risk for melanoma. On the basis of nevus number and type, clinicians can identify a population at high risk of this epidemic cancer for screening and intervention.	NCI,ENVIRONM EPIDEMIOL BRANCH,NIH,BETHESDA,MD 20892; UNIV PENN,SCH MED,PIGMENTED LES STUDY GRP,PHILADELPHIA,PA 19104; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MELANOMA CLIN,SAN FRANCISCO,CA 94143	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Pennsylvania; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Tucker, MA (corresponding author), NCI,GENET EPIDEMIOL BRANCH,NIH,EXECUT PLAXA N,SUITE 439,6130 EXECUT BLVD,BETHESDA,MD 20892, USA.		Tucker, Margaret A/B-4297-2015	halpern, allan/0000-0001-7320-1901				ALBELDA SM, 1990, CANCER RES, V50, P6757; AUGUSTSSON A, 1990, ACTA DERM-VENEREOL S, V71, P518; BOICE JD, 1996, NIH PUBLICATION; CLARK WH, 1978, ARCH DERMATOL, V114, P732, DOI 10.1001/archderm.114.5.732; CLARK WH, 1991, BRIT J CANCER, V64, P631, DOI 10.1038/bjc.1991.375; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; CLARK WH, 1995, CANC PREVENTION CONT, P185; COOKE KR, 1989, CANCER, V63, P1240, DOI 10.1002/1097-0142(19890315)63:6<1240::AID-CNCR2820630635>3.0.CO;2-9; COOKE KR, 1985, J EPIDEMIOL COMMUN H, V39, P48, DOI 10.1136/jech.39.1.48; CRISTOFOLINI M, 1987, INT J CANCER, V39, P150, DOI 10.1002/ijc.2910390205; ELDER DE, 1980, CANCER, V46, P1787, DOI 10.1002/1097-0142(19801015)46:8<1787::AID-CNCR2820460816>3.0.CO;2-S; ELDER DE, 1993, SEMIN DIAGN PATHOL, V10, P18; ELDER DE, 1992, PIGMENT CEL RES, V82, P136; FOULDS L, 1969, NEOPLASTIC DEV, P41; FRICHOT BC, 1977, LANCET, V1, P864; GARBE C, 1994, J INVEST DERMATOL, V102, P695, DOI 10.1111/1523-1747.ep12374280; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; HALPERN AC, 1993, J AM ACAD DERMATOL, V29, P51, DOI 10.1016/0190-9622(93)70151-I; HALPERN AC, 1991, ARCH DERMATOL, V127, P995, DOI 10.1001/archderm.127.7.995; HARTGE P, 1995, CANCER EPIDEM BIOMAR, V4, P37; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P459, DOI 10.1016/S0190-9622(87)70230-8; KANG SW, 1994, ARCH DERMATOL, V130, P999, DOI 10.1001/archderm.130.8.999; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KURMAN RJ, 1994, JAMA-J AM MED ASSOC, V271, P1866, DOI 10.1001/jama.271.23.1866; LYNCH HT, 1978, J MED GENET, V15, P352, DOI 10.1136/jmg.15.5.352; MACGEOCH C, 1994, HUM MOL GENET, V3, P2195, DOI 10.1093/hmg/3.12.2195; MARGHOOB AA, 1994, ARCH DERMATOL, V130, P993, DOI 10.1001/archderm.130.8.993; NEWTON JA, 1993, J AM ACAD DERMATOL, V29, P989, DOI 10.1016/0190-9622(93)70279-3; NICHOLLS EM, 1973, CANCER, V32, P191, DOI 10.1002/1097-0142(197307)32:1<191::AID-CNCR2820320129>3.0.CO;2-W; *NIH, 1992, JAMA-J AM MED ASSOC, V268, P1314; NORDLUND JJ, 1986, CANCER RES, V46, P1005; PIEPKORN MW, 1994, J AM ACAD DERMATOL, V30, P707, DOI 10.1016/S0190-9622(08)81499-5; ROUSH GC, 1991, BRIT J CANCER, V64, P373, DOI 10.1038/bjc.1991.310; ROUSH GC, 1988, PREV MED, V17, P273, DOI 10.1016/0091-7435(88)90003-5; SCHIFFMAN MH, 1995, CANCER-AM CANCER SOC, V76, P1888, DOI 10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H; SCHNEIDER JS, 1994, ARCH DERMATOL, V130, P1002, DOI 10.1001/archderm.130.8.1002; STEGMAIER OC, 1959, J INVEST DERMATOL, V32, P413, DOI 10.1038/jid.1959.70; SWERDLOW AJ, 1986, BRIT MED J, V292, P1555, DOI 10.1136/bmj.292.6535.1555; TAYLOR MR, 1984, AM J OPHTHALMOL, V98, P478, DOI 10.1016/0002-9394(84)90135-1; TUCKER MA, 1993, J INVEST DERMATOL, V100, pS350, DOI 10.1111/1523-1747.ep12470264; WEINSTOCK MA, 1994, J AM ACAD DERMATOL, V30, P807, DOI 10.1016/S0190-9622(08)81524-1; 1992, BMDP STAT SOFTWARE	44	301	302	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	1997	277	18					1439	1444		10.1001/jama.277.18.1439	http://dx.doi.org/10.1001/jama.277.18.1439			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX852	9145715				2022-12-28	WOS:A1997WX85200027
J	Creed, F; Mbaya, P; Lancashire, S; Tomenson, B; Williams, B; Holme, S				Creed, F; Mbaya, P; Lancashire, S; Tomenson, B; Williams, B; Holme, S			Cost effectiveness of day and inpatient psychiatric treatment: Results of a randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							SERIOUS MENTAL-ILLNESS; COMMUNITY CARE; HOSPITAL-CARE; PEOPLE; OUTPATIENT; DISORDERS; BENEFITS; SERVICE	Objective: To compare direct and indirect costs of day and inpatient treatment of acute psychiatric illness. Design: Randomised controlled trial with outcome and costs assessed over 12 months after the date of admission. Setting: Teaching hospital in an inner city area. Subjects: 179 patients with acute psychiatric illness referred for admission who were suitable for random allocation to day hospital or inpatient treatment. 77 (43%) patients had schizophrenia. Interventions: Routine inpatient or day hospital treatment. Main outcome measures: Direct and indirect costs over 12 months; clinical symptoms, social functioning, and burden on relatives over the follow up period. Results: Clinical and social outcomes were similar at 12 months, except that inpatients improved significantly faster than day patients and burden on relatives was significantly less in the day hospital group at one year. Median direct costs to the hospital were pound 1923 (95% confidence interval pound 750 to pound 3174) per patient less for day hospital treatment than inpatient treatment Indirect costs were greater for day patients; when these were included, overall day hospital treatment was pound 2165 cheaper than inpatient treatment (95% confidence interval of median difference pound 737 to pound 3593). Including costs to informants when appropriate meant that day hospital treatment was pound 1994 per patient cheaper (95% confidence interval pound 600 to pound 3543). Conclusions: Day patient treatment is cheaper for the 30-40% of potential admissions that can be treated in this way. Carers of day hospital patients may bear additional costs. Carers of all patients with acute psychiatric illness are often themselves severely distressed at the time of admission, but day hospital treatment leads to less burden on carers in the long term.			Creed, F (corresponding author), UNIV MANCHESTER,MANCHESTER ROYAL INFIRM,DEPT PSYCHIAT,RAWNSLEY BLDG,MANCHESTER M13 9WL,LANCS,ENGLAND.		Lancashire, Stuart/D-1791-2010					ASBERG M, 1978, ACTA PSYCHIATR SCA S, V271; AUDINI B, 1994, BRIT J PSYCHIAT, V165, P204, DOI 10.1192/bjp.165.2.204; BURNS T, 1993, BRIT J PSYCHIAT, V163, P49, DOI 10.1192/bjp.163.1.49; CREED F, 1989, BRIT J PSYCHIAT, V154, P341, DOI 10.1192/bjp.154.3.341; CREED F, 1989, BRIT J PSYCHIAT, V154, P300, DOI 10.1192/bjp.154.3.300; CREED F, 1991, BRIT J PSYCHIAT, V158, P183, DOI 10.1192/bjp.158.2.183; CREED F, 1990, BMJ-BRIT MED J, V300, P1033, DOI 10.1136/bmj.300.6731.1033; CREED F, 1995, COMMUNITY PSYCHIAT A, P11; DEAN C, 1993, BRIT MED J, V307, P473, DOI 10.1136/bmj.307.6902.473; DICK P, 1985, BRIT J PSYCHIAT, V147, P246, DOI 10.1192/bjp.147.3.246; Goldberg DP., 1972, DETECTION PSYCHIATRI; HOLLOWAY F, 1995, COMMUNITY PSYCHIAT A, P85; KLUITER H, 1992, AM J PSYCHIAT, V149, P1192; KNAPP M, 1994, BRIT J PSYCHIAT, V165, P195, DOI 10.1192/bjp.165.2.195; MBAYA P, 1995, THESIS U MANCHESTER; MUIJEN M, 1992, BRIT MED J, V304, P749, DOI 10.1136/bmj.304.6829.749; NETTEN A, 1994, UNIT COSTS COMMUNITY; ONYETT S, 1990, PSYCHIAT B, V124, P267; PLATT SD, 1981, ACTA PSYCHIAT SCAND, V63, P117, DOI 10.1111/j.1600-0447.1981.tb00658.x; Rosen A., 1992, CURRENT OPINION PSYC, V5, P257; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SCHENE AH, 1993, ACTA PSYCHIAT SCAND, V87, P427, DOI 10.1111/j.1600-0447.1993.tb03400.x; TEST MA, 1980, ARCH GEN PSYCHIAT, V37, P409; TYRER P, 1987, BRIT J PSYCHIAT, V151, P57, DOI 10.1192/bjp.151.1.57; TYRER PJ, 1979, LANCET, V1, P714; WIERSMA D, 1995, BRIT J PSYCHIAT, V166, P52, DOI 10.1192/S0007125000293409; WIERSMA D, 1991, SCHIZOPHRENIA BULL, V17, P411, DOI 10.1093/schbul/17.3.411; Wing JK, 1972, MEASUREMENT CLASSIFI; WYKES T, 1986, BRIT J PSYCHIAT, V148, P1, DOI 10.1192/bjp.148.1.1; Wykes T, 1995, COMMUNITY PSYCHIAT A, P97; ZWERLING I, 1964, ISR J PSYCHIAT REL D, V2, P162	31	62	63	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1381	1385						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WZ169	9161310				2022-12-28	WOS:A1997WZ16900025
J	Parikh, A; Scadding, GK				Parikh, A; Scadding, GK			Fortnightly review - Seasonal allergic rhinitis	BRITISH MEDICAL JOURNAL			English	Review							HAY-FEVER; MEDIATOR RELEASE; DOUBLE-BLIND; IMMUNOTHERAPY; PREVALENCE; ASTHMA; REACTIVITY; EFFICACY; ATOPY		ROYAL NATL THROAT NOSE & EAR HOSP,LONDON WC1X 8DA,ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London								ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; BAHMER FA, 1995, CLIN EXP ALLERGY, V25, P220, DOI 10.1111/j.1365-2222.1995.tb01032.x; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; Bousquet J, 1996, INT ARCH ALLERGY IMM, V110, P207, DOI 10.1159/000237289; Bousquet J, 1995, ASTHMA RHINITIS, P1309; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; CRETICOS PS, 1995, ASTHMA RHINITIS, P1394; DIXON CMS, 1989, BRIT J CLIN PHARMACO, V27, P831, DOI 10.1111/j.1365-2125.1989.tb03446.x; EMANUEL MB, 1988, CLIN ALLERGY, V18, P295, DOI 10.1111/j.1365-2222.1988.tb02872.x; EMBERLIN J, 1995, CLIN EXP ALLERGY, V25, P202, DOI 10.1111/j.1365-2222.1995.tb01029.x; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; GERRARD JW, 1976, ANN ALLERGY, V36, P10; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; KAY AB, 1987, RHINOLOGY, P93; KONIG P, 1988, J ALLERGY CLIN IMMUN, V82, P297, DOI 10.1016/0091-6749(88)91015-9; MACKOWIAK JI, 1994, ANN ALLERGY, V72, P99; MCMENAMIN P, 1994, ANN ALLERGY, V73, P35; McSharry C, 1997, CLIN EXP ALLERGY, V27, P125; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279, DOI 10.1159/000236199; SCADDING GK, 1995, CLIN EXP ALLERGY, V25, P391, DOI 10.1111/j.1365-2222.1995.tb01068.x; SCADDING GK, 1994, IMMUNOLOGY ENT DISOR; SIBBALD B, 1990, BRIT J GEN PRACT, V40, P338; SIBBALD B, 1995, ASTHMA RHINITIS, P32; Sibbald Bonnie, 1993, V31, P61; SMITH JM, 1993, ALLERGIC NONALLERGIC, P15; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P296, DOI 10.1111/j.1365-2222.1995.tb01046.x; TAKAFUJI S, 1989, IGE MAST CELLS ALLER, P199; THOMPSON RA, 1989, LANCET, V1, P259; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; WANG DY, 1994, ACTA OTO-LARYNGOL, V114, P552, DOI 10.3109/00016489409126103; WEEKS JR, 1988, POPUL BULL, V43, P1; [No title captured]	38	35	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1392	1395						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ169	9161315				2022-12-28	WOS:A1997WZ16900032
J	Astumian, RD				Astumian, RD			Thermodynamics and kinetics of a Brownian motor	SCIENCE			English	Article							STOCHASTIC RESONANCE; JOSEPHSON-JUNCTION; INDUCED TRANSPORT; THERMAL RATCHETS; MOLECULAR MOTORS; DRIVEN RATCHETS; ELECTRIC-FIELD; FREE-ENERGY; NOISE; PARTICLES	Nonequilibrium fluctuations, whether generated externally or by a chemical reaction far from equilibrium, can bias the Brownian motion of a particle in an anisotropic medium without thermal gradients, a net force such as gravity, or a macroscopic electric field. Fluctuation-driven transport is one mechanism by which chemical energy can directly drive the motion of particles and macromolecules and may find application in a wide variety of fields, including particle separation and the design of molecular motors and pumps.	UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637	University of Chicago	Astumian, RD (corresponding author), UNIV CHICAGO,DEPT SURG,MC6035,CHICAGO,IL 60637, USA.		Astumian, Raymond Dean/H-7440-2013	Astumian, Raymond Dean/0000-0001-7472-187X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES006620] Funding Source: NIH RePORTER; NIEHS NIH HHS [R29ES06620] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AJDARI A, 1992, CR ACAD SCI II, V315, P1635; ANISHCHENKO VS, 1994, INT J BIFURCAT CHAOS, V4, P441, DOI 10.1142/S0218127494000290; ASTUMIAN RD, 1994, PHYS REV LETT, V72, P1766, DOI 10.1103/PhysRevLett.72.1766; ASTUMIAN RD, 1987, P NATL ACAD SCI USA, V84, P434, DOI 10.1073/pnas.84.2.434; Astumian RD, 1996, J PHYS CHEM-US, V100, P19075, DOI 10.1021/jp961614m; ASTUMIAN RD, 1993, J AM CHEM SOC, V115, P11063, DOI 10.1021/ja00077a001; ASTUMIAN RD, 1995, P NATL ACAD SCI USA, V92, P3740, DOI 10.1073/pnas.92.9.3740; ASTUMIAN RD, 1989, PHYS REV A, V39, P6416, DOI 10.1103/PhysRevA.39.6416; ASTUMIAN RD, 1989, J CHEM PHYS, V91, P4891, DOI 10.1063/1.456728; ASTUMIAN RD, 1996, BIOPHYS J, V70, P689; BARTUSSEK R, 1994, EUROPHYS LETT, V28, P459, DOI 10.1209/0295-5075/28/7/001; Bartussek R, 1996, PHYS REV LETT, V76, P1166, DOI 10.1103/PhysRevLett.76.1166; BENNETT CH, 1982, INT J THEOR PHYS, V21, P905, DOI 10.1007/BF02084158; Berg H. C., 1983, RANDOM WALKS BIOL; Bier M, 1996, PHYS LETT A, V211, P12, DOI 10.1016/0375-9601(95)00920-5; Bier M, 1996, PHYS REV LETT, V76, P4277, DOI 10.1103/PhysRevLett.76.4277; Bier M, 1996, BIOELECTROCH BIOENER, V39, P67, DOI 10.1016/0302-4598(95)01833-6; Bulsara AR, 1996, PHYS TODAY, V49, P39, DOI 10.1063/1.881491; BUTTIKER M, 1983, PHYS REV B, V28, P1268, DOI 10.1103/PhysRevB.28.1268; Buttiker M., 1982, NONLINEAR PHENOMENA, P111; CHAWIN JF, 1995, EUROPHYS LETT, V32, P373; DERENYI I, 1995, PHYS REV LETT, V75, P374, DOI 10.1103/PhysRevLett.75.374; Derenyi I, 1996, PHYS REV E, V54, pR5, DOI 10.1103/PhysRevE.54.R5; DOERING CR, 1995, NUOVO CIMENTO D, V17, P685, DOI 10.1007/BF02451826; DOERING CR, 1994, PHYS REV LETT, V72, P2984, DOI 10.1103/PhysRevLett.72.2984; Einstein A, 1906, ANN PHYS-BERLIN, V19, P371; FAUCHEUX LP, 1995, PHYS REV LETT, V74, P1504, DOI 10.1103/PhysRevLett.74.1504; FEYNMAN RP, 1966, FEYNMAN LECT PHYS, V1, pCH46; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FULINSKI A, 1994, PHYS LETT A, V193, P267, DOI 10.1016/0375-9601(94)90595-9; HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/RevModPhys.62.251; HIBBS AD, 1995, J APPL PHYS, V77, P2582, DOI 10.1063/1.358720; JULICHER F, 1995, PHYS REV LETT, V75, P2618, DOI 10.1103/PhysRevLett.75.2618; LANDAUER R, 1985, PHYS SCRIPTA, VT9, P155, DOI 10.1088/0031-8949/1985/T9/027; Langevin P, 1908, CR HEBD ACAD SCI, V146, P530; LAUGER P, 1991, ELECTROGENIC ION PUM, P56; LEIBLER S, 1994, NATURE, V370, P412, DOI 10.1038/370412a0; LIU DS, 1990, J BIOL CHEM, V265, P7260; MAGNASCO MO, 1993, PHYS REV LETT, V71, P1477, DOI 10.1103/PhysRevLett.71.1477; Mielke A, 1995, ANN PHYS-LEIPZIG, V4, P721, DOI 10.1002/andp.19955070802; MIELKE A, 1995, ANN PHYS-LEIPZIG, V4, P476, DOI 10.1002/andp.19955070507; MILLONAS MM, 1994, PHYS LETT A, V185, P65, DOI 10.1016/0375-9601(94)90989-X; PESKIN CS, 1994, CELL MECH CELLULAR E; PROST J, 1994, PHYS REV LETT, V72, P2652, DOI 10.1103/PhysRevLett.72.2652; Risken H., 1989, FOKKER PLANCK EQUATI; ROUSE R, 1995, APPL PHYS LETT, V66, P108, DOI 10.1063/1.114161; ROUSSELET J, 1994, NATURE, V370, P446, DOI 10.1038/370446a0; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TARLIE M, UNPUB; TSONG TY, 1986, BIOELECTROCH BIOENER, V15, P457, DOI 10.1016/0302-4598(86)85034-6; von Smoluchowski M, 1912, PHYS Z, V13, P1069; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0; XIE TD, 1994, BIOPHYS J, V67, P1247, DOI 10.1016/S0006-3495(94)80594-6; XIE TD, IN PRESS BIOPHYS J; Zhou HX, 1996, PHYS REV LETT, V77, P194, DOI 10.1103/PhysRevLett.77.194	55	1195	1212	4	277	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					917	922		10.1126/science.276.5314.917	http://dx.doi.org/10.1126/science.276.5314.917			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9139648	Green Submitted			2022-12-28	WOS:A1997WY79200038
J	Haberli, RM; Gombosi, TI; DeZeeuw, DL; Combi, MR; Powell, KG				Haberli, RM; Gombosi, TI; DeZeeuw, DL; Combi, MR; Powell, KG			Modeling of cometary X-rays caused by solar wind minor ions	SCIENCE			English	Article							ELECTRON-CAPTURE; ABUNDANCES; OXYGEN; COLLISIONS; JUPITER; CARBON; H-2	X-ray emission was discovered in comet Hyakutake (C/1996 B2) by the Rontgen satellite in 1996, and these emissions were attributed to the excitation of high charge state solar wind ions due to electron capture from cometary molecules or atoms. Using the plasma flow in the coma of Hyakutake calculated by a three-dimensional adaptive magneto-hydrodynamic model, the density distribution of solar wind ions in the coma and the resulting x-ray emission were computed. The calculated High Resolution imager count rate of 4.4 per second and the spatial distribution of the x-ray emission agree with the observations. A detailed energy spectrum of cometary x-rays is predicted in the 80 to 2000 electronvolt energy range. Cometary x-rays present a sensitive tool to monitor cometary activity and solar wind ion composition.	UNIV MICHIGAN,SPACE PHYS RES LAB,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT AEROSP ENGN,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Gombosi, Tamas I/G-4238-2011; De Zeeuw, Darren L/F-3667-2011; Combi, Michael/J-1697-2012	Gombosi, Tamas I/0000-0001-9360-4951; De Zeeuw, Darren L/0000-0002-4313-5998; Combi, Michael/0000-0002-9805-0078; Powell, Kenneth/0000-0002-3708-8814				BAME SJ, 1975, SOL PHYS, V43, P463, DOI 10.1007/BF00152368; Bingham R, 1997, SCIENCE, V275, P49, DOI 10.1126/science.275.5296.49; BOCHSLER P, 1986, SOL PHYS, V103, P177, DOI 10.1007/BF00154867; Combi M. R., 1996, B AM ASTRON SOC, V28, P1094; Combi MR, 1996, ICARUS, V123, P207, DOI 10.1006/icar.1996.0150; CRAVENS TE, 1995, J GEOPHYS RES-SPACE, V100, P17153, DOI 10.1029/95JA00970; Cravens TE, 1997, GEOPHYS RES LETT, V24, P105, DOI 10.1029/96GL03780; DEZEEUW D, 1993, J COMPUT PHYS, V104, P56, DOI 10.1006/jcph.1993.1007; DIJKKAMP D, 1985, J PHYS B-AT MOL OPT, V18, P737, DOI 10.1088/0022-3700/18/4/018; GEISS J, 1994, EOS, V75, P278; Gombosi TI, 1996, J GEOPHYS RES-SPACE, V101, P15233, DOI 10.1029/96JA01075; HABERLI RM, 1996, B AM ASTRON SOC, V28, P1085; Haser L., 1957, B ACAD ROY SCI BELGI, V43, P740; ISLER RC, 1994, PLASMA PHYS CONTR F, V36, P171, DOI 10.1088/0741-3335/36/2/001; KRANKOWSKY D, 1986, NATURE, V321, P326, DOI 10.1038/321326a0; KRASNOPOLSKY VA, 1996, B AM ASTRON SOC, V28, P1095; Lisse CM, 1996, SCIENCE, V274, P205, DOI 10.1126/science.274.5285.205; MANN R, 1981, J PHYS B; Mumma MJ, 1996, SCIENCE, V272, P1310, DOI 10.1126/science.272.5266.1310; NORTHROP TG, IN PRESS ICARUS; OLSON RE, 1989, PHYS SCRIPTA, VT28, P71, DOI 10.1088/0031-8949/1989/T28/013; OLSON RE, 1980, J PHYS B-AT MOL OPT, V13, P483, DOI 10.1088/0022-3700/13/3/012; Palumbo L.J., 1973, ATOMIC IONIC EMISSIO; PHANEUF RA, 1982, PHYS REV A, V26, P1892, DOI 10.1103/PhysRevA.26.1892; Tawara H., 1978, Atomic Data and Nuclear Data Tables, V22, P491, DOI 10.1016/0092-640X(78)90021-9; VONSTEIGER R, 1992, ASTROPHYS J, V389, P791, DOI 10.1086/171252; WAITE JH, 1994, J GEOPHYS RES-SPACE, V99, P14799, DOI 10.1029/94JA01005	27	129	130	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					939	942		10.1126/science.276.5314.939	http://dx.doi.org/10.1126/science.276.5314.939			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9139655				2022-12-28	WOS:A1997WY79200045
J	Kadosh, D; Struhl, K				Kadosh, D; Struhl, K			Repression by Ume6 involves recruitment of a complex containing Sin3 corepressor and Rpd3 histone deacetylase to target promoters	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REPRESSION; YEAST; GENE; EXPRESSION; REGULATOR; ENCODES; DOMAIN; SITE	Sin3 and Rpd3 negatively regulate a diverse set of yeast genes. A mouse Sin3-related protein is a transcriptional corepressor, and a human Rpd3 homolog is a histone deacetylase. Here, we show that Sin3 and Rpd3 are specifically required for transcriptional repression by Ume6, a DNA-binding protein that regulates genes involved in meiosis. A short region of Ume6 is sufficient to repress transcription, and this repression domain mediates a two-hybrid and physical interaction with Sin3. Coimmunoprecipitation and two-hybrid experiments indicate that Sin3 and Rpd3 are associated in a complex distinct from TFIID and Pol II holoenzyme. Rpd3 is specifically required for repression by Sin3, and artificial recruitment of Rpd3 results in repression. These results suggest that repression by Ume6 involves recruitment of a Sin3-Rpd3 complex and targeted histone deacetylation.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NIGMS NIH HHS [GM 53720] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BOWDISH KS, 1995, MOL CELL BIOL, V15, P2955; BOWDISH KS, 1993, MOL CELL BIOL, V13, P2172, DOI 10.1128/MCB.13.4.2172; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; DeRubertis F, 1996, NATURE, V384, P589; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; Jackson JC, 1996, NUCLEIC ACIDS RES, V24, P1322, DOI 10.1093/nar/24.7.1322; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; MCKENZIE EA, 1993, MOL GEN GENET, V240, P374, DOI 10.1007/BF00280389; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; NEHLIN JO, 1992, NUCLEIC ACIDS RES, V20, P5271, DOI 10.1093/nar/20.20.5271; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PARK HD, 1992, NUCLEIC ACIDS RES, V20, P1909, DOI 10.1093/nar/20.8.1909; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SLEKAR KH, 1995, NUCLEIC ACIDS RES, V23, P1964, DOI 10.1093/nar/23.11.1964; STILLMAN DJ, 1994, GENETICS, V136, P781; STRICH R, 1994, GENE DEV, V8, P796, DOI 10.1101/gad.8.7.796; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VINCENT AC, 1992, MOL CELL BIOL, V12, P5394, DOI 10.1128/MCB.12.12.5394; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	33	463	475	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					365	371		10.1016/S0092-8674(00)80217-2	http://dx.doi.org/10.1016/S0092-8674(00)80217-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150136	Bronze			2022-12-28	WOS:A1997WX89900007
J	Zhang, Y; Iratni, R; ErdjumentBromage, H; Tempst, P; Reinberg, D				Zhang, Y; Iratni, R; ErdjumentBromage, H; Tempst, P; Reinberg, D			Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex	CELL			English	Article							NEGATIVE REGULATOR; SACCHAROMYCES-CEREVISIAE; REPRESSOR SIN3; YEAST; TRANSCRIPTION; ACETYLATION; GENE; ACTIVATION; HO; MECHANISM	An important event in gene expression is the covalent modification of histone proteins. We have found that the mammalian transcriptional repressor Sin3 (mSin3) exists in a complex with histone deacetylases HDAC1 and HDAC2. Consistent with the observation that mSin3-mediated repression of transcription involves the modification of histone polypeptides, we found that the mSin3-containing complex includes polypeptides that tether the mSin3 complex to core histone proteins. In addition, two novel mSin3-associated polypeptides, SAP18 and SAP30, were identified. We isolated a cDNA encoding human SAP18 and found that SAP18 is a component of an mSin3-containing complex in vivo. Moreover, we demonstrate a direct interaction between SAP18 and mSin3. SAP18 represses transcription in vivo when tethered to the promoter, consistent with the ability of SAP18 to interact with mSin3.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Memorial Sloan Kettering Cancer Center			Iratni, Rabah/M-5224-2016	Erdjument-Bromage, Hediye/0000-0003-0224-3594; Reinberg, Danny/0000-0003-4288-2016; Zhang, Yi/0000-0002-2789-0811	NCI NIH HHS [5P309CA08748] Funding Source: Medline; NIGMS NIH HHS [GM-48518, GM-37120] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037120, R01GM037120] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Bunker CA, 1996, P NATL ACAD SCI USA, V93, P10820, DOI 10.1073/pnas.93.20.10820; DeRubertis F, 1996, NATURE, V384, P589; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Harlow E., 1988, ANTIBODIES LAB MANUA; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; WADE PA, 1997, CURR BIOL, V7, P82; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; WANG HM, 1990, P NATL ACAD SCI USA, V87, P9761, DOI 10.1073/pnas.87.24.9761; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097	44	389	401	3	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					357	364		10.1016/S0092-8674(00)80216-0	http://dx.doi.org/10.1016/S0092-8674(00)80216-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150135	Bronze			2022-12-28	WOS:A1997WX89900006
J	Zhong, HH; SuYang, H; ErdjumentBromage, H; Tempst, P; Ghosh, S				Zhong, HH; SuYang, H; ErdjumentBromage, H; Tempst, P; Ghosh, S			The transcriptional activity of NF-kappa B is regulated by the I kappa B-associated PKAc subunit through a cyclic AMP-independent mechanism	CELL			English	Article							DEPENDENT PROTEIN-KINASE; SODIUM DODECYL-SULFATE; CATALYTIC SUBUNIT; DORSAL; ACTIVATION; DISSOCIATION; TOLL	Stimulation of cells with inducers of NF-kappa B such as LPS and IL-1 leads to the degradation of I kappa B-alpha and I kappa B-beta proteins and translocation of NF-kappa B to the nucleus. We now demonstrate that, besides the physical partitioning of inactive NF-kappa B to the cytosol, the transcriptional activity of NF-kappa B is regulated through phosphorylation of NF-kappa B p65 by protein kinase A (PKA). The catalytic subunit of PKA (PKAc) is maintained in an inactive state through association with I kappa B-alpha or I kappa B-beta in an NF-kappa B-I kappa B-PKAc complex. Signals that cause the degradation of I kappa B result in activation of PKAc in a cAMP-independent manner and the subsequent phosphorylation of p65. Therefore, this pathway represents a novel mechanism for the cAMP-independent activation of PKA and the regulation of NF-kappa B activity.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Memorial Sloan Kettering Cancer Center				Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033443] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI33443] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; MOSIALOS G, 1992, ONCOGENE, V8, P721; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; NORRIS JL, 1992, GENE DEV, V6, P1654, DOI 10.1101/gad.6.9.1654; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; Suyang H, 1996, MOL CELL BIOL, V16, P5444; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523	25	716	730	2	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					413	424		10.1016/S0092-8674(00)80222-6	http://dx.doi.org/10.1016/S0092-8674(00)80222-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150141	hybrid			2022-12-28	WOS:A1997WX89900012
J	Dolmetsch, RE; Lewis, RS; Goodnow, CC; Healy, JI				Dolmetsch, RE; Lewis, RS; Goodnow, CC; Healy, JI			Differential activation of transcription factors induced by Ca2+ response amplitude and duration	NATURE			English	Article							NF-KAPPA-B; T-LYMPHOCYTES; SIGNAL-TRANSDUCTION; RECEPTOR; PHOSPHORYLATION; DISSOCIATION; ASSOCIATION; EXPRESSION; CHANNELS	An increase in the intracellular calcium ion concentration ([Ca2+](i)) controls a diverse range of cell functions, including adhesion, motility, gene expression and proliferation(1,2). Calcium signalling patterns can occur as single transients, repetitive oscillations or sustained plateaux(2,3), but it is not known whether these patterns are responsible for encoding the specificity of cellular responses. We report here that the amplitude and duration of calcium signals in B lymphocytes controls differential activation of the pro-inflammatory transcriptional regulators NF-kappa B, c-Jun N-terminal kinase (JNK) and NFAT. NF-kappa B and JNK are selectively activated by a large transient [Ca2+](i) rise, whereas NFAT is activated by a low sustained Ca2+ plateau. Differential activation results from differences in the Ca2+ sensitivities and kinetic behaviour of the three pathways. Our results show how downstream effecters can decode information contained in the amplitude and duration of Ca2+ signals, revealing a mechanism by which a multifunctional second messenger such as Ca2+ can achieve specificity in signalling to the nucleus.	STANFORD UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,NEUROSCI PROGRAM,STANFORD,CA 94305; STANFORD UNIV,SCH MED,PROGRAM IMMUNOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University			Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155; Lewis, Richard/0000-0002-6010-7403	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045374] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM045374] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; ERNST P, 1995, IMMUNITY, V2, P311, DOI 10.1016/1074-7613(95)90139-6; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; GAJEWSKI TF, 1994, J EXP MED, V179, P481, DOI 10.1084/jem.179.2.481; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HEALY JI, IN PRESS IMMUNITY; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SloanLancaster J, 1996, J EXP MED, V184, P1525, DOI 10.1084/jem.184.4.1525; SU B, 1994, CELL, V77, P7727; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WILSON HA, 1987, J IMMUNOL, V138, P1712	30	1476	1522	1	82	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					855	858		10.1038/386855a0	http://dx.doi.org/10.1038/386855a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126747				2022-12-28	WOS:A1997WV70600060
J	Doyal, L				Doyal, L			Informed consent in medical research - Journals should not publish research to which patients have not given fully informed consent - With three exceptions	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ETHICS; TRIALS; PREFERENCES; INFORMATION; CANCER				Doyal, L (corresponding author), UNIV LONDON, QUEEN MARY & WESTFIELD COLL, ST BARTHOLOMEWS & ROYAL LONDON SCH MED & DENT, LONDON E1 2AD, ENGLAND.							[Anonymous], 1996, BRIT MED J, V313, P1448; APPELBAUM PS, 1987, INFORMED CONSENT LEG, P212; Baum M, 1995, Eur J Surg Oncol, V21, P136, DOI 10.1016/S0748-7983(95)90072-1; BAUM M, 1993, LANCET, V341, P812, DOI 10.1016/0140-6736(93)90573-Y; Bhagwanjee S, 1997, BRIT MED J, V314, P1077, DOI 10.1136/bmj.314.7087.1077a; BIROS MH, 1995, JAMA-J AM MED ASSOC, V273, P1283, DOI 10.1001/jama.273.16.1283; Bok S, 1978, LYING MORAL CHOICE P; CLAYTON EW, 1995, JAMA-J AM MED ASSOC, V274, P1786, DOI 10.1001/jama.274.22.1786; CRISP R, 1990, J LAW SOC, V17, P77, DOI 10.2307/1409956; DEBER RB, 1994, CAN MED ASSOC J, V151, P171; Dennis M, 1997, BRIT MED J, V314, P1071, DOI 10.1136/bmj.314.7087.1071; DIAMOND A, 1994, J ROY COLL PHYS LOND, V28, P439; DOYAL L, 1994, PRINCIPLES HLTH CARE, P217; Dresser R, 1996, JAMA-J AM MED ASSOC, V276, P67, DOI 10.1001/jama.276.1.67; *E LOND CIT HLTH A, 1996, GUID COMPL APPL FORM; EVANS D, 1996, DECENT PROPOSAL ETHI, P62; FALLOWFIELD L, 1994, LANCET, V344, P1576, DOI 10.1016/S0140-6736(94)90386-7; FINCH E, 1994, LANCET, V344, P688, DOI 10.1016/S0140-6736(94)92124-5; FULFORD KWM, 1993, J MED ETHICS, V19, P85, DOI 10.1136/jme.19.2.85; HARRIES UJ, 1994, J ROY COLL PHYS LOND, V28, P150; Jonas H., 1970, EXPT HUMAN SUBJECTS, P1; KANIS JA, 1993, BRIT MED J, V307, P1497, DOI 10.1136/bmj.307.6917.1497; KENNEDY I, 1994, MED LAW TEXTS MAT, P1042; KERRIGAN DD, 1993, BRIT MED J, V306, P298, DOI 10.1136/bmj.306.6873.298; Leaning J, 1996, BMJ-BRIT MED J, V313, P1413, DOI 10.1136/bmj.313.7070.1413; Martin Douglas K, 1995, IRB, V17, P8, DOI 10.2307/3563530; MASON JK, 1994, LAW MED ETHICS, P369; McArdle JMC, 1996, BMJ-BRIT MED J, V312, P813; McNeill P., 1993, ETHICS POLITICS HUMA, P17; *NUFF COUNC BIOETH, 1994, HUM TISS ETH LEG ISS, P23; Nuffield Council on Bioethics, 1993, GEN SCREEN ETH ISS, P29; ROTHMAN DJ, 1987, NEW ENGL J MED, V317, P1195, DOI 10.1056/NEJM198711053171906; Royal College of Physicians, 1996, GUID PRACT ETH COMM; THORNTON HM, 1992, LANCET, V339, P44, DOI 10.1016/0140-6736(92)90157-X; TOBIAS JS, 1993, BRIT MED J, V307, P1199, DOI 10.1136/bmj.307.6913.1199; TOBIAS JS, 1994, EUR J CANCER, V30A, P897, DOI 10.1016/0959-8049(94)90107-4; WALD N, 1994, BRIT MED J, V309, P1422, DOI 10.1136/bmj.309.6966.1422; Williams C, 1992, INTRO NEW TREATMENTS, P49; 1988, B I MED ETHICS, V40, P1315	39	107	107	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 12	1997	314	7087					1107	1111		10.1136/bmj.314.7087.1107	http://dx.doi.org/10.1136/bmj.314.7087.1107			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU236	9133897	Green Published			2022-12-28	WOS:A1997WU23600034
J	Cruikshank, DP				Cruikshank, DP			Comet Hale-Bopp - Stardust memories	SCIENCE			English	Editorial Material							INTERSTELLAR; DUST				Cruikshank, DP (corresponding author), NASA,AMES RES CTR,MOFFETT FIELD,CA 94035, USA.							BERNSTEIN MP, 1995, ASTROPHYS J, V454, P327, DOI 10.1086/176485; Biver N, 1997, SCIENCE, V275, P1915, DOI 10.1126/science.275.5308.1915; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; DAVIES JK, IN PRESS ICARUS; DELSEMME A, 1997, COMETS ORIGIN EVOLUT, P29; HALE A, 1995, 6187 IAU; Hayward TL, 1997, SCIENCE, V275, P1907, DOI 10.1126/science.275.5308.1907; *IAU, 1997, 6566 IAU; *IAU, 1997, 6568 IAU; *IAU, 1997, 6567 IAU; IRVINE WM, IN PRESS ORIGINS LIF; LOVE SG, 1993, SCIENCE, V262, P550, DOI 10.1126/science.262.5133.550; Mumma M. J., 1993, PROTOSTARS PLANETS, P1177; PENDLETON YJ, 1994, SKY TELESCOPE, V87, P36; RAUER R, 1997, SCIENCE, V275, P1909; Schleicher DG, 1997, SCIENCE, V275, P1913, DOI 10.1126/science.275.5308.1913; TOKUNAGA AT, 1990, ICARUS, V86, P208, DOI 10.1016/0019-1035(90)90209-R; Wagner RM, 1997, SCIENCE, V275, P1918, DOI 10.1126/science.275.5308.1918; WEAVER R, 1997, SCIENCE, V275, P1900	19	3	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1895	1896		10.1126/science.275.5308.1895	http://dx.doi.org/10.1126/science.275.5308.1895			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9122690				2022-12-28	WOS:A1997WQ51300030
J	Brown, MM; Venables, G; Clifton, A; Gaines, P; Taylor, RS				Brown, MM; Venables, G; Clifton, A; Gaines, P; Taylor, RS			Carotid endarterectomy vs carotid angioplasty	LANCET			English	Letter											Brown, MM (corresponding author), ST GEORGE HOSP,SCH MED,DIV CLIN NEUROSCI,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.			Brown, Martin M/0000-0002-3273-1356				Naylor AR, 1997, LANCET, V349, P203, DOI 10.1016/S0140-6736(96)07181-4; Sivaguru A, 1996, J ENDOVASC SURG, V3, P16, DOI 10.1583/1074-6218(1996)003<0016:ECAT>2.0.CO;2	2	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					880	881		10.1016/S0140-6736(05)61787-4	http://dx.doi.org/10.1016/S0140-6736(05)61787-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121285				2022-12-28	WOS:A1997WP40300057
J	Rothenberg, K; Fuller, B; Rothstein, M; Duster, T; Kahn, MJE; Cunningham, R; Fine, B; Hudson, K; King, MC; Murphy, P; Swergold, G; Collins, F				Rothenberg, K; Fuller, B; Rothstein, M; Duster, T; Kahn, MJE; Cunningham, R; Fine, B; Hudson, K; King, MC; Murphy, P; Swergold, G; Collins, F			Genetic information and the workplace: Legislative approaches and policy challenges	SCIENCE			English	Article									UNIV HOUSTON,CTR LAW,HLTH LAW & POLICY INST,HOUSTON,TX 77004; UNIV CALIF BERKELEY,INST STUDY SOCIAL CHANGE,BERKELEY,CA 94720; NORTHWESTERN UNIV,SCH MED,EVANSTON,IL 60208; NIH,NATL HUMAN GENOME RES INST,BETHESDA,MD 20892; UNIV WASHINGTON,DIV MED GENET,SEATTLE,WA 98195; ONCORMED,GAITHERSBURG,MD; US FDA,CTR BIOL EVALUAT & RES,ROCKVILLE,MD 20857	University of Houston System; University of Houston; University of California System; University of California Berkeley; Northwestern University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Washington; University of Washington Seattle; US Food & Drug Administration (FDA)	Rothenberg, K (corresponding author), UNIV MARYLAND,SCH LAW,LAW & HLTH CARE PROGRAM,500 W BALTIMORE ST,BALTIMORE,MD 21201, USA.			King, Mary-Claire/0000-0001-9426-1743				*COUNC ETH JUD AFF, 1991, JAMA-J AM MED ASSOC, V266, P1827; *EQ EMPL OPP COMM, 1995, COMPL MAN, V2, P902; HUDSON KL, 1995, SCIENCE, V270, P391, DOI 10.1126/science.270.5235.391; Kolata G., 1997, NY TIMES        0128, pC1; Lapham EV, 1996, SCIENCE, V274, P621, DOI 10.1126/science.274.5287.621; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; *NAPBC NIH DOE ELS, 1997, REC GEN INF WORKPL; Rothenberg KH, 1995, J LAW MED ETHICS, V23, P312, DOI 10.1111/j.1748-720X.1995.tb01373.x; ROTHSTEIN M, 1996, WORKSH GEN INF WORKP; ROTHSTEIN MA, 1992, HOUSTON LAW REV, V29, P25	10	104	106	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1755	1757		10.1126/science.275.5307.1755	http://dx.doi.org/10.1126/science.275.5307.1755			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9122681	Green Published			2022-12-28	WOS:A1997WP05600030
J	Senderowicz, AM; Vitetta, E; Headlee, D; Ghetie, V; Uhr, JW; Figg, WD; Lush, RM; StetlerStevenson, M; Kershaw, G; Kingma, DW; Jaffe, ES; Sausville, EA				Senderowicz, AM; Vitetta, E; Headlee, D; Ghetie, V; Uhr, JW; Figg, WD; Lush, RM; StetlerStevenson, M; Kershaw, G; Kingma, DW; Jaffe, ES; Sausville, EA			Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin	ANNALS OF INTERNAL MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; LYMPHOPROLIFERATIVE DISORDERS; ORGAN-TRANSPLANTATION; BONE-MARROW; PHASE-I; DISEASE; CLASSIFICATION; SITES		NCI, DEV THERAPEUT PROGRAM, NIH, ROCKVILLE, MD 20852 USA; NCI, MED BRANCH, DIV CLIN SCI, NIH, ROCKVILLE, MD 20852 USA; NCI, DIV CLIN SCI, PATHOL LAB, NIH, ROCKVILLE, MD 20852 USA; UNIV TEXAS, SW MED CTR, CTR CANC IMMUNOBIOL, DALLAS, TX 75235 USA; UNIV MASSACHUSETTS, MED CTR, DIV RENAL MED, WORCESTER, MA 01655 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Massachusetts System; University of Massachusetts Worcester			Figg, William D/M-2411-2016; Stetler-Stevenson, Maryalice/AAV-7393-2020; Jaffe, Elaine S/G-8984-2014	Jaffe, Elaine S/0000-0003-4632-0301	NCI NIH HHS [CA28149, CA41081] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA041081, R01CA028149, R37CA028149] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMLOT PL, 1993, BLOOD, V82, P2624; FISCHER A, 1991, NEW ENGL J MED, V324, P1451, DOI 10.1056/NEJM199105233242102; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; GHETIE MA, 1991, CANCER RES, V51, P5876; HANTO DW, 1995, ANNU REV MED, V46, P381; HARRIS NL, 1994, BLOOD, V84, P1361; KINGMA DW, 1994, AM J SURG PATHOL, V18, P48, DOI 10.1097/00000478-199401000-00005; LEBLOND V, 1995, J CLIN ONCOL, V13, P961, DOI 10.1200/JCO.1995.13.4.961; MORRISON VA, 1994, AM J MED, V97, P14, DOI 10.1016/0002-9343(94)90043-4; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; SANDER CA, 1993, BLOOD, V82, P1994; SAUSVILLE EA, 1995, BLOOD, V85, P3457, DOI 10.1182/blood.V85.12.3457.bloodjournal85123457; SAUSVILLE EA, 1997, ENCY CANC, P1703; SUNDEEN JT, 1992, AM J SURG PATHOL, V16, P130, DOI 10.1097/00000478-199202000-00005	15	47	64	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1997	126	11					882	885		10.7326/0003-4819-126-11-199706010-00005	http://dx.doi.org/10.7326/0003-4819-126-11-199706010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA911	9163289				2022-12-28	WOS:A1997XA91100005
J	Pretre, R; VonSegesser, LK				Pretre, R; VonSegesser, LK			Aortic dissection	LANCET			English	Article							DESCENDING THORACIC AORTA; LONG-TERM SURVIVAL; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; MARFAN-SYNDROME; INTRAMURAL HEMORRHAGE; THERAPEUTIC CHALLENGE; SURGICAL THERAPY; ASCENDING AORTA; ANEURYSMS; DIAGNOSIS		UNIV HOSP GENEVA, DEPT SURG, GENEVA, SWITZERLAND; UNIV LAUSANNE HOSP, LAUSANNE, SWITZERLAND	University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)								AMPARO EG, 1985, RADIOLOGY, V155, P399, DOI 10.1148/radiology.155.2.3983390; ANAGNOSTOPOULOS CE, 1972, AM J CARDIOL, V30, P263, DOI 10.1016/0002-9149(72)90070-7; BACHET JE, 1994, J THORAC CARDIOV SUR, V108, P199; BALLAL RS, 1991, CIRCULATION, V84, P1903, DOI 10.1161/01.CIR.84.5.1903; BANSAL RC, 1995, J AM COLL CARDIOL, V25, P1393, DOI 10.1016/0735-1097(94)00569-C; BICKERSTAFF LK, 1982, SURGERY, V92, P1103; Borst H G, 1991, Semin Thorac Cardiovasc Surg, V3, P238; CARREL T, 1993, EUR J CARDIO-THORAC, V7, P146, DOI 10.1016/1010-7940(93)90037-C; CIGARROA JE, 1993, NEW ENGL J MED, V328, P35, DOI 10.1056/NEJM199301073280107; CRAWFORD ES, 1988, ANN SURG, V208, P254, DOI 10.1097/00000658-198809000-00002; CRAWFORD ES, 1990, JAMA-J AM MED ASSOC, V264, P2537, DOI 10.1001/jama.264.19.2537; Daily P O, 1970, Ann Thorac Surg, V10, P237; DAKE MD, 1994, NEW ENGL J MED, V331, P1729, DOI 10.1056/NEJM199412293312601; Davies MJ, 1996, HEART, V75, P434, DOI 10.1136/hrt.75.5.434; DEBAKEY ME, 1995, JAMA-J AM MED ASSOC, V162, P1654; DEMOS TC, 1989, SEMIN ROENTGENOL, V24, P22, DOI 10.1016/0037-198X(89)90051-5; DESANCTIS RW, 1987, NEW ENGL J MED, V317, P1060, DOI 10.1056/NEJM198710223171705; DESANCTIS RW, 1989, CURR PROB CARDIOLOGY, V14, P227; DOROGHAZI RM, 1984, J AM COLL CARDIOL, V3, P1026, DOI 10.1016/S0735-1097(84)80363-0; ELEFTERIADES JA, 1992, ANN THORAC SURG, V53, P11, DOI 10.1016/0003-4975(92)90752-P; ERBEL R, 1989, LANCET, V1, P457; ERBEL R, 1993, CIRCULATION, V87, P1604, DOI 10.1161/01.CIR.87.5.1604; ERGIN MA, 1994, ANN THORAC SURG, V57, P820, DOI 10.1016/0003-4975(94)90182-1; FANN JI, 1995, CIRCULATION, V92, P113, DOI 10.1161/01.CIR.92.9.113; FANN JI, 1990, ANN SURG, V212, P705, DOI 10.1097/00000658-199012000-00009; FINKBOHNER R, 1995, CIRCULATION, V91, P728, DOI 10.1161/01.CIR.91.3.728; GLOWER DD, 1991, ANN SURG, V214, P31; GLOWER DD, 1990, CIRCULATION, V82, P39; GOTT VL, 1986, NEW ENGL J MED, V314, P1070, DOI 10.1056/NEJM198604243141702; HAVERICH A, 1985, CIRCULATION, V72, P22; HEINEMANN M, 1990, ANN THORAC SURG, V49, P580, DOI 10.1016/0003-4975(90)90304-O; HIRST AE, 1958, MEDICINE, V37, P217, DOI 10.1097/00005792-195809000-00003; JEX RK, 1986, J VASC SURG, V3, P226; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; LAAS J, 1992, ANN THORAC SURG, V53, P227, DOI 10.1016/0003-4975(92)91323-2; LARSON EW, 1984, AM J CARDIOL, V53, P849, DOI 10.1016/0002-9149(84)90418-1; LILIENFELD DE, 1987, ARTERIOSCLEROSIS, V7, P637, DOI 10.1161/01.ATV.7.6.637; MOHRKAHALY S, 1994, J AM COLL CARDIOL, V23, P658, DOI 10.1016/0735-1097(94)90751-X; NICOD P, 1989, J AM COLL CARDIOL, V13, P811, DOI 10.1016/0735-1097(89)90221-0; NIENABER CA, 1995, CIRCULATION, V92, P1465, DOI 10.1161/01.CIR.92.6.1465; NIENABER CA, 1993, NEW ENGL J MED, V328, P1, DOI 10.1056/NEJM199301073280101; NOLTE JE, 1995, J VASC SURG, V21, P515, DOI 10.1016/S0741-5214(95)70296-2; OKITA Y, 1995, EUR J CARDIO-THORAC, V9, P242, DOI 10.1016/S1010-7940(05)80157-5; PANDE A, 1991, AM J CARDIOL, V67, P662, DOI 10.1016/0002-9149(91)90916-9; PUMPHREY CW, 1986, BRIT HEART J, V55, P106; Pyeritz R E, 1993, Semin Thorac Cardiovasc Surg, V5, P11; ROBBINS RC, 1992, CIRCULATION, V86, P12; ROBERTS CS, 1991, ANN SURG, V213, P356, DOI 10.1097/00000658-199104000-00011; ROBICSEK F, 1994, ANN THORAC SURG, V58, P1247, DOI 10.1016/0003-4975(94)90523-1; SHORES J, 1994, NEW ENGL J MED, V330, P1335, DOI 10.1056/NEJM199405123301902; SISK HE, 1983, AM J CARDIOL, V52, P353, DOI 10.1016/0002-9149(83)90138-8; Slonim SM, 1996, J VASC SURG, V23, P241, DOI 10.1016/S0741-5214(96)70268-9; SORENSEN H R, 1964, Acta Chir Scand, V128, P644; STONE CD, 1994, ANN THORAC SURG, V57, P580, DOI 10.1016/0003-4975(94)90549-5; SVENSSON LG, 1990, CIRCULATION, V82, P24; SVENSSON LG, 1992, CURR PROB SURG, V29, P915; SVENSSON LG, 1993, CURR PROB SURG, V30, P1; TAKAMOTO YO, 1995, EUR J CARDIO-THORAC, V9, P242; TREASURE T, 1993, BRIT HEART J, V69, P101; TSIPOURAS P, 1992, NEW ENGL J MED, V326, P905, DOI 10.1056/NEJM199204023261401; vonSegesser LK, 1996, J THORAC CARDIOV SUR, V111, P381, DOI 10.1016/S0022-5223(96)70447-6; VONSEGESSER LK, 1994, J THORAC CARDIOV SUR, V108, P755; WILSON SK, 1982, ARCH PATHOL LAB MED, V106, P175; YOSHIDA H, 1994, ANN THORAC SURG, V58, P806, DOI 10.1016/0003-4975(94)90754-4	64	148	167	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	1997	349	9063					1461	1464		10.1016/S0140-6736(96)09372-5	http://dx.doi.org/10.1016/S0140-6736(96)09372-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164331				2022-12-28	WOS:A1997WZ76500043
J	Hirano, T; Kobayashi, R; Hirano, M				Hirano, T; Kobayashi, R; Hirano, M			Condensins, chromosome condensation protein complexes containing XCAP-C, XCAP-E and a Xenopus homolog of the Drosophila Barren protein	CELL			English	Article							TOPOISOMERASE-II; MITOTIC CHROMOSOMES; CELL-CYCLE; HISTONE H1; DOSAGE COMPENSATION; SMC FAMILY; EXTRACTS; INVITRO; DEFINES; GENE	We report here purification and characterization of chromosome condensation protein complexes (termed condensins) containing XCAP-C and XCAP-E, two Xenopus members of the SMC family. Sucrose density gradient centrifugation reveals two major forms of condensins. The 8S form is a heterodimer of XCAP-C and XCAP-E, whereas the 13S form contains three additional subunits. One of them is identified as a homolog of the Drosophila Barren protein whose mutation shows a defect in chromosome segregation. Chromosomal targeting of condensins is mitosis-specific and is independent of topoisomerase II alpha. 13S condensin is required for condensation, as demonstrated by immunodepletion and rescue experiments. Our results suggest that the condensin complexes represent the most abundant structural components of mitotic chromosomes and play a central role in driving chromosome condensation.			Hirano, T (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.		Hirano, Tatsuya/F-6008-2011	Hirano, Tatsuya/0000-0002-4219-6473	NCI NIH HHS [CA45508] Funding Source: Medline; NIGMS NIH HHS [GM53926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053926] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Chuang PT, 1996, SCIENCE, V274, P1736, DOI 10.1126/science.274.5293.1736; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1994, FASEB J, V8, P947, DOI 10.1096/fasebj.8.12.8088460; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HIRANO T, 1995, TRENDS BIOCHEM SCI, V20, P357, DOI 10.1016/S0968-0004(00)89076-3; HIRANO T, 1991, J CELL BIOL, V115, P1479, DOI 10.1083/jcb.115.6.1479; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; LEHMANN AR, 1995, MOL CELL BIOL, V15, P7067; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; SAITOH N, 1995, BIOESSAYS, V17, P759, DOI 10.1002/bies.950170905; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SAWIN KE, 1992, J CELL SCI, V101, P303; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Swedlow JR, 1993, CURR OPIN CELL BIOL, V5, P412, DOI 10.1016/0955-0674(93)90005-B; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Wolffe A., 1995, CHROMATIN STRUCTURE	40	441	456	1	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					511	521		10.1016/S0092-8674(00)80233-0	http://dx.doi.org/10.1016/S0092-8674(00)80233-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160743	Bronze			2022-12-28	WOS:A1997WZ32300005
J	Alfrey, CP; Rice, L; Udden, MM; Driscoll, TB				Alfrey, CP; Rice, L; Udden, MM; Driscoll, TB			Neocytolysis: Physiological down-regulator of red-cell mass	LANCET			English	Article							ERYTHROPOIETIN	It is usually considered that red-cell mass is controlled by erythropoietin-driven bone marrow red-cell production, and no physiological mechanisms can shorten survival of circulating red cells. In adapting to acute plethora in microgravity, astronauts' red-cell mass falls too rapidly to be explained by diminished red-cell production. Ferrokinetics show no early decline in erythropoiesis, but red cells radiolabelled 12 days before launch survive normally. Selective destruction of the youngest circulating red cells-a process we call neocytolysis-is the only plausible explanation. A fall in erythropoietin below a threshold is likely to initiate neocytolysis, probably by influencing surface-adhesion molecules. Recognition of neocytolysis will require reexamination of the pathophysiology and treatment of several blood disorders, including the anaemia of renal disease.			Alfrey, CP (corresponding author), BAYLOR COLL MED,DEPT MED,SECT HEMATOL,HOUSTON,TX 77030, USA.							ADAMSON JW, 1968, AM J MED, V44, P725, DOI 10.1016/0002-9343(68)90254-4; Alfrey CP, 1996, J APPL PHYSIOL, V81, P98, DOI 10.1152/jappl.1996.81.1.98; BERGLUND B, 1989, MED SCI SPORT EXER, V21, P637, DOI 10.1249/00005768-198912000-00002; CROSBY WH, 1977, BLOOD, V50, P643; ESCHBACH JW, 1989, KIDNEY INT, V35, P134, DOI 10.1038/ki.1989.18; FISCHER CL, 1967, J AMER MED ASSOC, V200, P579, DOI 10.1001/jama.200.7.579; FRYERS GR, 1952, AM J PHYSIOL, V171, P465, DOI 10.1152/ajplegacy.1952.171.2.465; GRANOLLERAS C, 1991, CONTRIB NEPHROL, V88, P144; HUFF RL, 1951, MEDICINE, V30, P197, DOI 10.1097/00005792-195109000-00001; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; MENTZER WC, 1971, J CLIN INVEST, V50, P688, DOI 10.1172/JCI106539; MERINO CF, 1950, BLOOD, V5, P1; PACE N, 1956, J APPL PHYSIOL, V9, P141, DOI 10.1152/jappl.1956.9.2.141; STEVENS ME, 1992, BRIT MED J, V304, P4741; TEST ST, 1994, BLOOD S, V15, P1601; UDDEN MM, 1995, J LAB CLIN MED, V125, P442; WICK TM, 1993, AM J HEMATOL, V42, P284, DOI 10.1002/ajh.2830420308; WILSON JG, 1994, ANN NY ACAD SCI, V78, P271	18	118	124	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1389	1390		10.1016/S0140-6736(96)09208-2	http://dx.doi.org/10.1016/S0140-6736(96)09208-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149714				2022-12-28	WOS:A1997WY34200044
J	Frenk, J; Sepulveda, J; GomezDantes, O; McGuinness, MJ; Knaul, F				Frenk, J; Sepulveda, J; GomezDantes, O; McGuinness, MJ; Knaul, F			The future of world health - The new world order and international health	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	Informal Meeting on the Current State and Future Role of International Health Institutions	FEB 03-04, 1997	NATL INST PUBL HLTH, CUERNAVACA, MEXICO		NATL INST PUBL HLTH				NATL INST PUBL HLTH,CUERNAVACA,MORELOS,MEXICO; CTR ECON RES & EDUC,PROGRAM HLTH ECON,MEXICO CITY,DF,MEXICO	Instituto Nacional de Salud Publica	Frenk, J (corresponding author), MEXICAN HLTH FDN,CTR HLTH & ECON,PERIFER SUR 4809,MEXICO CITY 14610,DF,MEXICO.			Knaul, Felicia/0000-0002-0512-4788				[Anonymous], 1992, BAS DOC; Barber Benjamin, 1996, JIHAD VS MCWORLD TER; BELL D, 1994, VUELTA, V213, P15; Berlin Isaiah, 1992, CROOKED TIMBER HUMAN, P1; FRENK J, 1996, POCANTICO RETREAT EN, P39; GELLERT GA, 1993, SOC SCI MED, V37, P1489, DOI 10.1016/0277-9536(93)90183-5; GODLEE F, 1994, BRIT MED J, V309, P1424, DOI 10.1136/bmj.309.6966.1424; GODLEE F, 1994, BRIT MED J, V309, P1491, DOI 10.1136/bmj.309.6967.1491; HAVEL VA, 1995, HARVARD GAZETTE  JUN, P15; Kennedy Paul, 1994, PREPARING 21 CENTURY; STERKY G, 1996, TOMORROWS GLOBAL HLT; WALT G, 1996, POCANTICO RETREAT EN, P23; WARNER KE, 1990, AM J PUBLIC HEALTH, V80, P529, DOI 10.2105/AJPH.80.5.529; *WHO AD HOC COMM H, 1996, INV HLTH RES DEV SUM; *WORLD BANK, 1993, WORLD DEV REP; World Health Organization, 1995, WORLD HLTH REP 1995; ZACARIAS F, 1996, GAC MED MEX, V132, P25	17	39	40	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1404	1407						6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ169	9161318				2022-12-28	WOS:A1997WZ16900038
J	Paul, M				Paul, M			Occupational reproductive hazards	LANCET			English	Article							SPONTANEOUS-ABORTION; PREGNANCY; EXPOSURE; HEALTH; FECUNDABILITY; ASSOCIATION; FERTILITY; BIRTH; WORK; LEAD	Although the causes of many reproductive disorders remain unknown, scientific evidence is accumulating to implicate occupational agents in fertility disorders and adverse pregnancy outcomes, Effective assessment and management of workers exposed to reproductive hazards often involves a team-based approach, By identifying potential reproductive hazards, making appropriate referrals, and by educating and advocating for patients, clinicians can play an Important part in safeguarding the reproductive health of workers.	UNIV MASSACHUSETTS, MED CTR, DEPT OBSTET & GYNECOL, WORCESTER, MA USA; UNIV MASSACHUSETTS, MED CTR, DEPT FAMILY & COMMUNITY MED, OCCUPAT HLTH PROGRAM, WORCESTER, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester								AHLBORG G, 1995, J OCCUP ENVIRON MED, V37, P957, DOI 10.1097/00043764-199508000-00012; BARANSKI B, 1993, ENVIRON HEALTH PERSP, V101, P81, DOI 10.2307/3431380; BELLINGER D, 1991, PEDIATRICS, V87, P219; BRENT R, 1993, OCCUPATIONAL ENV REP, P165; CLAUSS CA, 1993, ENVIRON HEALTH PERSP, V101, P205, DOI 10.2307/3431396; DEITRICH KN, 1990, ENV HLTH PERSPECT, V89, P13; EKBLAD U, 1995, J OCCUP ENVIRON MED, V37, P962, DOI 10.1097/00043764-199508000-00013; ESKENAZI B, 1995, AM J IND MED, V28, P817; FLORACK EIM, 1994, EPIDEMIOLOGY, V5, P14, DOI 10.1097/00001648-199401000-00004; Fortier I, 1995, SCAND J WORK ENV HEA, V21, P412, DOI 10.5271/sjweh.56; *I MED, 1988, ROL PRIM CAR PROV OC, P5; KOREN G, 1991, REPROD TOXICOL, V5, P397, DOI 10.1016/0890-6238(91)90002-W; LAHDETIE J, 1995, J OCCUP ENVIRON MED, V37, P922; LAUNER LJ, 1990, BRIT J OBSTET GYNAEC, V97, P62, DOI 10.1111/j.1471-0528.1990.tb01718.x; Lione A, 1988, Reprod Toxicol, V2, P83, DOI 10.1016/0890-6238(88)90002-0; LUKE B, 1995, AM J OBSTET GYNECOL, V173, P849, DOI 10.1016/0002-9378(95)90354-2; MARBURY MC, 1992, SCAND J WORK ENV HEA, V18, P73, DOI 10.5271/sjweh.1598; Miller R.H., 1993, OCCUPATIONAL ENV REP, P233; NIOSH, 1991, DHHS PUBL, V94-120; Olshan A.F., 1994, MALE MEDIATED DEV TO; PAUL M, 1994, AM J IND MED, V25, P403, DOI 10.1002/ajim.4700250308; POTASHNIK G, 1995, J OCCUP ENVIRON MED, V37, P1287, DOI 10.1097/00043764-199511000-00007; ROWLAND AS, 1992, NEW ENGL J MED, V327, P993, DOI 10.1056/NEJM199210013271405; ROWLAND AS, 1994, OCCUP ENVIRON MED, V51, P28, DOI 10.1136/oem.51.1.28; SAVITZ DA, 1994, AM J IND MED, V25, P361, DOI 10.1002/ajim.4700250306; SAVITZ DA, 1990, ENVIRON HEALTH PERSP, V88, P325, DOI 10.2307/3431095; SCHENKER MB, 1995, AM J IND MED, V28, P639; *US GEN ACC OFF, 1991, REPR DEV TOX REG ACT; Whelan EA, 1996, AM J IND MED, V29, P59, DOI 10.1002/(SICI)1097-0274(199601)29:1<59::AID-AJIM8>3.3.CO;2-O	29	16	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 10	1997	349	9062					1385	1388		10.1016/S0140-6736(96)07217-0	http://dx.doi.org/10.1016/S0140-6736(96)07217-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149713				2022-12-28	WOS:A1997WY34200043
J	Shearer, WT; Quinn, TC; LaRussa, P; Lew, JF; Mofenson, L; Almy, S; Rich, K; Handelsman, E; Diaz, C; Pagano, M; Smeriglio, V; Kalish, LA				Shearer, WT; Quinn, TC; LaRussa, P; Lew, JF; Mofenson, L; Almy, S; Rich, K; Handelsman, E; Diaz, C; Pagano, M; Smeriglio, V; Kalish, LA			Viral load and disease progression in infants infected with human immunodeficiency virus type 1	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-HISTORY; HIV-1	Background There are only limited data on human immunodeficiency virus type 1 (HIV-1) RNA in perinatally infected infants. Understanding the dynamics of HIV-1 infection and its relation to disease progression may help identify opportunities for effective antiviral treatment in infected infants. Methods We obtained plasma samples from 106 HIV-infected infants at birth; at 1, 2, 4, 6, 9, 12, 15, and 18 months of age; and subsequently every 6 months. HIV-1 RNA was assayed by means of a reverse-transcription polymerase chain reaction. The infants were born between 1990 and 1993, and only 21 percent of the infants' mothers received any treatment with zidovudine during pregnancy. Results Plasma HIV-1 RNA levels increased rapidly after birth, peaked at 1 to 2 months of age (median values at 1 and 2 months, 318,000 and 256,000 copies per milliliter, respectively), and then slowly declined to a median of 34,000 copies per milliliter at 24 months. Newborns with a first positive HIV-1 culture within 48 hours after birth had significantly higher HIV-1 RNA levels, although only during the first two months of life, than those with a first positive culture seven or more days after birth. Infants with a rapid progression of disease had higher peak HIV-I RNA levels in the first two months of life than those without rapid progression (median value, 724,000 vs. 219,000 copies per milliliter; P=0.006), as well as a higher geometric mean value during the first year of life (median value, 330,000 vs. 158,000 copies per milliliter; P=0.001). Conclusions in perinatally infected infants, HIV-1 RNA levels are high and decline only slowly during the first two years of life. Infants with very high viral loads in the first months of life are at increased risk for a rapid progression of disease, which suggests that early treatment with antiretroviral agents may be indicated for these infants. (C)1997, Massachusetts Medical Society.	BAYLOR COLL MED, DEPT PEDIAT, SECT ALLERGY & IMMUNOL, HOUSTON, TX 77030 USA; JOHNS HOPKINS UNIV, BALTIMORE, MD USA; NIAID, BETHESDA, MD 20892 USA; COLUMBIA PRESBYTERIAN MED CTR, DEPT VIROL, NEW YORK, NY USA; NICHHD, BETHESDA, MD 20892 USA; NEW ENGLAND RES INST, WATERTOWN, MA 02172 USA; UNIV ILLINOIS, CHICAGO, IL USA; SUNY, CTR HLTH SCI, BROOKLYN, NY USA; UNIV PUERTO RICO, SAN JUAN, PR 00936 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; NATL INST DRUG ABUSE, ROCKVILLE, MD USA	Baylor College of Medicine; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Columbia University; NewYork-Presbyterian Hospital; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); HealthCore, Inc; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; SUNY Maritime College; University of Puerto Rico; Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)			Mofenson, Lynne/P-9631-2019; Quinn, Thomas/A-2494-2010	Mofenson, Lynne/0000-0002-2818-9808; Shearer, William/0000-0002-2483-2130	NCRR NIH HHS [RR 00188] Funding Source: Medline; NIAID NIH HHS [U01 AI 34840, AI 36211] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211, U01AI034840] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS EJ, 1996, 11 INT C AIDS VANC B, V2, P25; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; Conway B., 1996, P102; DeRossi A, 1996, J CLIN INVEST, V97, P323, DOI 10.1172/JCI118419; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; Dickover Ruth, 1996, P93; Henrard Denis R., 1995, JAMA (Journal of the American Medical Association), V274, P554, DOI 10.1001/jama.274.7.554; Ho DD, 1996, SCIENCE, V272, P1124, DOI 10.1126/science.272.5265.1124; HOLLINGER FB, 1992, J CLIN MICROBIOL, V30, P1787, DOI 10.1128/JCM.30.7.1787-1794.1992; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; MCINTOSH K, 1994, J INFECT DIS, V170, P996, DOI 10.1093/infdis/170.4.996; McIntosh K, 1996, PEDIATR INFECT DIS J, V15, P1087, DOI 10.1097/00006454-199612000-00006; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MOFENSON LM, IN PRESS J INFECT DI; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; PALUMBO PE, 1995, J PEDIATR-US, V126, P592, DOI 10.1016/S0022-3476(95)70357-8; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; ROSNER B, 1990, FUNDAMENTALS BIOSTAT, P304; Tetali S., 1996, P99; ZAR JH, 1974, BIOSTAT ANAL, P390; 1994, MMWR-MORBID MORTAL W, V43, P1	25	392	400	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 8	1997	336	19					1337	1342		10.1056/NEJM199705083361901	http://dx.doi.org/10.1056/NEJM199705083361901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX851	9134873				2022-12-28	WOS:A1997WX85100001
J	Ducor, P				Ducor, P			Are patents and research compatible?	NATURE			English	Editorial Material									STANFORD UNIV,SCH LAW,STANFORD,CA 94305	Stanford University								BRUZZONE L, 1993, AIPLA OJ, V21, P52; EISENBERG R, 1994, RISK HLTH SAFETY ENV, V5, P163; PARKER D, 1994, HOUSTON J INT LAW, V16, P615; STONE R, 1995, SCIENCE, V268, P656, DOI 10.1126/science.268.5211.656	4	6	6	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 1	1997	387	6628					13	14		10.1038/387013a0	http://dx.doi.org/10.1038/387013a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139814				2022-12-28	WOS:A1997WW75800018
J	Poulter, NR; Chang, CL; Farley, TMM; Kelaghan, J; Meirlk, O; Marmot, MG; DebertRibeiro, M; Medina, E; Artigas, J; He, S; Zhong, YH; Zhang, DW; Zhao, WJ; Rojas, O; Heinemann, L; Donnan, S; Ho, S; Bartfai, G; Kisjanto, J; Wilks, R; Agwanda, R; Ruiz, R; KozuhNovak, M; Dusitsin, N; Virutamasen, P; Phanthumchinda, K; Koetsawang, S; PiyaAnant, M; Vessey, M; Demirovic, J; Belkic, K; Mwandila, WS; Mutale, CM; Matenga, J; Wilson, A; Vessey, MP; Petitti, D; Perlman, J; Kelaghan, J; Holck, S; Lawley, S; Smith, S; Shipley, M; Olsen, J; Thorogood, M				Poulter, NR; Chang, CL; Farley, TMM; Kelaghan, J; Meirlk, O; Marmot, MG; DebertRibeiro, M; Medina, E; Artigas, J; He, S; Zhong, YH; Zhang, DW; Zhao, WJ; Rojas, O; Heinemann, L; Donnan, S; Ho, S; Bartfai, G; Kisjanto, J; Wilks, R; Agwanda, R; Ruiz, R; KozuhNovak, M; Dusitsin, N; Virutamasen, P; Phanthumchinda, K; Koetsawang, S; PiyaAnant, M; Vessey, M; Demirovic, J; Belkic, K; Mwandila, WS; Mutale, CM; Matenga, J; Wilson, A; Vessey, MP; Petitti, D; Perlman, J; Kelaghan, J; Holck, S; Lawley, S; Smith, S; Shipley, M; Olsen, J; Thorogood, M			Acute myocardial infarction and combined oral contraceptives: Results of an international multicentre case-control study	LANCET			English	Article							YOUNG-WOMEN; CARDIOVASCULAR-DISEASE; RISK-FACTORS; DEATH	Background The association between oral contraceptive (OC) use and acute myocardial infarction (AMI) was established in studies from northern Europe and the USA, which took place during the 1960s and 1970s. Few data are available to quantify the risk worldwide of AMI associated with use of OCs introduced since those early studies. This hospital-based case-control study examined the association between a first AMI and current OC use in women from Africa, Asia, Europe, and Latin America (21 centres). Methods Cases were women aged 20-44 years who had definite or possible AMI (classified by history, electrocardiographic, and cardiac-enzyme criteria), who were admitted to hospital, and who survived for at least 24 h. Up to three hospital controls matched by 5-year age-band were recruited for each of the 368 cases (941 controls). All participants were interviewed while in hospital with the same questionnaire, which included information on medical and personal history, lifetime contraceptive use, and blood-pressure screening before the most recent episode of OC use. Odds ratios compared the risk of AMI in current OC users and in non-users (past users and never-users combined). Findings The overall odds ratio for AMI was 5.01 (95% CI 2.54-9.90) in Europe and 4.78 (2.52-9.07) in the non-European (developing) countries; however, these risk estimates reflect the frequent coexistence of other risk factors among OC users who have AMI. Very few AMIs were identified among women who had no cardiovascular risk factors and who reported that their blood pressure had been checked before OC use; odds ratios associated with OC use in such women were not increased in either Europe or the developing countries. Among OC users who smoked ten or more cigarettes per day, the odds ratios in Europe and in the developing countries were over 20. Similarly, among OC users with a history of hypertension (during pregnancy or at any other time), odds ratios were at least ten in both groups of countries, No consistent association between odds ratios for AMI and age of OC users or oestrogen dose was apparent in either group of countries, No significant increase in odds ratios was apparent with increasing duration of OC use among current users, and odds ratios were not significantly increased in women who had stopped using OCs, even after long exposure. The study had insufficient power to examine whether progestagen dose or type had any effect on AMI risk. Interpretation Current use of combined OCs is associated with an increased risk of AMI among women with known cardiovascular risk factors and among those who have not been effectively screened, particularly for blood pressure, AMI is extremely rare in younger (<35 years) non-smoking women who use OCs, and the estimated excess risk of AMI in such women in the European centres is about 3 per 10(6) woman-years. The risk is likely to be even lower if blood pressure is screened before, and presumably during, OC use. Only among older women who smoke is the degree of excess risk associated with OCs substantial (about 400 per 10(6) woman-years).	ESCOLA PAULISTA MED, BR-04023 SAO PAULO, BRAZIL; UNIV CHILE, ESCUELA SALUD PUBL, SANTIAGO, CHILE; NATL RES INST FAMILY PLANNING, BEIJING, PEOPLES R CHINA; SICHUAN FAMILY PLANNING RES INST, CHENGDU, PEOPLES R CHINA; SHANGHAI INST PLANNED PARENTHOOD RES, SHANGHAI, PEOPLES R CHINA; UNIV VALLE, FAC SALUD, CALI, COLOMBIA; ZENTRUM EPIDEMIOL & GESUNDHEITSFORSCH, BERLIN, GERMANY; CHINESE UNIV HONG KONG, SHATIN 100083, HONG KONG; ALBERT SZENT GYORGYI MED UNIV, H-6701 SZEGED, HUNGARY; UNIV INDONESIA, FAC MED, JAKARTA, INDONESIA; KENYA GOVT MED RES CTR, NAIROBI, KENYA; INTERUNIV MEXICANO INVEST EPIDEMIOL SALUD REPROD, DURANGO, MEXICO; UNIV W INDIES, TROP METAB RES UNIT, KINGSTON 7, JAMAICA; ESCUELA MED, VALPARAISO, CHILE; UNIV LJUBLJANA, INST PUBL HLTH, LJUBLJANA, SLOVENIA; CHULALONGKORN HOSP, BANGKOK, THAILAND; SIRIRAJ HOSP, BANGKOK, THAILAND; UNIV OXFORD, OXFORD, ENGLAND; UNIV BELGRADE, SCH MED, YU-11001 BELGRADE, YUGOSLAVIA; UNIV TEACHING HOSP, LUSAKA, ZAMBIA; UNIV ZIMBABWE, HARARE, ZIMBABWE; UNIV OXFORD, OXFORD OX1 2JD, ENGLAND; KAISER PERMANENTE, PASADENA, CA USA; NICHHD, BETHESDA, MD USA; AARHUS UNIV, DANISH EPIDMEIOL SCI CTR, DK-8000 AARHUS C, DENMARK; LONDON SCH HYG & TROP MED, LONDON WC1, ENGLAND	Universidade Federal de Sao Paulo (UNIFESP); Universidad de Chile; National Research Institute for Family Planning - China; Universidad del Valle; Chinese University of Hong Kong; Szeged University; University of Indonesia; Kenya Medical Research Institute; University West Indies Mona Jamaica; University of Ljubljana; Chulalongkorn University; Mahidol University; University of Oxford; University of Belgrade; University of Zambia; University of Zimbabwe; University of Oxford; Kaiser Permanente; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Aarhus University; University of London; London School of Hygiene & Tropical Medicine	Poulter, NR (corresponding author), UNIV LONDON UNIV COLL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, TORRINGTON PL, LONDON WC1E 6BT, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002914] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAM SA, 1981, BRIT J OBSTET GYNAEC, V88, P838, DOI 10.1111/j.1471-0528.1981.tb01311.x; ANANIJEVICPANDEY J, 1989, INT J EPIDEMIOL, V18, P585, DOI 10.1093/ije/18.3.585; [Anonymous], 1995, J Clin Epidemiol, V48, P1513; BOYCE J, 1963, LANCET, V1, P111, DOI 10.1016/S0140-6736(63)91117-6; Breslow N.E., 1980, STAT METHODS CANC RE, P192; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; FARLEY TMM, 1995, LANCET, V346, P1582; INMAN WHW, 1968, BRIT MED J, V2, P193, DOI 10.1136/bmj.2.5599.193; JAIN AK, 1976, AM J OBSTET GYNECOL, V126, P301, DOI 10.1016/0002-9378(76)90539-1; JICK H, 1978, JAMA-J AM MED ASSOC, V239, P1403, DOI 10.1001/jama.239.14.1403; KRUEGER DE, 1980, AM J EPIDEMIOL, V125, P832; LAVECCHIA C, 1987, AM J EPIDEMIOL, V125, P832, DOI 10.1093/oxfordjournals.aje.a114599; Lewis MA, 1996, BRIT MED J, V312, P88; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MANN JI, 1975, BRIT MED J, V2, P245, DOI 10.1136/bmj.2.5965.245; MANN JI, 1975, BRIT MED J, V3, P631, DOI 10.1136/bmj.3.5984.631; MANT D, 1987, J EPIDEMIOL COMMUN H, V41, P215, DOI 10.1136/jech.41.3.215; MEADE TW, 1980, BRIT MED J, V280, P1157, DOI 10.1136/bmj.280.6224.1157; Poulter NR, 1996, J EPIDEMIOL COMMUN H, V50, P674, DOI 10.1136/jech.50.6.674; POULTER NR, 1995, LANCET, V346, P1575; Poulter NR, 1996, LANCET, V348, P498; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; ROSENBERG L, 1990, AM J EPIDEMIOL, V131, P1009, DOI 10.1093/oxfordjournals.aje.a115592; ROSENBERG L, 1985, JAMA-J AM MED ASSOC, V253, P2965, DOI 10.1001/jama.253.20.2965; ROSENBERG L, 1980, AM J EPIDEMIOL, V111, P59, DOI 10.1093/oxfordjournals.aje.a112874; SHAPIRO S, 1979, LANCET, V1, P743; Sidney S, 1996, OBSTET GYNECOL, V88, P939, DOI 10.1016/S0029-7844(96)00351-1; SLONE D, 1981, NEW ENGL J MED, V305, P420, DOI 10.1056/NEJM198108203050802; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; TALBOTT EO, 1989, INT J EPIDEMIOL, V18, P589, DOI 10.1093/ije/18.3.589; THOROGOOD M, 1991, BRIT J OBSTET GYNAEC, V98, P1245, DOI 10.1111/j.1471-0528.1991.tb15397.x; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651; VESSEY MP, 1990, ORAL CONTRACEPTIVES, P121; *WHO COLL STUD CAR, 1996, LANCET, V38, P505; *WHO MONICA PROJ, 1990, MONICA MAN, P11	37	290	290	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 26	1997	349	9060					1202	1209						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130941				2022-12-28	WOS:A1997WW71700009
J	Wilson, M; Daly, M				Wilson, M; Daly, M			Life expectancy, economic inequality, homicide, and reproductive timing in Chicago neighbourhoods	BRITISH MEDICAL JOURNAL			English	Article							TIME PREFERENCE; RATES				Wilson, M (corresponding author), MCMASTER UNIV,DEPT PSYCHOL,HAMILTON,ON L8S 4K1,CANADA.			Daly, Martin/0000-0003-1697-8794				Barkow J.H., 1992, ADAPTED MIND; Charlton BG, 1996, J ROY SOC MED, V89, P3, DOI 10.1177/014107689608900103; DALY M, 1990, HUMAN NATURE, V0001; Daly M., 1988, HOMICIDE; Frank R. H., 1985, CHOOSING RIGHT POND; Geronimus Arline T., 1992, Ethnicity and Disease, V2, P207; Geronimus AT, 1996, HUM NATURE-INT BIOS, V7, P323, DOI 10.1007/BF02732898; Gigerenzer G, 1996, PSYCHOL REV, V103, P650, DOI 10.1037/0033-295X.103.4.650; Gottfredson M.R., 1990, GEN THEORY CRIME; GREEN L, 1994, PSYCHOL SCI, V5, P33, DOI 10.1111/j.1467-9280.1994.tb00610.x; Hagedorn J.M., 1988, PEOPLE FOLKS; HILL EM, IN PRESS HUMAN NATUR; Hsieh C.-C., 1993, CRIMINAL JUSTICE REV, V18, P182, DOI [10.1177/073401689301800203, DOI 10.1177/073401689301800203]; Jankowski MS, 1992, ISLANDS STREET; Kacelnik A, 1996, AM ZOOL, V36, P402; Kaplan GA, 1996, BRIT MED J, V312, P999; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; KRAHN H, 1986, CRIMINOLOGY, V24, P269, DOI 10.1111/j.1745-9125.1986.tb01496.x; LAWRANCE EC, 1991, J POLIT ECON, V99, P54, DOI 10.1086/261740; Loewenstein G., 1992, CHOICE TIME; Nisbett Richard E., 1996, CULTURE HONOR PSYCHO; ROGERS AR, 1994, AM ECON REV, V84, P460; RUBIN PH, 1979, ECON INQ, V18, P585; SCHOEN R, 1978, DEMOGRAPHY, V15, P625, DOI 10.2307/2061212; WALDMAN L, 1993, MY NEIGHBORHOOD WORD; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; Wilson J.Q., 1985, CRIME HUMAN NATURE; WILSON M, 1985, ETHOL SOCIOBIOL, V6, P59, DOI 10.1016/0162-3095(85)90041-X; Wilson Margo, 1992, P289; WILSON MI, 1992, CRIMINOLOGY, V30, P189, DOI 10.1111/j.1745-9125.1992.tb01102.x; WILSON WJ, 1987, TRULY DISADVANTAGERE; [No title captured]	33	409	419	0	92	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 26	1997	314	7089					1271	1274		10.1136/bmj.314.7089.1271	http://dx.doi.org/10.1136/bmj.314.7089.1271			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WW718	9154035	Green Published			2022-12-28	WOS:A1997WW71800037
J	Doyal, L				Doyal, L			The rationing debate: Rationing within the NHS should be explicit - The case for	BRITISH MEDICAL JOURNAL			English	Article							CARE											*AUD COMM, 1993, WHAT SEEMS MATTER CO, P1; BEAUCHAMP TC, 1994, PRINCIPLES BIOMEDICA, P395; Coast J, 1997, BRIT MED J, V314, P1118, DOI 10.1136/bmj.314.7087.1118; CURTIS S, 1995, HLTH SOC, P138; DAVEY B, 1993, DILEMMAS HLTH CARE, P27; DAVIS H, 1991, COUNSELLING COMMUNIC, P3; DOYAL L, 1990, J LAW SOC, V17, P1, DOI 10.2307/1409951; Doyal L, 1995, Qual Health Care, V4, P273, DOI 10.1136/qshc.4.4.273; DOYAL L, 1991, THEORY HUMAN NEED, P49; EVANS JG, 1993, RATIONING HLTH CARE; FRANKEL S, 1993, RATIONING RATIONALIT, P115; FUCHS VR, 1984, NEW ENGL J MED, V311, P1572, DOI 10.1056/NEJM198412133112411; GRIMSHAW J, 1995, RATIONING HLTH CARE; GUTMAN A, 1980, LIBERAL EQUALITY, P48; HOFFENBERG R, 1993, BRIT MED J, V306, P198; *HOUS COMM HLTH CO, 1995, PRIOR SETT NHS PURCH, P57; HUNTER D, 1995, RATIONING HLTH CARE, P877; KLEIN R, 1993, BRIT MED J, V307, P309, DOI 10.1136/bmj.307.6899.309; Klein R, 1992, Health Manage Q, V14, P2; KLEIN R, 1996, MANAGING SCARCITY, P83; Maxwell R., 1995, RATIONING HLTH CARE; MECHANIC D, 1995, BRIT MED J, V310, P1655, DOI 10.1136/bmj.310.6995.1655; MOONEY G, 1993, SOC SCI MED, V37, P873, DOI 10.1016/0277-9536(93)90140-Y; NEW B, 1996, RATIONING NHS, P63; Pfeffer N, 1991, IS QUALITY GOOD YOU, P45; Winslow GR, 1982, TRIAGE JUSTICE	26	38	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 12	1997	314	7087					1114	1118		10.1136/bmj.314.7087.1114	http://dx.doi.org/10.1136/bmj.314.7087.1114			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU236	9133899	Green Published			2022-12-28	WOS:A1997WU23600036
J	Liedes, J				Liedes, J			Copyright: Evolution, not revolution	SCIENCE			English	Editorial Material																		Lawler A, 1996, SCIENCE, V274, P494, DOI 10.1126/science.274.5287.494	1	6	6	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					223	225		10.1126/science.276.5310.223	http://dx.doi.org/10.1126/science.276.5310.223			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9132946				2022-12-28	WOS:A1997WT92500035
J	Harrison, S				Harrison, S			The rationing debate - Central government should have a greater role in rationing decisions - The case against	BRITISH MEDICAL JOURNAL			English	Article											Harrison, S (corresponding author), UNIV LEEDS,NUFFIELD INST HLTH,LEEDS LS2 9PL,W YORKSHIRE,ENGLAND.							*ASS METR AUTH, 1993, LOC AUTH HLTH SERV F; BOGDANOV V, 1994, OBSERVER        0320, P4; Bowling A, 1996, BRIT MED J, V312, P670; BOYD KM, 1979, ETHICS RESOURCE ALLO; Donaldson C, 1993, EC HLTH CARE FINANCI; Doyal L., 1991, THEORY HUMAN NEED, DOI DOI 10.1007/978-1-349-21500-3; HARRISON S, 1991, HLTH HLTH CARE; Harrison Stephan, 1994, RATIONING HLTH CARE; HEGINBOTHAM C, 1993, RATIONING ACTION; HOFFENBERG R, 1992, BRIT MED J, V304, P182, DOI 10.1136/bmj.304.6820.182; HUNTER DJ, 1995, BRIT MED J, V310, P587; HUNTER DJ, 1993, CRITICAL PUBLIC HLTH, V4, P27; KNOX C, 1995, PUBLIC ADMIN, V73, P413, DOI 10.1111/j.1467-9299.1995.tb00836.x; Lenaghan J, 1996, RATIONING RIGHTS HLT; MAYS N, 1993, CRITICAL PUBLIC HLTH, V4, P43; MECHANIC D, 1992, U PENN LAW REV, V140, P1713, DOI 10.2307/3312429; *NAT ASS HLTH AUT, 1993, SEC EFF PUBL ACC NHS; REGAN DE, 1982, SOC POLICY ADMIN, V16, P19, DOI 10.1111/j.1467-9515.1982.tb00158.x; STEWART J, 1992, ACCOUNTABILITY PUBLI; STEWART J, 1994, CITIZIENS JURIES; 1991, FINANCIAL TIMES 0606	21	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					970	973		10.1136/bmj.314.7085.970	http://dx.doi.org/10.1136/bmj.314.7085.970			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WQ169	9132146	Green Published			2022-12-28	WOS:A1997WQ16900037
J	Hemmings, BA				Hemmings, BA			Update: Signal transduction - PH domains - A universal membrane adapter	SCIENCE			English	Editorial Material							PLECKSTRIN-HOMOLOGY DOMAIN				Hemmings, BA (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.							Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; KIPPEL A, 1997, MOL CELL BIOL, V17, P338; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0	16	72	74	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1899	1899		10.1126/science.275.5308.1899	http://dx.doi.org/10.1126/science.275.5308.1899			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9122692				2022-12-28	WOS:A1997WQ51300033
J	Dolin, PJ; Faal, H; Johnson, GJ; Minassian, D; Sowa, S; Day, S; Ajewole, J; Mohamed, AA; Foster, A				Dolin, PJ; Faal, H; Johnson, GJ; Minassian, D; Sowa, S; Day, S; Ajewole, J; Mohamed, AA; Foster, A			Reduction of trachoma in a sub-Saharan village in absence of a disease control programme	LANCET			English	Article								Background Trachoma is a leading cause of blindness in the developing world and is most prevalent among people who live in poor rural communities in arid locations. Methods We analysed the results of surveys of trachoma prevalence in Marakissa, a rural village in The Gambia. These surveys were undertaken in 1959, by the Medical Research Council, and in 1987 and 1996 by the Gambian National Eye Care Programme. Findings During this 37-year period, the prevalence of active inflammatory trachoma among children aged 0-9 years fell from 65.7 cases per 100 children in 1959 to 2.4 cases per 100 children in 1996. The prevalence also fell dramatically among people of 10-19 years (52.5 to 1.4 per 100) and among people of 20 years and older (36.7 to 0 cases per 100). Interpretation The dramatic fall in disease occurrence was paralleled by improvements in sanitation, water supply, education, and access to health care in the village. Of particular importance is that the decline in trachoma occurred without any trachoma-specific intervention.	ROYAL VICTORIA HOSP, NATL EYE CARE PROGRAMME, BANJUL, GAMBIA		Dolin, PJ (corresponding author), UCL, INT CTR EYE HLTH, INST OPHTHALMOL, BATH ST, LONDON EC1V 9EL, ENGLAND.			Foster, Allen/0000-0003-2368-4436				COURTRIGHT P, 1991, BRIT J OPHTHALMOL, V75, P322, DOI 10.1136/bjo.75.6.322; FAAL H, 1989, BRIT J OPHTHALMOL, V73, P82, DOI 10.1136/bjo.73.2.82; MABEY DCW, 1991, ANN TROP PAEDIATR, V11, P295, DOI 10.1080/02724936.1991.11747518; MacCallan AF, 1936, TRACHOMA; SOWA S, 1965, MED RES COUNC SPECIA, V308; TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821, DOI 10.1001/archopht.1989.01070020903037; THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477	7	71	71	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 24	1997	349	9064					1511	1512		10.1016/S0140-6736(97)01355-X	http://dx.doi.org/10.1016/S0140-6736(97)01355-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167460				2022-12-28	WOS:A1997XA90100010
J	Kearon, C; Hirsh, J				Kearon, C; Hirsh, J			Management of anticoagulation before and after elective surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DEEP-VEIN THROMBOSIS; LOW-MOLECULAR-WEIGHT; LOW-DOSE HEPARIN; MAJOR ABDOMINAL-SURGERY; VENOUS THROMBOEMBOLISM; RANDOMIZED TRIAL; COMPRESSION STOCKINGS; SUBCUTANEOUS HEPARIN; ORAL ANTICOAGULANTS; SURGICAL PATIENTS		HAMILTON CIV HOSP, RES CTR, HAMILTON, ON L8V 1C3, CANADA	McMaster University	Kearon, C (corresponding author), MCMASTER UNIV, 711 CONCESS ST, HAMILTON, ON L8V 1C3, CANADA.							ANDERSON CS, 1994, STROKE, V25, P1935, DOI 10.1161/01.STR.25.10.1935; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; ANDERSON DR, 1991, THROMB HAEMOSTASIS, V65, P248; [Anonymous], 1986, Arch Neurol, V43, P71; [Anonymous], 1994, ARCH INTERN MED, V154, P2254; BARRITT DW, 1960, LANCET, V1, P1309; BASU D, 1972, NEW ENGL J MED, V287, P324, DOI 10.1056/NEJM197208172870703; BECKER RC, 1995, ARCH INTERN MED, V155, P149, DOI 10.1001/archinte.155.2.149; BERGQVIST D, 1994, PROG CARDIOVASC DIS, V37, P25, DOI 10.1016/S0033-0620(05)80049-0; BERN MM, 1990, ANN INTERN MED, V112, P423, DOI 10.7326/0003-4819-76-3-112-6-423; Blackshear JL, 1996, LANCET, V348, P633; CANNEGIETER SC, 1994, CIRCULATION, V89, P635, DOI 10.1161/01.CIR.89.2.635; CAPLAN LR, 1983, STROKE, V14, P530, DOI 10.1161/01.STR.14.4.530; CARTER CJ, 1994, PROG CARDIOVASC DIS, V36, P439, DOI 10.1016/S0033-0620(94)80052-9; CLAGETT GP, 1988, ANN SURG, V208, P227, DOI 10.1097/00000658-198808000-00016; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; COON WW, 1974, ARCH INTERN MED, V133, P386, DOI 10.1001/archinte.133.3.386; COON WW, 1973, SURGERY, V73, P823; DECOUSUS H, 1996, HAEMOSTASIS S3, V26, P177; FEINSTEIN AR, 1985, ARCH INTERN MED, V145, P1257, DOI 10.1001/archinte.145.7.1257; FLANC C, 1968, BRIT J SURG, V55, P742, DOI 10.1002/bjs.1800551007; Francis CW, 1996, THROMB HAEMOSTASIS, V75, P706; FRANCIS CW, 1983, JAMA-J AM MED ASSOC, V249, P374, DOI 10.1001/jama.249.3.374; Genewein U, 1996, BRIT J HAEMATOL, V92, P479, DOI 10.1046/j.1365-2141.1996.d01-1499.x; GREEN RM, 1975, SURGERY, V77, P24; GRIP L, 1991, EUR HEART J, V12, P1225, DOI 10.1093/eurheartj/12.11.1225; Harrison L, 1997, ANN INTERN MED, V126, P133, DOI 10.7326/0003-4819-126-2-199701150-00006; HIRSH J, 1995, CHEST, V108, pS258, DOI 10.1378/chest.108.4_Supplement.258S; HIRSH J, 1995, CHEST, V108, pS231, DOI 10.1378/chest.108.4_Supplement.231S; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1983, CIRCULATION, V67, P901, DOI 10.1161/01.CIR.67.4.901; HYAMS AL, 1995, ANN INTERN MED, V122, P450, DOI 10.7326/0003-4819-122-6-199503150-00008; KAKKAR VV, 1970, AM J SURG, V120, P527, DOI 10.1016/S0002-9610(70)80023-X; KAKKAR VV, 1993, LANCET, V341, P259, DOI 10.1016/0140-6736(93)92614-Y; KLUFT C, 1985, SCAND J CLIN LAB INV, V45, P605, DOI 10.3109/00365518509155267; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LAGERSTEDT CI, 1985, LANCET, V2, P515; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; LEVINE M, 1994, LANCET, V343, P886, DOI 10.1016/S0140-6736(94)90008-6; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LEVINE MN, 1995, THROMB HAEMOSTASIS, V74, P606; LEVINE MN, 1995, CHEST, V108, pS276, DOI 10.1378/chest.108.4_Supplement.276S; MCINTYRE KM, 1995, CHEST, V108, pS502, DOI 10.1378/chest.108.4_Supplement.502S; MOK CK, 1985, CIRCULATION, V72, P1059, DOI 10.1161/01.CIR.72.5.1059; NIEUWENHUIS HK, 1991, BLOOD, V78, P2337, DOI 10.1182/blood.V78.9.2337.2337; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; Palareti G, 1996, CLIN PHARMACOKINET, V30, P300, DOI 10.2165/00003088-199630040-00003; PALARETI G, 1994, THROMB HAEMOSTASIS, V72, P222; POLLER L, 1964, LANCET, V2, P62; Ramos R, 1996, CHEST, V109, P82, DOI 10.1378/chest.109.1.82; RASKOB GE, 1995, BLOOD, V85, P3034, DOI 10.1182/blood.V85.11.3034.bloodjournal85113034; RUSTAD H, 1963, ACTA MED SCAND, V173, P115; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; STEIN PD, 1995, CHEST, V108, pS371, DOI 10.1378/chest.108.4_Supplement.371S; SUDLOW MF, 1992, LANCET, V340, P873; TABERNER DA, 1978, BRIT MED J, V1, P272, DOI 10.1136/bmj.1.6108.272; TINKER JH, 1978, JAMA-J AM MED ASSOC, V239, P738, DOI 10.1001/jama.239.8.738; TORNGREN S, 1980, BRIT J SURG, V67, P482, DOI 10.1002/bjs.1800670710; TREIMAN RL, 1990, J VASC SURG, V12, P440, DOI 10.1067/mva.1990.22152; VALLES J, 1993, HAEMOSTASIS, V23, P212; WHITE RH, 1995, ANN INTERN MED, V122, P40, DOI 10.7326/0003-4819-122-1-199501010-00006; WILLEJORGENSEN P, 1985, BRIT J SURG, V72, P579, DOI 10.1002/bjs.1800720726; WILSON JR, 1979, AM HEART J, V97, P155, DOI 10.1016/0002-8703(79)90349-1	67	519	549	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	1997	336	21					1506	1511		10.1056/NEJM199705223362107	http://dx.doi.org/10.1056/NEJM199705223362107			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ767	9154771				2022-12-28	WOS:A1997WZ76700007
J	Sharma, P				Sharma, P			Medicine, Durer, and the praying hands	LANCET			English	Article									UNIV CAMBRIDGE GONVILLE & CAIUS COLL,CAMBRIDGE CB2 1TA,ENGLAND	University of Cambridge								*ALB FDN, 1984, OLD MAST DRAW ALB IN; CRISP AJ, 1984, J ROY COLL PHYS LOND, V18, P132; Emery A E, 1991, Proc R Coll Physicians Edinb, V21, P33; Ficker F, 1971, Munch Med Wochenschr, V113, P814; GOLDMAN L, 1979, AM J DIS CHILD, V133, P557, DOI 10.1001/archpedi.1979.02130050101025; Grosch G, 1971, Munch Med Wochenschr, V113, P810; HASLOCK I, 1987, OXFORD TXB MED; Meakins JL, 1996, ARCH SURG-CHICAGO, V131, P1289; SHARMA P, 1990, BRIT MED J, V300, P333, DOI 10.1136/bmj.300.6720.333-b	9	6	6	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 17	1997	349	9063					1470	1471		10.1016/S0140-6736(96)12216-9	http://dx.doi.org/10.1016/S0140-6736(96)12216-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164333				2022-12-28	WOS:A1997WZ76500045
J	Cusi, D; Barlassina, C; Azzani, T; Casari, G; Citterio, L; Devoto, M; Glorioso, N; Lanzani, C; Manunta, P; Righetti, M; Rivera, R; Stella, P; Troffa, C; Zagato, L; Bianchi, G				Cusi, D; Barlassina, C; Azzani, T; Casari, G; Citterio, L; Devoto, M; Glorioso, N; Lanzani, C; Manunta, P; Righetti, M; Rivera, R; Stella, P; Troffa, C; Zagato, L; Bianchi, G			Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension	LANCET			English	Article							GENETIC DISSECTION; COMPLEX TRAITS; MILAN STRAIN; RATS; LINKAGE; ERYTHROCYTES; MUTATIONS	Background Abnormalities in renal sodium transport may be involved in hypertension. Adducin, an alpha/beta heterodimeric protein found in the renal tubule is thought to regulate ion transport through changes in the actin cytoskeleton. We investigated whether an alpha-adducin polymorphism (Gly 460 Trp) is involved in essential hypertension in two separate populations. Methods Linkage analysis of three DNA markers at different distances from the alpha-adducin locus (20-2500 kb) was done in 137 hypertensive sibling-pairs. 477 hypertensive and 322 normotensive individuals were genotyped for the alpha-adducin polymorphism. The blood-pressure response to acute and chronic changes in sodium balance was studied in hypertensive individuals with and without the 460 Trp alpha-adducin allele. Findings Significant linkage was found for all three markers in the sibling-pair study. The extra shared alleles (9.1%, 6.5%, and 4.7%) and the significance level for linkage (p=0.0006, p=0.0119, and p=0.0211) both decreased with increasing distance from the alpha-adducin locus. There was a significant association between the 460 Trp mutation and hypertension (p=0.0003). In the salt-sensitivity test, to assess the acute blood-pressure response to changes in body sodium in 86 hypertensive patients, the decrease in mean arterial pressure was greater in 65 patients who were heterozygous for the mutant allele (Gly/Trp) than in 21 wild-type homozygotes (Gly/Gly) (mean decrease 15.9 [SE 2.0] vs 7.4 [1.3] mm Hg; p=0.001). Similarly, 21 heterozygous hypertensive patients showed a greater fall in mean arterial pressure in response to 2 months' treatment with hydrochlorothiazide than did 37 wild-type homozygous hypertensive patients (mean decrease 14.7 [2.2] vs 6.8 [1.4] mm Hg; p=0.002). with the mutant allele suggest that alpha-adducin is associated with a salt-sensitive form of essential hypertension. We suggest the alpha-adducin polymorphism may identify hypertensive patients who will benefit from diuretic treatment or manoeuvres to reduce total body sodium.	UNIV MILAN,HOSP SAN RAFFAELE,DIV NEPHROL DIALYSIS & HYPERTENS,I-20132 MILAN,ITALY; UNIV MILAN,POSTGRAD SCH NEPHROL,MILAN,ITALY; PRASSIS SIGMA TAU RES INST,MILAN,ITALY; ROCKEFELLER UNIV,LAB STAT GENET,NEW YORK,NY 10021; IST GIANNINA GASLINI,GENET MOL LAB,I-16148 GENOA,ITALY; UNIV SASSARI,IST CLIN MED,I-07100 SASSARI,ITALY	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; Rockefeller University; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Sassari			Manunta, Paolo/ABH-5476-2020; Casari, Giorgio/J-3070-2018; Lanzani, Chiara Livia/AAN-2284-2020; Citterio, Lorena/AAC-1589-2019; Devoto, Marcella/AAP-7595-2021; Zagato, Laura/AAC-7739-2022	Manunta, Paolo/0000-0003-3976-9696; Casari, Giorgio/0000-0002-0115-8980; Lanzani, Chiara Livia/0000-0002-5332-4012; Citterio, Lorena/0000-0001-6455-2291; Righetti, Marco/0000-0002-1148-6486; Zagato, Laura/0000-0002-0441-2120; Barlassina, Cristina/0000-0001-7407-2697; DEVOTO, MARCELLA/0000-0002-4431-5114; Bianchi, Giuseppe/0000-0002-8365-3618	NHGRI NIH HHS [HG00008] Funding Source: Medline; Telethon [TGM06S01] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Telethon(Fondazione Telethon)		Barber B. R., 1994, V16, P316; BIANCHI G, 1983, KIDNEY INT, V23, P870, DOI 10.1038/ki.1983.109; BIANCHI G, 1974, CLIN SCI MOL MED, V47, P435, DOI 10.1042/cs0470435; BIANCHI G, 1994, P NATL ACAD SCI USA, V91, P3999, DOI 10.1073/pnas.91.9.3999; BONNARDEAUX A, 1995, CIRCULATION, V91, P96, DOI 10.1161/01.CIR.91.1.96; CAMUSSI A, 1988, HYPERTENSION, V12, P620, DOI 10.1161/01.HYP.12.6.620; CASARI G, 1995, HYPERTENSION, V25, P320, DOI 10.1161/01.HYP.25.3.320; FERRARI P, 1992, BIOCHIM BIOPHYS ACTA, V1111, P111, DOI 10.1016/0005-2736(92)90280-Y; FERRARI P, 1991, J HYPERTENS, V9, P703, DOI 10.1097/00004872-199108000-00003; Ferrari Patrizia, 1995, P1261; Guidi E, 1996, J AM SOC NEPHROL, V7, P1131; HUGHES CA, 1995, J BIOL CHEM, V270, P18990, DOI 10.1074/jbc.270.32.18990; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; LIN BY, 1995, GENOMICS, V25, P93, DOI 10.1016/0888-7543(95)80113-Z; *LSU MED CTR, 1994, STAT AN GEN EP REL 2; Matsuoka Y, 1996, J BIOL CHEM, V271, P25157, DOI 10.1074/jbc.271.41.25157; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; SALARDI S, 1989, AM J HYPERTENS, V2, P229, DOI 10.1093/ajh/2.4.229; SALVATI P, 1987, J HYPERTENS, V5, P31, DOI 10.1097/00004872-198702000-00005; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Soubrier F, 1995, Curr Opin Nephrol Hypertens, V4, P177, DOI 10.1097/00041552-199503000-00011; Swales John D., 1995, P283; Tripodi G, 1996, J CLIN INVEST, V97, P2815, DOI 10.1172/JCI118737; WEINBERGER MH, 1986, HYPERTENSION, V8, P127, DOI 10.1161/01.HYP.8.6_Pt_2.II127; Woolfson RG, 1996, KIDNEY INT, V50, P717, DOI 10.1038/ki.1996.370	30	463	496	0	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1353	1357		10.1016/S0140-6736(97)01029-5	http://dx.doi.org/10.1016/S0140-6736(97)01029-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149697				2022-12-28	WOS:A1997WY34200009
J	Chameides, WL; Saylor, RD; Cowling, EB				Chameides, WL; Saylor, RD; Cowling, EB			Ozone pollution in the rural United States and the new NAAQS	SCIENCE			English	Editorial Material									N CAROLINA STATE UNIV,COLL FOREST RESOURCES,RALEIGH,NC 27695	University of North Carolina; North Carolina State University	Chameides, WL (corresponding author), GEORGIA INST TECHNOL,SCH EARTH & ATMOSPHER SCI,ATLANTA,GA 30332, USA.		Saylor, Rick/D-1252-2014	Saylor, Rick/0000-0003-4835-8290				Bascom R, 1996, AM J RESP CRIT CARE, V153, P477, DOI 10.1164/ajrccm.153.2.8564086; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3, DOI 10.1164/ajrccm.153.1.8542133; Chameides W., 1995, STATE SO OXIDANTS ST; Halpert MS, 1996, B AM METEOROL SOC, V77, pS1, DOI 10.1175/1520-0477-77.5s.S1; LIPPMANN M, 1992, ENV TOXICANTS HUMAN; Seinfeld JH, 1992, RETHINKING OZONE PRO; *US EPA, 1997, FED REG         1213, V61, P65717; *US EPA, 1995, EPA600R95086 NAT EXP; *US EPA, 1996, EPA452R96007 OFF AIR; WOLFF GT, 1996, ENV MANAGER     0927	10	57	58	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					916	916		10.1126/science.276.5314.916	http://dx.doi.org/10.1126/science.276.5314.916			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9163037				2022-12-28	WOS:A1997WY79200037
J	Hall, DA; Maus, DC; Gerfen, GJ; Inati, SJ; Becerra, LR; Dahlquist, FW; Griffin, RG				Hall, DA; Maus, DC; Gerfen, GJ; Inati, SJ; Becerra, LR; Dahlquist, FW; Griffin, RG			Polarization-enhanced NMR spectroscopy of biomolecules in frozen solution	SCIENCE			English	Article							DYNAMIC NUCLEAR-POLARIZATION; HIGH-RESOLUTION NMR; CROSS POLARIZATION; ROTATING SOLIDS; C-13 NMR; RESONANCE; BLENDS	Large dynamic nuclear polarization signal enhancements (up to a factor of 100) were obtained in the solid-state magic-angle spinning nuclear magnetic resonance (NMR) spectra of arginine and the protein T4 lysozyme in frozen glycerol-water solutions with the use of dynamic nuclear polarization. Polarization was transferred from the unpaired electrons of nitroxide free radicals to nuclear spins through microwave irradiation near the electron paramagnetic resonance frequency. This approach may be a generally applicable signal enhancement scheme for the high-resolution solid-state NMR spectroscopy of biomolecules.	MIT, FRANCIS BITTER NATL MAGNET LAB, CAMBRIDGE, MA 02139 USA; MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA; MIT, DEPT PHYS, CAMBRIDGE, MA 02139 USA; UNIV OREGON, DEPT CHEM, EUGENE, OR 97403 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Oregon				Maus, Douglas/0000-0002-8195-8637	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000995] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00995, RR-05539] Funding Source: Medline; NIGMS NIH HHS [GM-35382] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAGAM A, 1961, PRINCIPLES NUCLEAR M; AFEWORKI M, 1992, MACROMOLECULES, V25, P4084, DOI 10.1021/ma00042a006; ANDREW ER, 1958, NATURE, V182, P1659, DOI 10.1038/1821659a0; BECERRA LR, 1993, PHYS REV LETT, V71, P3561, DOI 10.1103/PhysRevLett.71.3561; BECERRA LR, 1995, J MAGN RESON SER A, V117, P28, DOI 10.1006/jmra.1995.9975; BENNETT AE, 1994, NMR-B PR PR, V33, P1; Berliner Lj, 1976, SEELING SPIN LABELLI; Bhartia P., 1984, MILLIMETER WAVE ENG; BRUNNER H, 1987, Z NATURFORSCH A, V42, P1456, DOI 10.1515/zna-1987-1217; CAMPBELL GC, 1992, J MAGN RESON, V96, P69, DOI 10.1016/0022-2364(92)90288-I; Douzou P., 1977, CRYOBIOCHEMISTRY INT; GERFEN GJ, 1995, J CHEM PHYS, V102, P9494, DOI 10.1063/1.468818; GRIFFITHS JM, 1993, ANAL CHIM ACTA, V283, P1081, DOI 10.1016/0003-2670(93)80267-O; HACKMANN A, 1988, J MAGN RESON, V79, P148, DOI 10.1016/0022-2364(88)90331-9; HENSTRA A, 1988, J MAGN RESON, V77, P389, DOI 10.1016/0022-2364(88)90190-4; MACHO V, 1983, J MAGN RESON, V52, P450, DOI 10.1016/0022-2364(83)90170-1; MCINTOSH LP, 1990, BIOCHEMISTRY-US, V29, P6341, DOI 10.1021/bi00479a003; Mehring M., 1983, PRINCIPLES HIGH RESO; Meier B. H., 1994, ADV MAGN OPT RESON, V18, P1; Navon G, 1996, SCIENCE, V271, P1848, DOI 10.1126/science.271.5257.1848; PINES A, 1972, J CHEM PHYS, V56, P1776, DOI 10.1063/1.1677439; ROSE DR, 1988, PROTEIN ENG, V2, P277, DOI 10.1093/protein/2.4.277; SINGEL DJ, 1989, J MAGN RESON, V81, P145, DOI 10.1016/0022-2364(89)90273-4; Slichter CP., 1989, PRINCIPLES MAGNETIC; Stejskal E.O., 1994, HIGH RESOLUTION NMR; Tycko R, 1996, J PHYS CHEM-US, V100, P13240, DOI 10.1021/jp953667u; WIND RA, 1985, PROG NUCL MAG RES SP, V17, P33, DOI 10.1016/0079-6565(85)80005-4; WIND RA, 1993, ADV CHEM SER, P3; ZHOU JW, 1994, SOLID STATE NUCL MAG, V3, P339, DOI 10.1016/0926-2040(94)90018-3; ZYSMILICH MG, 1994, J AM CHEM SOC, V116, P8362, DOI 10.1021/ja00097a052; [No title captured]; [No title captured]	33	389	400	1	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	1997	276	5314					930	932		10.1126/science.276.5314.930	http://dx.doi.org/10.1126/science.276.5314.930			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9139651				2022-12-28	WOS:A1997WY79200041
J	Chung, SSC; Lau, JYW; Sung, JJY; Chan, ACW; Lai, CW; Ng, EKW; Chan, FKL; Yung, MY; Li, AKC				Chung, SSC; Lau, JYW; Sung, JJY; Chan, ACW; Lai, CW; Ng, EKW; Chan, FKL; Yung, MY; Li, AKC			Randomised comparison between adrenaline injection alone and adrenaline injection plus heat probe treatment for actively bleeding ulcers	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UPPER GASTROINTESTINAL HEMORRHAGE; ND-YAG LASER; PEPTIC-ULCERS; CONTROLLED TRIAL; ENDOSCOPIC INJECTION; MULTIPOLAR ELECTROCOAGULATION; THERAPY; PHOTOCOAGULATION; EPINEPHRINE; HEMOSTASIS	Objective: To compare endoscopic adrenaline injection alone and adrenaline injection plus heat probe for the treatment of actively bleeding peptic ulcers. Design: Randomised prospective study of patients admitted with actively bleeding peptic ulcers. Setting: One university hospital. Subjects: 276 patients with actively bleeding ulcers detected by endoscopy within 24 hours of admission: 136 patients were randomised to endoscopic adrenaline injection atone and 140 to adrenaline injection plus heat probe treatment. Main outcome measures: Initial endoscopic haemostasis; clinical rebleeding; requirement for operation; requirement for blood transfusion; hospital stay, ulcer healing at four weeks; and mortality in hospital. Results:Initial haemostasis was achieved in 131/134 patients (98%) who received adrenaline injection alone and 135/136 patients (99%) who received additional heat probe treatment (P = 0.33). Outcome as measured by clinical rebleeding (12 v 5), requirement for emergency operation (14 v 8), blood transfusion (2 v 3 units), hospital stay (4 v 4 days), ulcer healing at four weeks (79.1% v 74%), and in hospital mortality (7 v 8) were not significantly different in the two groups. In the subgroup of patients with spurting haemorrhage 8/27 (29.6%; 14.5% to 50.3%) patients from the adrenaline injection alone group and 2/31 (6.5%; 1.1% to 22.9%) patients from the dual treatment group required operative intervention. The relative risk of this was lower in the dual treatment group (0.17; 0.03 to 0.87). Hospital stay was significantly shorter in the dual treatment group than the adrenaline injection alone group (4 v 6 days, P = 0.01). Conclusion: The addition of heat probe treatment after endoscopic adrenaline injection confers an advantage in ulcers with spurting haemorrhage.	CHINESE UNIV HONG KONG, PRINCE WALES HOSP, DEPT SURG, SHATIN, NEW TERRITORIES, HONG KONG; CHINESE UNIV HONG KONG, PRINCE WALES HOSP, DEPT MED, SHATIN, NEW TERRITORIES, HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital			Sung, Joseph J. Y./R-3203-2018; Chan, Francis K. L./F-4851-2010; Lau, James Y. W./O-2612-2016; Ng, Enders Kwok-wai/E-8276-2016	Sung, Joseph J. Y./0000-0003-3125-5199; Chan, Francis K. L./0000-0001-7388-2436; Lau, James Y. W./0000-0003-0122-4068; Ng, Enders Kwok-wai/0000-0001-7219-5810				BALZNO J, 1988, ENDOSCOPY, V20, P289; CHUNG SCS, 1987, ENDOSCOPY, V19, P47, DOI 10.1055/s-2007-1018229; CHUNG SCS, 1988, BRIT MED J, V296, P1631, DOI 10.1136/bmj.296.6637.1631; CHUNG SCS, 1991, GASTROENTEROLOGY, V100, P33, DOI 10.1016/0016-5085(91)90579-A; CHUNG SCS, 1993, GASTROINTEST ENDOSC, V39, P611; Chung SCS, 1996, GASTROINTEST ENDOSC, V43, P591, DOI 10.1016/S0016-5107(96)70197-9; CHUNG SCS, 1988, GASTROINTEST ENDOSC, V34, P174; COOK DJ, 1992, GASTROENTEROLOGY, V102, P139, DOI 10.1016/0016-5085(92)91793-4; FULLARTON GM, 1989, BRIT J SURG, V76, P541, DOI 10.1002/bjs.1800760606; HALL WH, 1989, JAMA-J AM MED ASSOC, V262, P1369; KREJS GJ, 1987, NEW ENGL J MED, V316, P1618, DOI 10.1056/NEJM198706253162602; LAI KH, 1994, ENDOSCOPY, V26, P338, DOI 10.1055/s-2007-1008987; LAINE L, 1990, GASTROENTEROLOGY, V99, P1303, DOI 10.1016/0016-5085(90)91154-X; LAINE L, 1987, NEW ENGL J MED, V316, P1613, DOI 10.1056/NEJM198706253162601; LAU JYW, 1995, GASTROINTEST ENDOSC, V41, P368, DOI 10.1016/S0016-5107(05)80326-8; LEUNG JWC, 1987, GASTROINTEST ENDOSC, V33, P73, DOI 10.1016/S0016-5107(87)71512-0; LOIZOU LA, 1991, GUT, V32, P1100, DOI 10.1136/gut.32.10.1100; MATTHEWSON K, 1990, GASTROENTEROLOGY, V98, P1239, DOI 10.1016/0016-5085(90)90339-3; OBRIEN JD, 1986, LANCET, V1, P464; PANES J, 1987, LANCET, V2, P1292; RUTGEERTS P, 1989, GASTROENTEROLOGY, V97, P610, DOI 10.1016/0016-5085(89)90632-X; RUTGEERTS P, 1989, LANCET, V1, P1164; SACKS HS, 1990, JAMA-J AM MED ASSOC, V264, P494, DOI 10.1001/jama.264.4.494; STEELE RJC, 1991, BRIT J SURG, V78, P477, DOI 10.1002/bjs.1800780428; SUNG JY, 1993, GASTROINTEST ENDOSC, V39, P20, DOI 10.1016/S0016-5107(93)70004-8; SWAIN CP, 1986, LANCET, V1, P1113; TEDESCO FJ, 1981, DIGEST DIS SCI, V26, pS102, DOI 10.1007/BF01300816; ULRICH CD, 1994, GASTROINTEST ENDOSC, V40, P89; WARING JP, 1991, GASTROINTEST ENDOSC, V37, P295	29	155	159	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	1997	314	7090					1307	1311		10.1136/bmj.314.7090.1307	http://dx.doi.org/10.1136/bmj.314.7090.1307			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX975	9158465	Green Published			2022-12-28	WOS:A1997WX97500021
J	Frewin, R; Henson, A; Provan, D				Frewin, R; Henson, A; Provan, D			ABC of clinical haematology - Haematological emergencies	BRITISH MEDICAL JOURNAL			English	Article									UNIV SOUTHAMPTON,ROYAL S HANTS HOSP,DEPT PRIMARY CARE,SOUTHAMPTON,HANTS,ENGLAND	University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital	Frewin, R (corresponding author), SOUTHAMPTON UNIV HOSP NHS TRUST,SOUTHAMPTON,HANTS,ENGLAND.		Provan, Drew/AAF-2766-2021	Provan, Drew/0000-0002-5110-8455					0	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 3	1997	314	7090					1333	1336		10.1136/bmj.314.7090.1333	http://dx.doi.org/10.1136/bmj.314.7090.1333			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX975	9158472	Green Published			2022-12-28	WOS:A1997WX97500029
J	Reus, VI				Reus, VI			Olanzapine: A novel atypical neuroleptic agent	LANCET			English	Editorial Material											Reus, VI (corresponding author), UNIV CALIF SAN FRANCISCO,LANGLEY PORTER PSYCHIAT INST,SAN FRANCISCO,CA 94143, USA.		reus, victor i/I-7923-2015	reus, victor i/0000-0002-8193-5697				Beasley CM, 1996, NEUROPSYCHOPHARMACOL, V14, P111, DOI 10.1016/0893-133X(95)00069-P; Bymaster FP, 1996, NEUROPSYCHOPHARMACOL, V14, P87, DOI 10.1016/0893-133X(94)00129-N; Meltzer HY, 1996, NEUROPSYCHOPHARMACOL, V14, P83, DOI 10.1016/0893-133X(95)00197-L; Moore NA., 1993, CURR OPIN INVEST DR, V2, P281; Richelson E, 1996, J CLIN PSYCHIAT, V57, P4; Robertson GS, 1996, NEUROPSYCHOPHARMACOL, V14, P105, DOI 10.1016/0893-133X(95)00196-K; SCHMIDT CJ, 1995, LIFE SCI, V56, P2209, DOI 10.1016/0024-3205(95)00210-W; Stockton ME, 1996, NEUROPSYCHOPHARMACOL, V14, P97, DOI 10.1016/0893-133X(94)00130-R; SYBERG S, 1997, NEUROPSYCHOPHARMACOL, V16, P1; TOLLEFSON DG, 1997, AM J PSYCHIAT, V154, P457	10	43	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1264	1265		10.1016/S0140-6736(97)22018-0	http://dx.doi.org/10.1016/S0140-6736(97)22018-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142055				2022-12-28	WOS:A1997WW89900002
J	McPherron, AC; Lawler, AM; Lee, SJ				McPherron, AC; Lawler, AM; Lee, SJ			Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member	NATURE			English	Article							CELLS	The transforming growth factor-beta (TGF-beta) superfamily encompasses a large group of growth and differentiation factors playing important roles in regulating embryonic development and in maintaining tissue homeostasis in adult animals(1). Using degenerate polymerase chain reaction, we have identified a new murine TGF-beta family member, growth/differentiation factor-8 (GDF-8), which is expressed specifically in developing and adult skeletal muscle, During early stages of embryogenesis, GDF-8 expression is restricted to the myotome compartment of developing somites. At later stages and in adult animals, GDF-8 is expressed in many different muscles throughout the body, To determine the biological function of GDF-8, we disrupted the GDF-8 gene by gene targeting in mice. GDF-8 null animals are significantly larger than wild-type animals and show a large and widespread increase in skeletal muscle mass. Individual muscles of mutant animals weigh 2-3 times more than those of wild-type animals, and the increase in mass appears to result from a combination of muscle cell hyperplasia and hypertrophy. These results suggest that GDF-8 functions specifically as a negative regulator of skeletal muscle growth.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT OBSTET & GYNECOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University								BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; KNECHT AK, 1995, DEVELOPMENT, V121, P1927; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LESHNER AI, 1972, PHYSIOL BEHAV, V9, P281, DOI 10.1016/0031-9384(72)90251-X; MCPHERRON AC, 1993, J BIOL CHEM, V268, P3444; McPherron AC., 1996, GROWTH FACTORS CYTOK, P357, DOI [10.1016/s1874-5687(96)80016-4, DOI 10.1016/S1874-5687(96)80016-4]; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75	10	2940	3396	15	241	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 1	1997	387	6628					83	90		10.1038/387083a0	http://dx.doi.org/10.1038/387083a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139826				2022-12-28	WOS:A1997WW75800052
J	Laufer, E; Dahn, R; Orozco, OE; Yeo, CY; Pisenti, J; Henrique, D; Abbott, UK; Fallon, JF; Tabin, C				Laufer, E; Dahn, R; Orozco, OE; Yeo, CY; Pisenti, J; Henrique, D; Abbott, UK; Fallon, JF; Tabin, C			Expression of radical fringe in limb-bud ectoderm regulates apical ectodermal ridge formation	NATURE			English	Article							PATTERN-FORMATION; WING DEVELOPMENT; VERTEBRATE LIMB; VENTRAL CELLS; CHICK-EMBRYO; MUTANT; DORSAL; DROSOPHILA; INDUCTION; MOUSE	The apical ectodermal ridge of the vertebrate limb bud lies at the junction of the dorsal and ventral ectoderm and directs patterning of the growing limb. Its formation is directed by the boundary between cells that do and cells that do not express the gene Radical fringe. This is similar to the establishment of the margin cells at the Drosophila wing dorsoventral border by fringe. Radical fringe expression in chick-limb dorsal ectoderm is established In part through repression by Engrailed-1 in the ventral ectoderm.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; UNIV WISCONSIN,DEPT ANAT,MADISON,WI 53706; LAWRENCE LIVERMORE NATL LAB,DEPT AVIAN SCI,DAVIS,CA 95616; IMPERIAL CANC RES FUND,DEV GENET LAB,LONDON WC2A 3PX,ENGLAND	Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Cancer Research UK			Henrique, Domingos M/E-5460-2010	Henrique, Domingos M/0000-0001-8869-1894; Laufer, Edward/0000-0002-4933-1017; Yeo, Chang-Yeol/0000-0002-4440-1215				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1988, MOL REPROD DEV; BLAIR SS, 1993, DEVELOPMENT, V119, P339; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; CARRINGTON JL, 1986, DEV BIOL, V116, P130, DOI 10.1016/0012-1606(86)90049-7; CARRINGTON JL, 1988, DEVELOPMENT, V104, P361; CARRINGTON JL, 1984, J EMBRYOL EXP MORPH, V84, P19; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; Fallon J F, 1983, Prog Clin Biol Res, V110 Pt A, P33; FRASER RA, 1971, J EXP ZOOL, V176, P237, DOI 10.1002/jez.1401760209; GOETINCK PF, 1964, DEV BIOL, V10, P71, DOI 10.1016/0012-1606(64)90005-3; GRIESHAMMER U, 1997, DEVELOPMENT, V122, P381; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; KIENY M, 1968, ARCH ANAT MICROSC MO, V57, P401; KIENY M, 1960, J EMBRYOL EXP MORPH, V8, P457; Logan C, 1996, CURR BIOL, V6, P1006, DOI 10.1016/S0960-9822(02)00645-0; Loomis CA, 1996, NATURE, V382, P360, DOI 10.1038/382360a0; MEINHARDT H, 1983, J EMBRYOL EXP MORPH, V76, P115; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Myat A, 1996, DEV BIOL, V174, P233, DOI 10.1006/dbio.1996.0069; Noramly S, 1996, DEV BIOL, V179, P339, DOI 10.1006/dbio.1996.0265; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; POTTS WM, 1987, J GEN VIROL, V68, P3177, DOI 10.1099/0022-1317-68-12-3177; PRAHLAD KV, 1979, J EXP ZOOL, V209, P427, DOI 10.1002/jez.1402090308; RASER RA, 1971, J EXP ZOOL, V176, P219; RICHMAN JM, 1992, DEV BIOL, V154, P299, DOI 10.1016/0012-1606(92)90069-S; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; RODRIGUEZ CA, UNPUB; Ros MA, 1996, DEVELOPMENT, V122, P2319; ROS MA, 1994, DEV BIOL, V166, P59, DOI 10.1006/dbio.1994.1296; ROSENBLATT LS, 1959, POULTRY SCI, V38, P1242; SAUNDERS JW, 1974, DEV BIOL, V38, P41, DOI 10.1016/0012-1606(74)90257-7; Tanaka M, 1997, DEV BIOL, V182, P191, DOI 10.1006/dbio.1996.8476; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; Vogel A, 1996, DEVELOPMENT, V122, P1737; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0; WALL NA, 1995, MECH DEVELOP, V53, P383, DOI 10.1016/0925-4773(95)00453-X; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wu JY, 1996, SCIENCE, V273, P355, DOI 10.1126/science.273.5273.355; Yang XJ, 1996, J NEUROSCI, V16, P6089	47	223	228	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					366	373		10.1038/386366a0	http://dx.doi.org/10.1038/386366a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121552				2022-12-28	WOS:A1997WQ17000056
J	Dorling, A; Riesbeck, K; Warrens, A; Lechler, R				Dorling, A; Riesbeck, K; Warrens, A; Lechler, R			Clinical xenotransplantation of solid organs	LANCET			English	Review							HUMAN-COMPLEMENT INHIBITOR; TRANSGENIC PIGS; T-CELLS; REJECTION; TRANSPLANTATION; XENOGRAFTS; ANTIBODIES; EXPRESSION; ANTIGENS; DONORS	A possible solution to the chronic shortage of allografts is xenotransplantation, the use of tissue from an animal donor. Most experts believe that the pig will provide the most suitable solid organs for use in human beings. Although porcine organs are rapidly rejected by a process called hyperacute rejection (HAR), there is hope that several novel therapeutic strategies, already tested in animal models, will overcome this hurdle in patients. Successful clinical trials of these strategies, expected within the next few years, may herald the era of clinical xenotransplantation. However, there is increasing evidence that other barriers, both immune and non-immune, might exist to limit the survival of xenografts beyond the HAR phase. Mew strategies to overcome these barriers will be needed if long-term xenograft survival equivalent to, or better than, that of allografts is ever to be achieved.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0NN,ENGLAND	Imperial College London				Riesbeck, Kristian/0000-0001-6274-6965; Dorling, Anthony/0000-0003-3102-2600				*ADV GROIUP ETH XE, 1997, AN TISS HUM; AUCHINCLOSS H, 1988, TRANSPLANTATION, V46, P1, DOI 10.1097/00007890-198807000-00001; Bach FH, 1996, IMMUNOL TODAY, V17, P379, DOI 10.1016/0167-5699(96)10024-4; BAILEY LL, 1985, JAMA-J AM MED ASSOC, V254, P3321, DOI 10.1001/jama.254.23.3321; Borg AJ, 1996, XENOTRANSPLANTATION, V3, P171, DOI 10.1111/j.1399-3089.1996.tb00135.x; CALNE RY, 1970, TRANSPL P, V2, P550; CHAPMAN LE, 1995, NEW ENGL J MED, V333, P1498, DOI 10.1056/NEJM199511303332211; Cooke SP, 1995, TRANSPLANTATION, V60, P1274; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; Diamond LE, 1996, TRANSPLANTATION, V61, P1241, DOI 10.1097/00007890-199604270-00021; Dorling A, 1996, XENOTRANSPLANTATION, V3, P112, DOI 10.1111/j.1399-3089.1996.tb00127.x; Dorling A, 1996, EUR J IMMUNOL, V26, P1378, DOI 10.1002/eji.1830260630; DORLING A, 1996, TRANSPLANTATION BIOL; EVANS RW, 1992, JAMA-J AM MED ASSOC, V267, P239, DOI 10.1001/jama.267.2.239; FODOR WL, 1994, P NATL ACAD SCI USA, V91, P11153, DOI 10.1073/pnas.91.23.11153; GOOD AH, 1992, TRANSPL P, V24, P559; Koike C, 1996, XENOTRANSPLANTATION, V3, P81, DOI 10.1111/j.1399-3089.1996.tb00123.x; Malyguine AM, 1996, TRANSPLANTATION, V61, P161, DOI 10.1097/00007890-199601150-00032; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; MURRAY AG, 1994, IMMUNITY, V1, P57, DOI 10.1016/1074-7613(94)90009-4; *NUFF COUNC BIOETH, 1996, AN TO HUM TRANSPL ET; Parker W, 1996, HUM IMMUNOL, V45, P94, DOI 10.1016/0198-8859(95)00216-2; Parker W, 1996, IMMUNOL TODAY, V17, P373, DOI 10.1016/0167-5699(96)10028-1; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; PIERSON RN, 1989, J EXP MED, V170, P991, DOI 10.1084/jem.170.3.991; PLATT JL, 1994, TRANSPLANTATION, V57, P327, DOI 10.1097/00007890-199402150-00003; PLATT JL, 1990, IMMUNOL TODAY, V11, P450, DOI 10.1016/0167-5699(90)90174-8; REEMTSMA K, 1964, ANN SURG, V160, P384, DOI 10.1097/00000658-196409000-00006; ROSENGARD AM, 1995, TRANSPLANTATION, V59, P1325, DOI 10.1097/00007890-199505150-00018; SACHS DH, 1995, NAT MED, V1, P969, DOI 10.1038/nm0995-969; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; Seebach JD, 1996, XENOTRANSPLANTATION, V3, P188, DOI 10.1111/j.1399-3089.1996.tb00137.x; SIMEONOVIC CJ, 1990, TRANSPLANTATION, V50, P657, DOI 10.1097/00007890-199010000-00026; STARZL TE, 1993, LANCET, V341, P65, DOI 10.1016/0140-6736(93)92553-6; THOMPSON G, 1995, LANCET, V346, P766; Wecker Hermann, 1994, Xenotransplantation, V1, P8, DOI 10.1111/j.1399-3089.1994.tb00045.x; WOLF LA, 1995, TRANSPLANTATION, V60, P1164, DOI 10.1097/00007890-199511270-00018; YE Y, 1994, TRANSPLANTATION, V58, P330, DOI 10.1097/00007890-199408000-00014; ZHAO J, 1991, J BIOL CHEM, V266, P13418	40	70	78	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					867	871		10.1016/S0140-6736(96)09404-4	http://dx.doi.org/10.1016/S0140-6736(96)09404-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121275				2022-12-28	WOS:A1997WP40300046
J	Inoue, A; Sanes, JR				Inoue, A; Sanes, JR			Lamina-specific connectivity in the brain: Regulation by N-cadherin, neurotrophins, and glycoconjugates	SCIENCE			English	Article							SYNAPSE-SPECIFIC CARBOHYDRATE; CELL-ADHESION MOLECULES; NEURITE OUTGROWTH; VISUAL-CORTEX; OPTIC TECTUM; ACETYLGALACTOSAMINE; EXPRESSION; NEURONS; SURFACE; EVENTS	In the vertebrate brain, neurons grouped in parallel laminae receive distinct sets of synaptic inputs. In the avian optic tectum, arbors and synapses of most retinal axons are confined to 3 of 15 laminae. The adhesion molecule N-cadherin and cell surface glycoconjugates recognized by a plant lectin are selectively associated with these ''retinorecipient'' laminae. The lectin and a monoclonal antibody to N-cadherin perturbed laminar selectivity in distinct fashions. In contrast, neurotrophins increased the complexity of retinal arbors without affecting their laminar distribution. Thus, cell surface molecules and soluble trophic factors may collaborate to shape lamina-specific arbors in the brain, with the former predominantly affecting their position and the latter their size.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)								BAYER SA, 1987, PROG NEUROBIOL, V29, P57, DOI 10.1016/0301-0082(87)90015-3; BIXBY JL, 1990, J CELL BIOL, V110, P1253, DOI 10.1083/jcb.110.4.1253; BOLZ J, 1993, TRENDS NEUROSCI, V16, P310, DOI 10.1016/0166-2236(93)90107-W; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; COHENCORY S, 1994, NEURON, V12, P747, DOI 10.1016/0896-6273(94)90328-X; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; DELAROSA EJ, 1994, NEUROSCIENCE, V58, P347, DOI 10.1016/0306-4522(94)90041-8; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; FROTSCHER M, 1995, J NEUROBIOL, V26, P350, DOI 10.1002/neu.480260307; Hallbook F, 1996, J COMP NEUROL, V364, P664; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; Hunt S.P., 1984, P619; ICHIKAWA M, 1994, DEV BRAIN RES, V78, P1, DOI 10.1016/0165-3806(94)90002-7; KARTEN HJ, 1982, CYTOCHEMICAL METHODS, P189; KATZ LC, 1992, ANNU REV NEUROSCI, V15, P31; LEMMON V, 1982, DEV BRAIN RES, V3, P349, DOI 10.1016/0165-3806(82)90003-7; MARTIN PT, 1995, NEURON, V14, P743, DOI 10.1016/0896-6273(95)90218-X; MATSUNAGA M, 1988, NATURE, V334, P62, DOI 10.1038/334062a0; MATSUNAGA M, 1988, NEURON, V1, P289, DOI 10.1016/0896-6273(88)90077-3; NAEGELE JR, 1990, J NEUROSCI, V10, P540; NAKAGAWA F, 1986, J COMP NEUROL, V243, P280, DOI 10.1002/cne.902430210; Prakash N, 1996, NATURE, V381, P702, DOI 10.1038/381702a0; SANES JR, 1982, NATURE, V300, P646, DOI 10.1038/300646a0; Sawai H, 1996, J NEUROSCI, V16, P3887; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Shatz CJ, 1996, P NATL ACAD SCI USA, V93, P602, DOI 10.1073/pnas.93.2.602; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; YAMAGATA M, 1995, DEVELOPMENT, V121, P189; YAMAGATA M, 1995, DEVELOPMENT, V121, P3763; YAMAGATA M, 1995, J NEUROSCI, V15, P4556	35	244	246	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1428	1431		10.1126/science.276.5317.1428	http://dx.doi.org/10.1126/science.276.5317.1428			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9162013				2022-12-28	WOS:A1997XB53300054
J	RubsamenWaigmann, H; Huguenel, E; Paessens, A; Kleim, JP; Wainberg, MA; Shah, A				RubsamenWaigmann, H; Huguenel, E; Paessens, A; Kleim, JP; Wainberg, MA; Shah, A			Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load	LANCET			English	Article									BAYER RES CTR,DIV PHARMACEUT,W HAVEN,CT; HOECHST AG,GEN PHARMA RES,FRANKFURT,GERMANY; MCGILL UNIV,AIDS CTR,MONTREAL,PQ,CANADA	Bayer AG; Sanofi-Aventis; McGill University	RubsamenWaigmann, H (corresponding author), BAYER PHARMA RES CTR,APRATHER WEG,D-42096 WUPPERTAL,GERMANY.							KLEIM JP, 1995, ANTIMICROB AGENTS CH, V39, P2253, DOI 10.1128/AAC.39.10.2253; MAYERS D, 1996, 36 INT C ANT AG CHEM; MYERS MW, 1996, 11 INT C AIDS VANC; STASZEWSKI S, 1995, J INFECT DIS, V171, P1159, DOI 10.1093/infdis/171.5.1159; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	5	11	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 24	1997	349	9064					1517	1517		10.1016/S0140-6736(97)24021-3	http://dx.doi.org/10.1016/S0140-6736(97)24021-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167463				2022-12-28	WOS:A1997XA90100013
J	Lindbaek, M; Hjortdahl, P; Johnsen, ULH				Lindbaek, M; Hjortdahl, P; Johnsen, ULH			Antibiotic treatment in acute bacterial sinusitis	LANCET			English	Letter									UNIV OSLO,ULLEVAL HOSP,DEPT NEURORADIOL,OSLO,NORWAY	University of Oslo	Lindbaek, M (corresponding author), UNIV OSLO,FAC MED,DEPT GEN PRACTICE,N-0317 OSLO,NORWAY.							Lindbaek M, 1996, BMJ-BRIT MED J, V313, P325, DOI 10.1136/bmj.313.7053.325; LINDBAEK M, 1996, FAM MED, V28, P181; vanBuchem FL, 1997, LANCET, V349, P683, DOI 10.1016/S0140-6736(96)07585-X; WILLETT LR, 1994, J GEN INTERN MED, V9, P38, DOI 10.1007/BF02599141; WILLETT LR, 1997, ACP J CLUB, V126, P10	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 17	1997	349	9063					1476	1476		10.1016/S0140-6736(05)63757-9	http://dx.doi.org/10.1016/S0140-6736(05)63757-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164340				2022-12-28	WOS:A1997WZ76500053
J	FinlaysonPitts, BJ; Pitts, JN				FinlaysonPitts, BJ; Pitts, JN			Tropospheric air pollution: Ozone, airborne toxics, polycyclic aromatic hydrocarbons, and particles	SCIENCE			English	Review							GAS-PHASE REACTIONS; VOLATILE ORGANIC-COMPOUNDS; MAXIMUM INCREMENTAL REACTIVITIES; MICROSOME MUTAGENICITY TEST; AMBIENT PARTICULATE MATTER; INORGANIC CHLORINE GASES; DIRECT-ACTING MUTAGENS; NITROUS-ACID; ATMOSPHERIC REACTIONS; SALMONELLA-TYPHIMURIUM	Tropospheric air pollution has impacts on scales ranging from local to global, Reactive intermediates in the oxidation of mixtures of volatile organic compounds (VOCs) and oxides of nitrogen (NOx) play central roles: the hydroxyl radical (OH), during the day; the nitrate radical (NO3), at night; and ozone (O-3), which contributes during the day and night, Halogen atoms can also play a role during the day, Here the implications of the complex VOC-NOx chemistry for O-3 control are discussed, In addition, OH, NO3, and O-3 are shown to play a central role in the formation and fate of airborne toxic chemicals, mutagenic polycyclic aromatic hydrocarbons, and fine particles.			FinlaysonPitts, BJ (corresponding author), UNIV CALIF IRVINE, DEPT CHEM, IRVINE, CA 92697 USA.			Finlayson-Pitts, Barbara/0000-0003-4650-168X				ALFHEIM I, 1984, ENVIRON MUTAGEN, V6, P91, DOI 10.1002/em.2860060111; ALFHEIM I, 1984, CRIT REV ENV CONTR, V14, P91, DOI 10.1080/10643388409381715; ALFHEIM I, 1983, ENVIRON HEALTH PERSP, V47, P227, DOI 10.2307/3429512; Allen HC, 1996, J PHYS CHEM-US, V100, P6371, DOI 10.1021/jp953675a; Allen JO, 1996, ENVIRON SCI TECHNOL, V30, P1023, DOI 10.1021/es950517o; ALTSHULLER AP, 1987, JAPCA J AIR WASTE MA, V37, P1409, DOI 10.1080/08940630.1987.10466335; AMES BN, 1975, MUTAT RES, V31, P347, DOI 10.1016/0165-1161(75)90046-1; Anderson LG, 1996, ATMOS ENVIRON, V30, P2113, DOI 10.1016/1352-2310(95)00175-1; ANDERSSONSKOLD Y, 1992, J AIR WASTE MANAGE, V42, P1152, DOI 10.1080/10473289.1992.10467060; Andreae MO, 1997, SCIENCE, V276, P1052, DOI 10.1126/science.276.5315.1052; ANFOSSI D, 1991, J GEOPHYS RES-ATMOS, V96, P17349, DOI 10.1029/91JD01474; AREY J, 1992, MUTAT RES, V281, P67, DOI 10.1016/0165-7992(92)90038-J; AREY J, 1986, ATMOS ENVIRON, V20, P2339, DOI 10.1016/0004-6981(86)90064-8; ATKINSON R, 1987, ENVIRON SCI TECHNOL, V21, P1014, DOI 10.1021/es50001a017; ATKINSON R, 1992, J GEOPHYS RES-ATMOS, V97, P6065, DOI 10.1029/92JD00062; ATKINSON R, 1993, ENVIRON SCI TECHNOL, V27, P1357, DOI 10.1021/es00044a010; ATKINSON R, 1994, ENVIRON HEALTH PERSP, V102, P117, DOI 10.2307/3431940; ATKINSON R, 1986, ATMOS ENVIRON, V20, P331, DOI 10.1016/0004-6981(86)90035-1; BAMBAUER A, 1994, ATMOS ENVIRON, V28, P3225, DOI 10.1016/1352-2310(94)00169-L; BARALE R, 1994, ENVIRON HEALTH PERSP, V102, P67, DOI 10.2307/3431933; BARRIE LA, 1988, NATURE, V334, P138, DOI 10.1038/334138a0; BAUMGARD KJ, 1996, SPEC PUBL, V1140, P37; Behnke W, 1997, J GEOPHYS RES-ATMOS, V102, P3795, DOI 10.1029/96JD03057; BELCHERT P, 1996, J PHYS CHEM-US, V100, P15218; BELSER WL, 1981, ENVIRON MUTAGEN, V3, P123, DOI 10.1002/em.2860030204; Bjergbakke E, 1996, J PHYS CHEM-US, V100, P5729, DOI 10.1021/jp951588c; Bjoerseth A., 1983, HDB POLYCYCLIC AROMA; BjOrseth A., 1985, HDB POLYCYCLIC AROMA, V2; BOJKOV RD, 1986, J CLIM APPL METEOROL, V25, P343, DOI 10.1175/1520-0450(1986)025<0343:SODTSH>2.0.CO;2; BOWMAN FM, 1995, ATMOS ENVIRON, V29, P579, DOI 10.1016/1352-2310(94)00283-Q; Bowman FM, 1994, J GEOPHYS RES-ATMOS, V99, P5309, DOI 10.1029/93JD03400; BRIMBLECOMBE P, 1978, NOTES REC ROY SOC, V32, P123, DOI 10.1098/rsnr.1978.0011; BROWN MA, 1993, ENVIRON SCI TECHNOL, V27, P388, DOI 10.1021/es00039a020; BUSBY WF, 1994, MUTAT RES-GENET TOX, V322, P221, DOI 10.1016/0165-1218(94)90098-1; BUSBY WF, 1995, MUTAT RES-GENET TOX, V342, P9, DOI 10.1016/0165-1218(95)90085-3; BUSBY WF, 1994, MUTAT RES-GENET TOX, V322, P233, DOI 10.1016/0165-1218(94)90099-X; *CAL AIR RES BOARD, 1994, BENZ TOX AIR CONT; CALVERT JG, 1993, SCIENCE, V261, P37, DOI 10.1126/science.261.5117.37; CARTER WPL, 1987, ENVIRON SCI TECHNOL, V21, P670, DOI 10.1021/es00161a008; CARTER WPL, 1995, ATMOS ENVIRON, V29, P2513, DOI 10.1016/1352-2310(95)00150-W; CARTER WPL, 1989, ENVIRON SCI TECHNOL, V23, P864, DOI 10.1021/es00065a017; CARTER WPL, 1995, ATMOS ENVIRON, V29, P2499, DOI 10.1016/1352-2310(95)00149-S; CARTER WPL, 1994, J AIR WASTE MANAGE, V44, P881; CHRISP CE, 1978, SCIENCE, V199, P73, DOI 10.1126/science.199.4324.73; Ciccioli P, 1996, J GEOPHYS RES-ATMOS, V101, P19567, DOI 10.1029/95JD02118; CICERONE RJ, 1981, REV GEOPHYS, V19, P123, DOI 10.1029/RG019i001p00123; CLAXTON LD, 1992, MUTAT RES, V276, P61, DOI 10.1016/0165-1110(92)90055-E; CROES BE, 1992, J AIR WASTE MANAGE, V42, P657, DOI 10.1080/10473289.1992.10467017; Crutzen PJ, 1995, FARADAY DISCUSS, V100, P1, DOI 10.1039/fd9950000001; DEHNEN W, 1978, CANCER LETT, V4, P5, DOI 10.1016/S0304-3835(78)93027-6; DeMore W.B., 1997, JPL PUBL, V12, P97; DENTENER FJ, 1993, J GEOPHYS RES-ATMOS, V98, P7149, DOI 10.1029/92JD02979; Derwent RG, 1996, ATMOS ENVIRON, V30, P181, DOI 10.1016/1352-2310(95)00303-G; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; FAN SM, 1992, NATURE, V359, P522, DOI 10.1038/359522a0; Fan ZH, 1996, ENVIRON SCI TECHNOL, V30, P2821, DOI 10.1021/es960076o; FAN ZH, 1995, ATMOS ENVIRON, V29, P1171, DOI 10.1016/1352-2310(94)00347-N; FEBO A, 1995, ATMOS ENVIRON, V29, P345, DOI 10.1016/1352-2310(94)00260-R; FEBO A, 1991, ATMOS ENVIRON A-GEN, V25, P1055, DOI 10.1016/0960-1686(91)90147-Y; Finlayson-Pitts B.J., 1986, ATMOSPHERIC CHEM FUN; FINLAYSONPITTS BJ, 1989, NATURE, V337, P241, DOI 10.1038/337241a0; FINLAYSONPITTS BJ, 1990, NATURE, V343, P622, DOI 10.1038/343622a0; FINLAYSONPITTS BJ, 1993, RES CHEM INTERMEDIAT, V19, P235, DOI 10.1163/156856793X00091; FINLAYSONPITTS BJ, 1993, J AIR WASTE MANAGE, V43, P1091; FISHMAN J, 1978, NATURE, V274, P855, DOI 10.1038/274855a0; FITZGERALD JW, 1991, ATMOS ENVIRON A-GEN, V25, P533, DOI 10.1016/0960-1686(91)90050-H; Goodhill V, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P463; GRAEDEL TE, 1995, GLOBAL BIOGEOCHEM CY, V9, P47, DOI 10.1029/94GB03103; Grimmer G., 1983, ENV CARCINOGENS POLY; GROSJEAN D, 1994, ENVIRON SCI TECHNOL, V28, P186, DOI 10.1021/es00050a026; Grosjean E, 1996, ENVIRON SCI TECHNOL, V30, P2687, DOI 10.1021/es950758w; GUNDEL LA, 1993, ENVIRON SCI TECHNOL, V27, P2112, DOI 10.1021/es00047a017; GUNDEL LA, 1995, ATMOS ENVIRON, V29, P1719, DOI 10.1016/1352-2310(94)00366-S; Gupta P, 1996, ATMOS ENVIRON, V30, P3157, DOI 10.1016/1352-2310(96)00024-6; HAAGENSMIT AJ, 1956, IND ENG CHEM, V48, P1484, DOI 10.1021/ie51400a033; HAMMERLE R, 1994, ENVIRON HEALTH PERSP, V102, P25, DOI 10.2307/3431927; Hannigan MP, 1996, ENVIRON HEALTH PERSP, V104, P428, DOI 10.2307/3432688; Hannigan MP, 1997, ENVIRON SCI TECHNOL, V31, P438, DOI 10.1021/es960266z; HANNIGAN MP, 1994, ENVIRON SCI TECHNOL, V28, P2014, DOI 10.1021/es00061a009; HARGER WP, 1992, ATMOS ENVIRON A-GEN, V26, P2463, DOI 10.1016/0960-1686(92)90378-X; HELMIG D, 1992, ENVIRON SCI TECHNOL, V26, P622, DOI 10.1021/es00027a028; HELMIG D, 1992, ENVIRON SCI TECHNOL, V26, P2207, DOI 10.1021/es00035a020; HOLTON JR, 1995, REV GEOPHYS, V33, P403, DOI 10.1029/95RG02097; HUISINGH J, 1979, APPL SHORT TERM BIOA, P383; IMPEY GA, IN PRESS J GEOPHYS R; *INT AG RES CANC, 1989, MON EV CARC RISK CHE, V46; JAGER J, 1978, J CHROMATOGR, V152, P575; JENKIN ME, 1988, ATMOS ENVIRON, V22, P487, DOI 10.1016/0004-6981(88)90194-1; JOBSON BT, 1994, J GEOPHYS RES-ATMOS, V99, P25355, DOI 10.1029/94JD01243; JOHNSON JH, 1994, SAE T, V103, P210; KADO NY, 1983, MUTAT RES, V121, P25, DOI 10.1016/0165-7992(83)90082-9; KAO AS, 1995, INHAL TOXICOL, V7, P149, DOI 10.3109/08958379509014278; KEENE WC, 1993, ENVIRON SCI TECHNOL, V27, P866, DOI 10.1021/es00042a008; Keene WC, 1996, ATMOS ENVIRON, V30, pR1; KELLY TJ, 1994, ENVIRON SCI TECHNOL, V28, pA378, DOI 10.1021/es00057a003; Kirchstetter TW, 1996, ENVIRON SCI TECHNOL, V30, P2843, DOI 10.1021/es960135y; KNISPEL R, 1990, BER BUNSEN PHYS CHEM, V94, P1375, DOI 10.1002/bbpc.199000036; KWOK ESC, 1994, ENVIRON SCI TECHNOL, V28, P521, DOI 10.1021/es00052a027; Lammel G, 1996, CHEM SOC REV, V25, P361, DOI 10.1039/cs9962500361; Langer S, 1997, J PHYS CHEM A, V101, P1277, DOI 10.1021/jp962122c; Laux JM, 1996, J PHYS CHEM-US, V100, P19891, DOI 10.1021/jp961517t; LAWSON DR, 1990, AEROSOL SCI TECH, V12, P64, DOI 10.1080/02786829008959326; LEBRAS G, 1995, GEOPHYS RES LETT, V22, P599, DOI 10.1029/94GL03334; Leiter J, 1942, JNCI-J NATL CANCER I, V3, P155; LENNER M, 1987, ATMOS ENVIRON, V21, P37, DOI 10.1016/0004-6981(87)90268-X; LEWTAS J, 1993, ENVIRON HEALTH PERSP, V100, P211, DOI 10.2307/3431527; LEWTAS J, 1990, ENVIR SCI R, V40, P61; LOFROTH G, 1978, CHEMOSPHERE, V7, P791, DOI 10.1016/0045-6535(78)90062-0; LOGAN JA, 1985, J GEOPHYS RES-ATMOS, V90, P10463, DOI 10.1029/JD090iD06p10463; LOWENTHAL DH, 1994, ATMOS ENVIRON, V28, P731, DOI 10.1016/1352-2310(94)90050-7; MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165-1161(83)90010-9; MCCONNELL JC, 1992, NATURE, V355, P150, DOI 10.1038/355150a0; MCKEEN SA, 1993, GEOPHYS RES LETT, V20, P2363, DOI 10.1029/93GL02527; MERTES S, 1995, J PHYS CHEM-US, V99, P14000, DOI 10.1021/j100038a035; MIGUEL AG, 1990, ENVIRON MOL MUTAGEN, V15, P36, DOI 10.1002/em.2850150106; *NAT AC SCI, 1972, PARTICULATE POLYCYCL; *NAT AC SCI, 1983, POL AR HYDR EV SOURC; National Academy of Sciences, 1991, RETH OZ PROBL URB RE; NIELSEN T, 1984, ENVIRON SCI TECHNOL, V18, P157, DOI 10.1021/es00121a005; Nielsen T, 1996, SCI TOTAL ENVIRON, V189, P41, DOI 10.1016/0048-9697(96)05189-3; NIELSEN T, 1983, ENVIRON HEALTH PERSP, V47, P103, DOI 10.2307/3429503; NIELSEN T, 1984, ATMOS ENVIRON, V18, P2159, DOI 10.1016/0004-6981(84)90203-8; Nielsen T, 1996, ATMOS ENVIRON, V30, P3481, DOI 10.1016/1352-2310(96)00096-9; NIELSEN T, 1986, ATMOS ENVIRON, V20, P1507, DOI 10.1016/0004-6981(86)90024-7; NIKI H, 1992, TROPOSPHERIC CHEM OZ; NIKOLAOU K, 1984, SCI TOTAL ENVIRON, V32, P103, DOI 10.1016/0048-9697(84)90125-6; ODowd CD, 1997, ATMOS ENVIRON, V31, P73, DOI 10.1016/S1352-2310(96)00106-9; PANDIS SN, 1995, J PHYS CHEM-US, V99, P9646, DOI 10.1021/j100024a003; Paulson SE, 1996, GEOPHYS RES LETT, V23, P3727, DOI 10.1029/96GL03477; PHALEN RF, 1995, INHAL TOXICOL, V7, P1; Phalen RF, 1984, INHALATION STUDIES F; PHILLIPS DH, 1983, NATURE, V303, P468, DOI 10.1038/303468a0; PITTS JN, 1989, JAPCA J AIR WASTE MA, V39, P1344, DOI 10.1080/08940630.1989.10466629; PITTS JN, 1985, ATMOS ENVIRON, V19, P763, DOI 10.1016/0004-6981(85)90064-2; PITTS JN, 1987, ATMOS ENVIRON, V21, P2531, DOI 10.1016/0004-6981(87)90186-7; PITTS JN, 1985, ENVIRON SCI TECHNOL, V19, P1115, DOI 10.1021/es00141a017; PITTS JN, 1984, ATMOS ENVIRON, V18, P847, DOI 10.1016/0004-6981(84)90270-1; PITTS JN, 1993, RES CHEM INTERMEDIAT, V19, P251, DOI 10.1163/156856793X00109; PITTS JN, 1985, ATMOS ENVIRON, V19, P1601, DOI 10.1016/0004-6981(85)90212-4; PITTS JN, 1977, TOXICOL LETT, V1, P65, DOI 10.1016/0378-4274(77)90023-6; PITTS JN, 1984, INT J CHEM KINET, V16, P919, DOI 10.1002/kin.550160712; PITTS JN, 1978, SCIENCE, V202, P515, DOI 10.1126/science.705341; PITTS JN, 1983, ENVIRON HEALTH PERSP, V47, P115, DOI 10.2307/3429504; PITTS JN, 1993, OCCUPATIONAL MED STA, P621; Platt U., 1994, CHEM ANAL SERIES, P27; PSZENNY AAP, 1993, GEOPHYS RES LETT, V20, P699, DOI 10.1029/93GL00047; RAMDAHL T, 1983, NATURE, V306, P580, DOI 10.1038/306580a0; RAMDAHL T, 1986, NATURE, V321, P425, DOI 10.1038/321425a0; Ravishankara AR, 1997, SCIENCE, V276, P1058, DOI 10.1126/science.276.5315.1058; ROGGE WF, 1993, ATMOS ENVIRON A-GEN, V27, P1309, DOI 10.1016/0960-1686(93)90257-Y; ROGGE WF, 1993, ENVIRON SCI TECHNOL, V27, P636, DOI 10.1021/es00041a007; ROSENKRANZ H S, 1985, Journal of Environmental Science and Health Part C Environmental Carcinogenesis Reviews, V3, P221, DOI 10.1080/10590508509373334; Rudolph J, 1996, ATMOS ENVIRON, V30, P1887, DOI 10.1016/1352-2310(95)00385-1; RUSSELL AG, 1985, ATMOS ENVIRON, V19, P893, DOI 10.1016/0004-6981(85)90234-3; SAKAMAKI F, 1983, INT J CHEM KINET, V15, P1013, DOI 10.1002/kin.550151006; SCHUETZLE D, 1986, ANAL CHEM, V58, P1060, DOI 10.1021/ac00124a001; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; Seiber JN, 1996, ATMOS ENVIRON, V30, P751, DOI 10.1016/1352-2310(94)00213-4; SEIBER JN, 1995, P 8 INT C PEST CHEM; Singh HB, 1996, GEOPHYS RES LETT, V23, P1529, DOI 10.1029/96GL01368; Singh HB, 1996, J GEOPHYS RES-ATMOS, V101, P1907, DOI 10.1029/95JD01028; SKOPEK TR, 1978, P NATL ACAD SCI USA, V75, P4465, DOI 10.1073/pnas.75.9.4465; SMITH JP, 1993, J GEOPHYS RES-ATMOS, V98, P8983, DOI 10.1029/93JD00041; SPENGLER JD, 1993, ENVIRON SCI TECHNOL, V27, P841, DOI 10.1021/es00042a005; SPICER CW, 1993, J AIR WASTE MANAGE, V43, P1479, DOI 10.1080/1073161X.1993.10467221; SPICER CW, UNPUB; SVENSSON R, 1987, ATMOS ENVIRON, V21, P1529, DOI 10.1016/0004-6981(87)90315-5; TALCOTT R, 1977, J NATL CANCER I, V58, P449, DOI 10.1093/jnci/58.2.449; THRANE KE, 1981, ATMOS ENVIRON, V15, P909, DOI 10.1016/0004-6981(81)90090-1; TOKIWA H, 1977, MUTAT RES, V48, P237, DOI 10.1016/0027-5107(77)90165-8; TOKIWA H, 1986, CRIT REV TOXICOL, V17, P23, DOI 10.3109/10408448609037070; TUAZON EC, 1984, ARCH ENVIRON CON TOX, V13, P691, DOI 10.1007/BF01055932; TUOMINEN J, 1988, ENVIRON SCI TECHNOL, V22, P1228, DOI 10.1021/es00175a017; TURPIN BJ, 1991, ENVIRON SCI TECHNOL, V25, P1788, DOI 10.1021/es00022a017; van Cauwenberghe K. A., 1985, HDB POLYCYCLIC AROMA, P351; VECERA Z, 1994, INT J ENVIRON AN CH, V56, P311, DOI 10.1080/03067319408034109; VENKATARAMAN C, 1994, ENVIRON SCI TECHNOL, V28, P563, DOI 10.1021/es00053a006; VILLALOBOSPIETRINI R, 1995, ATMOS ENVIRON, V29, P517, DOI 10.1016/1352-2310(94)00247-I; VIRAS LG, 1990, ATMOS ENVIRON B-URB, V24, P267, DOI 10.1016/0957-1272(90)90032-P; Vogt R, 1996, ATMOS ENVIRON, V30, P1729, DOI 10.1016/1352-2310(95)00392-4; Vogt R, 1996, NATURE, V383, P327, DOI 10.1038/383327a0; VOLZ A, 1988, NATURE, V332, P240, DOI 10.1038/332240a0; WANG CY, 1980, CHEMOSPHERE, V9, P83, DOI 10.1016/0045-6535(80)90093-4; WANG YY, 1978, CANCER LETT, V5, P39, DOI 10.1016/S0304-3835(78)80009-3; WESTERHOLM RN, 1991, ENVIRON SCI TECHNOL, V25, P332, DOI 10.1021/es00014a018; Whitby K., 1980, CHARACTER ORIG SMOG, P477; WHITE CM, 1985, NITRATED POLYCYCLIC; WINER AM, 1994, RES CHEM INTERMEDIAT, V20, P423, DOI 10.1163/156856794X00405; WINER AM, 1990, LONG RANGE TRANSPORT OF PESTICIDES, P115; WINER AM, 1985, HDB AIR POLLUTION AN, pCH3; Wingenter OW, 1996, J GEOPHYS RES-ATMOS, V101, P4331, DOI 10.1029/95JD02457; WOLFE MF, 1993, OCCUPATIONAL MED STA, P561; ZIELINSKA B, 1989, ENVIRON SCI TECHNOL, V23, P723, DOI 10.1021/es00064a011	193	861	890	33	596	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	1997	276	5315					1045	1052		10.1126/science.276.5315.1045	http://dx.doi.org/10.1126/science.276.5315.1045			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9148793				2022-12-28	WOS:A1997WZ22500025
J	Reppert, SM; Weaver, DR				Reppert, SM; Weaver, DR			Forward genetic approach strikes gold: Cloning of a mammalian Clock gene	CELL			English	Review							BEHAVIOR; MOUSE		HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Harvard Medical School	Reppert, SM (corresponding author), MASSACHUSETTS GEN HOSP,LAB DEV CHRONOBIOL,BOSTON,MA 02114, USA.			Weaver, David/0000-0001-7941-6719				Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DUNLAP JC, 1996, ANNU REV GENET, V30, P575; Green CB, 1996, P NATL ACAD SCI USA, V93, P14884, DOI 10.1073/pnas.93.25.14884; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; KING DP, 1997, IN PRESS GENETICS; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KRAFT M, 1995, DIS MON, V41, P501; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Sauman I, 1996, NEURON, V17, P889, DOI 10.1016/S0896-6273(00)80220-2; SHEN H, 1997, IN PRESS J NEUROSCI; TAKAHASHI JS, 1994, SCIENCE, V264, P1724, DOI 10.1126/science.8209253; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7	17	42	43	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					487	490		10.1016/S0092-8674(00)80229-9	http://dx.doi.org/10.1016/S0092-8674(00)80229-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160739	Bronze			2022-12-28	WOS:A1997WZ32300001
J	Turkstra, F; Kuijer, PMM; vanBeek, EJR; Brandjes, DPM; tenCate, JW; Buller, HR				Turkstra, F; Kuijer, PMM; vanBeek, EJR; Brandjes, DPM; tenCate, JW; Buller, HR			Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism	ANNALS OF INTERNAL MEDICINE			English	Article						pulmonary embolism; radionuclide imaging; ultrasonography; anticoagulants; thrombophlebitis	PERFUSION LUNG-SCAN; COLOR DOPPLER ULTRASOUND; CLINICAL VALIDITY; D-DIMER; THROMBOSIS; THROMBOEMBOLISM; ANGIOGRAPHY; STRATEGY; COMPLICATIONS; VENOGRAPHY	Background: The standard diagnostic approach in patients suspected of having pulmonary embolism starts with perfusion-ventilation lung scanning. If the resulting scan is not diagnostic, pulmonary angiography should be done. The use of tests for deep venous thrombosis has been advocated as an adjunct to establishing the diagnosis of pulmonary embolism, but no prospective studies have provided adequate information about the value of these tests. Objective: To determine the accuracy and potential clinical utility of compression ultrasonography in the diagnosis of pulmonary embolism. Design: Prospective cohort study with blinded assessment of ultrasonographic results. Setting: Teaching hospital. Patients: 397 consecutive inpatients and outpatients in whom pulmonary embolism was clinically suspected. Measurements: Sensitivity and specificity of compression ultrasonography. Perfusion-ventilation scanning and angiography were the conjoint gold standard for determining the presence or absence of pulmonary embolism. Also calculated were the number of angiograms and lung scans avoided and the number of patients unnecessarily treated when compression ultrasonography was included in the diagnostic strategy. Results: The overall sensitivity of compression ultrasonography for deep venous thrombosis in patients with pulmonary embolism was 29% (95% CI, 22% to 37%); the specificity was 97% (CI, 94% to 99%). Adding ultrasonography to the diagnostic approach before lung scanning would avoid approximately 14% of lung scans and 9% of angiograms but would lead to unnecessary treatment of 13% of patients who have an abnormal ultrasonographic result (2% to 4% of all those receiving anticoagulation). When compression ultrasonography is done only in patients with a nondiagnostic lung scan, 9% of angiographies are prevented at the cost of unnecessarily treating 26% of patients who have an abnormal ultrasonographic result (2% of all patients receiving anticoagulation). Conclusion: The diagnostic value of compression ultrasonography for the detection of deep venous thrombosis in patients suspected of having pulmonary embolism is limited; the gain in diagnostic efficiency obtained through the use of ultrasonography may be offset by a loss in diagnostic accuracy.	UNIV AMSTERDAM, ACAD MED CTR, DEPT INTERNAL MED, NL-1105 AZ AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT RADIOL, NL-1105 AZ AMSTERDAM, NETHERLANDS; SLOTERVAART HOSP, DEPT INTERNAL MED, NL-1066 EC AMSTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Slotervaart Hospital	Turkstra, F (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, CTR THROMBOSIS HAEMOSTASIS & ATHEROSCLEROSIS & IN, MEIBERGDREEF 9, NL-1105 AZ AMSTERDAM, NETHERLANDS.							BARRITT DW, 1960, LANCET, V1, P1309; BEECHAM RP, 1993, AM J ROENTGENOL, V161, P1289, DOI 10.2214/ajr.161.6.8249744; BOUNAMEAUX H, 1991, LANCET, V337, P196, DOI 10.1016/0140-6736(91)92158-X; BRADLEY MJ, 1995, CLIN RADIOL, V50, P232, DOI 10.1016/S0009-9260(05)83476-2; CELI A, 1989, CHEST, V95, P332, DOI 10.1378/chest.95.2.332; Christiansen F, 1996, ACTA RADIOL, V37, P14; DAVIDSON BL, 1992, ANN INTERN MED, V117, P735, DOI 10.7326/0003-4819-117-9-735; FERNANDEZCANTON G, 1994, EUR J RADIOL, V19, P50, DOI 10.1016/0720-048X(94)00569-X; FOURNIER P, 1993, ANN CARDIOL ANGEIOL, V42, P447; GINSBERG JS, 1995, THROMB HAEMOSTASIS, V73, P35; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HOELLERICH VL, 1986, ARCH INTERN MED, V146, P1699, DOI 10.1001/archinte.146.9.1699; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1994, ARCH INTERN MED, V154, P289, DOI 10.1001/archinte.154.3.289; HULL RD, 1990, CHEST, V97, P23, DOI 10.1378/chest.97.1.23; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; HULL RD, 1995, ARCH INTERN MED, V155, P1845; JONGBLOETS LMM, 1994, LANCET, V343, P1142, DOI 10.1016/S0140-6736(94)90240-2; KRUIT WHJ, 1991, J INTERN MED, V230, P333, DOI 10.1111/j.1365-2796.1991.tb00453.x; LENSING AWA, 1992, THROMB HAEMOSTASIS, V68, P245; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 1994, HEMOSTASIS THROMBOSI, P1297; MORRELL NW, 1992, BRIT MED J, V304, P1126, DOI 10.1136/bmj.304.6835.1126; MOSER KM, 1990, AM REV RESPIR DIS, V141, P235, DOI 10.1164/ajrccm/141.1.235; REMYJARDIN M, 1992, RADIOLOGY, V185, P381, DOI 10.1148/radiology.185.2.1410342; Rosen MP, 1996, AM J ROENTGENOL, V166, P285, DOI 10.2214/ajr.166.2.8553931; SCHIFF MJ, 1987, ARCH INTERN MED, V147, P505, DOI 10.1001/archinte.147.3.505; SMITH LL, 1994, RADIOLOGY, V191, P143, DOI 10.1148/radiology.191.1.8134561; STEIN PD, 1995, ARCH INTERN MED, V155, P2101, DOI 10.1001/archinte.155.19.2101; STEIN PD, 1992, CIRCULATION, V85, P462, DOI 10.1161/01.CIR.85.2.462; STEIN PD, 1993, CHEST, V103, P1553, DOI 10.1378/chest.103.5.1553; VANBEEK EJR, 1995, CHEST, V108, P170, DOI 10.1378/chest.108.1.170; vanBeek EJR, 1996, EUR RADIOL, V6, P415, DOI 10.1007/BF00182453; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008	36	208	213	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1997	126	10					775	+		10.7326/0003-4819-126-10-199705150-00005	http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ823	9148650				2022-12-28	WOS:A1997WZ82300006
J	Harrap, SB				Harrap, SB			Private genes, public health	LANCET			English	Editorial Material							BLOOD-PRESSURE; SALT				Harrap, SB (corresponding author), UNIV MELBOURNE,DEPT PHYSIOL,PARKVILLE,VIC 3052,AUSTRALIA.			Harrap, Stephen/0000-0003-2907-6714				BIANCHI G, 1973, CLIN SCI MOL MED, V45, pS153; Harrap SB, 1996, J HYPERTENS, V14, pS111; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; SEIDEL B, 1995, BRAIN RES, V700, P13, DOI 10.1016/0006-8993(95)00962-P; SWALES JD, 1995, J HUM HYPERTENS, V9, P517; WATT GCM, 1988, J CARDIOVASC PHARM, V12, pS21	6	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1338	1339		10.1016/S0140-6736(05)63198-4	http://dx.doi.org/10.1016/S0140-6736(05)63198-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149692				2022-12-28	WOS:A1997WY34200004
J	Waterston, T				Waterston, T			Dictating clinic letters in front of the patient - Further research should be qualitative	BRITISH MEDICAL JOURNAL			English	Letter											Waterston, T (corresponding author), ARTHURS HILL CLIN,NEWCASTLE TYNE NE4 6BT,TYNE & WEAR,ENGLAND.							Lloyd BW, 1997, BRIT MED J, V314, P347, DOI 10.1136/bmj.314.7077.347; RYLANCE G, 1990, BRIT MED J, V300, P608, DOI 10.1136/bmj.300.6724.608-c; Waterston T, 1994, Qual Health Care, V3, P142, DOI 10.1136/qshc.3.3.142	3	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1416	1416						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ169	9161336				2022-12-28	WOS:A1997WZ16900058
J	Tucker, SJ; Gribble, FM; Zhao, C; Trapp, S; Ashcroft, FM				Tucker, SJ; Gribble, FM; Zhao, C; Trapp, S; Ashcroft, FM			Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor	NATURE			English	Article								ATP-sensitive potassium channels (K-ATP channels) couple cell metabolism to electrical activity and are important in the physiology and pathophysiology of many tissues(1). In pancreatic beta-cells, K-ATP channels Link changes in blood glucose concentration to insulin secretion(2). They are also the target for clinically important drugs such as sulphonylureas, which stimulate secretion, and the K+ channel opener diazoxide, which inhibits insulin release(3,4). Metabolic regulation of K-ATP channels is mediated by changes in intracellular ATP and Mg-ADP levels, which inhibit and activate the channel, respectively(2). The beta-cell K-ATP channel is a complex of two proteins(5,6): an inward-rectifier K+ channel subunit, Kir6.2, and the sulphonylurea receptor, SUR1. We show here that the primary site at which ATP acts to mediate K-ATP channel inhibition is located on Kir6.2, and that SUR1 is required for sensitivity to sulphonylureas and diazoxide and for activation by Mg-ADP.	UNIV OXFORD,PHYSIOL LAB,OXFORD OX1 3PT,ENGLAND	University of Oxford			Trapp, Stefan/D-9240-2011; Tucker, Stephen J./ABE-6741-2020; Tucker, Stephen J./ABE-7468-2020	Trapp, Stefan/0000-0003-0665-4948; Tucker, Stephen J./0000-0001-8996-2000; Tucker, Stephen J./0000-0001-8996-2000; Gribble, Fiona/0000-0002-4232-2898	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ammala C, 1996, J PHYSIOL-LONDON, V494, P709, DOI 10.1113/jphysiol.1996.sp021526; ANGUILARBRYAN L, 1995, SCIENCE, V268, P423; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT FM, 1992, BIOCHIM BIOPHYS ACTA, V175, P45; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Collins A, 1996, J NEUROSCI, V16, P1; DUNNE MJ, 1993, FRONTIERS INSULIN SE, P153; GRIBBLE EM, 1997, EMBO J, V16, P1145; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; KARSCHIN C, 1996, FEBS LETT, V401, P59; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; McNicholas CM, 1996, AM J PHYSIOL-RENAL, V271, pF275, DOI 10.1152/ajprenal.1996.271.2.F275; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; PROKS P, 1993, PFLUG ARCH EUR J PHY, V424, P63, DOI 10.1007/BF00375103; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; YAMADA YM, 1997, J PHYSL, V499, P715	22	646	664	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					179	183		10.1038/387179a0	http://dx.doi.org/10.1038/387179a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144288				2022-12-28	WOS:A1997WX94500054
J	Clark, S				Clark, S			Dangers of non-sedating antihistamines	LANCET			English	Editorial Material																			0	11	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1268	1268		10.1016/S0140-6736(05)62504-4	http://dx.doi.org/10.1016/S0140-6736(05)62504-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142059				2022-12-28	WOS:A1997WW89900006
J	Lindheimer, MD; Woodruff, TK				Lindheimer, MD; Woodruff, TK			Activin A, inhibin A, and pre-eclampsia	LANCET			English	Editorial Material							HYPERTENSION; PREGNANCY		UNIV CHICAGO,PRITZKER SCH MED,DEPT MED,CHICAGO,IL 60637; NORTHWESTERN UNIV,DEPT MED,CHICAGO,IL 60611; NORTHWESTERN UNIV,DEPT NEUROBIOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,DEPT PHYSIOL,CHICAGO,IL 60611	University of Chicago; Northwestern University; Northwestern University; Northwestern University	Lindheimer, MD (corresponding author), UNIV CHICAGO,PRITZKER SCH MED,DEPT OBSTET & GYNECOL,CHICAGO,IL 60637, USA.			Woodruff, Teresa/0000-0002-1197-3399				August Phyllis, 1995, P2407; Conrad KP, 1997, AM J REPROD IMMUNOL, V37, P240; CRAVEN C, 1997, J SOC GYNECOL INV.S1, V4, pA137; DEKKER GA, 1991, AM J OBSTET GYNECOL, V165, P160, DOI 10.1016/0002-9378(91)90245-M; FISHER KA, 1981, MEDICINE, V60, P267, DOI 10.1097/00005792-198107000-00002; Lindheimer M D, 1996, Curr Opin Nephrol Hypertens, V5, P452, DOI 10.1097/00041552-199609000-00013; Ness RB, 1996, AM J OBSTET GYNECOL, V175, P1365, DOI 10.1016/S0002-9378(96)70056-X; PETRAGLIA F, 1995, PLACENTA, V16, P447, DOI 10.1016/0143-4004(95)90102-7; ROBERTS JM, 1993, LANCET, V342, P504; WOODRUFF TK, 1995, ANNU REV PHYSIOL, V57, P219	10	6	6	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1266	1267		10.1016/S0140-6736(05)62502-0	http://dx.doi.org/10.1016/S0140-6736(05)62502-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142057				2022-12-28	WOS:A1997WW89900004
J	Heinzel, T; Lavinsky, RM; Mullen, TM; Soderstrom, M; Laherty, CD; Torchia, J; Yang, WM; Brard, G; Ngo, SD; Davie, JR; Seto, E; Eisenman, RN; Rose, DW; Glass, CK; Rosenfeld, MG				Heinzel, T; Lavinsky, RM; Mullen, TM; Soderstrom, M; Laherty, CD; Torchia, J; Yang, WM; Brard, G; Ngo, SD; Davie, JR; Seto, E; Eisenman, RN; Rose, DW; Glass, CK; Rosenfeld, MG			A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression	NATURE			English	Article							THYROID-HORMONE RECEPTOR; SACCHAROMYCES-CEREVISIAE; SIN3 GENE; YEAST; ACTIVATION; DOMAIN; MAD; ACETYLATION; HO; DIFFERENTIATION	Transcriptional repression by nuclear receptors has been correlated to binding of the putative co-repressor, N-CoR, A complex has been identified that contains N-CoR, the Mad presumptive co-repressor mSin3, and the histone deacetylase mRPD3, and which is required for both nuclear receptor- and Mad-dependent repression, but not for repression by transcription factors of the ets-domain family, These data predict that the ligand-induced switch of heterodimeric nuclear receptors from repressor to activator functions involves the exchange of complexes containing histone deacetylases with those that have histone acetylase activity.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,GRAD PROGRAM BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,WHITTIER DIABET PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CELLULAR & MOL MED DEPT,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,LA JOLLA,CA 92093; FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104; UNIV S FLORIDA,DEPT MED MICROBIOL & IMMUNOL,H LEE MOFFIT CANC CTR & RES INST,TAMPA,FL 33612; UNIV MANITOBA,DEPT BIOCHEM & MOL BIOL,WINNIPEG,MB R3E 0W3,CANADA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Fred Hutchinson Cancer Center; State University System of Florida; University of South Florida; University of Manitoba			Glass, Christopher/AAI-3933-2021; Heinzel, Thorsten/B-1013-2015; Söderström, Mats/C-4005-2009	Glass, Christopher/0000-0003-4344-3592; Söderström, Mats/0000-0003-3927-4394; MULLEN, Tina-Marie/0000-0001-6150-8084; Yang, Wen-Ming/0000-0002-5871-5979; Davie, James/0000-0002-0420-6888				ALMOUZNI G, 1994, DEV BIOL, V165, P654, DOI 10.1006/dbio.1994.1283; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KAMEI Y, 1996, CELL, V85, P1; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAHERTY CD, IN PRESS CELL; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Li W, 1996, BIOCHEM J, V314, P631, DOI 10.1042/bj3140631; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NAWAZ Z, 1994, MOL GEN GENET, V245, P724, DOI 10.1007/BF00297279; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; Svaren J, 1996, CURR OPIN GENET DEV, V6, P164, DOI 10.1016/S0959-437X(96)80046-3; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zamir I, 1996, MOL CELL BIOL, V16, P5458	51	1071	1119	1	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 1	1997	387	6628					43	48		10.1038/387043a0	http://dx.doi.org/10.1038/387043a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139820				2022-12-28	WOS:A1997WW75800041
J	Kelsell, DP; Dunlop, J; Stevens, HP; Lench, NJ; Liang, JN; Parry, G; Mueller, RF; Leigh, IM				Kelsell, DP; Dunlop, J; Stevens, HP; Lench, NJ; Liang, JN; Parry, G; Mueller, RF; Leigh, IM			Connexin 26 mutations in hereditary non-syndromic sensorineural deafness	NATURE			English	Article							RECESSIVE DEAFNESS; GENE; EXPRESSION; HOMOLOG	Severe deafness or hearing impairment is the most prevalent inherited sensory disorder, affecting about 1 in 1,000 children(1). Most deafness results from peripheral auditory defects that occur as a consequence of either conductive (outer or middle ear) or sensorineuronal (cochlea) abnormalities. Although a number of mutant genes have been identified that are responsible for syndromic (multiple phenotypic disease) deafness such as Waardenburg syndrome and Usher 1B syndrome(2-4), little is known about the genetic basis of non-syndromic (single phenotypic disease) deafness, Here we study a pedigree containing cases of autosomal dominant deafness and have identified a mutation in the gene encoding the gap-junction protein connexin 26 (Cx26) that segregates with the profound deafness In the family, Cx26 mutations resulting in premature stop codons were also found in three autosomal recessive non-syndromic sensorineuronal deafness pedigrees, genetically linked to chromosome 13q11-12 (DFNB1), where the Cx26 gene is localized. Immunohistochemical staining of human cochlear cells for Cx26 demonstrated high levels of expression. To our knowledge, this is the first nonsyndromic sensorineural autosomal deafness susceptibility gene to be identified, which implicates Cx26 as an important component of the human cochlea.	ST JAMES UNIV HOSP, MOL MED UNIT, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND; UCL, INST LARYNGOL & OTOL, TEMPORAL BONE LAB, LONDON WC1X 8EE, ENGLAND; ST LUKES HOSP, DEPT PAEDIAT, BRADFORD BD5 0NA, W YORKSHIRE, ENGLAND	Saint James's University Hospital; University of Leeds; University of London; University College London	Kelsell, DP (corresponding author), UNIV LONDON QUEEN MARY & WESTFIELD COLL, ST BARTHOLOMEWS & ROYAL LONDON SCH MED & DENT, LONDON E1 2AT, ENGLAND.		Lench, Nicholas/AAB-1791-2021; Kelsell, David P/F-8767-2011	Kelsell, David/0000-0002-9910-7144; Lench, Nicholas/0000-0002-6108-0759	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BEYER EC, 1993, INT REV CYTOL, V137, P231; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; Brown KA, 1996, HUM MOL GENET, V5, P169, DOI 10.1093/hmg/5.1.169; CHAIB H, 1994, HUM MOL GENET, V3, P2219, DOI 10.1093/hmg/3.12.2219; Fitzgerald DA, 1996, BRIT J DERMATOL, V134, P939; GOLIGER JA, 1994, DEV DYNAM, V200, P1, DOI 10.1002/aja.1002000102; GUILFORD P, 1994, HUM MOL GENET, V3, P989, DOI 10.1093/hmg/3.6.989; Kibar Z, 1996, HUM MOL GENET, V5, P543, DOI 10.1093/hmg/5.4.543; KIKUCHI T, 1995, ANAT EMBRYOL, V191, P101, DOI 10.1007/BF00186783; Kumar N M, 1992, Semin Cell Biol, V3, P3; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; MARKEY AC, 1992, BRIT J DERMATOL, V126, P154, DOI 10.1111/j.1365-2133.1992.tb07813.x; Mignon C, 1996, CYTOGENET CELL GENET, V72, P185, DOI 10.1159/000134183; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; RISEK B, 1992, DEVELOPMENT, V116, P639; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; VERBOV J, 1987, BRIT J DERMATOL, V116, P881, DOI 10.1111/j.1365-2133.1987.tb04914.x; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Yeager M, 1996, CURR OPIN STRUC BIOL, V6, P183, DOI 10.1016/S0959-440X(96)80073-X	22	1119	1216	0	49	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 1	1997	387	6628					80	83		10.1038/387080a0	http://dx.doi.org/10.1038/387080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139825				2022-12-28	WOS:A1997WW75800051
J	Colhoun, H; BenShlomo, Y; Dong, W; Bost, L; Marmot, M				Colhoun, H; BenShlomo, Y; Dong, W; Bost, L; Marmot, M			Ecological analysis of collectivity of alcohol consumption in England: Importance of average drinker	BRITISH MEDICAL JOURNAL			English	Article								Objective: To assess whether the average consumption of alcohol is associated with the prevalence of heavy drinking, problem drinking, and abstention in England. Design: Ecological analysis using data from a cross sectional household based survey of English adults. Subjects: Random sample of 32 333 adults from the English population who participated in the 1993 and 1994 health surveys for England. Main outcome measures: Association, expressed as the correlation coefficient, between the regional mean and median alcohol consumption and the regional prevalence of heavy drinking, problem drinking, and abstention. Results: Mean consumption of alcohol in light to moderate drinkers was strongly positively associated with the prevalence of heavy drinking (r = 0.75 in men and r = 0.62 in women for drinking more than 21 and 14 units per week respectively). A similar association was found between median consumption and prevalence of heavy drinking, Abstention was not significantly associated with mean consumption in drinkers (r = 0.08 for men and r = -0.29 for women). Both the median and mean consumption in drinkers were positively associated with the prevalence of problem drinking as defined by the CAGE questionnaire on alcohol use (r = 0.53 for men and r = 0.42 for women for the association with mean consumption). Conclusion: Factors that increase the average consumption of alcohol in the population may result in an increase in the prevalence of heavy drinking and related problems.	UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND	University of Bristol	Colhoun, H (corresponding author), UNIV LONDON UNIV COLL,DEPT EPIDEMIOL & PUBL HLTH,TORRINGTON PL,LONDON WC1E 6BT,ENGLAND.		Marmot, M G/Y-3920-2019; Ben-Shlomo, Yoav/ABD-2004-2021	Marmot, M G/0000-0002-2431-6419; Ben-Shlomo, Yoav/0000-0001-6648-3007; Colhoun, Helen/0000-0002-8345-3288	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bennett N, 1995, HLTH SURVEY ENGLAND; Colhoun H., 1995, HLTH SURVEY ENGLAND; DUFFY JC, 1986, BRIT J ADDICT, V81, P735; Edwards G, 1996, BRIT MED J, V312, P1, DOI 10.1136/bmj.312.7022.1; Edwards G., 1994, ALCOHOL POLICY PUBLI; GODDARD E, 1988, DRINKING ENGLAND WAL; *INT WORK GROUP, 1995, SENS DRINK; Marmot M, 1995, LANCET, V346, P1643, DOI 10.1016/S0140-6736(95)92833-2; MARMOT MG, 1994, BRIT MED J, V303, P565; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MIDANIK L, 1982, BRIT J ADDICT, V77, P357; Nespor K, 1990, Int J Psychosom, V37, P50; ROSE G, 1990, BRIT MED J, V301, P1031, DOI 10.1136/bmj.301.6759.1031; SKOG OJ, 1985, BRIT J ADDICT, V80, P83; THOMAS M, 1994, GEN HOUSEHOLD SURVEY; WILSON P, 1981, STATISTICIAN, V30, P159, DOI 10.2307/2988046; *WORK GROUP ROYAL, 1995, ALC CARD DIS SENS LI	17	36	37	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 19	1997	314	7088					1164	1168		10.1136/bmj.314.7088.1164	http://dx.doi.org/10.1136/bmj.314.7088.1164			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV705	9146389	Green Published			2022-12-28	WOS:A1997WV70500023
J	Weinberger, R; Kerber, F				Weinberger, R; Kerber, F			Planetary nebulae: Understanding the physical and chemical evolution of dying stars	SCIENCE			English	Article							WHITE-DWARFS	Planetary nebulae are one of the few classes of celestial objects that are active in every part of the electromagnetic spectrum. These fluorescing and often dusty expanding gaseous envelopes were recently found to be quite complex in their dynamics and morphology, but refined theoretical models can account for these discoveries. Great progress was also made in understanding the mechanisms that shape the nebulae and the spectra of their central stars. In addition, applications for planetary nebulae have been worked out; for example, they have been used as standard candles for long-range distances and as tracers of the enigmatic dark matter.			Weinberger, R (corresponding author), UNIV INNSBRUCK, INST ASTRON, TECHNIKERSTR 25-8, A-6020 INNSBRUCK, AUSTRIA.							ALLER LH, 1984, PHYSICS THERMAL GASE, P98; ARNABOLDI M, 1995, ESO WORKSH SCI VLT, P232; Balick B, 1996, AM SCI, V84, P342; BOND HE, IN PRESS P INT ASTRO, V180; BOND HE, 1992, SCI HUBBLE SPACE TEL, P139; BORKOWSKI KJ, 1990, ASTROPHYS J, V360, P173, DOI 10.1086/169106; Curtis H.D., 1918, PUBLICATIONS LICK OB, V13, P55; Dorfi EA, 1996, ASTRON ASTROPHYS, V313, P605; Duerbeck HW, 1996, ASTROPHYS J, V468, pL111, DOI 10.1086/310241; Feldmeier JJ, 1996, ASTROPHYS J, V461, pL25, DOI 10.1086/309994; HUGGINS PJ, 1993, P IAU S, V155, P147; IBEN I, 1983, ASTROPHYS J, V264, P605, DOI 10.1086/160631; IBEN I, 1993, P INT ASTRON UNION S, V155, P587; Iben I.  Jr., 1995, Physics Reports, V250, P1, DOI 10.1016/0370-1573(94)00063-9; JACOBY GH, 1990, ASTROPHYS J, V356, P332, DOI 10.1086/168843; JACOBY GH, 1993, P IAU S, V155, P503; KALER JB, 1985, ANNU REV ASTRON ASTR, V23, P89; KERBER F, 1997, 6601 INT ASTR UN; KERBER F, IN PRESS P INT ASTRO, V180; KINGSBURGH RL, 1994, MON NOT R ASTRON SOC, V271, P257, DOI 10.1093/mnras/271.2.257; KWOK S, 1994, PUBL ASTRON SOC PAC, V106, P344, DOI 10.1086/133384; LUTZ JH, 1993, P INT ASTRON UNION S, V155, P19; MELLEMA G, 1995, MON NOT R ASTRON SOC, V273, P401, DOI 10.1093/mnras/273.2.401; MENDEZ RH, 1988, ASTRON ASTROPHYS, V190, P113; MESSIER CMESS, 1784, CONNAISS TEMPS; NAPIWOTZKI R, 1993, THESIS C ALBRECHTS U; ODell CR, 1996, ASTRON J, V111, P1630, DOI 10.1086/117902; PEQUIGNOT D, IN PRESS P INT ASTRO, V180; PERINOTTO M, 1993, IAU S, V155, P57; Rasio FA, 1996, ASTROPHYS J, V471, P366, DOI 10.1086/177975; RAUCH T, 1994, ASTRON ASTROPHYS, V286, P543; SAKURAI Y, 1996, 6328 INT ASTR UN; SAKURAI Y, 1996, 6325 INT ASTR UN; SHAPLEY H, 1918, OBSERVATORY, V41, P318; TWEEDY RW, 1994, ASTRON J, V108, P978, DOI 10.1086/117127; VANGENDEREN AM, 1995, ASTRON ASTROPHYS, V294, P453; WEIDEMANN V, 1990, ANNU REV ASTRON ASTR, V28, P103; WEINBERGER R, 1993, P INT ASTRON UNION S, V155; WERNER K, 1994, ASTRON ASTROPHYS, V284, pL5; WERNER K, 1991, ASTRON ASTROPHYS, V247, P476; Xilouris KM, 1996, ASTRON ASTROPHYS, V310, P603; 1995, SKY TELESCOPE, V90, P35	42	5	5	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1382	1386		10.1126/science.276.5317.1382	http://dx.doi.org/10.1126/science.276.5317.1382			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9161999				2022-12-28	WOS:A1997XB53300040
J	Zhang, ZJ; Kundu, GC; Yuan, CJ; Ward, JM; Lee, EJ; DeMayo, F; Westphal, H; Mukherjee, AB				Zhang, ZJ; Kundu, GC; Yuan, CJ; Ward, JM; Lee, EJ; DeMayo, F; Westphal, H; Mukherjee, AB			Severe fibronectin-deposit renal glomerular disease in mice lacking uteroglobin	SCIENCE			English	Article							GENE-EXPRESSION; PROTEIN; RABBIT; BINDING; GLOMERULONEPHRITIS; TRANSGLUTAMINASE; ANTIGENICITY; PROLACTIN; REGION; FAMILY	Despite myriads of biological activities ascribed to uteroglobin (UG), a steroid-inducible secreted protein, its physiological functions are unknown. Mice in which the uteroglobin gene was disrupted had severe renal disease that was associated with massive glomerular deposition of predominantly multimeric fibronectin (Fn), The molecular mechanism that normally prevents Fn deposition appears to involve high-affinity binding of UG with Fn to form Fn-UG heteromers that counteract Fn self-aggregation,which is required for abnormal tissue deposition, Thus, UG is essential for maintaining normal renal function in mice, which raises the possibility that an analogous pathogenic mechanism may underlie genetic Fn-deposit human glomerular disease.	NICHHD,SECT DEV GENET,HERITABLE DISORDERS BRANCH,NIH,BETHESDA,MD 20892; NCI,VET & TUMOR PATHOL SECT,OFF LAB ANIM SCI,FREDERICK,MD 21702; NICHHD,LAB MAMMALIAN GENET & DEV,NIH,BETHESDA,MD 20892; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Baylor College of Medicine			Kundu, Gopal C./ABA-9897-2020		NHLBI NIH HHS [HL47620] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047620] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aoki A, 1996, MOL HUM REPROD, V2, P489, DOI 10.1093/molehr/2.7.489; ASSMANN KJM, 1995, AM J KIDNEY DIS, V25, P781, DOI 10.1016/0272-6386(95)90555-3; BEATO M, 1976, J STEROID BIOCHEM, V7, P327, DOI 10.1016/0022-4731(76)90091-1; BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; CHILTON BS, 1988, MOL ENDOCRINOL, V2, P1169, DOI 10.1210/mend-2-12-1169; Gemperle O, 1996, AM J KIDNEY DIS, V28, P668, DOI 10.1016/S0272-6386(96)90247-4; GILLNER M, 1988, J STEROID BIOCHEM, V31, P27, DOI 10.1016/0022-4731(88)90201-4; GONZALEZ KD, 1995, FEBS LETT, V361, P255, DOI 10.1016/0014-5793(95)00167-8; HYNES RO, 1991, FIBRONECTINS; JACKSON PJ, 1988, J CHROMATOGR, V452, P359, DOI 10.1016/S0021-9673(01)81460-6; KIKUKAWA T, 1989, MOL CELL ENDOCRINOL, V62, P177, DOI 10.1016/0303-7207(89)90004-X; KOLLER BH, 1992, ANNU REV IMMUNOL, V10, P705, DOI 10.1146/annurev.iy.10.040192.003421; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; Kundu GC, 1996, P NATL ACAD SCI USA, V93, P2915, DOI 10.1073/pnas.93.7.2915; LEVIN SW, 1986, LIFE SCI, V38, P1813, DOI 10.1016/0024-3205(86)90135-9; MAGDALENO SM, IN PRESS AM J PHYSL; MAZZUCCO G, 1992, HUM PATHOL, V23, P63, DOI 10.1016/0046-8177(92)90013-S; MIELE L, 1987, ENDOCR REV, V8, P474, DOI 10.1210/edrv-8-4-474; MIELE L, 1994, J ENDOCRINOL INVEST, V17, P679, DOI 10.1007/BF03349687; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; MUKHERJEE AB, 1982, AM J REPROD IMMUNOL, V2, P135, DOI 10.1111/j.1600-0897.1982.tb00154.x; MUKHERJEE DC, 1983, SCIENCE, V219, P989, DOI 10.1126/science.6130601; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; OH E, 1981, P NATL ACAD SCI-BIOL, V78, P3218, DOI 10.1073/pnas.78.5.3218; PERI A, 1995, J CLIN INVEST, V96, P343, DOI 10.1172/JCI118040; PERI A, 1993, J CLIN INVEST, V92, P2099, DOI 10.1172/JCI116810; RANDALL GW, 1991, J REPROD FERTIL, V91, P249, DOI 10.1530/jrf.0.0910249; RAY MK, 1993, BIOCHEM BIOPH RES CO, V197, P163, DOI 10.1006/bbrc.1993.2455; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SINGH G, 1988, BIOCHIM BIOPHYS ACTA, V950, P329, DOI 10.1016/0167-4781(88)90129-7; STROM EH, 1995, KIDNEY INT, V48, P163, DOI 10.1038/ki.1995.280; VASANTHAKUMAR G, 1988, BIOCHEM PHARMACOL, V37, P389, DOI 10.1016/0006-2952(88)90204-3; Watson MA, 1996, CANCER RES, V56, P860; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Zhang QH, 1996, J BIOL CHEM, V271, P33284, DOI 10.1074/jbc.271.52.33284; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447; Zhang Z., UNPUB; Zhang ZJ, 1997, DNA CELL BIOL, V16, P73, DOI 10.1089/dna.1997.16.73	42	114	128	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1408	1412		10.1126/science.276.5317.1408	http://dx.doi.org/10.1126/science.276.5317.1408			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9162006				2022-12-28	WOS:A1997XB53300047
J	Benhorin, J; Medina, A				Benhorin, J; Medina, A			Congenital long-QT syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Benhorin, J (corresponding author), BIKUR CHOLIM HOSP,IL-91004 JERUSALEM,ISRAEL.			Medina, Aharon/0000-0002-0274-1406					0	15	15	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	1997	336	22					1568	1568		10.1056/NEJM199705293362205	http://dx.doi.org/10.1056/NEJM199705293362205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB087	9164813				2022-12-28	WOS:A1997XB08700005
J	Ahissar, M; Hochstein, S				Ahissar, M; Hochstein, S			Task difficulty and the specificity of perceptual learning	NATURE			English	Article							VISUAL-CORTEX; ORIENTATION; DISCRIMINATION; INFORMATION; VISION	Practising simple visual tasks leads to a dramatic improvement in performing them. This learning is specific to the stimuli used for training. We show here that the degree of specificity depends on the difficulty of the training conditions. We find that the pattern of specificities maps onto the pattern of receptive held selectivities along the visual pathway. With easy conditions, learning generalizes across orientation and retinal position, matching the spatial generalization of higher visual areas. As task difficulty increases, learning becomes more specific with respect to both orientation and position, matching the fine spatial retinotopy exhibited by lower areas. Consequently, we enjoy the benefits of learning generalization when possible, and of fine grain but specific training when necessary. The dynamics of learning show a corresponding feature. Improvement begins with easy cases (when the subject is allowed long processing times) and only subsequently proceeds to harder cases. This learning cascade implies that easy conditions guide the learning of hard ones. Taken together, the specificity and dynamics suggest that learning proceeds as a countercurrent along the cortical hierarchy. Improvement begins at higher generalizing levels, which, in turn, direct harder-condition learning to the subdomain of their lower-level inputs. As predicted by this reverse hierarchy model, learning can be effective using only difficult trials, but on condition that learning onset has previously been enabled, A single prolonged presentation suffices to initiate learning. We call this single-encounter enabling effect 'eureka'.	HEBREW UNIV JERUSALEM,INST LIFE SCI,CTR NERUAL COMPUTAT,DEPT NEUROBIOL,IL-91904 JERUSALEM,ISRAEL; WEIZMANN INST SCI,DEPT NEUROBIOL,CTR HIGHER BRAIN FUNCT,IL-76100 REHOVOT,ISRAEL	Hebrew University of Jerusalem; Weizmann Institute of Science				Ahissar, Merav/0000-0001-7694-8111				AHISSAR M, 1993, P NATL ACAD SCI USA, V90, P5718, DOI 10.1073/pnas.90.12.5718; Ahissar M, 1996, VISION RES, V36, P3487, DOI 10.1016/0042-6989(96)00036-3; Ahissar M, 1996, INVEST OPHTH VIS SCI, V37, P3183; BALL K, 1982, SCIENCE, V218, P697, DOI 10.1126/science.7134968; BEARD BL, 1995, VISION RES, V35, P1679, DOI 10.1016/0042-6989(94)00267-P; BERARDI N, 1987, J PHYSIOL-LONDON, V384, P633, DOI 10.1113/jphysiol.1987.sp016474; Desimone R., 1989, HDB NEUROPSYCHOLOGY, P267; DILL M, IN PRESS PERCEPT PSY; FAHLE M, 1993, VISION RES, V33, P397, DOI 10.1016/0042-6989(93)90094-D; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FIORENTINI A, 1981, VISION RES, V21, P1149, DOI 10.1016/0042-6989(81)90017-1; JULESZ B, 1981, NATURE, V290, P91, DOI 10.1038/290091a0; KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966; KARNI A, 1993, NATURE, V365, P250, DOI 10.1038/365250a0; LIU Z, 1995, 95177 NEC; MILLER J, 1988, J EXP PSYCHOL HUMAN, V14, P453, DOI 10.1037/0096-1523.14.3.453; NAKAYAMA K, 1991, VISION CODING EFFICI, P411; NAZIR T A, 1990, Spatial Vision, V5, P81, DOI 10.1163/156856890X00011; Papathomas TV, 1996, INVEST OPHTH VIS SCI, V37, P2415; POGGIO T, 1992, SCIENCE, V256, P1018, DOI 10.1126/science.1589770; RAMACHANDRAN VS, 1973, PERCEPTION, V2, P371, DOI 10.1068/p020371; Rubin N, 1996, INVEST OPHTH VIS SCI, V37, P859; SCHOUPS AA, 1995, J PHYSIOL-LONDON, V483, P797, DOI 10.1113/jphysiol.1995.sp020623; Schoups AA, 1996, P NATL ACAD SCI USA, V93, P7358, DOI 10.1073/pnas.93.14.7358; TREISMAN A, 1992, AM J PSYCHOL, V105, P341, DOI 10.2307/1423032; Treisman A, 1996, CURR OPIN NEUROBIOL, V6, P171, DOI 10.1016/S0959-4388(96)80070-5; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; TSOTSOS JK, 1990, BEHAV BRAIN SCI, V13, P423, DOI 10.1017/S0140525X00079577; ULLMAN S, 1995, CEREB CORTEX, V5, P1, DOI 10.1093/cercor/5.1.1; VOGELS R, 1985, VISION RES, V25, P1679, DOI 10.1016/0042-6989(85)90140-3	30	571	582	5	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					401	406		10.1038/387401a0	http://dx.doi.org/10.1038/387401a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XA496	9163425				2022-12-28	WOS:A1997XA49600060
J	Kozarsky, KF; Donahee, MH; Rigotti, A; Iqbal, SN; Edelman, ER; Krieger, M				Kozarsky, KF; Donahee, MH; Rigotti, A; Iqbal, SN; Edelman, ER; Krieger, M			Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels	NATURE			English	Article							HIGH-DENSITY-LIPOPROTEIN; SELECTIVE UPTAKE; GENE-TRANSFER; A-I; RAT; HYPERCHOLESTEROLEMIA; HEPATOCYTES; MICE; ADENOVIRUSES; METABOLISM	The risk of atherosclerosis, a leading cause of cardiovascular disease and death, is inversely related to plasma levels of high-density lipoprotein (HDL) cholesterol, although the mechanism of this protective effect is unclear(1). The class B scavenger receptor, SR-BI, is the first HDL receptor to be well defined at a molecular level and is a mediator of selective cholesterol uptake in vitro(2). It is expressed most abundantly in steroidogenic tissues, where it is coordinately regulated with steroidogenesis by adrenocorticotropic hormone (ACTH), human chorionic gonadotropin (hCG) and oestrogen, and in the liver, where its expression in rats is suppressed by oestrogen(3,4). Here we show that adenovirus-mediated, hepatic overexpression of SR-BI in mice on both sinusoidal and canalicular surfaces of hepatocytes results in the virtual disappearance of plasma HDL and a substantial increase in biliary cholesterol, SR-BI may directly mediate these effects by increasing hepatic HDL cholesterol uptake or by increasing cholesterol secretion into bile, or both, These results indicate that SR-BI may be important in hepatic HDL metabolism, in determining plasma HDL concentrations, and in controlling cholesterol concentrations in bile, and thus may influence the development and progression of atherosclerosis and gallstone disease.	UNIV PENN,MED CTR,DEPT MOL & CELLULAR ENGN,PHILADELPHIA,PA 19104; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,MIT,DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139	University of Pennsylvania; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT)	Kozarsky, KF (corresponding author), UNIV PENN,MED CTR,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104, USA.		Eckhardt, Erik/G-1567-2010					Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BOTHAM KM, 1995, PROG LIPID RES, V34, P71, DOI 10.1016/0163-7827(94)00007-9; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAREY MC, 1996, BILE ACIDS CHOLESTAS, P147; DELPOZO R, 1983, BIOCHIM BIOPHYS ACTA, V753, P164, DOI 10.1016/0005-2760(83)90004-8; DOMINGO N, 1992, J LIPID RES, V33, P1419; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KOZARSKY K, 1993, SOMAT CELL MOLEC GEN, V19, P449, DOI 10.1007/BF01233250; Kozarsky KF, 1996, NAT GENET, V13, P54, DOI 10.1038/ng0596-54; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LEITERSDORF E, 1984, BIOCHIM BIOPHYS ACTA, V796, P72, DOI 10.1016/0005-2760(84)90240-6; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1989, J LIPID RES, V30, P1041; Rigotti Attilio, 1994, V40, P579; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; SEWELL RB, 1983, J LIPID RES, V24, P391; THORNTON JR, 1981, BRIT MED J, V283, P1352, DOI 10.1136/bmj.283.6303.1352; TURLEY SD, 1988, LIVER BIOL PATHOBIOL, P617; ULLOA N, 1987, HEPATOLOGY, V7, P234; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; Ye XH, 1996, J BIOL CHEM, V271, P3639; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	30	603	620	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					414	417		10.1038/387414a0	http://dx.doi.org/10.1038/387414a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163428				2022-12-28	WOS:A1997XA49600063
J	Jacobson, MA; Zegans, M; Pavan, PR; ODonnell, JJ; Sattler, F; Rao, N; Owens, S; Pollard, R				Jacobson, MA; Zegans, M; Pavan, PR; ODonnell, JJ; Sattler, F; Rao, N; Owens, S; Pollard, R			Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy	LANCET			English	Article							CELLS; AIDS; DNA	Background In previous natural history studies and clinical trials, AIDS-related cytomegalovirus (CMV) retinitis has occurred primarily in patients with absolute CD4 counts of 50 cells/mu L or less (0.05x10(9)/L) at the time of diagnosis. Methods We report five patients identified from our clinical practices who were diagnosed with CMV retinitis while their CD4 counts were above 195 cells/mu L. We also analysed, based on CD4 counts, 76 AIDS patients with newly diagnosed CMV retinitis whose CD4 lymphocyte enumerations were done in laboratories that maintained certification in a common external quality control programme. Findings 5-24 weeks before retinitis was diagnosed, all five patients had had absolute CD4 lymphocyte counts of less than 85 cells/mu L, and 4-7 weeks before diagnosis, all five patients had started taking highly active antiretroviral treatment (HAART) regimens. Only one (4%) of 27 patients enrolled in the trial between July, 1995, and February, 1996, had an absolute CD4 count of more than 50 cells/mu L, and none of 27 had an absolute CD4 count of more than 100/mu L on entry to the trial. However, from March, 1996 (when indinavir and ritonavir were approved by the FDA for marketing in the USA), to August, 1996, 14 (29%) of 49 patients had CD4 counts of more than 50/mu L and seven (14%) of 49 had a CD4 count of more than 100 cells/mu L on entry. Interpretation These findings suggest that the early immunological effects of HAART may not provide sufficient protection to prevent CMV retinitis in patients who have very low CD4 counts when therapy is started. Clinicians should note that CMV retinitis may now occur in patients who have CD4 counts of more than 100 cells/mu L.	UNIV CALIF SAN FRANCISCO,DEPT OPHTHALMOL,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,FRANCIS I PROCTOR FDN,SAN FRANCISCO,CA 94143; UNIV S FLORIDA,DEPT OPHTHALMOL,TAMPA,FL; UNIV SO CALIF,DEPT MED,LOS ANGELES,CA; UNIV SO CALIF,DEPT OPHTHALMOL,LOS ANGELES,CA; UNIV SO CALIF,LOS ANGELES CTY MED CTR,LOS ANGELES,CA 90033; FRONTIER SCI,BUFFALO,NY; UNIV TEXAS,DEPT MED,GALVESTON,TX	University of California System; University of California San Francisco; University of California System; University of California San Francisco; State University System of Florida; University of South Florida; University of Southern California; University of Southern California; University of Southern California; University of Texas System; University of Texas Medical Branch Galveston	Jacobson, MA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,995 POTRERO,SAN FRANCISCO,CA 94110, USA.		Pavan, Peter/B-6473-2013		NIAID NIH HHS [P30-AI27663, U01-AI27663] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027663] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAMERON B, 1996, 3 C RETR OPP INF WAS; *CHIR GANC IMPL ST, 1995, 2 NAT C HUM RETR REL; DREW WL, 1995, NEW ENGL J MED, V333, P615, DOI 10.1056/NEJM199509073331002; GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223; HANSEN KK, 1994, J INFECT DIS, V170, P1271, DOI 10.1093/infdis/170.5.1271; HIRSCH M, 1997, 4 C RETR OPP INF WAS; PASTERNACK MS, 1990, REV INFECT DIS, V12, pS720; RASMUSSEN L, 1995, J INFECT DIS, V171, P177, DOI 10.1093/infdis/171.1.177; ROOK AH, 1985, J INFECT DIS, V152, P627, DOI 10.1093/infdis/152.3.627; Shinkai M, 1997, J INFECT DIS, V175, P302, DOI 10.1093/infdis/175.2.302; SPECTOR SA, 1996, 11 INT C AIDS VANC; Streilein JW, 1996, OCULAR INFECT IMMUNI, P19; *STUD OC COMPL AID, 1994, OPHTHALMOLOGY, V101, P1250; *STUD OC COMPL AID, 1992, NEW ENGL J MED, V326, P213	14	335	349	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 17	1997	349	9063					1443	1445		10.1016/S0140-6736(96)11431-8	http://dx.doi.org/10.1016/S0140-6736(96)11431-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164318				2022-12-28	WOS:A1997WZ76500012
J	Beckerman, JL; Naider, F; Ebbole, DJ				Beckerman, JL; Naider, F; Ebbole, DJ			Inhibition of pathogenicity of the rice blast fungus by Saccharomyces cerevisiae alpha-factor	SCIENCE			English	Article							MAGNAPORTHE-GRISEA; MATING PHEROMONES; YEAST	Magnaporthe grisea is a fungal pathogen with two mating types, MAT1-1 and MAT1-2, that forms a specialized cell necessary for pathogenesis, the appressorium, Saccharomyces cerevisiae alpha-factor pheromone blocked appressorium formation in a mating type-specific manner and protected plants from infection by MAT1-2 strains. Experiments with alpha-factor analogs suggest that the observed activity is due to a specific interaction of alpha-factor with an M. grisea receptor. Culture filtrates of a MAT1-1 strain contained an activity that inhibited appressorium formation of mating type MAT1-2 strains. These findings provide evidence that a pheromone response pathway exists in M. grisea that can be exploited for plant protection.	TEXAS A&M UNIV,DEPT PLANT PATHOL & MICROBIOL,COLLEGE STN,TX 77843; CUNY COLL STATEN ISL,DEPT CHEM,STATEN ISL,NY 10314	Texas A&M University System; Texas A&M University College Station; City University of New York (CUNY) System; College of Staten Island (CUNY)					NIGMS NIH HHS [R29GM47977, GM22086] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047977, R56GM022086, R01GM022086] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER J, R29GM47977 USPHS TEX; BECKER J, GM22086 USPHS FN TEX; Beckerman JL, 1996, MOL PLANT MICROBE IN, V9, P450, DOI 10.1094/MPMI-9-0450; GARIBALDI JA, 1955, J AM CHEM SOC, V77, P2429, DOI 10.1021/ja01614a021; HAMER JE, 1988, SCIENCE, V239, P288, DOI 10.1126/science.239.4837.288; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HISATOMI T, 1988, CURR GENET, V13, P25, DOI 10.1007/BF00365752; HOWARD RJ, 1991, P NATL ACAD SCI USA, V88, P11281, DOI 10.1073/pnas.88.24.11281; HOWARD RJ, 1994, RICE BLAST DISEASE, P3; KANG SC, 1994, GENETICS, V138, P289; LEE YH, 1993, PLANT CELL, V5, P693, DOI 10.1105/tpc.5.6.693; LOUMAYE E, 1982, SCIENCE, V218, P1323, DOI 10.1126/science.6293058; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; MCCULLOUGH J, 1979, J BACTERIOL, V138, P146, DOI 10.1128/JB.138.1.146-154.1979; Nelson MA, 1996, TRENDS GENET, V12, P69, DOI 10.1016/0168-9525(96)81403-X; RATHS SK, 1988, J BIOL CHEM, V263, P17333; VALENT B, 1990, PHYTOPATHOLOGY, V80, P33, DOI 10.1094/Phyto-80-33; XUE CB, 1989, BIOCHEM BIOPH RES CO, V162, P253, DOI 10.1016/0006-291X(89)91989-X	18	30	34	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 16	1997	276	5315					1116	1119		10.1126/science.276.5315.1116	http://dx.doi.org/10.1126/science.276.5315.1116			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9148806				2022-12-28	WOS:A1997WZ22500045
J	Coulehan, J				Coulehan, J			The man with stars inside	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								Public opinion polls show that a large percentage of persons in the United States currently favor the legalization of professionally assisted death. This support reflects widespread fear and confusion over the tortuously prolonged and painful process of dying countenanced by contemporary medicine. Physician-assisted suicide and euthanasia are complex moral issues. The current drive to translate them into debates about ''rights'' and public policy is curious: Does the energy directed toward ''palliation-by-death'' mean that our society is more compassionate now, or more just, than in the past? To the contrary, I believe that the movement toward assisted death reflects inadequate palliative care, poor patient-physician communication, great confusion about the right to refuse treatment, and profound inequity in U.S. health care. Legalization of assisted death diverts us from addressing these problems. Palliation-by-death will drive us farther apart, not closer together.			Coulehan, J (corresponding author), SUNY STONY BROOK, HLTH SCI CTR L3 092, INST MED CONTEMPORARY SOC, STONY BROOK, NY 11794 USA.								0	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1997	126	10					799	802		10.7326/0003-4819-126-10-199705150-00010	http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ823	9148654				2022-12-28	WOS:A1997WZ82300010
J	Schrag, D; Kuntz, KM; Garber, JE; Weeks, JC				Schrag, D; Kuntz, KM; Garber, JE; Weeks, JC			Decision analysis - Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL-OVARIAN-CANCER; PRIMARY BREAST-CANCER; COST-EFFECTIVENESS; FOLLOW-UP; SUBCUTANEOUS MASTECTOMY; ADJUVANT THERAPY; CARRIERS; EFFICACY; TRIAL; RISK	Background Women with BRCA1 or BRCA2 mutations have an increased risk of breast cancer and ovarian cancer. Prophylactic mastectomy and oophorectomy are often considered as ways of reducing these risks, but the effect of the procedures on life expectancy has not been established. Methods In a decision analysis, we compared prophylactic mastectomy and prophylactic oophorectomy with no prophylactic surgery among women who carry mutations in the BRCA1 or BRCA2 gene. We used available data about the incidence of cancer, the prognosis for women with cancer, and the efficacy of prophylactic mastectomy and oophorectomy in preventing breast and ovarian cancer to estimate the effects of these interventions on life expectancy among women with different levels of risk of cancer. Results We calculated that, on average, 30-year-old women who carry BRCA1 or BRCA2 mutations gain from 2.9 to 5.3 years of life expectancy from prophylactic mastectomy and from 0.3 to 1.7 years of life expectancy from prophylactic oophorectomy, depending on their cumulative risk of cancer. Gains in life expectancy decline with age at the time of prophylactic surgery and are minimal for 60-year-old women. Among 30-year-old women, oophorectomy may be delayed 10 years with little loss of life expectancy. Conclusions On the basis of a range of estimates of the incidence of cancer, prognosis, and efficacy of prophylactic surgery, our model suggests that prophylactic mastectomy provides substantial gains in life expectancy and prophylactic oophorectomy more limited gains for young women with BRCA1 or BRCA2 mutations. (C) 1997, Massachusetts Medical Society.	DANA FARBER CANC INST, CTR OUTCOMES & POLICY RES, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DIV CANC EPIDEMIOL & CONTROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, CLIN EPIDEMIOL SECT, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital								ABE O, 1992, LANCET, V339, P71; BONADONNA G, 1995, NEW ENGL J MED, V332, P901, DOI 10.1056/NEJM199504063321401; BOURNE TH, 1991, GYNECOL ONCOL, V43, P92, DOI 10.1016/0090-8258(91)90051-6; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; DELTURCO MR, 1994, JAMA-J AM MED ASSOC, V271, P1593, DOI 10.1001/jama.1994.03510440053032; EASTON DF, 1995, AM J HUM GENET, V56, P265; Eisinger F, 1996, CANCER RES, V56, P471; ELDAR S, 1984, AM J SURG, V148, P692, DOI 10.1016/0002-9610(84)90352-0; FISHER B, 1995, NEW ENGL J MED, V333, P1456, DOI 10.1056/NEJM199511303332203; FORD D, 1995, AM J HUM GENET, V57, P1457; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; GHEZZI P, 1994, JAMA-J AM MED ASSOC, V271, P1587, DOI 10.1001/jama.1994.03510440047031; GREENWALD P, 1978, NEW ENGL J MED, V299, P271, DOI 10.1056/NEJM197808102990602; GROSS TP, 1994, OBSTET GYNECOL, V83, P419; HILLNER BE, 1991, NEW ENGL J MED, V324, P160, DOI 10.1056/NEJM199101173240305; HILLNER BE, 1992, JAMA-J AM MED ASSOC, V267, P2055, DOI 10.1001/jama.267.15.2055; HOLLENBERG JP, 1985, SSMLTREE ALL PURPOSE; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KING MC, 1993, JAMA-J AM MED ASSOC, V269, P1975, DOI 10.1001/jama.269.15.1975; KOSARY CL, 1995, NIH PUBLICATION; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; Neuhausen SL, 1996, AM J HUM GENET, V58, P271; PENNISI VR, 1989, AESTHET PLAST SURG, V13, P15, DOI 10.1007/BF01570320; Phelan CM, 1996, NAT GENET, V12, P309, DOI 10.1038/ng0396-309; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P582; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P2751, DOI 10.1002/1097-0142(19930501)71:9<2751::AID-CNCR2820710911>3.0.CO;2-J; PORTER DE, 1993, LANCET, V341, P184, DOI 10.1016/0140-6736(93)90052-I; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; Rubin SC, 1996, NEW ENGL J MED, V335, P1413, DOI 10.1056/NEJM199611073351901; SMITH TJ, 1993, J CLIN ONCOL, V11, P771, DOI 10.1200/JCO.1993.11.4.771; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; STEFANEK ME, 1995, NCI MONOGRAPHS, V17, P37; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; STRUEWING JP, 1995, NCI MONOGRAPHS, V17, P33; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; TSEVAT J, 1991, CIRCULATION, V84, P2610; Whittemore AS, 1997, AM J HUM GENET, V60, P496; YOUNG RC, 1990, NEW ENGL J MED, V322, P1021, DOI 10.1056/NEJM199004123221501; ZIEGLER LD, 1991, AM J CLIN ONCOL-CANC, V14, P451, DOI 10.1097/00000421-199110000-00018	43	311	316	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 15	1997	336	20					1465	1471		10.1056/NEJM199705153362022	http://dx.doi.org/10.1056/NEJM199705153362022			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY577	9148160				2022-12-28	WOS:A1997WY57700032
J	Voth, EA; Schwartz, RH				Voth, EA; Schwartz, RH			Medicinal applications of delta-9-tetrahydrocannabinol and marijuana	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RECEIVING CANCER-CHEMOTHERAPY; SMOKING MARIJUANA; CANNABIS DEPENDENCE; COGNITIVE FUNCTIONS; MARIHUANA USE; FETAL GROWTH; COCAINE USE; DRUG-USE; TOBACCO; SMOKERS	The use of crude marijuana for herbal medicinal applications is now being widely discussed in both the medical and lay literature. Ballot initiatives in California and Arizona have recently made crude marijuana accessible to patients under certain circumstances. As medicinal applications of pure forms of delta-9-tetrahydrocannabinol (THC) and crude marijuana are being considered, the most promising uses of a ny form of THC are to counteract the nausea associated with cancer chemotherapy and to stimulate appetite. We evaluated the relevant research published between 1975 and 1996 on the medical applications, physical complications, and legal precedents for the use of pure THC or crude marijuana. Our review focused on the medical use of THC derivatives for nausea associated with cancer chemotherapy, glaucoma, stimulation of appetite, and spinal cord spasticity. Despite the toxicity of THC delivered in any form, evidence supports the selective use of pure THC preparations to treat nausea associated with cancer chemotherapy and to stimulate appetite. The evidence does not support the reclassification of crude marijuana as a prescribable medicine.	UNIV KANSAS, SCH MED, KANSAS CITY, KS USA; FAIRFAX HOSP, FALLS CHURCH, VA 22046 USA	University of Kansas; University of Kansas Medical Center; Inova Fairfax Hospital	Voth, EA (corresponding author), INT DRUG STRATEGY INST, 901 GARFIELD, TOPEKA, KS 66606 USA.							BARBERS RG, 1987, AM REV RESPIR DIS, V135, P1271; BEAL JE, 1995, J PAIN SYMPTOM MANAG, V10, P89, DOI 10.1016/0885-3924(94)00117-4; BLOCK RI, 1986, INT J ADDICT, V21, P281, DOI 10.3109/10826088609063457; BONNER R, 1992, FED REGISTER, V10, P499; BROOKOFF D, 1993, AM J PUBLIC HEALTH, V83, P369, DOI 10.2105/AJPH.83.3.369; CABRAL GA, 1992, P SOC EXP BIOL MED, V199, P255; CABRAL GA, 1993, CANNABIS: PHYSIOPATHOLOGY, EPIDEMIOLOGY, DETECTION, P137; CHANG AE, 1979, ANN INTERN MED, V91, P819, DOI 10.7326/0003-4819-91-6-819; *COMM DRUG AB COUN, 1987, AM J PSYCHIAT, V144, P698; COMPTON D R, 1990, Advances in Alcohol and Substance Abuse, V9, P129; DAHL RE, 1995, ARCH PEDIAT ADOL MED, V149, P145, DOI 10.1001/archpedi.1995.02170140027004; DAY NL, 1994, NEUROTOXICOL TERATOL, V16, P169, DOI 10.1016/0892-0362(94)90114-7; DOBLIN RE, 1991, J CLIN ONCOL, V9, P1314, DOI 10.1200/JCO.1991.9.7.1314; EKERT H, 1979, MED J AUSTRALIA, V2, P657, DOI 10.5694/j.1326-5377.1979.tb127271.x; ELSOHLY MA, 1984, CURR EYE RES, V3, P841, DOI 10.3109/02713688409000797; ELSOHLY MA, 1981, J CLIN PHARMACOL, V21, pS472, DOI 10.1002/j.1552-4604.1981.tb02627.x; FLEISHER M, 1991, ANN INTERN MED, V115, P576; FLIGIEL SEG, 1988, J PSYCHOACTIVE DRUGS, V20, P33, DOI 10.1080/02791072.1988.10524369; FRIED PA, 1995, LIFE SCI, V56, P2159, DOI 10.1016/0024-3205(95)00203-I; FRIED PA, 1984, AM J OBSTET GYNECOL, V150, P23, DOI 10.1016/S0002-9378(84)80103-9; FRIED PA, 1980, DRUG ALCOHOL DEPEN, V6, P415, DOI 10.1016/0376-8716(80)90023-X; FRYTAK S, 1979, ANN INTERN MED, V91, P825, DOI 10.7326/0003-4819-91-6-825; GEROSTAMOULOS J, 1993, J FORENSIC SCI, V38, P649; GJERDE H, 1991, FORENSIC SCI INT, V50, P57, DOI 10.1016/0379-0738(91)90133-4; Gralla RJ, 1982, P AN M AM SOC CLIN, V1, P58; GREENBERG HS, 1994, CLIN PHARMACOL THER, V55, P324, DOI 10.1038/clpt.1994.33; GRINSPOON L, 1995, JAMA-J AM MED ASSOC, V273, P1875, DOI 10.1001/jama.273.23.1875; GRINSPOON L, 1993, FORBIDDEN MED; GROSS G, 1991, DERMATOLOGICA, V183, P203, DOI 10.1159/000247670; HINDRICK WJ, 1993, 808078 DOT HS US DEP; HINGSON R, 1982, PEDIATRICS, V70, P539; JURGENSEN K, 1995, US TODAY        0718, pA14; KAPLAN HB, 1986, J HEALTH SOC BEHAV, V27, P44, DOI 10.2307/2136502; KIPLINGER GF, 1971, CLIN PHARMACOL THER, V12, P650; KIRBY JM, 1992, SOUTHERN MED J, V85, P800, DOI 10.1097/00007611-199208000-00003; KLINE J, 1987, INT J EPIDEMIOL, V16, P44, DOI 10.1093/ije/16.1.44; KLUINNELEMAN JC, 1979, VET HUM TOXICOL, V21, P338; LANE M, 1991, J PAIN SYMPTOM MANAG, V6, P352, DOI 10.1016/0885-3924(91)90026-Z; LEIRER VO, 1993, CANNABIS: PHYSIOPATHOLOGY, EPIDEMIOLOGY, DETECTION, P47; LEONCARRION J, 1990, PSYCHOL REP, V67, P947, DOI 10.2466/pr0.1990.67.3.947; Levitt M, 1984, P AN M AM SOC CLIN, V3, P91; LUCAS VS, 1980, JAMA-J AM MED ASSOC, V243, P1241, DOI 10.1001/jama.243.12.1241; Martin BR, 1997, DRUG ABUSE IN THE DECADE OF THE BRAIN, P139; MARZUK PM, 1990, JAMA-J AM MED ASSOC, V263, P250, DOI 10.1001/jama.263.2.250; MATHERS DC, 1992, BRIT J PSYCHIAT, V161, P648, DOI 10.1192/bjp.161.5.648; MATTES RD, 1994, PHARMACOL BIOCHEM BE, V49, P187, DOI 10.1016/0091-3057(94)90475-8; McLaughlin M A, 1985, J Ocul Pharmacol, V1, P101, DOI 10.1089/jop.1985.1.101; MECHOULAM R, 1987, PROGR MED CHEM, V24; MEINCK HM, 1989, J NEUROL, V236, P120, DOI 10.1007/BF00314410; MERRITT JC, 1980, OPHTHALMOLOGY, V87, P222; MILLER NS, 1989, J SUBST ABUSE TREAT, V6, P241, DOI 10.1016/0740-5472(89)90048-2; MILLER NS, 1989, J SUBST ABUSE TREAT, V6, P183, DOI 10.1016/0740-5472(89)90005-6; MURISON G, 1987, P NATL ACAD SCI USA, V84, P5414, DOI 10.1073/pnas.84.15.5414; MURRAY JB, 1986, J GEN PSYCHOL, V113, P23, DOI 10.1080/00221309.1986.9710540; NAHAS CG, 1993, CANNABIS PHYSIOPATHO, P95; Nelson K, 1994, J Palliat Care, V10, P14; Orr L E, 1980, Arch Intern Med, V140, P1431; Pope HG, 1996, JAMA-J AM MED ASSOC, V275, P521, DOI 10.1001/jama.275.7.521; POSTER DS, 1981, JAMA-J AM MED ASSOC, V245, P2047, DOI 10.1001/jama.245.20.2047; ROBISON LL, 1989, CANCER, V63, P1904; ROSS SA, 1995, J PHARM SCI, V4, P1; Runeckles V.C., 1975, RECENT ADV PHYTOCHEM, P63; SALLAN SE, 1980, NEW ENGL J MED, V302, P135, DOI 10.1056/NEJM198001173020302; SALLAN SE, 1975, NEW ENGL J MED, V293, P795, DOI 10.1056/NEJM197510162931603; SCHWARTZ RH, 1989, AM J DIS CHILD, V143, P1214, DOI 10.1001/archpedi.1989.02150220110030; Schwartz RH, 1997, SOUTH MED J, V90, P167, DOI 10.1097/00007611-199702000-00001; SCHWARTZ RH, 1987, PEDIATR CLIN N AM, V34, P305; Schwartz Richard H., 1994, Journal of Addictive Diseases, V13, P53; SHERMAN MP, 1995, LIFE SCI, V56, P2201, DOI 10.1016/0024-3205(95)00208-N; SODERSTROM CA, 1993, CANNABIS: PHYSIOPATHOLOGY, EPIDEMIOLOGY, DETECTION, P79; SOLOMONS K, 1990, S AFR MED J, V78, P476; SOLOWIJ N, 1995, BIOL PSYCHIAT, V37, P731, DOI 10.1016/0006-3223(94)00178-6; SOLOWIJ N, 1995, LIFE SCI, V56, P2119, DOI 10.1016/0024-3205(95)00197-E; SPECTER SC, 1986, INT J IMMUNOPHARMACO, V8, P741, DOI 10.1016/0192-0561(86)90010-X; TASHKIN DP, 1976, NEW ENGL J MED, V294, P125, DOI 10.1056/NEJM197601152940302; TASHKIN DP, 1988, J PSYCHOACTIVE DRUGS, V20, P21, DOI 10.1080/02791072.1988.10524367; TASHKIN DP, 1987, AM REV RESPIR DIS, V135, P209; TASHKIN DP, 1980, CHEST, V78, P699, DOI 10.1378/chest.78.5.699; TASHKIN DP, 1993, WESTERN J MED, V158, P635; TAYLOR DN, 1982, NEW ENGL J MED, V306, P1249, DOI 10.1056/NEJM198205273062101; UNGERLEIDER JT, 1982, CANCER, V50, P636; UNGERLEIDER JT, 1982, CANCER TREAT REP, V66, P589; VARMA VK, 1988, DRUG ALCOHOL DEPEN, V21, P147, DOI 10.1016/0376-8716(88)90061-0; VINCENT BJ, 1983, DRUGS, V25, P52, DOI 10.2165/00003495-198300251-00006; VINCIGUERRA V, 1988, NEW YORK STATE J MED, V88, P525; VOTH EA, 1994, ANN INTERN MED, V120, P348; WU TC, 1988, NEW ENGL J MED, V318, P347, DOI 10.1056/NEJM198802113180603; YESAVAGE JA, 1985, AM J PSYCHIAT, V142, P1325; YOUNG FL, 1988, 8622 US DEP JUST DRU; ZIMMERMAN S, 1990, INT J ADDICT, V25, P19, DOI 10.3109/10826089009067003; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203	91	121	124	0	41	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1997	126	10					791	798		10.7326/0003-4819-126-10-199705150-00008	http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WZ823	9148653				2022-12-28	WOS:A1997WZ82300009
J	Nigg, EA				Nigg, EA			Nucleocytoplasmic transport: Signals, mechanisms and regulation	NATURE			English	Review							NUCLEAR-PORE COMPLEX; CAP-BINDING-PROTEIN; MESSENGER-RNA; LOCALIZATION SIGNAL; CYTOSOLIC FACTORS; HNRNP A1; IMPORT SUBSTRATE; EXPORT PATHWAY; GTP HYDROLYSIS; YEAST PROTEIN	In eukaryotic organisms, DNA replication and RNA biogenesis occur in the cell nucleus, whereas protein synthesis occurs in the cytoplasm. Integration of these activities depends on selective transport of proteins and ribonucleoprotein particles between the two compartments. Transport across the nuclear envelope occurs through large multiprotein structures, termed nuclear pore complexes. It is signal-mediated and requires both energy and soluble factors, including shuttling carriers. Here I summarize current understanding of nucleocytoplasmic transport and illustrate the importance of regulated transport for signal transduction.			Nigg, EA (corresponding author), UNIV GENEVA, DEPT MOL BIOL, 30 QUAI ERNEST ANSERMET, CH-1211 GENEVA 4, SWITZERLAND.			nigg, erich/0000-0003-4835-5719				ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; AZUMA Y, 1995, P NATL ACAD SCI USA, V92, P5159, DOI 10.1073/pnas.92.11.5159; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bastos R, 1995, INT REV CYTOL, V162B, P257; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; Bullock TL, 1996, J MOL BIOL, V260, P422, DOI 10.1006/jmbi.1996.0411; BUSS F, 1995, J CELL BIOL, V128, P251, DOI 10.1083/jcb.128.3.251; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; Corbett AH, 1996, J BIOL CHEM, V271, P18477, DOI 10.1074/jbc.271.31.18477; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1995, P NATL ACAD SCI USA, V92, P7525, DOI 10.1073/pnas.92.16.7525; DOYE V, 1995, TRENDS GENET, V11, P235, DOI 10.1016/S0168-9525(00)89057-5; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; FELDHERR CM, 1990, ELECTRON MICROSC REV, V3, P73, DOI 10.1016/0892-0354(90)90014-J; FELDHERR CM, 1994, INT REV CYTOL, V151, P183, DOI 10.1016/S0074-7696(08)62633-9; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P4421, DOI 10.1073/pnas.93.9.4421; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P2936, DOI 10.1073/pnas.93.7.2936; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GOLDBERG MW, 1995, CURR OPIN CELL BIOL, V7, P301, DOI 10.1016/0955-0674(95)80083-2; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; GRANDI P, 1995, J CELL BIOL, V130, P1263, DOI 10.1083/jcb.130.6.1263; GRANDI P, 1995, EMBO J, V14, P76, DOI 10.1002/j.1460-2075.1995.tb06977.x; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; KUSSEL P, 1995, J CELL BIOL, V129, P1491, DOI 10.1083/jcb.129.6.1491; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; Lounsbury KM, 1996, J BIOL CHEM, V271, P2357, DOI 10.1074/jbc.271.5.2357; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; MARSHALLSAY C, 1994, EMBO J, V13, P222, DOI 10.1002/j.1460-2075.1994.tb06252.x; MEHLIN H, 1995, J CELL BIOL, V129, P1205, DOI 10.1083/jcb.129.5.1205; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MICHAEL WM, 1995, CELL, V83, P415; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P4318, DOI 10.1073/pnas.92.10.4318; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Nakielny S, 1997, ANNU REV NEUROSCI, V20, P269, DOI 10.1146/annurev.neuro.20.1.269; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; PANTE N, 1994, J STRUCT BIOL, V113, P179, DOI 10.1006/jsbi.1994.1052; Pante N, 1996, SCIENCE, V273, P1729, DOI 10.1126/science.273.5282.1729; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; Pante N, 1995, J CELL SCI, P1; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POKRYWKA NJ, 1995, J BIOL CHEM, V270, P3619, DOI 10.1074/jbc.270.8.3619; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROUT MP, 1993, J CELL BIOL, V123, P771, DOI 10.1083/jcb.123.4.771; Saavedra C, 1996, GENE DEV, V10, P1608, DOI 10.1101/gad.10.13.1608; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SINGLETON DR, 1995, J CELL SCI, V108, P265; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Stutz F, 1996, MOL CELL BIOL, V16, P7144; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; TOROK I, 1995, J CELL BIOL, V129, P1473, DOI 10.1083/jcb.129.6.1473; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	137	919	940	1	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	1997	386	6627					779	787		10.1038/386779a0	http://dx.doi.org/10.1038/386779a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126736				2022-12-28	WOS:A1997WV70600043
J	McDonald, P; Friedman, EHI; Banks, A; Anderson, R; Carman, V				McDonald, P; Friedman, EHI; Banks, A; Anderson, R; Carman, V			Pneumococcal vaccine campaign based in general practice	BRITISH MEDICAL JOURNAL			English	Article							POLYSACCHARIDE VACCINE; HIGH-RISK; PNEUMONIA; EFFICACY; CARE; INFECTIONS; INFLUENZA; AGE	Objective: To show whether a general practice setting is a practical and effective medium for increasing uptake of pneumococcal vaccine. Design: Follow up study of responses of general practices (debriefing by questionnaire or small group session) and patients (questionnaire sent to 429 patients vaccinated in a two week period) to vaccination campaign. Setting and subjects: Patients registered with general practices of one family health services authority. Interventions: Pneumococcal vaccination campaign including clinical guidelines and support materials. Main outcome measures: Proportion of general practitioners offering pneumococcal vaccine; proportion of patients at risk who were vaccinated between 1 May and 31 December 1995; number of splenectomised patients identified and vaccinated in same period; views of patients who were vaccinated. Results: Proportion of general practitioners offering pneumococcal vaccine increased from 17% to 89% during the campaign. Estimated number of patients at risk who were vaccinated increased from 656 (4%) to 5982 (33%) during campaign. Of 61 splenectomised patients identified, 30 had been vaccinated previously and 27 were vaccinated during campaign. Practices in which a general practitioner took or shared the lead had higher vaccination rates and used vaccine up faster. Of the 384 patients whose questionnaires were used in analysis, only 35 had heard of pneumococcal vaccine before the campaign, 198 reported side effects (mostly minor and local, but systemic and severe local reactions were more common than expected), and 337 were pleased they had been vaccinated (only five expressed dissatisfaction). Conclusion: A practice based campaign is an effective method of increasing uptake of pneumococcal vaccine by high risk groups.	W PENNINE HLTH AUTHOR,OLDHAM OL1 2PL,ENGLAND									Aszkenasy O M, 1995, Commun Dis Rep CDR Rev, V5, pR45; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; BLOOM HG, 1988, J AM GERIATR SOC, V36, P897, DOI 10.1111/j.1532-5415.1988.tb05782.x; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; CARTWRIGHT KAV, 1995, INT C S SERIES, V210, P63; CLANCY CM, 1992, J GEN INTERN MED, V7, P14, DOI 10.1007/BF02599095; *DEP HLTH WELSH OF, 1992, IMM INF DIS; FEDSON DS, 1994, ARCH INTERN MED, V154, P2531, DOI 10.1001/archinte.154.22.2531; FEDSON DS, 1982, JAMA-J AM MED ASSOC, V248, P1989; Fedson DS, 1994, VACCINES, P517; FEDSON DS, 1995, INT C S SERIES, V210, P49; GABLE CB, 1990, JAMA-J AM MED ASSOC, V264, P2910, DOI 10.1001/jama.264.22.2910; GEORGE R, 1995, INT C S SERIES, V210, P1; GILLILAND AEW, 1992, FAM PRACT, V9, P441, DOI 10.1093/fampra/9.4.441; GOWDA R, 1995, BRIT MED J, V311, P26, DOI 10.1136/bmj.311.6996.26; HEDLUND JU, 1992, LANCET, V340, P396, DOI 10.1016/0140-6736(92)91473-L; HILLEMAN MR, 1981, REV INFECT DIS, V3, pS31; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; JACOBY LL, 1993, J EXPT PSYCHOL GENER, V2, P1; KLEIN RS, 1983, ARCH INTERN MED, V143, P1878, DOI 10.1001/archinte.143.10.1878; KOIVULA I, 1994, AM J MED, V96, P313, DOI 10.1016/0002-9343(94)90060-4; LINNEMANN CC, 1986, ARCH INTERN MED, V146, P1554, DOI 10.1001/archinte.146.8.1554; MACINNES J, 1995, CDR REV, V12, pR173; MAKELA PH, 1995, INT C S SERIES, V210, P41; MAYOWHITE D, 1994, CARE ELDERLY, P355; MCFARLIN RF, 1995, ABSTR PAP AM CHEM S, V210, P9; NOAH N, 1996, GUIDE PNEUMOCOCCAL V; POLIS M, 1988, ANN EMERG MED, V37, P1016; RODRIGUEZ R, 1993, ANN INTERN MED, V22, P93; ROSE DN, 1993, AM J MED, V94, P161; SHAPIRO ED, 1984, ANN INTERN MED, V101, P325, DOI 10.7326/0003-4819-101-3-325; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; SIMS RV, 1992, AGE AGEING, V21, P357, DOI 10.1093/ageing/21.5.357; SISK JE, 1986, ANN INTERN MED, V104, P79, DOI 10.7326/0003-4819-104-1-79; STEVEN A, 1994, HLTH CARE NEEDS ASSE, V1, P307; STEWART DA, 1995, MMWR-MORBID MORTAL W, V44, P741; TOBACMAN JK, 1992, INFECT CONT HOSP EP, V13, P144; Whitelaw FG, 1996, BRIT J GEN PRACT, V46, P181; WISCHNACK LL, 1995, PEDIATRICS, V95, P350; WRENN K, 1994, J GEN INTERN MED, V9, P425, DOI 10.1007/BF02599056; 1995, MMWR-MORBID MORTAL W, V44, P741; 1995, CARE ELDERLY, V7, P11	42	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 12	1997	314	7087					1094	1098		10.1136/bmj.314.7087.1094	http://dx.doi.org/10.1136/bmj.314.7087.1094			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU236	9133894	Green Published			2022-12-28	WOS:A1997WU23600029
J	Tobias, JS				Tobias, JS			Informed consent in medical research - BMJs present policy (sometimes approving research in which patients have not given fully informed consent) is wholly correct	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIAL; CANCER		MIDDLESEX HOSP, LONDON W1N 8AA, ENGLAND	University of London; University College London	Tobias, JS (corresponding author), UCL HOSP, DIRECTORATE CANC SERV, LONDON W1N 8AA, ENGLAND.							Bhagwanjee S, 1997, BRIT MED J, V314, P1077, DOI 10.1136/bmj.314.7087.1077a; BREWIN TB, 1982, LANCET, V2, P919; BREWIN TB, 1985, LANCET, V2, P490; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; Foster C, 1996, BRIT MED J, V312, P817; Goodare H, 1996, BRIT MED J, V313, P361, DOI 10.1136/bmj.313.7053.361a; LEFANU J, 1983, MED NEWS, V12, P30; Magnusson S, 1996, BRIT MED J, V313, P1601, DOI 10.1136/bmj.313.7072.1601; McArdle JMC, 1996, BMJ-BRIT MED J, V312, P813; Moodie AR, 1996, BRIT MED J, V313, P362, DOI 10.1136/bmj.313.7053.362; Royal College of Physicians, 1990, GUID PRACT ETH COMM; SEGELOV E, 1992, ANN ONCOL, V3, P103, DOI 10.1093/oxfordjournals.annonc.a058119; SIMES RJ, 1986, BRIT MED J, V293, P1065, DOI 10.1136/bmj.293.6554.1065; TOBIAS JS, 1988, LANCET, V2, P1194; TOBIAS JS, 1994, EUR J CANCER, V30A, P897, DOI 10.1016/0959-8049(94)90107-4; TOBIAS JS, 1993, BRIT MED J, V307, P119; Williams C, 1992, INTRO NEW TREATMENTS, P49; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203	18	35	35	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 12	1997	314	7087					1111	1114		10.1136/bmj.314.7087.1111	http://dx.doi.org/10.1136/bmj.314.7087.1111			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU236	9133898	Green Published			2022-12-28	WOS:A1997WU23600035
J	Berns, GS; Cohen, JD; Mintun, MA				Berns, GS; Cohen, JD; Mintun, MA			Brain regions responsive to novelty in the absence of awareness	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; CEREBRAL BLOOD-FLOW; INTRAVENOUS (H2O)-O-15; MEMORY; PET; IMPLICIT; ATTENTION; HUMANS; MONKEY	Brain regions responsive to novelty, without awareness, were mapped in humans by positron emission tomography. Participants performed a simple reaction-time task in which all stimuli were equally likely but, unknown to them, followed a complex sequence. Measures of behavioral performance indicated that participants learned the sequences even though they were unaware of the existence of any order. Once the participants were trained, a subtle and unperceived change in the nature of the sequence resulted in increased blood flow in a network comprising the left premotor area, left anterior cingulate, and right ventral striatum. Blood flow decreases were observed in the right dorsolateral prefrontal and parietal areas. The time course of these changes suggests that the ventral striatum is responsive to novel information, and the right prefrontal area is associated with the maintenance of contextual information, and both processes can occur without awareness.	CARNEGIE MELLON UNIV,DEPT PSYCHOL,PITTSBURGH,PA 15213; WASHINGTON UNIV,SCH MED,DEPT RADIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110	Carnegie Mellon University; Washington University (WUSTL); Washington University (WUSTL)	Berns, GS (corresponding author), UNIV PITTSBURGH,WESTERN PSYCHIAT INST & CLIN,DEPT PSYCHIAT,MED CTR,3811 OHARA ST,PITTSBURGH,PA 15213, USA.				NIMH NIH HHS [MH 49815] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Andreasen NC, 1995, NEUROIMAGE, V2, P296, DOI 10.1006/nimg.1995.1037; BARONE P, 1989, EXP BRAIN RES, V78, P447; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; CHERRY SR, 1993, J CEREBR BLOOD F MET, V13, P630, DOI 10.1038/jcbfm.1993.81; CLEEREMANS A, 1991, J EXP PSYCHOL GEN, V120, P235, DOI 10.1037/0096-3445.120.3.235; COHEN A, 1990, J EXP PSYCHOL LEARN, V16, P17, DOI 10.1037/0278-7393.16.1.17; Cohen JD, 1996, PHILOS T R SOC B, V351, P1515, DOI 10.1098/rstb.1996.0138; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; CURRAN T, 1993, J EXP PSYCHOL LEARN, V19, P189, DOI 10.1037/0278-7393.19.1.189; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; GRAFTON ST, 1995, J COGNITIVE NEUROSCI, V7, P497, DOI 10.1162/jocn.1995.7.4.497; GRAFTON ST, 1992, J NEUROSCI, V12, P2542; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; HARTMAN M, 1989, J EXP PSYCHOL LEARN, V15, P1070, DOI 10.1037/0278-7393.15.6.1070; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; JENKINS IH, 1994, J NEUROSCI, V14, P3775; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; MATHEWS RC, 1989, J EXP PSYCHOL LEARN, V15, P1083, DOI 10.1037/0278-7393.15.6.1083; Miller EK, 1996, J NEUROSCI, V16, P5154; Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996; NIKI H, 1974, BRAIN RES, V68, P185, DOI 10.1016/0006-8993(74)90388-6; RAICHLE ME, 1983, J NUCL MED, V24, P790; Rauch SL, 1995, HUM BRAIN MAPP, V3, P271, DOI 10.1002/hbm.460030403; Reber A. S., 1967, J VERB LEARN VERB BE, V77, P317; Reber A. S., 1993, OXFORD PSYCHOL SERIE; SEITZ RJ, 1992, EUR J NEUROSCI, V4, P154, DOI 10.1111/j.1460-9568.1992.tb00862.x; Shannon C. E., 1949, MATH THEORY COMMUNIC; STADLER MA, 1995, J EXP PSYCHOL LEARN, V21, P674, DOI 10.1037/0278-7393.21.3.674; TALAIRACH J, 1988, STEREOTAXIC ATLAS HU; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2012, DOI 10.1073/pnas.91.6.2012; Tulving E, 1996, CEREB CORTEX, V6, P71, DOI 10.1093/cercor/6.1.71; TULVING E, 1994, NEUROREPORT, V5, P2525, DOI 10.1097/00001756-199412000-00030; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004	36	274	282	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1272	1275		10.1126/science.276.5316.1272	http://dx.doi.org/10.1126/science.276.5316.1272			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XA497	9157889				2022-12-28	WOS:A1997XA49700048
J	Bell, CC; Han, VZ; Sugawara, Y; Grant, K				Bell, CC; Han, VZ; Sugawara, Y; Grant, K			Synaptic plasticity in a cerebellum-like structure depends on temporal order	NATURE			English	Article							LONG-TERM DEPRESSION; PURKINJE-CELL; IN-VITRO; POTENTIATION; SYNAPSES; FISH; CA1	Cerebellum-like structures in fish appear to act as adaptive sensory processors, in which learned predictions about sensory input are generated and subtracted from actual sensory input, allowing unpredicted inputs to stand out(1-3). Pairing sensory input with centrally originating predictive signals, such as corollary discharge signals linked to motor commands, results in neural responses to the predictive signals alone that are 'negative images' of the previously paired sensory responses, Adding these 'negative images' to actual sensory inputs minimizes the neural response to predictable sensory features, At the cellular level, sensory input is relayed to the basal region of Purkinje-like cells, whereas predictive signals are relayed by parallel fibres to the apical dendrites of the same cells(4). The generation of negative images could be explained by plasticity at parallel fibre synapses(5-7). We show here that such plasticity exists in the electrosensory lobe of mormyrid electric fish and that it has the necessary properties for such a model: it is reversible, anti-hebbian (excitatory postsynaptic potentials (EPSPs) are depressed after pairing with a postsynaptic spike) and tightly dependent on the sequence of pre- and postsynaptic events, with depression occurring only if the postsynaptic spike follows EPSP onset within 60 ms.	CNRS,INST ALFRED FESSARD,F-91190 GIF SUR YVETTE,FRANCE; TEIKYO UNIV,SCH MED,DEPT PHYSIOL,ITABASHI KU,TOKYO 173,JAPAN	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Teikyo University	Bell, CC (corresponding author), GOOD SAMARITAN HOSP,RS DOW NEUROL SCI INST,1120 NW 20TH AVE,PORTLAND,OR 97209, USA.							BASTIAN J, 1995, J COMP PHYSIOL A, V176, P63; BELL C, 1993, P NATL ACAD SCI USA, V9, P4560; BELL C, IN PRESS BRAIN BEHAV; BELL CC, 1981, SCIENCE, V214, P450, DOI 10.1126/science.7291985; CHEN C, 1995, LEARN MEMORY, V2, P185, DOI 10.1101/lm.2.3-4.185; DEBANNE D, 1994, P NATL ACAD SCI USA, V91, P1148, DOI 10.1073/pnas.91.3.1148; EKEROT CF, 1989, NEUROSCI RES, V6, P264, DOI 10.1016/0168-0102(89)90065-5; Grant K, 1996, J COMP NEUROL, V375, P18; GUSTAFSSON B, 1987, J NEUROSCI, V7, P774; HASHEMZADEHGARGARI H, 1991, NEUROSCI LETT, V126, P37, DOI 10.1016/0304-3940(91)90365-Z; HEBB DO, 1949, ORG BEHAVIOR; HIRANO T, 1991, SYNAPSE, V7, P321, DOI 10.1002/syn.890070408; HUERTA P, 1991, NEUROSCI LETT, V126, P37; HUERTA PT, 1995, NEURON, V15, P1053, DOI 10.1016/0896-6273(95)90094-2; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Meek J, 1996, J COMP NEUROL, V375, P43, DOI 10.1002/(SICI)1096-9861(19961104)375:1<43::AID-CNE3>3.0.CO;2-O; Montgomery J. C., 1995, AUDIT NEUROSCI, P207; MONTGOMERY JC, 1994, NEUROSCI LETT, V174, P145, DOI 10.1016/0304-3940(94)90007-8; NELSON ME, 1995, J COMP PHYSIOL A, V177, P723; SAKURAI M, 1987, J PHYSIOL-LONDON, V394, P463, DOI 10.1113/jphysiol.1987.sp016881	21	422	431	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					278	281		10.1038/387278a0	http://dx.doi.org/10.1038/387278a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153391				2022-12-28	WOS:A1997WZ16700051
J	Burns, CM; Chu, H; Rueter, SM; Hutchinson, LK; Canton, H; SandersBush, E; Emeson, RB				Burns, CM; Chu, H; Rueter, SM; Hutchinson, LK; Canton, H; SandersBush, E; Emeson, RB			Regulation of serotonin-2C receptor G-protein coupling by RNA editing	NATURE			English	Article							CA2+ PERMEABILITY; IN-VITRO; ADENOSINE; CHANNELS; DETERMINANTS; INHIBITION; INVITRO	The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) elicits a wide array of physiological effects by binding to several receptor subtypes. The 5-HT2 family of receptors belongs to a large group of seven-transmembrane-spanning G-protein-coupled receptors and includes three receptor subtypes (5-HT2A, 5-HT2B and 5-HT2C) which are linked to phospholipase C, promoting the hydrolysis of membrane phospholipids and a subsequent increase in the intracellular levels of inositol phosphates and diacylglycerol(1). Here we show that transcripts encoding the 2C subtype of serotonin receptor (5-HT2CR) undergo RNA editing events in which genomically encoded adenosine residues are converted to inosines by the action of double-stranded RNA adenosine deaminase(s). Sequence analysis of complementary DNA isolates from dissected brain regions have indicated the tissue-specific expression of seven major 5-HT2C receptor isoforms encoded by eleven distinct RNA species. Editing of J-HT2CR messenger RNAs alters the amino-acid coding potential of the predicted second intracellular loop of the receptor and can lead to a 10-15-fold reduction in the efficacy of the interaction between receptors and their G proteins. These observations indicate that RNA editing is a new mechanism for regulating serotonergic signal transduction and suggest that this post-transcriptional modification may be critical for modulating the different cellular functions that are mediated by other members of the G-protein-coupled receptor superfamily.	VANDERBILT UNIV, SCH MED, DEPT PHARMACOL, NASHVILLE, TN 37232 USA	Vanderbilt University				Emeson, Ronald/0000-0002-4585-1648				ARTENS EJ, 1979, RECEPTORS, P33; AUSUBEL EM, 1989, CURRENT PROTOCOLS MO; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BASS BL, 1993, RNA WORLD, P383; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; EGEBJERG J, 1993, P NATL ACAD SCI USA, V90, P755, DOI 10.1073/pnas.90.2.755; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOYER D, 1994, PHARMACOL REV, V46, P157; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; LEONHARDT S, 1992, MOL PHARMACOL, V42, P328; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; MELLER E, 1991, J PHARMACOL EXP THER, V257, P668; MORO O, 1993, J BIOL CHEM, V268, P22273; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; Polson AG, 1996, NATURE, V380, P454; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; WESTPHAL RS, 1995, MOL PHARMACOL, V48, P200; WESTPHAL RS, 1994, MOL PHARMACOL, V46, P937; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0; YU L, 1991, MOL BRAIN RES, V11, P143, DOI 10.1016/0169-328X(91)90116-F; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	30	856	883	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 15	1997	387	6630					303	308		10.1038/387303a0	http://dx.doi.org/10.1038/387303a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153397				2022-12-28	WOS:A1997WZ16700058
J	Lan, RS; Lo, SK; Chuang, ML; Yang, CT; Tsao, TCY; Lee, CH				Lan, RS; Lo, SK; Chuang, ML; Yang, CT; Tsao, TCY; Lee, CH			Elastance of the pleural space: A predictor for the outcome of pleurodesis in patients with malignant pleural effusion	ANNALS OF INTERNAL MEDICINE			English	Article						pleurodesis; pleural effusion, malignant; bleomycin; thoracostomy; elastance	TETRACYCLINE PLEURODESIS; INTRACAVITARY BLEOMYCIN; LOW GLUCOSE; MANAGEMENT; PH; ROTATION; FLUID; TERM	Background: In patients who have malignant pleural effusion, it is difficult to diagnose trapped lung before thoracoscopy, thoracostomy, and drainage of the effusion. Predicting the outcome of pleurodesis in patients who have malignant pleural effusion without trapped lung is also difficult. Objective: To investigate the factors that may be useful in diagnosing trapped lung and predicting the outcome of pleurodesis. Design: Prospective cohort study. Setting: University medical center. Patients: 65 patients with symptomatic malignant pleural effusion. Intervention: A chest tube was inserted for drainage of the effusion, and pleurodesis was done using bleomycin as the sclerosant. Measurements: The pH and glucose levels of the effusion and the elastance of the pleural space (defined as the decline in pleural fluid pressure in cm H2O after removal of 500 mt of effusion) were measured. The outcome of pleurodesis was evaluated 1 month after the chest tube was removed. Results: Patients with an elastance of 19 cm H2O or more had a higher incidence of trapped lung (11 of 14 patients) than did those with an elastance less than 19 cm H2O (3 of 51 patients) (P < 0.001). None of the 14 patients with an elastance of 19 cm H2O or more and none of the 14 patients with a trapped lung had successful pleurodesis. Forty-two of 43 patients with an elastance less than 19 cm H2O who did not have a trapped lung had successful pleurodesis. Elastance seemed to be the best predictor for trapped lung and outcome of pleurodesis, although outcome was also correlated with pH and glucose levels of the effusion. Low-dose bleomycin (30 mg) is as effective as the usual dose of bleomycin (60 mg) for pleurodesis. Conclusion: In patients with symptomatic malignant pleural effusion, measurement of the elastance of the pleural space is a simple and effective method for the diagnosis of trapped lung and prediction of the outcome of chemical pleurodesis with bleomycin.	DEAKIN UNIV, BURWOOD, VIC 3125, AUSTRALIA	Deakin University	Lan, RS (corresponding author), CHANG GUNG MEM HOSP, DEPT CHEST MED, 199 TUNG HWA N RD, TAIPEI 10591, TAIWAN.			LO, Sing Kai/0000-0001-8401-1759; Yang, Cheng-Ta/0000-0003-1846-1027				AELONY Y, 1995, CHEST S, V108, pS111; CHERNOW B, 1977, AM J MED, V63, P695, DOI 10.1016/0002-9343(77)90154-1; DRYZER SR, 1993, CHEST, V104, P1763, DOI 10.1378/chest.104.6.1763; GOOD JT, 1978, CHEST, V74, P602, DOI 10.1378/chest.74.5.602a; GOOD JT, 1985, AM REV RESPIR DIS, V131, P737; HAUSHEER FH, 1985, SEMIN ONCOL, V12, P54; LIGHT RW, 1980, AM REV RESPIR DIS, V121, P799; LIGHT RW, 1995, PLEURAL DISEASES; Moffett M J, 1992, Semin Oncol, V19, P59; OSTROWSKI MJ, 1982, CANCER TREAT REP, V66, P1903; OSTROWSKI MJ, 1986, CANCER, V57, P721, DOI 10.1002/1097-0142(19860215)57:4<721::AID-CNCR2820570407>3.0.CO;2-5; PALADINE W, 1976, CANCER, V38, P1903, DOI 10.1002/1097-0142(197611)38:5<1903::AID-CNCR2820380506>3.0.CO;2-A; RODRIGUEZPANADE.F, 1990, EUR RESP J S10, V3, pS247; RODRIGUEZPANADERO F, 1989, AM REV RESPIR DIS, V139, P663, DOI 10.1164/ajrccm/139.3.663; RUCKDESCHEL JC, 1995, SEMIN ONCOL, V22, P58; RUCKDESCHEL JC, 1992, MALIGNANT PLEURAL EF; SAHN SA, 1985, CLIN CHEST MED, V6, P113; SAHN SA, 1988, ANN INTERN MED, V108, P345, DOI 10.7326/0003-4819-108-3-345; SANCHEZARMENGOL A, 1993, CHEST, V104, P1482, DOI 10.1378/chest.104.5.1482; VARGAS FS, 1994, CHEST, V106, P1246, DOI 10.1378/chest.106.4.1246; VILLANUEVA AG, 1994, THORAX, V49, P23, DOI 10.1136/thx.49.1.23; WALKERRENARD PB, 1994, ANN INTERN MED, V120, P56, DOI 10.7326/0003-4819-120-1-199401010-00010	22	91	94	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1997	126	10					768	+		10.7326/0003-4819-126-10-199705150-00003	http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ823	9148649				2022-12-28	WOS:A1997WZ82300005
J	Struewing, JP; Hartge, P; Wacholder, S; Baker, SM; Berlin, M; McAdams, M; Timmerman, MM; Brody, LC; Tucker, MA				Struewing, JP; Hartge, P; Wacholder, S; Baker, SM; Berlin, M; McAdams, M; Timmerman, MM; Brody, LC; Tucker, MA			The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-CANCER; OVARIAN-CANCER; SUSCEPTIBILITY GENE; FAMILIES; CARRIERS; WOMEN	Background Carriers of germ-line mutations in BRCA1 and BRCA2 from families at high risk for cancer have been estimated to have an 85 percent risk of breast cancer. Since the combined frequency of BRCA1 and BRCA2 mutations exceeds 2 percent among Ashkenazi Jews, we were able to estimate the risk of cancer in a large group of Jewish men and women from the Washington, D.C., area. Methods We collected blood samples from 5318 Jewish subjects who had filled out epidemiologic questionnaires. Carriers of the 185delAG and 5382insC mutations in BRCA1 and the 6174delT mutation in BRCA2 were identified with assays based on the polymerase chain reaction. We estimated the risks of breast and other cancers by comparing the cancer histories of relatives of carriers of the mutations and noncarriers. Results One hundred twenty carriers of a BRCA1 or BRCA2 mutation were identified. By the age of 70, the estimated risk of breast cancer among carriers was 56 percent (95 percent confidence interval, 40 to 73 percent); of ovarian cancer, 16 percent (95 percent confidence interval, 6 to 28 percent); and of prostate cancer, 16 percent (95 percent confidence interval, 4 to 30 percent). There were no significant differences in the risk of breast cancer between carriers of BRCA1 mutations and carriers of BRCA2 mutations, and the incidence of colon cancer among the relatives of carriers was not elevated. Conclusions Over 2 percent of Ashkenazi Jews carry mutations in BRCA1 or BRCA2 that confer increased risks of breast, ovarian, and prostate cancer. The risks of breast cancer may be overestimated, but they fall well below previous estimates based on subjects from high-risk families. (C) 1997, Massachusetts Medical Society.	NATL CANC INST,DIV CANC EPIDEMIOL & GENET,NIH,BETHESDA,MD; NATL HUMAN GENOME RES INST,LAB GENE TRANSFER,NIH,BETHESDA,MD; WESTAT CORP,ROCKVILLE,MD; IMS INC,SILVER SPRING,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Westat			Struewing, Jeffery P/I-7502-2013; Tucker, Margaret A/B-4297-2015; Struewing, Jeffery P/C-3221-2008	Struewing, Jeffery P/0000-0002-4848-3334; 				Berman DB, 1996, AM J HUM GENET, V58, P1166; BRINTON LA, 1995, J NATL CANCER I, V87, P827, DOI 10.1093/jnci/87.11.827; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; EASTON DF, 1995, AM J HUM GENET, V56, P265; EASTON DF, 1993, AM J HUM GENET, V52, P678; Egan KM, 1996, LANCET, V347, P1645, DOI 10.1016/S0140-6736(96)91485-3; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; HARTGE P, 1989, AM J OBSTET GYNECOL, V161, P10, DOI 10.1016/0002-9378(89)90221-4; Hubbard R, 1996, NEW ENGL J MED, V334, P1192, DOI 10.1056/NEJM199605023341812; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; Lapham EV, 1996, SCIENCE, V274, P621, DOI 10.1126/science.274.5287.621; LERMAN C, 1994, ARCH INTERN MED, V154, P609, DOI 10.1001/archinte.154.6.609; Muto MG, 1996, CANCER RES, V56, P1250; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Offit K, 1996, LANCET, V347, P1643, DOI 10.1016/S0140-6736(96)91484-1; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; Rothenberg KH, 1995, J LAW MED ETHICS, V23, P312, DOI 10.1111/j.1748-720X.1995.tb01373.x; SOMMER SS, 1992, BIOTECHNIQUES, V12, P82; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; TONIN P, 1995, J MED GENET, V32, P982, DOI 10.1136/jmg.32.12.982; TONIN P, 1995, AM J HUM GENET, V57, P189; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	34	1673	1707	0	61	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	1997	336	20					1401	1408		10.1056/NEJM199705153362001	http://dx.doi.org/10.1056/NEJM199705153362001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY577	9145676	Bronze			2022-12-28	WOS:A1997WY57700001
J	Hamilton, W; Round, A; Taylor, P				Hamilton, W; Round, A; Taylor, P			Dictating clinic letters in front of the patient - Letting patients see copy of consultant's letter is being studied in trial	BRITISH MEDICAL JOURNAL			English	Letter							OUTPATIENT		DEAN CLARKE HOUSE,EXETER EX1 1RB,DEVON,ENGLAND					Hamilton, William/0000-0003-1611-1373				ASCH R, 1991, BRIT J MED PSYCHOL, V64, P3, DOI 10.1111/j.2044-8341.1991.tb01637.x; JENKINS RM, 1993, BRIT J GEN PRACT, V43, P111; Lloyd BW, 1997, BRIT MED J, V314, P347, DOI 10.1136/bmj.314.7077.347; RUTHERFORD W, 1991, BRIT MED J, V303, P968, DOI 10.1136/bmj.303.6808.968	4	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1416	1416						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ169	9161335				2022-12-28	WOS:A1997WZ16900057
J	Mohammadi, M; McMahon, G; Sun, L; Tang, C; Hirth, P; Yeh, BK; Hubbard, SR; Schlessinger, J				Mohammadi, M; McMahon, G; Sun, L; Tang, C; Hirth, P; Yeh, BK; Hubbard, SR; Schlessinger, J			Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors	SCIENCE			English	Article							BREAST-CARCINOMA CELLS; SIGNAL TRANSDUCTION; HUMAN ASTROCYTOMAS; INSULIN-RECEPTOR; CROUZON-SYNDROME; POINT MUTATION; FGF FAMILY; EXPRESSION; CANCER; GENES	A new class of protein tyrosine kinase inhibitors was identified that is based on an oxindole core (indolinones). Two compounds from this class inhibited the kinase activity of fibroblast growth factor receptor 1 (FGFR1) and showed differential specificity toward other receptor tyrosine kinases. Crystal structures of the tyrosine kinase domain of FGFR1 in complex with the two compounds were determined. The oxindole occupies the site in which the adenine of adenosine triphosphate binds, whereas the moieties that extend from the oxindole contact residues in the hinge region between the two kinase lobes. The more specific inhibitor of FGFR1 induces a conformational change in the nucleotide-binding loop. This structural information will facilitate the design of new inhibitors for use in the treatment of cancer and other diseases in which cell signaling by tyrosine kinases plays a crucial role in disease pathogenesis.	NYU,MED CTR,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; SUGEN,REDWOOD CITY,CA 94063	New York University; New York University			Mohammadi, Moosa/ABA-6745-2020; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; Hubbard, Stevan/0000-0002-2707-9383				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ADNANE J, 1991, ONCOGENE, V6, P659; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Brem H., 1993, ONCOGENES TUMOR SUPP, P211; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; Engh RA, 1996, J BIOL CHEM, V271, P26157, DOI 10.1074/jbc.271.42.26157; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; HUBBARD SR, UNPUB; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; JAAKKOLA S, 1993, INT J CANCER, V54, P374; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LEUNG HY, 1994, INT J CANCER, V59, P667, DOI 10.1002/ijc.2910590515; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LI JJ, 1993, CANCER-AM CANCER SOC, V72, P2253, DOI 10.1002/1097-0142(19931001)72:7<2253::AID-CNCR2820720732>3.0.CO;2-4; LUQMANI YA, 1995, INT J CANCER, V64, P274, DOI 10.1002/ijc.2910640411; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MALKIN MG, 1996, P AM M AM SOC CLIN O, V15, pA1573; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MCLESKEY SW, 1994, CANCER RES, V54, P523; MCMAHON G, UNPUB; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORRISON RS, 1994, J NEURO-ONCOL, V18, P207, DOI 10.1007/BF01328955; Myoken Y, 1996, INT J CANCER, V65, P650, DOI 10.1002/(SICI)1097-0215(19960301)65:5<650::AID-IJC15>3.0.CO;2-B; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; STORY MT, 1995, WORLD J UROL, V13, P297; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARE JL, 1993, CANCER METAST REV, V12, P287, DOI 10.1007/BF00665959; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Webster MK, 1996, MOL CELL BIOL, V16, P4081; Xu RM, 1996, P NATL ACAD SCI USA, V93, P6308, DOI 10.1073/pnas.93.13.6308; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484	54	987	1084	0	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					955	960		10.1126/science.276.5314.955	http://dx.doi.org/10.1126/science.276.5314.955			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9139660				2022-12-28	WOS:A1997WY79200050
J	Luzuriaga, K; Bryson, Y; Krogstad, P; Robinson, J; Stechenberg, B; Lamson, M; Cort, S; Sullivan, JL				Luzuriaga, K; Bryson, Y; Krogstad, P; Robinson, J; Stechenberg, B; Lamson, M; Cort, S; Sullivan, JL			Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIV-1; TRANSMISSION; LYMPHOCYTES; CHILDREN; MOTHERS; PLASMA; VIVO	Background In infants and children with maternally acquired human immunodeficiency virus type 1 (HIV-1) infection, treatment with a single antiretroviral agent has limited efficacy. We evaluated the safety and efficacy of a three-drug regimen in a small group of maternally infected infants. Methods Zidovudine, didanosine, and nevirapine were administered in combination orally to eight infants 2 to 16 months of age. The efficacy of antiretroviral treatment was evaluated by serial measurements of plasma HIV-1 RNA, quantitative plasma cultures, and quantitative cultures of peripheral-blood mononuclear cells. Results The three-drug regimen was well tolerated, without clinically important adverse events. Within four weeks, there were reductions in plasma levels of HIV-1 RNA of at least 96 percent (1.5 log) in seven of the eight study patients. Over the 6-month study period, replication of HIV-1 was controlled in two infants who began therapy at 2 1/2 months of age. Plasma RNA levels were reduced by 0.5 to 1.5 log in five of the other six infants. Conclusions Although further observations are needed, it appears that in infants with maternally acquired HIV-1 infection, combined treatment with zidovudine, didanosine, and nevirapine is well tolerated and has sustained efficacy against HIV-1. (C)1997, Massachusetts Medical Society.	UNIV CALIF LOS ANGELES, DEPT PEDIAT, LOS ANGELES, CA 90024 USA; UNIV CONNECTICUT, SCH MED, DEPT PEDIAT, FARMINGTON, CT 06032 USA; BAYSTATE MED CTR, DEPT PEDIAT, SPRINGFIELD, MA 01199 USA; BOEHRINGER INGELHEIM PHARMACEUT INC, RIDGEFIELD, CT 06877 USA	University of California System; University of California Los Angeles; University of Connecticut; Baystate Medical Center; Boehringer Ingelheim	Luzuriaga, K (corresponding author), UNIV MASSACHUSETTS, SCH MED,DEPT PEDIAT,RM 318,BIOTECH 2, 373 PLANTAT ST, WORCESTER, MA 01605 USA.				NIAID NIH HHS [AI30629, AI32907, AI27550] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027550, U01AI032907, R01AI030629] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		*AIDS CLIN TRIALS, 1993, VIR REF MAN; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; CHRISTOPHERSON C, 1997, 4 C RETR OPP INF WAS; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; GREENOUGH TC, IN PRESS J INFECT DI; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; LIDINJANSSON G, 1994, PEDIATRICS, V94, P815; LUBAKI MN, 1994, AIDS RES HUM RETROV, V10, P1427, DOI 10.1089/aid.1994.10.1427; Luzuriaga K, 1996, J INFECT DIS, V174, P713, DOI 10.1093/infdis/174.4.713; LUZURIAGA K, 1991, J PEDIATR-US, V119, P230, DOI 10.1016/S0022-3476(05)80732-2; Luzuriaga K, 1996, JAMA-J AM MED ASSOC, V275, P1360; MARTIN NL, 1991, J PEDIATR-US, V118, P354, DOI 10.1016/S0022-3476(05)82146-8; Myers Maureen W., 1996, P22; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Peters VB, 1996, J PEDIATR-US, V128, P363, DOI 10.1016/S0022-3476(96)70282-2; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; SCARLATTI G, 1993, P NATL ACAD SCI USA, V90, P1721, DOI 10.1073/pnas.90.5.1721; STONEBURNER RL, 1994, ACTA PAEDIATR, V83, P1, DOI 10.1111/j.1651-2227.1994.tb13323.x; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; Wyand MS, 1997, NAT MED, V3, P32, DOI 10.1038/nm0197-32	24	160	163	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 8	1997	336	19					1343	1349		10.1056/NEJM199705083361902	http://dx.doi.org/10.1056/NEJM199705083361902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX851	9134874	Green Published			2022-12-28	WOS:A1997WX85100002
J	Wright, BA; Lombardino, LJ; King, WM; Puranik, CS; Leonard, CM; Merzenich, MM				Wright, BA; Lombardino, LJ; King, WM; Puranik, CS; Leonard, CM; Merzenich, MM			Deficits in auditory temporal and spectral resolution in language-impaired children	NATURE			English	Article							PERCEPTION	Between 3 and 6 per cent of children who are otherwise unimpaired have extreme difficulties producing and understanding spoken language(1). This disorder is typically labelled specific language impairment. Children diagnosed with specific language impairment often have accompanying reading difficulties (dyslexia)(2), but not all children with reading difficulties have specific language impairment(3). Some researchers claim that language impairment arises from failures specific to language or cognitive processing(4-6). Others hold that language impairment results from a more elemental problem that makes affected children unable to hear the acoustic distinctions among successive brief sounds in speech(7-11). Here we report the results of psychophysical tests employing simple tones and noises showing that children with specific language impairment have severe auditory perceptual deficits for brief but not long tones in particular sound contexts. Our data support the view that language difficulties result from problems in auditory perception, and provide further information about the nature of these perceptual problems that should contribute to improving the diagnosis and treatment of language impairment and related disorders.	UNIV FLORIDA,DEPT COMMUN PROC & DISORDERS,GAINESVILLE,FL 32611; UNIV FLORIDA,DEPT NEUROSCI,GAINESVILLE,FL 32611; UNIV FLORIDA,INST BRAIN,GAINESVILLE,FL 32611	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Wright, BA (corresponding author), UNIV CALIF SAN FRANCISCO,WM KECK AUTOIMMUNE DIS CTR,BOX 0732,SAN FRANCISCO,CA 94143, USA.							AARON PG, 1988, ANN DYSLEXIA, V36, P33; ARAM DM, 1975, J SPEECH HEAR RES, V18, P229, DOI 10.1044/jshr.1802.229; BRADLEY L, 1978, NATURE, V271, P746, DOI 10.1038/271746a0; Brown L., 1990, TEST NONVERBAL INTEL; CARLYON RP, 1989, HEARING RES, V41, P223, DOI 10.1016/0378-5955(89)90014-2; CATTS HW, 1993, J SPEECH HEAR RES, V36, P948, DOI 10.1044/jshr.3605.948; ELLIOTT LL, 1989, J SPEECH HEAR RES, V32, P112, DOI 10.1044/jshr.3201.112; Farmer ME, 1995, PSYCHON B REV, V2, P460, DOI 10.3758/BF03210983; FASTL H, 1976, ACUSTICA, V36, P317; FRUMKIN B, 1980, NEUROPSYCHOLOGIA, V18, P443, DOI 10.1016/0028-3932(80)90147-5; GAUGER LM, IN PRESS J SPEECH HE; GREEN DM, 1990, J ACOUST SOC AM, V87, P2662, DOI 10.1121/1.399058; Kraus N, 1996, SCIENCE, V273, P971, DOI 10.1126/science.273.5277.971; LUBERT N, 1981, J SPEECH HEAR DISORD, V46, P3, DOI 10.1044/jshd.4601.03; Merzenich MM, 1996, SCIENCE, V271, P77, DOI 10.1126/science.271.5245.77; MOORE BCJ, 1987, J ACOUST SOC AM, V81, P1873, DOI 10.1121/1.394751; Patterson R.D., 1986, FREQUENCY SELECTIVIT, P123; PATTERSON RD, 1982, J ACOUST SOC AM, V72, P1788, DOI 10.1121/1.388652; Semel EM, 1987, CLIN EVALUATION LANG; SODERQUIST D R, 1981, Journal of Auditory Research, V21, P227; StuddertKennedy M, 1995, PSYCHON B REV, V2, P508, DOI 10.3758/BF03210986; Tallal P, 1996, SCIENCE, V271, P81, DOI 10.1126/science.271.5245.81; TALLAL P, 1973, NATURE, V241, P468, DOI 10.1038/241468a0; VELLUTINO FR, 1977, J LEARN DISABIL, V10, P375, DOI 10.1177/002221947701000614; WAGENAAR WA, 1969, PSYCHOL BULL, V72, P384, DOI 10.1037/h0028329; 1988, P NATL C LEARN DIS B	26	383	394	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					176	178		10.1038/387176a0	http://dx.doi.org/10.1038/387176a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WX945	9144287				2022-12-28	WOS:A1997WX94500053
J	Brookoff, D; OBrien, KK; Cook, CS; Thompson, TD; Williams, C				Brookoff, D; OBrien, KK; Cook, CS; Thompson, TD; Williams, C			Characteristics of participants in domestic violence - Assessment at the scene of domestic assault	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUBSTANCE ABUSE; BATTERED WOMEN; COCAINE; ALCOHOL; PREVALENCE; BEHAVIOR; HEALTH; DRUG; MEN; MIX	Objective.-To evaluate the characteristics of victims and perpetrators of domestic assault. Design and Setting.-Consecutive-sample survey study conducted at the scenes of police calls for domestic assault in Memphis, Tenn, in 1995. Participants.-A total of 136 participants (72 victims and 64 assailants) involved in 62 incidents of domestic violence and 75 adult family members at the scene. Main Outcome Measures.-Participants' responses to a confidential survey and review of police records. Results.-Of 62 episodes of domestic assault, 42 (68%) involved weapons and 11 (15%) resulted in serious injury. Fifty-five (89%) of 62 assault victims reported previous assaults by their current assailants, 19 (35%) of them on a daily basis. Although nearly all assault victims had called the police for help on previous occasions, only 12 (22%) reported having ever sought medical care, counseling, or shelter because of domestic assault. Sixty (92%) of the 64 assailants reportedly used alcohol or other drugs on the day of the assault. Of the assailants, 28 (44%) had a history of arrest for charges related to violence, and 46 (72%) had an arrest for substance abuse. Eleven (15%) of the victims were children. Children directly witnessed 53 (85%) of the assaults. Conclusions-Most victims of domestic violence who had called the police rarely used medical or mental health facilities for problems related to family violence despite frequent assaults. Victims and assailants were willing to discuss their histories of family violence and undergo assessments at the scenes of police calls.	MEMPHIS POLICE DEPT,MEMPHIS,TN; UNIV MEMPHIS,DEPT ANTHROPOL,MEMPHIS,TN 38152	University of Memphis	Brookoff, D (corresponding author), METHODIST HOSP,DEPT MED EDUC,1265 UNION AVE,MEMPHIS,TN 38104, USA.							ABBOTT J, 1995, JAMA-J AM MED ASSOC, V273, P1763, DOI 10.1001/jama.273.22.1763; APPLETON W, 1980, ANN EMERG MED, V9, P84, DOI 10.1016/S0196-0644(80)80336-2; BROOKOFF D, 1994, NEW ENGL J MED, V331, P518, DOI 10.1056/NEJM199408253310807; Brookoff D, 1996, ANN EMERG MED, V27, P316, DOI 10.1016/S0196-0644(96)70266-4; Cappell C., 1990, J FAM VIOLENCE, V5, P135, DOI DOI 10.1007/BF00978516; Davidson LL, 1996, AM J PUBLIC HEALTH, V86, P12, DOI 10.2105/AJPH.86.1.12; FAGAN J, 1993, HLTH AFF MILLWOOD, V4, P65; FITCH FJ, 1983, J NERV MENT DIS, V171, P190, DOI 10.1097/00005053-198303000-00011; FLITCRAFT A, 1995, ANN INTERN MED, V123, P800, DOI 10.7326/0003-4819-123-10-199511150-00009; FLITCRAFT AH, 1992, JAMA-J AM MED ASSOC, V267, P3194, DOI 10.1001/jama.267.23.3194; Freund KM, 1996, J GEN INTERN MED, V11, P44, DOI 10.1007/BF02603485; FRIEDMAN LS, 1992, ARCH INTERN MED, V152, P1186, DOI 10.1001/archinte.152.6.1186; GORNEY B, 1989, J PSYCHOACTIVE DRUGS, V21, P229, DOI 10.1080/02791072.1989.10472163; GRANT BF, 1990, DRUG ALCOHOL DEPEN, V25, P97, DOI 10.1016/0376-8716(90)90147-7; Grisso JA, 1996, AM J PUBLIC HEALTH, V86, P67, DOI 10.2105/AJPH.86.1.67; HART B, 1993, AM BEHAV SCI, V36, P624, DOI 10.1177/0002764293036005007; HEARN WL, 1991, J NEUROCHEM, V56, P698, DOI 10.1111/j.1471-4159.1991.tb08205.x; HONER WG, 1987, LANCET, V2, P451; HYMAN A, 1995, JAMA-J AM MED ASSOC, V273, P1781, DOI 10.1001/jama.273.22.1781; JONES A, 1994, NEXT TIME SELL BE DE, P88; KANTOR GK, 1989, AM J DRUG ALCOHOL AB, V15, P173, DOI 10.3109/00952998909092719; KELLEHER K, 1994, AM J PUBLIC HEALTH, V84, P1586, DOI 10.2105/AJPH.84.10.1586; Levy A. J., 1990, AGGRESSION FAMILY VI, P81; MARWICK C, 1994, JAMA-J AM MED ASSOC, V271, P1147; MCCAULEY J, 1995, ANN INTERN MED, V123, P737, DOI 10.7326/0003-4819-123-10-199511150-00001; Miller B A, 1990, NIDA Res Monogr, V103, P177; PARSONS LH, 1995, AM J OBSTET GYNECOL, V173, P381, DOI 10.1016/0002-9378(95)90256-2; *POL FDN, 1977, DOM VIOL POL STUD DE, P14; RANDALL T, 1990, JAMA-J AM MED ASSOC, V264, P939, DOI 10.1001/jama.264.8.939; RANDALL T, 1992, JAMA-J AM MED ASSOC, V267, P1043, DOI 10.1001/jama.267.8.1043; Rath G D, 1989, J Am Board Fam Pract, V2, P227; ROBERTS AR, 1988, J SUBST ABUSE TREAT, V5, P83, DOI 10.1016/0740-5472(88)90017-7; SLADE M, 1991, J FORENSIC SCI, V36, P708; STATMAN JB, 1995, BATTERED WOMANS SURV, P22; STERNBERG KJ, 1993, DEV PSYCHOL, V29, P44, DOI 10.1037/0012-1649.29.1.44; SUGG NK, 1992, JAMA-J AM MED ASSOC, V267, P3157, DOI 10.1001/jama.267.23.3157; WILLIAMS C, 1995, TENNESSEE OUTCOMES A; WOLFE DA, 1994, PEDIATRICS, V94, P594; WOLFE DA, 1985, J CONSULT CLIN PSYCH, V53, P657, DOI 10.1037/0022-006X.53.5.657	39	131	132	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	1997	277	17					1369	1373		10.1001/jama.277.17.1369	http://dx.doi.org/10.1001/jama.277.17.1369			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WW261	9134942				2022-12-28	WOS:A1997WW26100026
J	Pazin, MJ; Kadonaga, JT				Pazin, MJ; Kadonaga, JT			What's up and down with histone deacetylation and transcription?	CELL			English	Review									UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego			Ito, Kazuhiro/AAF-5994-2019; Adcock, Ian/L-3217-2019; Pace, Paul E/A-3104-2012	Pace, Paul E/0000-0003-1855-5760; Pazin, Michael/0000-0002-7561-3640				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; DeRubertis F, 1996, NATURE, V384, P589; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; GRUNSTEIN M, 1997, IN PRESS NATURE; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; STILLMAN DJ, 1994, GENETICS, V136, P781; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; VanLint C, 1996, GENE EXPRESSION, V5, P245; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	20	771	803	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					325	328		10.1016/S0092-8674(00)80211-1	http://dx.doi.org/10.1016/S0092-8674(00)80211-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150131	Bronze			2022-12-28	WOS:A1997WX89900002
J	Ward, W; Alvarado, L; Rawlings, ND; Engel, JC; Franklin, C; McKerrow, JH				Ward, W; Alvarado, L; Rawlings, ND; Engel, JC; Franklin, C; McKerrow, JH			A primitive enzyme for a primitive cell: The protease required for excystation of Giardia	CELL			English	Article							CATHEPSIN-B; CYSTEINE PROTEASE; CRYSTAL-STRUCTURE; ACID-PHOSPHATASE; LAMBLIA; LOCALIZATION; TROPHOZOITES; PROTEINASE; MURIS; PURIFICATION	Protozoan parasites of the genus Giardia are one of the earliest lineages of eukaryotic cells. To initiate infection, trophozoites emerge from a cyst in the host. Excystation is blocked by specific cysteine protease inhibitors. Using a biotinylated inhibitor, the target protease was identified and its corresponding gene cloned. The protease was localized to vesicles that release their contents just prior to excystation. The Giardia protease is the earliest known branch of the cathepsin B family. Its phylogeny confirms that the cathepsin B lineage evolved in primitive eukaryotic cells, prior to the divergence of plant and animal kingdoms, and underscores the diversity of cellular functions that this enzyme family facilitates.	IMSS,CMNSXX1,UNIDAD INVEST MED ENFERMEDADES INFECCIOSAS & PARA,MEXICO CITY 06725,DF,MEXICO; BABRAHAM INST,PEPTIDASE LAB,DEPT IMMUNOL,CAMBRIDGE CB2 4AT,ENGLAND; VET AFFAIRS MED CTR,SAN FRANCISCO,CA 94121	Instituto Mexicano del Seguro Social; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ward, W (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143, USA.		Rawlings, Neil D./I-4867-2012; Rawlings, Neil/M-5566-2013	Rawlings, Neil/0000-0001-5557-7665	NIAID NIH HHS [AI35707] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035707] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BERTI PJ, 1995, J MOL BIOL, V246, P373; CHUNG YB, 1995, J PARASITOL, V81, P137, DOI 10.2307/3283911; COGGINS JR, 1986, EXP PARASITOL, V61, P219, DOI 10.1016/0014-4894(86)90155-4; EAKIN AE, 1990, MOL BIOCHEM PARASIT, V39, P1, DOI 10.1016/0166-6851(90)90002-4; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; ELLIOTT E, 1996, SERIES PERSPECTIVES, P12; FARTHING MJG, 1992, J MED MICROBIOL, V37, P1, DOI 10.1099/00222615-37-1-1; FEELY DE, 1991, J PARASITOL, V77, P441, DOI 10.2307/3283133; FEELY DE, 1987, J PROTOZOOL, V34, P80, DOI 10.1111/j.1550-7408.1987.tb03137.x; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FRIEND DS, 1966, J CELL BIOL, V29, P317, DOI 10.1083/jcb.29.2.317; *GEN COMP GROUP, 1994, PROGR MAN WISC SEQ A; GILLIN FD, 1991, PARASITOL TODAY, V7, P113, DOI 10.1016/0169-4758(91)90169-O; Gillin FD, 1996, ANNU REV MICROBIOL, V50, P679, DOI 10.1146/annurev.micro.50.1.679; HARE DF, 1989, EXP PARASITOL, V68, P168, DOI 10.1016/0014-4894(89)90094-5; HASNAIN S, 1992, BIOL CHEM H-S, V373, P413, DOI 10.1515/bchm3.1992.373.2.413; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KANE AV, 1991, J PARASITOL, V77, P974, DOI 10.2307/3282752; KAPPUS KD, 1994, AM J TROP MED HYG, V50, P705, DOI 10.4269/ajtmh.1994.50.705; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; KURATA S, 1992, EUR J BIOCHEM, V204, P911, DOI 10.1111/j.1432-1033.1992.tb16711.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2617, DOI 10.1128/AEM.57.9.2617-2621.1991; LEIPE DD, 1993, MOL BIOCHEM PARASIT, V59, P41, DOI 10.1016/0166-6851(93)90005-I; LEVINE WC, 1990, MMWR-MORBID MORTAL W, V89, P1; LINDMARK DG, 1988, EXP PARASITOL, V65, P141, DOI 10.1016/0014-4894(88)90116-6; MANIATIS T, 1987, MOL CLONING; MANNING P, 1992, J PROTOZOOL, V89, P290; MEESTER FD, 1990, INFECT IMMUN, V58, P1396; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; PARENTI DM, 1989, J INFECT DIS, V160, P1076, DOI 10.1093/infdis/160.6.1076; PEATTIE DA, 1990, PARASITOL TODAY, V6, P52, DOI 10.1016/0169-4758(90)90070-K; QUICK R, 1992, J INFECT DIS, V166, P673, DOI 10.1093/infdis/166.3.673; RASNICK D, 1985, ANAL BIOCHEM, V149, P461, DOI 10.1016/0003-2697(85)90598-6; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SIDDALL ME, 1992, J PROTOZOOL, V39, P361, DOI 10.1111/j.1550-7408.1992.tb01465.x; SMITH PD, 1982, INFECT IMMUN, V36, P714, DOI 10.1128/IAI.36.2.714-719.1982; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Sullivan PB, 1990, ARCH DIS CHILD, V65, P304; VIDAL MFC, 1991, J CLIN MICROBIOL, V29, P636, DOI 10.1128/JCM.29.3.636-637.1991; WANG AL, 1986, MOL BIOCHEM PARASIT, V21, P269, DOI 10.1016/0166-6851(86)90132-5; Wasilewski MM, 1996, MOL BIOCHEM PARASIT, V81, P179, DOI 10.1016/0166-6851(96)02703-X; WERRIES E, 1991, J PROTOZOOL, V38, P378, DOI 10.1111/j.1550-7408.1991.tb01374.x	46	120	125	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					437	444		10.1016/S0092-8674(00)80224-X	http://dx.doi.org/10.1016/S0092-8674(00)80224-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150143	Bronze			2022-12-28	WOS:A1997WX89900014
J	Saunders, KB; Amerasinghe, AKCP; Saunders, KL				Saunders, KB; Amerasinghe, AKCP; Saunders, KL			Dose of digoxin prescribed in the UK compared with France and the USA	LANCET			English	Article							CONGESTIVE-HEART-FAILURE; TRIAL; WITHDRAWAL; DRUG	Background Two trials in patients with heart failure showed that some patients grew worse if digoxin was withdrawn. The median daily dose of digoxin in these trials was 375 mu g. We suspected that doses used in the UK were much lower. Methods We studied the prescription of digoxin to 119 patients who were discharged from St George's Hospital, London, UK, in April and May, 1994. We calculated the appropriate digoxin prescription dose by Jelliffe's formula. Appropriate doses were put into a scale of six levels: 62.5 mu g, 125 mu g, 187.5 mu g, 250 mu g, 375 mu g, or 500 mu g. We compared our findings with information from a database of prescription records. These records, gathered during 1993-94, came from the UK (1085 prescriptions), France (1148), and the USA (2303). Findings In the St George's Hospital series, the median daily dose of digoxin was 125 mu g (mean 170 [SD 80] mu g). The dose was significantly higher in patients who had heart failure than those who did not, by a mean of 40 mu g. Among the 100 patients for whom appropriate dose was calculated, the dose was as predicted in 28, one level too low in 34, two or more levels too low in 32, and one level too high in six. There was no difference between St George's Hospital and UK practice as a whole (p>0.05), but the dosage was significantly higher in the USA and France than in the UK (p<0.001 for both) and significantly higher in France than in the USA (p<0.001). Interpretation Differences in dosage may be correlated to the range of tablet strengths available in each country in our analysis. Underdosing can be detected with certainty only if plasma digoxin concentration is measured. However, our study provides strong circumstantial evidence that many patients in the UK are receiving too little digoxin.	ST GEORGE HOSP, SCH MED, DEPT MED, LONDON SW17 0RE, ENGLAND; AGB HEALTHCARE, EPSOM, SURREY, ENGLAND	St Georges University London								ARONSON JK, 1992, BRIT MED J, V305, P1149, DOI 10.1136/bmj.305.6862.1149; ARONSON JK, 1976, BRIT J CLIN PHARMACO, V3, P639, DOI 10.1111/j.1365-2125.1976.tb04888.x; CHAMBERLAIN DA, 1970, BMJ-BRIT MED J, V3, P429, DOI 10.1136/bmj.3.5720.429; DIBIANCO R, 1989, NEW ENGL J MED, V320, P677, DOI 10.1056/NEJM198903163201101; GOLDSTEIN S, 1988, JAMA-J AM MED ASSOC, V259, P539; GRAHAMESMITH DG, 1984, OXFORD TXB CLIN PHAR, P108; GREENBLATT D J, 1976, Clinical Pharmacokinetics, V1, P36, DOI 10.2165/00003088-197601010-00004; GUYATT GH, 1988, AM J CARDIOL, V61, P371, DOI 10.1016/0002-9149(88)90947-2; JELLIFFE RW, 1969, DIS CHEST, V56, P56; LEE DCS, 1982, NEW ENGL J MED, V306, P699, DOI 10.1056/NEJM198203253061202; LINDQUIST M, 1994, DRUG INVEST, V8, P73, DOI 10.1007/BF03257430; MATZUK MM, 1991, THER DRUG MONIT, V13, P215, DOI 10.1097/00007691-199105000-00005; *NAT PHARM ASS, 1994, DRUGS WHICH SHOULD S; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; SIERSBAE.K, 1971, LANCET, V1, P1133; SMITH TW, 1970, J CLIN INVEST, V49, P2377, DOI 10.1172/JCI106457; URETSKY BF, 1993, J AM COLL CARDIOL, V22, P955, DOI 10.1016/0735-1097(93)90403-N; VONOLSHAUSEN KE, 1988, LANCET, V1, P489; 1996, DRUG THER B, V34, P41	19	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 22	1997	349	9055					833	836		10.1016/S0140-6736(96)09057-5	http://dx.doi.org/10.1016/S0140-6736(96)09057-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121258				2022-12-28	WOS:A1997WP40300011
J	Splawski, I; Timothy, KW; Vincent, GM; Atkinson, DL; Keating, MT				Splawski, I; Timothy, KW; Vincent, GM; Atkinson, DL; Keating, MT			Molecular basis of the long-QT syndrome associated with deafness	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INHERITED CARDIAC-ARRHYTHMIA; LINKAGE ANALYSIS; MUTATIONS; GENE; CHILD		UNIV UTAH, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, ECCLES INST HUMAN GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DIV CARDIOL, SALT LAKE CITY, UT 84112 USA; LATTER DAY ST HOSP, DEPT MED, SALT LAKE CITY, UT 84143 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NCRR NIH HHS [M01 RR00064] Funding Source: Medline; NHLBI NIH HHS [R01 HL48074, HL53773] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL053773] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; FRASER GR, 1964, Q J MED, V33, P361; Friedmann I, 1966, J Laryngol Otol, V80, P451, DOI 10.1017/S002221510006552X; HOLLAND JJ, 1993, ANAESTHESIA, V48, P149; JEFFERY S, 1992, LANCET, V339, P255, DOI 10.1016/0140-6736(92)90071-A; JERVELL A, 1966, AM HEART J, V72, P582, DOI 10.1016/0002-8703(66)90340-1; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; KEATING M, 1991, AM J HUM GENET, V49, P1335; KEATING M, 1992, CIRCULATION, V85, P1973, DOI 10.1161/01.CIR.85.6.1973; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; LATHROP GM, 1985, AM J HUM GENET, V37, P482; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ROMANO C, 1963, Clin Pediatr (Bologna), V45, P656; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SCHOTT JJ, 1995, AM J HUM GENET, V57, P1114; Tesson F, 1996, J MOL CELL CARDIOL, V28, P2051, DOI 10.1006/jmcc.1996.0198; TILL JA, 1988, AM J CARDIOL, V62, P1319, DOI 10.1016/0002-9149(88)90289-5; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WANG Q, 1995, HUM MOL GENET, V4, P1603, DOI 10.1093/hmg/4.9.1603; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WARD O C, 1964, J Ir Med Assoc, V54, P103	28	231	240	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 29	1997	336	22					1562	1567		10.1056/NEJM199705293362204	http://dx.doi.org/10.1056/NEJM199705293362204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB087	9164812				2022-12-28	WOS:A1997XB08700004
J	Porkka-Heiskanen, T; Strecker, RE; Thakkar, M; Bjorkum, AA; Greene, RW; McCarley, RW				Porkka-Heiskanen, T; Strecker, RE; Thakkar, M; Bjorkum, AA; Greene, RW; McCarley, RW			Adenosine: A mediator of the sleep-inducing effects of prolonged wakefulness	SCIENCE			English	Article							ENDOGENOUS ADENOSINE; CEREBRAL-CORTEX; RAT-BRAIN; CAFFEINE; INHIBITION; METABOLISM; EEG; DERIVATIVES; ALERTNESS; NEURONS	Both subjective and electroencephalographic arousal diminish as a function of the duration of prior wakefulness. Data reported here suggest that the major criteria for a neural sleep factor mediating the somnogenic effects of prolonged wakefulness are satisfied by adenosine, a neuromodulator whose extracellular concentration increases with brain metabolism and which, in vitro, inhibits basal forebrain cholinergic neurons. In vivo microdialysis measurements in freely behaving cats showed that adenosine extracellular concentrations in the basal forebrain cholinergic region increased during spontaneous wakefulness as contrasted with slow wave sleep; exhibited progressive increases during sustained, prolonged wakefulness; and declined slowly during recovery sleep. Furthermore, the sleep-wakefulness profile occurring after prolonged wakefulness was mimicked by increased extracellular adenosine induced by microdialysis perfusion of an adenosine transport inhibitor in the cholinergic basal forebrain but not by perfusion in a control noncholinergic region.	HARVARD UNIV, SCH MED, DEPT PSYCHIAT, VAMC, BROCKTON, MA 02401 USA; UNIV HELSINKI, INST BIOMED, HELSINKI, FINLAND	Harvard University; University of Helsinki			McCarley, Robert W/N-5562-2014; Shenton, Martha/V-8780-2019	McCarley, Robert W/0000-0001-5705-7495; Thakkar, Mahesh/0000-0001-6876-9850	NIMH NIH HHS [R37 MH39,683, R01 MH039683] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039683, R01MH039683] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BENINGTON JH, 1995, PROG NEUROBIOL, V45, P347, DOI 10.1016/0301-0082(94)00057-O; Berman AL, 1982, THALAMUS BASAL TELEN; BERNE M, 1982, CEREBRAL HYPOXIA PAT, P82; Borbely A A, 1982, Hum Neurobiol, V1, P195; Brundege JM, 1996, J NEUROSCI, V16, P5603; CRAIG CG, 1993, J NEUROCHEM, V60, P1073, DOI 10.1111/j.1471-4159.1993.tb03256.x; CRAIG CG, 1992, J PHARMACOL EXP THER, V260, P1278; DESANCHEZ VC, 1993, BRAIN RES, V612, P115, DOI 10.1016/0006-8993(93)91651-8; DUNWIDDIE TV, 1981, N-S ARCH PHARMACOL, V316, P326, DOI 10.1007/BF00501365; FEINBERG I, 1985, ELECTROEN CLIN NEURO, V61, P134, DOI 10.1016/0013-4694(85)91051-X; FINDLEY LJ, 1988, J APPL PHYSIOL, V64, P556, DOI 10.1152/jappl.1988.64.2.556; GEREAU RW, 1994, NEURON, V12, P1121, DOI 10.1016/0896-6273(94)90319-0; GREENE RW, 1985, BRIT J PHARMACOL, V85, P163, DOI 10.1111/j.1476-5381.1985.tb08843.x; GU JG, 1992, J NEUROCHEM, V58, P1699, DOI 10.1111/j.1471-4159.1992.tb10043.x; HAAS HL, 1988, N-S ARCH PHARMACOL, V337, P561; HAAS HL, 1987, NEUR ABSTR, V13, P155; Huston JP, 1996, NEUROSCIENCE, V73, P99, DOI 10.1016/0306-4522(96)00021-8; JONES BE, 1993, PROG BRAIN RES, V98, P61; KRUEGER JM, IN PRESS SLEEP SLEEP; LANDOLT HP, 1995, NEUROPSYCHOPHARMACOL, V12, P229, DOI 10.1016/0893-133X(94)00079-F; MADSEN PL, 1991, J APPL PHYSIOL, V70, P2597, DOI 10.1152/jappl.1991.70.6.2597; MAQUET P, 1992, BRAIN RES, V571, P149, DOI 10.1016/0006-8993(92)90522-B; MCILWAIN H, 1985, NEUROCHEM INT, V7, P103, DOI 10.1016/0197-0186(85)90014-2; PADUA R, 1990, J NEUROCHEM, V54, P1169, DOI 10.1111/j.1471-4159.1990.tb01945.x; PENETAR D, 1993, PSYCHOPHARMACOLOGY, V112, P359, DOI 10.1007/BF02244933; PORTAS CM, IN PRESS NEUROSCIENC; PULL I, 1972, BIOCHEM J, V126, P965, DOI 10.1042/bj1260965; RADULOVACKI M, 1985, Reviews in Clinical and Basic Pharmacology, V5, P327; RAINNIE DG, 1994, SCIENCE, V263, P689, DOI 10.1126/science.8303279; ROSENBERG PA, 1994, J NEUROSCI, V14, P2953; SANDERSON G, 1996, PFLUEGERS ARCH EUR J, V406, P25; SCHRADER J, 1980, PFLUG ARCH EUR J PHY, V387, P245, DOI 10.1007/BF00580977; Schwierin B, 1996, EUR J PHARMACOL, V300, P163, DOI 10.1016/0014-2999(96)00021-0; Shiromani PJ, 1996, MOL BRAIN RES, V38, P77, DOI 10.1016/0169-328X(95)00325-M; STENIADE M, 1996, SCIENCE, V272, P225; STENIADE M, 1990, J NEUROSCI, V10, P2541; Ursin R., 1981, MANUAL STANDARDIZED; VANWYLEN DGL, 1986, J CEREBR BLOOD F MET, V6, P522, DOI 10.1038/jcbfm.1986.97; WINN HR, 1980, CIRC RES, V47, P568, DOI 10.1161/01.RES.47.4.568; WORLEY PF, 1987, P NATL ACAD SCI USA, V84, P3467, DOI 10.1073/pnas.84.10.3467; WU PH, 1984, GEN PHARMACOL, V15, P251, DOI 10.1016/0306-3623(84)90169-1; ZWYGHUIZENDOORENBOS A, 1990, PSYCHOPHARMACOLOGY, V100, P36, DOI 10.1007/BF02245786	42	757	781	2	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	1997	276	5316					1265	1268		10.1126/science.276.5316.1265	http://dx.doi.org/10.1126/science.276.5316.1265			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157887	Green Accepted, Green Submitted			2022-12-28	WOS:A1997XA49700046
J	Greenough, A; Nicolaides, KH				Greenough, A; Nicolaides, KH			Chorionic villus sampling and early amniocentesis for prenatal diagnosis	LANCET			English	Letter									UNIV LONDON KINGS COLL,SCH MED,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON,ENGLAND	University of London; King's College London	Greenough, A (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT CHILD HLTH,LONDON SE5 9RS,ENGLAND.			Nicolaides, Kypros/0000-0003-1266-0711				Greenough A., 1996, Biology of the Neonate, V70, P187; GREENOUGH A, 1996, EUR RESPIR J, V9, P466; GREENOUGH A, IN PRESS EUR J PEDIA; Stranc LC, 1997, LANCET, V349, P711, DOI 10.1016/S0140-6736(96)08169-X; Yuksel B, 1997, THORAX, V52, P181, DOI 10.1136/thx.52.2.181	5	2	2	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1395	1396		10.1016/S0140-6736(05)63235-7	http://dx.doi.org/10.1016/S0140-6736(05)63235-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149723				2022-12-28	WOS:A1997WY34200052
J	Hoeg, JM				Hoeg, JM			Evaluating coronary heart disease risk - Tiles in the mosaic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ULTRAFAST COMPUTED-TOMOGRAPHY; ATHEROSCLEROTIC LESIONS; BLOOD-PRESSURE; ARTERY DISEASE; PREVENTION; QUANTIFICATION; HYPERCHOLESTEROLEMIA; QUANTITATION; PRAVASTATIN; REGRESSION				Hoeg, JM (corresponding author), NHLBI, SECT CELL BIOL,MOL DIS BRANCH,BLDG 10,ROOM 7N115, 10 CTR DR, MSC 1666, BETHESDA, MD 20892 USA.							AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; Amarenco P, 1996, NEW ENGL J MED, V334, P1216; [Anonymous], 1991, JAMA, V265, P3255; Arad Y, 1996, CIRCULATION, V93, P1951, DOI 10.1161/01.CIR.93.11.1951; Beadle GW, 1941, P NATL ACAD SCI USA, V27, P499, DOI 10.1073/pnas.27.11.499; BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391; BYINGTON RP, 1995, AM J CARDIOL, V76, pC54, DOI 10.1016/S0002-9149(99)80471-8; CABIN HS, 1981, AM HEART J, V101, P52, DOI 10.1016/0002-8703(81)90383-5; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DEMER LL, 1994, TRENDS CARDIOVAS MED, V4, P45, DOI 10.1016/1050-1738(94)90025-6; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRUCHART JC, 1992, CLIN CHEM, V38, P793; GARROD AE, 1989, INBORN FACTORS DIS, P248; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Guerci AD, 1997, AM J CARDIOL, V79, P128, DOI 10.1016/S0002-9149(96)00698-4; HOEG JM, 1994, ARTERIOSCLER THROMB, V14, P1066, DOI 10.1161/01.ATV.14.7.1066; Hoeg JM, 1996, P NATL ACAD SCI USA, V93, P11448, DOI 10.1073/pnas.93.21.11448; HONG MK, 1994, ANN INTERN MED, V121, P348, DOI 10.7326/0003-4819-121-5-199409010-00007; KAJINAMI K, 1996, CARDIOL REV, V13, P34; KANNEL WB, 1961, ANN INTERN MED, V55, P33, DOI 10.7326/0003-4819-55-1-33; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; Keren G, 1994, Am J Card Imaging, V8, P129; LENK T, 1927, ROFO-FORTSCHR RONTG, V35, P1265; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MATAR FA, 1994, CATHETER CARDIO DIAG, V33, P214, DOI 10.1002/ccd.1810330305; McCully KS, 1996, NAT MED, V2, P386, DOI 10.1038/nm0496-386; PEDERSEN TR, 1994, LANCET, V344, P1383; RADER DJ, 1994, ANN INTERN MED, V120, P1012, DOI 10.7326/0003-4819-120-12-199406150-00008; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUMBERGER JA, 1994, AM J CARDIOL, V73, P1169, DOI 10.1016/0002-9149(94)90176-7; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SINGER MJ, 1995, CLAY CLAY MINER, V43, P1, DOI 10.1346/CCMN.1995.0430101; STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355; STEINBERG D, 1995, ADV EXP MED BIOL, V369, P39; The Coronary Drug Project, 1973, JAMA-J AM MED ASSOC, V226, P652, DOI DOI 10.1001/JAMA.1973.03230060030009; TOUSSAINT JF, 1995, ARTERIOSCL THROM VAS, V15, P1533; WALSH BW, 1993, J CLIN INVEST, V91, P2126, DOI 10.1172/JCI116437; WISSLER RW, 1994, ATHEROSCLEROSIS, V108, pS3, DOI 10.1016/0021-9150(94)90149-X	43	41	44	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	1997	277	17					1387	1390		10.1001/jama.277.17.1387	http://dx.doi.org/10.1001/jama.277.17.1387			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW261	9134945				2022-12-28	WOS:A1997WW26100029
J	Murray, CJL; Lopez, AD				Murray, CJL; Lopez, AD			Mortality by cause for eight regions of the world: Global Burden of Disease Study	LANCET			English	Article							HEALTH-CARE; TRANSITION	Background Reliable information on causes of death is essential to the development of national and international health policies for prevention and control of disease and injury. Medically certified information is available for less than 30% of the estimated 50.5 million deaths that occur each year worldwide. However, other data sources can be used to develop cause-of-death estimates for populations. To be useful, estimates must be internally consistent, plausible, and reflect epidemiological characteristics suggested by community-level data, The Global Burden of Disease Study (GBD) used various data sources and made corrections for miscoding of important diseases (eg, ischaemic heart disease) to estimate worldwide and regional cause-of-death patterns in 1990 for 14 age-sex groups in eight regions, for 107 causes. Methods Preliminary estimates were developed with available vital-registration data, sample-registration data for India and China, and small-scale population-study data sources, Registration data were corrected for miscoding, and Lorenz-curve analysis was used to estimate cause-of-death patterns in areas without registration. Preliminary estimates were modified to reflect the epidemiology of selected diseases and injuries. Final estimates were checked to ensure that numbers of deaths in specific age-sex groups did not exceed estimates suggested by independent demographic methods. Findings 98% of all deaths in children younger than 15 years are in the developing world. 83% and 59% of deaths at 15-59 and 70 years, respectively, are in the developing world. The probability of death between birth and 15 years ranges from 22.0% in sub-Saharan Africa to 1.1% in the established market economies. Probabilities of death between 15 and 60 years range from 7.2% for women in established market economies to 39.1% for men in sub-Saharan Africa. The probability of a man or woman dying from a non-communicable disease is higher in sub-Saharan Africa and other developing regions than in established market economies. Worldwide in 1990, communicable, maternal, perinatal, and nutritional disorders accounted for 17.2 million deaths, non-communicable diseases for 28.1 million deaths and injuries for 5.1 million deaths. The leading causes of death in 1990 were ischaemic heart disease (6.3 million deaths), cerebrovascular accidents (4.4 million deaths), lower respiratory infections (4.3 diseases (2.9 million), perinatal million), chronic obstructive pulmonary disease (2.2 million), tuberculosis (2.0 million), measles (1.1 million), road-traffic accidents (1.0 million), and lung cancer (0.9 million). Interpretation Five of the ten leading killers are communicable, perinatal, and nutritional disorders largely affecting children. Non-communicable diseases are, however, already major public health challenges in all regions, Injuries, which account for 10% of global mortality, are often ignored as a major cause of death and may require innovative strategies to reduce their toll. The estimates by cause have wide CIs, but provide a foundation for a more informed debate on public-health priorities.	HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; WHO, CH-1211 GENEVA, SWITZERLAND	Harvard University; Harvard T.H. Chan School of Public Health; World Health Organization			Lopez, Alan D/F-1487-2010; Lopez, Alan/AAA-2734-2022	Lopez, Alan D/0000-0001-5818-6512; 				*ADULT MORT MORB P, 1993, POL IMPL AD MORB MOR; ANAND S, IN PRESS J HLTH EC; [Anonymous], 1996, GLOBAL BURDEN DIS CO; CAMPBELL M, 1963, Br Med J, V2, P528; DEFRANCISCO A, 1994, J TROP MED HYG, V97, P69; Frenk J., 1989, Health Policy and Planning, V4, P29, DOI 10.1093/heapol/4.1.29; GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L; Ghana VAST study Team, 1993, LANCET, V342, P7; HAKULINEN T, 1986, INT J EPIDEMIOL, V15, P226, DOI 10.1093/ije/15.2.226; HILL K, BACKGROUND PAPER SER, V6; HULL TH, 1981, MAJALAH DEMOGRAFI IN, V15, P77; LOPEZ AD, 1983, POP B UN, V14, P66; LOZANO R, 1996, FRENCH PARADOX REVIS; Murray C.J, 1994, GLOBAL COMP ASSESSME; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; Murray CJL., 1996, GLOBAL HLTH STAT COM, V1996; MURRAY CJL, 1992, HLTH ADULTS DEV WORL, P23; *OFF REG GEN, 1991, SURV CAUS DEATH RUR; OMONDIODHIAMBO, 1990, J BIOSOC SCI, V22, P63, DOI 10.1017/S0021932000018381; OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375; PARKER DJP, 1992, J EPIDEMIOL COMMUN H, V46, P8, DOI 10.1136/jech.46.1.8; PARKIN DM, 1994, INT J CANCER, V59, P494, DOI 10.1002/ijc.2910590411; Preston SH, 1976, MORTALITY PATTERNS N; Robb-Smith AHT, 1967, ENIGMA CORONARY HEAR; STEHBENS WE, 1987, LANCET, V1, P606; TIMAEUS IM, 1991, DIS MORTALITY SUBSAH; *UN, 1992, WORLD POP PROSP 1992; *WORLD BANK, 1993, WORLD DEV REP	28	2890	3038	3	348	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 3	1997	349	9061					1269	1276		10.1016/S0140-6736(96)07493-4	http://dx.doi.org/10.1016/S0140-6736(96)07493-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142060				2022-12-28	WOS:A1997WW89900007
J	Pedersen, LL; Leese, B				Pedersen, LL; Leese, B			What will a primary care led NHS mean for GP workload? The problem of the lack of an evidence base	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; RANDOMIZED TRIAL; HOME; DISCHARGE; SERVICES; SURGERY; COST	Ongoing negotiations on the general practitioner contract raise the question of remunerating general practitioners for increased workload resulting from the shift from secondary to primary care. A review of the literature shows that there is little evidence on whether a shift of services from secondary to primary care is responsible for general practitioners' increased workload, and scope for making generalisations is limited. The implication is that general practitioners have Little more than anecdotal evidence to support their claims of greatly increased workloads, and there is insufficient evidence to make informed decisions about remunerating general practitioners for the extra work resulting from the changes. Lack of evidence does not, however, mean that there is no problem with workload. It will be increasingly important to identify mechanisms for ensuring that resources follow workload.			Pedersen, LL (corresponding author), UNIV MANCHESTER, NATL PRIMARY CARE RES & DEV CTR, MANCHESTER M13 9PL, LANCS, ENGLAND.							ANDREW RA, 1988, J ROY COLL GEN PRACT, V38, P546; Audit Commission, 1992, ALL DAYS WORK AUD DA; Beecham J, 1995, EC EVALUATION MENTAL; BOWER H, 1996, DOCTOR          0125, P1; BOYCE J, 1992, BRIT MED J, V304, P1174, DOI 10.1136/bmj.304.6835.1174-b; BURNS T, 1991, SCHIZOPHRENIA BULL, V17, P407, DOI 10.1093/schbul/17.3.407; BURNS T, 1993, BRIT J PSYCHIAT, V163, P55, DOI 10.1192/bjp.163.1.55; *DEP HLTH WELSH OF, 1989, GEN PRACT NHS NEW CO; DICK P, 1985, BRIT J PSYCHIAT, V147, P246, DOI 10.1192/bjp.147.3.246; ELLIOT A, 1996, GP              0126, P2; EVANS D, 1995, CHANGING WORK PRACTI; Eyre S, 1996, BRIT J GEN PRACT, V46, P739; Fletcher J, 1996, BR J GEN PRACT, V46, P477; FLOREY CD, 1994, J PUBLIC HEALTH MED, V16, P455; FRY J, 1993, GEN PRACTICE FACTS; *GEN MED SERV COMM, 1996, COR SERV TAK IN; GHOSH S, 1994, BRIT J SURG, V81, P1635, DOI 10.1002/bjs.1800811124; *GRUMP ASTHM STUD, 1994, BRIT MED J, V305, P559; HALLAM A, 1995, EC EVALUATION MENTAL; HAYTER P, 1996, MORALE GEN PRACTICE; HUDHES D, 1993, HLTH POLICY, V25, P39; HUSAIN O, 1996, DOCTOR          0205, P84; KNAPP M, 1994, BRIT J PSYCHIAT, V165, P195, DOI 10.1192/bjp.165.2.195; KNAPP M, 1994, INT J GERIATR PSYCH, V9, P297, DOI 10.1002/gps.930090406; KRASNIK A, 1990, BRIT MED J, V300, P1698, DOI 10.1136/bmj.300.6741.1698; LANGHAM S, 1995, BRIT J GEN PRACT, V45, P665; LILLEY R, 1996, GUARDIAN        1113, P2; LIPLEY N, 1996, GP              0209, P2; MARSH GN, 1992, BRIT J GEN PRACT, V42, P266; NAJI S, 1994, BRIT MED J, V308, P1208; *NHS EX, 1995, DEV NHS PURCH GP FUN; *NHS EX, 1996, PRIM CAR FUT; *NHS EX, 1994, EL9479 NHS EX DEP HL; *NHS EX, 1996, HSG9631 NHSE; *NHS EX, 1995, PRIM CAR LED NHS BRI; *NHS EX DEP HLTH, 1989, 3 NHS EX DEP HLTH; *NHS MAN EX, 1993, HSG9314 NHSME; OCATHAIN A, 1994, J PUBLIC HEALTH MED, V16, P205, DOI 10.1093/oxfordjournals.pubmed.a042958; PETCHEY R, 1996, JUNIOR DOCTORS MED C; PILL RM, 1995, INVESTIGATION IMPACT; SCOTT A, 1995, HEALTH POLICY, V31, P183, DOI 10.1016/0168-8510(94)00697-D; *SECR STAT HLTH, 1996, CHOIC OPP PRIM CAR F; *SECR STAT HLTH SO, 1989, CM849; *SECR STAT HLTH WA, 1989, CM555; WARRY R, 1996, GP              0223, P2; 1996, GP              0119, P1; [No title captured]; 1996, PULSE           0615, P7	48	16	16	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	1997	314	7090					1337	1341		10.1136/bmj.314.7090.1337	http://dx.doi.org/10.1136/bmj.314.7090.1337			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WX975	9158473	Green Published			2022-12-28	WOS:A1997WX97500030
J	Toren, K; Blanc, PD				Toren, K; Blanc, PD			The history of pulp and paper bleaching: Respiratory-health effects	LANCET			English	Article							EXPOSURE		SAHLGRENS UNIV HOSP,INST INTERNAL MED,SECT OCCUPAT MED,S-41345 GOTHENBURG,SWEDEN; UNIV CALIF SAN FRANCISCO,DEPT MED,DIV ENVIRONM & OCCUPAT MED,SAN FRANCISCO,CA	Sahlgrenska University Hospital; University of California System; University of California San Francisco								Berthollet C. L., 1791, ESSAY NEW METHOD BLE; BERTHOLLET CL, 1944, DEPHLOGISTICATED MUR; BLEACHING A, 1993, TAPPI PRESS ANTHOLOG; BOEHM R, 1976, HDB INTOXICATIONEN; Brunello Franco, 1963, LANIERA, V76, P1423; CAMERON C, 1877, DUBLIN J, V49, P116; Ch'iao-Ping L., 1948, CHEM ARTS OLD CHINA; CHARMES CPD, 1799, ART BLEACH PIERC GOO; CLOW NI, 1958, HIST TECHNOLOGY; DAS R, 1993, TOXICOL IND HEALTH, V9, P439, DOI 10.1177/074823379300900304; DAVY H, 1811, PHILOS T R SOC LON 1, P155; EDELSTEIN SM, 1960, DYSTUFF REPORTER, V49, P39; Elkins H. B., 1950, CHEM IND TOXICOLOGY; EULENBERG H, 1876, HDB GEWERBE HYGIENE; Flury F., 1931, SCHADLICHE GASE; GRENQUISTNORDEN B, 1983, RESP EFFECTS IND CHL; HAMILTON A, 1929, IND POISONINGS US; HGGINS SH, 1924, HIST BLEACHING; HIRT L, 1873, GASINHALATIONSKRANKH; Home F., 1756, EXPT BLEACHING; KENNEDY SM, 1992, OCCUP MED, V7, P287; LEHMAN KB, 1886, ARCH HYG, V15, P1; Lehmann Karl B., 1887, ARCH HYG, V17, P231; MCCORD PC, 1926, JAMA-J AM MED ASSOC, V86, P1687; NORDIN J, 1943, YRKESSJUKDOMAR; *ROYAL COLL PHYS, 1869, NOM DIS, P185; SCHEELE CW, 1774, VERENSKAPSACADEMIENS, V35, P89; Singh R. P., 1979, BLEACHING PULP; TARVAINEN K, 1991, CLIN EXP ALLERGY, V21, P609, DOI 10.1111/j.1365-2222.1991.tb00854.x; Thackrah C., 1832, EFFECTS ARTS TRADES; Toren K, 1996, AM J IND MED, V29, P111, DOI 10.1002/(SICI)1097-0274(199602)29:2<111::AID-AJIM1>3.3.CO;2-X	31	30	30	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1316	1318		10.1016/S0140-6736(96)10141-0	http://dx.doi.org/10.1016/S0140-6736(96)10141-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142078				2022-12-28	WOS:A1997WW89900044
J	Hassig, CA; Fleischer, TC; Billin, AN; Schreiber, SL; Ayer, DE				Hassig, CA; Fleischer, TC; Billin, AN; Schreiber, SL; Ayer, DE			Histone deacetylase activity is required for full transcriptional repression by mSin3A	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; MYC-MAX; NEGATIVE REGULATOR; SODIUM-BUTYRATE; YEAST; PROTEIN; ACTIVATION; DIFFERENTIATION; ACETYLATION; NUCLEOSOME	Members of the Mad family of bHLH-Zip proteins heterodimerize with Max to repress transcription in a sequence-specific manner. Transcriptional repression by Mad:Max heterodimers is mediated by ternary complex formation with either of the corepressors mSin3A or mSin3B. We report here that mSin3A is an in vivo component of large, heterogeneous multiprotein complexes and is tightly and specifically associated with at least seven polypeptides. Two of the mSin3A-associated proteins, p50 and p55, are highly related to the histone deacetylase HDAC1. The mSin3A immunecomplexes possess histone deacetylase activity that is sensitive to the specific deacetylase inhibitor trapoxin. mSin3A-targeted repression of a reporter gene is reduced by trapoxin treatment, suggesting that histone deacetylation mediates transcriptional repression through Mad-Max-mSin3A multimeric complexes.	UNIV UTAH,HUNTSMAN CANC INST,DEPT ONCOL SCI,DIV MOL BIOL & GENET,SALT LAKE CITY,UT 84112; HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Harvard University; Howard Hughes Medical Institute; Harvard University; Howard Hughes Medical Institute				Fleischer, Tracey C/0000-0002-7141-4265; Ayer, Donald/0000-0002-5595-3269; Billin, Andrew/0000-0001-7752-0934	NIGMS NIH HHS [GM38617] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BEMARDS R, 1995, CURR BIOL, V5, P859; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; DeRubertis F, 1996, NATURE, V384, P589; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; JOHNSTON LA, 1992, MOL CELL BIOL, V12, P5123, DOI 10.1128/MCB.12.11.5123; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LOIDL P, 1994, CHROMOSOMA, V103, P441; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MCKNIGHT GS, 1980, CELL, V22, P469; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; STERNECK E, 1992, MOL CELL BIOL, V12, P1728, DOI 10.1128/MCB.12.4.1728; STILLMAN DJ, 1994, GENETICS, V136, P781; SUSSEL L, 1995, GENETICS, V141, P873; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Taunton J, 1996, J AM CHEM SOC, V118, P10412, DOI 10.1021/ja9615841; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; WANG HM, 1994, MOL GEN GENET, V245, P675, DOI 10.1007/BF00297274; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIMOTO H, 1992, MOL GEN GENET, V233, P327, DOI 10.1007/BF00587597; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	43	654	678	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					341	347		10.1016/S0092-8674(00)80214-7	http://dx.doi.org/10.1016/S0092-8674(00)80214-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150133	Bronze			2022-12-28	WOS:A1997WX89900004
J	Yoo, CJ; Wolin, SL				Yoo, CJ; Wolin, SL			The yeast la protein is required for the 3' endonucleolytic cleavage that matures tRNA precursors	CELL			English	Article							RNA POLYMERASE-III; SUPPRESSOR TRANSFER-RNA; LUPUS ANTIGEN-LA; SACCHAROMYCES-CEREVISIAE; INTERVENING SEQUENCE; TRANSCRIPTION; AUTOANTIGEN; EXPRESSION; GENES; ASSOCIATION	Although the La autoantigen binds to the 3' ends of all nascent polymerase III transcripts, its function in vivo has long been unclear. Although S. cerevisiae cells lacking the La protein homolog Lhp1p are viable, cells containing a mutation that disrupts the anticodon stem of tRNAS(CGA)(Ser) require Lhp1p for growth. We demonstrate that for the wild-type pre-tRNAS(CGA)(Ser) and other pretRNAs, Lhp1p is required for the normal endonucleolytic removal of the 3' trailer sequence. In cells lacking Lhp1p, the 3' trailer is removed by exonuclease(s). Although maturation of the mutant pre-tRNA(CGA)(Ser) requires Lhp1p, introduction of a second mutation that restores base pairing eliminates the requirement. We propose that binding by Lhp1p stabilizes pre-tRNAs in conformations that allow the 3' endonucleolytic cleavage to occur.	YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA	Howard Hughes Medical Institute; Yale University	Yoo, CJ (corresponding author), YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA.		Wolin, Sandra/H-2333-2016	Wolin, Sandra/0000-0001-6730-0399	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048410] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29-GM48410] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman Sidney, 1995, P67; BARRELL BG, 1971, PROCEDURES NUCL ACID, P751; BOELENS WC, 1995, RNA, V1, P273; BRANCH AD, 1989, METHOD ENZYMOL, V180, P130; CHAMBERS JC, 1988, J BIOL CHEM, V263, P18043; CHAMBERS JC, 1983, J BIOL CHEM, V258, P1438; ETCHEVERRY T, 1979, CELL, V18, P11, DOI 10.1016/0092-8674(79)90349-0; ETCHEVERRY T, 1982, J MOL BIOL, V158, P599, DOI 10.1016/0022-2836(82)90251-0; EVANS CF, 1990, METHOD ENZYMOL, V181, P439; FURTER R, 1992, BIOCHEMISTRY-US, V31, P10817, DOI 10.1021/bi00159a024; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOFF CG, 1984, GENE, V27, P35, DOI 10.1016/0378-1119(84)90236-1; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; Grimm C, 1997, EMBO J, V16, P793, DOI 10.1093/emboj/16.4.793; HENDRICK JP, 1981, MOL CELL BIOL, V1, P1138, DOI 10.1128/MCB.1.12.1138; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; LINMARQ N, 1995, J MOL BIOL, V245, P81, DOI 10.1006/jmbi.1994.0008; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; McBratney S, 1996, MOL CELL BIOL, V16, P3523; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; NICHOLS M, 1990, METHOD ENZYMOL, V181, P377; OCONNOR JP, 1991, MOL CELL BIOL, V11, P425, DOI 10.1128/MCB.11.1.425; OLSON MV, 1981, NATURE, V291, P464, DOI 10.1038/291464a0; PEARSON D, 1985, MOL CELL BIOL, V5, P808, DOI 10.1128/MCB.5.4.808; Peek R, 1996, EUR J BIOCHEM, V236, P649, DOI 10.1111/j.1432-1033.1996.0649d.x; RINKE J, 1985, NUCLEIC ACIDS RES, V13, P2617, DOI 10.1093/nar/13.7.2617; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SCHERLY D, 1993, J MOL BIOL, V231, P196, DOI 10.1006/jmbi.1993.1275; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Simons FHM, 1996, RNA, V2, P264; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; TARN WY, 1995, RNA, V1, P644; VALENZUELA P, 1978, P NATL ACAD SCI USA, V75, P190, DOI 10.1073/pnas.75.1.190; YOO CJ, 1994, MOL CELL BIOL, V14, P5412, DOI 10.1128/MCB.14.8.5412; Yu W, 1996, MOL CELL BIOL, V16, P2464	38	221	225	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	1997	89	3					393	402		10.1016/S0092-8674(00)80220-2	http://dx.doi.org/10.1016/S0092-8674(00)80220-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150139	hybrid			2022-12-28	WOS:A1997WX89900010
J	Bujalska, IJ; Kumar, S; Stewart, PM				Bujalska, IJ; Kumar, S; Stewart, PM			Does central obesity reflect ''Cushing's disease of the omentum''?	LANCET			English	Article							BODY-FAT DISTRIBUTION; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; TISSUE DISTRIBUTION; ADIPOSE-TISSUE; CELLS; GLUCOCORTICOIDS; LOCALIZATION; HEPATOCYTES; ISOFORM; ENZYME	Background Central obesity results in a cluster of metabolic abnormalities contributing to premature death. Glucocorticoids regulate adipose-tissue differentiation, function, and distribution, and in excess, cause central obesity. Glucocorticoid hormone action is, in part, controlled by two isoforms of the enzyme 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) which interconverts hormonally active cortisol to inactive cortisone. We studied cortisol metabolism within different adipose tissue depots. Methods We analysed expression and activity of the two isoforms (1 and 2) of 11 beta-HSD in cultured omental and subcutaneous adipose stromal cells from 16 patients undergoing elective abdominal surgery. Findings Only the type 1 isoform (11 beta-HSD1) was expressed in adipose stromal cells. The predominant activity was oxo-reductase (conversion of cortisone to cortisol greater than cortisol to cortisone) and was higher in omental than subcutaneous fat (cortisone to cortisol, median 57.6 pmol mg(-1) h(-1) [95% CI 25.8-112.9] vs 0 pmol mg(-1) h(-1) [0-0.6], p < 0.001). 11 beta-HSD1 oxo-reductase activity was further increased (127.5 pmol mg(-1) h(-1) [82.1-209], p < 0.05) when omental adipose stromal cells were treated with cortisol and insulin. Interpretation Adipose stromal cells from omental fat, but not subcutaneous fat, can generate active cortisol from inactive cortisone through the expression of 11 beta-HSD1. The expression of this enzyme is increased further after exposure to cortisol and insulin. In vivo, such a mechanism would ensure a constant exposure of glucocorticoid specifically to omental adipose tissue, suggesting that central obesity may reflect ''Cushing's disease of the omentum''.	UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham			kumar, sudhesh/D-6945-2013	kumar, sudhesh/0000-0003-4326-5941				ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; BJORNTORP P, 1991, DIABETES CARE, V14, P1132, DOI 10.2337/diacare.14.12.1132; BRONNEGARD M, 1995, J CLIN ENDOCR METAB, V80, P3608, DOI 10.1210/jc.80.12.3608; BRONNEGARD M, 1990, ENDOCRINOLOGY, V127, P1689; DAROMINT C, 1994, ENDOCRINOLOGY, V135, P2030; DUNKELMAN SS, 1964, J CLIN ENDOCR METAB, V24, P832, DOI 10.1210/jcem-24-9-832; EDWARDS C R W, 1985, Journal of Endocrinology, V104, P53; EDWARDS CRW, 1988, LANCET, V2, P836; FRIED SK, 1993, J CLIN INVEST, V92, P2191, DOI 10.1172/JCI116821; GLASS AR, 1981, METABOLISM, V30, P89, DOI 10.1016/0026-0495(81)90224-9; HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345; JAMIESON PM, 1995, ENDOCRINOLOGY, V136, P4754, DOI 10.1210/en.136.11.4754; MARTIN P, 1992, METABOLISM, V41, P882; MAYOSMITH W, 1989, RADIOLOGY, V170, P515, DOI 10.1148/radiology.170.2.2911678; MUNE T, 1995, NAT GENET, V10, P394, DOI 10.1038/ng0895-394; PASQUALI R, 1993, J CLIN ENDOCR METAB, V77, P341, DOI 10.1210/jc.77.2.341; REBUFFESCRIVE M, 1988, J CLIN ENDOCR METAB, V67, P1122, DOI 10.1210/jcem-67-6-1122; SIMPSON ER, 1989, ENDOCR REV, V10, P136, DOI 10.1210/edrv-10-2-136; Stewart PM, 1996, LANCET, V347, P88, DOI 10.1016/S0140-6736(96)90211-1; STEWART PM, 1994, J CLIN ENDOCR METAB, V79, P480, DOI 10.1210/jc.79.2.480; Stewart PM, 1996, CLIN ENDOCRINOL, V44, P493, DOI 10.1046/j.1365-2265.1996.716535.x; TANNIN GM, 1991, J BIOL CHEM, V266, P16653; WHORWOOD CB, 1995, MOL CELL ENDOCRINOL, V110, pR7, DOI 10.1016/0303-7207(95)03546-J; ZHAO Y, 1995, MOL ENDOCRINOL, V9, P340, DOI 10.1210/me.9.3.340	24	608	639	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1210	1213		10.1016/S0140-6736(96)11222-8	http://dx.doi.org/10.1016/S0140-6736(96)11222-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130942				2022-12-28	WOS:A1997WW71700010
J	Cheung, P; Hungin, APS; Verrill, J; Russell, AJ; Smith, H				Cheung, P; Hungin, APS; Verrill, J; Russell, AJ; Smith, H			Are the Health of the Nation's targets attainable? Postal survey of general practitioners' views	BRITISH MEDICAL JOURNAL			English	Article											Cheung, P (corresponding author), UNIV DURHAM,CTR HLTH STUDIES,DURHAM DH1 3JT,ENGLAND.		Smith, Helen E/M-2449-2016	Smith, Helen E/0000-0003-1883-6124; hungin, amritpal Pali/0000-0001-7275-8927				*DEP HLTH, 1995, HLTH PERS SOC SERV S; *HOUS COMM COMM PU, 1996, HLTH NAT PROGR REP; McAvoy BR, 1996, BRIT MED J, V313, P732; Secretary of State for Health, 1992, HLTH NAT STRAT HLTH	4	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 26	1997	314	7089					1250	1251		10.1136/bmj.314.7089.1250	http://dx.doi.org/10.1136/bmj.314.7089.1250			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW718	9154030	Green Published, Green Submitted			2022-12-28	WOS:A1997WW71800022
J	Hourihane, JO; Bedwani, SJ; Dean, TP; Warner, JO				Hourihane, JO; Bedwani, SJ; Dean, TP; Warner, JO			Randomised, double blind, crossover challenge study of allergenicity of peanut oils in subjects allergic to peanuts	BRITISH MEDICAL JOURNAL			English	Article							FOOD; ANAPHYLAXIS	Objective: To determine the in vivo allergenicity of two grades of peanut oil for a large group of subjects with proved allergy to peanuts. Design: Double blind, crossover food challenge with crude peanut oil and refined peanut oil. Setting: Dedicated clinical investigation unit in a university hospital. Subjects: 60 subjects allergic to peanuts; allergy was confirmed by challenge tests. Outcome measures: Allergic reaction to the tested peanut oils. Results: None of the 60 subjects reacted to the refined oil; six (10%) reacted to the crude oil. Supervised peanut challenge caused considerably less severe reactions than subjects had reported previously. Conclusions: Crude peanut oil caused allergic reactions in 10% of allergic subjects studied and should continue to be avoided. Refined peanut oil did not pose a risk to any of the subjects. It would be reasonable to recommend a change in labelling to distinguish refined from crude peanut oil.			Hourihane, JO (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT CHILD HLTH,MAILPOINT 803,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.		Warner, John/AAF-9587-2020	Dean, Taraneh/0000-0002-0123-7646				AMLOT PL, 1987, CLIN ALLERGY, V17, P33, DOI 10.1111/j.1365-2222.1987.tb02317.x; ATKINS FM, 1988, J ALLERGY CLIN IMMUN, V82, P242, DOI 10.1016/0091-6749(88)91006-8; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; David T. J., 1993, FOOD FOOD ADDITIVE I; EWEN P, 1996, BRIT MED J, V312, P1074; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P1101; HOFFMAN DR, 1994, J ALLERGY CLIN IMMUN, V93, P801, DOI 10.1016/0091-6749(94)90262-3; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; KEATING MU, 1990, J ALLERGY CLIN IMMUN, V86, P41, DOI 10.1016/S0091-6749(05)80121-6; *NAT PEAN COUNC AM, 1994, INF SHEET; Sampson HA, 1996, BRIT MED J, V312, P1050; SAMPSON HA, 1990, J ALLERGY CLIN IMMUN, V86, P1, DOI 10.1016/S0091-6749(05)80115-0; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	17	112	115	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 12	1997	314	7087					1084	1088		10.1136/bmj.314.7087.1084	http://dx.doi.org/10.1136/bmj.314.7087.1084			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU236	9133891	Green Published			2022-12-28	WOS:A1997WU23600025
J	Mostov, K; Werb, Z				Mostov, K; Werb, Z			Cell biology - Journey across the osteoclast	SCIENCE			English	Editorial Material							MODULATION				Mostov, K (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA.			mostov, keith/0000-0002-8123-6247	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036953, R01AI025144, R37AI025144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25144, AI36953] Funding Source: Medline; NIDCR NIH HHS [DE10306] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Apodaca G, 1996, EMBO J, V15, P1471, DOI 10.1002/j.1460-2075.1996.tb00491.x; BARON R, 1988, J CELL BIOL, V106, P1863, DOI 10.1083/jcb.106.6.1863; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; GRIFFITHS GM, 1995, CURR OPIN IMMUNOL, V7, P343, DOI 10.1016/0952-7915(95)80108-1; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208; NESBITT S, 1993, J BIOL CHEM, V268, P16737; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Salo J, 1996, J CELL SCI, V109, P301; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; WERB Z, 1989, AM J PATHOL, V134, P661	17	60	64	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	1997	276	5310					219	220		10.1126/science.276.5310.219	http://dx.doi.org/10.1126/science.276.5310.219			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9132944				2022-12-28	WOS:A1997WT92500032
J	Ghayur, T; Banerjee, S; Hugunin, M; Butler, D; Herzog, L; Carter, A; Quintal, L; Sekut, L; Talanian, R; Paskind, M; Wong, W; Kamen, R; Tracey, D; Allen, H				Ghayur, T; Banerjee, S; Hugunin, M; Butler, D; Herzog, L; Carter, A; Quintal, L; Sekut, L; Talanian, R; Paskind, M; Wong, W; Kamen, R; Tracey, D; Allen, H			Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production	NATURE			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; INTERFERON-GAMMA; ENDOTOXIC-SHOCK; MICE DEFICIENT; CELLS; IL-1-BETA; APOPTOSIS; PATHOGENS; CYTOKINE; PROTEASE	Interferon-gamma-inducing factor (IGIF, interleukin-18) is a recently described cytokine that shares structural features with the interleukin-1 (IL-1) family of proteins and functional properties with IL-12(1-4). Like IL-12, IGIF is a potent inducer of interferon (IFN)-gamma from T cells and natural killer cells(1-3,5,6). IGIF is synthesized as a biologically inactive precursor molecule (proIGIF). The cellular production of IL-1 beta, a cytokine implicated in a variety of inflammatory diseases, requires cleavage of its precursor (proIL-1 beta) at an Asp-X site by interleukin-1 beta-converting enzyme(7,8) (ICE, recently termed caspase-1(9)), The Asp-X sequence at the putative processing site in proIGIF(2,3) suggests that a protease such as caspase-1 might be involved in the maturation of IGIF(4). Here we demonstrate that caspase-1 processes proIGIF and pron-1 beta with equivalent efficiencies in vitro. A selective caspase-1 inhibitor blocks both lipopolysaccharide-induced IL-1 beta and IFN-gamma production from human mononuclear cells. Furthermore, caspase-1-deficient mice are defective in lipopolysaccharide-induced IFN-gamma production, Our results thus implicate caspase-1 in the physiological production of IGIF and demonstrate that it plays a critical role in the regulation of multiple proinflammatory cytokines. Specific caspase-1 inhibitors would provide a new class of antiinflammatory drugs with multipotent action.			Ghayur, T (corresponding author), BASF BIORES CORP,100 RES DR,WORCESTER,MA 01605, USA.							Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bazan JF, 1996, NATURE, V379, P591, DOI 10.1038/379591a0; CAMPBELL IL, 1991, J CLIN INVEST, V87, P739, DOI 10.1172/JCI115055; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; FLETCHER DS, 1995, J INTERF CYTOK RES, V15, P243, DOI 10.1089/jir.1995.15.243; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; HUNTER CA, 1995, J IMMUNOL, V155, P4347; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOCKSLEY RM, 1993, P NATL ACAD SCI USA, V90, P5879, DOI 10.1073/pnas.90.13.5879; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736; NAKAMURA K, 1993, INFECT IMMUN, V61, P64, DOI 10.1128/IAI.61.1.64-70.1993; NEURATH MF, 1995, J EXP MED, V182, P1281, DOI 10.1084/jem.182.5.1281; OKAMURA H, 1995, INFECT IMMUN, V63, P3966, DOI 10.1128/IAI.63.10.3966-3972.1995; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Ushio S, 1996, J IMMUNOL, V156, P4274	25	1014	1064	1	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 10	1997	386	6625					619	623		10.1038/386619a0	http://dx.doi.org/10.1038/386619a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121587				2022-12-28	WOS:A1997WT27300062
J	McNamee, D; Horton, R				McNamee, D; Horton, R			Fast-track to publication in The Lancet	LANCET			English	Editorial Material																			0	5	5	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					970	970		10.1016/S0140-6736(05)62891-7	http://dx.doi.org/10.1016/S0140-6736(05)62891-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9132517				2022-12-28	WOS:A1997WR62100007
J	Ellis, PA; Smith, IE; McCarthy, K; Detre, S; Salter, J; Dowsett, M				Ellis, PA; Smith, IE; McCarthy, K; Detre, S; Salter, J; Dowsett, M			Preoperative chemotherapy induces apoptosis in early breast cancer	LANCET			English	Article									ROYAL MARSDEN HOSP,DEPT ACAD BIOCHEM,LONDON SW3 6JJ,ENGLAND; ROYAL MARSDEN HOSP,DEPT PATHOL,LONDON SW3 6JJ,ENGLAND; ROYAL MARSDEN HOSP,BREAST UNIT,LONDON SW3 6JJ,ENGLAND	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust	Ellis, PA (corresponding author), ROYAL MARSDEN HOSP,DEPT MED,LONDON SW3 6JJ,ENGLAND.							HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; MEYN RE, 1994, CANCER CHEMOTH PHARM, V33, P410, DOI 10.1007/BF00686270; SMITH IE, 1995, J CLIN ONCOL, V13, P424, DOI 10.1200/JCO.1995.13.2.424; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025	5	118	125	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					849	849		10.1016/S0140-6736(05)61752-7	http://dx.doi.org/10.1016/S0140-6736(05)61752-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121265				2022-12-28	WOS:A1997WP40300018
J	Daugherty, CK; Siegler, M; Ratain, MJ; Zimmer, G				Daugherty, CK; Siegler, M; Ratain, MJ; Zimmer, G			Learning from our patients: One participant's impact on clinical trial research and informed consent	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PHASE-I; AIDS; DRUGS	This Perspective includes an essay on modifying phase I clinical trials, written by George Zimmer, who was a professor of English and a commentary on that essay. Professor Zimmer was a cancer patient who participated in the phase I clinical trial program at the University of Chicago. His ideas are eloquently expressed and have had a profound effect on our investigational research for anticancer agents. Although at times his suggestions may seem radical, Professor Zimmer urges us to reconsider the 50-year-old Nuremberg paradigm that participants in human research are ignorant and vulnerable and must be protected. Although we must protect patients who have life-threatening diseases from coercive inducements and misplaced hopes, we must also listen carefully and thoughtfully to our patients. This is particularly true when, as research participants in the face of sacrifice and the threat of a life-ending diagnosis, they have made the effort to express their concerns. With the effect of the acquired immunodeficiency syndrome movement on clinical studies and on drug research and development, a precedent has been set that allows patients to reshape their role as participants in research trials. On a personal level, the essay by Professor Zimmer has had a significant effect on our research methods and, indeed, the focus of our research efforts. Thus, it is with a sense of respect and honor that we share George Zimmer's thoughts and our comments about the influence he has had on our research practices.	UNIV CHICAGO, CANC RES CTR, SECT HEMATOL & ONCOL, COMM CLIN PHARMACOL, CHICAGO, IL 60637 USA	University of Chicago	Daugherty, CK (corresponding author), UNIV CHICAGO, MACLEAN CTR CLIN MED ETH, HEMATOL ONCOL SECT, MC-2115, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA.				NCI NIH HHS [N01-CMO7301] Funding Source: Medline; DIVISION OF CANCER TREATMENT [N01CM007301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER TREATMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Treatment & Diagnosis)		ARNO PETER S., 1992, ODDS STORY AIDS DRUG, P109; CAPENTER CC, 1996, JAMA-J AM MED ASSOC, V276, P146; CARTER SK, 1995, J ACQ IMMUN DEF SYND, V10, pS107; COTTON P, 1991, JAMA-J AM MED ASSOC, V266, P757, DOI 10.1001/jama.266.6.757; DAUGHERTY C, 1995, J CLIN ONCOL, V13, P1062, DOI 10.1200/JCO.1995.13.5.1062; DAUGHERTY C, 1996, P AN M AM SOC CLIN, V15, pA1713; Daugherty CK, 1996, P AN M AM SOC CLIN, V15, p352a; DECOSTER G, 1990, ANN ONCOL, V1, P175, DOI 10.1093/oxfordjournals.annonc.a057716; DEVITA VT, 1993, CANCER PRINCIPLES PR, P276; *DRUG ADV COMM M, 1996, DRUG ADV COMM M JUN; EDGAR H, 1990, MILBANK Q, V68, P111, DOI 10.2307/3350178; FADEN RR, 1986, HIST THOERY INFORMED; FLINTOR L, 1991, JNCI-J NATL CANCER I, V83, P528; GOTAY CC, 1991, SOC SCI MED, V33, P569, DOI 10.1016/0277-9536(91)90214-W; HENDEE WR, 1991, J NATL CANCER I, V83, P254; JONAS H, 1970, EXPT HUMAN SUBJECTS; Langer A S, 1992, J Am Med Womens Assoc (1972), V47, P207; Levine RJ, 1986, ETHICS REGULATION CL, V2nd; Levine Robert J., 1994, Kennedy Institute of Ethics Journal, V4, P93; McIntosh H, 1990, J Natl Cancer Inst, V82, P730, DOI 10.1093/jnci/82.9.730; *NAT COMM PROT HUM, 1978, 780012G OS DHEW; RATAIN MJ, 1993, J NATL CANCER I, V85, P1637, DOI 10.1093/jnci/85.20.1637; Rothenberg ML, 1996, J CLIN ONCOL, V14, P1128, DOI 10.1200/JCO.1996.14.4.1128; STEELE F, 1995, NAT MED, V1, P285, DOI 10.1038/nm0495-285; STOUT H, 1996, WALL STREET J   0329, pB1; SUBPART H, 1992, FED REG 314; VONHOFF DD, 1991, INVEST NEW DRUG, V9, P115, DOI 10.1007/BF00194562; WACHTER RM, 1992, NEW ENGL J MED, V326, P128, DOI 10.1056/NEJM199201093260209	28	26	26	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1997	126	11					892	897		10.7326/0003-4819-126-11-199706010-00008	http://dx.doi.org/10.7326/0003-4819-126-11-199706010-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XA911	9163291				2022-12-28	WOS:A1997XA91100007
J	Liem, MSL; vanderGraaf, Y; vanSteensel, CJ; Boelhouwer, RU; Clevers, GJ; Meijer, WS; Stassen, LPS; Vente, JP; Weidema, WF; Schrijvers, AJP; vanVroonhoven, TJMV				Liem, MSL; vanderGraaf, Y; vanSteensel, CJ; Boelhouwer, RU; Clevers, GJ; Meijer, WS; Stassen, LPS; Vente, JP; Weidema, WF; Schrijvers, AJP; vanVroonhoven, TJMV			Comparison of conventional anterior surgery and laparoscopic surgery for inguinal-hernia repair	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED TRIAL; HERNIORRHAPHY; GROIN; WORK	Background Inguinal hernias can be repaired by laparoscopic techniques, which have had better results than open surgery in several small studies. Methods We performed a randomized, multicenter trial in which 487 patients with inguinal hernias were treated by extraperitoneal laparoscopic repair and 507 patients were treated by conventional anterior repair. We recorded information about postoperative recovery and complications and examined the patients for recurrences one and six weeks, six months, and one and two years after surgery. Results Six patients in the open-surgery group but none in the laparoscopic-surgery group had wound abscesses (P=0.03), and the patients in the laparoscopic-surgery group had a more rapid recovery (median time to the resumption of normal daily activity, 6 vs. 10 days; time to the return to work, 14 vs. 21 days; and time to the resumption of athletic activities, 24 vs. 36 days; P<0.001 for all comparisons). With a median follow-up of 607 days, 31 patients (6 percent) in the open-surgery group had recurrences, as compared with 17 patients (3 percent) in the laparoscopic-surgery group (P=0.05). All but three of the recurrences in the latter group were within one year after surgery and were caused by surgeon-related errors. In the open-surgery group, 15 patients had recurrences during the first year, and 16 during the second year. Follow-up was complete for 97 percent of the patients. Conclusions Patients with inguinal hernias who undergo laparoscopic repair recover more rapidly and have fewer recurrences than those who undergo open surgical repair. (C) 1997, Massachusetts Medical Society.	UNIV UTRECHT HOSP,DEPT SURG,UTRECHT,NETHERLANDS; UNIV UTRECHT,DEPT EPIDEMIOL & PUBL HLTH,UTRECHT,NETHERLANDS; IKAZIA HOSP,DEPT SURG,ROTTERDAM,NETHERLANDS; DIAKONESSEN HOSP,DEPT SURG,UTRECHT,NETHERLANDS; ST CLARA HOSP,DEPT SURG,ROTTERDAM,NETHERLANDS; REINER DE GRAAF GASTHUIS,DEPT SURG,DELFT,NETHERLANDS; HOFPOORT HOSP,DEPT SURG,WOERDEN,NETHERLANDS	Utrecht University; Utrecht University Medical Center; Utrecht University; Ikazia Hospital; Diakonessenhuis; Reinier de Graaf Hospital								BARKUN JS, 1995, SURGERY, V118, P703, DOI 10.1016/S0039-6060(05)80038-8; *DUTCH CTR HLTH CA, 1995, ANN COMP DISK HOSP A; FELIX EL, 1995, SURG ENDOSC-ULTRAS, V9, P984; HAY JM, 1995, ANN SURG, V222, P719, DOI 10.1097/00000658-199512000-00005; ILES JDH, 1965, LANCET, V1, P751, DOI 10.1016/S0140-6736(65)92109-4; LAWRENCE K, 1995, BRIT MED J, V311, P981; LICHTENSTEIN IL, 1993, SURG CLIN N AM, V73, P529; LICHTENSTEIN IL, 1976, AM J SURG, V132, P307, DOI 10.1016/0002-9610(76)90381-0; Liem MSL, 1997, BRIT J SURG, V84, P64; Liem MSL, 1996, BRIT J SURG, V83, P1197, DOI 10.1002/bjs.1800830907; Liem MSL, 1996, AM J SURG, V171, P281, DOI 10.1016/S0002-9610(97)89569-4; MCKERNAN JB, 1993, SURG ENDOSC-ULTRAS, V7, P26, DOI 10.1007/BF00591232; NYHUS LM, 1993, SURGERY, V114, P1; PAYNE JH, 1994, ARCH SURG-CHICAGO, V129, P979; PEACOCK EE, 1974, ANN SURG, V179, P567, DOI 10.1097/00000658-197405000-00007; PICAVET HSJ, 1992, MNDBER GEZONDHEID CB, V7, P5; RIDER MA, 1993, BRIT J SURG, V80, P745, DOI 10.1002/bjs.1800800629; SALCEDOWASICEK MC, 1995, ARCH SURG-CHICAGO, V130, P129; SCHUMPELICK V, 1994, LANCET, V344, P375; SHULMAN AG, 1994, BRIT MED J, V309, P216, DOI 10.1136/bmj.309.6949.216; SOPER NJ, 1994, NEW ENGL J MED, V330, P409, DOI 10.1056/NEJM199402103300608; STOKER D, 1994, LANCET, V343, P1243, DOI 10.1016/S0140-6736(94)92148-2; STOPPA RE, 1989, WORLD J SURG, V13, P545, DOI 10.1007/BF01658869; Streiner DL., 2001, HLTH MEASUREMENT SCA, V2nd; VOGT DM, 1995, AM J SURG, V169, P84, DOI 10.1016/S0002-9610(99)80114-7; 1977, BRIT MED J, V2, P3; 1994, MNDSTAT BEVOLK, V10, P24	27	365	397	0	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	1997	336	22					1541	1547		10.1056/NEJM199705293362201	http://dx.doi.org/10.1056/NEJM199705293362201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB087	9164809				2022-12-28	WOS:A1997XB08700001
J	Cole, CW				Cole, CW			Prospects for screening for abdominal aortic aneurysms	LANCET			English	Editorial Material											Cole, CW (corresponding author), OTTAWA GEN HOSP,DEPT SURG,OTTAWA,ON K1H 8L6,CANADA.							Cole C W, 1996, Chronic Dis Can, V17, P51; FRAME PS, 1993, ANN INTERN MED, V119, P411, DOI 10.7326/0003-4819-119-5-199309010-00010; LEDERLE FA, 1994, J VASC SURG, V20, P296, DOI 10.1016/0741-5214(94)90019-1; Lindholt JS, 1997, BRIT J SURG, V84, P40; POWELL JT, 1993, LANCET, V342, P1473, DOI 10.1016/0140-6736(93)92939-Q; SCOTT RAP, 1995, BRIT J SURG, V82, P1066, DOI 10.1002/bjs.1800820821	6	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 24	1997	349	9064					1490	1491		10.1016/S0140-6736(05)62093-4	http://dx.doi.org/10.1016/S0140-6736(05)62093-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167454				2022-12-28	WOS:A1997XA90100004
J	Marder, SR; Torruellas, WE; BlanchardDesce, M; Ricci, V; Stegeman, GI; Gilmour, S; Bredas, JL; Li, J; Bublitz, GU; Boxer, SG				Marder, SR; Torruellas, WE; BlanchardDesce, M; Ricci, V; Stegeman, GI; Gilmour, S; Bredas, JL; Li, J; Bublitz, GU; Boxer, SG			Large molecular third-order optical nonlinearities in polarized carotenoids	SCIENCE			English	Article							POLARIZABILITIES; SUSCEPTIBILITY; GENERATION; POLYENES; LENGTH; BETA	Garito and cc-workers have suggested a mechanism to dramatically increase the second hyperpolarizability, gamma, in linear pi-electron-conjugated molecules. Polarization is introduced that leads to a difference between the dipole moments of the molecule's ground state and excited state. Here a series of carotenoids was examined that had increasing intramolecular charge transfer (ICT) from the polyenic chain to the acceptor moiety in the ground state, and gamma was measured for these compounds as a function of wavelength by third-harmonic generation. The compound with the greatest ICT exhibited a 35-fold enhancement of gamma(max) (the gamma measured at the peak of the three-photon resonance) relative to the symmetric molecule beta-carotene, which itself has one of the largest third-order nonlinearities known. Stark spectroscopic measurements revealed the existence of a large difference dipole moment, Delta mu, between the ground and excited state. Quantum-chemical calculations underline the importance of interactions involving states with large Delta mu.	CALTECH,JET PROP LAB,PASADENA,CA 91109; UNIV CENT FLORIDA,CTR RES EDUC OPT & LASERS,ORLANDO,FL 32816; ECOLE NORMALE SUPER,DEPT CHIM,URA 1679,CNRS,F-75231 PARIS 05,FRANCE; UNIV MONS,CTR RES MOL ELECT & PHOTON,B-7000 MONS,BELGIUM; STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); State University System of Florida; University of Central Florida; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); University of Mons; Stanford University	Marder, SR (corresponding author), CALTECH,BECKMAN INST,PASADENA,CA 91125, USA.		Bredas, Jean-Luc E/A-3431-2008	Bredas, Jean-Luc E/0000-0001-7278-4471; Boxer, Steven/0000-0001-9167-4286				ALMOGY G, 1994, OPT LETT, V19, P1828, DOI 10.1364/OL.19.001828; ARAMAKI S, 1991, OPT COMMUN, V85, P527, DOI 10.1016/0030-4018(91)90590-A; BELJONNE D, IN PRESS PHYS REV B; Blanchard-Desce M., 1995, Nonlinear Optics, Principles, Materials, Phenomena and Devices, V10, P23; BLANCHARDDESCE M, IN PRESS J PHOTOCH A; BLANCHARDFDESCE M, IN PRESS CHEM EUR J; CAPASSO F, 1994, IEEE J QUANTUM ELECT, V30, P1313, DOI 10.1109/3.303697; DEHU C, 1993, J AM CHEM SOC, V115, P6198, DOI 10.1021/ja00067a039; DIRK CW, 1992, INT J QUANTUM CHEM, V43, P27, DOI 10.1002/qua.560430106; FEJER MM, 1989, PHYS REV LETT, V62, P1041, DOI 10.1103/PhysRevLett.62.1041; Garito A. F., 1988, Proceedings of the SPIE - The International Society for Optical Engineering, V971, P2, DOI 10.1117/12.948209; GARITO AF, 1989, ORGANIC MAT NONLINEA, P16; GILMOUR S, 1993, J CHEM SOC CHEM COMM, P432, DOI 10.1039/c39930000432; HALVORSON C, 1994, SCIENCE, V265, P1215, DOI 10.1126/science.265.5176.1215; HERMANN JP, 1974, J APPL PHYS, V45, P5100, DOI 10.1063/1.1663197; LAO KQ, 1995, J PHYS CHEM-US, V99, P496, DOI 10.1021/j100002a007; Liptay W., 1974, Excited states. Vol.1, P129; MARDER SR, 1994, SCIENCE, V265, P632, DOI 10.1126/science.265.5172.632; Messier J., 1992, Nonlinear Optics, Principles, Materials, Phenomena and Devices, V2, P53; MEYERS F, 1994, J AM CHEM SOC, V116, P10703, DOI 10.1021/ja00102a040; PIERCE BM, 1991, SPIE P, V1560, P148; PUCCETTI G, 1993, J PHYS CHEM-US, V97, P9385, DOI 10.1021/j100139a022	22	338	346	0	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1233	1236		10.1126/science.276.5316.1233	http://dx.doi.org/10.1126/science.276.5316.1233			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157876				2022-12-28	WOS:A1997XA49700035
J	Muttukrishna, S; Knight, PG; Groome, NP; Redman, CWG; Ledger, WL				Muttukrishna, S; Knight, PG; Groome, NP; Redman, CWG; Ledger, WL			Activin A and inhibin A as possible endocrine markers for pre-eclampsia	LANCET			English	Article							HUMAN MENSTRUAL-CYCLE; SERUM CONCENTRATIONS; DIMERIC INHIBIN; PREGNANCY; PREECLAMPSIA; HYPERTENSION; PLACENTA	Background Inhibin A and activin A are produced by the placenta during human pregnancy. This study aimed to measure circulating concentrations of inhibin A, pro alpha C-containing inhibins, and activin A in the serum of women with pre-eclampsia and of healthy matched control pregnant women, and to establish the molecular-weight forms of circulating inhibin A and activin A in pre-eclampsia. Methods In a retrospective cross-sectional study, blood samples were taken from 20 women in hospital with established pre-eclampsia, and from 20 control pregnant women attending antenatal clinics, who were matched for duration of gestation (preeclampsia mean 29.15 [SD 3.75] weeks; controls 29.30 [3.93] weeks), parity, and maternal age. Serum samples were analysed for inhibin A, inhibin B, pro alpha C, and activin A. Pooled samples of control (n=3) and pre-eclampsia serum (n=3) subsequently underwent fast protein liquid chromatographic analysis to assess the molecular-weight forms of inhibin A and activin A. Results are expressed as mean and SD for all variables measured. Findings Serum concentrations of inhibin A, activin A, and pro alpha C were significantly higher in pre-eclampsia than in control normal pregnancy (inhibin A 3.05 [1.8] vs 0.36 [0.14] ng/mL, p<0.001; activin A 38.08 [25.88] vs 3.95 [2.32] ng/mL, p<0.001; pro alpha C-containing inhibins 2.2 [0.81] vs 0.71 [0.33] ng/mL, p<0.001). Inhibin B concentrations in maternal serum were not increased. Molecular-weight forms of inhibin A (32 kDa) and activin A (>100 kDa) were similar in pre-eclampsia and normal pregnancy. The mean concentrations of hCG were 59.05 [43.98] and 16.3 [8.72] ng/mL, respectively. Interpretation Higher maternal serum concentrations of inhibin A, pro alpha C, and total activin A in preeclampsia than in control pregnancies could be helpful in the diagnosis of preeclampsia. These changes are interpreted as further evidence for trophoblast dysfunction in pre-eclampsia.	UNIV READING,SCH ANIM & MICROBIAL SCI,READING RG6 2AJ,BERKS,ENGLAND; OXFORD BROOKES UNIV,SCH BIOL & MOL SCI,OXFORD OX3 0BP,ENGLAND	University of Reading; Oxford Brookes University	Muttukrishna, S (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.		Ledger, William/L-9089-2017	Ledger, William/0000-0001-6465-4343; knight, philip/0000-0003-0300-1554				ARNHOLDT H, 1991, VIRCHOWS ARCH B, V60, P365, DOI 10.1007/BF02899568; Baird D T, 1993, Oxf Rev Reprod Biol, V15, P191; GROOME N, 1993, J IMMUNOL METHODS, V165, P167, DOI 10.1016/0022-1759(93)90342-5; GROOME NP, 1994, CLIN ENDOCRINOL, V40, P717, DOI 10.1111/j.1365-2265.1994.tb02504.x; GROOME NP, 1995, J CLIN ENDOCR METAB, V80, P2926, DOI 10.1210/jc.80.10.2926; Groome NP, 1996, J CLIN ENDOCR METAB, V81, P1401, DOI 10.1210/jcem.81.4.8636341; Illingworth PJ, 1996, J CLIN ENDOCR METAB, V81, P1471, DOI 10.1210/jc.81.4.1471; Knight PG, 1996, J ENDOCRINOL, V148, P267, DOI 10.1677/joe.0.1480267; Muller F, 1996, AM J OBSTET GYNECOL, V175, P37, DOI 10.1016/S0002-9378(96)70247-8; Muttukrishna S, 1996, J CLIN ENDOCR METAB, V81, P3328, DOI 10.1210/jc.81.9.3328; MUTTUKRISHNA S, 1994, HUM REPROD, V9, P1634, DOI 10.1093/oxfordjournals.humrep.a138765; MUTTUKRISHNA S, 1995, CLIN ENDOCRINOL, V42, P391, DOI 10.1111/j.1365-2265.1995.tb02648.x; MUTTUKRISHNA S, 1996, HUM REPROD, V11, P155; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; PETRAGLIA F, 1995, PLACENTA, V16, P447, DOI 10.1016/0143-4004(95)90102-7; REDMAN CWG, 1991, PLACENTA, V12, P301, DOI 10.1016/0143-4004(91)90339-H; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; Vale Wylie, 1994, P1861; WOLFE CDA, 1988, BRIT J OBSTET GYNAEC, V95, P1003, DOI 10.1111/j.1471-0528.1988.tb06504.x; WONG WLT, 1993, J IMMUNOL METHODS, V165, P1, DOI 10.1016/0022-1759(93)90100-L	20	232	241	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1285	1288		10.1016/S0140-6736(96)09264-1	http://dx.doi.org/10.1016/S0140-6736(96)09264-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142063				2022-12-28	WOS:A1997WW89900010
J	vanderHorst, GTJ; vanSteeg, H; Berg, RJW; vanGool, AJ; deWit, J; Weeda, G; Morreau, H; Beems, RB; vanKreijl, CF; deGruijl, FR; Bootsma, D; Hoeijmakers, JHJ				vanderHorst, GTJ; vanSteeg, H; Berg, RJW; vanGool, AJ; deWit, J; Weeda, G; Morreau, H; Beems, RB; vanKreijl, CF; deGruijl, FR; Bootsma, D; Hoeijmakers, JHJ			Defective transcription-coupled repair in Cockayne syndrome B mice is associated with skin cancer predisposition	CELL			English	Article							GROUP-A GENE; DNA-REPAIR; XERODERMA-PIGMENTOSUM; ULTRAVIOLET-B; ACTIVE GENES; DHFR GENE; PROTEIN; LACKING; CELLS; SUSCEPTIBILITY	A mouse model for the nucleotide excision repair disorder Cockayne syndrome (CS) was generated by mimicking a truncation in the CSB(ERCC6) gene of a CS-B patient. CSB-deficient mice exhibit all of the CS repair characteristics: ultraviolet (UV) sensitivity, inactivation of transcription-coupled repair, unaffected global genome repair, and inability to resume RNA synthesis after UV exposure. Other CS features thought to involve the functioning of basal transcription/repair factor TFIIH, such as growth failure and neurologic dysfunction, are present in mild form. In contrast to the human syndrome, CSB-deficient mice show increased susceptibility to skin cancer. Our results demonstrate that transcription-coupled repair of UV-induced cyclobutane pyrimidine dimers contributes to the prevention of carcinogenesis in mice. Further, they suggest that the lack of cancer predisposition in CS patients is attributable to a global genome repair process that in humans is more effective than in rodents.	NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT CARCINOGENESIS MUTAGENESIS & GENET,NL-3720 BA BILTHOVEN,NETHERLANDS; UNIV UTRECHT,DEPT DERMATOL,NL-3584 CX UTRECHT,NETHERLANDS; UNIV LEIDEN HOSP,DEPT PATHOL,NL-2300 RL LEIDEN,NETHERLANDS	Netherlands National Institute for Public Health & the Environment; Utrecht University; Leiden University; Leiden University Medical Center (LUMC)	vanderHorst, GTJ (corresponding author), ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL & GENET,CTR MED GENET,POB 1738,NL-3000 DR ROTTERDAM,NETHERLANDS.		van der Horst, Gijsbertus TJ/E-3661-2015; Hoeijmakers, Jan/AAX-6972-2021; van Gool, Alain J./L-4328-2015; van Gool, Alain J/G-3806-2010	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; van Gool, Alain/0000-0003-0010-5286				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; BOOTSMA D, 1996, IN PRESS METABOLIC B; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; FRIEDBERG EC, 1995, DNA REPAIR; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; ITIN PH, 1990, J AM ACAD DERMATOL, V22, P705, DOI 10.1016/0190-9622(90)70096-Z; Ljungman M, 1996, ONCOGENE, V13, P823; MAYNE LV, 1982, CANCER RES, V42, P1473; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; RUVEN HJT, 1994, MUTAT RES-DNA REPAIR, V315, P189, DOI 10.1016/0921-8777(94)90018-3; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; vanOosterwijk MF, 1996, MOL CELL BIOL, V16, P4436; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Verhage RA, 1996, MOL CELL BIOL, V16, P496; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	33	264	265	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					425	435		10.1016/S0092-8674(00)80223-8	http://dx.doi.org/10.1016/S0092-8674(00)80223-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150142	Green Published, Bronze			2022-12-28	WOS:A1997WX89900013
J	Thomas, SA; Palmiter, RD				Thomas, SA; Palmiter, RD			Thermoregulatory and metabolic phenotypes of mice lacking noradrenaline and adrenaline	NATURE			English	Article							BROWN ADIPOSE-TISSUE; DIET-INDUCED THERMOGENESIS; NOREPINEPHRINE; PROTEIN; OBESITY; STIMULATION; RATS; GENE	Adrenaline and noradrenaline, the main effecters of the sympathetic nervous system and adrenal medulla, respectively, are thought to control adiposity and energy balance through several mechanisms, They promote catabolism of triglycerides and glycogen(1), stimulate food intake when injected into the central nervous system(2), activate thermogenesis in brown adipose tissue(3,4), and regulate heat loss through modulation of peripheral vasoconstriction and piloerection(1), Thermogenesis in brown adipose tissue occurs in response to cold and overeating (diet induced)(5-7), and there is an inverse relationship between diet-induced thermogenesis and obesity bath in humans(8) and in animal models(9-12). As a potential model for obesity, we generated mice that cannot synthesize noradrenaline or adrenaline by inactivating the gene that encodes dopamine beta-hydroxylase. These mice are cold intolerant because they have impaired peripheral vasoconstriction and are unable to induce thermogenesis in brown adipose tissue through uncoupling protein (UCP1), The mutants have increased food intake but do not become obese because their basal metabolic rate is also elevated, The unexpected increase in basal metabolic rate is not due to hyperthyroidism, compensation by the widely expressed uncoupling protein UCP2, or shivering.	UNIV WASHINGTON, HOWARD HUGHES MED INST, DEPT BIOCHEM, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle								AHREN B, IN PRESS AM J PHYSL; BRAY GA, 1989, VITAM HORM, V45, P1; BROOKS SL, 1980, NATURE, V286, P274, DOI 10.1038/286274a0; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; GELOEN A, 1988, AM J PHYSIOL, V254, pC175, DOI 10.1152/ajpcell.1988.254.1.C175; GLICK Z, 1981, SCIENCE, V213, P1125, DOI 10.1126/science.7268419; GOLDMAN CK, 1985, EUR J PHARMACOL, V115, P11, DOI 10.1016/0014-2999(85)90578-3; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; HIMMSHAGEN J, 1995, P SOC EXP BIOL MED, V208, P159, DOI 10.3181/00379727-208-43847A; JUNG RT, 1979, NATURE, V279, P322, DOI 10.1038/279322a0; KLAUS S, 1991, INT J BIOCHEM, V23, P791, DOI 10.1016/0020-711X(91)90062-R; Landsberg L., 1992, WILLIAMS TXB ENDOCRI, P621; Larsen PR, 1992, WILLIAMS TXB ENDOCRI, P357; LEIBOWITZ SF, 1991, BRAIN RES BULL, V27, P333, DOI 10.1016/0361-9230(91)90121-Y; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MCGREGOR IS, 1991, BRAIN RES BULL, V26, P683, DOI 10.1016/0361-9230(91)90161-C; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; SILVA JE, 1988, MOL ENDOCRINOL, V2, P706, DOI 10.1210/mend-2-8-706; SIVIY SM, 1989, BRAIN RES, V487, P79, DOI 10.1016/0006-8993(89)90942-6; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; ZOLOVICK AJ, 1982, EUR J PHARMACOL, V77, P265, DOI 10.1016/0014-2999(82)90128-5	25	214	220	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	1997	387	6628					94	97		10.1038/387094a0	http://dx.doi.org/10.1038/387094a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139828				2022-12-28	WOS:A1997WW75800054
J	Lengauer, C; Kinzler, KW; Vogelstein, B				Lengauer, C; Kinzler, KW; Vogelstein, B			Genetic instability in colorectal cancers	NATURE			English	Article							WILD-TYPE P53; INSITU HYBRIDIZATION; GENOMIC INSTABILITY; CELL-LINES; MUTATIONS; TUMORIGENICITY; AMPLIFICATION; FLUORESCENCE; DEFECTS; TUMORS	It has long been considered that genetic instability is an integral component of human neoplasia(1-3), In a small fraction of tumours, mismatch repair deficiency leads to a microsatellite instability at the nucleotide sequence level(4,5), In other tumours, an abnormal chromosome number (aneuploidy) has suggested an instability, but the nature and magnitude of the postulated instability is a matter of conjecture. We show here that colorectal tumours without microsatellite instability exhibit a striking defect in chromosome segregation, resulting in gains or losses in excess of 10(-2) per chromosome per generation. This form of chromosomal instability reflected a continuing cellular defect that persisted throughout the lifetime of the tumour cell and was not simply related to chromosome number. While microsatellite instability is a recessive trait(6,7), chromosomal instability appeared to be dominant, These data indicate that persistent genetic instability may be critical for the development of all colorectal cancers, and that such instability can arise through two distinct pathways.	HOWARD HUGHES MED INST,BALTIMORE,MD 21231; JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1990, P NATL ACAD SCI USA, V87, P7555; BOCKER M, 1996, J PATHOL, V179, P15; Casares S, 1995, ONCOGENE, V11, P2303; Cottu PH, 1996, ONCOGENE, V13, P2727; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; HARTWELL L, 1994, COLD SPRING HARB SYM, V59, P259, DOI 10.1101/SQB.1994.059.01.030; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HEIM S, 1987, CANC CYTOGENETICS; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; KOI M, 1994, CANCER RES, V54, P4302; LENGAUER C, 1994, GENET ANAL-BIOMOL E, V11, P140, DOI 10.1016/1050-3862(94)90034-5; LICHTER P, 1991, GENET ANAL-BIOMOL E, V8, P24, DOI 10.1016/1050-3862(91)90005-C; LICHTER P, 1992, HUMAN CYTOGENETICS P, P157; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1991, CANCER RES, V51, P3075; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MAYER VW, 1990, MUTAT RES, V231, P177, DOI 10.1016/0027-5107(90)90024-X; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; RIED T, 1992, GENE CHROMOSOME CANC, V4, P69, DOI 10.1002/gcc.2870040109; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SHACKNEY SE, 1989, CANCER RES, V49, P3344; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; UMAR A, 1994, J BIOL CHEM, V269, P14367; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	29	1554	1604	2	76	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 10	1997	386	6625					623	627		10.1038/386623a0	http://dx.doi.org/10.1038/386623a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121588				2022-12-28	WOS:A1997WT27300063
J	Tong, S; Caddy, D; Short, RV				Tong, S; Caddy, D; Short, RV			Use of dizygotic to monozygotic twinning ratio as a measure of fertility	LANCET			English	Article							QUALITY; SEMEN; RATES	Background Monozygotic (Mt, identical) twinning occurs at a rate of around three per 1000 maternities in all populations, whereas dizygotic (Dz, fraternal) twinning is highly heritable, and varies with age and race, The Dz/Mz twinning ratio reflects the frequency of twin ovulations, and can provide a useful measure of human fertility. Methods 1625 pairs of twins of known sex were born in Tsan Yuk Obstetric Hospital in Hong Kong during the period 1960-95. The yearly Dz/Mz ratio was calculated, and trends were analysed by chi(2) test with the Bonferroni correction. Ages of mothers of all opposite-sexed twins were recorded and trends analysed by ANOVA and linear regression. Findings The Dz/Mz ratio declined significantly from 1.12 in 1960 to 0.05 in 1978 (p<0.001), and then rose significantly to an average of 0.86 in 1994-95 (p<0.003). There was a significant declining trend in age of mothers of opposite-sexed twins from 1960 to 1978 (p<0.001), but there were no significant changes in maternal age after 1978(p=0.38). Interpretation If we are correct in assuming that the frequency of Mt twinning remained constant during the study period, the declining Dz/Mz ratio from 1960 to 1978, which also occurred in many developed countries, could reflect some adverse environmental effect on human fertility. The increasing proportion of Dz twins in the past two decades is probably due to increasing use of ovulation-inducing drugs such as clomiphene citrate, which could mask a serious and continuing decline in human fertility. It is therefore important to continue to monitor the Dz/Mz ratio in the future in this and other subpopulations, after exclusion of any women who have taken drugs that stimulate fertility.	ROYAL HOSP WOMEN,DEPT PERINATAL MED,MELBOURNE,VIC,AUSTRALIA		Tong, S (corresponding author), MONASH UNIV,DEPT PHYSIOL,MELBOURNE,VIC 3168,AUSTRALIA.			Tong, Stephen/0000-0002-2319-0586				AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; BLAND M, 1992, INTRO MED STAT; Bulmer M. G., 1970, BIOL TWINNING MAN; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; CHANG KSF, 1960, J ANAT, V94, P543; CHEN CJ, 1987, ACTA GENET MED GEMEL, V36, P335, DOI 10.1017/S0001566000006085; COBORN T, 1996, OUR STOLEN FUTURE; DEROM C, 1993, FERTIL STERIL, V60, P493; IMAIZUMI Y, 1992, ACTA GENET MED GEMEL, V41, P165, DOI 10.1017/S0001566000002373; Irvine S, 1996, BMJ-BRIT MED J, V312, P467, DOI 10.1136/bmj.312.7029.467; James WH, 1995, HUM REPROD, V10, P3042, DOI 10.1093/oxfordjournals.humrep.a135843; JAMES WH, 1982, J BIOSOC SCI, V14, P481, DOI 10.1017/S0021932000014346; Lichtenstein P, 1996, BRIT MED J, V312, P879; ORELEBEKE JF, 1991, ACTA GENET MED GEMEL, V40, P319; Pajarinen J, 1997, BRIT MED J, V314, P13, DOI 10.1136/bmj.314.7073.13; PARAZZINI F, 1994, HUM REPROD, V9, P1784, DOI 10.1093/oxfordjournals.humrep.a138797; SHORT RV, 1984, 1 MED; WOOD JW, 1989, OXFORD REV REPROD B, V11, P61; *WORLD BANK, 1993, WORLD BANK WORLD DEV	19	45	45	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					843	845		10.1016/S0140-6736(96)10003-9	http://dx.doi.org/10.1016/S0140-6736(96)10003-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121260				2022-12-28	WOS:A1997WP40300013
